<SEC-DOCUMENT>0001493152-24-012058.txt : 20240401
<SEC-HEADER>0001493152-24-012058.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240329211825
ACCESSION NUMBER:		0001493152-24-012058
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				520845822
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-27072
		FILM NUMBER:		24805267

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:AIM="http://aimimmuno.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_024_US%2DGAAP%2D2023_stpr -->
<!-- Field: Set; Name: xdx; ID: xdx_030_AIM_aimimmuno.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0000946644 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0000946644</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0128" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0130" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0132" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0134" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:CashlessWarrantConversion" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:AbandonmentOfPatentAndTrademarkRights" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:LossGainFromSaleOfIncomeTaxOperatingLosses" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" id="xdx2ixbrl0515" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0817" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0819" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0853" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0855" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0857" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0859" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0861" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0863" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0881" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0883" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0885" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0887" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0889" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="xdx2ixbrl0891" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0975" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0977" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0979" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0981" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0983" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="xdx2ixbrl0985" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1045" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1047" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1055" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1077" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1085" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1093" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1114" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1138" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1165" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1175" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1183" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1185" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1203" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1205" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1228" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1236" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1258" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1278" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1333" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1334" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1336" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1338" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1339" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1341" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1355" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1356" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1358" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1406" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1408" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1410" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1412" unitRef="Shares" xs:nil="true"/>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="xdx2ixbrl1513" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="xdx2ixbrl1520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="xdx2ixbrl1530" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="xdx2ixbrl1537" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P10Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" id="xdx2ixbrl1545" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P10Y</ix:nonNumeric>
  <ix:nonFraction name="AIM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2023-12-31" id="xdx2ixbrl1627" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1717" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1745" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1761" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1763" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1769" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1771" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1777" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1779" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1785" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1787" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1807" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1808" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1810" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1811" unitRef="Pure" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aim-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">AIM:PatentAndTrademarkRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AIM:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MutualFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AIM:MutualFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:BoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AIM:DirectorsOfficersAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-06</xbrli:startDate>
        <xbrli:endDate>2020-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-26</xbrli:startDate>
        <xbrli:endDate>2019-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-302020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-182023-04-19_custom_MaximGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-18</xbrli:startDate>
        <xbrli:endDate>2023-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MaximGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MaximGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-12</xbrli:startDate>
        <xbrli:endDate>2018-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlansTwoThousandAndEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember289844531">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PancreaticCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PancreaticCancerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_JubilantHollisterStierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_JubilantHollisterStierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_JubilantHollisterStierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ResearchConsultingAndSupplyAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ResearchConsultingAndSupplyAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:PharmaSolutionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JjointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_custom_AzenovaSalesInternationalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaSalesInternationalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaSalesInternationalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_AlcamiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AlcamiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AlcamiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">AIM:FourZeroOnekPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:ThomasKEquelsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquelsandRodinoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EquelsandRodinoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:ThomasKEquelsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EllenLintalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EquelsRodinoAndFormerOfficerLintalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_BE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_stpr_NJ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_NJ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_NJ">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RestatementAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember289848921">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="AIM:DebtIstrumentAxis">AIM:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-16</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-28</xbrli:startDate>
        <xbrli:endDate>2024-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EmployeesPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:DirectorsPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EmployeesPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:DirectorsPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>AIM:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_903_edei--DocumentType_c20230101__20231231_zpMwNCU3pUlj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_907_edei--DocumentAnnualReport_c20230101__20231231_zgPRpaZgqe8k"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20230101__20231231_znZmb6SpqtVi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_904_edei--CurrentFiscalYearEndDate_c20230101__20231231_zGpx6uPU90t5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_903_edei--DocumentFiscalYearFocus_c20230101__20231231_zFFRFk20UnQi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--DocumentTransitionReport_c20230101__20231231_zgQKgWsZutii"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ________ to ________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File No. <span id="xdx_901_edei--EntityFileNumber_c20230101__20231231_zkl5d7OhC4Ch"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityFileNumber">001-27072</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20230101__20231231_zCpko5F6ElNg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityRegistrantName">AIM
IMMUNOTECH INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230101__20231231_ze9JNNBq0iC9"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20230101__20231231_zerHDeQKfWfl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">52-0845822</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer Identification</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityAddressAddressLine1_c20230101__20231231_zlFG8mNwBjmi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">2117
    SW Highway 484</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20230101__20231231_z6mFCrzObvcf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressCityOrTown">Ocala</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressStateOrProvince_c20230101__20231231_zQjhd8zweXRl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20230101__20231231_zKGmMz9sX6ci"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressPostalZipCode">34473</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span id="xdx_902_edei--CityAreaCode_c20230101__20231231_zVWr87iZUdYa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000026" name="dei:CityAreaCode">(352)</ix:nonNumeric></span> <span id="xdx_90A_edei--LocalPhoneNumber_c20230101__20231231_zOuH0P66ke4k"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:LocalPhoneNumber">448-7797</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(Former
name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20230101__20231231_zYTB0hAm6VDk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20230101__20231231_zDXLrjgvOABa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:TradingSymbol">AIM</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20230101__20231231_zq11bnB24TUh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">NYSE
    American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title
of Each Class)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NONE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zI7eeG5QK5me"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000031" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric></span> &#9746;
No </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_909_edei--EntityVoluntaryFilers_c20230101__20231231_zBXkrAxcfr3a"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000032" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_909_edei--EntityCurrentReportingStatus_c20230101__20231231_zG6Yi4NcMgga"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746;  No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20230101__20231231_zbpBIJLCOgN5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    Large accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    Accelerated filer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
    <span id="xdx_90B_edei--EntityFilerCategory_c20230101__20231231_zmVjVmexEl0h"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000035" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntitySmallBusiness_c20230101__20231231_zwHroCeytWGb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000036" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span>
    Smaller reporting company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20230101__20231231_zQEoG2kSHl5a"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span> Emerging growth company</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by checkmark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public
accounting firm that prepared or issued its audit report. <span id="xdx_902_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zTwdI1uy9Ty5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000038" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_ziBv1RelOeR7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No
<span id="xdx_90C_edei--EntityShellCompany_dbF_c20230101__20231231_zyvZwAmpvgNh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2023, the last business day of the
registrant&#8217;s most recently completed second fiscal quarter was $<span id="xdx_90D_edei--EntityPublicFloat_iI_c20230630_zd0VlPLTyxFl"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,829,482</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of the registrant&#8217;s Common Stock outstanding as of March 27, 2024 was <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20240327_ztpUMmBaq7ra"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-27" id="Fact000042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,901,177</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DOCUMENTS
INCORPORATED BY REFERENCE:</b> <span id="xdx_902_edei--DocumentsIncorporatedByReferenceTextBlock_c20230101__20231231_zLuqV57Raza3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000043" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><a href="#nd_001">PART I</a></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_002">ITEM 1. Business.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#nd_003">ITEM 1A. Risk Factors.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_001">ITEM 1B. Unresolved Staff Comments.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_002">ITEM 1C. Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_003">ITEM 2. Properties.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_004">ITEM 3. Legal Proceedings.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">34<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_005">ITEM 4. Mine Safety Disclosures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><a href="#ku_006">PART II</a></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_007">ITEM 5. Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_008">ITEM 6. [Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_009">ITEM 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_010">ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_011">ITEM 8. Financial Statements and Supplementary Data.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">41</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_012">ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_013">ITEM 9A. Controls and Procedures.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_014">ITEM 9B. Other Information.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_015">ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">42</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><a href="#ku_016">PART III</a></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_017">ITEM 10. Directors, Executive Officers and Corporate Governance.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">43</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_018">ITEM 11. Executive Compensation.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">48</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_019">ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">55</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_020">ITEM 13. Certain Relationships and Related Transactions and Director Independence.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_021">ITEM 14. Principal Accountant Fees and Services.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">58</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><a href="#ku_022">PART IV</a></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_023">ITEM 15. Exhibits and Financial Statement Schedules.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">59</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ku_024">ITEM 16. Form 10-K Summary.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_002"></span>ITEM
  </b></span><b>1.</b></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Business</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">GENERAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline"></span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon alfa). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial
sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (&#8220;CFS&#8221;). Our primary business focus involves
Ampligen. Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;) molecule being developed for globally important cancers, viral diseases
and disorders of the immune system. We are currently proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
    a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced
    pancreatic cancer patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
    Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor
    responses to checkpoint inhibitors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring
    Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated
    viruses thereof.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
    Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;) and fatigue and/or Post-COVID
    conditions of fatigue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer,
ME/CFS and Post-COVID conditions having priority over antiviral experimentation. We intend that priority clinical work be conducted in
trials authorized by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or European Medicines Agency (&#8220;EMA&#8221;), which
trials support a potential future NDA. However, our antiviral experimentation is designed to accumulate additional preliminary data supporting
our hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity
and cross-protection. Accordingly, we will conduct antiviral programs in those venues most readily available and able to generate valid
proof-of-concept data, including foreign venues. Please see &#8220;Immuno-Oncology&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Immuno-Oncology</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on pancreatic cancer because testing results, to date, primarily conducted in the Netherlands, have been very promising.
The Netherlands study generated statistically significant data indicating that Ampligen extended survival well beyond the Standard of
Care (&#8220;SOC&#8221;), when compared to well-matched historical controls. These data support the proposition that Ampligen, when administered
to either patients with locally advanced or metastatic pancreatic cancer after systemic chemotherapy showed a statistically significant
increase in survival rate. In October 2021, we and our Contract Research Organization, Amarex, submitted an Investigational New Drug
(&#8220;IND&#8221;) application to the FDA for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage
pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the differences in the scale of necessary trials, our initial primary focus when it comes to pancreatic cancer will be cases that
are locally advanced, rather than metastatic. The number of different approaches to treating metastatic pancreatic cancer &#8212; approaches
which would be determined by treating physicians &#8212; would require a much larger, far more expensive trial than would a trial for
locally advanced pancreatic cancer. Therefore, we are focusing on patients who have completed FOLFIRINOX and have stable disease. In
August 2022, we received Institutional Review Board (&#8220;IRB&#8221;) approval of the trial protocol in locally advanced pancreatic
cancer and so announced the trial&#8217;s commencement. The study is recruiting patients. Assuming this trial and subsequent planned
clinical trials confirm the existing data, our goal is to then submit an NDA for use of Ampligen in pancreatic cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen
has also demonstrated in the clinic the potential for standalone efficacy in a number of other solid tumors. We have also seen success
in increasing survival rates and efficacy in the treatment of animal tumors when Ampligen is used in combination with checkpoint blockade
therapies. In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial
to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen
(TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
We believe that data from the study, which is being conducted by the University of Pittsburgh Medical Center and funded by a Merck grant,
demonstrated that when combining three drugs &#8211; Ampligen and pembrolizumab, which are both immune therapies, with cisplatin, a chemotherapy
&#8211; evidence of increased biomarkers associated with T cell chemotaxis and cytolytic function has been seen. Importantly, increases
of these biomarkers in the tumor microenvironment have been correlated with favorable tumor responses. These successes in the field of
immuno-oncology have guided our efforts toward the potential use of Ampligen as a combinational therapy for the treatment of a variety
of solid tumor types. The first of our patent applications in this space was granted by the Netherlands on March 15, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a Potential Antiviral</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a research and pre-clinical history that indicates broad-spectrum antiviral capability of Ampligen in animals. We hope to demonstrate
that it has the same effect in humans. To do this, among other things, we need a population infected with a virus. That is why we have
spent significant resources on COVID-19 (the disease caused by SARS-CoV-2) which is active and still infecting many subjects. While much
would need to be done to get Ampligen to market as a broad-spectrum antiviral, we believe that it is important to focus our efforts first
and foremost on thoroughly proving the concept, especially while there is still a large COVID-19-infected population. Previously, animal
studies were conducted that yielded positive results utilizing Ampligen to treat numerous viruses, such as Western Equine Encephalitis
Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1. We have conducted experiments in
SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. The prior studies of Ampligen in SARS-CoV-1 animal experimentation
may predict similar protective effects against SARS-CoV-2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has requested that we provide additional data to assist the agency in evaluating the potential risks and benefits of administering
Ampligen to asymptomatic and mild COVID-19 individuals. However, as discussed in more detail below, where the threat to the patient from
COVID-19 is high, the FDA has already authorized Ampligen in a clinical trial of patients with COVID-19 who have a pre-existing cancer.
We have also elected to explore studies (initially with healthy volunteers) outside the United States and have already conducted a study
in the Netherlands to determine the safety profile of the intranasal delivery of Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this regard, CHDR, a foundation located in Leiden in the Netherlands, managed a Phase 1 randomized, double-blind study for us to evaluate
the safety, tolerability, and biological activity of repeated administration of Ampligen intranasally. A total of 40 healthy subjects
received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum
level of 1,250 micrograms. The study was completed, and the Final Safety Report reported no Serious or Severe Adverse Events at any dosage
level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are approved therapies for COVID-19, we believe that, if Ampligen has the broad-spectrum antiviral properties that we believe that
it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that arise
in the future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. We believe that it activates antiviral
immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;Ampligen as a Potential Antiviral&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a Treatment for Post-COVID Conditions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen&#174; as a potential therapeutic for people
with post-COVID conditions (&#8220;AMP-518&#8221;). We announced in August 2023 that the study had met the planned enrollment of 80 subjects
ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with
a follow-up phase of two weeks. All patients have completed the study and topline data was reported in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;Ampligen as a Treatment for Post-COVID Conditions&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a treatment for ME/CFS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have long been focused on seeking the FDA&#8217;s approval for the use of Ampligen to treat myalgic encephalomyelitis/chronic fatigue
syndrome (&#8220;ME/CFS&#8221;). In fact, in February 2013, we received a Complete Response letter (&#8220;CRL&#8221;) from the FDA for
our Ampligen NDA for ME/CFS, stating that we should conduct at least one additional clinical trial, complete various nonclinical studies
and perform a number of data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
developing a comprehensive response to the FDA and a plan for a confirmatory trial for the FDA NDA, we proceeded independently in Argentina
and, in August 2016, we received approval of an NDA from ANMAT for commercial sale of Ampligen in the Argentine Republic for the treatment
of severe CFS. In September 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent
sales. On June 10, 2020, we received import clearance from ANMAT to import the first shipment of commercial grade vials of Ampligen into
Argentina. The next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release
tests before granting final approval to begin commercial sales. This testing and approval process is ongoing due to ANMAT&#8217;s internal
processes. Once final approval by ANMAT is obtained, GP Pharm will be responsible for distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA authorized an open-label treatment protocol (&#8220;AMP-511&#8221;) allowing patient access to Ampligen for treatment in a study
under which severely debilitated CFS patients have the opportunity to be on Ampligen to treat this very serious and chronic condition.
The data collected from the AMP-511 protocol through a consortium group of clinical sites provide safety information regarding the use
of Ampligen in patients with CFS. The AMP-511 protocol is ongoing. In October 2020, we received IRB approval for the expansion of the
AMP-511 protocol to include patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate
chronic fatigue-like symptoms that we refer to as Post-COVID conditions. As of September 30, 2023, there were 11 patients enrolled in
this open-label expanded access treatment protocol (including four patients with Post-COVID Conditions). To date, there have been seven
such Post-COVID patients treated in the study. AIM previously reported positive preliminary results based on data from the first four
Post-COVID Condition patients enrolled in the study. The data show that, by week 12, compared to baseline, there was what the investigators
considered a clinically significant decrease in fatigue-related measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on a comprehensive follow through with the FDA regarding the use of Ampligen as a treatment for ME/CFS. We have learned a great
deal since the FDA&#8217;s CRL and plan to adjust our approach to concentrate on specific ME/CFS symptoms. Responses to the CRL and a
proposed confirmatory trial are being worked on now by our R&amp;D team and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Atlas
Equity Line of Credit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, we entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the
&#8220;Registration Rights Agreement&#8221;) with Atlas Sciences, LLC, a Utah limited liability company (&#8220;Atlas&#8221;), pursuant
to which Atlas has committed to purchase up to $15 million of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Atlas, and Atlas
is obligated to purchase up to $15 million of our Common Stock (the &#8220;Commitment Amount&#8221;). Such sales by us, if any, will
be subject to certain limitations, and may occur from time to time, at our sole discretion, over the 24-month period commencing on the
date that a registration statement covering the resale of shares that have been and may be issued under the Purchase Agreement. We agreed
to file the registration statement with the SEC pursuant to the Registration Rights Agreement. Sales cannot commence until the registration
statement is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth
in the Purchase Agreement are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas
has no right to require us to sell any shares to Atlas, but Atlas is obligated to make purchases as we direct, subject to certain conditions.
There are no upper limits on the price per share that Atlas must pay for shares of Common Stock. Actual sales of shares to Atlas will
depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price
of the Common Stock and determinations by us as to the appropriate sources of funding for us and our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds under the Purchase Agreement will depend on the frequency and prices at which we sell shares to Atlas. We expect that any
proceeds received by us will be used for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot sell shares below the Minimum Price (as defined by the NYSE American) under the Purchase Agreement that would represent, in the
aggregate, more than 19.99% of the outstanding shares on the date that the Purchase Agreement was executed or more than one percent of
such shares to Substantial Security Holders (as defined by the NYSE American). Before we could do that, we would need to obtain stockholder
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed with Atlas that we will not enter into any &#8220;variable rate&#8221; transactions with any third party for a period defined
in the Purchase Agreement. Atlas has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling
or hedging of the Company&#8217;s shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for Atlas&#8217;s irrevocable commitment to purchase shares upon the terms of and subject to satisfaction of the conditions
set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company agreed to pay Atlas an initial commitment
fee in shares equal to 1.0% of the Commitment Amount. The initial commitment fee was paid upon execution of the Purchase Agreement through
the issuance of 338,600 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification
obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
any period where bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for
relief under any bankruptcy law or any law for the relief of debtors shall be instituted or anticipated by or against the Company or
any subsidiary of the Company, and in the case of such a proceeding being involuntary or commenced against the Company, which is not
dismissed within 60 days, the Company may not initiate any purchase of shares by Atlas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement are qualified in their entirety by reference to
the full text of such agreements, copies of which are attached hereto as Exhibits 10.104 and 10.105, respectively, and each of which
is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such agreements were
made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and
may be subject to limitations agreed upon by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 20pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND SUMMARY RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E
of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. All statements, other than statements of historical
fact, included or incorporated herein regarding our strategy, future operations, financial position, future revenues, projected costs,
plans, prospects and objectives are forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221;
&#8220;opportunity&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements but
are not the exclusive means of identifying forward-looking statements and their absence does not mean that a statement is not forward-looking.
Our forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or
expressed by such statements due to risks and uncertainties. These statements are based on our management&#8217;s current beliefs, expectations
and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these
forward-looking statements may be found, among other places, in this Report in Part I, Item 2. &#8220;Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations&#8221;; Part II, Item 1. &#8220;Legal Proceedings&#8221;; and Part II, Item
1A. &#8220;Risk Factors&#8221;, as well as the following sections of our Annual Report on Form 10-K for the year ended December 31, 2022:
Item 1. &#8220;Business&#8221;, Part I; Item 1A. &#8220;Risk Factors&#8221;, Part I; Item 3. &#8220;Legal Proceedings&#8221;, Part I
and Part II; Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. Among
other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation.
We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
We are in various stages of seeking to determine whether Ampligen&#174; will be effective in the treatment of multiple types of viral
diseases, cancers, and immune-deficiency disorders and the presentation sets forth our current and anticipated future activities. These
activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether
Ampligen&#174; will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results
in humans. Human clinical trials will be necessary to prove whether or not Ampligen&#174; will be efficacious in humans. No assurance
can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to
many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other
trials. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful
data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects,
and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results.
Some of the world&#8217;s largest pharmaceutical companies and medical institutions are working on a treatment for COVID-19. Even if
Ampligen&#174; proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first
priority or that another treatment that eventually proves capable will not make our efforts ultimately unproductive, as multiple vaccines,
and some treatments, are now available and major pharma companies are working to develop their own disease treatments. No assurance can
be given that future studies will not result in findings that are different from those reported in the studies referenced in this Report.
Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property
rights. In addition, many countries, including Argentina, are still dealing with COVID-19 outbreaks and have made that their primary
focus. We believe that this may be delaying our commercialization of Ampligen&#174; in Argentina until COVID-19 is more under control.
We cannot assure that our potential foreign operations will not be adversely affected by these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
filings are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this Report and
is included for reference purposes only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SUMMARY
RISK FACTORS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Risk Related to our Business</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may require additional financing which may not be available.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may continue to incur substantial losses and our future profitability is uncertain.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    drug and related technologies are investigational and subject to regulatory approval. If we are unable to obtain regulatory approval
    in a timely manner, or at all, our operations will be materially harmed and our stock adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    COVID-19 coronavirus or other global pandemics could adversely impact our business, including our clinical trials. We cannot predict
    the ultimate effects of the COVID-19 virus on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to product liability claims from the use of Ampligen, Alferon N Injection, or other of our products which could negatively
    affect our future operations. We have limited product liability and clinical trial insurance.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
    of health care reimbursement for our products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are risks of liabilities associated with handling and disposing of hazardous materials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely upon information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity
    incidents, could harm our ability to operate our business effectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    loss of services of key personnel could hurt our chances for success.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GAAP requires estimates, judgements and assumptions which inherently contain
    uncertainties.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently, and may in the future, have assets held at financial institutions that may exceed the insurance coverage offered by the
    Federal Deposit Insurance Corporation, and the loss of such assets would have a severe negative affect on our operations and liquidity.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks Associated with Our Products</i></span></p>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The development of Ampligen is subject to significant risks.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The development of Alferon N Injection is subject to significant risks.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible
    side effects from the use of Ampligen or Alferon N Injection could adversely affect potential revenues and physician/patient acceptability
    of our product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Related to our activities associated with Ampligen&#8217;s potential effectiveness as a treatment for COVID-19 or Post-Covid Conditions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to predict the future of COVID-19, and related Post-COVID Conditions, as a global public health threat or the development
of related therapies. No assurance can be given that Ampligen will aid in or be applied to the treatment of this virus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    in foreign countries carries with it many risks.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our Intellectual Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be profitable unless we can protect our patents and/or receive approval for additional pending patents.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    patent position of biotechnology and pharmaceutical firms is highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    can be no assurance that we will be able to obtain necessary licenses if we cannot enforce patent rights we may hold. In addition,
    the failure of third parties from whom we currently license certain proprietary information or from whom we may be required to obtain
    such licenses in the future, to adequately enforce their rights to such proprietary information, could adversely affect the value
    of such licenses to us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is no guarantee that our trade secrets will not be disclosed or known by our competitors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our R&amp;D</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: justify; width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.25in">&#9679;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict what additional studies and/or additional testing or information may be required by the FDA. Accordingly, we are unable
to estimate the nature, timing, costs and necessary efforts to complete these projects nor the anticipated completion dates. In addition,
we have no basis for estimating when material net cash inflows may commence. We have yet to generate significant revenues from the sale
of these developmental products.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our Manufacturing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Alferon N Injection Commercial Sales were halted due to lack of finished goods inventory. If we are unable to gain the necessary
    FDA approvals related to Alferon N Injection, or if we are unable to identify a CMO or CMOs that meet our requirements, then our
    operations would most likely be materially and/or adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are no long-term agreements with suppliers of required materials and services for Ampligen and there are a limited number of raw
    material suppliers. If we are unable to obtain the required raw materials and/or services, we may not be able to manufacture Ampligen.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    are  limited number of organizations in the United States available to provide the final manufacturing steps of formulation, fill,
    finish and packing sets for Alferon N Injection and Ampligen.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
    is no assurance that, upon success, manufacture of a drug on a limited-scale basis for investigational use would lead to a successful
    transition to commercial, large-scale production.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited manufacturing experience for Ampligen and Alferon N Injection. We may not be profitable unless we can produce Ampligen,
    Alferon N Injection or other products in commercial quantities at costs acceptable to us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our Licensing/Collaborations/Joint Ventures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to achieve licensing, collaboration and/or joint ventures, our marketing strategy for Ampligen will be part of the
    differing health care systems around the world along with the different marketing and distribution systems that are used to supply
    pharmaceutical products to those systems.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our Marketing and Distribution</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have limited marketing and sales capability. If we are unable to obtain additional distributors and our current and future distributors
    do not market our products successfully, we may not generate significant revenues or become profitable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with Our Competition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid
    technological change may render our products obsolete or non-competitive.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    products may be subject to substantial competition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
Associated with an Investment in Our Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our stock may be adversely affected by market volatility</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could
    depress the market price of our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    of our Certificate of Incorporation and Delaware law could defer a change of our Management, which could discourage or delay offers
    to acquire us.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business, financial condition and operating results could be negatively affected as a result of actions by activist investors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">AVAILABLE
INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file electronically with the United States Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports
on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended. We make available on our website at www.ao-inc.com free of charge, copies of these reports
as soon as reasonably practicable after filing these reports with, or furnishing them to, the SEC. We are subject to the information
and periodic reporting requirements of the Exchange Act and, in accordance therewith, we file periodic reports, proxy statements and
other information with the SEC. Such periodic reports, proxy statements and other information are available for inspection and copying
at the website of the SEC <span style="text-decoration: underline">www.sec.gov</span>. You also may obtain a free copy of our annual reports on Form 10-K, quarterly reports on
Form 10-Q, current reports on Form 8-K, proxy statements and amendments to those reports on the day of filing with the SEC on our website
at <span style="text-decoration: underline">http://www.aimimmuno.com</span> under the Investor Relations tab for SEC Filings or by contacting the Investor Relations Department
by calling (833) 475-8247 or (352) 448-7797 or sending an e-mail message to AIM@jtcir.com. Our Internet website and the information contained
on that website, or accessible from our website, is not intended to be incorporated into this Annual Report on Form 10-K or any other
filings we make with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">OUR
PRODUCTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary pharmaceutical product platform consists of Ampligen (rintatolimod), a first-in-class drug of large macromolecular double-stranded
(ds) RNA (ribonucleic acid) molecules, and our FDA-approved natural alpha-interferon product, Alferon N Injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ampligen&#174;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen
is approved for sale in Argentina (to 2026) for severe CFS and is an experimental drug in the United States currently undergoing clinical
development for the treatment of certain cancers and ME/CFS. Over its developmental history, Ampligen has received various designations,
including Orphan Drug Product Designation (FDA and EMA), Treatment protocol (e.g., &#8220;Expanded Access&#8221; or &#8220;Compassionate&#8221;
use authorization) with Cost Recovery Authorization (FDA) and &#8220;promising&#8221; clinical outcome recognition based on the evaluation
of certain summary clinical reports (&#8220;AHRQ&#8221; or Agency for Healthcare Research and Quality). Based on the results of published,
peer-reviewed pre-clinical studies and clinical trials, we believe that Ampligen may have broad-spectrum antiviral and anti-cancer properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that nucleic acid compounds represent a potential new class of pharmaceutical products designed to act at the molecular level
for treatment of many human diseases. Ampligen represents the first drug in the class of large (macromolecular) dsRNA molecules to apply
for NDA review. There are two forms of nucleic acids: deoxyribonucleic acid (&#8220;DNA&#8221;) and ribonucleic acid (&#8220;RNA&#8221;).
DNA is a group of naturally occurring molecules found in chromosomes, the cell&#8217;s genetic machinery. RNA is a group of naturally
occurring informational molecules which orchestrate a cell&#8217;s behavior which, in turn, regulates the action of groups of cells,
including the cells which comprise the body&#8217;s immune system. RNA directs the production of proteins and regulates certain cell
activities including the activation of an otherwise dormant cellular defense against viruses and tumors. Our drug technology utilizes
specifically configured RNA and is a selective Toll-like Receptor 3 (&#8220;TLR3&#8221;) agonist that can be administered intravenously,
intranasally and intraperitoneally. Ampligen has been assigned the generic name rintatolimod by the United States Adopted Names Council
(&#8220;USANC&#8221;) and has the chemical designation poly(I):poly(C12U).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded
Access Program/Early Access Programs/clinical trials of Ampligen that have been conducted or that are ongoing include studies of the
potential treatment of patients with pancreatic cancer, renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian
cancer, breast cancer, colorectal cancer, prostate cancer, ME/CFS, Hepatitis B, HIV, COVID-19 and Post-COVID conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received approval of our NDA from ANMAT for the commercial sale of Ampligen in the Argentine Republic for the treatment of severe
CFS. The product will be marketed by GP Pharm, our commercial partner in Latin America. Shipment of the drug product to Argentina was
initiated in 2018 to complete the release testing by ANMAT needed for commercial distribution. In September 2019, we received clearance
from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. In June 2020, we received import clearance
from ANMAT to import the first shipment of commercial grade vials of Ampligen into Argentina. We are currently working with GP Pharm
on the commercial launch of Ampligen in Argentina. Commercialization in Argentina will require, among other things, GP Pharm to establish
disease awareness, medical education, creation of an appropriate reimbursement level, design of marketing strategies and completion of
manufacturing preparations for launch and ANMAT conducting a final inspection of the product and release tests before granting final
approval to begin commercial sales. AIM has supplied GP Pharm with the Ampligen required for testing and ANMAT release. This testing
and approval process is ongoing due to ANMAT&#8217;s internal processes. Once final approval by ANMAT is obtained, GP Pharm will begin
distributing Ampligen in Argentina. We continue to pursue our Ampligen NDA, for the treatment of CFS with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has authorized an open-label expanded access treatment protocol (AMP-511) allowing patient access to Ampligen in a study under which
severely debilitated CFS patients have the opportunity to be on Ampligen to treat this serious and chronic condition. The AMP-511 protocol
started in the 1990s and is ongoing. The data collected from the AMP-511 protocol through clinical sites provide safety information regarding
the use of Ampligen in patients with CFS. We are establishing an enlarged database of clinical safety information which we believe will
provide further documentation regarding the absence of autoimmune disease associated with Ampligen treatment. We believe that continued
efforts to understand existing data, and to advance the development of new data and information, will ultimately support our future filings
for Ampligen and/or the design of future clinical studies that the FDA requested in a CRL. The FDA approved an increased reimbursement
level from $200 to $345 per 200 mg vial of Ampligen, due to increased production costs; which was re-authorized in 2021 and again in
2022. At this time, we do not plan on passing this adjustment along to the patients in this program. In October 2020, we received IRB
approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include patients previously diagnosed
with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms that we refer to as Post-COVID
conditions. As of December 31, 2023, there are 10 patients enrolled in this open-label expanded access treatment protocol. In July 2022,
AIM reported positive preliminary results based on data from the first four Post-COVID Condition patients enrolled in the study. The
data show that, by week 12, compared to baseline, the investigators observed what they considered a clinically significant decrease in
fatigue-related measures. To date, there have been eight such Post-COVID patients treated in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year agreement with myTomorrows, a Netherlands based company, for the commencement and management of
an Early Access Program (&#8220;EAP&#8221;) in Europe and Turkey related to ME/CFS. Pursuant to the agreement, as amended, myTomorrows
also is managing all Early Access Programs and Special Access Programs in Europe, Canada, and Turkey to treat pancreatic cancer and ME/CFS
patients. The agreement was automatically extended for a period of 12 months on May 20, 2021; has been automatically extended for 12
months on each subsequent May 20; and will continue to be automatically extended for periods of 12 months every May 20 until terminated
or the terms of the agreement are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, Ampligen was cited as outperforming two other TLR3 agonists &#8212; poly IC and natural double stranded RNA &#8212; in creating
an enhanced tumor microenvironment for checkpoint blockade therapy in the journal of Cancer Research (http://cancerres.aacrjournals.org/content/early/2018/05/31/0008-5472.CAN-17-3985).
In a head-to-head study in explant culture models, Ampligen activated the TLR3 pathway and promoted an accumulation of killer T cells
but, unlike the other two TLR3 agonists, it did so without causing regulatory T cell (Treg) attraction. These findings were considered
important because they indicate that Ampligen selectively reprograms the tumor microenvironment by inducing the beneficial aspects of
tumor inflammation (attracting killer T cells), without amplifying immune-suppressive elements such as regulatory T cells. The study
was conducted at the University of Pittsburgh and Roswell Park as a part of the NIH-funded P01 CA132714 and Ovarian Cancer Specialized
Program of Research Excellence (&#8220;SPORE&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, we completed production of two commercial-size batches of more than 16,000 vials of Ampligen, following its &#8220;Fill &amp; Finish&#8221;
at Jubilant HollisterStier, the Contract Manufacturing Organization. These lots passed all required testing for regulatory release for
human use and are being used for multiple programs, including: the treatment of ME/CFS; the pancreatic cancer EAP in the Netherlands;
and will continue to be used for ongoing and future clinical studies in oncology. Additionally, two lots of Ampligen were manufactured
in December 2019 and January 2020 at Jubilant HollisterStier and we recently issued a purchase order for a total of $1,432,257 to manufacture
additional lots of Ampligen at Jubilant. The current manufactured lots of Ampligen have been fully tested and released for commercial
product launch in Argentina and for clinical trials. Additionally, in December 2020, we added Pii as a &#8220;Fill &amp; Finish&#8221;
provider to enhance our capacity to produce Ampligen. This addition amplifies our manufacturing capability by providing redundancy and
cost savings. The contracts augment our active and in-process fill and finish capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alferon
N Injection&#174;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alferon
N Injection is the registered trademark for our injectable formulation of natural alpha interferon. Alferon N Injection is the only natural-source,
multi-species alpha interferon currently approved for sale in the United States and Argentina for the intralesional (within lesions)
treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Alferon
N Injection is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant
interferons. Certain types of human papilloma viruses (&#8220;HPV&#8221;) cause genital warts, a sexually transmitted disease (&#8220;STD&#8221;).
According to the CDC, HPV is the most common sexually transmitted infection, with approximately 79 million Americans &#8212; most in
their late teens and early 20s &#8212; infected with HPV. In fact, the CDC states that &#8220;HPV is so common that nearly all sexually
active men and women get the virus at some point in their lives.&#8221; Although they do not usually result in death, genital warts commonly
recur, causing significant morbidity and entail substantial health care costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interferons
are a group of proteins produced and secreted by cells to combat diseases. Researchers have identified four major classes of human interferon:
alpha, beta, gamma and omega. Alferon N Injection contains a multi-species form of alpha interferon. The worldwide market for injectable
alpha interferon-based products has experienced rapid growth and various alpha interferon injectable products are approved for many major
medical uses worldwide. Alpha interferons are manufactured commercially in three ways: by genetic engineering, by cell culture, and from
human white blood cells. All three of these types of alpha interferon are or were approved for commercial sale in the United States.
Our natural alpha interferon is produced from human white blood cells. The potential advantages of natural alpha interferon over recombinant
(i.e., synthetic) interferon produced and marketed by other pharmaceutical firms may be based upon their respective molecular compositions.
Natural alpha interferon is composed of a family of proteins containing many molecular species of interferon. In contrast, commercial
recombinant alpha interferon products each contain only a single species. Researchers have reported that the various species of interferons
may have differing antiviral activity depending upon the type of virus. Natural alpha interferon presents a broad complement of species,
which we believe may account for its higher activity in laboratory studies. Natural alpha interferon is also glycosylated (i.e., partially
covered with sugar molecules). Such glycosylation is not present on the currently U.S.-marketed recombinant alpha interferons. We believe
that the absence of glycosylation may be in part responsible for the production of interferon-neutralizing antibodies seen in patients
treated with recombinant alpha interferon. Although cell culture-derived interferon is also composed of multiple glycosylated alpha interferon
species, the types and relative quantity of these species are different from our natural alpha interferon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alferon
N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon
product. There are essentially no neutralizing antibodies observed against Alferon N Injection to date and the product has a relatively
low side-effect profile. The recombinant DNA derived alpha interferon formulations have been reported to have decreased effectiveness
after one year of treatment, probably due to neutralizing antibody formation (See &#8220;Manufacturing&#8221; and &#8220;Marketing/Distribution&#8221;
sections below for more details on the manufacture and marketing/distribution of Alferon N Injection). The production of new Alferon
N Injection Active Pharmaceutical Ingredient, or API, is currently on hold. We do not know when, if ever, our products will be generally
available for commercial sale for any indication. Additionally, on May 9, 2023, we were granted a U.S. Patent for a method for preventing
or reducing antigenic drift or viral reassortment in a host animal comprising determining if a host animal has been exposed to or infected
by an avian influenza virus and administering to the exposed host animal alpha-interferon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">PATENTS
AND NON-PATENT EXCLUSIVITY RIGHTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider patent exclusivity as a crucial component of our business. As of December 31, 2023, we had 54 patents worldwide with 66 additional
pending patent applications comprising our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continually review our patents to determine if they have continuing value. Please see &#8220;Note 4: Patents, and Trademark Rights, Net&#8221;
under Notes to the Consolidated Financial Statements for more information on these patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no current patent litigation proceedings involving us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orphan
drug designation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Orphan drug designation qualifies sponsors for incentives including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits for qualified clinical trials</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from user fees</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    seven years of market exclusivity after FDA approval</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received Orphan Drug Designation (ODD) from the FDA for Ampligen used in the treatment of Chronic Fatigue Syndrome, HIV, Metastatic
Melanoma, Renal Cell Carcinoma, Pancreatic Adenocarcinoma and Ebola Virus Disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, ODD carries ten years of market exclusivity after receiving marketing authorization. We have received ODD from the
EU for Ampligen used in the treatment of Ebola Virus Disease and Pancreatic Adenocarcinoma and for Alferon used in the treatment of Middle
East Respiratory Syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">RESEARCH
AND DEVELOPMENT (&#8220;R&amp;D&#8221;)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general focus during the past several fiscal years has been on expanding the market potential of Ampligen through investigation of efficacy
(in vitro and in vivo) in different immune-based disorders including cancer and CFS. We also have focused on research and development
of potential prophylactic and therapeutic applications for the treatment of COVID-19, including the long-term effects of COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Immuno-Oncology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential of Ampligen as an immuno-oncology therapeutic has been a major focus of AIM since our current leadership took over in 2016.
We have been working with the University of Pittsburgh&#8217;s chemokine modulation research initiative, which includes the use of Ampligen
as a potential adjuvant to modify the tumor microenvironment (&#8220;TME&#8221;) with the goal of increasing anti-tumor responses to
check point inhibitors (&#8220;CPI&#8221;). As part of this collaboration, we have supplied Ampligen to the University. The study, under
the leadership of Robert P. Edwards, MD, chair of gynecologic services at Magee-Women&#8217;s Hospital of the University of Pittsburgh
School of Medicine, and Professor of Surgery Pawel Kalinski, M.D., Ph.D., at Roswell Park, Buffalo, N.Y., involved the chemokine modulatory
regimen developed by Dr. Kalinski&#8217;s group and successfully completed the Phase 1 dose escalation in patients with resectable colorectal
cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
Ampligen clinical trials are underway or recently completed at major university cancer centers testing whether tumor microenvironments
can be reprogrammed to increase the effectiveness of cancer immunotherapy, including checkpoint inhibitors. The underway trials include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pancreatic
                                            Cancer Trial</b> - The Phase 2 AMP-270 clinical trial is a randomized, open-label, controlled,
                                            parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus
                                            a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic
                                            adenocarcinoma. Secondary objectives include comparing safety and tolerability. The AMP-270
                                            is expected to enroll approximately 90 subjects in up to 30 centers across the U.S. and Europe.
                                            In March 2022, the FDA granted clearance to proceed with the study. In April 2022, we executed
                                            a work order with Amarex to manage the clinical trial. In August 2022, we received IRB approval
                                            of the trial protocol and so announced the trial&#8217;s commencement. The authorization
                                            to proceed with the Phase 2 pancreatic cancer clinical trial has been received with potential
                                            sites in the Netherlands at Erasmus MC under Prof. C.H.J. van Eijck, and also at major cancer
                                            research centers in the United States such as The Buffett Cancer Center at the University
                                            of Nebraska Medical Center (UNMC). The study is recruiting patients. (https://clinicaltrials.gov/ct2/show/NCT05494697).</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advanced
    Recurrent Ovarian Cancer</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9675;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
    of the Phase 1 portion of a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer were published
    in the American Association for Cancer Research publication, Clinical Cancer Research (Clin Cancer Res January 19, 2022 DOI: 10.1158/1078-0432.CCR-21-3659).
    The study results represent an important extension of prior studies using human tumor explants that showed Ampligen&#8217;s potentially
    important role as a TLR3 agonist acting synergistically with high-dose IFN&#945; and celecoxib to selectively enhance Teff cell-attractants
    while suppressing Treg-attractants in the tumor microenvironment with a concomitant increase in the Teff/Treg ratio. The importance
    of boosting the Teff/Treg ratio in the tumor microenvironment is that it is associated with the conversion of &#8216;cold&#8217;
    tumors into &#8216;hot&#8217; tumors, which have an increased sensitivity to chemo-immunotherapy and an improved chance of showing
    tumor regression. The Phase 1 portion was designed to establish intraperitoneal safety. The Phase 2 portion of the study is planned
    to be conducted in the future. <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT02432378</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9675;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    Phase 2 study of advanced recurrent ovarian cancer using cisplatin, pembrolizumab, plus Ampligen; up to 45 patients to be enrolled;
    enrollment has commenced, and numerous patients have commenced treatment. <span style="text-decoration: underline">We announced interim data from the study</span> demonstrating
    that evidence of increased biomarkers associated with T cell chemotaxis and cytolytic function was seen when combining Ampligen,
    pembrolizumab and cisplatin. Increases of these biomarkers in the tumor microenvironment have been correlated with favorable tumor
    responses. Interim results announced March 2022 detailed an observed clinical response rate of 61% includes two complete and three
    partial tumor responses, plus three patients with stable disease among the 13 evaluable patients. An important priority will be to
    confirm these findings through continuing to enroll patients onto this study. <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT03734692</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, we were granted a patent by the Netherlands Patent Office with granted patent claims that include, but are not limited to,
the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors (e.g. pembrolizumab, nivolumab). Interim data
from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial demonstrated that evidence of increased biomarkers associated
with T cell chemotaxis and cytolytic function was seen when combining Ampligen, pembrolizumab and cisplatin. It is critical to note that
increases of these biomarkers in the tumor microenvironment have been correlated with favorable tumor responses. All told, the study
has seen an Objective Response Rate (ORR) of 38.5%; <span style="text-decoration: underline">a study of pembrolizumab alone in the treatment of advanced recurrent ovarian
cancer</span> found ORR of 8.1% and 9.9% across two cohorts. We believe that the positive data makes this patent have heightened potential.
Similar patents are pending in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stage
    4 Metastatic Triple Negative Breast Cancer</b> - Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation
    therapy, including Ampligen and pembrolizumab. Eight patients were enrolled and 6 patients were evaluable. <span style="text-decoration: underline">https://www.clinicaltrials.gov/ct2/show/NCT03599453</span>.
    The key findings announced in April 2022 included:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pre-determined primary endpoint of efficacy was met (increase in CD8 in TME).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uniform
    increase of immune markers upon treatment was observed: CD8 mRNA (6.1-fold; p-0.034), GZMB mRNA (3.5-fold; p=0.058), ratios of CD8
    /FOXP3 and GZMB/FOXP3 (5.7-fold; p=0.036, and 7.6-fold; p=0.024 respectively), thus successfully meeting the pre-determined primary
    endpoint in the study (increase in CD8 in TME).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, an increase in CTL attractants CXCL10 (2.6-fold; p=0.104) and CCL5 (3.3-fold; p=0.019) was observed. In contrast, Treg
    marker FOXP3 or Treg attractants CCL22 or CXCL12 were not enhanced.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    patients had stable disease lasting 2.4, 2.5 and 3.8 months, as of data cut off September 1, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    additional patient (non-evaluable) had a partial response (breast tumor autoamputation) with massive tumor necrosis in the post-CKM
    biopsy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stage
    4 Colorectal Cancer Metastatic to the Liver</b> - Phase 2a study of Ampligen as a component of chemokine modulatory regimen on colorectal
    cancer metastatic to liver; recruitment has been completed; 19 patients were enrolled and 12 patients were evaluable for the primary
    endpoint <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT03403634</span>. The key findings announced in April 2022 included:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    study&#8217;s primary endpoint was met, evidenced by increased CD8a expression post-treatment (p=0.046).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saw
    increase in the CD8a/CD4 (p=0.03), CD8a/FOXP3 (p&lt;0.01) and GZMB/FOXP3 (p&lt;0.01) ratios.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    expression of CTL-attracting chemokines CCL5 (p=0.08), CXCL9 (p=0.05), and CXCL10 (p=0.06) were increased, while expression of the
    Treg/MDSC attractant CXCL12 (p=0.07) was decreased post-treatment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
    OS was 10.5 (90% CI 2.2-15.2) months, and the median PFS was 1.5 (90% CI 1.4, 1.8) months.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </span>&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    tumor responses were seen. The treatment was well tolerated. Of all enrolled patients (N=19), adverse events were noted in 74% of
    patients, with the most common being fatigue (58%). Grade 3 or higher adverse events were rare (5%).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Early-Stage
    Prostate Cancer</b> - Phase 2 study investigating the effectiveness and safety of aspirin and Ampligen with or without interferon-alpha
    2b (Intron A) compared to no drug treatments in a randomized three-arm study of patients with prostate cancer before undergoing radical
    prostatectomy. Patient enrollment has been initiated in this study designed for up to 45 patients. The study is temporarily suspended
    due to the Merck discontinuation of Intron-A production. Roswell Park has had a Type-C meeting with the FDA and is currently performing
    the necessary experiments to replace Intron-A with a generic alpha-interferon. We expect this trial to resume in the near future.
    <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT03899987</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Early-Stage
    Triple Negative Breast Cancer</b> - The objective of this Phase 1 study is to evaluate the safety and tolerability of a combination
    of Ampligen, celecoxib with or without Intron A, when given along with chemotherapy in patients with early-stage triple negative
    breast cancer. <span style="background-color: white">The now completed (as of September 2022) topline results from the study confirm
    the positive findings that were previously presented at the <span style="text-decoration: underline">2022 Society for Immunotherapy of Cancer (SITC) 37</span></span><span style="text-decoration: underline"><sup>th
    </sup><span style="background-color: white">Annual Meeting</span></span><span style="background-color: white"> in a poster presentation
    titled </span><i>Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using
    chemokine-modulating regimen (rintatolimod, IFN-&#945;2b, celecoxib)</i><span style="background-color: white"><span style="text-decoration: underline">.</span></span> The
    primary endpoint of the study was safety and tolerability. The results demonstrated that treatment was well-tolerated with mostly
    grade 1 or 2 treatment-related adverse events (TRAEs) without dose-limiting toxicities (DLTs) or delayed or immune-related toxicities.
    DLT was defined as grade 3 or higher toxicities within the first 3 weeks. Secondary endpoints included pCR rate where 5/9 (56%) of
    patients attained pCR and 1 more patient attained ypTmic. Tumor and blood biomarkers were also analyzed in exploratory studies.<span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT04081389</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Refractory
    Melanoma</b> &#8212; Roswell Park Comprehensive Cancer Center (&#8220;Roswell Park&#8221;), in a clinical trial fully funded by the
    National Cancer Institute (NCI), has commenced patient enrollment in its Phase 2 study in subjects with primary PD-1/PD-L1 resistant
    melanoma. The Phase 2 study will evaluate type-1 polarized dendritic cell (&#945;DC1) vaccine in combination with tumor-selective
    chemokine modulation (&#8220;CKM&#8221;) comprised of Interferon alpha 2b, Ampligen (rintatolimod) and Celecoxib. Up to 24 patients
    are to be enrolled. The study was temporarily suspended due to the Merck discontinuation of Intron-A production but has since resumed
    recruitment (See: <span style="text-decoration: underline">https://www.clinicaltrials.gov/show/NCT04093323</span>).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metastatic
    or Unresectable Triple Negative Breast Cancer &#8211; </b>This phase &#189;a trial tests the safety, side effects, and best dose
    of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the
    treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places
    in the body (metastatic) or that cannot be removed by surgery (unresectable). The study is recruiting subjects.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">https://clinicaltrials.gov/study/NCT05756166</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Progress and Analysis Related to Pancreatic Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the EAP established under our agreement with myTomorrows to enable access of Ampligen to ME/CFS patients was extended to
pancreatic cancer patients beginning in the Netherlands. myTomorrows is our exclusive service provider in Europe and Turkey and will
manage all EAP activities relating to the pancreatic cancer extension of the program. In February 2018, the agreement with myTomorrows
was extended to cover Canada to treat pancreatic cancer patients, pending government approval. There have been no physician requests
to date that would cause the program to move forward with the approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">A total of 42 pancreatic cancer patients initially
received treatment with Ampligen immuno-oncology therapy under the EAP program at Erasmus MC in the Netherlands; that initial program
has since continued to expand and proceed with additional patients to be treated with Ampligen supervised by Prof. C.H.J. van Eijck, MD.
In March 2024, the team at Erasmus MC published a thorough data analysis in an article titled &#8220;<i>Rintatolimod in Advanced Pancreatic
Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses</i>&#8221; in the journal&#160;<i>Clinical Cancer
Research</i>. The positive clinical findings relate to changes in the tumor microenvironment after Ampligen use. We are working with our
Contract Research Organization, Amarex Clinical Research LLC, to seek FDA &#8220;fast-track.&#8221; We have applied for fast-track status;
have received denials to date; and are currently working through the FDA process to provide all the materials and information required
to achieve fast-track status.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, we entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under
the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled &#8220;Combining anti-PD-L1 immune
checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy
effect. DURIPANC Study,&#8221; in which it will use study drugs provided by both AstraZeneca and us. In June 2023 we received the required
approvals from the Central Committee on Research Involving Human Subjects, which is the Competent Authority for the review of clinical
trials in the Netherlands, and the Medical Ethics Review Committee Erasmus MC, which is the governing ethics board. The study is open
and has dosed its first subject.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    December 2020, the FDA granted Ampligen Orphan Drug Designation status for the treatment of pancreatic cancer. The Orphan Drug Designation
    program provides orphan status to drugs and biologics which are defined as those intended for the treatment, prevention or diagnosis
    of a rare disease or condition, which is one that affects less than 200,000 persons in the United States or meets cost recovery provisions
    of the act. The status helps incentivize the treatment of therapies to treat unmet medical needs by providing a company with seven
    years of exclusivity rights once a drug reaches market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February 2021, our subsidiary, NV Hemispherx Biopharma Europe, received formal notification from the European Commission (&#8220;EC&#8221;)
    granting Orphan Medicinal Product Designation for Ampligen as a treatment for pancreatic cancer. Orphan products, once commercially
    approved in the European Union (&#8220;EU&#8221;), receive benefits including up to ten years of protection from market competition
    from similar medicines with similar active component and indication for use that are not shown to be clinically superior.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, Ampligen was featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal <span style="text-decoration: underline">Cancers
</span>as a potential treatment option for cancer patients who are infected with SARS-CoV-2. The study&#8217;s authors stated that Ampligen
has the potential to reduce the severity of the deadly respiratory disease COVID-19. According to laboratory data presented in the publication,
&#8220;Rintatolimod [Ampligen] activated the innate and the adaptive immune systems by activating a cascade of actions in human pancreatic
cancer cells&#8221;, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulation
    of interferon regulatory factors and activation of the interferon signaling pathway,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
    of immunomodulatory activity and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induction
    of the expression of MHC class I and II histocompatibility</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full journal article is titled: &#8220;<span style="text-decoration: underline">Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an
Anti-COVID-19 Opportunity in Cancer Patients?</span>&#8221; <i>Cancers</i> is a peer-reviewed, open access journal of oncology published
semimonthly online by MDPI. The study&#8217;s authors include Prof. C.H.J. van Eijck, MD, PhD, the lead investigator at Erasmus Medical
Center in the Netherlands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, we and Amarex submitted an IND application with the FDA for a planned Phase 2 study of Ampligen as a therapy for locally
advanced or metastatic late-stage pancreatic cancer. In December 2021, the FDA responded with a Clinical Hold on the proposed study.
We submitted our response to the FDA in February 2022. In March 2022, we received notification from the FDA that the Clinical Hold was
released and cleared, meaning that we are now able to proceed with the study specifically to treat locally advanced pancreatic cancer
patients. In August 2022, we received IRB approval of the trial protocol and so announced the trial&#8217;s commencement. The study is
recruiting patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
data was published in March 2022 in a manuscript titled, &#8220;<span style="text-decoration: underline">Rintatolimod (Ampligen&#174;) enhances numbers of peripheral B cells
and is associated with longer survival in patients with locally advanced and metastasized pancreatic cancer pre-treated with FOLFIRINOX:
a single-center named patient program</span>,&#8221; in <i>Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer</i>.
In the single-center, named-patient program, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated
with Ampligen for 6 weeks, at 2 doses per week with 400 mg per infusion. The study found that Ampligen improved the median survival of
these patients. The study&#8217;s primary endpoints were the Systemic Immune-Inflammation Index (SIII), the Neutrophils to Lymphocyte
Ratio (NLR), and absolute counts of 18 different populations of circulating immune cells as measured by flow cytometry. Secondary endpoints
were progression-free survival (PFS) and overall survival (OS). The median overall survival in the Ampligen group was 19 months, compared
to a historical control group and subgroup (7.5 and 12.5, respectively) that did not receive Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in March 2022, we announced that study data evaluating the direct effects of Ampligen on human pancreatic ductal adenocarcinoma (PDAC)
cells was accepted for presentation at the 15th Annual International Hepato-Pancreato-Biliary Association World Congress in New York,
NY. For the study, three PDAC cell lines (CFPAC-1, MIAPaCa-2, and PANC-1) were treated with various concentrations of Ampligen and their
corresponding vehicle control. The proliferation and migration effects were examined using in-vitro assays and the molecular effect was
examined by targeted gene expression profiling. Additionally human PDAC samples were used to validate the expression of toll-like receptor
3 (TLR3) by immunohistochemistry. Results from the study demonstrated Ampligen decreased the proliferation and migration ability of CFPAC-1
cells. In addition, it decreased the proliferation of MIAPaCa-2 cells and the migration of PANC-1 cells. However, it did not have a dual
effect in MIAPaCa-2 and PANC-1 cells. Interestingly, TLR3 was highly expressed in CFPAC-1 cells, low expressed in MIAPaCa-2 and not expressed
in PANC-1. Gene expression analysis revealed the upregulation of interferon-related genes, chemokines, interleukins and cell cycle regulatory
genes. The heterogeneity of TLR3 expression was confirmed in human PDAC samples. Based on these results, treating pancreatic cancer with
Ampligen may have a direct anti-tumor effect in pancreatic cancer cells expressing TLR-3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ampligen
as a Potential Antiviral</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the SARS-CoV-1 outbreak in 2002-03, Ampligen exhibited excellent antiviral properties and protective survival effect in NIH-contracted
studies of SARS-CoV-1-infected mice, which is very similar to SARS-CoV-2, the novel virus that causes COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Barnard 2006 study (<span style="text-decoration: underline">https://journals.sagepub.com/doi/abs/10.1177/095632020601700505</span>) found that Ampligen reduced virus lung
    levels to below detectable limits.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Day 2009 study (<span style="text-decoration: underline">https://www.sciencedirect.com/science/article/pii/S0042682209005832</span>) found that, instead of 100% mortality,
    there was 100% protective survival using Ampligen.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compared key transcription regulatory sequences of SARS-CoV-1 to SARS-CoV-2 and found significant similarities, suggesting highly probable
extension of the antiviral effects of Ampligen in the earlier NIH-contracted SARS experiments to COVID-19. The SARS-CoV-2 virus &#8211;
which causes COVID-19 &#8211; shares important genomic and pathogenic similarities with SARS-CoV-1 (hence its name). Since Ampligen has
shown antiviral activity against more distantly related coronaviruses, there was a reasonable probability that the antiviral effects
of Ampligen against SARS-CoV-1 will likely extend to SARS-CoV-2, and as discussed below, recently, Ampligen has demonstrated ex vivo
antiviral activity against SARS-CoV-2. We believe that this creates a compelling case for clinical trials to evaluate Ampligen as a potential
tool in the fight against COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the late 2019 outbreak of SARS-CoV-2, we have been actively engaged in determining whether Ampligen could be an effective treatment for
this virus or could be part of a vaccine. We believe that Ampligen has the potential to be both an early-onset treatment for and prophylaxis
against SARS-CoV-2. We believe that prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects
against the new virus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2020, we filed three provisional patent applications related to Ampligen in our efforts toward joining the global health community
in the fight against the deadly coronavirus (See: https://aimimmuno.com/press-release/aim-immunotech-files-provisional-patent-application-for-the-use-of-ampligenr-as-a-potential-therapy-for-covid-19-induced-chronic-fatigue/).
Our three provisional patent applications include: 1) Ampligen as a therapy for the coronavirus; 2) Ampligen as part of a proposed intranasal
universal coronavirus vaccine that combines Ampligen with inactivated coronavirus, conveying immunity and cross-protection and; 3) a
high-volume manufacturing process for Ampligen. Under the Patent Cooperation Treaty of 1970, which provides international protections
for patents, these three provisional patent applications were converted into two international patent applications based on the date
of their filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we contracted Amarex to act as our Clinical Research Organization and provide regulatory support with regard to a possible
clinical trial testing Ampligen&#8217;s potential as a COVID-19 prophylaxis via intranasal delivery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in April 2020, we entered into confidentiality and non-disclosure agreements with numerous companies for the potential outsourcing of
the production of polymer, enzyme, placebo as well as Ampligen, and one Contract Research Organization, Amarex, which will provide regulatory
and monitoring support related to a clinical trial testing Ampligen&#8217;s intranasal safety and potential as a COVID-19 prophylaxis
via intranasal delivery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the FDA authorized an IND for Roswell Park to conduct a Phase 1/2a study of a regimen of Ampligen and interferon alpha in cancer
patients with COVID-19 infections. This clinical trial, sponsored by Roswell Park in collaboration with us, will test the safety of this
combination regimen in patients with cancer and COVID-19, and the extent to which this therapy will promote clearance of the SARS-CoV-2
virus from the upper airway. Several subjects have been treated. It is planned that the phase 1/2a study will enroll up to 44 patients
in two stages. Phase 1 will see 12-24 patients receiving both Ampligen and interferon alpha-2b at escalating doses. Once that initial
phase is complete, further study participants will be randomized to two arms: one receiving the two-drug combination and a control group
who will not receive Ampligen or interferon alpha but will receive best available care. We are a financial sponsor of the study and will
provide Ampligen at no charge for this study. In November 2020, the first patient in the study had been enrolled and treated. This study
was amended to add 20 patients, with 10 randomized to receive a single dose of Ampligen and 10 patients to receive current best therapies.
(See <span style="text-decoration: underline">clinicaltrials.gov/NCT04379518</span>). Due to a shortage of qualifying subjects with COVID-19 and cancer as a result of the positive
impact of vaccinations and treatments for COVID-19, Roswell is seeking approval to expand the qualifying subject criteria to include
other diseases lethal to immuno-compromised cancer patients, such as influenza. Accordingly, the study is temporarily suspended while
seeking said approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also entered into a specialized services agreement with Utah State University and have supplied Ampligen to support the University&#8217;s
Institute for Viral Research in its research into SARS-CoV-2. The Utah State results show that Ampligen was able to decrease SARS-CoV-2
infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we received IRB approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include
patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic fatigue-like symptoms. Patients in the trial are treated
with our flagship pipeline drug Ampligen. In January 2021, we commenced with the treatment of the first previously diagnosed COVID-19
patient with long-COVID symptoms (i.e., Long Hauler) also known as Post-COVID Conditions in the AMP-511 study. Enrollment of post-COVID
patients continues in the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, we entered into a Sponsor Agreement with CHDR to manage a Phase 1 randomized, double-blind study to evaluate the safety
and activity of repeated intranasal administration of Ampligen. AIM funded and sponsored the study. This study was designed to assess
the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. A total of 40 healthy subjects
received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum
level of 1,250 micrograms. The study was completed, and the Final Safety Report reported no Serious or Severe Adverse Events at any dosage
level. We believe that the trial is a critical step in our ongoing efforts to develop Ampligen as a potential prophylaxis or treatment
for COVID-19 and other respiratory viral diseases. Amarex provided us with monitoring support during the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we filed two COVID-19-related provisional patent applications in the third quarter of 2021. In August, we filed an application for Ampligen
as both an intranasal and an intravenous therapy for what we describe as Post-COVID conditions. The people suffering from Post-COVID
conditions, including some young adults, can be afflicted with severe difficulties in concentrating; serious memory problems; and the
inability to live an active lifestyle, to work and even to perform everyday tasks. Early data has demonstrated that patients with symptoms
of Post-COVID conditions being treated with Ampligen in the ongoing AMP-511 Expanded Access Program have reported improvements in fatigue
symptoms. Similarly, in ME/CFS, data supports the claim that Ampligen improves fatigue symptoms. Then in September 2022, we filed a patent
application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope
spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses
and SARS-CoV-2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to securing these two provisional patent applications, we also moved forward with proposed studies in these areas and with Pre-Investigational
New Drug Applications in September 2021. One pre-IND was for a Phase 2, two-arm, randomized, double-blind, placebo-controlled, multicenter
study to evaluate the efficacy and safety of Ampligen in patients experiencing Post-COVID conditions (originally referred to as Post-COVID
Cognitive Dysfunction (PCCD) and has been revised to Post-COVID conditions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ampligen
as a Treatment for Post-COVID Conditions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen&#174; as a potential therapeutic for people
with post-COVID conditions (&#8220;AMP-518&#8221;). We announced in August 2023 that the study had met the planned enrollment of 80 subjects
ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with
a follow-up phase of two weeks. All patients have completed the study and topline data was reported in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 9, 2023, we were granted a U.S. Patent for a method for preventing or reducing antigenic drift or viral reassortment in a host animal
comprising determining if a host animal has been exposed to or infected by an avian influenza virus and administering to the exposed
host animal alpha-interferon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), also known as Chronic Fatigue Immune Dysfunction Syndrome (&#8220;CFIDS&#8221;)
and Chronic Fatigue Syndrome (CFS), is a serious and debilitating chronic illness and a major public health problem. ME/CFS is recognized
by both the government and private sector as a significant unmet medical need, including the U.S. National Institutes of Health (&#8220;NIH&#8221;),
FDA and the CDC. The CDC states on its website at <span style="text-decoration: underline">https://www.cdc.gov/me-cfs/</span> that &#8220;<i>Myalgic encephalomyelitis/chronic
fatigue syndrome (ME/CFS) is a serious, long-term illness that affects many body systems. People with ME/CFS are often not able to do
their usual activities. At times, ME/CFS may confine them to bed. People with ME/CFS have severe fatigue and sleep problems. ME/CFS may
get worse after people with the illness try to do as much as they want or need to do. This symptom is called post-exertional malaise
(PEM). Other symptoms can include problems with thinking and concentrating, pain, and dizziness.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
severe ME/CFS patients become completely disabled or totally bedridden and are afflicted with severe pain and mental confusion even at
rest. ME/CFS is characterized by incapacitating fatigue with profound exhaustion and extremely poor stamina, sleep difficulties and problems
with concentration and short-term memory. It is also accompanied by flu-like symptoms, pain in the joints and muscles, tender lymph nodes,
sore throat and new headaches. A distinctive characteristic of the illness is a worsening of symptoms following physical or mental exertion,
which do not subside with rest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
high number of younger people being hospitalized for COVID-19 suggests considerable numbers of people in the prime of their lives may
have a COVID-induced ME/CFS-like illness in their future. According to a 2016 journal article, the estimated annual cost of lost productivity
related to ME/CFS was $9-37 billion in the United States, and for direct medical costs it was $9-14 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
June of 2020, we filed a provisional patent application for, among other discoveries, the use of Ampligen as a potential early-onset
therapy for the treatment of COVID-19 induced chronic fatigue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
survivors of the first SARS-CoV-1 epidemic in 2003 continued to report chronic fatigue, difficulty sleeping and shortness of breath months
after recovering from the acute illness. &#8220;After one year, 17% of patients had not returned to work and 9% more had not returned
to their pre-SARS work levels,&#8221; according to Simmaron Research. Now there is increasing evidence that patients with COVID-19 can
develop a similar, ME/CFS-like illness. These patients are commonly referred to as &#8220;Long Haulers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we received IRB approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include
patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms.
For more information on our AMP-511 Expanded Access Program, please see &#8220;<i>OUR PRODUCTS: Ampligen</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, we announced the publication of statistically significant data detailing how Ampligen could have a considerable positive
impact on people living with ME/CFS when administered in the early stages of the disease. The data were published in <i>PLOS ONE</i>,
a peer-reviewed open access scientific journal published by the Public Library of Science. AIM researchers found that the TLR3 agonist
Ampligen substantially improved physical performance in a subset of ME/CFS patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above in <i>Overview; General; Ampligen as a treatment for ME/CFS</i>, we have long been focused on seeking the FDA&#8217;s approval
for the use of Ampligen to treat ME/CFS. In fact, in February 2013, we received a CRL from the FDA for our Ampligen NDA for ME/CFS, stating
that we should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
developing a comprehensive response to the FDA and a plan for a confirmatory trial for the FDA NDA, we proceeded independently in Argentina
and, in August 2016, we received approval of an NDA from ANMAT for commercial sale of Ampligen in the Argentine Republic for the treatment
of severe CFS. In September 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent
sales. On June 10, 2020, we received import clearance from ANMAT to import the first shipment of commercial grade vials of Ampligen into
Argentina. The next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release
tests before granting final approval to begin commercial sales. This testing and approval process is currently delayed due to ANMAT&#8217;s
internal processes. Once final approval by ANMAT is obtained, GP Pharm will begin distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on a comprehensive follow through with the FDA regarding the use of Ampligen as a treatment for ME/CFS. We have learned a great
deal since the FDA&#8217;s CRL and plan to adjust our approach to concentrate on specific ME/CFS symptoms. Responses to the CRL and a
proposed confirmatory trial are being worked on now by our R&amp;D team and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Diseases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the EMA has approved the Orphan Medicinal Products Designation for Ampligen as a potential treatment of Ebola virus disease and
for Alferon N Injection as a potential treatment of MERS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concluded our series of collaborations designed to determine the potential effectiveness of Ampligen and Alferon N Injection as potential
preventive and/or therapeutic treatments for Ebola-related disorders. Although we believe that the threat of both MERS and Ebola globally
may reemerge in the future, it appears that the spread of these disorders has diminished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, we entered into an MTA with the University of Cagliari Dipartimento di Scienze della Vita e dell&#8217;Ambiente (&#8220;UNICA&#8221;),
an educational institution, under the laws of Italy, located in Monserrato (Cagliari), Italy. The MTA relates to the research and development
of the effects of Ampligen and its ability to induce interferon production in several cell lines, and also on the ability of the Ebola
virus protein VP35 to bind to viral dsRNA and impede interferon&#8217;s upregulation and activity, and on Ampligen&#8217;s ability to
reverse VP35 inhibition of interferon production in biological systems. The data analysis was published in the peer-reviewed journal
<i>Antiviral Research</i>, in a manuscript titled &#8220;Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3
agonist rintatolimod and its mechanism of action.&#8221; We believe that the analysis supports a dual mechanism of action when Ampligen
is used as a prophylactic therapy against Ebola Virus Disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, we filed a U.S. Provisional Patent Application for Ampligen as a potential therapeutic to possibly slow, halt, or reverse the
progression of Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we received notice that the FDA had granted Orphan Drug Designation to Ampligen for the treatment of Ebola virus disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MANUFACTURING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANMAT
in Argentina approved Ampligen for commercial distribution for the treatment of CFS in 2016. Shipment of the drug product to Argentina
was initiated in 2018 to complete the release testing by ANMAT needed for commercial distribution. In September 2019, we received clearance
from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. In June 2020, we received import clearance
from ANMAT to import the first shipment of commercial grade vials of Ampligen into Argentina. We are currently working with GP Pharm
on the commercial launch of Ampligen in Argentina (See &#8220;Our Products; Ampligen&#8221; above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our approval in Argentina, in 2017 we engaged Jubilant HollisterStier (&#8220;Jubilant&#8221;) to be our authorized CMO for Ampligen.
Two lots of Ampligen consisting of more than 16,000 units were manufactured and released in 2018; these lots have been designated for
human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The production of additional
polymer (Ampligen intermediates) took place in 2019 at our New Brunswick facility. Additionally, Jubilant manufactured two more lots
of Ampligen in December 2019 and January 2020. The current manufactured lots of Ampligen have been fully tested and released for commercial
product launch in Argentina and for clinical trials. In addition, we have supplied GP Pharm with the Ampligen required for testing and
ANMAT release. Once final approval by ANMAT is obtained, we anticipate that GP Pharm will begin distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we added Pii as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce Ampligen. This addition
amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment our existing fill and finish capacity.
We are prepared to initiate the production of additional Ampligen when and if needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2022 we entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square-foot, state-of-the-art
R&amp;D facility at the New Jersey Bioscience Center (NJBC), primarily consisting of two separate laboratory suites. The lease commenced
on July 1, 2022, and runs through August 31, 2027, but can be extended for an additional five-year period. The facility is AIM&#8217;s
operations, research and development center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan calls for the utilization of one or more CMOs to produce Ampligen API. While we believe we have sufficient Ampligen API
to meet our current needs, we are also continually exploring new efficiencies so as to maximize our ability to fulfill future obligations.
In this regard, on December 5, 2022, we entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions
(&#8220;Sterling&#8221;) for the manufacture of our Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. We are utilizing Sterling&#8217;s expertise to
refine our approach to polymer production. While we believe we have sufficient Ampligen API to meet current needs, we are also continually
exploring new efficiencies in order to maximize its ability to fulfill future obligations. In March 2023, we submitted a work order for
a total of $1,432,257 to manufacture additional lots of Ampligen at Jubilant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product, Alferon N Injection, is approved by the FDA for commercial sales in the United States for the treatment of genital warts.
It is also approved by ANMAT in Argentina for commercial sales for the treatment of genital warts and in patients who are refractory
to treatment with recombinant interferons. Commercial sales of Alferon N Injection in the United States will not resume until new batches
of commercial filled and finished product are produced and released by the FDA. We will need the FDA&#8217;s approval to release commercial
product once we have identified our new manufacturing approach and submitted satisfactory stability and quality release data. Currently,
we are not manufacturing Alferon N Injection and there is no definitive timetable to resume production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="text-decoration: underline">Licensing/Collaborations/Joint
Ventures</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enable potential availability of Ampligen to patients on a worldwide basis, we have embarked on a strategy to license the product and/or
to collaborate and/or create a joint venture with companies that have the demonstrated capabilities and commitment to successfully gain
approval and commercialize Ampligen in their respective global territories of the world. Ideal partners would have the following characteristics:
well-established global and regional experience and coverage; robust commercial infrastructure; a strong track record of successful development
and registration of in-licensed products; and a therapeutic area fit (e.g., ME/CFS, immuno-oncology).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MARKETING/DISTRIBUTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year exclusive Renewed Sales, Marketing, Distribution and Supply Agreement (the &#8220;Agreement&#8221;)
with GP Pharm. Under this Agreement, GP Pharm was responsible for gaining regulatory approval in Argentina for Ampligen to treat severe
CFS in Argentina and for commercializing Ampligen for this indication in Argentina. We granted GP Pharm the right to expand rights to
sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones. We
also granted GP Pharm an option to market Alferon N Injection in Argentina and other Latin America countries (See &#8220;Our Products;
Ampligen&#8221; above). The GP Pharm contract was extended in May 2021, and will now end on May 24, 2024. In August 2021, ANMAT granted
a five-year extension to a previous approval to sell and distribute Ampligen to treat severe CFS in Argentina. This extends the approval
until 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year agreement (the &#8220;Impatients Agreement&#8221;) with Impatients, N.V. (&#8220;myTomorrows&#8221;),
a Netherlands-based company, for the commencement and management of an EAP in Europe and Turkey (the &#8220;Territory&#8221;) related
to ME/CFS. Pursuant to the agreement, myTomorrows, as our exclusive service provider and distributor in the Territory, is performing
EAP activities. These activities will be directed to (a) the education of physicians and patients regarding the possibility of early
access to innovative medical treatments not yet the subject of a Marketing Authorization (regulatory approval) through named-patient
use, compassionate use, expanded access and hospital exemption, (b) patient and physician outreach related to a patient-physician platform,
(c) the securing of Early Access Approvals (exemptions and/or waivers required by regulatory authorities for medical treatments prior
to Marketing Authorization) for the use of such treatments, (d) the distribution and sale of such treatments pursuant to such Early Access
Approvals, (e) pharmacovigilance (drug safety) activities and/or (f) the collection of data such as patient-reported outcomes, doctor-reported
experiences and registry data. We are supporting these efforts and supplying Ampligen to myTomorrows at a predetermined transfer price.
In the event that we receive Marketing Authorization in any country in the Territory, we will pay myTomorrows a royalty on products sold.
Pursuant to the Impatients Agreement, the royalty would be a percentage of Net Sales (as defined in the Impatients Agreement) of Ampligen
sold in the Territory where Marketing Authorization was obtained. The formula to determine the percentage of Net Sales will be based
on the number of patients that are entered into the EAP. We believe that disclosure of the exact maximum royalty rate and royalty termination
date could cause competitive harm. However, to assist the public in gauging these terms, the actual maximum royalty rate is somewhere
between 2% and 10% and the royalty termination date is somewhere between five and fifteen years from the First Commercial Sale of a product
within a specific country. The parties established a Joint Steering Committee comprised of representatives of both parties to oversee
the EAP. No assurance can be given that activities under the EAP will result in Marketing Authorization or the sale of substantial amounts
of Ampligen in the Territory. The agreement was automatically extended for a period of 12 months on May 20, 2021; has been automatically
extended for 12 months on each subsequent May 20; and will continue to be automatically extended for periods of 12 months every May 20
until terminated or the terms of the agreement are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, ANMAT granted a five-year extension to a previous approval to sell and distribute Alferon N Injection (under the brand
name &#8220;Naturaferon&#8221;) in Argentina. This extended the approval until 2022. A request to extend the approval beyond 2022 has
been filed and is still under review. In February 2013, we received ANMAT approval for the treatment of refractory patients that failed
or were intolerant to treatment with recombinant interferon, with Naturaferon in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the EAP through our agreement with myTomorrows designed to enable access of Ampligen to ME/CFS patients was extended to
pancreatic cancer patients beginning in the Netherlands. myTomorrows is our exclusive service provider in the Territory and will manage
all EAP activities relating to the pancreatic cancer extension of the program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2017, we extended our agreement with Asembia LLC, formerly Armada Healthcare, LLC, to undertake the marketing, education and sales
of Alferon N Injection throughout the United States. This agreement has expired. We were in discussions with Asembia about the possibility
of continuing the relationship, while also exploring the possibility of working with other, similar companies. However, we still do not
foresee an immediate need for this service and continue to push this search further out in our expected timeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2018, we signed an amendment to the EAP with myTomorrows. This amendment extended the Territory to cover Canada to treat pancreatic
cancer patients, pending government approval. In March 2018, we signed an amendment to the EAP with myTomorrows, pursuant to which myTomorrows
will be our exclusive service provider for special access activities in Canada for the supply of Ampligen for the treatment of ME/CFS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen for the treatment of up to
16 pancreatic cancer patients. In November 2021, we entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen
for the treatment of up to an additional 5 pancreatic cancer patients. In March 2022, we entered into a signed Letter of Agreement with
myTomorrows for the delivery of Ampligen for the treatment of up to an additional 10 pancreatic cancer patients. In November 2022, we
entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen for the treatment of up to an additional 10 pancreatic
cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">COMPETITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
major pharmaceutical competitors for Ampligen include Pfizer, GlaxoSmithKline, Merck &amp; Co., Novartis and AstraZeneca. Biotech competitors
include Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">GOVERNMENT
REGULATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
by governmental authorities in the U.S. and foreign countries is and will be a significant factor in the manufacture and marketing of
our products and our ongoing research and product development activities. Ampligen and other products developed from the ongoing research
and product development activities will require regulatory clearances prior to commercialization. In particular, new drug products for
humans are subject to rigorous pre-clinical and clinical testing as a condition for clearance by the FDA and by similar authorities in
foreign countries. The process of seeking these approvals, and the ongoing process of compliance with applicable statutes and regulations,
has and will continue to require the expenditure of substantial resources. Any failure by us or our collaborators or licensees to obtain,
or any delay in obtaining, regulatory approvals could materially adversely affect the marketing of any products developed by us and our
ability to receive product or royalty revenue. We have received Orphan Drug designation for certain therapeutic indications, which we
believe might under certain conditions help to accelerate the process of drug development and commercialization. Alferon N Injection
is only approved for use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or
older. Use of Alferon N Injection for other applications requires regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions,
laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous
substances, including infectious disease agents, used in connection with our research work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about the current status of Alferon N Injection and Ampligen, please see &#8220;Our Products&#8221; above. See also,
&#8220;<i>Our drug and related technologies are investigational and subject to regulatory approval. If we are unable to obtain regulatory
approval in a timely manner, or at all, our operations will be materially harmed and our stock adversely affected</i>&#8221; in Part
II; Item 1A &#8220;Risk Factors&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">HUMAN
CAPITAL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had personnel consisting of 26 full-time employees and two part-time employees. Six of the combined personnel
are engaged in our research, development, clinical and manufacturing efforts, with 22 performing regulatory, general administration,
data processing, including bio-statistics, financial and investor relations functions. We have no union employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee
Engagement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business results depend in part on our ability to successfully manage our human capital resources, including attracting, identifying,
and retaining key talent. Factors that may affect our ability to attract and retain qualified employees include employee morale, our
reputation, competition from other employers, and availability of qualified individuals. We believe our commitment to our human capital
resources is an important component of our mission. We provide all employees with the opportunity to share their opinions in open dialogues
with our human resources department and senior management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Compensation,
Benefits and Wellness</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
offer fair, competitive compensation and benefits that support our employees&#8217; overall wellness. Further, the health and wellness
of our employees are critical to our success. While we have been successful in attracting skilled and experienced scientific personnel,
there can be no assurance that we will be able to attract or retain the necessary qualified employees and/or consultants in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="nd_003"></span>ITEM</b></span><b> 1A:</b></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Risk Factors</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following cautionary statements identify important factors that could cause our actual results to differ materially from those projected
in the forward-looking statements made in this Form 10-K. Please see &#8220;Special Note Regarding Forward Looking Statements and Summary
Risk Factors&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may require additional financing which may not be available.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our products requires the commitment of substantial resources to conduct the time-consuming research, preclinical
development, and clinical trials that are necessary to bring pharmaceutical products to market. As of December 31, 2023, we had
approximately $13,070,000 in cash and cash equivalents. At present we do not generate any material revenue from our operations, and
we do not anticipate doing so in the near future. We may need to obtain additional funding in the future for new studies and/or if
current studies do not yield positive results, require unanticipated changes and/or additional studies. In February 2022, the SEC
declared our universal shelf registration statement on Form S-3 effective. Pursuant to that registration statement, we can sell up
to $100 million of our securities and raise additional capital as needed in the future. Subsequent to the end of 2023, we raised
$2,500,000 in net proceeds from the sale of an unsecured Note and we have entered into an equity line agreement (see, <i>Part II; Item 7. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations and Part I; Item 1. Business; Atlas Equity Line of Credit</i>). No assurance can be given as to the amount of funds that could be
raised pursuant to this registration statement or the potential dilution to current stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to allocate capital to eventually commercialize and sell Ampligen and/or recommence sales of Alferon N Injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe, based on our current financial condition, that we have adequate funds to meet our anticipated operational cash needs and fund
current clinical trials over approximately the next twenty-four months. If our funds are not adequate, and we are subsequently unable
to obtain additional funding, through joint venturing, sales of securities and/or otherwise, our ability to develop our products, commercially
produce inventory or continue our operations may be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may continue to incur substantial losses and our future profitability is uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, our accumulated deficit was approximately $409,508,000. As with many biotechnology companies, we have not yet generated
significant revenues from our products and may incur substantial and increased losses in the future. We cannot assure that we will ever
achieve significant revenues from product sales or become profitable. We require, and will continue to require, the commitment of substantial
resources to develop our products. We cannot assure that our product development efforts will be successfully completed or that required
regulatory approvals will be obtained or that any products will be manufactured and marketed successfully or be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
drug and related technologies are investigational and subject to regulatory approval. If we are unable to obtain regulatory approval
in a timely manner, or at all, our operations will be materially harmed and our stock adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have received regulatory approval for the commercialization of Ampligen in Argentina (pending additional release testing and subsequent
steps), all of our drugs and associated technologies, other than Alferon N Injection, are investigational in the U.S. and must receive
prior regulatory approval by appropriate regulatory authorities for commercial distribution and sale and are currently legally available
only through clinical trials in the U.S. with specified disorders. At present, Alferon N Injection is approved for the intralesional
treatment of refractory or recurring external genital warts in patients 18 years of age or older. However, it is not at present available
for purchase on the market. Use of Alferon N Injection for other indications will require regulatory approval in the United States and
abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products, including Ampligen, are subject to extensive regulation by numerous governmental authorities in the U.S. and other countries,
including, but not limited to, the U.S. FDA, the Health Protection Branch (&#8220;HPB&#8221;) of Canada, the Agency for the European
Medicines Agency (&#8220;EMA&#8221;) in Europe; and the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (&#8220;ANMAT&#8221;)
in Argentina. Obtaining regulatory approvals is a rigorous and lengthy process and requires the expenditure of substantial resources.
In order to obtain final regulatory approval of a new drug, we must demonstrate to the satisfaction of the regulatory agency that the
product is safe and effective for its intended uses and that we are capable of manufacturing the product to the applicable regulatory
standards. We require regulatory approval in order to market Ampligen or any other proposed product and receive product revenues or royalties.
We cannot assure you that Ampligen will ultimately be demonstrated to be safe and efficacious. While Ampligen is authorized for use in
clinical trials in the U.S., we cannot assure you that additional clinical trial approvals will be authorized in the United States or
in other countries, in a timely fashion or at all, or that we will complete these clinical trials. In addition, although Ampligen has
been authorized by the FDA for treatment use under certain conditions, including provision for cost recovery, there can be no assurance
that such authorization will continue in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we received approval of our Argentinian NDA from ANMAT for commercial sale of rintatolimod (U.S. tradename: Ampligen) in the Argentine
Republic for the treatment of severe ME/CFS, ANMAT approval is only an initial, but important, step in the overall successful commercialization
of our product. In September 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent
sales. However, there are a number of additional actions that must occur before we would be able to commence commercial sales in Argentina.
For example, Ampligen is still in the process of release testing the product that has already been sent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s regulatory review and approval process is extensive, lengthy, expensive and inherently uncertain. To receive approval for
a product candidate, we must, among other things, demonstrate to the FDA&#8217;s satisfaction with substantial evidence from well-controlled
pre-clinical and clinical trials that the product candidate is both safe and effective for each indication for which approval is sought.
Before we can sell Ampligen for any use or promote Alferon N Injection for any use other than as Alferon N Injection for treatment of
refractory or recurring genital warts, we will need to file the appropriate NDA with the FDA in the U.S. and the appropriate regulatory
agency outside of the U.S. where we intend to market and sell such products. At present the only NDA we have filed with the FDA is the
NDA for the use of Ampligen to treat CFS. The FDA issued a Complete Response Letter (&#8220;CRL&#8221;) in February 2013 for this NDA
and provided recommendations to address certain outstanding issues before they could approve Ampligen for Commercial Sales. The Agency
stated that the submitted data do not provide substantial evidence of efficacy of Ampligen for the treatment of CFS and that the data
do not provide sufficient information to determine whether the product is safe for use in CFS due to the limited size of the safety database
and multiple discrepancies within the submitted data. The FDA indicated that we needed to conduct additional work. Therefore, ultimate
FDA approval, if any, may be delayed indefinitely and may require us to expend more resources than we have available. It is also possible
that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to
make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our future applications
for approval, which might significantly harm our business and prospects. As a result, we cannot predict if or when we might receive regulatory
approval for the use of Ampligen to treat CFS or for the use of any other products. Even if regulatory approval from the FDA is received
for the use of Ampligen to treat CFS or eventually, for the use of any other product, any approvals that we obtain could contain significant
limitations in the form of narrow indications, patient populations, warnings, precautions or contra-indications or other conditions of
use, or the requirement that we implement a risk evaluation and mitigation strategy. In such an event, our ability to generate revenues
from such products could be greatly reduced and our business could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to gain necessary FDA approvals related to Ampligen and Alferon N Injection on a timely basis, or we are unable to generate
the additional data, successfully complete inspections or obtain approvals as required by the FDA on a timely manner, or at all, or determine
that any of our clinical studies are not cost/justified to undertake or if, for that or any other reason, Ampligen, Alferon N Injection
or one of our other products or production processes do not receive necessary regulatory approval in the U.S. or elsewhere, our operations
most likely will be materially and/or adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
obtaining approval of an NDA by the FDA, or a comparable foreign regulatory authority, is inherently uncertain. Even after completing
clinical trials and other studies, a product candidate could fail to receive regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    be able to demonstrate to the satisfaction of the FDA that our product candidate is safe and effective for any indication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with the design or implementation of our clinical trials or other studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of the clinical trials or other studies may not demonstrate that a product candidate&#8217;s clinical and other benefits
    outweigh its safety risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may disagree with our interpretation of data from clinical trials or other studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials and other studies of a product candidate may not be sufficient to support the submission of an
    NDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA may significantly change in a manner rendering our clinical and other study data insufficient
    for approval; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA may not approve the proposed manufacturing processes and facilities for a product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
COVID-19 coronavirus or other global pandemics could adversely impact our business, including our clinical trials. We cannot predict
the ultimate effects of the COVID-19 virus on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic had and to a certain extent continues to have a major disruptive effect in the US and worldwide, including in countries
in which there are planned or active clinical trial sites studying Ampligen. The COVID-19 pandemic or a future major pandemic could severely
impact our business and clinical trials, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling patients in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
    sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees
    or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in issuing reports, results and publishing papers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which
    our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted elsewhere in this Report, progress of our commercial launch in Argentina has been delayed due to pandemic factors. The ongoing
impact of COVID-19 in Argentina is taxing the nation&#8217;s health care system and is, understandably, a main priority of its regulators.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are not able to estimate the effects of the COVID-19 outbreak or future pandemics, they may have a material adverse effect on our
results of future operations, financial position, and liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to product liability claims from the use of Ampligen, Alferon N Injection, or other of our products which could negatively
affect our future operations. We have limited product liability and clinical trial insurance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a limited amount of Products Liability and Clinical Trial insurance coverage worldwide for Ampligen and Alferon N Injection
due to the minimal amount of historical loss claims regarding these products in the marketplace. Any claims against our products, Ampligen
and Alferon N Injection, could have a materially adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent business risk of exposure to product liability claims in the event that the use of Ampligen, Alferon N Injection or
other of our products results in adverse effects. This liability might result from claims made directly by patients, hospitals, clinics
or other consumers, or by pharmaceutical companies or others manufacturing these products on our behalf. Our future operations may be
negatively affected from the litigation costs, settlement expenses and lost product sales inherent to these claims. While we will continue
to attempt to take appropriate precautions, we cannot assure that we will avoid significant product liability exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Uncertainty
of health care reimbursement for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize our products will depend, in part, on the extent to which reimbursement for the cost of such products
and related treatment will be available from government health administration authorities, private health coverage insurers and other
organizations. Significant uncertainty exists as to the reimbursement status of newly approved health care products, and from time to
time legislation is proposed, which, if adopted, could further restrict the prices charged by and/or amounts reimbursable to manufacturers
of pharmaceutical products. We cannot predict what, if any, legislation will ultimately be adopted or the impact of such legislation
on us. There can be no assurance that third party insurance companies will allow us to charge and receive payments for products sufficient
to realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are risks of liabilities associated with handling and disposing of hazardous materials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business involves the controlled use of hazardous materials, carcinogenic chemicals, and flammable solvents. Although we believe that
our safety procedures for handling and disposing of such materials comply in all material respects with the standards prescribed by applicable
regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such
an accident or the failure to comply with applicable regulations, we could be held liable for any damages that result. However, we have
obtained insurance coverage to mitigate any potential significant loss in this area.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely upon information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity
incidents, could harm our ability to operate our business effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations could be disrupted if our information systems fail, if we are unsuccessful in implementing necessary upgrades or if we are
subject to cyber-attacks. Our business depends on the efficient and uninterrupted operation of our computer and communications systems
and networks, hardware and software systems and our other information technology. We collect and maintain information, which includes
confidential and proprietary information, as well as personal information regarding our customers and employees, in digital form. Data
maintained in digital form is subject to risk of cyber-attacks, which are increasing in frequency and sophistication. Cyber-attacks could
include the deployment of harmful malware, viruses, worms, and other means to affect service reliability and threaten data confidentiality,
integrity and availability. Despite our efforts to monitor and safeguard our systems to prevent data compromise, the possibility of a
future data compromise cannot be eliminated entirely, and risks associated with intrusion, tampering, and theft remain. In addition,
we do not have insurance coverage with respect to system failures or cyber- attacks. A failure of our systems, or an inability to successfully
expand the capacity of these systems, or an inability to successfully integrate new technologies into our existing systems could have
a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our vendors&#8217; sophisticated information technology operations are spread across multiple, sometimes inconsistent, platforms,
which pose difficulties in maintaining data integrity across systems. The ever-increasing use and evolution of technology, including
cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction of confidential information
stored in our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse
of trade secrets, proprietary information or other confidential information, whether as a result of theft, hacking, fraud, trickery or
other forms of deception, or for any other cause, could enable others to produce competing products, use our proprietary technology or
information and/or adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential
information could result in financial, legal, business and reputational harm to our company and could have a material adverse effect
on our business, financial condition, results of operations, cash flows and stock price. Please see Part I; Item 1C &#8220;Cybersecurity&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
loss of services of key personnel could hurt our chances for success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success is dependent on the continued efforts of our staff, especially certain doctors and researchers. The loss of the services of personnel
key to our operations could have a material adverse effect on our operations and chances for success. The loss of key personnel or the
failure to recruit additional personnel as needed could have a materially adverse effect on our ability to achieve our objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GAAP
requires estimates, judgements and assumptions which inherently contain uncertainties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance
with GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions
could lead to a restatement of our results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements included in this Annual Report on Form 10-K are prepared in accordance with GAAP. This involves making estimates,
judgments and assumptions that affect reported amounts of assets (including intangible assets), liabilities, mezzanine equity, stockholders&#8217;
equity, operating revenues, costs of sales, operating expenses, other income, and other expenses. Estimates, judgments, and assumptions
are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to
a restatement. Any such changes could result in corresponding changes to the amounts of assets (including goodwill and other intangible
assets), liabilities, mezzanine equity, stockholders&#8217; equity, operating revenues, costs of sales, operating expenses, other income
and other expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently, and may in the future, have assets held at financial institutions that may exceed the insurance coverage offered by the Federal
Deposit Insurance Corporation (&#8220;FDIC&#8221;), and the loss of such assets would have a severe negative affect on our operations
and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation,
which appointed the FDIC as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into
receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would
have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. Although
we do not have any funds deposited with SVB and Signature Bank, we currently have deposits with Bank of America and Truist Bank, each
exceeding $250,000. In the future, we may maintain our cash assets at these and other financial institutions in the United States in
amounts that may be in excess of the FDIC insurance limit of $250,000. In the event of a failure of any of these financial institutions
where we maintain our deposits or other assets, we may incur a loss to the extent such loss exceeds the FDIC insurance limitation, which
could have a material adverse effect upon our liquidity, financial condition and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>The development of
Ampligen is subject to significant risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen may be found
to be ineffective or to have adverse side effects, fail to receive necessary regulatory clearances, be difficult to manufacture on a
commercial scale, be uneconomical to market or be precluded from commercialization by proprietary right of third parties. Our investigational
products are in various stages of clinical and pre-clinical development and require further clinical studies and appropriate regulatory
approval processes before any such products can be marketed. We do not know when, if ever, Ampligen or our other products will be generally
available for commercial sale for any indication. Generally, only a small percentage of potential therapeutic products are eventually
approved by the FDA for commercial sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that we are required by the FDA, pursuant to the Ampligen NDA, to conduct additional studies and take additional actions,
approval of any applications that we submit may be delayed by several years or may require us to expend more resources than we have available.
It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for
approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our
future applications for approval, which might significantly harm our business and prospects. As a result, we cannot predict when or whether
regulatory approval will be obtained for any product candidate we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, one or more of the potential side effects of the drug might deter usage of Ampligen in certain clinical situations and, therefore,
could adversely affect potential revenues and physician/patient acceptability of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>The development of Alferon N Injection
is subject to significant risks.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Alferon N Injection is approved for marketing in the United States for intralesional treatment of refractory or recurring external genital
warts in patients 18 years of age or older, to date it has not been approved for other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Possible
side effects from the use of Ampligen or Alferon N Injection could adversely affect potential revenues and physician/patient acceptability
of our product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Ampligen has been generally well tolerated with a low incidence of clinical toxicity, particularly given the severely debilitating
or life-threatening diseases that have been treated. A mild flushing reaction has been observed in approximately 15-20% of patients treated
in our various studies. This reaction is occasionally accompanied by a rapid heartbeat, a tightness of the chest, urticaria (swelling
of the skin), anxiety, shortness of breath, subjective reports of &#8220;feeling hot&#8221;, sweating and nausea. The reaction is usually
infusion-rate related and can generally be controlled by reducing the rate of infusion. Other adverse side effects include liver enzyme
level elevations, diarrhea, itching, asthma, low blood pressure, photophobia, rash, visual disturbances, slow or irregular heart rate,
decreases in platelets and white blood cell counts, anemia, dizziness, confusion, elevation of kidney function tests, occasional temporary
hair loss and various flu-like symptoms, including fever, chills, fatigue, muscular aches, joint pains, headaches, nausea and vomiting.
These flu-like side effects typically subside within several months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA in its February 1, 2013, CRL, provided recommendations to address certain outstanding issues before they could approve Ampligen for
Commercial Sales. The Agency stated that the submitted data do not provide sufficient information to determine whether the product is
safe for use in CFS due to the limited size of the safety database and multiple discrepancies within the submitted data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, one or more of the potential side effects of the drug might deter usage of Ampligen in certain clinical situations and therefore,
could adversely affect potential revenues and physician/patient acceptability of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, Alferon N Injection is approved for the intralesional (within the lesion) treatment of refractory or recurring external genital
warts in adults. In clinical trials conducted for the treatment of genital warts with Alferon N Injection, patients did not experience
serious side effects; however, there can be no assurance that unexpected or unacceptable side effects will not be found in the future
for this use or other potential uses of Alferon N Injection which could threaten or limit such product&#8217;s usefulness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our activities associated with Ampligen&#8217;s potential effectiveness as a treatment for COVID-19 of Post-COVID Conditions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It is not possible to predict the future of COVID-19, and related Post-COVID
Conditions, as a global public health threat or the development of related therapies. No assurance can be given that Ampligen will aid
in or be applied to the treatment of this virus.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 or Post-COVID
conditions, and no assurance can be given that it will be the case. We base our belief that Ampligen may be effective in the treatment
of COVID-19 or Post-COVID conditions on the result of studies that we reviewed and referenced. No assurance can be given that future
studies will not result in findings that are different from those in the studies that we have relied upon. We are one of many companies
working to develop a treatment for this virus, most of whom have far greater resources than us. This includes research into a range of
COVID-19-related circumstances, from prophylactic and early-onset treatments to therapies for Post-COVID conditions. If one of these
companies develops an effective treatment along the same lines as a therapy being developed by AIM, the development of Ampligen for this
virus most likely will be adversely affected. Moreover, there already are available treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
in foreign countries carries with it many risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our studies are being conducted in the Netherlands and we may conduct other studies and or we may enter into agreements such as supply
agreements. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual
property rights. We cannot assure that our potential foreign operations will not be adversely affected by these risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be profitable unless we can protect our patents and/or receive approval for additional pending patents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
need to preserve and acquire enforceable patents covering the use of Ampligen for a particular disease in order to obtain exclusive rights
for the commercial sale of Ampligen for such disease. We obtained all rights to Alferon N Injection, and we plan to preserve and acquire
enforceable patents covering its use for existing and potentially new diseases once we have had a successful FDA Pre Approval Inspection.
Our success depends, in large part, on our ability to preserve and obtain patent protection for our products and to obtain and preserve
our trade secrets and expertise. Certain of our know-how and technology is not patentable, particularly the procedures for the manufacture
of our experimental drug, Ampligen. We also have been issued a patent which affords protection on the use of Ampligen in patients with
Chronic Fatigue Syndrome. We have not yet been issued any patents in the United States for the use of Ampligen as a sole treatment for
any of the cancers which we have sought to target. For more information on Patents, please see PART I, Item 1 &#8220;Business; Patents&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure that our competitors will not seek and obtain patents regarding the use of similar products in combination with various
other agents, for a particular target indication prior to our doing so. If we cannot protect our patents covering the use of our products
for a particular disease, or obtain additional patents, we may not be able to successfully market our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
patent position of biotechnology and pharmaceutical firms is highly uncertain and involves complex legal and factual questions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, no consistent policy has emerged regarding the breadth of protection afforded by pharmaceutical and biotechnology patents. There
can be no assurance that new patent applications relating to our products, process or technology will result in patents being issued
or that, if issued, such patents will afford meaningful protection against competitors with similar technology. It is generally anticipated
that there may be significant litigation in the industry regarding patent and intellectual property rights. Such litigation could require
substantial resources from us, and we may not have the financial resources necessary to enforce the patent rights that we hold. No assurance
can be made that our patents will provide competitive advantages for our products, process and technology or will not be successfully
challenged by competitors. No assurance can be given that patents do not exist or could not be filed which would have a materially adverse
effect on our ability to develop or market our products or to obtain or maintain any competitive position that we may achieve with respect
to our products. Our patents also may not prevent others from developing competitive products or processes using related technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that we will be able to obtain necessary licenses if we cannot enforce patent rights we may hold. In addition, the
failure of third parties from whom we currently license certain proprietary information or from whom we may be required to obtain such
licenses in the future, to adequately enforce their rights to such proprietary information, could adversely affect the value of such
licenses to us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot enforce the patent rights we currently hold we may be required to obtain licenses from others to develop, manufacture or market
our products. There can be no assurance that we would be able to obtain any such licenses on commercially reasonable terms, if at all.
We currently license certain proprietary information from third parties, some of which may have been developed with government grants
under circumstances where the government maintained certain rights with respect to the proprietary information developed. No assurances
can be given that such third parties will adequately enforce any rights they may have or that the rights, if any, retained by the government
will not adversely affect the value of our license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no guarantee that our trade secrets will not be disclosed or known by our competitors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
protect our rights, we require all employees and certain consultants to enter into confidentiality agreements with us. There can be no
assurance that these agreements will not be breached, that we would have adequate and enforceable remedies for any breach, or that any
trade secrets of ours will not otherwise become known or be independently developed by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our R&amp;D</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>We
cannot predict what additional studies and/or additional testing or information may be required by the FDA. Accordingly, we are unable
to estimate the nature, timing, costs and necessary efforts to complete these projects nor the anticipated completion dates. In addition,
we have no basis for estimating when material net cash inflows may commence. We have yet to generate significant revenues from the sale
of these developmental products.</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the inherent uncertainty involved in the design and conduct of clinical trials and the applicable regulatory requirements, including
the factors discussed above in &#8220;Our Products&#8221;, we cannot predict what additional studies and/or additional testing or information
may be required by the FDA. In addition, most of our studies to date have involved only a small group of participants and positive results
in such a small group does not mean that such results will prove true in studies with a much larger group of participants. Accordingly,
we are unable to estimate the nature, timing, costs and necessary efforts to complete these projects nor the anticipated completion dates.
In addition, we have no basis for estimating when material net cash inflows may commence. We have yet to generate significant revenues
from the sale of these developmental products. As of December 31, 2023, we had approximately $13,070,000 in Cash, Cash Equivalents. Please
see &#8220;<i>We may require additional financing which may not be available</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Alferon N Injection Commercial Sales were halted due to lack of finished goods inventory. If we are unable to gain the necessary FDA
approvals related to Alferon N Injection, or if we are unable to identify a CMO or CMOs that meet our requirements, then our operations
would most likely be materially and/or adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exploring engaging a Contract Manufacturing Organization (&#8220;CMO&#8221;) to produce Alferon API. At present, we do not have a
supply of Alferon N Injection or the requisite API. Additionally, although our old New Brunswick facility was FDA approval under the
BLA for Alferon N Injection, this status will need to be reapproved when a CMO or a new facility is identified for the production of
the drug. We cannot provide any guarantee that a CMO or other future facility will pass an FDA pre-approval inspection for Ampligen or
Alferon N Injection manufacture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to gain the necessary FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection
inventory or contract with a CMO, our operations most likely will be materially adversely affected. For more information on Alferon N
Injection regarding potential commercial sales, please see PART I, Item 1 - &#8220;Business; Manufacturing&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are no long-term agreements with suppliers of required materials and services for Ampligen and there are a limited number of raw material
suppliers. If we are unable to obtain the required raw materials and/or services, we may not be able to manufacture Ampligen.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of essential raw materials are used in the production of Ampligen as well as packaging materials utilized in the fill and finish
process. We do not have, but continue to work toward having, long-term agreements for the supply of such materials, when possible. There
can be no assurance we can enter into long-term supply agreements covering essential materials on commercially reasonable terms, if at
all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use
in manufacturing Ampligen and Alferon N Injection. At present, we do not have any agreements with third parties for the supply of any
of these materials or we are relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection. Jubilant
HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. We anticipate, but cannot assure, that additional
orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, we added Pharmaceutics
International Inc. (&#8220;Pii&#8221;) as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce the drug Ampligen.
This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment our existing fill
and finish capacity. If we are unable to place adequate acceptable purchase orders with Jubilant or Pii in the future at acceptable prices
upon acceptable terms, we will need to find another manufacturer. If we need to find another contract manufacturer to produce Ampligen,
it would create a significant delay and expense to get the manufacturer up and running. The costs and availability of products and materials
we would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond our control, including
competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations. There can be
no assurance that we will be able to obtain such products and materials on terms acceptable to us or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we produced limited quantities of active pharmaceutical ingredients (&#8220;API&#8221;) for our products in our old New Brunswick, NJ
facility, the sale of this facility necessitated our exploring the engagement of a CMO to produce API for both Ampligen and Alferon.
While we believe we have sufficient API to meet our current Ampligen needs, we are also continually exploring new efficiencies so as
to maximize our ability to fulfill future obligations. Currently, the Alferon N Injection manufacturing process is on hold and there
is no definitive timetable for its restart. Please see &#8220;<i>Our Alferon N. Injection commercial sales were halted due to lack of
finished goods inventory. If we are unable to gain the necessary FDA approvals related to Alferon N Injection, our operations most likely
will be materially and/or adversely affected</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain or manufacture the required materials/reagents, and/or procure services needed in the final steps in the manufacturing
process, we may be unable to manufacture Ampligen. The costs and availability of products and materials we need for the production of
Ampligen are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology,
ownership of intellectual property, FDA and other governmental regulations. There can be no assurance that we will be able to obtain
such products and materials on terms acceptable to us or at all. For more information on Ampligen manufacturing, please see PART I, Item
1 - &#8220;Business; Our Products; Manufacturing&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are  limited number of organizations in the United States available to provide the final manufacturing steps of formulation, fill, finish
and packing sets for Alferon N Injection and Ampligen.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a limited number of organizations in the United States available to provide the final steps in the manufacturing for Alferon N Injection
and Ampligen. To formulate, fill, finish and package our products (&#8220;fill and finish&#8221;), we require an FDA approved third party
CMO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, we approved a quote and provided a purchase order with Jubilant HollisterStier LLC pursuant to which Jubilant manufactured
batches of Ampligen for us. We anticipate, but cannot assure, that additional orders will be placed upon approved quotes and purchase
orders provided by us to Jubilant. If we are unable to place adequate acceptable purchase orders with Jubilant in the future at acceptable
prices upon acceptable terms our business would be materially and adversely affected. Please see the prior risk factor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we added Pii as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce the drug Ampligen. This
addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment our existing fill and
finish capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
there be an unanticipated delay in receiving new product or should we experience an unexpected demand for Ampligen, our ability to supply
Ampligen most likely will be adversely affected. If we are unable to procure services needed in the final steps in the manufacturing
process, we may be unable to manufacture Alferon N Injection and/or Ampligen. The costs and availability of products and materials we
need for the production of Ampligen and the commercial production of Alferon N Injection and other products which we may commercially
produce are subject to fluctuation depending on a variety of factors beyond our control, including competitive factors, changes in technology,
and FDA and other governmental regulations and there can be no assurance that we will be able to obtain such products and materials on
terms acceptable to us or at all. For more information on Ampligen and Alferon N Injection manufacturing, please see PART I, Item 1 -
&#8220;Business; Our Products; Manufacturing&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no assurance that, upon success, manufacture of a drug on a limited-scale basis for investigational use would lead to a successful
transition to commercial, large-scale production.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in methods of manufacturing, including commercial scale-up, may affect the chemical structure of Ampligen and other RNA drugs, as well
as their safety and efficacy. The transition from limited production of pre-clinical and clinical research quantities to production of
commercial quantities of our products will involve distinct management and technical challenges, and may require additional management,
technical personnel and capital. While we intend to identify a CMO (or CMOs) with a state-of-the-art facility capable of meeting potential
increased demand for Ampligen, there can be no assurance that our manufacturing will be successful or that any given product will be
determined to be safe and effective, or capable of being manufactured under applicable quality standards, economically, and in commercial
quantities, or successfully marketed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited manufacturing experience for Ampligen and Alferon N Injection. We may not be profitable unless we can produce Ampligen,
Alferon N Injection or other products in commercial quantities at costs acceptable to us</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen
has been produced to date in limited quantities for use in our clinical trials, Early Access Program and Expanded Access Program. In
addition, in Argentina, Ampligen is still in the process of release testing the product that has already been sent. To be successful,
our products must be manufactured in commercial quantities in compliance with regulatory requirements and at acceptable costs. We believe,
but cannot assure, that it will not be necessary to increase our current product plans to meet our production obligations. We intend
to utilize third-party facilities if and when the need arises. We will need to comply with regulatory requirements for such facilities,
including those of the FDA pertaining to cGMP requirements or maintaining our BLA status. There can be no assurance that such facilities
can be used, built, or acquired on commercially acceptable terms, or that such facilities, if used, built, or acquired, will be adequate
for the production of our proposed products for large-scale commercialization or our long-term needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never produced Ampligen, Alferon N Injection or any other products in large commercial quantities. We must manufacture our products
in compliance with regulatory requirements in large commercial quantities and at acceptable costs in order for us to be profitable. We
intend to utilize third-party manufacturers and/or facilities if and when the need arises or, if we are unable to do so, to build or
acquire commercial-scale manufacturing facilities. If we cannot manufacture commercial quantities of Ampligen and/or Alferon N Injection
or continue to maintain third party agreements for its manufacture at costs acceptable to us, our operations will be significantly affected.
If and when the Ampligen NDA is approved, we may need to find an additional vendor to manufacture the product for commercial sales. Also,
each production lot of Alferon N Injection is subject to FDA review and approval prior to releasing the lots to be sold. This review
and approval process could take considerable time, which would delay our having product in inventory to sell, nor can we provide any
assurance as to the receipt of FDA approval of our finished inventory product. There can be no assurances that the Ampligen and/or Alferon
N Injection can be commercially produced at costs acceptable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Licensing/Collaborations/Joint Ventures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to achieve licensing, collaboration and/or joint ventures, our marketing strategy for Ampligen will be part of the differing
health care systems around the world along with the different marketing and distribution systems that are used to supply pharmaceutical
products to those systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received approval of our NDA from ANMAT for commercial sale of rintatolimod (U.S. tradename: Ampligen) in the Argentine Republic
for the treatment of severe CFS. The product will be marketed by GP Pharm, our commercial partner in Latin America. In September 2019,
we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. We are currently working
with GP Pharma on the commercial launch of Ampligen in Argentina. Commercialization in Argentina will require, among other things, GP
Pharm to establish disease awareness, medical education, creation of an appropriate reimbursement level, design of marketing strategies
and completion of manufacturing preparations for launch.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release tests before granting
final approval to begin commercial sales. This testing and approval process is currently delayed due ANMAT&#8217;s internal processes.
Once final approval by ANMAT is obtained, GP Pharm will begin distributing Ampligen in Argentina. We continue to pursue our Ampligen
NDA, for the treatment of CFS with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Marketing and Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited marketing and sales capability. If we are unable to obtain additional distributors and our current and future distributors
do not market our products successfully, we may not generate significant revenues or become profitable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited marketing and sales capability. We are dependent upon existing, and possibly future, marketing agreements and third-party
distribution agreements for our products in order to generate significant revenues and become profitable. As a result, any revenues received
by us will be dependent in large part on the efforts of third parties, and there is no assurance that these efforts will be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercialization strategy for Ampligen, if and when it is approved for marketing and sale by the FDA, may include licensing/co-marketing
agreements utilizing the resources and capacities of a strategic partner(s). We continue to seek a world-wide marketing partner with
the goal of having a relationship in place before approval is obtained. In parallel to partnering discussions, appropriate pre-marketing
activities will be undertaken. It is our current intention to control manufacturing of Ampligen on a world-wide basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercialization strategy for Alferon N Injection may include the utilization of internal functions and/or licensing/co-marketing agreements
that would utilize the resources and capacities of one or more strategic partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure that our U.S. or foreign marketing strategy will be successful or that we will be able to establish future marketing or
third-party distribution agreements on terms acceptable to us, or that the cost of establishing these arrangements will not exceed any
product revenues. Our inability to establish viable marketing and sales capabilities would most likely have a materially adverse effect
on us. There can be no assurances that the approved Alferon N Injection product will be returned to prior sales levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with Our Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rapid
technological change may render our products obsolete or non-competitive.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical and biotechnology industries are subject to rapid and substantial technological change. Technological competition from
pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and
is expected to increase. Most of these entities have significantly greater research and development capabilities than us, as well as
substantial marketing, financial and managerial resources, and represent significant competition for us. There can be no assurance that
developments by others will not render our products or technologies obsolete or noncompetitive, or that we will be able to keep pace
with technological developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may be subject to substantial competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ampligen.
</i>Our flagship product, Ampligen is being evaluated as a potential treatment for COVID-19, myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS) and COVID-induced CFS symptoms (&#8220;Long Haulers&#8221;); as well as multiple types of cancers. With regard to COVID-19,
multiple global companies are actively working to develop therapies for COVID-19, including several companies which have successfully
developed vaccines and treatments. It is possible that these or other companies may be developing therapies that are similar to that
which we are attempting to develop, and could therefore develop them first. Some of these potential products may have an entirely different
approach or means of accomplishing similar therapeutic effects to products being developed by us. These competing products may be more
effective and less costly than our products. In addition, conventional drug therapy, surgery and other more familiar treatments may offer
competition to our products. Furthermore, many of our competitors have significantly greater experience than we do in preclinical testing
and human clinical trials of pharmaceutical products and in obtaining FDA, The Health Protection Branch of the Canada Department of National
Health and Welfare (HPB) and other regulatory approvals of products. Accordingly, our competitors may succeed in obtaining FDA, HPB or
other regulatory product approvals more rapidly than us. There are no drugs approved for U.S. commercial sale for the treatment of CFS;
standard of care is to focus on symptom relief, such as addressing pain or depression. The dominant competitors with drugs to treat disease
indications which we plan to address include Pfizer, GlaxoSmithKline, Merck &amp; Co., Novartis and AstraZeneca. Biotech competitors
include Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta. These potential competitors are among
the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater
financial resources, product development, and manufacturing and marketing capabilities than we have. Although we believe our principal
advantage is the unique mechanism of action of Ampligen on the immune system, we cannot assure that we will be able to compete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alferon
N Injection.</i> Our competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical
community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities than
we have. Alferon N Injection currently competes with Merck&#8217;s injectable recombinant alpha interferon product (Intron&#174; A) for
the treatment of genital warts. In addition, other pharmaceutical firms offer self-administered topical cream, for the treatment of external
genital and perianal warts such as Graceway Pharmaceuticals (Aldara&#174;), <span style="background-color: white">Perrigo Company (Imiquimod
Cream - Generic Equivalent to Aldara&#174;), </span>Watson Pharma (Condylox&#174;) and MediGene (Veregen&#174;). Alferon N Injection also
competes with surgical, chemical, and other methods of treating genital warts. We cannot assess the impact products developed by our
competitors, or advances in other methods of the treatment of genital warts, will have on the commercial viability of Alferon N Injection.
If and when we obtain additional approvals of uses of this product, we expect to compete primarily on the basis of product performance.
Our competitors have developed or may develop products (containing either alpha or beta interferon or other therapeutic compounds) or
other treatment modalities for those uses. There can be no assurance that, if we are able to obtain regulatory approval of Alferon N
Injection for the treatment of new indications, we will be able to achieve any significant penetration into those markets. In addition,
because certain competitive products are not dependent on a source of human blood cells, such products may be able to be produced in
greater volume and at a lower cost than Alferon N Injection. Currently, our wholesale price on a per unit basis of Alferon N Injection
is higher than that of the competitive recombinant alpha and beta interferon products. Please see risk factor &#8220;We may not be profitable
unless we can protect our patents and/or receive approval for additional pending patents&#8221; above for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
companies may succeed in developing products earlier than we do, obtaining approvals for such products from the FDA more rapidly than
we do, or developing products that are more effective than those we may develop. While we will attempt to expand our technological capabilities
in order to remain competitive, there can be no assurance that research and development by others or other medical advances will not
render our technology or products obsolete or non-competitive or result in treatments or cures superior to any therapy we develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Associated with an Investment in Our Common Stock:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our stock may be adversely affected by market volatility.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock has been and is likely to be volatile. This is especially true given the current significant instability
in the financial markets, and the adverse effects and disruptions caused by the war in the Ukraine, Israel and Gaza. Should our progress
slow or results of testing or activities by others negatively impact our efforts, it is just as likely that our stock price will be significantly
adversely affected, and in such case, investors could sustain substantial losses. In addition to the foregoing and, general economic,
political and market conditions, the price and trading volume of our stock could fluctuate widely in response to many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of the results of clinical trials by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of availability or projections of our products for commercial sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of legal actions against us and/or settlements or verdicts adverse to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    reactions to products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">governmental
    approvals, delays in expected governmental approvals or withdrawals of any prior governmental approvals or public or regulatory agency
    comments regarding the safety or effectiveness of our products, or the adequacy of the procedures, facilities or controls employed
    in the manufacture of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in U.S. or foreign regulatory policy during the period of product development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    in patent or other proprietary rights, including any third-party challenges of our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of new products or new contracts by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our operating results due to the level of development expenses and other factors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates by securities analysts and whether our earnings meet or exceed the estimates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    and trends in the pharmaceutical and other industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    accounting standards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    investment market fluctuation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restatement
    of prior financial results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">notice
    of NYSE American non-compliance with requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of any of the risks described in these risk factors and the risk factors incorporated by reference herein.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed for quotation on the NYSE American. For the year ended December 31, 2023, the trading price of our common stock
has ranged from $0.32 to $0.77 per share. We expect the price of our common stock to remain volatile. The average daily trading volume
of our common stock varies significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue shares to be used to meet our capital requirements or use shares to compensate employees, consultants and/or Directors. We
have registered securities for public sale pursuant to a universal shelf registration statement which will allow us to raise additional
capital as needed in the future from the sale of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are unable to estimate the amount, timing or nature of future sales of outstanding common stock or instruments convertible into or exercisable
for our common stock. Sales of a significant number of shares of our common stock in the public markets, or the perception that such
sales could occur as a result of our utilization of our shelf registration statement or otherwise could depress the market price of our
common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that
future sales of our common stock or the market perception that we are permitted to sell a significant number of our securities would
have on the market price of our common stock. Please see Item 7- &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Result of Operations; Liquidity and Capital Resources&#8221; in PART II.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of our Certificate of Incorporation and Delaware law could defer a change of our Management, which could discourage or delay offers to
acquire us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Certificate of Incorporation and Delaware law may make it more difficult for someone to acquire control of us or for our stockholders
to remove existing management and might discourage a third party from offering to acquire us, even if a change in control or in Management
would be beneficial to our stockholders. For example, our Certificate of Incorporation allows us to issue shares of preferred stock without
any vote or further action by our stockholders. Our Board of Directors has the authority to fix and determine the relative rights and
preferences of preferred stock. Our Board of Directors also has the authority to issue preferred stock without further stockholder approval.
As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred
right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common
stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. On November
14, 2017, at the direction of the Board, we amended and restated the Rights Agreement between us and, American Stock Transfer &amp; Trust
Company, LLC, its current Rights Agent. Pursuant to the original Rights Agreement, our Board of Directors declared a dividend distribution
of one Right for each outstanding share of common stock to stockholders of record at the close of business on November 29, 2002. Each
Right entitles the registered holder to purchase from us a unit consisting of one one-hundredth of a share (a &#8220;Unit&#8221;) of
Series A Junior Participating Preferred Stock, par value $0.01 per share at a Purchase Price of $21.00 per Unit, subject to adjustment.
While our Rights Agreement was scheduled to expire in late 2022, we extended it on May 14, 2023 and will now expire on May 14, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, financial condition and operating results could be negatively affected as a result of actions by activist investors. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
activist group (the &#8220;Activist Group&#8221;) submitted a notice (the &#8220;Notice&#8221;) to our Board, seeking to put forth three
individuals for election as directors to our four-person Board at our 2023 Annual Meeting. The Activist Group includes many of the persons
who made a similar but failed attempt at our 2022 Annual Meeting. The Board once again found that the Activist Group&#8217;s Notice was
invalid and rejected it. After a full trial, the Delaware Chancery Court upheld our rejection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
proxy contest and related litigation, along the lines discussed above, could have a material adverse effect on us for the following reasons:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activist
    investors may attempt to effect changes in our governance and strategic direction or to acquire control over the Board or AIM. In
    particular, if the Activist is successful in its litigation and subsequent proxy contest, it may gain control of the Board.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
    we welcome the opinions of all stockholders, responding to proxy contests and related litigation by activist investors is likely
    to be costly and time-consuming, disrupt our operations, and potentially divert the attention of our Board, management team and other
    employees away from their regular duties and the pursuit of business opportunities to enhance stockholder value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perceived
    uncertainties as to our future direction as a result of potential changes to the composition of the Board may lead to the perception
    of a change in the strategic direction of the business, instability or lack of continuity, which may cause concern to our existing
    or potential strategic partners, customers, employees and stockholders; may be exploited by our competitors; may result in the loss
    of potential business opportunities or limit our ability to timely initiate or advance clinical trials; and may make it more difficult
    to attract and retain qualified personnel and business partners.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy
    contests and related litigation by activist investors could cause significant fluctuations in our stock price based on temporary
    or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our
    business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_001"></span>ITEM</b></span><b>
  1B.</b></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Unresolved Staff Comments.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_002"></span>ITEM</b></span><b>
  1C.</b></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a cyber risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on
the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our
business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include
identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks. Following these risk
assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified
gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engage consultants or other third parties in connection with our risk assessment processes. These service providers assist us to design
and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards. We have not encountered cybersecurity
challenges that have materially impaired our operations or financial standing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team, in conjunction with third-party IT and cybersecurity service providers is responsible for oversight and administration
of our cyber risk management program, and for informing senior management and other relevant stakeholders regarding the prevention, detection,
mitigation, and remediation of cybersecurity incidents. Our management team have prior experience selecting, deploying, and overseeing
cybersecurity technologies, initiatives, and processes directly or via selection of strategic third-party partners, and relies on threat
intelligence as well as other information obtained from governmental, public, or private sources, including external consultants engaged
by us for strategic cyber risk management, advisory and decision making. Our Audit Committee assists management in oversight and administration
of our cyber risk management program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an annual assessment performed by a third-party specialist of our cyber risk management program. The annual risk assessment identifies,
quantifies, and categorizes material cyber risks. In addition, in conjunction with the third-party cyber risk management specialists
we develop a risk mitigation plan to address such risks, and where necessary, remediate potential vulnerabilities identified through
the annual assessment process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face risks from cybersecurity threats that could have a material adverse effect on its business, financial condition, results of operations,
cash flows or reputation. We acknowledge that the risk of cyber incidents is prevalent in the current threat landscape and that a future
cyber incident may occur in the normal course of its business. However, prior cybersecurity incidents have not had a material adverse
effect on our business, financial condition, results of operations, or cash flows. We proactively seek to detect and investigate unauthorized
attempts and attacks against IT assets, data, and services, and to prevent their occurrence and recurrence where practicable through
changes or updates to internal processes and tools and changes or updates to our service delivery; however, potential vulnerabilities
to known or unknown threats will still remain. Further, there is increasing regulation regarding responses to cybersecurity incidents,
including reporting to regulators, investors, and additional stakeholders, which could subject us to additional liability and reputational
harm. In response to such risks, we have implemented initiatives such as implementation of the cybersecurity risk assessment process
and development of an incident response plan. See Item 1A. &#8220;Risk Factors&#8221; for more information on our cybersecurity risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_003"></span>ITEM 2.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office and finance is located at 2117 SW Highway 484, Ocala FL 34473, human resource office is located at 604 Main
Street, Riverton, NJ 08077 and manufacturing is located at 671A US-1 South, North Brunswick, NJ 08902. We currently lease our principal
executive office and finance for $2,780 per month, our human resource office for $2,850 per month and our manufacturing office for $16,100
per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_004"></span>ITEM
  3.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are, and from time to time may become, subject to litigation and various legal proceedings that involve claims for substantial amounts
of money or for other relief or that might necessitate changes to our business or operations. Please see Note 16 &#8220;Contingencies&#8221;
to the consolidated financial statements included in Part II, &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of this
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
litigation is inherently unpredictable, assessing contingencies&#160;related to litigation is a complex process involving highly subjective
judgment about potential outcomes of future events. When evaluating litigation contingencies, we may be unable to provide a meaningful
estimate due to a number of factors, including the procedural status of the matter in question, the availability of appellate remedies,
insurance coverage related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery
and development of information important to the matter. In addition, damage amounts claimed in litigation against us may be unsupported,
exaggerated, or unrelated to possible outcomes, and as such are not meaningful indicators of our potential liability or financial exposure.
Accordingly, we review the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and we assess the probability
and range of possible losses associated with&#160;contingencies&#160;for potential accrual in the consolidated financial statements.
However, the ultimate resolution of litigated claims may differ from our current estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, there are various claims in process,
matters in litigation, and other contingencies, certain of which are covered by insurance policies. While it is not possible to predict
the outcome of these suits, legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential
losses associated with these matters has been made in the financial statements and that the ultimate resolution of any one of these matters
will not have a material adverse effect on our financial position and results of operations. A significant increase in the number of these
claims, or one or more successful claims resulting in greater liabilities than the we currently anticipate, could materially and adversely
affect our business, financial condition, results of operations, and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Hemispherx
Biopharma, Inc (n/ka) AIM Immunotech vs BioLife Plasma Services,</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">LP
No 1711391858 ( Phila CCP)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commenced an action in the Philadelphia Court of Common Pleas in 2017 against Biolife Plasma Services, LP related to the defendants&#8217;
breach of a contract requiring the defendant to supply certain blood related products used by and necessary to us in the manufacture
of our products, including the loss profits associated with the defendants&#8217; breaches. The Defendant asserted defenses, including a counterclaim
asserting our failure to have paid invoices billed for the product in the amount of $96,676 following the Defendant&#8217;s notification that
it would not be fulfilling the terms of the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trial court issued a ruling in March 2023 on cross Motions for Summary Judgment in which it denied all of our motions and granted defendant&#8217;s
Motion to exclude evidence of future loss of profit damages. The ruling specified that we had properly pled, and the Court was specifically
allowing our damages theory to proceed on reliance damages. We sought reconsideration of the ruling based on its internal inconsistency
with the contemporaneously issued Order which allowed only the counterclaims to proceed. In July 2023, we sought appellate review of
the inconsistent lower Court pretrial rulings. In September 2023, the Court issued an Order in response to our Motion for Reconsideration
granting the Motion, vacating its prior Order on summary judgment, and issued a new Order and Opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new Order and Opinion again denied our motion for summary judgment, and granted defendants&#8217; motion for summary judgment. The effect
of the Order was to again allow only the defendant&#8217;s counterclaim to proceed. The Order mooted the pending appellate review. On December
6, 2023, we petitioned the Superior (appellate) Court to allow immediate appeal. The Superior Court has not ruled on the Petition. The
parties have twice mediated the matter with no resolution achieved. No estimate can be made of when the trial court and appellate court
will address the pending matters. No estimate of the outcome can be made at this time pending determination of the Petition and the underlying
issues presented in the appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AIM
ImmunoTech, Inc. v. Tudor., Case No. 2021-CA-393 (Marion County, FL)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 13, 2021, the Marion County Circuit Court entered an Agreed Order Granting Joint Motion for Entry of Stipulated Injunction (&#8220;Injunction&#8221;),
which precluded Tudor from contacting any of our business relations. We are currently pursuing enforcement of the Injunction against
Tudor, who recently violated the Injunction. We are not seeking damages against Tudor. We intend on filing a motion to enforce the Injunction
and will seek to recover its attorney&#8217;s fees and costs, along with any other sanction necessary to preclude Tudor from violating
the injunction again.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jorgl
v. AIM Immunotech, Inc. et al., C.A. No. 2022-0669-LWW (Del. Ch.)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 29, 2022, Jonathan Jorgl (&#8220;Jorgl&#8221;) filed a complaint
against us and the then-members of our Board of Directors in the Delaware Court of Chancery (the &#8220;Jorgl Action&#8221;). The complaint
challenged the decision of our Board of Directors to reject Jorgl&#8217;s notice of intent to nominate two candidates for election to
the our Board of Directors on the basis that the notice failed to comply with our bylaws. The Complaint sought a declaration that Jorgl&#8217;s
nomination was valid and effective and complied with our bylaws and that the we must list Jorgl&#8217;s candidates in our proxy materials,
as well as a temporary restraining order, preliminary injunction, and permanent injunction enjoining defendants from taking any action
to prevent Jorgl from exercising his alleged nomination rights and from making any statements that disparage Jorgl&#8217;s candidates
prior to or during our annual meeting of stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2022, the Court denied Jorgl&#8217;s motion for temporary restraining order, granted the motion to expedite, and scheduled
a hearing on Jorgl&#8217;s preliminary injunction motion. After expedited discovery and briefing, the Court issued an opinion on October
28, 2022, denying Jorgl&#8217;s motion for preliminary injunction. On November 1, 2022, Jorgl and the other participants in his nomination
efforts and attempted proxy contest announced in a press release that they did not plan to proceed to trial or seek an appeal of the
Court&#8217;s ruling denying the motion for preliminary injunction and that the proxies they solicited would not be voted at our annual
meeting of stockholders. We held our annual meeting of stockholders on November 3, 2022, and the stockholders re-elected Thomas Equels,
William Mitchell, and Stewart Appelrouth as directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2023, Jorgl filed a motion to dismiss the Jorgl Action. On June 20, 2023, the Court entered an order dismissing the Jorgl Action
and retaining jurisdiction to adjudicate any related fee disputes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, defendants filed a motion to shift all litigation fees they incurred in connection with the Jorgl Action to Jorgl on the
basis that he brought the litigation in bad faith (the &#8220;AIM Fee Motion&#8221;). Also on July 20, 2023, Jorgl filed a motion to
shift certain legal fees to defendants that he incurred in connection with contesting a subpoena defendants served on the legal counsel
that advised Jorgl in his nomination efforts, Baker &amp; Hostetler LLP (the &#8220;Jorgl Fee Motion&#8221;). The Delaware Court of Chancery
ruled on certain discovery motions in October 2023 pertaining to the AIM Fee Motion, and on March 25, 2024, ordered the parties to provide
a joint status report regarding the AIM Fee Motion and the Jorgl Fee Motion within 30 days. We anticipate that the parties will negotiate
a schedule to complete briefing on the motions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AIM
ImmunoTech, Inc. v. Tudor, et al., Case 5:22-cv-00323 (M.D. Florida 2022)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2022, we filed suit against Franz Tudor, Todd Deutsch, Ted
Kellner, Jonathan Jorgl, Walter Lautz, Robert Chioini, and Michael Rice (collectively, the &#8220;Tudor Group&#8221;) for injunctive relief
arising from the Tudor Group&#8217;s alleged violations of the Securities Exchange Act for failing to register as a group and provide
required disclosures. On July 8, 2022, Jorgl served a notice of intent to nominate two director candidates from the Tudor Group for election
at our 2022 annual meeting. We rejected the notice because we believed the notice did not comply with the bylaws, federal law, or Delaware
law. We allege the notice is missing critical information required by the bylaws and made material misrepresentations and omissions. We
believe the Tudor Group was acting in concert to appoint the nominees and sued these individuals to enjoin them from violating our bylaws
and federal law. On July 10, 2023, the court dismissed the complaint. We filed a motion for reconsideration, which the trial court denied.
We filed an appeal of the dismissal, which is pending and referenced below. The defendants have filed motions for sanctions seeking to
recover their legal costs from the inception of the case, which total hundreds of thousands of dollars, according to the defendants, and
additional sums, also not quantified, to act as a deterrent. On December 19, 2023, the court heard oral argument on the motions. The parties
submitted post-hearing briefs, and the matter is pending before the Court.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>AIM
ImmunoTech, Inc. v. Tudor, et al., Case No. 0:2023prici13576 (11th Cir. 2023)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
filed a notice of appeal of the order of dismissal and the order denying its motion for reconsideration that were entered in AIM ImmunoTech,
Inc. v. Tudor, et al., Case 5:22-cv-00323 (M.D. Fla. 2022) (above). The appellate deadlines are stayed until the lower court rules on
the pending motions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kellner
v. AIM Immunotech, Inc. et al.</i>, C.A. No. 2023-0879-LWW (Del. Ch.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 25, 2023, Ted D. Kellner (&#8220;Kellner&#8221;) filed a complaint against us and the four current members of our Board of Directors
in the Delaware Court of Chancery (the &#8220;Kellner Action&#8221;). The complaint challenged (1) our adoption of amendments to the
advance notice provision of our bylaws; and (2) the decision of our Board of Directors to reject Kellner&#8217;s notice of intent to
nominate himself and two other candidates&#8217; election to our Board of Directors at our 2023 annual meeting of stockholders on the
basis that the nomination notice failed to comply with our amended bylaws. The complaint seeks, among other things, a declaration that
(1) the amendments to our Bylaws were unlawful; and/or (2) the Board&#8217;s application of the amended bylaws to reject Kellner&#8217;s
nomination notice was unlawful or inequitable. On September 11, 2023, defendants in the Kellner Action filed an answer responding to
Kellner&#8217;s complaint and we filed a counterclaim. Our counterclaim seeks a declaration that (1) our bylaw amendments are lawful
and valid; and (2) Kellner&#8217;s nomination notice did not comply with our bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of expedited discovery and briefing, the Court held trial in the Kellner Action from October 30, 2023, to November 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Court of Chancery issued an opinion on December 28, 2023, that declared (1) the Board&#8217;s rejection of Kellner&#8217;s nomination
notice was lawful and equitable, (2) certain of our bylaw amendments were valid, and (3) certain of the our bylaw amendments were invalid.
Kellner has appealed the court&#8217;s ruling concerning the Board&#8217;s rejection of his nomination notice, and the bylaw amendments
the court ruled were valid. The Defendants have appealed the court&#8217;s ruling as to the bylaw amendments the court ruled were invalid.
The parties agreed to, and the Delaware Supreme Court ordered, expedited briefing, which is now complete. Oral argument is scheduled
for April 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Kellner is not presently seeking monetary relief from us in the Kellner Action, he has reserved the right to seek reimbursement of certain
legal fees and expenses from us if the Delaware Supreme Court upholds the invalidation of certain bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_005"></span>ITEM 4.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mine Safety Disclosures.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_006"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_007"></span>ITEM
  5.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market for Registrant&#8217;s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Market
Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed and traded on the NYSE American under the symbol AIM.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 25, 2023, there were approximately 150 holders of record of our Common Stock. This number was determined from records maintained
by our transfer agent and does not include beneficial owners of our securities whose securities are held in the names of various dealers
and/or clearing agencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Information
about securities authorized for issuance under our equity compensation plans is incorporated herein by reference to Item 12 of Part III
of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our Common Stock in recent years. It is management&#8217;s intention not to declare or pay dividends
on our Common Stock, but to retain earnings, if any, for the operation and expansion of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Recent
Sales of Unregistered Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2018
Equity Incentive Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, we issued a total of 850,000 options under the 2018 Equity Incentive Plan, effective September 12,
2018, which will continue in effect for a period of 10 years from its effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, we issued a total of 400,000 options under the 2018 Equity Incentive Plan, effective September 12,
2018, which will continue in effect for a period of 10 years from its effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employees
and Directors Purchase Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2020, the board of directors approved a plan pursuant to which all directors, officers, and employees could purchase from us
up to an aggregate of $500,000 worth of shares at the market price. Pursuant to NYSE American rules, this plan was effective for a sixty-day
period commencing upon the date that the NYSE American approved our Supplemental Listing Application. We issued 10,730 shares of our
common stock at a price of $2.33 for a total of $25,000 under this plan. When this plan expired, the board of directors approved subsequent
similar $500,000 plans for all directors, officers and employees to buy shares from us at the market price. Subsequent plans were approved
by the board of directors upon the expiration of prior plans. The last plan approved by the Board of Directors for the fiscal year ended
December 31, 2023, was on October 26, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended December 31, 2022, we issued a total of 86,817 shares of our common stock at prices ranging from $0.76 to $1.02
for a total of $80,000 under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal year ended December 31, 2023, we issued a total of 419,285 shares of our common stock at prices ranging from $0.31 to $0.67
for a total of $150,500 under the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In March 2024, we sold 204,547
and 38,462 shares of our common stock at prices of $0.33 and $0.39 per share, respectively, under the plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Azenova</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 6, 2023, the Company issued to Azenova, LLC, an option to purchase up to three hundred and sixty thousand (360,000) shares of
our &#8220;Common Stock&#8221; at a price equal to $0.46 per share. This Option was awarded pursuant to the Consulting Agreement dated
October 16, 2023 between the Company and Azenova, LLC. On December 6, 2023, 180,000 options were transferred to Jeffrey Southerton and
180,000 options were transferred to Stacy J. Evans; both transfers with an exercise price of $0.46.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offers, sales and issuances of securities described above was deemed to be exempt from registration under the Securities Act in reliance
on either Section 4(a)(2) in that the issuance of securities to the accredited investors did not involve a public offering, or Rule 701
in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_008"></span>ITEM
  6.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Reserved]</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_009"></span>ITEM
  7.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion and analysis is related to our financial condition and results of operations for the two years ended December 31,
2023 This information should be read in conjunction with our consolidated financial statements and related notes thereto beginning on
F-1 of this Form 10-K. Please also see &#8220;Special Note Regarding Forward Looking Statements and Summary Risk Factors&#8221; in ITEM
1. Business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued warrants (the &#8220;Warrants&#8221;) in February 2017, June 2017, August 2017, April 2018, and March 2019 that are single
compound derivatives containing both an embedded right to obtain stock upon exercise (a &#8220;Call&#8221;) and a series of embedded
rights to settle the Warrants for cash upon the occurrence of certain events (each, a &#8220;Put&#8221;). Generally, the Put provisions
allow the Warrant Holders liquidity protection; the right to receive cash in certain situations where the Holders would not have a means
of readily selling the shares issuable upon exercise of the Warrants (e.g., where there would no longer be a significant public market
for our common stock). However, because the contractual formula used to determine the cash settlement value of the embedded Put requires
use of certain assumptions, the cash settlement value of the embedded Put can differ from the fair value of the unexercised embedded
Call option at the time the embedded Put option is exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recompute the fair value of the Warrants at the end of each quarterly reporting period. Such value computation includes subjective input
assumptions that are consistently applied each period. If we were to alter our assumptions or the numbers input based on such assumptions,
the resulting fair value could be materially different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESULTS
OF OPERATIONS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Year
ended December 31, 2023 versus year ended December 31, 2022</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss was approximately $28,962,000 and $19,445,000 for the years ended December 31, 2023 and 2022, respectively, representing an
increase in net loss of approximately $9,517,000 or (49%) when compared to the same period in 2022. This increase in net loss for the
year ended December 31, 2023, was primarily due to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in general and administrative expenses of $8,063,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in research and development expenses of $3,949,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in production costs of $42,000; offset by</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in revenue of $61,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase on income from investments of $1,879,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in interest/other income of $440,000; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in gain from sale of Income tax operating losses of $177,000; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase on the gain from sale of fixed assets of $15,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decrease of the quarterly revaluation of certain redeemable warrants of $35,000.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share was $ (0.60) and $(0.40) for the years ended December 31, 2023 and 2022, respectively. The weighted average number of
shares of our common stock outstanding as of December 31, 2023, was 48,585,404 as compared to 48,047,288 as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Revenues</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from our Ampligen&#174; Cost Recovery Program were $202,000 and $141,000 for the years ended December 31, 2023 and 2022, representing
an increase of $61,000 which is primarily related to the fluctuation of patient participation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, we had no Alferon N Injection&#174; Finished Good product to commercially sell and all revenue
was generated from the EAP and our FDA approved open-label treatment protocol, (&#8220;AMP 511&#8221;), that allows patient access to
Ampligen&#174; for treatment in an open-label safety study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Production
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
costs were approximately $42,000 and $0, respectively, for the years ended December 31, 2023 and 2022, representing an increase of $42,000
in production costs in the current period. The increase was due to the cost incurred for production of Ampligen that occurred in the
last quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Research
and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall
Research and Development (&#8220;R&amp;D&#8221;) costs for the year ended December 31, 2023, were approximately $10,939,000 as compared
to $6,990,000 a year ago, reflecting an increase of approximately $3,949,000. The primary reason for the increase in research and development
costs was due to the increases in Company sponsored clinical trials expenses of approximately $2,162,000 and an increase in outside consultant
costs of approximately $1,787,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">General
and Administrative Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative (&#8220;G&amp;A&#8221;) expenses for the years ended December 31, 2023 and 2022, were approximately $21,137,000 and
$13,074,000, respectively, reflecting an increase of approximately $8,063,000. The increase in G&amp;A expenses during the current period
was largely due to increases in legal fees of approximately $6,500,000 primarily related to responding to an attempt by a group of shareholders
to bypass our bylaws and nominating procedures, and financial consultant fees of $2,407,000 offset by a decrease in stock compensation
of $711,000. We are in the process of submitting an insurance claim and hopes to recover a portion of the legal expenses related to the
shareholder action, but recovery, if any, at this time cannot be determined.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
(loss) on Investments </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
(loss) on investments for the years ended December 31, 2023 and 2022 was approximately $200,000 and ($1,679,000), respectively, reflecting
an increased gain on investments of approximately $1,879,000. The gain was due to the change in the fair value of equity investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Redeemable
Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
revaluation of certain redeemable warrants resulted in a non-cash adjustment to the redeemable warrants liability. There was no change
for the twelve months ended December 31, 2023, compared with a gain of $35,000 for the twelve months ended December 31, 2022 (see &#8220;Financial
Statements: Note 15: Fair Value&#8221; for the various factors considered in the valuation of redeemable warrants).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
from sale of income tax operating losses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, we effectively sold $14,156,000 of our New Jersey state net operating loss carryforward and $38,600 in R&amp;D credits
for the year 2022 for approximately $1,313,000. Additionally, we recorded a deferred tax asset in the amount of approximately $1,604,000
for the current year 2023 operating losses to be sold in 2024. (see Note 12 Income Taxes (FASB ASC 740 Income Taxes).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Liquidity
and Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the year ended December 31, 2023, was approximately $21,267,000 compared to approximately $16,108,000
for the same period in 2022, an increase of $5,159,000. The primary reasons for this increase in cash used in operations in 2023 was
an increased net loss during the year of $9,517,000 and a gain on investments of $1,879,000, a decrease in stock compensation of $711,000 which was partially offset by an increase in accounts payable of
$5,887,000 an increase in accrued expenses of $812,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in investing activities for the year ended December 31, 2023, was approximately ($832,000) compared to cash provided by investing
activities in 2022 of approximately $10,988,000, representing a change of $11,820,000. The primary reason for the change during the
current period is the net purchase and sale of marketable investments activity of ($294,000) &#160;&#160;compared to the $7,359,000 for
the same period in 2022, and by the proceeds from the sale of property and equipment of $47,000 in 2023, compared with $3,900,000 in
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2023, was approximately $485,000 compared to approximately $80,000 for
the same period in 2022, an increase of $405,000. The primary reason for this increase was the receipt of $485,000 in net proceeds from
the sale of shares in 2023 compared to $80,000 from the proceeds from sale of stock, net of issuance costs in 2022. As discussed below,
in April 2023 we entered into an Equity Distribution Agreement, which was the primary source of additional equity proceeds in 2023 compared
with 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had approximately $13,070,000 in cash, cash equivalents and marketable investments, inclusive of approximately
$7,631,000 in marketable investments, representing a decrease of approximately $21,120,000 from December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed
to commercialize the many potential therapeutic aspects of our experimental drugs and our FDA approved drug Alferon N Injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Today,
some three years after COVID-19 first appeared, the world has a number of vaccines and some promising therapeutics. Our quest to prove
the antiviral activities of Ampligen continues. If Ampligen has the broad-spectrum antiviral properties that we believe that it has,
it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that arise in the
future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. We believe that it activates antiviral
immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our products requires the commitment of substantial resources to conduct the time-consuming research, preclinical
development, and clinical trials that are necessary to bring pharmaceutical products to market. We believe, based on our current
financial condition, that we have adequate funds to meet our anticipated operational cash needs and fund current clinical trials
over approximately the next twenty-four months. In this regard, in April, 2023, we entered into an Equity Distribution Agreement
(the &#8220;EDA&#8221;), with Maxim Group LLC (&#8220;Maxim&#8221;), pursuant to which we may sell from time to time, shares of our
common stock having an aggregate offering price of up to $8.5 million through Maxim, as agent. During the year ended December 31,
2023, we sold 598,114 shares under the EDA for total gross proceeds of approximately $344,000, which includes a 3.0% fee to Maxim of
$10,326. In February 2022, the SEC declared our universal shelf registration statement on Form S-3 effective. Pursuant to that
registration statement, we can sell up to $100 million of our securities and raise additional capital as needed in the future.
Subsequent to the end of 2023, we raised $2,500,000 in net proceeds from the sale of an unsecured Note and entered into an equity
line of credit (see exhibits 10.104 and 10.105). No assurance can be given as to the amount of funds that could be raised or the
potential dilution to current stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present we do not generate any material revenues from operations, and we do not anticipate doing so in the near future. We may need to
obtain additional funding in the future for new studies and/or if current studies do not yield positive results, require unanticipated
changes and/or additional studies. If we are unable to commercialize and sell Ampligen and/or recommence material sales of Alferon N
Injection, our operations, financial position and liquidity may be adversely impacted, and additional financing may be required. There
can be no assurances that, if needed, we will be able to raise adequate funds or enter into licensing, partnering or other arrangements
to advance our business goals. We may seek to access the public equity market whenever conditions are favorable, even if we do not have
an immediate need for additional capital at that time. We are unable to estimate the amount, timing or nature of future sales of outstanding
common stock or instruments convertible into or exercisable for our common stock. Any additional funding may result in significant dilution
and could involve the issuance of securities with rights, which are senior to those of existing stockholders. See Part I, Item 1A - &#8220;Risk
Factors; <i>We may require additional financing which may not be available</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to PART III, ITEM 13 - &#8220;Certain Relationships and Related Transactions, and Director Independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refer
to &#8220;Note 2(g) &#8211; Recent Accounting Standards and Pronouncements&#8221; under Notes to Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting estimates are described in the Notes to Consolidated Financial Statements. The significant accounting estimates
that we believe are most critical to aid in fully understanding our reported financial results are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Long-Lived
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assess long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets or the
asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which a long-lived
asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business climate
that could affect the value of a long-lived asset (asset group, including an adverse action or assessment by a regulator, an accumulation
of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group),
a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or forecast that
demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that, more likely
than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously estimated
useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
assessing for impairment, we measure the recoverability of assets that it will continue to use in its operations by comparing the carrying
value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#8217;s carrying
value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure the impairment by comparing the difference between the asset grouping&#8217;s carrying value and its fair value. Long-lived assets
are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are determined
for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments in determining
the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing process
and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated, it accelerates
the rate of depreciation over the assets&#8217; new, shorter useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Redeemable
Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize the guidance contained in ASC 480 Distinguishing Liabilities from Equity in the determination of whether to record warrants and
options as Equity and/or Liability. If the guidance of ASC 480 is deemed inconclusive, we continue our analysis utilizing ASC 815 Derivatives
and Hedging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
method of recording the related value is consistent with the standards as defined by the Financial Accounting Standards Board utilizing
the concept of &#8220;Fair Value&#8221; from ASC 820-10-55-1 that states that any fair value measurement requires that the reporting
entity, to determine the valuation technique(s) appropriate for the measurement, consider the availability of data with which to develop
inputs that represent the assumptions that market participants would use in pricing the asset or liability and the level in the fair
value hierarchy within which the inputs fall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recomputed the value of the redeemable warrants at the end of each quarterly period. We use the Monte Carlo Simulation approach which
includes subjective input assumptions that are consistently applied each quarter. If we were to alter our assumptions or the numbers
input based on such assumptions, the resulting fair value could be materially different. As discussed in greater detail in &#8220;Fair
Value&#8221; at the beginning of this ITEM 7, the significant assumptions using this model are: (i) Risk-Free Interest Rate; (ii) Expected
Holding Period; (iii) Expected Volatility; (iv) Expected Dividend Yield; (v) Expected Probability of a Fundamental Transaction; (vi)
Expected Timing of Announcement of a Fundamental Transaction; (vii) Expected 100 Day Volatility at Announcement of a Fundamental Transaction;
(viii) Expected Risk-Free Interest Rate at Announcement of a Fundamental Transaction; and (ix) Expected Time Between Announcement and
Consummation of a Fundamental Transaction. The derivative is values using Level 3 inputs which are highly subjective and require a high
degree of judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentration
of Credit Risk</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to limit the amount of credit exposure to any one financial institution and place investments with financial institutions evaluated
as being credit worthy, or in short-term money markets, which are exposed to minimal interest rate and credit risks. We have bank deposits
and overnight repurchase agreements that exceed federally insured limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration
of credit risk, with respect to receivables, is limited through our credit evaluation process. We do not require collateral on our receivables.
Our receivables historically consisted principally of amounts due from wholesale drug companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_010"></span>ITEM
  7A.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative and Qualitative Disclosures About Market Risk.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_011"></span>ITEM 8.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Supplementary Data.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see the &#8220;Index to Financial Statements and Financial Statement Schedule&#8221; on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_012"></span>ITEM
  9.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes in and Disagreements with Accountants on Accounting
and Financial Disclosures.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_013"></span>ITEM
  9A.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Controls and Procedures.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Effectiveness
of Control Procedures</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the end of the period covered by this report, we carried out an evaluation under the supervision and with the participation
of our Management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation
of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act. Our disclosure
controls and procedures are intended to ensure that the information we are required to disclose in the reports that we file or submit
under the Securities Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities
Exchange Commission&#8217;s rules and forms and (ii) accumulated and communicated to our management, including the Chief Executive Officer
and Chief Financial Officer, as the principal executive and financial officers, respectively, to allow final decisions regarding required
disclosures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the controls and procedures
were effective as of December 31, 2023, to ensure that material information was accumulated and communicated to our management, including
our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our
management has concluded that the financial statements included in this Form 10-K present fairly, in all material respects our financial
position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Changes
in Internal Control over Financial Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
made no changes in our internal control over financial reporting during the last fiscal quarter that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under
the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Management&#8217;s
Report on Internal Control over Financial Reporting</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined
in Rules 13a-15(f) or 15d-15(f), under the Exchange Act. Internal control over financial reporting is a process designed by, or under
the supervision of, our principal executive and principal financial officers and affected by our Board of Directors, Management and other
personnel, and to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial
reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded
as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s
assets that could have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment,
Management used the criteria set forth in the framework in 2013 established by the Committee of Sponsoring Organizations of the
Treadway Commission Internal Control&#8212;Integrated Framework, (COSO). A material weakness is a deficiency, or combination of
deficiencies, such that there is a reasonable possibility  that a material misstatement of
our annual or interim financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has concluded that we did maintain effective internal control over financial reporting as of December 31, 2023, based on the criteria
set forth in &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the COSO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_014"></span>ITEM
  9B.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Information. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_015"></span>ITEM
  9C.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_017"></span>ITEM
  10.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Executive Officers and Corporate Governance.
</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following sets forth biographical information about each of our Directors and Executive Officers as of the date of this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    W. Rodino III</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer, General Counsel &amp; Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    M. Mitchell, M.D., Ph.D.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stewart
    L. Appelrouth</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nancy
    Bryan</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Director has been elected to serve until the next annual meeting of stockholders, or until their earlier resignation, removal from office,
death or incapacity. Each Executive Officer serves at the discretion of the Board of Directors, subject to rights, if any, under contracts
of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our Board Members represent a desirable diversity of backgrounds, skills, education and experiences, and they all share the personal
attributes of dedication to be effective directors. In recommending Board candidates, Corporate Governance and Nomination Committee considers
a candidate&#8217;s: (1) general understanding of elements relevant to the success of a publicly traded company in the current business
environment; (2) understanding of our business; and (3) diversity in educational and professional background. The Committee also gives
consideration to a candidate&#8217;s judgment, competence, dedication and anticipated participation in Board activities along with experience,
geographic location and special talents or personal attributes. The following are qualifications, experience and skills for Board members
which are important to our business and its future:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Leadership
Experience</span>: We seek directors who have demonstrated strong leadership qualities. Such leaders bring diverse perspectives and broad
business insight to our Company. The relevant leadership experience that we seek includes a past or current leadership role in a large
or entrepreneurial company, a senior faculty position at a prominent educational institution or a past elected or appointed senior government
position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Industry
or Academic Experience</span>: We seek directors who have relevant industry experience, both with respect to the disease areas where we
are developing new therapies as well as with the economic and competitive dynamics of pharmaceutical markets, including those in which
our drugs will be prescribed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Scientific,
Legal or Regulatory Experience</span>: Given the highly technical and specialized nature of biotechnology, we desire that certain of our
directors have advanced degrees, as well as drug development experience. Since we are subject to substantial regulatory oversight, both
here and abroad by the FDA and other agencies, we also desire directors who have legal or regulatory experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Finance
Experience</span>: We believe that our directors should possess an understanding of finance and related reporting processes, particularly
given the complex budgets and long timelines associated with drug development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THOMAS
K. EQUELS, </b>is our Chief Executive Officer (since 2016), President (since 2015) and Executive
Vice Chairman (since 2008). He has also been one of our Directors since 2008. Mr. Equels was formerly the President and Managing Director
of the Equels Law Firm in Miami, Fla. For over a quarter century, he represented national governments, state governments and private companies
in banking, insurance, aviation, pharmaceutical and construction matters. He also was on numerous occasions the court-appointed receiver
to turn around distressed companies. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He received
his Bachelor of Science, summa cum laude, from Troy University and also obtained his Master of Science Degree from Troy University. Mr.
Equels began his professional career as a military pilot. He served in Vietnam and was awarded two Distinguished Flying Crosses, the Bronze
Star, the Purple Heart, and fifteen Air Medals. In 2012, he was Knighted by Pope Benedict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THOMAS
K. EQUELS, Esq. </b>- Director Qualifications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leadership
    Experience &#8211; Military, Owner and former President, Managing Director of Equels Law Firm, Court appointed receiver in numerous
    industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
    Experience &#8211; as legal counsel, General Counsel, CFO and CEO; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biotech,
Scientific, Legal or Regulatory Experience - Law degree with over 25 years as a practicing attorney specializing in litigation, development
of clinical trials, creating intellectual property concepts, and established plan to finance drug development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WILLIAM
M. MITCHELL, M.D., Ph.D., </b>has been a Director since July 1998 and Chairman of the Board since February 2016. Dr. Mitchell is a Professor
of Pathology, Microbiology &amp; Immunology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell
earned an M.D. from Vanderbilt University and a Ph.D. from Johns Hopkins University, where he served as a House Officer in Internal Medicine,
followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to
viral pathogenesis, anti-viral drugs, immune responses to infection, cancer diagnostics, as well as other biomedical topics. Dr. Mitchell
has been active in many professional societies that have included the American Society of Investigative Pathology, the International
Society for Antiviral Research, the American Society of Clinical Oncology, the American Society of Biochemistry and Molecular Biology,
the American Chemical Society, the International Academy of Pathology, the United States and Canadian Academy of Pathology, and the American
Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numerous government review committees,
among them the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health, including the initial AIDS and
Related Research Review Group. Dr. Mitchell previously served as one of our Directors from 1987 to 1989.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WILLIAM
M. MITCHELL, M.D., Ph.D. - </b>Director Qualifications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leadership
    Experience &#8211; Professor at Vanderbilt University School of Medicine. He was an independent member of the Board of Directors
    for Chronix Biomedical and was Chairman of its Medical Advisory Board. Additionally, he has served on multiple governmental review
    committees of the National Institutes of Health, Centers for Disease Control and Prevention and for the European Union, including
    key roles as Chairman;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Academic
    and Industry Experience &#8211; Physician scientist with extensive investigative experience on viral and immunology, and cancer issues
    relevant to our scientific business along with being a former independent Director of an entrepreneurial diagnostic company (Chronix
    Biomedical) that is involved in next generation DNA sequencing for blood based cancer diagnosis (i.e.- the liquid biopsy).; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific,
    Legal or Regulatory Experience - M.D., Ph.D. and professor at a top ranked school of medicine, and inventor of record on numerous
    U.S. and international patents who is experienced in regulatory affairs through filings with the FDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STEWART
L. APPELROUTH, CPA </b>was appointed as a director and head of the Audit Committee in August 2016 and is a certified public accountant
and partner at Appelrouth Farah &amp; Co., P.A. and, since March 2022, a partner at Citrin Cooperman Advisors, LLP, both Certified Public
Accountants. Mr. Appelrouth is also a certified forensic accountant and possesses 40 years of experience in Accounting and Consulting.
He is a member of or has affiliations with the AICPA, American College of Forensic Examiners, Association of Certified Fraud Examiners,
past member of the Florida Bar Grievance Committee, Florida Institute of Certified Public Accountants and InfraGard Member, a national
information sharing program between the Federal Bureau of Investigation and the private sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Appelrouth graduated from Florida State University in 1975 and received his Master&#8217;s Degree in Finance from Florida International
University in 1980. The Board has determined Mr. Appelrouth to be an Independent Director as required under Section 803(2) of the NYSE:
American Company Guide and Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STEWART
L. APPELROUTH </b>- Director Qualifications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leadership
    Experience &#8211;has served in leadership positions on numerous Boards and other organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
    Experience &#8211; Partner at certified public accounting and advisory firm; Certified Public Accountant and Certified Fraud Examiner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    Experience &#8211; FINRA Arbitrator.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Expert &#8211; over 40 years of accounting and audit experience.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NANCY
K. BRYAN</b> - was appointed as a director in March 2023. Ms. Bryan is an established leader with more than 35 years of experience
in the life sciences industry. She has served on executive leadership teams and played key roles in biopharmaceutical
companies&#8217; successes, including marketing, sales, business development, financing, and communications. From 2013 to 2023, Ms.
Bryan served as President and CEO of BioFlorida Inc., an association supporting the advancement of life sciences in Florida. Prior
to joining BioFlorida, Ms. Bryan began her career with major pharmaceutical companies including Merck, GlaxoSmithKline and Bayer
Pharmaceuticals. She then went on to serve in a number of executive leadership positions in specialty pharmaceuticals and smaller,
start-up biotech companies, including Indevus Pharmaceuticals and NPS Pharmaceuticals. Throughout her career, Ms. Bryan helped
develop, launch, and commercialize many products including blockbusters (Zantac, Levitra), major biologics (Tysabri) and orphan
drugs for rare diseases (Valstar for bladder cancer, Supprelin LA for central precocious puberty), and helped establish franchises
in a wide variety of therapeutic areas, including Oncology, Anti-infectives, GI and Autoimmune (MS, CD). She has established a
successful track record with introducing strategic and tactical solutions to develop global markets as well as launch, grow and turn
around established and underperforming drugs, resulting in greater revenue, market share, profitability, and stockholder
value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Bryan holds a BA in Economics from the University of Virginia and an MBA from Columbia University, and her academic honors include Phi
Beta Kappa and Beta Gamma Sigma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NANCY
K. BRYAN</b> &#8211; Director Qualifications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leadership
    Experience &#8211; President and CEO of BioFlorida; served on executive leadership teams and played a key role in biopharmaceutical
    companies&#8217; successes including marketing, sales, business development, financing initiatives and investor and PR communications;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercialization
    Experience &#8211; 25 years of experience in Biopharmaceuticals in commercial positions of increasing responsibility involving primary
    care, biologics and specialty markets; throughout her career, she has developed, launched and commercialized many products, major
    biologics and orphan drugs for rare diseases and has established franchises in a wide variety of therapeutic areas including: Oncology,
    Anti-infectives, GI and Autoimmune (MS,CD).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
about our Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to Mr. Equels (discussed above), the following are our Executive Officers during fiscal 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PETER
W. RODINO III</b> has been a Director since July 2013. On September 30, 2016, Mr. Rodino resigned as a member of our Board to permit
him to serve us in a new capacity. Effective October 1, 2016, we retained Mr. Rodino as our Executive Director for Governmental Relations,
and as our General Counsel and, as of October 16, 2019, Mr. Rodino assumed the role of Chief Operating Officer. Mr. Rodino has been our
Secretary since November 2016. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino
Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO
of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment
executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. Previously, as founder
and president of Rodino Consulting, Mr. Rodino provided business and government relations consulting services to smaller companies with
a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S.
in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ROBERT
DICKEY, IV </b>has been our Chief Financial Officer since April 4, 2022. Mr. Dickey has more than 25 years of experience in C-suite financial
leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial
operations and across a variety of disease areas and medical technologies. Mr. Dickey has served as Managing Director at Foresite Advisors
since March 2020 assuming responsibility for CFO advisory, financial analysis, capital raising, and transactional support/execution for
public offerings and M&amp;A services at life science companies and was previously a Managing Director at Danforth Advisors from August
2018 to March 2020. Both Foresite Advisors and Danforth Advisors provide financial support and investment advisory services. Mr. Dickey
served as a member on the board of directors at Emmaus Life Sciences, a biopharmaceutical company, from July 2019 to August 2022; served
as a member on the board of directors at Sanuthera, Inc., a privately held medical device company, from 2013 to 2017, and was employed
as Chief Financial Officer of Motif Bio Plc., a NASDAQ and London AIM exchange-listed antibiotics company, from January 2017 to February
2018. Earlier in his career, Mr. Dickey spent 18 years in investment banking, primarily at Lehman Brothers, with a background split between
mergers and acquisitions and capital markets transactions. Mr. Dickey was a senior vice president of the Company from 2008 until 2013.
Throughout his career he has demonstrated C-level (CFO, COO and CEO) and Board level experience in public, private, revenue stage and
development stage life sciences and medical device companies and has played a leading role in two start-ups. His prior career as an investment
banker included 14 years at Lehman Brothers. Mr. Dickey is experienced in all stages of the business lifecycle, including start-up, high-growth
and turnarounds, and in building businesses and achieving an exit. He also has international experience, expertise in public and private
financings, M&amp;A, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interacting with
boards, VC&#8217;s, shareholders and Wall Street. Dickey has an MBA from The Wharton School and an AB from Princeton University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Audit
Committee and Audit Committee Expert</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of our Board consists of Stewart L. Appelrouth (Chair) and Dr. Mitchell, both determined by the Board to be Independent
Directors as required under Section 803(2) of the NYSE: American Company Guide and Rule 10A-3 under the Exchange Act. The Board has determined
that Mr. Appelrouth qualifies as an &#8220;audit committee financial expert&#8221; as that term is defined by Section 803B(2) of the
NYSE: American Company Guide and the rules and regulations of the SEC. On March 28, 2023, Ms. Bryan was appointed as an additional member
of the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Dr. Mitchell, Ms. Bryan and Mr. Appelrouth to be independent of management and free of any relationship that would interfere
with their exercise of independent judgment as members of this Committee. The principal functions of the Audit Committee are to (1) assist
the Board in fulfilling its oversight responsibility relating to the annual independent audit of our consolidated financial statements
and management&#8217;s assessment of internal control over financial reporting, the engagement of the independent registered public accounting
firm and the evaluation of the independent registered public accounting firm&#8217;s qualifications, independence and performance; (2)
select the independent registered public accounting firm, oversee the work of the independent registered public accounting firm, pre-approve
all auditing services of the independent registered public accounting firm and evaluate the independent registered public accounting
firm&#8217;s qualifications, independence and performance; (3) prepare the reports or statements as may be required by NYSE American
or the securities laws; (4) assist the Board in fulfilling its oversight responsibility relating to the integrity of our financial statements
and financial reporting process and our system of internal accounting and financial controls; (5) discuss the financial statements and
reports with management and the independent registered public accounting firm, including critical accounting policies and practices,
our disclosures in our Annual Report and any significant financial reporting that arose in the preparation of the audited financial statements;
and (6) oversee the Disclosure Control Committee. The Audit Committee is authorized to engage independent counsel and other advisors
as it deems necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Audit Committee formally met twelve times in 2023 with all committee members in attendance. Our General Counsel and Chief Financial Officer
support the Audit Committee in its work. The full text of the Audit Committee&#8217;s Charter, as approved by the Board, is available
on our website: <span style="text-decoration: underline">http://www.aimimmuno.com</span> in the &#8220;Investor Relations&#8221; tab under &#8220;Corporate Governance&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Scientific
Advisory Board (&#8220;SAB&#8221;)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAB was established to leverage its member&#8217;s scientific and pharmaceutical expertise and advice to advance our drug development
programs by providing guidance on steering us forward and capitalizing on business opportunities as well as interactions with the FDA.
It is responsible for: (i) reviewing all submissions made by us to the FDA and other regulators to ensure that the submissions fully,
accurately, and timely describe the status of any clinical trials, tests, or other studies or analyses of drug safety and efficacy undertaken
by us, and any agreements, protocols, or guidance provided by relevant regulatory agencies; and (ii) monitoring and supervising our relationship
with the FDA. The SAB shall have free and open access to our scientific and executive personnel, including the Chief Scientific Officer
and the members of our Board of Directors. The SAB is comprised of William Mitchell, M.D., Chairman, and Ronald Brus, M.D., W. Neal Burnette,
M.D., Christopher Nicodemus, M.D., and Philip Ransom Roane, Ph.D. all of whom are members. The SAB met one time in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Disclosure
Controls Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Disclosure Controls Committee (&#8220;DCC&#8221;) reports to the Audit Committee and is responsible for procedures and guidelines on
managing disclosure information. The purpose of the DCC is to make certain that information required to be publicly disclosed is properly
accumulated, recorded, summarized and communicated to the Board and management. This process is intended to allow for timely decisions
regarding communications and disclosures and to help ensure that we comply with related SEC rules and regulations. The DCC is responsible
for (1) implementing, monitoring and evaluating our disclosure controls and procedures; (2) reviewing and evaluating our interactions
with the FDA and other similar regulatory bodies; and (3) reviewing with the Audit Committee our earnings and other press releases and
periodic reports and proxy statements that are to be filed with the SEC. Robert Dickey, our CFO, is the DCC&#8217;s Investor Relations
Coordinator and Chair. The other members of the DCC are Peter Rodino, our COO and General Counsel, Dr. William Mitchell, one of our Independent
Directors, Dr. David Strayer, Chief Scientific Officer, Diane Young, our Clinical Project Manager, Jodie Pelz, our Director of Finance,
and Ann Marie Coverly, Director of HR and Administration serving as the Deputy Investor Relations Coordinator. The full text of the DCC&#8217;s
Charter, as approved by the Board, is available on our website: www.aimimmuno.com in the &#8220;Investor Relations&#8221; tab under &#8220;Corporate
Governance.&#8221; The DCC actively met on numerous occasions in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Executive
Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, our Board formed the Executive Committee. On March 28, 2023, Ms. Bryan was appointed as an additional member of this committee.
The Executive Committee reports to the Board, and its purpose is to aid the Board in handling matters which, in the opinion of the Chairman
of the Board, should not be postponed until the next scheduled meeting of the Board. Mr. Equels, our Chief Executive Officer is the chair
of the Committee and is a member of the Committee along with three of our independent directors, Mr. Appelrouth, Dr. Mitchell and Ms.
Bryan. The full text of the Executive Committee Charter, as approved by the Board, is available on our website: www.aimimmuno.com in
the &#8220;Investor Relations&#8221; tab under &#8220;Corporate Governance&#8221;. The Committee did not meet in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Corporate
Governance and Nomination Committee</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Governance and Nomination Committee consists of Dr. William M. Mitchell (Chair) and Director, and Mr. Stewart L. Appelrouth,
Director. On March 28, 2023, Ms. Nancy Bryan was appointed as an additional member of this committee. In 2023, the Corporate Governance
and Nomination Committee met two times. All committee members were in attendance for the meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the members of the Committee meet the independence standards contained within the NYSE American Company Guide and AIM&#8217;s Corporate
Governance Guidelines. The full text of the Corporate Governance and Nomination Committee Charter as well as the Corporate Governance
Guidelines, are available on our website: https://aimimmuno.com/corporate-governance/.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporate Governance and Nomination Committee is responsible for (1) assisting the Board in identifying, recommending, assessing, recruiting
and selecting candidates to serve as members of the Board, including in connection with filling vacancies; (2) assisting the Board in
developing criteria for identifying and selecting individuals for nomination to the Board; (3) advising the Board with respect to the
Board&#8217;s composition, procedures and committees; (4) reviewing, assessing and recommending appropriate Corporate Governance Guidelines;
(5) reviewing the charter of each committee of the Board and recommending to the Board the number, identity and responsibilities of each
committee; (6) reviewing our business practices as they relate to preserving our good reputation; (7) developing and recommending to
the Board procedures for succession planning for our executives and continuity of the Board; and (8) assessing the effectiveness of the
Board in meeting the long-terms interest of the stockholders. The Committee is authorized to retain search firms and other consultants
to assist it in identifying candidates and fulfilling its other duties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
who wish to suggest qualified candidates should write to the Corporate Secretary, AIM ImmunoTech Inc., 2117 SW Highway 484, Ocala, Florida
34473, stating in detail the qualifications of such persons for consideration by the Committee. Director candidates should demonstrate
the qualifications, experience and skills for Board members which are important to AIM&#8217;s business and its future, as outlined in
Proposal 1 below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
aspire to the highest standards of ethical conduct; reporting results with accuracy and transparency; and maintaining full compliance
with the laws, rules and regulations that govern our business. AIM&#8217;s Corporate Governance Guidelines embody many of our policies
and procedures which are at the foundation of our commitment to best practices. The guidelines are reviewed annually and revised if deemed
necessary, to continue to reflect best practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Code
of Ethics</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors adopted a revision to the 2003 Code of Ethics and business conduct for officers, directors, employees, agents and
consultants. The principal amendments included broadening the Code&#8217;s application to our agents and consultants, adoption of a regulatory
compliance policy and adoption of a policy for protection and use of Company computer technology for business purposes only. On an annual
basis, this Code is reviewed and signed by each Officer, Director, employee and strategic consultant with none of the amendments constituting
a waiver of provision of the Code of Ethics on behalf of our Chief Executive Officer, Chief Financial Officer, or persons performing
similar functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may obtain a copy of this Code by visiting our website at <span style="text-decoration: underline">www.aimimmuno.com</span> (Investor Relations / Corporate Governance) or by
written request to our office at 2117 SW Highway 484, Ocala, FL 34473.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Section
16(a) Beneficial Ownership Reporting Compliance</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
federal securities laws, our directors and officers, and any beneficial owner of more than 10% of a class of our equity securities,
are required to report their ownership of the Company&#8217;s equity securities and any changes in such ownership in a timely
manner. We are required to disclose in this Report any delinquent filing of such reports and any failure to file such reports during
the fiscal year ended December 31, 2023. Based solely upon information provided by officers and directors and greater than 10%
owners, we are not aware of any filings not made on a timely basis, except for two Forms 4 filed on March 27, 2024, to report awards
of options to Thomas Equels and Peter Rodino on November 30, 2023.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_018"></span>ITEM
  11.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive Compensation. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPENSATION
DISCUSSION AND ANALYSIS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis describes our executive compensation philosophy, process, plans and practices as they relate to our &#8220;Named
Executive Officers&#8221; (&#8220;NEO&#8221;) listed below and gives the context for understanding and evaluating the more specific compensation
information contained in the narratives, tables and related disclosures that follow. For the purposes of discussion and analysis, the
following NEOs are included in the narratives, tables and related disclosures that follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Chief Executive Officer (&#8220;CEO&#8221;) and President;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV, Chief Financial Officer (&#8220;CFO&#8221;); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Rodino, Chief Operating Officer (&#8220;COO&#8221;), General Counsel and Company Secretary (&#8220;CS&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, we entered into an employment agreement with Thomas Equels, the agreement runs for five years with a base salary of $850,000.
Mr. Equels will be awarded a year-end target bonus of $350,000. In March 2021, subsequent to the fiscal year ended December 31, 2020,
we entered into employment agreements with Peter Rodino. The agreement runs for three years, respectively. Compensation is divided into
both short- and long-term compensation. Short-term (cash) compensation will consist of a base salary of $425,000. Mr. Rodino will be
awarded a year-end target bonus based on performance and goals established by the Compensation Committee. Long term compensation will
be provided by 100,000 non-qualified yearly stock options with one-year vesting commencing on November 30, 2021. In addition, Mr. Equels
and Mr. Rodino will be entitled to awards (&#8220;Event Awards&#8221;) equal to 3% for Mr. Equels and 1% for Mr. Rodino of the &#8220;Gross
Proceeds&#8221; from specific events such as acquisitions, licensing agreements or &#8220;therapeutic indication&#8221; (each, an &#8220;Event&#8221;).
Gross Proceeds means those cash amounts paid to us by the other parties for licensing agreements, therapeutic acquisitions or any other
one-time cash generating event. Therapeutic indications are for example target organ specific pathologically defined cancer indications,
vaccine enhancers, broad spectrum antiviral indications, or medical entities associated with persistent severe fatigue. Mr. Equels and
Mr. Rodino also will each be entitled to an award (an &#8220;Acquisition Award&#8221;) equal to 3% for Mr. Equels and 1% for Mr. Rodino
of the Gross Proceeds, upon the sale of our Company or substantially all of its assets (an &#8220;Acquisition&#8221;). An Event Award
or Acquisition Award shall be paid in cash within 90 days of our receipt of the Gross Proceeds. On March 2022, the Company entered into
a consulting agreement with Foresite Advisors, LLC, a company wholly owned by Robert Dickey IV, for $375 an hour pursuant to which Mr.
Dickey serves as our Chief Financial Officer, effective April 4, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance
of Compensation Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee consists of the following three directors, each of whom is &#8220;independent&#8221; under applicable NYSE American
rules, a &#8220;Non-Employee Director&#8221; as defined in Rule 16b-3 under the Exchange Act, and an &#8220;Outside Director&#8221; as
defined under the U.S. Treasury regulations promulgated under Section 162(m) of the Internal Revenue Code of 1986, as amended (the &#8220;Internal
Revenue Code&#8221;): William Mitchell, M.D., Ph.D. (Chair) and Stewart L. Appelrouth. On March 28, 2023, Ms. Bryan was appointed as
an additional member of this committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee oversees implementation and administration of our compensation and employee benefits programs with the goal of
attracting, retaining and motivating executives and officers, as well as other employees, to improve their performance and our financial
performance. In that regard, the Compensation Committee (1) reviews and approves corporate goals and objectives relevant to compensation;
(2) evaluates the performance and compensation of our officers and executives and reviews the compensation of all other non-officer executives
that are considered highly paid; (3) reviews and approves employment agreements, severance agreements, change of control agreements,
deferred compensation agreements, perquisites and similar compensation arrangements of our executive officers; (4) makes recommendations
to the Board on the compensation of non-employee members of the Board; (5) administers our incentive and equity-based compensation plans,
including, approving the grant of equity awards under such plans, reviewing such plans and making recommendations to the Board regarding
the adoption, amendment or termination of such plans; (6) selects and determines the fees and scope of work of its compensation consultants;
and (7) reviews our compensation strategy to assure that it continues to advance our objectives and promote stockholder value. The full
text of the Compensation Committee&#8217;s Charter, as approved by the Board, is available on our website: www.aimimmuno.com in the &#8220;Investor
Relations&#8221; tab under &#8220;Corporate Governance&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Committee formally met four times in 2023 and all committee members were in attendance for the meetings. Our General Counsel, Chief Financial
Officer and Director of Human Resources support the Compensation Committee in its work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Stockholder Advisory Vote on Executive Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the November 2022 Annual Meeting of Stockholders, the Stockholders did not approve the annual, non-binding advisory vote on Executive
Compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Objectives
and Philosophy of Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of the Compensation Committee of our Board of Directors with respect to Executive compensation are to attract and
retain the most talented and dedicated Executives possible, to tie annual and long-term cash and stock incentives to achievement of measurable
performance objectives, and to align Executives&#8217; incentives with stockholder value creation. To achieve these objectives, the Compensation
Committee expects to implement and maintain compensation plans that tie a substantial portion of Executives&#8217; overall compensation
to key strategic financial and operational goals such as the establishment and maintenance of key strategic relationships, the development
of our products, the identification and advancement of additional products and the performance of our common stock price. The Compensation
Committee evaluates individual Executive performance with the goal of setting compensation at levels the Committee believes are comparable
with Executives in other companies of similar size and stage of development operating in the biotechnology industry while taking into
account our relative performance, our own strategic goals, governmental regulations and the results of Stockholder Advisory Votes regarding
executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
COMPENSATION </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information on the compensation during the fiscal years ended December 31, 2023 and 2022 of Thomas Equels, our
Chief Executive Officer, Peter Rodino our Chief Operating Officer, General Counsel and Secretary, Robert Dickey IV our Chief Financial
Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Name &amp; Principal Position</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Year</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Salary / Fees<br/>
$&#160;(2)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin: 0pt">Bonus<br/>
$ (3) (6)</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Awards<br/>
$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin: 0pt">Option <br/>Awards<br/>
$
(1)</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Non-Equity Incentive Plan Compensation<br/>
$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Change in Pension Valued and NQDC Earnings<br/>
$</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">All Other Compensation<br/>
$ (3)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total<br/>
$</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 19%; text-align: left">Thomas K Equels</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">850,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">128,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">103,189</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,081,301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CEO &amp; President (2)3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,352,028</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Dickey IV</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,484</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>CFO (2)4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Rodino</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">COO, General Counsel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,940</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&amp; Secretary (2)5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">425,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">699,298</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    option awards were valued using the Black-Scholes method. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Named Executive Officers, who are also Directors that receive compensation for their services as a Director, the Salary/Fees and
    Option Awards columns include compensation that was received by them for their role as a member of the Board of Directors. As is
    required by Regulation S-K, Item 402(c), compensation for services as a Director have been reported within the &#8220;Summary Compensation
    Table&#8221; (above) for fiscal years of 2023 and 2022 as well as reported separately in the &#8220;Compensation of Directors&#8221;
    section (see below) for calendar year 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to his current employment agreement, Mr. Equels is entitled to 3% of the &#8220;Gross Proceeds&#8221; (as defined in the employment
    agreement) for &#8220;significant events&#8221; (as described in the employment agreement) There were no payments during 2023 and
    2022. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; width: 0.5in">(3)</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Equels&#8217; All Other Compensations consists of:</span></td>
    </tr>
</table>

<p style="margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Life &amp; Disability Insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">41,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">31,375</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Healthcare Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,316</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,764</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Car Expenses/Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">401(k) Matching Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">103,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">90,472</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.5in">(4)</td>
  <td> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Dickey&#8217;s All Other Compensations consists of:</span></td></tr>
</table>




<p style="margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Life &amp; Disability Insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Healthcare Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Car Expenses/Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">401(k) Matching Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.5in">(5)</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Rodino&#8217;s All Other Compensations consists of:</span></td></tr>
</table>




<p style="margin: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Life &amp; Disability Insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,450</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Healthcare Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,216</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,820</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Car Expenses/Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">401(k) Matching Funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59,940</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.5in"><span style="font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-size: 10pt">All bonus compensation for 2023 was deferred to 2024. </span></td></tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; padding-bottom: 1.5pt">Outstanding Equity Awards at Fiscal Year End</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="17" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; padding-bottom: 1.5pt">Option Awards</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td colspan="13" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards</b></span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Name</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Securities Underlying Unexercised Options (#)<br/>
Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Securities Underlying Unexercised Options (#)<br/>
Unexercisable</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options<br/>
(#)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercise Price<br/>
($)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Expiration<br/>
 Date</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares or Units of Stock that Have Not Vested<br/>
(#)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Value of Shares or Units of Stock that Have Not Vested<br/>
($)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that Have Not Vested<br/>
(#)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested<br/>
($)</span></td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left">Thomas K Equels</td><td style="width: 2%">&#160;</td>
    <td style="width: 5%; text-align: right">568</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">190.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/6/2024</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">President and Chief</td><td>&#160;</td>
    <td style="text-align: right">568</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/8/2025</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Executive Officer</td><td>&#160;</td>
    <td style="text-align: right">568</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/8/2026</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">6,818</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/8/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">323</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">323</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;412</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">472</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">485</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">556</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">8,446</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/13/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">2,841</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/12/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">6,818</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/16/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">5,682</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/16/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">3,666</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/18/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">6,457</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/17/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">23</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">9,685</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/28/2029</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">300,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/12/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">300,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/11/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">300,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/11/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2032</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2033</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 1.5pt">Total</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,254,711</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Robert Dickey IV Chief financial Officer</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/03/2032</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 1.5pt">Total</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">50,000</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Rodino</td><td>&#160;</td>
    <td style="text-align: right">284</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/21/2026</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">COO, General Counsel and Secretary</td><td>&#160;</td>
    <td style="text-align: right">151</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">151</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">192</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">220</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">226</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/15/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">259</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/31/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">3,941</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/13/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">2,273</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/12/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">2,652</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/16/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">1,711</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/18/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">3,013</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/17/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">23</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">4,520</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/28/2029</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">75,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/9/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">100,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">50,000</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/03/2032</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2032</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.47</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/30/2033</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-bottom: 1.5pt">Total</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">344,616</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payments
on Disability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, we had an employment agreement with Mr. Equels which entitled him to his base salary, applicable benefits otherwise
due and payable through the last day of the month in which disability occurs and immediate vesting of stock options. In the event of
permanent disability, the Company will provide an additional two years of base salary. On March 24, 2021, we entered into employment
agreements with Mr. Rodino which entitled him to his base salary, applicable benefits otherwise due and payable through the last day
of the month in which disability occurs and immediate vesting of stock options. In the event of permanent disability, the Company will
provide an additional two years of base salary. In addition, each NEO has the same short and long-term disability coverage which is available
to all eligible employees. The coverage for short-term disability provides up to six months of full salary continuation up to 60% of
weekly pay, less other income, with a $1,500 weekly maximum limit. The coverage for group long-term disability provides coverage at the
exhaustion of short-term disability benefits of full salary continuation up to 60% of monthly pay, less other income, with a $10,000
monthly maximum limit. The maximum benefit period for the group long-term disability coverage is 60 months for those age 60 and younger
at the time of the claim with the coverage period proportionately reduced with the advanced age of the eligible employee to a minimum
coverage period of 12 months for those of 69 years old and older as of the date of the claim. For the period June 2010 through December
2023, Mr. Equels was entitled to receive total disability coverage of $400,000 pursuant to his employment agreement and payable by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payments
on Death</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to their employment agreements, the NEOS are entitled to their base salary and applicable benefits otherwise due and payable through
the last day of the month in which death occurs and immediate vesting of stock options. Each NEO has coverage of group life insurance,
along with accidental death and dismemberment benefits, consistent to the dollar value available to all eligible employees. The benefit
is equal to two times current salary or wage with a maximum limit of $300,000, plus any supplemental life insurance elected and paid
for by the NEO. For the period June 2010 and through December 2023, Mr. Equels is entitled to receive total death benefit coverage of
$3,000,000 pursuant to his employment agreement and payable by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
Payments Following Severance &#8212; Named Executive Officers (NEO)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to his employment agreement, Mr. Equels is entitled to severance benefits on certain types of employment terminations not related to
a change in control or termination not for cause. Mr. Rodino and Mr. Dickey are not covered by an employment severance agreement and
therefore would only receive severance as determined by the Compensation Committee in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dollar amounts below assume that the termination occurred on January 2, 2024. The actual dollar amounts to be paid can only be determined
at the time of the NEO&#8217;s separation from us based on their prevailing compensation and employment agreements along with any determination
by the Compensation Committee in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Event</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cash <br/>Severance&#160;($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value of Stock&#160;Awards That&#160;Will Become <br/>Vested&#160;(1)&#160;($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin: 0pt">Continuation&#160;of <br/>Medical</p>
                                                                                <p style="margin: 0pt">Benefits&#160;($)</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Additional <br/>Life <br/>Insurance&#160;($)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total&#160;($)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 13%; text-align: left">Thomas K. Equels,</td><td style="width: 2%">&#160;</td>
    <td style="width: 13%; text-align: left">Involuntary (no cause)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,436,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">128,112</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,564,112</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">CEO &amp; President</td><td>&#160;</td>
    <td style="text-align: left">Termination (for cause)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Death or disability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,700,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,828,112</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Termination by employee or retirement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">128,112</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Dickey IV</td><td>&#160;</td>
    <td style="text-align: left">Involuntary (no cause)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>CFO</td><td>&#160;</td>
    <td style="text-align: left">Termination (for cause)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Death or disability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Termination by employee or retirement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Rodino</td><td>&#160;</td>
    <td style="text-align: left">Involuntary (no cause)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">107,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">150,584</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">COO, General Counsel and</td><td>&#160;</td>
    <td style="text-align: left">Termination (for cause)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Secretary</td><td>&#160;</td>
    <td style="text-align: left">Death or disability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">892,704</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">Termination by employee or retirement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">42,704</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of stock options contractually required per the employee&#8217;s respective employment agreement or arrangement to be granted during
    each calendar year of the term under our 2018 Equity Incentive Plan. The stock options have a ten-year term and an exercise price
    equal to the closing market price of our common stock on the date of grant. The value was obtained using the Black-Scholes-Merton
    pricing model for stock-based compensation in accordance with FASB ASC 718.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payments
on Termination in Connection with a Change in Control of Named Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to their employment agreements, each NEO is entitled to severance benefits on certain types of employment terminations related to a change
in control. In such an event, the term of their employment agreements would automatically be extended for three additional years, except
where such change in control occurs as a result of certain &#8220;significant events&#8221; (as described in his employment agreement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dollar amounts in the chart below assume that change in control termination occurred on January 2, 2024, based on the employment agreements
that existed at that time. The actual dollar amounts to be paid can only be determined at the time of the NEO&#8217;s separation from
us based on their prevailing compensation and employment agreements along with any determination by the Compensation Committee in its
discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
Benefits on Termination Following a Change in Control &#8212; December 31, 2023 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows potential payments to the NEO if employment terminates following a change in control under contracts, agreements,
plans or arrangements at December 31, 2023. The amounts assume a January 2, 2024, termination date regarding base pay and use of the
opening price of $0.44 on the NYSE American for our common stock at that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Name</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Aggregate<br/>
Severance<br/>
Pay<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">PVSU Acceleration<br/>
(2)&#160;($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Early Vesting of Restricted Stock<br/>
(4)&#160;(5)<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Early Vesting of Stock Options and SARs<br/>
(3)&#160;($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Acceleration and Vesting of Supplemental Award<br/>
(5)&#160;($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Welfare Benefits Continuation<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Outplacement Assistance<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Parachute Tax Gross-up Payment<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Total<br/>
($)</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; text-align: left">Thomas K. Equels</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4,340,000 (</span></td><td style="width: 2%; text-align: left">1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$651,000 (</span></td><td style="width: 2%; text-align: left">4)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">4,991,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Robert Dickey IV</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Rodino</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    amount represents the Base Salary and benefits for the remaining current term of the NEO&#8217;s employment agreement plus a three-year
    extension in the term upon the occurrence of a termination from a change in control. The employment agreement with Mr. Equels has
    a term through December 31, 2025. This amount excludes the following payments as they cannot be calculated unless and until certain
    events occur: Mr. Equels is entitled to 3% of the &#8220;Gross Proceeds&#8221; (as defined in the employment agreement) for &#8220;significant
    events&#8221; (as described in his employment agreement) and 3% of the Gross Proceeds from any sale of our Company or substantially
    all of our assets.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    amount represents the payout of all outstanding performance-vesting share units (&#8220;PVSU&#8221;) awarded on a change in control
    at the target payout level with each award then pro-rated based on the time elapsed for the applicable three-year performance period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    amount is the intrinsic value [fair market value] on January 2, 2024 ($0.48 per share) minus the weighted average per share exercise
    price of $0.43 of all unvested stock options for each NEO, including Stock Appreciation Rights (&#8220;SAR&#8221;). Any option with
    an exercise price of greater than fair market value was assumed to be cancelled for no consideration and, therefore, had no intrinsic
    value.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    amount represents the options to be issued annually for the remaining term of the NEO&#8217;s employment agreement plus a three-year
    extension in the occurrence of termination from a change in control. For the purpose of this schedule, a NYSE American closing price
    at January 2, 2024 of $0.48 was used with an estimated exercise price of $0.48 for Mr. Equels. The value was obtained using the Black-Scholes-Merton
    pricing model for stock-based compensation in accordance with FASB ASC 718.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    purchase rights represented by the Option not then vested shall, upon a change in control, shall become vested.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Post-Employment
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of post-employment compensation payable to the respective NEO. If a NEO does not have a specific benefit,
they will not be mentioned in the subsection. In such an event, the NEO does not have any such benefits upon termination unless otherwise
required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
for Cause</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our NEOs can be terminated for cause. For each NEO &#8220;Cause&#8221; means willful engaging by any NEO in illegal conduct, gross
misconduct or gross violation of our Code of Ethics and Business Conduct for Officers, which is demonstrably and materially injurious
to our Company. Mr. Equels&#8217; agreement provides that he shall not be deemed to have been terminated for Cause unless and until we
initiate a process by delivery to him a copy of a resolution duly adopted by the affirmative vote of not less than a majority of the
directors of the Board specifying the grounds for termination. After reasonable notice to Mr. Equels and an opportunity for him to be
heard, the issues shall be adjudicated by a retired Florida judge or a Florida certified mediator mutually acceptable to the Board of
Directors and Mr. Equels. Termination requires a finding that Mr. Equels was guilty of intentional and material misconduct according
to the standards set forth above, and specifying the particulars thereof in detail supported by legally admissible evidence and utilizing
the legal standard of beyond reasonable doubt. In the event that an NEO&#8217;s employment is terminated for Cause, we shall pay such
NEO, at the time of such termination, only the compensation and benefits otherwise due and payable to him through the last day of his
actual employment by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Termination
without Cause</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that an NEO is terminated at any time without &#8220;Cause&#8221;, we shall pay to him, at the time of such termination, the
compensation and benefits otherwise due and payable through the last day of the then current term of his Agreement. However, benefit
distributions that are made due to a &#8220;separation from service&#8221; occurring while he is a Named Executive Officer shall not
be made during the first six months following separation from service. Rather, any distribution which would otherwise be paid to him
during such period shall be accumulated and paid to him in a lump sum on the first day of the seventh month following the &#8220;separation
from service&#8221;. All subsequent distributions shall be paid in the manner specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Death
or Disability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
NEO can be terminated for death or disability. &#8220;Disability&#8221; means the NEO&#8217;s inability effectively to carry out substantially
all of his duties by reason of any medically determinable physical or mental impairment which can be expected to result in death or which
has lasted or can be expected to last for a continuous period of not less than 12 months. In the event his employment is terminated due
to his death or disability, we will pay him (or his estate as the case may be), at the time of such termination, his base salary, applicable
benefits, and immediate vesting of unvested stock options. In the event of permanent disability, we will provide an additional two years
of base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Compensation, Audit and Corporate Governance and Nomination Committees, consist of Dr. William M. Mitchell, Compensation and Corporate
Governance and Nomination Committee Chair, Stewart L. Appelrouth, Audit Committee Chair, and Nancy K. Byrn all of whom are independent
Board of Director members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
reimburse Directors for travel expenses incurred in connection with attending board, committee, stockholder and special meetings along
with other Company business-related expenses. We do not provide retirement benefits or other perquisites to non-employee Directors under
any current program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no cost of living increase granted in 2022 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Directors have been granted options to purchase common stock under our Stock Option Plans and/or Warrants to purchase common stock. We
believe such compensation and payments are necessary in order for us to attract and retain qualified outside directors. Options shares
for stock compensation were issued under the 2018 Equity Incentive Plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation &#8211; 2023 &amp; 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and Title of Director</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin: 0pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
                                            Earned or</span></p> <p style="margin: 0pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid
                                            in Cash&#160;$ </span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Award&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    Award&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Equity
    Incentive Plan Compensation&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in Pension Value &amp; Nonqualified Deferred Compensation Earnings&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Compensation As Director&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total&#160;$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">T.
    Equels</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    Chairman</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">W.
    Mitchell</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,365</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,365</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,462</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,165</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Board</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S.
    Appelrouth</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,462</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,165</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.
    Bryan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93,750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Board reduced annual cash compensation from $182,462 to $125,000 to allow for additional Board members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_019"></span>ITEM
  12.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth as of March 24, 2024, the number and percentage of outstanding shares of Common Stock beneficially owned
by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    person, individually or as a group, known to us to be deemed the beneficial owners of five percent or more of our issued and outstanding
    Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    of our Directors and the Named Executives Officers; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our officers and directors as a group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
number of shares of Common Stock at March 27, 2024 was 49,901,177.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 60%; text-align: left">Name and Address of <br/>Beneficial Owner</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></p>
                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficially</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></p></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% Of Shares</span></p>
                                                                                                                                                          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficially</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owned</span></p></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas K. Equels, Executive Vice Chairman, Chief Executive Officer, President</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,971,166</span></td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*0.04</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter W. Rodino III, Chief Operating Officer, General Counsel, Secretary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">526,335</span></td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">William M. Mitchell, M.D., Chairman of the Board of Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">306,001</span></td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stewart L. Appelrouth, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">379,364</span></td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Dickey IV, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nancy K. Bryan, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">38,462</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All directors and executive officers as a group (6 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,271,328</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0. 065 </span></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For Mr. Equels, shares beneficially owned include 1,254,711 shares issuable upon exercise of options and excludes 300,000 shares issuable
upon exercise of options not vested or not exercisable within the next 60 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For Mr. Rodino, shares beneficially owned include 344,617 shares issuable upon exercise of options and excludes 100,000 shares issuable upon
exercise of options not vested or not exercisable within the next 60 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)For
Dr. Mitchell, shares beneficially owned include 229,589 shares issuable upon exercise of options and excludes no shares issuable upon
exercise of options not vested or not exercisable within the next 60 days. Also includes 190 shares of common stock owned by his spouse
and 190 shares owned by family trusts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)For
Mr. Appelrouth, shares beneficially owned include 139,599 shares issuable upon exercise of options and excludes no shares issuable upon
exercise of options not vested or not exercisable within the next 60 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)For
Mr. Dickey IV, shares beneficially owned include 50,000 shares issuable upon exercise of options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table gives information about our Common Stock that may be issued upon the exercise of options, warrants and rights under all
of our equity compensation plans as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Plan Category</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Securities to be <br/>issued upon <br/>exercise of outstanding <br/>options, warrants and <br/>rights</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price <br/>Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of securities <br/>Remaining available for <br/>future issuance under equity <br/>compensation plans <br/>(excluding securities <br/>reflected in column) (a)</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 41%; text-align: left">Equity compensation plans approved by security holders:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">3,293,493</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4.03</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,210,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity compensation plans not approved by security holders:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.03</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,445,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,210,286</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_020"></span>ITEM
  13.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain Relationships and Related Transactions, and Director
Independence.</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval or Ratification of Transactions with Related Persons</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to require that any transaction with a related party required to be reported under applicable SEC rules, other than compensation
related matters and waivers of our code of business conduct and ethics, be reviewed and approved or ratified by a majority of independent,
disinterested Directors. We have adopted procedures in which the Audit Committee shall conduct an appropriate review of all related party
transactions for potential conflict of interest situations on an annual and case-by-case basis with the approval of this Committee required
for all such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have employment agreements with certain of our executive officers and have granted such Officers and Directors options and warrants to
purchase our Common Stock, as discussed under the headings, Item 11. &#8220;Executive Compensation&#8221;, and Item 12. &#8220;Security
Ownership of Certain Beneficial Owners and Management&#8221;, as noted above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_021"></span>ITEM
  14.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Accountant Fees and Services. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
audit and professional services are approved in advance by the Audit Committee to assure such services do not impair the auditor&#8217;s
independence from us. The total fees by BDO USA, P.C. (&#8220;BDO&#8221;) for 2023 were $594,474 and total fees for 2022 were $545,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    ($)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#8239;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Fees:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">560,984</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">522,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,490</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">594,474</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">545,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees include the audit of our annual financial statements and the review of our financial statements included in our quarterly reports
and services in connection with statutory and regulatory filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
also includes fees for assurance and related services that were reasonably related to the performance of the audit or review of our financial
statements. Audit-related fees include professional services related to the Company&#8217;s filing of SEC Form S-3 and S-8 (i.e., stock
shelf offering procedures).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Fees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
fees include fees billed by BDO for professional services rendered for tax return preparation, compliance, advice and planning services.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has determined that BDO&#8217;s rendering of these audit-related services and all other fees were compatible with maintaining
auditor&#8217;s independence. The Board of Directors considered BDO to be well qualified to serve as our independent public accountants.
The Committee also pre-approved the charges for services performed in 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee pre-approves all auditing and accounting services and the terms thereof (which may include providing comfort letters
in connection with securities underwriting) and non-audit services (other than non-audit services prohibited under Section 10A(g) of
the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board) to be provided to us by the independent
auditor; provided, however, the pre-approval requirement is waived with respect to the provisions of non-audit services for us if the
&#8220;de minimus&#8221; provisions of Section 10A (i)(1)(B) of the Exchange Act are satisfied. This authority to pre-approve non-audit
services may be delegated to one or more members of the Audit Committee, who shall present all decisions to pre-approve an activity to
the full Audit Committee at its first meeting following such decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_022"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_023"></span>ITEM
  15.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits and Financial Statement Schedules. </b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statements and Schedules - See index to financial statements on page F-1 of this Annual Report. All other schedules called for under
regulation S-X are not submitted because they are not applicable or not required, or because the required information is included in
the financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Exhibits - See exhibit index below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Certificate of Incorporation, as amended, along with Certificates of Designations (incorporated by reference
    to exhibits of the Company&#8217;s Registration Statement on Form S-1 (No. 33-93314) filed November 2, 1995). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420411053516/v234408_def14a.htm" style="-sec-extract: exhibit">Amendment to Certificate of Incorporation (incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A (No. 001-13441) filed September 16, 2011).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416006083/s103576_def14a.htm" style="-sec-extract: exhibit">Amendment to Certificate of Incorporation(incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A (No. 000-27072) filed June 27, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219008701/ex3i-1.htm" style="-sec-extract: exhibit">Amendment to Certificate of Incorporation(incorporated by reference to exhibit 3.11 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed June 5, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219013294/ex3i-1.htm" style="-sec-extract: exhibit">Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.11 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed August 23, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219001474/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Designation of Preference, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the Amendment to the Company&#8217;s Registration Statement on Form S-1/A (No. 333-229051) filed February 6, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/ex3-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated By-Laws. (incorporated by reference to Exhibit 3.7 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2022).</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    certificate representing our Common Stock (incorporated by reference to Exhibits of the Company&#8217;s Registration Statement on
    Form S-1 (No. 33-93314) filed November 2, 1995).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217013243/ex1.htm" style="-sec-extract: exhibit">Amended and Restated Rights Agreement, dated as of November 14, 2017, between the Company and American Stock Transfer &amp; Trust Company LLC. The Amended and Restated Right Agreement includes the Form of Certificate of Designation, Preferences and Rights of the Series A Junior Participating Preferred Stock, the Form of Rights Certificate and the Summary of the Right to Purchase Preferred Stock (incorporated by reference to Exhibit 1 to the Company&#8217;s Registration Statement on Form 8-A12B (No. 001-27072) filed November 14, 2017).</a>    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217013243/ex1.htm" style="-sec-extract: exhibit">Amended and Restated Rights Agreement, dated as of November 9, 2022, between the Company and American Stock Transfer &amp; Trust Company LLC. (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form 8-A12B (No. 001-27072) filed November 14 2022 )</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223004304/ex4-5.htm" style="-sec-extract: exhibit">Amended and Restated Rights Agreement, dated as of February 9, 2023, between the Company and American Stock Transfer &amp; Trust Company LLC. (incorporated by reference to Exhibit 1 to the Company&#8217;s Registration Statement on Form 8-A12B (No. 001-27072) filed February 10, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222001953/ex4-4.htm" style="-sec-extract: exhibit">Form of Indenture filed with Form S-3 Universal Shelf Registration Statement (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Form S-3 Registration Statement (No. 333- 262280) filed January 21, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416007014/s104021_ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant pursuant to August 30, 2016 Securities Purchase Agreement (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No. 000-270720 filed September 1, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577417000348/s105221_ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant pursuant to February 1, 2017 Securities Purchase Agreement (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed February 3, 2017).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217006056/ex4-1.htm" style="-sec-extract: exhibit">Form of Series A Warrant-June 2017 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed June 1, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217006056/ex4-2.htm" style="-sec-extract: exhibit">Form of Series B Warrant-June 2017(incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed June 1, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009746/ex4-1.htm" style="-sec-extract: exhibit">Form of New Series A Warrant-August 2017 (incorporated by reference to Exhibit 4.1 the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 23, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009746/ex4-2.htm" style="-sec-extract: exhibit">Form of New Series B Warrant-August 2017 (incorporated by reference to Exhibit 4.2 the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 23, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex4-8.htm" style="-sec-extract: exhibit">Form of Warrant issued to Purchaser of facility (incorporated by reference to Exhibit 4.8 to the Company&#8217;s Annual report on Form 10-K (No. 000-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218005575/ex4-1.htm" style="-sec-extract: exhibit">Form of Class A Warrant- April 2018 (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed April 20, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218005575/ex4-2.htm" style="-sec-extract: exhibit">Form of Class B Warrant- April 2018 (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed April 20, 2018).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218014063/ex10-2.htm" style="-sec-extract: exhibit">September 28, 2018 Secured Convertible Promissory Note from the Company to Iliad Research and Trading, L.P. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed October 4, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219001474/ex4-14.htm" style="-sec-extract: exhibit">Rights Offering Form of Non-Transferable Subscription Rights Certificate (incorporated by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-1/A (No. 333-229051) filed February 6, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219002649/ex4-1.htm" style="-sec-extract: exhibit">Rights Offering Form of Warrant Agreement (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K filed February 27, 2019 and is hereby incorporated by reference).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219001474/ex4-15.htm" style="-sec-extract: exhibit">Rights Offering Form of Warrant Certificate (incorporated by reference to Exhibit 4.15 to the Company&#8217;s Registration Statement on Form S-1/A (No. 333-229051) filed February 6, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219003021/ex4-1.htm" style="-sec-extract: exhibit">Rights Offering Warrant Agency Agreement with American Stock Transfer &amp; Trust (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No.001-27072) filed March 8, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219014689/ex4-1.htm" style="-sec-extract: exhibit">AGP Offering-Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed September 27, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219014689/ex4-2.htm" style="-sec-extract: exhibit">AGP Offering-Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed September 27, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219014454/ex4-20.htm" style="-sec-extract: exhibit">AGP Offering-Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.20 to the Company&#8217;s Registration Statement on Form S-1/A (No. 333-233657) filed September 24, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219003394/ex10-1.htm" style="-sec-extract: exhibit">March 2019 Amendment to September 28, 2018 Secured Convertible Promissory Note from the Company to Iliad Research and Trading, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed March 15, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219019007/ex10-2.htm" style="-sec-extract: exhibit">December 5, 2019 Secured Promissory Note with Atlas Sciences, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No.001-27072) filed December 11, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-25.htm">Description of Common Stock.*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Confidentiality, Invention and Non-Compete Agreement (incorporated by reference to Exhibits of the Company&#8217;s Registration
    Statement on Form S-1 (No. 33-93314) filed November 2, 1995). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Clinical Research Agreement (incorporated by reference to Exhibits of the Company&#8217;s Registration Statement on Form S-1 (No.
    33-93314) filed November 2, 1995.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420406013365/v039320_ex10-46.txt" style="-sec-extract: exhibit">Supply Agreement with HollisterStier Laboratories LLC dated December 5, 2005 (incorporated by reference to Exhibit 10.46 to the Company&#8217;s Annual report on Form 10-K (No. 001-13441) for the year ended December 31, 2005).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420410013215/v177135_ex10-68.htm" style="-sec-extract: exhibit">Amendment to Supply Agreement with HollisterStier Laboratories LLC dated February 25, 2010 (incorporated by reference to Exhibit 10.68 to the Company&#8217;s Annual report on Form 10-K (No. 001-13441) for the year ended December 31, 2009).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420411062354/v239122_ex10-2.htm" style="-sec-extract: exhibit">Vendor Agreement with Armada Healthcare, LLC dated August 15, 2011 (incorporated by reference Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-131) for the period ended September 30, 2011).</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420412014793/v304962_ex10-22.htm" style="-sec-extract: exhibit">Amendment to Supply Agreement with HollisterStier Laboratories LLC executed September 9, 2011 (incorporated by reference to Exhibit 10.22 to the Company&#8217;s Annual report on Form 10-K (No. 001-13441) for the year ended December 31, 2011).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000114420412046324/v321637_ex10-1.htm" style="-sec-extract: exhibit">Vendor Agreement extension with Armada Healthcare, LLC dated August 14, 2012 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 15, 2012).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664414000005/a1022-armada.htm" style="-sec-extract: exhibit">Vendor Agreement extension with Armada Healthcare, LLC dated July 19, 2013 (incorporated by reference to Exhibit 10.22 to the Company&#8217;s Annual report on Form 10-K (No. 000-27072) for the year ended December 31, 2013).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000008/a1024-armadabioridge1.htm" style="-sec-extract: exhibit">Vendor Agreement extension with Bio Ridge Pharma, LLC and Armada Healthcare, LLC dated August 8, 2014. (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Annual report on Form 10-K (No. 000-27072) for the year ended December 31, 2014).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000008/a1025-emergehemispherxagre.htm" style="-sec-extract: exhibit">Sales, Marketing, Distribution, and Supply Agreement with Emerge Health Pty Ltd. dated March 9, 2015. (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.25 to the Company&#8217;s Annual report on Form 10-K (No. 000-27072) for the year ended December 31, 2014).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000048/heb-20150630xex101armada.htm" style="-sec-extract: exhibit">Vendor Agreement extension with Armada Healthcare, LLC dated July 29, 2015 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000067/ex101-mytomorrowxredacted.htm" style="-sec-extract: exhibit">Early Access Agreement with Impatients N.V. dated August 3, 2015.(Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-13441) for the period ended September 30, 2015).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000048/heb-20150630xex104emergeal.htm" style="-sec-extract: exhibit">Sales, Marketing, Distribution, and Supply Agreement with Emerge Health Pty Ltd. dated August 6, 2015. (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000094664415000067/ex102-mytomorrowsaddeapxre.htm" style="-sec-extract: exhibit">Addendum to Early Access Agreement with Impatients N.V. dated October 16, 2015. (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-13441) for the period ended September 30, 2015).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416004101/s102595_ex10-1.htm" style="-sec-extract: exhibit">2016 Senior Executive Deferred Cash Performance Award Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed February 4, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416004101/s102595_ex10-2.htm" style="-sec-extract: exhibit">2016 Voluntary Incentive Stock Award Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed February 4, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416004368/s102736_ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated 2016 Senior Executive Deferred Cash Performance Award Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed March 1, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416005470/s103209_ex10-1.htm" style="-sec-extract: exhibit">Sales, Marketing, Distribution and Supply Agreement (the &#8220;Agreement&#8221;) with Scientific Products Pharmaceutical Co. LTD dated March 3, 2016 (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended March 31, 2016).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416006802/s103890_ex10-1.htm" style="-sec-extract: exhibit">Agreement between Avrio Biopharmaceuticals (&#8220;Avrio&#8221;) and the Company dated July 20, 2016 (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No.000-27072) for the period ended June 30, 2016).</a> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416006981/s103999_ex10-2.htm" style="-sec-extract: exhibit">Licensing Agreement dated April 13, 2016 with Lonza Sales AG (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s report Form 10-Q/A (No. 000-27072) for the period ended March 31, 2016).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577416007014/s104021_ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement entered into on August 30, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report Form 8-K (No. 000-27072) filed September 1, 2016).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217004866/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Early Access Agreement with Impatients N.V. dated May 20, 2016. (Confidential Treatment granted with respect to portions of the Agreement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s report Form 8-K/A (No. 000-27072) filed May 8, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-45.htm" style="-sec-extract: exhibit">December 13, 2016 Amendment No. 1 to Amended and Restated Early Access Agreement with Impatients N.V. (incorporated by reference to Exhibit 10.45 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-46.htm" style="-sec-extract: exhibit">June 28, 2017 Amendment No. 2 to Amended and Restated Early Access Agreement with Impatients N.V. (incorporated by reference to Exhibit 10.46 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-47.htm" style="-sec-extract: exhibit">February 14, 2018 Amendment No. 3 to Amended and Restated Early Access Agreement with Impatients N.V. (incorporated by reference to Exhibit 10.47 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-48.htm" style="-sec-extract: exhibit">March 26, 2018 Amendment No. 4 to Amended and Restated Early Access Agreement with Impatients N.V. (incorporated by reference to Exhibit 10.48 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000161577417000348/s105221_ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement entered into on February 1, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed February 3, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009966/ex10-1.htm" style="-sec-extract: exhibit">August 2017 Form of Employee Pay Reduction Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 29, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009966/ex10-2.htm" style="-sec-extract: exhibit">August 2017 Form of Executive Compensation Deferral Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 29, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009966/ex10-3.htm" style="-sec-extract: exhibit">August 2017 Form of Directors&#8217; Compensation Deferral Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 29, 2017).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217009746/ex10-1.htm" style="-sec-extract: exhibit">Form of August 2017 Agreement between the Company and the Warrant holders. (incorporated by reference to Exhibit 10.1 the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed August 23, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217006056/ex10-1.htm" style="-sec-extract: exhibit">Form of June 2017 Agreement between the Company and the Warrant holders (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 000-27072) filed June 1, 2017).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217005355/ex10-1.htm" style="-sec-extract: exhibit">Mortgage and Security Agreement with SW Partners LLC dated May 12, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended March 31, 2017).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315217005355/ex10-2.htm" style="-sec-extract: exhibit">Promissory Note with SW Partners LLC dated May 12, 2017 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended March 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-57.htm" style="-sec-extract: exhibit">September 11, 2017 Purchase and Sale Agreement- 5 Jules Lane (incorporated by reference to Exhibit 10.57 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-58.htm" style="-sec-extract: exhibit">January 8, 2018 Purchase and Sale Agreement- 783 Jersey Lane (incorporated by reference to Exhibit 10.58 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218004291/ex10-59.htm" style="-sec-extract: exhibit">Lease Agreement for 783 Jersey Lane (incorporated by reference to Exhibit 10.59 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2017).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218003734/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Purchase Agreement entered into on March 21, 2018 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed March 22, 2018). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218005575/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement entered into on May 24, 2018 (incorporated by reference to Exhibit 10.55 to the Company&#8217;s Registration Statement on Form S-1 (No. 333-226057) filed July 2, 2018). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218010893/formdef14a.htm" style="-sec-extract: exhibit">2018 Equity Incentive Plan (filed with the Securities and Exchange Commission as Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A (No. 001-27072) filed on August 3, 2018).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218014063/ex10-1.htm" style="-sec-extract: exhibit">September 28, 2018 Securities Purchase Agreement with Iliad Research and Trading, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed October 4, 2018).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218014063/ex10-3.htm" style="-sec-extract: exhibit">September 28, 2018 Security Agreement with Iliad Research and Trading, L.P. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed October 4, 2018).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218016149/ex10-1.htm" style="-sec-extract: exhibit">October 9, 2018, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended September 30, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218016149/ex10-2.htm" style="-sec-extract: exhibit">October 8, 2018, Restated First Amendment to Purchase and Sale Agreement (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended September 30, 2018).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315218016149/ex10-3.htm" style="-sec-extract: exhibit">October 9, 2018, Restated Bill of Sale for the Restated First Amendment and Sale Agreement (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended September 30, 2018).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219006271/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Agreement between the Company and the Warrant holders.- May 2, 2019 (incorporated by reference to Exhibit 10.1 to the
    Company&#8217;s Current report on Form 8-K (No. 001-27072) filed May 2, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219012572/ex10-1.htm" style="-sec-extract: exhibit">Note Purchase Agreement dated August 5, 2019 with Chicago Venture Partners, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended June 30, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219012572/ex10-2.htm" style="-sec-extract: exhibit">Secured Promissory Note dated August 5, 2019 issued to Chicago Venture Partners, L.P. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended June 30, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219012572/ex10-3.htm" style="-sec-extract: exhibit">Security Agreement dated August 5, 2019 with Chicago Venture Partners, L.P. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended June 30, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219013386/ex10-1.htm" style="-sec-extract: exhibit">Salary Reduction and Restricted Stock Award Memo (August 2019) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed August 26, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219013386/ex10-2.htm" style="-sec-extract: exhibit">Form of Restricted Stock Award (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed August 26, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219019007/ex10-1.htm" style="-sec-extract: exhibit">December 5, 2019 Note Purchase Agreement with Atlas Sciences, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No.001-27072) filed December 11, 2019).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219019007/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 5, 2019 Security Agreement with Atlas Sciences, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No.001-27072) filed December 11, 2019). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220004768/ex10-1.htm" style="-sec-extract: exhibit">March 20, 2020 Amendment to 2017 Material Transfer and Research Agreement with Roswell Park Cancer Institute (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed March 26, 2020).</a> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220005912/ex10-1.htm" style="-sec-extract: exhibit">April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. )001-27072) filed April 6, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220007168/ex10-1.htm" style="-sec-extract: exhibit">April 21, 2020 Mutual Confidentiality Agreement with UMN Pharma Inc., National Institute of Infectious Diseases, and Shionogi &amp; Co., Ltd (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed April 27, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/ex10-1.htm" style="-sec-extract: exhibit">June 1, 2020, Material Transfer and Research Agreement with the University of Rochester. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/ex10-2.htm" style="-sec-extract: exhibit">June 23, 2020, Specialized Services Agreement with Utah State University. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/ex10-3.htm" style="-sec-extract: exhibit">July 1, 2020, Material Transfer and Research Agreement with the Japanese National Institute of Infectious Diseases and Shionogi &amp; Co., Ltd. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 6, 2020, Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2020). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220015932/ex10-5.htm" style="-sec-extract: exhibit">August 6, 2020, Project Work Order with Amarex Clinical Research LLC. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315220021121/ex10-1.htm" style="-sec-extract: exhibit">November 10, 2020 employment agreement with Thomas K. Equels. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended September 30, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-75.htm" style="-sec-extract: exhibit">December 22, 2020 Master Service Agreement with Pharmaceutics International Inc. as a Fill &amp; Finish provider for Ampligen (incorporated by reference to Exhibit 10.75 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.64</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-76.htm" style="-sec-extract: exhibit">January 11, 2021 Sponsor Agreement with Centre for Human Drug Research. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.76 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-77.htm" style="-sec-extract: exhibit">November 29, 2020, Material Transfer and Research Agreement with Leyden Laboratories, B.V. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.77 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-78.htm" style="-sec-extract: exhibit">December 30, 2020 Amendment to Project Work Order with Amarex Clinical Research LLC. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.78 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-79.htm" style="-sec-extract: exhibit">December 23, 2020 Amendment to Master Service Agreement with Pharmaceutics International Inc. as a Fill &amp; Finish provider for Ampligen (incorporated by reference to Exhibit 10.79 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-80.htm" style="-sec-extract: exhibit">March 24, 2021 employment agreement with Peter Rodino (incorporated by reference to Exhibit 10.80 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2020).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221007259/ex10-81.htm" style="-sec-extract: exhibit">March
24, 2021 employment agreement with Ellen Lintal (incorporated by reference to Exhibit 10.81 to the Company&#8217;s Annual report on Form
10-K (No. 001-27072) for the year ended December 31, 2020).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221020230/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 1, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.71</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221011883/ex10-4.htm" style="-sec-extract: exhibit">Material Transfer And Research Agreement with the University of Cagliari Dipartimento di Scienze della Vita e dell&#8217;Ambiente executed on April 5, 2021 (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221011883/ex10-2.htm" style="-sec-extract: exhibit">Material Transfer and Research agreement with Roswell Park Comprehensive Cancer Center executed on April 14, 2021 (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221011883/ex10-1.htm" style="-sec-extract: exhibit">April 19, 2021 Purchase and Sale Agreement with Phoenix Equipment Corporation, Branford Auctions, LLC and Perry Videx LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221011883/ex10-5.htm" style="-sec-extract: exhibit">May 12, 2021 Amendment to the Renewed Sales, Marketing, Distribution and Supply Agreement with GP Pharm. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221020230/ex10-2.htm" style="-sec-extract: exhibit">May 21, 2021 extension of April 1, 2020 Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended June 30, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221020230/ex10-1.htm" style="-sec-extract: exhibit">July 8, 2021 Reservation and Start-Up Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q (No. 000-27072) for the period ended June 30, 2021 filed August 16, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.77</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315221028650/ex10-2.htm" style="-sec-extract: exhibit">September 27, 2021 Clinical Trial Agreement with hVIVO Services Limited (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended September 30, 2021)</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.78</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/ex10-78.htm" style="-sec-extract: exhibit">March 1, 2022 Consulting Agreement with Foresite Advisors, LLC pursuant to which Robert Dickey IV will serve as the Company&#8217;s Chief Financial Officer (Portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.78 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.79</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/ex10-79.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 24, 2022 Consulting Agreement with Ellen Lintal (Portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.79 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/ex10-80.htm" style="-sec-extract: exhibit">March 1, 2022 Amendment to Clinical Trial Agreement with hVIVO Services Ltd dated September 27, 2021. (incorporated by reference to Exhibit 10.80 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.81</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/ex10-81.htm" style="-sec-extract: exhibit">March 3, 2022 Agreement of Sale and Purchase with Acellories, Inc for sale of 783 Jersey Avenue, New Brunswick, NJ building. (incorporated by reference to Exhibit 10.81 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2021).</a>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.82</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222008324/ex10-82.htm" style="-sec-extract: exhibit">March 8, 2022 Change order to Master Service Agreement with Pharmaceutics International Inc. as a Fill &amp; Finish provider for Ampligen. (incorporated by reference to Exhibit 10.82 to the Company&#8217;s Annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.83</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222009656/ex10-1.htm" style="-sec-extract: exhibit">April 7, 2022 Project Work Order with Amarex Clinical Research LLC.to manage Phase 2 clinical trial in advanced pancreatic cancer patients (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed April 12, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.84</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222017052/ex10-1.htm" style="-sec-extract: exhibit">June 13, 2022 Project Work Order with Amarex Clinical Research LLC. for a Randomized Double Blind, Placebo Controlled study to Evaluate the Efficacy and Safety of Ampligen in Patients with Post Covid Conditions (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed June 17, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.85</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222017273/ex10-1.htm" style="-sec-extract: exhibit">June 16, 2022 Lease agreement entered into with New Jersey Economic Development Authority for 5,210 square-foot R&amp;D facility at the New Jersey Bioscience Center (incorporated by reference 10.1 to the Company&#8217;s Current Report on Form 8-K (No.001-27072) filed June 21, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.86</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222022600/ex10-86.htm" style="-sec-extract: exhibit">June 27, 2022 First Amendment to Agreement of Sale and Purchase with Acellories, Inc. (incorporated by reference 10.86 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2022 filed August 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.87</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222022600/ex10-87.htm" style="-sec-extract: exhibit">August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc. (incorporated by reference 10.87 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2022 filed August 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.88</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222022600/ex10-88.htm" style="-sec-extract: exhibit">August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (incorporated by reference 10.88 to the Company&#8217;s Quarterly report on Form 10-Q (No. 000-27072) for the period ended June 30, 2022 filed August 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.89</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222032118/ex10-4.htm" style="-sec-extract: exhibit">October 5, 2022 Lease extension for Riverton office (incorporated by reference 10.4 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended September 30, 2022 filed November 14, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.90</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222032118/ex10-5.htm" style="-sec-extract: exhibit">October 11, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.5 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended September 30, 2022 filed November 14, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.91</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222032118/ex10-6.htm" style="-sec-extract: exhibit">October 21, 2022 Material Transfer and Research Agreement with University of Pittsburgh (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference 10.6 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended September 30, 2022 filed November 14, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.92</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315222032118/ex10-7.htm" style="-sec-extract: exhibit">October 21, 2022 Fourth Amendment to Agreement of Sale and Purchase with Acellories, Inc)) (incorporated by reference 10.7 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended September 30, 2022 filed November 14, 2022).</a> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.93</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/ex10-93.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc. (incorporated by reference to Exhibit 10.93 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.94</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/ex10-94.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2023 Study Support Agreement with Erasmus University Medical Center Rotterdam (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.94 to the Company&#8217;s annual report on Form 10-K (No.001-27072) for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.95</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/ex10-95.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2023 Co-ordination Agreement with Erasmus University Medical Center Rotterdam and AstraZeneca BV (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.95 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.96</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223010351/ex10-96.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
1, 2023 Extension Agreement with Foresite Advisors LLC (incorporated by reference to Exhibit 10.96 to the Company&#8217;s annual report
on Form 10-K (No. 001-27072) for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.97</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/ex10-1.htm" style="-sec-extract: exhibit">April 4, 2023 Unrestricted Grant Agreement with Erasmus University Medical Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed April 7, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.98</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/ex10-2.htm" style="-sec-extract: exhibit">April 5, 2023 Independent Contractor Service Agreement with Casper H.J van Eijck (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed April 7, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.99</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223012921/ex10-1.htm" style="-sec-extract: exhibit">April 19, 2023 Equity Distribution Agreement with Maxim Group, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed April 19, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.100</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/ex10-1.htm" style="-sec-extract: exhibit">Material Transfer and Research Agreement, dated as of May 22, 2023, with Japanese National Institute of Infectious Disease (portions of this agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed May 30, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.101</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223034740/ex10-1.htm" style="-sec-extract: exhibit">September 20, 2023 Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report of Form 8-K (No. 001-27072) filed September 29, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.102</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224007230/ex10-1.htm" style="-sec-extract: exhibit">February 16, 2024 Note Purchase Agreement with Streeterville Capital LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed February 20, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.103</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224007230/ex10-2.htm" style="-sec-extract: exhibit">February 16, 2024 Promissory Note with Streeterville Capital LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed February 20, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-104.htm">Atlas Equity Purchase Agreement *</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.105</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-105.htm">Atlas Registration Rights Agreement *</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">List of Subsidiaries*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of BDO USA, P.C.*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Executive Officer. *</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Financial Officer. *</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Executive Officer. *</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Financial Officer. *</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">97.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex97-1.htm">Company Clawback Policy*</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following materials from AIM&#8217; Annual Report on Form 10-K for the year ended December 31, 2019, formatted in eXtensible Business
    Reporting Language (&#8220;XBRL&#8221;): (i) the Condensed Consolidated Statements of Income; (ii) the Condensed Consolidated Balance
    Sheets; (iii) the Condensed Consolidated Statements of Cash Flows; and (iv) Notes to Condensed Consolidated Financial Statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt; width: 40%"><div style="border-top: Black 1.5pt solid; margin: 0pt; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(b)
Financial Statement Schedules</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the
financial statements and related notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ku_024"></span>Item
  16.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form 10-K Summary</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
    IMMUNOTECH INC.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Thomas K. Equels</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
29, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange of 1934, as amended, this report has been signed below by the following
persons on behalf of this Registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Thomas K Equels</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; President,</span></td>
    <td style="width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of the Board</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    William Mitchell</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Mitchell, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Stewart L Appelrouth</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stewart
    L. Appelrouth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert Dickey IV E</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Nancy Bryan E</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    29, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nancy
    Bryan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Index
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_001">Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; Miami, Florida</a>; PCAOB ID #<span id="xdx_907_edei--AuditorFirmId_c20230101__20231231_zB1juroqqHq7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000044" name="dei:AuditorFirmId">243</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_002">Consolidated Balance Sheets at December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_003">Consolidated
    Statements of Operations and Comprehensive Loss for each of the years in the two-year period ended December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for each of the years in the two-year period ended December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_005">Consolidated Statements of Cash Flows for each of the years in the two-year period ended December 31, 2023</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#ar_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">F-8</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="ar_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stockholders
and Board of Directors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM
ImmunoTech Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Ocala,
Florida</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have audited the accompanying consolidated balance sheets of AIM ImmunoTech Inc. (the &#8220;Company&#8221;) as of December 31, 2023
and 2022, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash
flows for each of the two years in the period ended December 31, 2023 and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its
cash flows for each of the two years in the period ended December 31, 2023<b>,</b> in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that
was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material
to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication
of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or
disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Research and Development Costs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As described in Note 8 to the consolidated financial statements, the Company entered into research, consulting and
supply agreements with third party service providers to perform research and development activities on therapeutics, including clinical
trials. The Company recorded research and development costs of approximately $10.9 million for the year ended December 31, 2023, and accrued
clinical trial expenses of approximately $0.8 million at December 31, 2023. The identification of research and development costs involves
reviewing open contracts and purchase orders, communicating with applicable company and third-party personnel to identify services that
have been performed, and corroborating the level of service performed and the associated cost incurred for the service when the Company
has not yet been invoiced or otherwise notified of actual expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We identified the recognition of research and development costs as a critical
audit matter. The principal consideration for our determination was that performing procedures and evaluating audit evidence relating
to research and development costs involved a high degree of auditor effort required to address this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
primary procedures we performed to address this critical audit matter included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Testing
research and development costs on a sample basis, which included tracing relevant information to certain underlying agreements, purchase
orders, and invoices received.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; layout-grid-mode: line">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Confirming
certain research and development costs incurred for the fiscal year with third party service providers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">/s/
<span id="xdx_90E_edei--AuditorName_c20230101__20231231_zg0yNfqzeMn4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000045" name="dei:AuditorName">BDO USA, P.C.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have served as the Company&#8217;s auditor since 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: fuchsia"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_edei--AuditorLocation_c20230101__20231231_zDHYmSxHqTLa"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000046" name="dei:AuditorLocation">Miami,
Florida</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
29, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="ar_002"></span>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>December
31, 2023 and 2022 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands, except for share and per share amounts)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_pn3n3_zYdrc1p15Dc5" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_znhLm6pBS4Zd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zls8mVNLh5L7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsAbstract_iB_zRNWVqe9DiL" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">ASSETS</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_z4b8vQU3dfad" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Current assets:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzDQi_zLiAaiJjdqY6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; color: Black; text-align: left">Cash and cash equivalents</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,439</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,053</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--MarketableSecuritiesCurrent_i02I_maCzDQi_zSNp141qSJG4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Marketable investments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzDQi_zvCwQA0b3hje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Funds receivable from New Jersey net operating loss</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,184</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,676</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzDQi_z9SrRkJU7PQi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Prepaid expenses and other current assets</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">455</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtCzDQi_maCzoi0_zkyLOgwfITMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total current assets</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,556</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,321</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzoi0_zfyUdtYN54wb" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Property and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzoi0_zOuYCIzogQR3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Right of use asset, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">697</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">829</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maCzoi0_zBGVq2RlArPd" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Patent and trademark rights, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,941</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_i01I_maCzoi0_z1ATInrM8fqf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Other assets</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,688</ix:nonFraction></p>
</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,202</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzoi0_zHVpou9TSsz2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total assets</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,381</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,488</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z6fCuSxGJk5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zvn1lac4olha" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Current liabilities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCz0EN_z45cG5sQtF3k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Accounts payable</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,443</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">377</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCz0EN_zFYDxeQwdJHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Accrued expenses</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,986</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">806</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCz0EN_zAcbrCtmmYCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Current portion of operating lease liability</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_mtCz0EN_maLzUDs_z1ynyncar8S7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total current liabilities</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,652</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,361</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zs6RS5qYZg0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Long-term liability:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLASEzMQs_maLzUDs_zlVMaAW0xcL2" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Operating lease liability</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">495</ix:nonFraction> </span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">659</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i02TI_mtLzUDs_maLASEzK2r_zX4T7UQaTeXe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total liabilities</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,147</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,020</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzK2r_zQqIDbZcwrdj" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Commitments and contingencies (Notes 8, 10, 11, 16)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Stockholders&#8217; equity:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_maSEzr3b_zQyf8Jb44HU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Series A Junior Participating Preferred Stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zb7K9jQdTVL9" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zCLJQZNzIXvi" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zJID7xhLAKb7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction> </span>and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zYupnpUvDKA7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares authorized as of December 31, 2023 and 2022, respectively; issued and outstanding &#8211; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zfQ5hprClrVh" title="Preferred stock, shares issued::XDX::-"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zjY3vfmKT2Y8" title="Preferred stock, shares outstanding::XDX::-"><span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zUB9KvAlHU9a" title="Preferred stock, shares issued::XDX::-"><span id="xdx_90B_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dxL_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zJsw8sXbydK4" title="Preferred stock, shares outstanding::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0128"><span style="-sec-ix-hidden: xdx2ixbrl0130"><span style="-sec-ix-hidden: xdx2ixbrl0132"><span style="-sec-ix-hidden: xdx2ixbrl0134">none</span></span></span></span></span></span></span></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEzr3b_zva9a49VgJ0f" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Series B Convertible Preferred Stock, stated value $<span id="xdx_90F_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zrnMaQlGvhpa" title="Preferred stock, stated value"><span id="xdx_903_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z8fhzS69lSOf" title="Preferred stock, stated value"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zckxqTHOG525" title="Preferred stock, shares authorized"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zzx7fCOwLPgd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zndtxBzhaxLk" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zIvUuWTe5VFc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">689</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zbu5QYcQZH46" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zd8v01TpHGMi" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000153" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2023 and 2022, respectively</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maSEzr3b_zUwetzHbD5Ml" style="display: none; vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock,
    Value</span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"/><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"/><td style="color: Black; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzr3b_zgZ2XK3tV7N2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Common Stock, $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zHN4d4OpF3oc" title="Common stock, par value"><span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zbt4qfWsfNh4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>
    par value, authorized shares - <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z2cHwKKscdr1" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zoRRpAYFNMji" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span>;
    issued and outstanding shares <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_znY8CwNz1eri" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zPiKRqBNG91g" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></ix:nonFraction></span></span>
    and <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_z6f4eAq8o9Xc" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z5Sx3yWNFYu6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></ix:nonFraction></span></span>
    (including <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20231231_zbd8cW7YMWi9" title="Unvested stock awards"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">701,667</ix:nonFraction></span>
    and <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20221231_zBiy2505fYg1" title="Unvested stock awards"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">694,324</ix:nonFraction></span>
    of unvested stock awards) as of December 31, 2023 and 2022, respectively</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i02I_maSEzr3b_z3eu6MwZgsbh" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Additional paid-in capital</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419,004</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,270</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzr3b_z7HrQQzuhEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Accumulated deficit</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">409,508</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">380,546</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_mtSEzr3b_maLASEzK2r_z2aGLG2imCN1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total stockholders&#8217; equity</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,234</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,468</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzK2r_zWgcJWFiYYC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; color: Black; text-align: left">Total liabilities and stockholders&#8217; equity</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,381</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,488</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="ar_003"></span>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Consolidated
Statements of Operations and Comprehensive Loss </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands, except share and per share data)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_pn3n3_zC0nlwO1tBT6" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zLaBtV4yXTei" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_z1gfbR7XMzd9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenuesAbstract_iB_zE1uQqzAxtrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Revenues:</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maRzofd_zCNLPNkmAUhd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Clinical treatment programs &#8211; US</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_i01T_mtRzofd_maOILzKKT_zzQ8C0k95VKd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Total Revenues</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostsAndExpensesAbstract_iB_zQXJ7qdLGPxj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Costs and Expenses:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ManufacturingCosts_i01_maCAEz5ii_zEjAGF0DCan4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Production costs</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maCAEz5ii_z6u7LjdP1Bba" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Research and development</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,939</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,990</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maCAEz5ii_zYbDSfTk7u1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; color: Black; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostsAndExpenses_i01T_mtCAEz5ii_msOILzKKT_zHeeWbQAzavb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Total Costs and Expenses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2022-01-012022-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtOILzKKT_maNILzGQf_ziNyC9fEdcL2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Operating loss</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">31,916</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,923</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainLossOnInvestments_maNILzGQf_zB9M5rw47dT4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Gain (loss) on investments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,679</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_maNILzGQf_zuMzH0bemV4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Interest and other income</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,069</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">629</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_maNILzGQf_zJk5obo44uL9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Gain on sale of fixed assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_msNILzGQf_zg9gX105ypGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Redeemable warrants valuation adjustment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GainFromSaleOfIncomeTaxOperatingLoss_iN_di_msNILzGQf_zcIZwn7ZNsXa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; color: Black; text-align: left">Gain from sale of income tax operating losses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2022-01-012022-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,490</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_iT_mtNILzGQf_z3vS2V8nkCh2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Net Loss</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,445</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Basic and diluted loss per share</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zfUK4A2RlKU2" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zgPVzT2766Pd" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.60</ix:nonFraction></ix:nonFraction></span></span></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_zN4WAq6RFCw5" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zOrri5WxFga2" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.40</ix:nonFraction></ix:nonFraction></span></span></td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Weighted average shares outstanding basic and diluted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_pid_c20230101__20231231_z1HidoCcNThj" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zV9P7DPxcvx4" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,585,404</ix:nonFraction></ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_pid_c20220101__20221231_zra1nedu8C4" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20221231_zplFCLQjGsz4" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2022-01-012022-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,047,288</ix:nonFraction></ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="ar_004"></span>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Consolidated
Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands except share data)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the Year Ended December 31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_114_pn3n3_z2Zk4UQeXws3" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_za1ain6d7WK8" style="color: Black; text-align: center">Series B</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Common Stock</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zVWBdOkrpLre" style="color: Black; text-align: center">Common Stock .001</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKrGBy1nTrl4" style="color: Black; text-align: center">Additional Paid-in</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zB2yiSTg1Hm1" style="color: Black; text-align: center">Accumulated other Comprehensive</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zJEBSARZbGBf" style="color: Black; text-align: center">Accumulated</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" id="xdx_4B0_zOaUWB5y1oDc" style="color: Black; text-align: center">Total Stockholders&#8217;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Preferred</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Par Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Income (Loss)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zMewFvALT3y3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 23%; color: Black">Balance December 31, 2022</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDLEdFCjd1jk" title="Balance, shares" style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000261" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">380,546</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zqejBgZZJh17" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Common stock issuance, net of costs</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlL11szAA92b" title="Common stock issuance, net of costs, shares" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,017,399</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">484</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zX4luQca2tMl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Equity-based compensation</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">243</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">243</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zGsumYqnLuQ7" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Series B preferred shares converted to common shares</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5zN6oVcVfQa" title="Series B preferred shares converted to common shares, shares" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000286" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">798</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zypyONVl9d18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--StockholdersEquity_iE_z0s0jBdlKIq8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Balance December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWFNqCMt6tRk" title="Balance, shares" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">409,508</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
the Year Ended December 31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Series B</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Common <br/>Stock</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Common Stock .001</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Additional Paid-in</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Accumulated other Comprehensive</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Accumulated</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Total Stockholders&#8217;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Preferred</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Par Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Capital</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Income (Loss)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zPjZ0QYDS6c9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 23%; color: Black">Balance December 31, 2021</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOzNGu3AH6ck" title="Balance, shares" style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000311" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,994,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">417,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">361,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zqb5Siv2aBH2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black">Balance </td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBNOuuAYVGp1" title="Balance, shares" style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,994,672</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">417,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">361,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">$</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,879</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHmtkpvhkyxh" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Common stock issuance, net of costs</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcrXaA5YVb5j" title="Common stock issuance, net of costs, shares" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,749</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zBSh44vsxAr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Equity-based compensation</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">954</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">954</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CashlessWarrantConversion_zUqz9oW3TnQj" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Cashless warrant conversion</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_ecustom--CashlessWarrantConversionShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKa7buQvBM0b" title="Cashless warrant conversion, shares" style="color: Black; text-align: right"><ix:nonFraction name="AIM:CashlessWarrantConversionShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">638</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zKvRCrfEzDYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Series B preferred shares converted to common shares</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcO0lGpjEWI4" title="Series B preferred shares converted to common shares, shares" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zyyJJ11CUEzd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_430_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zGiPEEfbfk5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Balance December 31, 2022</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0uGXK00beZf" title="Balance, shares" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,270</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">380,546</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,468</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zsUSj5UYBTd7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 1.5pt; color: Black">Balance </td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2L1JrdeMwbe" title="Balance, shares" style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000374" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,270</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">380,546</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="display: none; padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; display: none; color: Black; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,468</ix:nonFraction></td><td style="display: none; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="ar_005"></span>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(in
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Years
ended December 31,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_pn3n3_zYlsPkxgsKic" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zb07aDMJJcO2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_ztfkTXp6VbH6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zxws8VTgyif8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Cash flows from operating activities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maNCPBUzzbp_zL9m6sX3cFBf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; color: Black; text-align: left">Net loss</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,962</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">)</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,445</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zlHFAsQVv3ch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_i02_maNCPBUzzbp_zAcLHDOt3bR5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Depreciation of property and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact000390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzzbp_z3Q03rzaHON1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Redeemable warrants valuation adjustment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnDispositionOfAssets1_i02N_di_msNCPBUzzbp_zHug58nRtns3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Gain on sale of fixed assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2023-01-01to2023-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AbandonmentOfPatentAndTrademarkRights_i02_maNCPBUzzbp_zsXKvqccpVab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Abandonment and expiration of patents and trademark rights</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="AIM:AbandonmentOfPatentAndTrademarkRights" contextRef="From2023-01-01to2023-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzzbp_zqoyxfgKytd6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Amortization of patent and trademark rights</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000403" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NoncashLeaseExpense_i02_maNCPBUzzbp_zu71qY6bDhN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Non-cash lease expense</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="AIM:NoncashLeaseExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="AIM:NoncashLeaseExpense" contextRef="From2022-01-012022-12-31" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">680</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--LossGainFromSaleOfIncomeTaxOperatingLosses_i02N_di_msNCPBUzzbp_zBPVQUpjVLpj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Loss from sale of income tax operating losses</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="AIM:LossGainFromSaleOfIncomeTaxOperatingLosses" contextRef="From2022-01-012022-12-31" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">197</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maNCPBUzzbp_zYHxqfZ12w2k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Equity-based compensation</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">243</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">954</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i02N_di_msNCPBUzzbp_znfbkluWVN5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Loss (gain) on sale of marketable investments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-01to2023-12-31" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,679</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zRl8ADOeFnxk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Change in assets and liabilities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzzbp_zYH6xiErdk03" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Funds receivable from New Jersey operating loss sales</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">492</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzzbp_zxvtaprIUU9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Prepaid expenses and other current assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">153</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzzbp_zErbdnRhR8cb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Lease liability</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">274</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msNCPBUzzbp_zROitVjr3UL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Other assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">486</ix:nonFraction></span></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-01-012022-12-31" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzzbp_zoCEA41UeiDe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Accounts payable</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,066</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">179</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzzbp_z8xwZ9abfjd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; color: Black; text-align: left">Accrued expenses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzzfN_mtNCPBUzzbp_zGrk2b0PHn6g" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zAEOqEqohqEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Cash flows from investing activities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromSaleOfInvestmentProjects_i01_maCzwKm_zZDoO8R0kpUe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Proceeds from sale of marketable investments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="From2023-01-01to2023-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,299</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="From2022-01-012022-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,083</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquireInvestments_i01N_di_msCzwKm_zvCcrskGmK04" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Purchase of marketable investments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,593</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2022-01-012022-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,724</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzwKm_zu9bW99FRCk3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Purchase of property and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">86</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maCzwKm_zFvoRUCAKgya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Proceeds from sale of property and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,900</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCzwKm_zLW5aRg8txb7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; color: Black; text-align: left">Purchase of patent and trademark rights</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">585</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzwKm_maCCERCzzfN_z4pVMyKAWl8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Net cash (used in) provided by investing activities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">832</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zmfUZ90PZHcj" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Cash flows from financing activities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maCzLhe_maNCPBUzoYS_z67BsnN5S7Pl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; color: Black; text-align: left">Proceeds from sale of stock, net of issuance costs</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-01to2023-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-12-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzoYS_maCCERCzzfN_zeqLI8nM3Dhg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzzfN_z3gFQs86L9X2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Net decrease in cash and cash equivalents</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,614</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,040</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zrcKxEINvBLc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Cash and cash equivalents at beginning of year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,093</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zDmdhl3gCdjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Cash and cash equivalents at end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,439</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zNExRBV23amf" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Supplemental disclosures of non-cash investing and financing cash flow information:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--UnrealizedGainLossOnMarketableInvestments_i01_zmntZrO03Zdc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; color: Black; text-align: left">Unrealized gain (loss) on marketable investments</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:UnrealizedGainLossOnMarketableInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">376</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(<ix:nonFraction name="AIM:UnrealizedGainLossOnMarketableInvestments" contextRef="From2022-01-012022-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">928</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ConversionOfSeriesBPreferred_i01_zL5MfEx0RBGd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; color: Black; text-align: left">Conversion of Series B preferred</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ConversionOfSeriesBPreferred" contextRef="From2023-01-01to2023-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ConversionOfSeriesBPreferred" contextRef="From2022-01-012022-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset_i01_zSeBDpVxNvvd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; color: Black; text-align: left">Operating lease liability arising from obtaining right of use asset</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" contextRef="From2023-01-01to2023-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" contextRef="From2022-01-012022-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left"/></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000492" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYoXxHAglyRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)
<span id="xdx_82D_zOYCi5rn3MF3">Description of Business </span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A<span style="color: Black">IM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM&#8217;s
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (&#8220;CFS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company&#8217;s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;) molecule being developed
for globally important cancers, viral diseases and disorders of the immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM
currently is proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Conducting
    a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced
    pancreatic cancer patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating
Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses
to check point inhibitors.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Exploring
    Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated
    viruses thereof. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating
    Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;) and fatigue and/or Post-COVID
    conditions of fatigue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM
is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer,
ME/CFS and Post-COVID conditions having priority over antiviral experimentation. AIM intends that priority clinical work be conducted
in trials authorized by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or European Medicines Agency (&#8220;EMA&#8221;), which
trials support a potential future NDA. However, the Company&#8217;s antiviral experimentation is designed to accumulate additional preliminary
data supporting its hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced
immunity and cross-protection. Accordingly, the Company will conduct antiviral programs in those venues most readily available and able
to generate valid proof-of-concept data, including foreign venues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Basis of Preparation and Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements include the accounts of AIM ImmunoTech and all entities in which a controlling interest is held by the Company. All
significant intercompany balances and transactions have been eliminated in consolidation. The consolidated financial statements are prepared
in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000494" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zJ1ZOSYNwxG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(2)
<span id="xdx_823_zw8y4UAd3rS8">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000496" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
<span id="xdx_86B_zmgK91eyCGD6">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid
instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year
ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></span>
thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000500" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
<span id="xdx_861_zilUSHqnAcu">Marketable Investment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company&#8217;s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments
using the specific identification method and measure the fair value of our marketable investments using a market approach where identical
or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices
from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000502" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
<span id="xdx_869_z8KJmsuGquql">Property and Equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000504" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,448</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2022-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,233</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective
assets, ranging from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">three</span></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000517" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">ten years</ix:nonNumeric></span>. Depreciation expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,000</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $<span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2021-01-012021-12-31" id="Fact000523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,000</ix:nonFraction></span> during
the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000525" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
<span id="xdx_862_zxLttbDekJv3">Patent and Trademark Rights, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful
life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember" format="ixt-sec:duryear" id="Fact000527" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span> years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value,
or their value has become impaired. Such review includes an analysis of the patent and trademark&#8217;s ultimate revenue and profitability
potential. Management&#8217;s review addresses whether each patent continues to fit into the Company&#8217;s strategic business plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000529" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
<span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#8220;GAAP&#8221;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000531" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
<span id="xdx_863_zYVcu2A7t1be">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with
Customers (&#8220;Topic 606&#8221;). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model
to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses
whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that
is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped.
The Company has no other obligation associated with its products once shipment has been accepted by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000533" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)
<span id="xdx_86A_zzDBc4KDPNel">Accounting for Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement
of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized.
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes
are enacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#8217;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating
loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company
has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at
this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000535" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)
<span id="xdx_86E_z3BzQaCVKJkf">Recent Accounting Standards and Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements. </i>The standard requires additional or amended disclosure requirements
for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation
for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective
dependent upon the SEC&#8217;s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has
evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined
that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) Improvements to Income Tax Disclosures. </i>The amendments in
this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and
(2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items
is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income
tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting
currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about
income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign
taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid
(net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments
in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income
tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated
by federal (national), state, and foreign.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably
possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range
cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference
when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries
and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations
and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#8217;s
present or future financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000537" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
<span id="xdx_86F_zmfAfvjRbn6g">Stock-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &#8220;Compensation &#8211; Stock Compensation&#8221;,
which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee
is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net
of estimated forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000539" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j)
<span id="xdx_866_zorjzfOx4Rcg">Common Stock Per Share Calculation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic
and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period.
Equivalent Common shares, consisting of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,523,949</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,966,538</ix:nonFraction></span> of stock options and warrants, are excluded from the calculation of diluted
net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000545" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k)
<span id="xdx_864_zU9Jock3a3v3">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets
or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which
a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business
climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an
accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset
(asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or
forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that,
more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously
estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">When
assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing
the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#8217;s
carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company measures the impairment by comparing the difference between the asset grouping&#8217;s carrying value and its fair value. Long-lived
assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are
determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments
in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing
process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated,
it accelerates the rate of depreciation over the assets&#8217; new, shorter useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(l) Lease accounting</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a party to leases
for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception
of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification
affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases,
which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit
rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate
the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lease term is defined as the
non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will
exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments
made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs,
are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease
liability, while any variable portion is recognized as variable lease expenses as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected not to
recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months
or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(m) <span>Reclassifications</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior year amounts have
been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders&#8217;
equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

</ix:nonNumeric><p id="xdx_85A_z1fn1KYI6FM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000547" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zTbja26Cmuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(3)
<span id="xdx_82A_zSViMNDiu0Ed">Marketable Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Marketable
investments consist of mutual funds. At December 31, 2023 and 2022, it was determined that none of the marketable investments had an
other-than-temporary impairment. At December 31, 2023 and 2022, all securities were measured as Level 1 instruments of the fair value
measurements standard (See Note 15: Fair Value). As of December 31, 2023 and 2022, the Company held $<span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaK6yejGQ241" title="Marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,631,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zComyrmh8nje" title="Marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,137,000</ix:nonFraction></span>, respectively,
in mutual funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" continuedAt="ConU000556-01" escape="true" id="Fact000556" name="us-gaap:InvestmentIncomeTextBlock"><p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mutual
Funds classified as available for sale consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2SSJvsud5uh" style="display: none">Schedule
of Available of Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="margin: 0pt">Fair</p>
                                                                                <p style="margin: 0pt">Value</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" title="Fair Value" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_custom_MutualFundsMember" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" title="Short-Term Investments" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31_custom_MutualFundsMember" id="Fact000560" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" title="Fair Value" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" title="Short-Term Investments" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2023-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z6vVU3pLgF7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" continuedAt="ConU000569-01" escape="true" id="Fact000569" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock"><p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zUPSSRfoE6P7" style="display: none">Schedule
of Equity Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000571" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity
    securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">376</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z0kzXWEdl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_C02_gL3IITB-MRQXJLX_zIFPIMa84vC9"><ix:continuation continuedAt="ConU000556-02" id="ConU000556-01">Mutual
Funds classified as available for sale consisted of:</ix:continuation></span></span></p>

<div id="xdx_C02_gL3IITB-MRQXJLX_zRHdn8ayZMe7" style="margin: 0pt"><ix:continuation continuedAt="ConU000556-03" id="ConU000556-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" summary="xdx: Disclosure - Schedule of Available of Sale (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" title="Fair Value" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2022-12-31_custom_MutualFundsMember" id="Fact000577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" title="Short-Term Investments" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-12-31_custom_MutualFundsMember" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" title="Fair Value" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:MarketableSecurities" contextRef="AsOf2022-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" title="Short-Term Investments" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2022-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0B_gL3IITB-MRQXJLX_zg71DmxfXC4c"><ix:continuation id="ConU000556-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_C0A_gL3TSACTATB-ODD_zwKXQc3515c9"><ix:continuation continuedAt="ConU000569-02" id="ConU000569-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></ix:continuation></span></p>

<div id="xdx_C09_gL3TSACTATB-ODD_zph8HTxAKTql" style="margin: 0pt"><ix:continuation continuedAt="ConU000569-03" id="ConU000569-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" summary="xdx: Disclosure - Schedule of Equity Securities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,679</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">928</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_C04_gL3TSACTATB-ODD_zItYqthd6dId"><ix:continuation id="ConU000569-03">&#160;</ix:continuation></span></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000591" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zhCBjNsh8aZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(4)
<span id="xdx_824_zIwSq2BmzXGd">Patents and Trademark Rights, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000593" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patent and trademark rights consist of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;<span id="xdx_8BC_zivttU9adyx8">Schedule
of Patent and Trademark Rights</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" title="Gross carrying value" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" title="Accumulated amortization" style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">750</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" title="Net carrying value" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" title="Gross carrying value" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" title="Accumulated amortization" style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">595</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" title="Net carrying value" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,794</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" title="Gross carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" title="Net carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000611" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" title="Gross carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">216</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" title="Net carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" id="Fact000617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" title="Gross carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,176</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">863</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" title="Net carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" title="Gross carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,605</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" title="Net carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zltZ3lxz6Vhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt">The following table presents the changes in the patents and
trademark rights:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000631" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_8BF_z0tf6fFOuc0c" style="display: none">Schedule
of Changes in Patents, Trademark Rights</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(in thousands)</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" title="Beginning balance" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,941</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Acquisitions</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" title="Acquisitions" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2023-01-01to2023-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">585</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Abandonments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" title="Abandonments" style="color: Black; text-align: right">(<ix:nonFraction name="AIM:FinitelivedIntangibleAssetsAbandonments" contextRef="From2023-01-01to2023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> Amortization</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" title="Accumulated Amortization" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" title="Ending balance" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zc2mmwIFrD0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life
of <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwhL5qbgPzK4" title="Finite lived intangible assets, estimated useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_PatentsMember" format="ixt-sec:duryear" id="Fact000643" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span> years and <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOWuHlDIF6i2" title="Finite lived intangible assets, estimated useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" format="ixt-sec:duryear" id="Fact000645" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000647" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
of patents and trademarks for each of the next five years is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B9_zhAkaswPrKwl" style="display: none">Schedule
of Amortization of Patents and Trademarks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact000649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">241</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2023-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2023-12-31" id="Fact000655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2023-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2023-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,213</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zGJII59iaimi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000663" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zeEijkQZOUYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(5)
<span id="xdx_827_zSBL5lj9xQkf">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000665" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accrued
expenses at December 31, 2023 and 2022 consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BC_zyhFSMGVUH97" style="display: none">Schedule
of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000668" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,352</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" id="Fact000671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="AIM:AccruedClinicalTrialExpensesCurrent" contextRef="AsOf2023-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="AIM:AccruedClinicalTrialExpensesCurrent" contextRef="AsOf2022-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,986</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">806</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zEU7bP6y9Fl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000682" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqitzPN2xp8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(6)
<span id="xdx_823_z4u6BXmAK5W">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zS1iQPwaahH" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_BoardMember" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zyt8J7mVj9tg" title="Preferred stock stated value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_BoardMember" id="Fact000686" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zealkqpR9eDc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> shares have been designated as Series A Junior Participating
Preferred Stock and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvlMIC5enur8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000690" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares have been designated as Series B Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series
A Junior Participating Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z74l9b9hkGJ9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000692" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> from <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zCjyE5nJ0rU8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series
B Convertible Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has designated <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zyUvHgfAa0n9"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of its preferred stock as Series B Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;).
Each share of Preferred Stock has a par value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUZVOl7yMsYl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share and a stated value equal to $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zluVtpLH6Osk" title="Preferred stock, stated value"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> (the &#8220;Stated Value&#8221;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#8220;DTC&#8221;) shall initially be the sole registered holder of the shares of Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20231231_zPphwTZ4MXS9" title="Preferred stock conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.20</ix:nonFraction></span>,
subject to adjustment herein (the &#8220;Conversion Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant
to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its
holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable
subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase
one unit, at a subscription price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_znVBEGKrxhSj" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_RightsMember" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per unit, consisting of one share of Series B Convertible Preferred Stock with a face value
of $<span id="xdx_907_ecustom--FaceValueOfStock_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zQesT79xUSc9" title="Preferred stock face value"><ix:nonFraction name="AIM:FaceValueOfStock" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember" id="Fact000705" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></span> (and immediately convertible into common stock at an assumed conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqTl7bQPcnMf" title="Preferred stock conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000707" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span>) and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFAs70jaJFbe" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000709" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114</ix:nonFraction></span> warrants with an assumed exercise
price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRa77juDYnRb" title="Subscription/exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span>. The redeemable warrants are exercisable for <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGXFztwsjXVk"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_WarrantMember" format="ixt-sec:durwordsen" id="Fact000712" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> after the date of issuance. The net proceeds realized from the
rights offering were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zRJF43tg183l" title="Proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_RightsMember" id="Fact000714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,700,000</ix:nonFraction></span>. During the year ended December 31, 2023, <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zn2II1ahpKN5"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7</ix:nonFraction></span> shares of Series B Convertible Preferred Stock
were converted into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2023 and 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP6HJLnaOIZi" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">689</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zufJWl3Cz0u4" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696</ix:nonFraction></span> shares of Series B Convertible Preferred Stock outstanding, respectively.
Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis) to and in the same form as dividend actually paid on shares of Common Stock when as and if such dividends are paid on shares of
the Common Stock. Each such Preferred Share is convertible into <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zsjCPknBszub" title="Number of shares to be issued on conversion"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114</ix:nonFraction></span> shares of common stock. Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary, the Holders shall be entitled to receive out of the assets, whether capital or surplus
of the Company the same amount that a holder of Common Stock would receive if the Preferred Stock was fully converted. The Series B Convertible
Preferred Stock does not carry voting Rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Common Stock and Equity Finances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has authorized shares of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zKs6QK6ZjIs8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span> with specific limitations and restrictions on the usage of <span id="xdx_903_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20231231_zCFCveCaorp9" title="Common stock specific limitations and restrictions on usage"><ix:nonFraction name="AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage" contextRef="AsOf2023-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span> of the <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zGTsqQZ6xYxa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span>
authorized shares. <span style="background-color: white">As of December 31, 2023 and 2022, there were <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zl0Rlmup6df6" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z6db1PxcsX1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zEB324dHpD77" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zo4X699gHUUj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></ix:nonFraction></span></span> shares
of Common Stock issued and outstanding, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Employee
Stock Purchase Plan (Not equity compensation)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200706__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zA3rkt9liEhk" title="Common stock shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> worth of shares at the market price (including subsequent plans, the &#8220;Employee Stock Purchase Plan&#8221;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#8217;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board in January 2024 and expires in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023, the Company issued a total of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zviztUmxoLje" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">419,285</ix:nonFraction></span> shares of its Common Stock at a price ranging from $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zdJMaElsXvJ1" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span> to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zZJhuARTYw22" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.67</ix:nonFraction></span>
for total proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSPJHE2neJwb" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265" id="Fact000745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,500</ix:nonFraction></span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zfTmenNILks9" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296" id="Fact000747" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">86,817</ix:nonFraction></span> shares of its Common Stock at prices ranging from $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z44dlehfZ2uf" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.76</ix:nonFraction></span> to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zcYvfoEWRseb" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span>
for total proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMIIUdDZAHO5" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Warrants
(Rights offering)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#8220;Offering&#8221;)
of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zPxn6Z5v7yPa" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,740,550</ix:nonFraction></span> shares of Common Stock; (ii) pre-funded warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z95jjsb0xCgf" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,148,310</ix:nonFraction></span> shares of Common Stock (the &#8220;Pre-funded
Warrants&#8221;), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zZktK4vOrA5a" title="Number of warrant to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,888,860</ix:nonFraction></span> shares of Common Stock (the &#8220;Warrants&#8221;).
In conjunction with the Offering, we issued </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a
Representative&#8217;s Warrant to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zcUVBXAOEfFe" title="Number of warrant to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">266,665</ix:nonFraction></span> shares of common stock (the &#8220;Representative&#8217;s Warrant&#8221;)<span style="background-color: white">.
The shares of Common Stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zG0XCk86BvSl" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.90</ix:nonFraction></span>, less underwriting discounts and commissions.
Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of
$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z45VysI4Rdh7" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-27_us-gaap_WarrantMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span> per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zQODiBo59fs7" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.899</ix:nonFraction></span>, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKDoG8e4n7Nk" title="Percentage of outstanding stock"><ix:nonFraction name="AIM:PercentageOfOutstandingStock" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of the Company&#8217;s
outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant
represents the right to purchase one share of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqDXj99Nqi93" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zZNgiCM0cLbl" title="Proceeds from Issuance or Sale of Equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember" id="Fact000773" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,200,000</ix:nonFraction></span>. During the year ended </span>December 31<span style="background-color: white">, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z3g8fsCi3e93" title="Stock issued during period shares other"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-012020-12-31_custom_PreFundedWarrantsMember" id="Fact000775" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,870,000</ix:nonFraction></span> of the Pre-funded Warrants
were exercised and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TUJZd6f9eb" title="Pre-funded warrants exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,873,960</ix:nonFraction></span> Warrants were exercised. </span>In addition, on March 25, 2020, the Representative&#8217;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020 and an aggregate of
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBNFf2hF7fXf" title="Warrants exercised aggregate"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">266,665</ix:nonFraction></span> shares were issued upon exercise of this warrant for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zt1Btk7f3ku4" title="Warrant gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-03-302020-03-31" id="Fact000781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,000</ix:nonFraction></span> and a $<span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_z781IO7BCGn9" title="Warrant modification"><ix:nonFraction name="AIM:WarrantModifications" contextRef="From2020-03-302020-03-31" id="Fact000783" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></span> expense for the warrant
modification. No Warrants were exercised during the year ended December 31, 2023 and 2022. As of December 31, 2023 and 2022 there are
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zkWxC6X5Uyl1" title="Warrant outstanding"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zrwFNaFiUAVi" title="Warrant outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></ix:nonFraction></span></span> Warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Equity
Distribution Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#8220;EDA&#8221;) with Maxim Group LLC
(&#8220;Maxim&#8221;), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate
offering price of up to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zNlgcvJurGw"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,500,000</ix:nonFraction></span>
through Maxim, as agent (the &#8220;Offering&#8221;). Sales under the EDA were registered under the S-3 Shelf Registration
Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zMbKWKkSgAB1" title="Transaction fee rate"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember" id="Fact000790" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%
of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zIliAU2gMc1a" title="Shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" id="Fact000792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">598,114</ix:nonFraction></span>
shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zCHyKPIRBnx6" title="Gross proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" id="Fact000794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,000</ix:nonFraction></span>,
which includes a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zTOA1FDdlyr4" title="Transaction fee rate"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember" id="Fact000796" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>%
fee to Maxim of $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zxan4REYwBEh"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2023-12-31_custom_MaximGroupLLCMember" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,326</ix:nonFraction></span>. Subsequent to the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDyG2c83P0r1" title="Shares sold"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">699,568</ix:nonFraction></span> shares under the EDA for total gross proceeds
of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRQPJ8F7ZeUj" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,392</ix:nonFraction></span>, which includes a <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBW1BZtSXEI7" title="Transaction fee rate"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% fee to Maxim of $<span id="xdx_90D_eus-gaap--DebtInstrumentFeeAmount_iI_c20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYidNbQUvnb3"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,492</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Rights
Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp; Trust Company as
Rights Agent (the &#8220;Rights Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Common Stock Options and Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>(i)
Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock
Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards,
(vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zxtEOC1VeTG4" title="Number of common stock reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember" id="Fact000806" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000,000</ix:nonFraction></span> shares of common stock is reserved for
potential issuance pursuant to awards under the 2018 Equity Incentive Plan. Unless sooner terminated, the 2018 Equity Incentive Plan
will continue in effect for a period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zJTZfbENHDnc"><ix:nonNumeric contextRef="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember" format="ixt-sec:duryear" id="Fact000807" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">10</ix:nonNumeric></span> years from its effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Equity Incentive Plans of 2018 are administered by the Board of Directors. The Plans provide for awards to be made to such Officers,
other key employees, non-employee Directors, consultants and advisors of the Company and its subsidiaries as the Board may select.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
options awarded under the Plans may be exercisable at such times (not later than 10 years after the date of grant) and at such exercise
prices (not less than fair market value at the date of grant) as the Board may determine. The Board may provide for options to become
immediately exercisable upon a &#8220;change in control&#8221;, which is defined in the Plans to occur upon any of the following events:
(a) the acquisition by any person or group, as beneficial owner, of 20% or more of the outstanding shares or the voting power of the
outstanding securities of the Company; (b) either a majority of the Directors of the Company at the annual stockholders meeting has been
nominated other than by or at the direction of the incumbent Directors of the Board, or the incumbent Directors cease to constitute a
majority of the Company&#8217;s Board; (c) the Company&#8217;s stockholders approve a merger or other business combination pursuant to
which the outstanding common stock of the Company no longer represents more than 50% of the combined entity after the transaction; (d)
the Company&#8217;s stockholders approve a plan of complete liquidation or an agreement for the sale or disposition of all or substantially
all of the Company&#8217;s assets; or (e) any other event or circumstance determined by the Company&#8217;s Board to affect control of
the Company and designated by resolution of the Board as a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate
expected dividend yield, life and forfeiture rates. The expected life of the options and equity warrants was estimated based on historical
option and equity warrant holders&#8217; behavior and represents the period of time that options and equity warrants are expected to
be outstanding. The fair values of the options granted were estimated based on the following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000809" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zRdQc4lhI2ed" style="display: none">Schedule
of Options and Equity Estimated Based on Weighted Average Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.37</ix:nonFraction></span></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.74</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.88</ix:nonFraction></span>%</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" title="Expected dividend yield" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" title="Expected dividend yield" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Expected life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact000821" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact000823" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-12-31" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.91</ix:nonFraction></span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_srt_MinimumMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">98.43</ix:nonFraction></span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_srt_MaximumMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">107.18</ix:nonFraction></span>%</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000831" name="AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued">$0.43 per option for 400,000 options</ix:nonNumeric></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued"><ix:nonNumeric contextRef="From2022-01-012022-12-31" id="Fact000833" name="AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued">$0.51 per option for 850,000 options</ix:nonNumeric></span></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zpgKNkwD8rIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
exercise price of all stock options and equity warrants granted was equal to or greater than the fair market value of the underlying
common stock on the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember" escape="true" id="Fact000835" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June
24, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" title="Number of options outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000837" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,399</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span> &#8211; <span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,003.20</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" title="Weighted average exercise price outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.23</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" title="Number of options outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,504</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span> &#8211; <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,127.84</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" title="Weighted average exercise price outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.58</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" title="Number of options, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" title="Option price, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" title="Weighted average exercise price, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" title="Number of options, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" title="Option price, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" title="Weighted average exercise price, granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" title="Number of options, forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,047</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span>-<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">327.36</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" title="Weighted average exercise price, forfeited" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.79</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" title="Number of options, forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,105</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.76</ix:nonFraction></span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,127.84</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" title="Weighted average exercise price, forfeited" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">129.88</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" title="Number of options, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" title="Option price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0885">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" title="Number of options, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" title="Option price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" title="Number of options outstanding, ending of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>-<span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,127.84</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" title="Weighted average exercise price outstanding, end of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" title="Number of options outstanding, ending of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000901" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,399</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>-<span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,003.20</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" title="Weighted average exercise price outstanding, end of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.23</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" title="Number of options exercisable, end of year" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,352</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000913" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,127.84</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" title="Number of options exercisable, end of year" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">124,399</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>-<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,003.20</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member" format="ixt-sec:duryear" id="Fact000921" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.06</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member" format="ixt-sec:duryear" id="Fact000923" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.98</ix:nonNumeric></span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zwEfEfkEYN0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember" escape="true" id="Fact000925" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zjBHKIJSnVTc" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" title="Number of options outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,474,971</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>-<span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" title="Weighted average exercise price outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000933" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" title="Number of options outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,017</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span> &#8211; <span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" title="Weighted average exercise price outstanding, beginning of year" style="width: 7%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" title="Number of options, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" title="Weighted average exercise price, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" title="Number of options, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span> &#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.71</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" title="Weighted average exercise price, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" title="Number of options, forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,829</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" title="Weighted average exercise price, forfeited" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" title="Number of options, forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,046</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.85</ix:nonFraction></span> &#8211; <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" title="Weighted average exercise price, forfeited" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" title="Number of options, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" title="Option price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" title="Number of options, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" title="Option price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" title="Number of options outstanding, ending of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,814,142</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>-<span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" title="Weighted average exercise price outstanding, end of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.54</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" title="Number of options outstanding, ending of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,474,971</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span> &#8211; <span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" title="Weighted average exercise price outstanding, end of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" title="Number of options exercisable, end of year" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,397,474</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">327.36</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.71</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" title="Number of options exercisable, end of year" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact001010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,916,637</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></span> &#8211; <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact001015" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member" format="ixt-sec:duryear" id="Fact001017" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.96</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member" format="ixt-sec:duryear" id="Fact001019" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">9.65</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member" id="Fact001021" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,210,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">466,120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zCt6AGdS0HJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
option activity during the years ended December 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" escape="true" id="Fact001025" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zF0PfjjCWiX8" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" title="Number of options outstanding, beginning of year" style="width: 10%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,498,798</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.22</ix:nonFraction></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001031" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.11</ix:nonNumeric></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="width: 10%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" title="Number of options, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.49</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001039" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">9.71</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" title="Number of Options, Forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,584</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.71</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" title="Number of Options, Expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,020,214</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001053" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.86</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" title="Aggregate Intrinsic Value Outstanding, beginning of Period" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" title="Number of options, granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001061" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">10.17</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" title="Number of Options, Forfeited" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,601</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" title="Number of Options, Expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.61</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,408,438</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001075" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.70</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" title="Aggregate Intrinsic Value Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,041,772</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.90</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001083" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">6.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,041,772</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.90</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001091" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">6.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" title="Aggregate Intrinsic Value, Exercisable at End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zaPFwFMU6Lmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
weighted-average grant-date fair value of employee options vested during the year ended December 31, 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDLLW4mKBtch" title="Share-based payment award options vested in period fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2023-01-012023-12-31_custom_EmployeesMember" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,000</ix:nonFraction></span> for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zexAY94cljFd" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_EmployeesMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">424,999</ix:nonFraction></span> options
at $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwhJUHGEuao6" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.43</ix:nonFraction></span> per option and during year ended December 31, 2022 was $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqKhD2stjHF7" title="Number of options, granted"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2022-01-012022-12-31_custom_EmployeesMember" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">768,666</ix:nonFraction></span> for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z3UmXsez7IE1" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_EmployeesMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">575,000</ix:nonFraction></span> options at $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIGmU7JOYkvk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesMember" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.34</ix:nonFraction></span> per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" escape="true" id="Fact001106" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_znkiS1cgVg4i" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2021</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" title="Number of Options Unvested, Beginning of Period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">412,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.15</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001112" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">5.85</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 13%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001120" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">9.71</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" title="Number of Options, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">541,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" title="Weighted Average Exercise Price, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001126" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">9.73</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Unvested December 31, 2022</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" title="Number of Options Unvested, brginning of Period" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">392,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" title="Weighted Average Exercise Price Unvested, beginning of Period" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001136" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">8.86</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001143" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">10.17</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" title="Number of Options, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">413,884</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" title="Weighted Average Exercise Price, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001149" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">6.73</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" title="Number of Options, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,601</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001153" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" title="Number of Options, Expired" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.61</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001159" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">366,666</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001163" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">12.44</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AD_zG18YW8IC09l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" escape="true" id="Fact001167" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_zsalMMWYrOo9" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" title="Number of Options Outstanding, Beginning of Period" style="width: 13%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">279,723</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" title="Weighted Average Exercise Price Outstanding, Beginning of Period" style="width: 13%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.12</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001173" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.93</ix:nonNumeric></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="width: 13%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" title="Number of Options, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001177" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" title="Weighted Average Exercise Price, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.54</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001181" name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted">9.68</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" title="Number of Options, exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1183">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" title="Weighted Average Exercise Price, Exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">568</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001188" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">153.12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" title="Number of Options Outstanding, beginning of Period" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">579,155</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" title="Weighted Average Exercise Price Outstanding, beginning of Period" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.09</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001194" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.36</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" title="Aggregate Intrinsic Value Outstanding, beginning of Period" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" title="Weighted Average Exercise Price, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.46</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001201" name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted">10.04</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" title="Number of Options, exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" title="Weighted Average Exercise Price, Exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" title="Number of Options,expired" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">653</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" title="Weighted Average Exercise Price, Expired" style="color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">145.24</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">885,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" title="Weighted Average Exercise Price Outstanding, End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001218" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.23</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" title="Aggregate Intrinsic Value Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" title="Weighted Average Exercise Price, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.56</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001226" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">10.02</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" title="Weighted Average Exercise Price Exercisable, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.56</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10.02</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" title="Aggregate Intrinsic Value, Exercisable at End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1236">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zHocvI0bZukb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
weighted-average grant-date fair value of non-employee options vested during year 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_znEFRK5NZ8l7" title="Share-based payment award options vested in period fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" id="Fact001238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span> for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zzSmpvfyg8Q2" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">191,666</ix:nonFraction></span> options at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zSgr1cy7Cd98" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span> per option
and during the year 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zuhPnyCsCu55" title="Share-based payment award options vested in period fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" id="Fact001244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,166</ix:nonFraction></span> for<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zvJmne3ZNVc1" title="Number of options, granted"> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">229,053</ix:nonFraction></span> options at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zBl8iBiuAg14" title="Weighted average exercise price, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.08</ix:nonFraction></span> per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" escape="true" id="Fact001250" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zmTaiMUsaseh" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2021</span></td><td style="width: 2%; color: Black; text-align: left">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" title="Number of Options Unvested, Beginning of Period" style="width: 13%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,831</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 13%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.89</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001256" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">7.82</ix:nonNumeric></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 13%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" title="Number of Options, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" title="Weighted Average Exercise Price, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.54</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001264" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">9.68</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" title="Number of Options, Vested" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">229,053</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" title="Weighted Average Exercise Price, Vested" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001268" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.82</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2022</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" title="Number of Options Unvested, brginning of Period" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,789</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" title="Weighted Average Exercise Price Unvested, beginning of Period" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.05</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001276" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">9.49</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" title="Aggregate Intrinsic Value Unvested, beginning of Period" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" title="Number of Options, Granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.46</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001283" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">10.18</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" title="Number of Options, Vested" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">137,565</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" title="Weighted Average Exercise Price, Vested" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001289" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">9.47</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expired</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" title="Number of Options, Vested" style="color: Black; text-align: right">(<ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">776</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" title="Weighted Average Exercise Price, Expired" style="color: Black; text-align: right"><ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">145.24</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" title="Number of Options, Forfeited" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001303" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">10.70</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z4C2lN2A5n75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
compensation expense was approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMWuIx6ShLVe" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001307" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">243,000</ix:nonFraction> </span>and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjGrfLdWeJ5" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001309" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">954,000</ix:nonFraction></span> for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2023 and 2022, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20231231_zXhQqABm0kwh" title="Unrecognized stock-based compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31" id="Fact001311" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20221231_zjMEq1YsxSw2" title="Unrecognized stock-based compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">217,000</ix:nonFraction></span>, respectively, of unrecognized stock-based compensation cost related to
options granted under the Equity Incentive Plans. Stock-based compensation related to options granted under the Equity Incentive Plans
will be recorded over the vesting period which is typically one year or upon reaching agreed upon Company and/or individual performance
milestones being met which is indefinite.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(ii)
Stock Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
warrants are issued as needed by the Board of Directors and have no formal plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend
yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder&#8217;s behavior
and represents the period of time that options are expected to be outstanding. No warrants were granted in 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001315" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"><p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding warrants outstanding and exercisable into shares of common stock is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_z5LMDxbstbGf" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"/><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"/><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year <br/>&#160; <br/></td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" title="Number of options outstanding, beginning of year" style="width: 8%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">226,610</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">132.00</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" title="Weighted average exercise price outstanding, beginning of year" style="width: 8%; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.10</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" title="Number of options outstanding, beginning of year" style="width: 8%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">294,939</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span> &#8211; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">469.92</ix:nonFraction></span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" title="Weighted average exercise price outstanding, beginning of year" style="width: 8%; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.19</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1338">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" title="Number of options outstanding, beginning of year" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,450</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.05</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.05</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" title="Number of options outstanding, beginning of year" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,215</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">469.92</ix:nonFraction></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">469.92</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1358">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001361" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001363" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.03</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" title="Number of options outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">226,610</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">132.00</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" title="Number of options outstanding, beginning of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.03</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" title="Number of options outstanding, beginning of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">226,610</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001393" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">132.00</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" title="Weighted average exercise price outstanding, beginning of year" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.10</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001396" name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber">.75</ix:nonNumeric> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001398" name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber">.94</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001400" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear">2024</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Number of options outstanding, beginning of year" style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001402" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear">2023</ix:nonNumeric></span>-<span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001404" name="AIM:WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear">2024</ix:nonNumeric></span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td title="Weighted average exercise price outstanding, beginning of year" style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zEdcVdPnO2dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
warrants are issued at the discretion of the Board. During the year ended December 31, 2023, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20230101__20231231_zkkhVy30p3Zg" title="Warrants issued::XDX::-"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_doxL_c20230101__20231231_zlawOgcMWi01" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1406"><span style="-sec-ix-hidden: xdx2ixbrl1408">no</span></span></span></span> warrants issued or exercised.
During the year ended December 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20220101__20221231_zaNSjiTXnKtd" title="Warrants issued::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1410">no</span></span> warrants issued and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_dixL_c20220101__20221231_zHfpY7YXfrz5" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1412">114</span></span> were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001414" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zJJslBquIkL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(7)
<span id="xdx_82D_zREfYxgxL3z4">Segment and Related Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company operates in <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zc5D3JCz9mj5" title="Number of segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2023-01-01to2023-12-31" id="Fact001416" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></span> segment, which performs research and development activities related to Ampligen and other drugs under development.
The Company&#8217;s revenues for the two-year period ended December 31, 2023, were earned in the United States. All assets are maintained
in the United States of America.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001418" name="AIM:ResearchConsultingAndSupplyAgreementsTextBlock"><p id="xdx_805_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4fLtYbN7Vll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(8)
<span id="xdx_822_zEJLf0INZyc8">Research, Consulting and Supply Agreements</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, research and development expenses
were comprised of: clinical studies ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyjDnZGFgh62" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ClinicalStudiesMember" id="Fact001420" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,014,000</ix:nonFraction></span>), manufacturing and engineering ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zfI5Va6rI0d5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember" id="Fact001422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,220,000</ix:nonFraction></span>), quality control ($<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--QualityControlMember_zj6NBYEJsDr9" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_QualityControlMember" id="Fact001424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,271,000</ix:nonFraction></span>) and regulatory
($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--RegulatoryMember_z6SeNVOYYyG5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_RegulatoryMember" id="Fact001426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span>During the year ended December 31, 2022, research and development expenses
were comprised of: clinical studies ($<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyuQ9B3Ls66h" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ClinicalStudiesMember" id="Fact001428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,070,000</ix:nonFraction></span>), manufacturing and engineering ($<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zrzfkeFObV29" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember" id="Fact001430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,241,000</ix:nonFraction></span>), quality control ($<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--QualityControlMember_zGzSy0BCHlT8" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_QualityControlMember" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,000</ix:nonFraction></span>) and regulatory
($<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--RegulatoryMember_zwhviG7susAi" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_RegulatoryMember" id="Fact001434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,000</ix:nonFraction></span>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Amarex
Clinical Research LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amarex
is the principal administrator of several of AIM&#8217;s largest clinical studies. AIM has multiple contracts with Amarex Clinical
Research LLC (&#8220;Amarex&#8221;). During the year ended December 31, 2023 and 2022, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zjsKeSbwVgt3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember" id="Fact001436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,290,000</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zoTYVGpzRIHh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,272,000</ix:nonFraction></span>, respectively, related to these ongoing agreements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pancreatic
    Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally
    advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex&#8217;s management of the
    study will cost approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj0b7yetqVHi" title="Research and development expense excluding acquired in process cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" id="Fact001440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400,000</ix:nonFraction></span>. This estimate includes pass-through costs of approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z6E238Oy8zCa" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" id="Fact001442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> and excludes certain
    third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately
    <span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zvzpsBBUJNJ6" title="Estimated lives"><ix:nonNumeric contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" format="ixt-sec:duryear" id="Fact001444" name="AIM:ResearchAndDevelopmentExpenseCostEstimatedLives">4.6</ix:nonNumeric></span> years to complete.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zEogaZmww6xe" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember" id="Fact001446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zRA9HhWySi2b" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember" id="Fact001448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,691,000</ix:nonFraction></span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Post-COVID
    Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients
    with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z3OtcXkdCxH5"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,400,000</ix:nonFraction></span>, which
    includes pass through costs of approximately $<span id="xdx_90C_eus-gaap--DevelopmentCosts_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z68nU02VjkCg" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span>, investigator costs estimated at about $<span id="xdx_900_eus-gaap--CostMaintenance_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zwAikhPsTji7" title="Invigilators cost"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,400,000</ix:nonFraction></span>, and excludes certain other
    third-party costs and escalations. During 2023, the original work order increased to approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zN5anhmwgnI8" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,600,000</ix:nonFraction></span> for the addition of
    patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the
    ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which
    resulted in additional IND submissions to FDA. This study was effectively concluded in 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zX4oZsJX0Xcg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember" id="Fact001457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,690,000</ix:nonFraction></span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zBWSLzE4RDt" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember" id="Fact001459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,000</ix:nonFraction></span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Jubilant
HollisterStier</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Jubilant
HollisterStier (&#8220;Jubilant&#8221;) is AIM&#8217;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company
entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen&#174; for the Company. Since the
2017 engagement of Jubilant, two lots of Ampligen consisting of more than <span id="xdx_90F_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zJaL14ANND35" title="Number of units manufactured"><ix:nonFraction name="AIM:UnitsManufactured" contextRef="From2017-01-012017-12-31_custom_JubilantHollisterStierMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">16,000</ix:nonFraction></span> units were manufactured and released in the year 2018.
The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials.
The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant
manufactured additional two lots of Ampligen in December 2019 and January 2020. In March 2023, the Company ordered an additional <span id="xdx_904_ecustom--NumberOfVials_uInteger_c20230101__20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zpL9XLWaZCf5" title="Additional number of vials"><ix:nonFraction name="AIM:NumberOfVials" contextRef="From2023-01-012023-03-31_custom_JubilantHollisterStierMember" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">27,900</ix:nonFraction></span>
vials from Jubilant at a cost of approximately $<span id="xdx_90E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zCBLLFuNAPH9" title="Inventory work in process and raw materials"><ix:nonFraction name="us-gaap:InventoryWorkInProcessAndRawMaterials" contextRef="AsOf2023-03-31_custom_JubilantHollisterStierMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,000</ix:nonFraction></span>. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zfI7t5QWlnMa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,000</ix:nonFraction></span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zCKeu8FivXJ" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,000</ix:nonFraction></span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Sterling
Pharma Solutions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#8220;Sterling&#8221;)
for the manufacture of the Company&#8217;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--PharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zKzuIfnLYHIk" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" id="Fact001471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Erasmus</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#8217;s limited responsibilities
are limited to providing Ampligen. Additionally, AIM agreed to provide a grant of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20221201__20221231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zrZLNisgBPx" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> for the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JjointClinicalStudyAgreementMember_zbzGQ71Oq9Yg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> pursuant to the Grant Agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova
Sales International</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services
for AIM&#8217;s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange
for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zDtRuFC8pDte" title="Stock options, aggregate intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> per month in addition to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zoUQauZAXSz5" title="Stock options, vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember" id="Fact001479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">360,000</ix:nonFraction></span> stock options that vest monthly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zwr8JgvdTSQa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember" id="Fact001481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiMember_zF5WPVvD5UFa" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-09-012023-09-30_custom_AlcamiMember" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AlcamiMember_zjgWBiPtStJ3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AlcamiMember" id="Fact001485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,000</ix:nonFraction></span> of lab services from Alcami.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AlcamiMember_zKyWKv2prIx3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_AlcamiMember" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></span> of lab services from Alcami.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001489" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z41Ccz5PSXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)
<span id="xdx_827_zYskLrLHgAXi">401(k) Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
has a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the &#8220;401(k) Plan&#8221;).
AIM&#8217;s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations
imposed by federal tax laws, participants are eligible to contribute up to <span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOnekPlanMember_zux9xhht0cd7" title="Percentage of maximum annual contribution per employee, as percentage of their annual salary"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of their salary (including bonuses and/or commissions)
per annum. Participants&#8217; contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
participant immediately vests in his or her deferred salary contributions as well as the Company&#8217;s safe harbor contributions.
A <span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20230101__20231231_zPmL7gjec7M6" title="Deferred compensation arrangementl, cash awards granted, percentage"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001493" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%
safe harbor matching contribution by us was reinstated effective January 1, 2021. For the year ended December 31, 2023 and 2022, the
Company&#8217;s matching contributions were approximately $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zDzlD8umTTua" title="Contribution amount"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-01to2023-12-31" id="Fact001495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,000</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zWVac5329b" title="Contribution amount"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-01-012022-12-31" id="Fact001497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction></span>,
respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001499" name="AIM:EmploymentAgreementsTextBlock"><p id="xdx_80E_ecustom--EmploymentAgreementsTextBlock_z3dZg3hif1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)
<span id="xdx_829_zMyC1KKbWmIl">Employment Agreements</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had contractual agreements with Named Executive Officers (&#8220;NEO&#8221;) in 2023, and 2022. The aggregate annual base compensation
for these NEO under their respective contractual agreements for 2023 and 2022 was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zj0ShGkuJnL1" title="Employee benefits and share-based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,275,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zaEP2bBxhiGd" title="Employee benefits and share-based compensation"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,275,000</ix:nonFraction></span>, respectively. In addition,
certain of these Officers were entitled to receive performance bonuses of up to <span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zAWrRcxlY5Ya" title="Revenue, remaining performance obligation, percentage"><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% or <span id="xdx_902_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_ziu4G3VqCNwd" title="Revenue, remaining performance obligation, percentage"><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of their respective annual base salary, at
the sole discretion of the Compensation Committee of the Board of Directors. For the years ended December 31, 2023 and 2022, Officers&#8217;
bonuses were $<span id="xdx_903_ecustom--Bonus_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zEMZSOc8AYE5"><ix:nonFraction name="AIM:Bonus" contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span>, to be deferred and paid in 2024 and $<span id="xdx_90B_ecustom--Bonus_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_z1JvkmqZRr9h"><ix:nonFraction name="AIM:Bonus" contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember" id="Fact001509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, equity was granted as a form of compensation to these Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLuhZd8cUGIg" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5g6mpgvgvc3" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1513">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5z5Hbpc0Nte" title="Stock options exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span> per share to vest in <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zP3lUqpy1hlg"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" format="ixt-sec:durwordsen" id="Fact001516" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">one year</ix:nonNumeric></span> to
    Thomas K. Equels, Chief Executive Officer. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zC6zjeGF8sLe" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zwzTNS7Bj5Xe" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1520">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zTrS2M1Re0Ai" title="Stock options exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span> per share which vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_ztOxwIqUCeed" title="Vesting period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" format="ixt-sec:durwordsen" id="Fact001524" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">one year</ix:nonNumeric></span>
    to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock compensation expense of approximately $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsandRodinoMember_zf8vnYpJe6ol" title="Stock compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EquelsandRodinoMember" id="Fact001526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,000</ix:nonFraction></span> during the year ended December 31, 2023 with regard to these issuances
to Officers Equels and Rodino.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, equity was granted as a form of compensation to these Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z6KkeQwFNM9l" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zkTwRI3bRFRj" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1530">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zlND1tOnooGc" title="Stock options exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></span> per share to vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLAigI8Ixqb6"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember" format="ixt-sec:durwordsen" id="Fact001533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">one year</ix:nonNumeric></span> to
    Thomas K. Equels, Chief Executive Officer. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zqR0Vn4Va4Ni" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zCXKUdCehaDe" title="Options term::XDX::P10Y"> <span style="-sec-ix-hidden: xdx2ixbrl1537">ten-year</span></span> options to purchase common stock with exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MinimumMember_zVGM4kglJob6" title="Stock options exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember" id="Fact001539" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MaximumMember_z0pDSSJI41T5" title="Stock options exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember" id="Fact001541" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.70</ix:nonFraction></span> per share which vest in <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zW8O62SfRcNh" title="Vesting period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember" format="ixt-sec:durwordsen" id="Fact001543" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">one
    year</ix:nonNumeric></span> to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_zF2JjGbqRn9h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z9axaCjww9u9" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1545">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3sSALWeLDHh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" id="Fact001546" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.70</ix:nonFraction></span> per share which vest in <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_ztrwY3O2VUSk"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember" format="ixt-sec:durwordsen" id="Fact001547" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">one year</ix:nonNumeric></span>
    to Ellen Lintal, former Chief Financial Officer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock compensation expense of approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsRodinoAndFormerOfficerLintalMember_zy4Yu23qvXD1" title="Stock compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember" id="Fact001549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></span> during the year ended December 31, 2023 with regard to these issuances
to Officers Equels, Rodino, and former Officer Lintal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001551" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zQOOVYpaB976" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)
<span id="xdx_829_zlz5v5PdPTu6">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zVaiRjTuXbg8" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001553" name="us-gaap:LesseeOperatingLeaseRenewalTerm">1</ix:nonNumeric></span> to <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zeNDPYLL2htc" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001555" name="us-gaap:LesseeOperatingLeaseRenewalTerm">5</ix:nonNumeric></span> years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_903_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zPaGW6A9yk8l" title="Operating lease Payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31_srt_MinimumMember" id="Fact001557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span>
to $<span id="xdx_905_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ziPjjkhnYaY2" title="Operating lease Payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31_srt_MaximumMember" id="Fact001559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span>. Certain leases include additional renewal options ranging from <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zYHnZjDWxwf3" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001561" name="us-gaap:LesseeOperatingLeaseRenewalTerm">1</ix:nonNumeric></span> to <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zlgXnWxMrNn7" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001563" name="us-gaap:LesseeOperatingLeaseRenewalTerm">5</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001565" name="AIM:ScheduleOfOperatingLeaseTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



</ix:nonNumeric><p id="xdx_8A2_z85JlF1Xgu1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
has classified all of its leases as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the balance of the right of use assets was $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zbMGwrMOU9uc" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001567" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">697,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_zdRwzGCHavDc" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact001569" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">829,000</ix:nonFraction></span>, respectively,
and the corresponding operating lease liability balance was $<span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_c20231231_z1GBWvCTxGS2" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001571" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20221231_z4bM4Ll48O9g" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" id="Fact001573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">837,000</ix:nonFraction></span>, respectively. Right of use assets are recorded net
of accumulated amortization of $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20231231_zJhI6zUqL3P8" title="Accumulated amortization"><ix:nonFraction name="AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20221231_zLjp2IYKIKjg" title="Accumulated amortization"><ix:nonFraction name="AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2022-12-31" id="Fact001577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,000</ix:nonFraction></span> as of December 31, 2023 and 2022, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001579" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;&#160;&#160;<span id="xdx_8BF_zGZL5uejvTRh" style="display: none">Schedule of AIM
Recognized Rent Expense Associated with Operating Lease</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact001584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2022-01-012022-12-31" id="Fact001588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact001590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-12-31" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Classification of lease costs</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Research &amp; development</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">498</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost </td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001599" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001600" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact001602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-12-31" id="Fact001603" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zvy3LB7wwUQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s leases have remaining lease terms between <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zATfJuQh90Y8" title="Operating lease, remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember" format="ixt-sec:durmonth" id="Fact001605" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric></span> and <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_zmpjeMDRy71c" title="Operating lease, remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember" format="ixt-sec:durmonth" id="Fact001607" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">44</ix:nonNumeric></span> months. As of December
31, 2023 and 2022, the weighted-average remaining term was <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zDINuqx6mOY4" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:durmonth" id="Fact001609" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">41</ix:nonNumeric></span> and <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20221231_zbLzyoyha2G3" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:durmonth" id="Fact001611" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">43</ix:nonNumeric></span> months, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted average incremental borrowing rate for its leases was <span id="xdx_90A_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zbCfGO82WmBh" title="Weighted average incremental borrowing rate"><span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20221231_z0MPgINDETAf" title="Weighted average incremental borrowing rate"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2023-12-31" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2022-12-31" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>%
as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001617" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zbWNcHMSJbZg" style="display: none">Schedule of Operating Lease Future Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zcJjykldx2C">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact001619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" id="Fact001621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" id="Fact001623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" id="Fact001625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" id="Fact001629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">718</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zZYGeQSguPLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001633" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zrklqGUSkgpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)
<span id="xdx_827_zvlAk2Kg9xT7">Income Taxes (FASB ASC 740 Income Taxes)</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#8217;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses and research and development credits generated in New Jersey, all tax benefits will likely not be recognized
due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of December 31, 2023,
the Company has approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL6twwVY9lF2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,300,000</ix:nonFraction></span> of Federal net operating loss carryforwards (expiring in the years 2023 through 2038), and
$<span id="xdx_90D_ecustom--OperatingLossCarryforwardsWithNoExpirationDate_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zEauPMWJIJW4" title="Operating loss carry forwards with no expiration date"><ix:nonFraction name="AIM:OperatingLossCarryforwardsWithNoExpirationDate" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,300,000</ix:nonFraction></span> of Federal net operating loss carryforwards with no expiration date, both of which have been limited by Internal Revenue
Code Section 382, available to offset future federal taxable income. The Company has approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--NewJerseyDivisionOfTaxationMember_z6XxYw8iV7C5" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember" id="Fact001639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,800,000</ix:nonFraction></span> of New Jersey state net
operating loss carryforwards (expiring in 2044). The Company has approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdUMO0kEmCag" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,500,000</ix:nonFraction></span> of Florida state net operating loss carryforwards
with no expiration date to offset future Florida taxable income. The Company has approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__country--BE_zG6U1zZnlsSc" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_country_BE" id="Fact001643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,600,000</ix:nonFraction></span> of Belgium net operating loss
carryforwards with no expiration date to offset future taxable income In December 2023, the Company effectively sold $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__stpr--NJ_zMjFiyczoPS9" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_stpr_NJ" id="Fact001645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,156,000</ix:nonFraction></span> of its
New Jersey state net operating loss carryforward and $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20230101__20231231__srt--StatementGeographicalAxis__stpr--NJ_zcApvIcqtUC4" title="Effective income tax rate reconciliation, tax credit, amount"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="From2023-01-012023-12-31_stpr_NJ" id="Fact001647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,600</ix:nonFraction></span> in R&amp;D credits for the year 2022 for approximately $<span id="xdx_905_eus-gaap--IncomeTaxReconciliationTaxCredits_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__stpr--NJ_zEMfLp5M7ibk" title="Effective income tax rate reconciliation, tax credit, amount"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="From2022-01-012022-12-31_stpr_NJ" id="Fact001649" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,313,000</ix:nonFraction></span>. The utilization
of certain state net operating loss carryforwards may be subject to annual limitations. With no tax due for the foreseeable future, the
Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary
at this time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Tax Reform Act of 1986, the utilization of a corporation&#8217;s net operating loss carryforward is limited following a greater than
50% change in ownership. As noted above, due to the Company&#8217;s prior and current equity transactions, some of the Company&#8217;s
net operating loss carryforwards are subject to an annual limitation generally determined by multiplying the value of the Company on
the date of the ownership change by the federal long-term tax-exempt rate. Any unused annual limitation may be carried forward to future
years for the balance of the net operating loss carryforward period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the carrying amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management considers
whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net
future deductible amounts become deductible. With the exception of net operating losses generated in New Jersey which can be surrendered
for 80% of their value, due to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax asset, the remainder
of our deferred tax assets are fully offset by a valuation allowance at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001651" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an
immaterial deferred tax error of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31_srt_RestatementAdjustmentMember" id="Fact001653" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022,
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none">Schedule of Components of Net Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,114</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact001656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,674</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research and Development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact001659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization &amp; depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:DeferredTaxAssetsAmortizationAndDepreciation" contextRef="AsOf2023-12-31" id="Fact001661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,791</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:DeferredTaxAssetsAmortizationAndDepreciation" contextRef="AsOf2022-12-31" id="Fact001662" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,342</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">R&amp;D credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001664" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" id="Fact001665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact001668" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:DeferredTaxAssetsRightOfUseAssets" contextRef="AsOf2023-12-31" id="Fact001670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:DeferredTaxAssetsRightOfUseAssets" contextRef="AsOf2022-12-31" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact001674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,472</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" id="Fact001677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="Fact001682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,604</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="Fact001683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A0_zeUFKzIwyEv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are included within other assets in the accompanying Consolidated Balance Sheets. The benefits of deferred tax assets are
included within the gain from sale of income tax operating losses in the accompanying Consolidated Statements of Operations and
Comprehensive Loss. The Company&#8217;s deferred tax asset estimates the projected sale of 2023 and 2022 New Jersey state operating
losses to be sold in the subsequent year, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate
Reconciliation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001685" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zluv3XFKo1Aj" style="display: none">Schedule of Effective Tax Rate and Statutory Tax Rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" title="Pre Tax Book Loss" style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" contextRef="From2023-01-01to2023-12-31" id="Fact001687" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,962</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" title="Federal Rate" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001689" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,082</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" title="Federal Rate" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001691" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" title="State Taxes" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001693" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,244</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" title="State Taxes" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.75</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Perms</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Other Perms" id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-01to2023-12-31" id="Fact001697" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Other Perms" id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-01to2023-12-31" id="Fact001699" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.29</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RTP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" title="RTP" style="text-align: right">(<ix:nonFraction name="AIM:IncomeTaxReconciliationForeignIncomeRTP" contextRef="From2023-01-01to2023-12-31" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" title="RTP" style="text-align: right"><ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationRTPPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.03</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Income Tax Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Income Tax Income" id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2023-01-01to2023-12-31" id="Fact001705" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">479</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Income Tax Income" id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2023-01-01to2023-12-31" id="Fact001707" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.65</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State Rate Change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="State Rate Change" id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal" contextRef="From2023-01-01to2023-12-31" id="Fact001709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="State Rate Change" id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" contextRef="From2023-01-01to2023-12-31" id="Fact001711" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="R&amp;D" id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-01to2023-12-31" id="Fact001713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">272</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="R&amp;D" id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-01to2023-12-31" id="Fact001715" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.94</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State NOL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="State NOL" id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="State NOL" id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right"><ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>NJ NOL True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="NJ NOL True Up" id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right"><ix:nonFraction name="AIM:IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" contextRef="From2023-01-01to2023-12-31" id="Fact001721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="NJ NOL True Up" id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right">-<ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001723" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.88</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock Compensation True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Stock Compensation True Up" id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-01to2023-12-31" id="Fact001725" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,347</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Stock Compensation True Up" id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2023-01-01to2023-12-31" id="Fact001727" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.65</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fixed Assets True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Fixed Assets True Up" id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right"><ix:nonFraction name="AIM:IncomeTaxReconciliationNondeductibleExpenseFixedAssets" contextRef="From2023-01-01to2023-12-31" id="Fact001729" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">925</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Fixed Assets True Up" id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right">-<ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" contextRef="From2023-01-01to2023-12-31" id="Fact001731" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.19</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" title="Other" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" title="Other" style="text-align: right"><ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationOther" contextRef="From2023-01-01to2023-12-31" id="Fact001735" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.08</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="NOL Refund VA True Up" id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AIM:IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="NOL Refund VA True Up" id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right">-<ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001739" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td title="Other" style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td title="Statutory Other" style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" title="Valuation Allowance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001741" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" title="Statutory Valuation Allowance" style="border-bottom: Black 1.5pt solid; text-align: right">-<ix:nonFraction name="AIM:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001743" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1745">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" title="Statutory Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact001747" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zyVBat4fM2Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001749" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpy4TpPKA85b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)
<span id="xdx_827_zxlV1UX3tDal">Certain Relationships and Related Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an employment agreement with its NEOs and has granted its NEOs and directors options to purchase its common stock. Please
see details of these Employment Agreements in Note 10 - Employment Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001751" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zyjoNCG16AJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)
<span id="xdx_827_zJu5FExLjD6e">Concentrations of Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments
and accounts receivable. The Company places its cash with high-quality financial institutions and, at times, such amounts in non-interest-bearing
accounts may be in excess of Federal Deposit Insurance Corporation insurance limits. There were no credit-based sales for 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use
in manufacturing Ampligen and Alferon N Injection. At present, the Company does not have any agreements with third parties for the supply
of any of these materials or it is relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection.
Jubilant HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. The Company anticipates that additional
orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, it added Pharmaceutics
International Inc. (&#8220;Pii&#8221;) as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce the drug Ampligen.
This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment the Company&#8217;s
existing fill and finish capacity. If the Company is unable to place adequate acceptable purchase orders with Jubilant or Pii in the
future at acceptable prices upon acceptable terms, it will need to find another manufacturer. The costs and availability of products
and materials the Company would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond
our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations.
There can be no assurance that the Company will be able to obtain such products and materials on terms acceptable to it or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the Alferon N Injection manufacturing process is on hold and there is no definitive timetable to restart production. If the Company is
unable to acquire FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection inventory or contract
with a CMO, its operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no
assurances that the approved Alferon N Injection product will be returned to production on a timely basis, if at all, or that if and
when it is again made commercially available, it will return to prior sales levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001753" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_z7t6Ujmx0eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(15)
<span id="xdx_82A_zGHl6kYoQvOj">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the provisions of FASB ASC 820 &#8220;Fair Value Measurements&#8221; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &#8211; Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this
    includes debt and equity securities that are traded in an active market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &#8211; Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets
    that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full
    term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models,
    discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value
    requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash
    settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As
    discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001755" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYDPDRYoMkN5" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" title="Cash equivalents-Marketable investments" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact001757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,805</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" title="Cash equivalents-Marketable investments" style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001759" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,805</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" title="Cash equivalents-Marketable investments" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" title="Cash equivalents-Marketable investments" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact001765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" title="Marketable securities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1769">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" title="Marketable securities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1771">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" title="Cash equivalent-Marketable investments" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31" id="Fact001773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" title="Cash equivalent-Marketable investments" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,180</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" title="Cash equivalent-Marketable investments" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1777">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" title="Cash equivalent-Marketable investments" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1779">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" id="Fact001781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" title="Marketable securities" style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" title="Marketable securities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1785">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" title="Marketable securities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zBi8m8zL5Qy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash balances are representative of their fair values as these balances are comprised of deposits available on demand.
For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was
estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair
value of the redeemable warrants (&#8220;Redeemable Warrants&#8221;) related to the Company&#8217;s March 2019 common stock and warrant
issuance, are calculated using a Monte Carlo Simulation (Level 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such
value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions
or the numbers input based on such assumptions, the resulting fair value could be materially different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001789" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zrbXdtHsst85" style="display: none">Schedule
of Assumptions to Estimate Fair Value of Warrants&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember" id="Fact001791" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember" id="Fact001792" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">8.80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">8.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001797" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">5.47</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">4.67</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001800" name="us-gaap:WarrantsAndRightsOutstandingTerm">.19</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001802" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.19</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001804" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">80</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001805" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Pure">70</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants measurement input</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zsBs6amkn04c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
    Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate
    with the remaining expected holding periods of the warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Holding Period</i>. The expected holding period represents the period of time that the Warrants are expected to be outstanding until
    they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Volatility</i>. Expected stock volatility is based on daily observations of the Company&#8217;s historical stock values for a period
    commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Dividend Yield</i>. Expected dividend yield is based on the Company&#8217;s anticipated dividend payments over the remaining expected
    holding period. As the Company has never issued dividends, the expected dividend yield is <span id="xdx_901_ecustom--FairValueMeasurementInputPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zqowt4ev68Yb" title="Fair value measurement, input percentage"><ix:nonFraction name="AIM:FairValueMeasurementInputPercentage" contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001813" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% and this assumption will be continued
    in future calculations unless the Company changes its dividend policy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Probability of a Fundamental Transaction.</i> The possibility of the occurrence of a Fundamental Transaction triggering a Put right
    is extremely remote. As discussed above, a Put right would only arise if a Fundamental Transaction 1) is an all cash transaction;
    (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities
    exchange. The Company believes such an occurrence is highly unlikely because:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company only has one product that is FDA approved but is currently not available for commercial sales.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company will have to perform additional clinical trials for FDA approval of its flagship product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
    and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available
    capital for a potential buyer in a cash transaction continues to be limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research &amp; Development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction
    at their manufacturing facility; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the above factors utilized in analysis of the likelihood of the Put&#8217;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001815" name="AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z3IoaIciMb6l" style="display: none">Schedule of Range of Probabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: center">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability"><ix:nonFraction name="AIM:PercentageOfProbability" contextRef="From2023-01-012023-12-31_srt_MinimumMember" id="Fact001817" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability"><ix:nonFraction name="AIM:PercentageOfProbability" contextRef="From2023-01-012023-12-31_srt_WeightedAverageMember" id="Fact001819" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability"><ix:nonFraction name="AIM:PercentageOfProbability" contextRef="From2023-01-012023-12-31_srt_MaximumMember" id="Fact001821" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zq7Luw79jzU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Monte Carlo Simulation has incorporated a <span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231_zaqAl3tBTbV6" title="Percentage of probability"><ix:nonFraction name="AIM:PercentageOfProbability" contextRef="From2023-01-01to2023-12-31" id="Fact001823" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation of a Fundamental Transaction,
    for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to
    model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future volatility is necessary as there is no
    mechanism for directly measuring future stock price movements. Daily observations of the Company&#8217;s historical stock values
    for the 100 days immediately prior to the Warrants&#8217; grant dates, with a floor of <span id="xdx_902_ecustom--FloorRateUsedAsProxyForFutureVolatilityPercentage_pid_dp_uPure_c20230101__20231231_zW1ASrkrbeO6" title="Floor rate used as proxy for future volatility percentage"><ix:nonFraction name="AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001825" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%, were utilized as a proxy for the future
    volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized a risk-free interest rate corresponding
    to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental
    Transaction and the Warrant expiration date for each simulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix)
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected time between the announcement and the consummation
    of a Fundamental Transaction is based on the Company&#8217;s experience with the due diligence process performed by acquirers and
    is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant
    Holders would experience in receiving the proceeds of the Put.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period
to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above
Warrants was approximately $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKtiUPvS1ARh"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember289848921" id="Fact001826" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001828" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaZ4cv9BcK5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(16)</b> <b><span id="xdx_82D_zZ6GqmFQwI41">Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Because litigation is inherently
unpredictable, assessing contingencies&#160;related to litigation is a complex process involving highly subjective judgment about potential
outcomes of future events. When evaluating litigation contingencies, the Company may be unable to provide a meaningful estimate due to
a number of factors, including the procedural status of the matter in question, the availability of appellate remedies, insurance coverage
related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery and development
of information important to the matter. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated,
or unrelated to possible outcomes, and as such are not meaningful indicators of the Company&#8217;s potential liability or financial exposure.
Accordingly, the Company reviews the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and it assesses
the probability and range of possible losses associated with&#160;contingencies&#160;for potential accrual in the condensed consolidated
financial statements. However, the ultimate resolution of litigated claims may differ from the Company current estimates.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In the normal course of business,
there are various claims in process, matters in litigation, and other contingencies, certain of which are covered by insurance policies.
When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. We do not record liabilities for
reasonably possible loss contingencies but do disclose a range of reasonably possible losses if they are material and we are able to estimate
such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such
a range. Historically, adjustments to our estimates have not been material. While it is not possible to predict the outcome of these suits,
legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential losses associated with
these matters has been made in the financial statements and that the ultimate resolution of any one of these matters will not have a material
adverse effect on the Company&#8217;s financial position and results of operations. A significant increase in the number of these claims,
or one or more successful claims resulting in greater liabilities than the Company currently anticipates, could materially and adversely
affect the Company&#8217;s business, financial condition, results of operations, and cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001830" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_z12tS2VfdSp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(17)
<span id="xdx_82E_znFnaiO3kAei">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2024, the Company entered into a Note Purchase Agreement with an unrelated party raising $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240216__20240216__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__custom--DebtIstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zPd1bN9HZ8Q7" title="Net Proceeds"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember" id="Fact001832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span>
in net proceeds from the sale of an unsecured promissory Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024, the Company entered into a purchase agreement and a
registration rights agreement with an unrelated party, pursuant to which this party committed to purchase up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240328__20240328__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zph9uGpTxlja" title="Purchase commitment"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember" id="Fact001834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction></span> of common
stock of the Company for a period of 24 months from the date of the agreement. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zlBh2vNi0Dkc" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember" id="Fact001836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">204,547</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zZhZfO9CzpT4" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember" id="Fact001838" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,462</ix:nonFraction></span> shares of its common stock at prices of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zDVhkDDuwSc3" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember" id="Fact001840" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.33</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zxIPrz3YjgB3" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember" id="Fact001842" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.39</ix:nonFraction></span> per share, respectively, under
the Employees and Directors Purchase Plan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><p id="xdx_811_zr1FIL366UD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.25
<SEQUENCE>2
<FILENAME>ex4-25.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.25</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 47.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary description of the common stock of AIM ImmunoTech Inc. (&ldquo;we&rdquo;, &ldquo;our&rdquo; or &ldquo;us&rdquo;) is
based on the provisions of our amended and restated certificate of incorporation as amended (&ldquo;Certificate of Incorporation&rdquo;),
as well as our amended and restated bylaws (&ldquo;Bylaws&rdquo;), and the applicable provisions of the Delaware General Corporation
Law. This information is qualified entirely by reference to the applicable provisions of our Certificate of Incorporation, Bylaws, and
the Delaware General Corporation Law. Our Certificate of Incorporation and Bylaws have previously been filed as exhibits with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 47.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote per share in the election of directors and on all other matters on which stockholders are
entitled or permitted to vote. Holders of our common stock are not entitled to cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividend
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of any then outstanding series of preferred stock, the holders of our common stock are entitled to dividends in the amounts
and at times as may be declared by our board of directors out of funds legally available therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
liquidation or dissolution, holders of our common stock are entitled to share ratably in all net assets available, if any, for distribution
to stockholders after we have paid, or provided for payment of, all of our debts and liabilities, and after payment of any liquidation
preferences to holders of any then outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock have no redemption, conversion or preemptive rights. There are no sinking fund provisions applicable to our common
stock. The rights, preferences and privileges of the holders of our common stock are subject to the rights of the holders of shares of
any series of preferred stock that we may issue in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our outstanding shares of common stock are fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Provisions of Delaware Law, Our Certificate of Incorporation, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Bylaws and Our Stockholders&rsquo; Rights Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delaware
Anti-Takeover Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Section
203 of the Delaware General Corporation Law</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business
combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder,
with the following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before
    such date, our board of directors of the corporation approved either the business combination or the transaction that resulted in
    the stockholder becoming an interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
    at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining
    the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by
    persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to
    determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or after such date, the business combination is approved by our board of directors and authorized at an annual or special meeting
    of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that
    is not owned by the interested stockholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines business combination to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series
    of the corporation beneficially owned by the interested stockholder; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or
    through the corporation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an &ldquo;interested stockholder&rdquo; as an entity or person who, together with the person&rsquo;s affiliates
and associates, beneficially owns, or within three years before the time of determination of interested stockholder status did own, 15%
or more of the outstanding voting stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certificate
of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Certificate of Incorporation and/or Bylaws provide that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Bylaws may be amended or repealed by our board of directors or our stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    board of directors will be authorized to issue, without stockholder approval, preferred stock, the rights of which will be determined
    at the discretion of our board of directors and that, if issued, could operate as a &ldquo;poison pill&rdquo; to dilute the stock
    ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    stockholders do not have cumulative voting rights, and therefore our stockholders holding a majority of the shares of common stock
    outstanding will be able to elect all of our directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;our
    stockholders must comply with advance notice provisions to bring business before or nominate directors for election at a stockholder
    meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stockholder
Rights Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2002, our board of directors declared a dividend distribution
of one Right for each outstanding share of Common Stock to stockholders of record at the close of business on November 29, 2002 pursuant
to our rights agreement (as subsequently amended and restated, the &ldquo;Rights Agreement&rdquo;) between us and our Rights Agent. Each
Right entitles the registered holder of one share of our Common Stock to purchase from the Company a unit consisting of one one-hundredth
of a share (a &ldquo;Unit&rdquo;) of Series A Junior Participating Preferred Stock, par value $0.01 per share at a Purchase Price of $4.00
per Unit, subject to adjustment. All terms not specifically defined herein have the definition set forth in the Rights Agreement. The
description and terms of the Rights are set forth in the Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The current Amended and Restated Rights Agreement is included as an
exhibit to the Company&rsquo;s Quarterly Report on Form 10-Q for the period ended March 31, 2023 (File No. 001-27072) filed with the SEC
on May, 15, 2023. Such Plan and the Rights are described In Part II, ITEM 5: Other Information in the foregoing Report on Form 10-Q. All
of the foregoing are incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Potential
Effects of Authorized but Unissued Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional
shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions
or payment as a dividend on the capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly
to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to
obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management.
In addition, our board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including
voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of preferred stock,
all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in our Certificate
of Incorporation. The purpose of authorizing our board of directors to issue preferred stock and to determine the rights and preferences
applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred
stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could
have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority
of our outstanding voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.104
<SEQUENCE>3
<FILENAME>ex10-104.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
10.104</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EQUITY
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Equity Purchase Agreement is entered into as of March 28, 2024 (this &ldquo;<U>Agreement</U>&rdquo;), by and between AIM ImmunoTech,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and Atlas Sciences, LLC, a Utah limited liability company (the &ldquo;<U>Investor</U>&rdquo;,
and collectively with the Company, the &ldquo;<U>Parties</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties desire that, upon the terms and subject to the conditions contained herein, the Company shall issue and sell to the Investor,
from time to time as provided herein, and the Investor shall purchase up to Fifteen Million Dollars ($15,000,000.00) of the Company&rsquo;s
Common Stock (as defined below);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, the Parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
1.1 <U>DEFINED TERMS</U>. As used in this Agreement, the following terms shall have the following meanings specified or indicated (such
meanings to be equally applicable to both the singular and plural forms of the terms defined):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning specified in the preamble hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Laws</U>&rdquo; shall mean all applicable laws, statutes, rules, regulations, orders, executive orders, directives, policies, guidelines
and codes having the force of law, whether local, national, or international, as amended from time to time, including without limitation
(i) all applicable laws that relate to money laundering, terrorist financing, financial record keeping and reporting, (ii) all applicable
laws that relate to anti-bribery, anti-corruption, books and records and internal controls, including the United States Foreign Corrupt
Practices Act of 1977, and (iii) any Sanctions laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bankruptcy
Law</U>&rdquo; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Clearing
Costs</U>&rdquo; shall mean all the Investor&rsquo;s brokerage firm, clearing firm, legal and Transfer Agent fees with respect to the
Put Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Clearing
Date</U>&rdquo; shall be the date on which the Investor receives the Put Shares in its brokerage account and such Put Shares are cleared
and approved for trading by Investor&rsquo;s brokerage firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
shall mean one of the closings of a purchase and sale of shares of Common Stock pursuant to Section 2.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Certificate</U>&rdquo; shall mean the closing certificate of the Company in the form of <U>Exhibit B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; shall mean the date of any Closing hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commitment
Period</U>&rdquo; shall mean the period commencing on the Execution Date, and ending on the earlier of (i) the date on which the Investor
shall have purchased Put Shares pursuant to this Agreement equal to the Maximum Commitment Amount, (ii) twenty-four (24) months after
the date of this Agreement, (iii) written notice of termination by the Company to the Investor (which shall not occur during any Valuation
Period), or (iv) the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any
Person commences a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of its property
or the Company makes a general assignment for the benefit of its creditors; provided, however, that the provisions of Articles III, IV,
V, VI, IX and the agreements and covenants of the Company and the Investor set forth in Article X shall survive the termination of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commitment
Shares</U>&rdquo; shall mean 338,600 shares of the Company&rsquo;s Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; shall mean the Company&rsquo;s common stock, $0.001 par value per share, and any shares of any other class of common
stock whether now or hereafter authorized, having the right to participate in the distribution of dividends (as and when declared) and
assets (upon liquidation of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Custodian</U>&rdquo;
means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Damages</U>&rdquo;
shall mean any loss, claim, damage, liability, cost and expense (including, without limitation, reasonable attorneys&rsquo; fees and
disbursements and costs and expenses of expert witnesses and investigation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DTC</U>&rdquo;
shall mean The Depository Trust Company, or any successor performing substantially the same function for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DTC/FAST
Program</U>&rdquo; shall mean the DTC&rsquo;s Fast Automated Securities Transfer Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DWAC</U>&rdquo;
shall mean Deposit Withdrawal at Custodian as defined by the DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DWAC
Eligible</U>&rdquo; shall mean that (a) the Common Stock is eligible at DTC for full services pursuant to DTC&rsquo;s Operational Arrangements,
including, without limitation, transfer through DTC&rsquo;s DWAC system, (b) the Company has been approved (without revocation) by the
DTC&rsquo;s underwriting department, (c) the Transfer Agent is approved as an agent in the DTC/FAST Program, (d) the Commitment Shares
or Put Shares, as applicable, are otherwise eligible for delivery via DWAC, and (e) the Transfer Agent does not have a policy prohibiting
or limiting delivery of the Commitment Shares or Put Shares, as applicable, via DWAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>DWAC
Shares</U>&rdquo; means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without
restriction on resale and (iii) timely credited by the Company to the Investor&rsquo;s or its designee&rsquo;s specified DWAC account
with DTC under the DTC/FAST Program, or any similar program hereafter adopted by DTC performing substantially the same function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Execution
Date</U>&rdquo; shall mean the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FINRA</U>&rdquo;
shall mean the Financial Industry Regulatory Authority, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Investment
Amount</U>&rdquo; shall mean the dollar value equal to the number of Put Shares referenced in the applicable Put Notice multiplied by
the applicable Purchase Price, minus the Clearing Costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lien</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Market
Price</U>&rdquo; shall mean the lowest daily volume weighted average price of the Company&rsquo;s Common Stock on the Principal Market
during the Valuation Period, in each case as reported by Bloomberg, L.P. or other reputable source designated by the Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall mean any effect on the business, operations, properties, or financial condition of the Company and the
Subsidiaries that is material and adverse to the Company and the Subsidiaries and/or any condition, circumstance, or situation that would
prohibit or otherwise materially interfere with the ability of the Company to enter into and perform its obligations under any Transaction
Document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Maximum
Commitment Amount</U>&rdquo; shall mean Fifteen Million Dollars ($15,000,000.00).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Median
Daily Trading Volume</U>&rdquo; shall mean the median daily trading volume of the Company&rsquo;s Common Stock on the Principal Market
during the five (5) Trading Days immediately preceding the respective Put Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
shall mean an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Principal
Market</U>&rdquo; shall mean trading from 9:30 AM to 4:00 PM ET on any of the national exchanges (i.e. NYSE, NYSE American, and Nasdaq),
or principal quotation systems (i.e. OTCQX, OTCQB, and OTC Pink), or other principal exchange or recognized quotation system which is
at the time the principal trading platform or market for the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Price</U>&rdquo; shall mean 95% of the Market Price on such date on which the Purchase Price is calculated in accordance with the terms
and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Put</U>&rdquo;
shall mean the right of the Company to require the Investor to purchase shares of Common Stock, subject to the terms and conditions of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Put
Date</U>&rdquo; shall mean any Trading Day during the Commitment Period that a Put Notice is deemed delivered pursuant to Section 2.2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Put
Notice</U>&rdquo; shall mean a written notice, substantially in the form of <U>Exhibit A</U> hereto, to Investor setting forth the Put
Shares which the Company intends to require Investor to purchase pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Put
Shares</U>&rdquo; shall mean all shares of Common Stock issued, or that the Company shall be entitled to issue, per any applicable Put
Notice in accordance with the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Regulation
D</U>&rdquo; shall mean Regulation D promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Minimum Share Reserve</U>&rdquo; shall mean, as of any date, the maximum aggregate number of shares of Common Stock potentially issuable
at such time pursuant to the Transaction Documents, which shall be calculated on each such date as follows: the then remaining Maximum
Commitment Amount divided by the Purchase Price on each such date, ignoring any beneficial ownership limitations set forth herein, except
that such amount shall not exceed the number of Put Shares actually registered for resale under the Registration Statement. Notwithstanding
the foregoing, until such time as the Company obtains the Approval (as defined below), the Required Minimum Share Reserve shall mean
9,975,000 shares of Common Stock. Following Approval, the Required Minimum Share Reserve will be calculated in accordance with the formula
set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; shall mean Rule 144 under the Securities Act or any similar provision then in force under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC</U>&rdquo;
shall mean the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means, collectively, the Put Shares and Commitment Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; shall mean the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; shall mean all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any Person the Company wholly-owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting
stock or similar voting interest, in each case that would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; shall mean a day on which the Principal Market shall be open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; shall mean this Agreement, the registration rights agreement of even date, and all exhibits hereto and thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; shall mean the Company&rsquo;s transfer agent as of the date of this Agreement <FONT STYLE="background-color: white">and
any successor transfer agent of the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Valuation
Period</U>&rdquo; shall mean the period beginning on the date three (3) Trading Days immediately preceding the applicable Put Date and
ending on the date that is two (2) Trading Days after the Clearing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
AND SALE OF COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.1 <U>PUTS</U>. Upon the terms and conditions set forth in this Agreement (including, without limitation, the provisions of Article
VII), the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a Put Notice
from time to time during the Commitment Period, to purchase Put Shares (i) in a minimum amount not less than $25,000.00 and (ii) in a
maximum amount up to the lesser of (a) $500,000.00, or (b) the Median Daily Trading Volume, or such other greater amount mutually agreed
upon by the parties; provided, however, in no event will the number of Put Shares exceed the Beneficial Ownership Limitation (as defined
below). The minimum and maximum values described above will be determined by multiplying the number of Put Shares set forth in the applicable
Put Notice by the closing trade price of the Common Stock on the Principal Market as reported by Bloomberg, L.P. on the Trading Day immediately
preceding the date the Put Notice is delivered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.2 <U>MECHANICS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>PUT NOTICE</U>. At any time and from time to time during the Commitment Period, except as provided in this Agreement, the Company
may deliver a Put Notice to Investor, subject to satisfaction of the conditions set forth in Section 7.2 and otherwise provided herein.
The Company shall deliver, or cause to be delivered, the Put Shares as DWAC Shares to the Investor within one (1) Trading Day following
the Put Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>DATE OF DELIVERY OF PUT NOTICE</U>. A Put Notice shall be deemed delivered on (i) the Trading Day it is received by email by the Investor
if such notice is received on or prior to 9:00 a.m. EST or (ii) the immediately succeeding Trading Day if it is received by email after
9:00 a.m. EST on a Trading Day or at any time on a day which is not a Trading Day. The Company shall not deliver a Put Notice to Investor
during any Valuation Period, unless waived by the Investor in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.3 <U>CLOSINGS</U>. At the end of the Valuation Period, the Investment Amount for the respective Put Shares shall be established as
provided in this Agreement. If the value of the Put Shares delivered to the Investor causes the Company to exceed the Maximum Commitment
Amount, then immediately after the Valuation Period the Investor shall return to the Company the surplus amount of Put Shares associated
with such Put and the Investment Amount with respect to such Put shall be reduced by any Clearing Costs related to the return of such
Put Shares. The Closing of a Put shall occur within one (1) Trading Day following the end of the respective Valuation Period, whereby
the Investor shall deliver the Investment Amount by wire transfer of immediately available funds to an account designated by the Company.
The Investment Amount for the first Put Notice submitted by the Company will be reduced by $15,000.00 to cover Investor&rsquo;s legal
and due diligence fees incurred in connection with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
2.4 <U>PRINCIPAL MARKET REGULATION</U>. The Company shall not affect any sales of the Put Shares under this Agreement and the Investor
shall not have the obligation to purchase any Put Shares under this Agreement to the extent (but only to the extent) that after giving
effect to such purchase and sale the aggregate number of Put Shares and Commitment Shares issued under this Agreement would exceed 19.99%
of the outstanding Common Stock as of the date of this Agreement which number of shares shall be reduced, on a share-for-share basis,
by the number of shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated
with the transactions contemplated by this Agreement under applicable rules of the Principal Market (the &ldquo;<U>Exchange Cap</U>&rdquo;),
subject to appropriate adjustment for any stock dividend, stock split, stock combination, rights offerings, reclassification or similar
transaction that proportionately decreases or increases the Common Stock until the Company has obtained shareholder approval to issue
shares of Common Stock hereunder exceeding the Exchange Cap (the &ldquo;<U>Approval</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES OF INVESTOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Investor represents and warrants to the Company that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.1 <U>INTENT</U>. The Investor is entering into this Agreement for its own account and the Investor has no present arrangement (whether
or not legally binding) at any time to sell the Securities to or through any Person in violation of the Securities Act or any applicable
state securities laws; <U>provided</U>, <U>however</U>, that the Investor reserves the right to dispose of the Securities at any time
in accordance with federal and state securities laws applicable to such disposition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.2 <U>NO LEGAL ADVICE FROM THE COMPANY</U>. The Investor acknowledges that it has had the opportunity to review this Agreement and the
transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying solely
on such counsel and advisors and not on any statements or representations of the Company or any of its representatives or agents for
legal, tax or investment advice with respect to this investment, the transactions contemplated by this Agreement or the securities laws
of any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.3 <U>ACCREDITED INVESTOR</U>. The Investor is an accredited investor as defined in Rule 501(a)(3) of Regulation D, and the Investor
has such experience in business and financial matters that it is capable of evaluating the merits and risks of an investment in the Securities.
The Investor acknowledges that an investment in the Securities is speculative and involves a high degree of risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.4 <U>AUTHORITY</U>. The Investor has the requisite power and authority to enter into and perform its obligations under this Agreement
and the other Transaction Documents and to consummate the transactions contemplated hereby and thereby. The execution and delivery of
this Agreement and the other Transaction Documents and the consummation by it of the transactions contemplated hereby and thereby have
been duly authorized by all necessary action and no further consent or authorization of the Investor is required. Each Transaction Document
to which it is a party has been duly executed by the Investor, and when delivered by the Investor in accordance with the terms hereof,
will constitute the valid and binding obligation of the Investor enforceable against it in accordance with its terms, subject to applicable
bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors&rsquo; rights and remedies
or by other equitable principles of general application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.5 <U>NOT AN AFFILIATE</U>. The Investor is not an officer, director or &ldquo;affiliate&rdquo; (as that term is defined in Rule 405
of the Securities Act) of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.6 <U>ORGANIZATION AND STANDING</U>. The Investor is an entity duly incorporated or formed, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or
similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and the other Transaction
Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.7 <U>ABSENCE OF CONFLICTS</U>. The execution and delivery of this Agreement and the other Transaction Documents, and the consummation
of the transactions contemplated hereby and thereby and compliance with the requirements hereof and thereof, will not (a) violate any
order, writ, judgment, injunction, decree or award binding on the Investor, (b) violate any provision of any indenture, instrument or
agreement to which the Investor is a party or is subject, or by which the Investor or any of its assets is bound, or conflict with or
constitute a material default thereunder, (c) result in the creation or imposition of any lien pursuant to the terms of any such indenture,
instrument or agreement, or constitute a breach of any fiduciary duty owed by the Investor to any third party, (d) require the approval
of any third-party (that has not been obtained) pursuant to any material contract, instrument, agreement, relationship or legal obligation
to which the Investor is subject or to which any of its assets, operations or management may be subject or (e) result in a violation
of Investor&rsquo;s certificate or articles of incorporation, by-laws or other organizational or charter documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.8 <U>DISCLOSURE; ACCESS TO INFORMATION</U>. The Investor had an opportunity to review copies of the SEC Documents (as defined below)
filed on behalf of the Company and has had access to all publicly available information with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.9 <U>MANNER OF SALE</U>. At no time was the Investor presented with or solicited by or through any leaflet, public promotional meeting,
television advertisement or any other form of general solicitation or advertising. The Investor is not purchasing or acquiring the Securities
as a result of any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer
or sale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.10 <FONT STYLE="text-transform: uppercase"><U>RELIANCE ON EXEMPTIONS</U></FONT>. The Investor understands that the Securities are being
offered and sold to it in reliance on specific exemptions from the registration requirements of U.S. federal and state securities laws
and that the Company is relying in part upon the truth and accuracy of, and the Investor&rsquo;s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the availability of
such exemptions and the eligibility of the Investor to acquire the Securities. The Investor understands that (i) the Securities may not
be offered for sale, sold, assigned or transferred unless (A) registered pursuant to the Securities Act or (B) an exemption exists permitting
such Securities to be sold, assigned or transferred without such registration; and (ii) any sale of the Securities made in reliance on
Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities
under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term
is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations
of the SEC thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.11 <FONT STYLE="text-transform: uppercase"><U>Statutory Underwriter Status</U></FONT>. The Investor acknowledges that it will be disclosed
as an &ldquo;underwriter&rdquo; and a &ldquo;selling stockholder&rdquo; in each Registration Statement and in any Prospectus contained
therein to the extent required by applicable law and to the extent the Prospectus is related to the resale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
3.12 <FONT STYLE="text-transform: uppercase"><U>Resales of Securities</U></FONT>. The Investor represents, warrants and covenants that
it will resell such Securities only (i) pursuant to the Registration Statement in which the resale of such Securities is registered under
the Securities Act, in a manner described under the caption &ldquo;Plan of Distribution&rdquo; in such Registration Statement, and in
a manner in compliance with all applicable U.S. federal and state securities laws, rules and regulations, including, without limitation,
any applicable prospectus delivery requirements of the Securities Act, or (ii) in compliance with some other exemption under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents and warrants to the Investor that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.1 <U>ORGANIZATION OF THE COMPANY</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could
not have or reasonably be expected to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.2 <U>AUTHORITY</U>. The Company has the requisite corporate power and authority to enter into and perform its obligations under this
Agreement and the other Transaction Documents. The execution and delivery of this Agreement and the other Transaction Documents by the
Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate
action and no further consent or authorization of the Company or its Board of Directors or stockholders is required. Each of this Agreement
and the other Transaction Documents has been duly executed and delivered by the Company and constitutes a valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors&rsquo; rights and remedies
or by other equitable principles of general application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.3 <U>CAPITALIZATION</U>. As of the date hereof, the authorized capital stock of the Company consists of 350,000,000 shares of Common
Stock, $0.001 par value per share, of which 49,901,177 shares of Common Stock are issued and outstanding as of the date hereof. Except
as set forth in the SEC Documents, the Company has not issued any capital stock since its most recently filed periodic report under the
Exchange Act, other than pursuant to Exempt Transactions (as defined in this Agreement), the exercise of employee stock options under
the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee
stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most
recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation,
or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as set forth in the SEC Documents
and except as a result of Exempt Transactions or the purchase and sale of the Securities, there are no outstanding options, warrants,
scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible
into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of
Common Stock or other securities to any Person (other than the Investor) and will not result in a right of any holder of Company securities
to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge
of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.4 <U>LISTING AND MAINTENANCE REQUIREMENTS</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the SEC is contemplating terminating such
registration. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with
all such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.5 <U>SEC DOCUMENTS; DISCLOSURE</U>. The Company has filed all reports, schedules, forms, statements and other documents required to
be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one (1) year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the &ldquo;<U>SEC Documents</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has
filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates, the SEC Documents complied
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and other federal laws, rules
and regulations applicable to such SEC Documents, and none of the SEC Documents when filed contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light
of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents
comply as to form and substance in all material respects with applicable accounting requirements and the published rules and regulations
of the SEC or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance
with generally accepted accounting principles applied on a consistent basis during the periods involved (except (a) as may be otherwise
indicated in such financial statements or the notes thereto or (b) in the case of unaudited interim statements, to the extent they may
not include footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of
the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments). Except with respect to the material terms and conditions of
the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf
has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public
information. The Company understands and confirms that the Investor will rely on the foregoing representation in effecting transactions
in securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.6 <U>VALID ISSUANCES</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid, and non-assessable, free and clear of all Liens imposed by the Company other
than restrictions on transfer provided for in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.7 <U>NO CONFLICTS</U>. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company
and the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance
of the Put Shares and Commitment Shares, do not and will not: (a) result in a violation of the Company&rsquo;s or any Subsidiary&rsquo;s
certificate or articles of incorporation, by-laws or other organizational or charter documents, (b) conflict with, or constitute a material
default (or an event that with notice or lapse of time or both would become a material default) under, result in the creation of any
Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture, instrument or any &ldquo;lock-up&rdquo; or similar provision of any underwriting or similar
agreement to which the Company or any Subsidiary is a party, or (c) result in a violation of any federal, state or local law, rule, regulation,
order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or any Subsidiary or
by which any property or asset of the Company or any Subsidiary is bound or affected (except for such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect)
nor is the Company otherwise in violation of, conflict with or in default under any of the foregoing. The business of the Company is
not being conducted in violation of any law, ordinance or regulation of any governmental entity, except for possible violations that
either singly or in the aggregate do not and will not have a Material Adverse Effect. The Company is not required under federal, state
or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court
or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or the other Transaction
Documents (other than any SEC, FINRA or state securities filings that may be required to be made by the Company subsequent to any Closing
or any registration statement that may be filed pursuant hereto); provided that, for purposes of the representation made in this sentence,
the Company is assuming and relying upon the accuracy of the relevant representations and agreements of Investor herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.8 <U>NO MATERIAL ADVERSE CHANGE</U>. No event has occurred that would have a Material Adverse Effect on the Company that has not been
disclosed in subsequent SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.9 <U>LITIGATION AND OTHER PROCEEDINGS</U>. Except as disclosed in the SEC Documents, there are no actions, suits, investigations, inquiries
or proceedings pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties, nor has the Company received any written or oral notice of any such action, suit, proceeding, inquiry or investigation,
which would have a Material Adverse Effect. No judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge
of the Company, requested of any court, arbitrator or governmental agency which would have a Material Adverse Effect. There has not been,
and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company, any Subsidiary
or any current or former director or officer of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.10 <U>REGISTRATION RIGHTS</U>. Except as set forth in the SEC Documents and the Exempt Transactions, no Person (other than the Investor)
has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
4.11 <FONT STYLE="text-transform: uppercase"><U>No Solicitation</U></FONT><U>; NO BROKERS</U>. Except with respect to Ascendiant Capital
Markets, LLC, a registered broker-dealer (CRD#: 152912) (the &ldquo;<U>Placement Agent</U>&rdquo;), the Company has taken no action which
would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments relating to this Agreement
or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
V</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COVENANTS
OF INVESTOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5.1 <U>COMPLIANCE WITH LAW; TRADING IN SECURITIES</U>. The Investor&rsquo;s trading activities with respect to shares of Common Stock
will be in compliance with all applicable state and federal securities laws and regulations and the rules and regulations of FINRA and
the Principal Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
5.2 <U>SHORT SALES AND CONFIDENTIALITY</U>. Neither the Investor, nor any affiliate of the Investor acting on its behalf or pursuant
to any understanding with it, will execute any Short Sales during the period from the date hereof to the end of the Commitment Period.
For the purposes hereof, and in accordance with Regulation SHO, the sale after delivery of a Put Notice of such number of shares of Common
Stock reasonably expected to be purchased under a Put Notice shall not be deemed a Short Sale. The Investor shall, until such time as
the transactions contemplated by this Agreement are publicly disclosed by the Company in accordance with the terms of this Agreement,
maintain the confidentiality of the existence and terms of this transaction and the information included in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COVENANTS
OF THE COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.1 <U>LISTING OR QUOTATION OF COMMON STOCK</U>. During the Commitment Period and until this Agreement is terminated, the Company shall
promptly secure the listing or quotation of all of the Put Shares to be issued to the Investor hereunder and the Commitment Shares on
the Principal Market (subject to official notice of issuance) and shall maintain the listing or quotation of all such Put Shares from
time to time issuable hereunder and the Commitment Shares. The Company shall maintain the (i) listing or quotation and (ii) trading of
the Common Stock on the Principal Market (including, without limitation, maintaining sufficient net tangible assets) and will comply
in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of FINRA and the Principal
Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.2 <U>OTHER EQUITY LINES AND TRANSACTIONS</U>. So long as this Agreement remains in effect, the Company covenants and agrees that it
will not, without the prior written consent of the Investor, enter into any other Variable Rate Transaction (as defined below) or equity
line of credit with any other party. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues
or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional
shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies
with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity
securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial
issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the
business of the Company or the market for the Common Stock or (ii) issues securities at a future determined price. Notwithstanding anything
herein to the contrary, a Variable Rate Transaction shall not include any issuance pursuant to an Exempt Transaction (as defined in this
Agreement). &ldquo;<U>Exempt Transaction</U>&rdquo; shall mean the issuance of (a) shares of Common Stock or other securities to officers,
directors, employees, service providers, or vendors of the Company, including but not limited to under any equity compensation or incentive
plan of the Company; (b) any &ldquo;at-the-market offering&rdquo; through a registered broker-dealer, whereby such registered broker-dealer
is acting as principal or agent in the purchase of Common Stock from the Company, (c) a public offering of securities of the Company,
including but not limited to an underwritten primary offering; and (d) securities pursuant to a merger, consolidation, acquisition, or
similar business combination or strategic transactions, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection
therewith, and provided that any such issuance shall only be to an entity (or to the equityholders of an entity) which is, itself or
through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and
shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.3 <U>FILING OF CURRENT REPORT AND REGISTRATION STATEMENT</U>. The Company agrees that it shall file a Current Report on Form 8-K, including
the Transaction Documents as exhibits thereto, with the SEC within the time required by the Exchange Act, relating to the transactions
contemplated by, and describing the material terms and conditions of, the Transaction Documents (the &ldquo;<U>Current Report</U>&rdquo;).
Pursuant to the terms of the Registration Rights Agreement, the Company shall also file with the SEC, within forty-five (45) Business
Days from the date hereof, a new registration statement (the &ldquo;<U>Registration Statement</U>&rdquo;) covering only the resale of
the Put Shares and the Commitment Shares or at the Company election in the alternative, take all required action to file the sale of
the Put Shares and the Commitment Shares under a current shelf registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.4 <U>NO BROKER-DEALER ACKNOWLEDGEMENT</U>. Absent a final adjudication from a court of competent jurisdiction stating otherwise, the
Company shall not to any person, institution, governmental or other entity, state, claim, allege, or in any way assert, that Investor
is currently, or ever has been, a broker-dealer under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.5 <U>RESERVATION OF COMMON STOCK</U>. The Company shall maintain a reserve from its duly authorized shares of Common Stock equal to
100% of the Required Minimum Share Reserve in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
6.6 <U>ISSUANCE OF COMMITMENT SHARES</U>. In consideration for the Investor&rsquo;s execution and delivery of, and performance under
this Agreement, the Company shall cause the Transfer Agent to issue the Commitment Shares to the Investor on the Execution Date. For
the avoidance of doubt, all of the Commitment Shares shall be fully earned as of the Execution Date, and the issuance of the Commitment
Shares is not contingent upon any other event or condition, including, without limitation, the effectiveness of the Registration Statement
or the Company&rsquo;s submission of a Put Notice to the Investor and irrespective of any termination of this Agreement. The Company
shall include in the Registration Statement all the Commitment Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONDITIONS
TO DELIVERY OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PUT
NOTICES AND CONDITIONS TO CLOSING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.1 <U>CONDITIONS PRECEDENT TO THE RIGHT OF THE COMPANY TO ISSUE AND SELL PUT SHARES</U>. In addition to the other provisions of this
Agreement, the right of the Company to issue and sell the Put Shares to the Investor is subject to the satisfaction of each of the conditions
set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>ACCURACY OF INVESTOR&rsquo;S REPRESENTATIONS AND WARRANTIES</U>. The representations and warranties of the Investor shall be true
and correct in all material respects as of the date of this Agreement and as of the date of each Closing as though made at each such
time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>PERFORMANCE BY INVESTOR</U>. Investor shall have performed, satisfied and complied in all respects with all covenants, agreements
and conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to such Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.2 <U>CONDITIONS PRECEDENT TO THE OBLIGATION OF INVESTOR TO PURCHASE PUT SHARES</U>. The obligation of the Investor hereunder to purchase
Put Shares is subject to the satisfaction of each of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>EFFECTIVE REGISTRATION STATEMENT</U>. The Registration Statement covering the resale of the Put Shares and the Commitment Shares,
and any amendment or supplement thereto, shall remain effective for the resale by the Investor of the Put Shares and Commitment Shares
in accordance with the terms of this Agreement and (i) neither the Company nor the Investor shall have received notice that the SEC has
issued or intends to issue a stop order with respect to such Registration Statement or that the SEC otherwise has suspended or withdrawn
the effectiveness of such Registration Statement, either temporarily or permanently, or intends or has threatened to do so and (ii) no
other suspension of the use of, or withdrawal of the effectiveness of, such Registration Statement or related prospectus shall exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>ACCURACY OF THE COMPANY&rsquo;S REPRESENTATIONS AND WARRANTIES</U>. The representations and warranties of the Company (such representations
and warranties whenever mentioned in this Agreement means as updated in SEC Reports) shall be true and correct in all material respects
as of the date of this Agreement and as of the date of each Closing (except for representations and warranties specifically made as of
a particular date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>PERFORMANCE BY THE COMPANY</U>. The Company shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company, including but not limited
to the delivery of the Put Shares as provided in Section 2.2(a) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>NO INJUNCTION</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or adopted by any court or governmental authority of competent jurisdiction that prohibits or directly and materially adversely affects
any of the transactions contemplated by the Transaction Documents, and no proceeding shall have been commenced that may have the effect
of prohibiting or materially adversely affecting any of the transactions contemplated by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>ADVERSE CHANGES</U>. Since the date of filing of the Company&rsquo;s most recent SEC Document, no event that had or is reasonably
likely to have a Material Adverse Effect has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>NO SUSPENSION OF TRADING IN OR DELISTING OF COMMON STOCK</U>. The trading of the Common Stock shall not have been suspended by the
SEC, the Principal Market or FINRA, or otherwise halted for any reason, and the Common Stock shall have been approved for listing or
quotation on and shall not have been delisted from its Principal Market (determined as of the execution date of this Agreement). In the
event of a suspension, delisting, or halting for any reason, of the trading of the Common Stock, as contemplated by this Section 7.2(f),
the Investor shall have the right to return to the Company any remaining amount of Put Shares associated with such Put, and the Purchase
Price with respect to such Put shall be reduced accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>BENEFICIAL OWNERSHIP LIMITATION</U>. The number of Put Shares then to be purchased by the Investor shall not exceed the number of
such shares that, when aggregated with all other shares of Common Stock then owned by the Investor beneficially or deemed beneficially
owned by the Investor together with its affiliates, would result in the Investor owning more than the Beneficial Ownership Limitation
(as defined below), as determined in accordance with Section 16 of the Exchange Act and the regulations promulgated thereunder. For purposes
of this Section 7.2(g), in the event that the amount of Common Stock outstanding, as determined in accordance with Section 16 of the
Exchange Act and the regulations promulgated thereunder, is greater on a Closing Date than on the date upon which the Put Notice associated
with such Closing Date is given, the amount of Common Stock outstanding on such Closing Date shall govern for purposes of determining
whether the Investor, when aggregating all purchases of Common Stock made pursuant to this Agreement, would own more than the Beneficial
Ownership Limitation following such Closing Date. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable pursuant
to a Put Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>NO KNOWLEDGE</U>. The Company shall have no knowledge of any event more likely than not to have the effect of causing the Registration
Statement to be suspended or otherwise ineffective (which event is more likely than not to occur within the fifteen (15) Trading Days
following the Trading Day on which such Put Notice is deemed delivered). The Company shall have no knowledge of any untrue statement
(or alleged untrue statement) of a material fact or omission (or alleged omission) of a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, in the Registration
Statement, any effective registration statement filed pursuant to the Registration Rights Agreement or any post-effective amendment or
prospectus which is a part of the foregoing, unless the Company has filed an amendment with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>OFFICER&rsquo;S CERTIFICATE</U>. On the date of delivery of each Put Notice, the Investor shall have received the Closing Certificate
executed by an executive officer of the Company and to the effect that all the conditions to such Closing shall have been satisfied as
of the date of each such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>DWAC ELIGIBLE</U>. The Common Stock must be DWAC Eligible and not subject to a &ldquo;DTC chill.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>SEC DOCUMENTS</U>. All reports, schedules, registrations, forms, statements, information and other documents required to have been
filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC within
the applicable time periods prescribed for such filings under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>BANKRUPTCY</U>. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary,
for relief under any bankruptcy law or any law for the relief of debtors shall not be instituted by or against the Company or any subsidiary
of the Company, and in the case of such a proceeding being involuntary or commenced against the Company, which is not dismissed within
sixty (60) days (the &ldquo;<U>Bankruptcy Proceedings</U>&rdquo;), and the Company shall have no knowledge of any event more likely than
not to have the effect of causing Bankruptcy Proceedings to arise. In the event of Bankruptcy Proceedings as contemplated by this Section
7.2(l), the Investor shall have the right to return to the Company any remaining amount of Put Shares associated with such Put, and the
Purchase Price with respect to such Put shall be reduced accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>SUFFICIENT AUTHORIZED SHARES</U>. In respect of each Put, the Company has at the time of making the Put sufficient authorized Common
Stock to be able to deliver the Put Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>NO VIOLATION OF EXCHANGE CAP</U>. The issuance of the Put Shares shall not violate the Exchange Cap or Approval requirements of the
Principal Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>RESERVE</U>. The Company shall have reserved the Required Minimum Share Reserve for the Investor&rsquo;s benefit under this Agreement,
the Company satisfied the reserve requirements with respect to all other contracts between the Company and Investor, and the Transfer
Agent Instruction Letter shall have been executed by the Company and the Transfer Agent as well as acknowledged and agreed to in writing
by the Transfer Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>NO VIOLATION</U>. No statute, regulation, order, guidance, decree, writ, ruling or injunction shall have been enacted, entered, promulgated,
threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent jurisdiction, including,
without limitation, the SEC, which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated
by the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>LEGAL OPINION</U>. The Company shall cause to be delivered to the Investor a written opinion of counsel satisfactory to the Investor,
in form and substance satisfactory to the Investor and its counsel, relating to the availability and effectiveness of the Registration
Statement, as supplemented by any prospectus supplement or amendment thereto, and regarding the Company&rsquo;s compliance with the federal
securities laws of the United States in the issuance, sale and registration of the Put Shares and the Commitment Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
VIII</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGENDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8.1 <U>NO RESTRICTIVE STOCK LEGEND</U>. No restrictive stock legend shall be placed on the share certificates representing the Put Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
8.2 <U>INVESTOR&rsquo;S COMPLIANCE</U>. Nothing in this Article VIII shall affect in any way the Investor&rsquo;s obligations hereunder
to comply with all applicable securities laws upon the sale of the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
IX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES;
INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.1 <U>NOTICES</U>. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall
be in writing and, unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by
hand delivery, telegram, or email as a PDF, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice given in accordance herewith. Any notice or other communication required or permitted to be given hereunder
shall be deemed effective (i) upon hand delivery or delivery by email at the address designated below (if delivered on a business day
during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other
than on a business day during normal business hours where such notice is to be received) or (ii) on the second business day following
the date of mailing by express courier service or on the fifth business day after deposited in the mail, in each case, fully prepaid,
addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Thomas K. Equels</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2117
SW Highway 484</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocala,
Florida 34473</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 30.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas
Sciences, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">303
East Wacker Drive, Suite 1040</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago,
IL 60601</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jfife@chicagoventure.com and coby@chicagoventure.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 30.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which copy shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 30.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hansen
Black Anderson Ashcraft PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Jonathan Hansen</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3051
West Maple Loop Drive, Suite 325</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lehi,
Utah 84043</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party hereto may from time to time change its address or email for notices under this Section 9.1 by giving at least ten (10) days&rsquo;
prior written notice of such changed address to the other party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.2 <U>INDEMNIFICATION BY THE COMPANY</U>. In consideration of the Investor&rsquo;s execution and delivery of this Agreement and acquiring
the Put Shares hereunder, and in addition to all of the Company&rsquo;s other obligations under this Agreement, the Company shall defend,
protect, indemnify and hold harmless the Investor and its officers, directors, managers, members, partners, employees and agents (including,
without limitation, those retained in connection with the transactions contemplated by this Agreement) and each person who controls the
Investor within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the &ldquo;<U>Investor
Indemnitees</U>&rdquo;) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities
and damages, and reasonable and documented expenses in connection therewith (irrespective of whether any such Investor Indemnitee is
a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&rsquo; fees and disbursements
(the &ldquo;<U>Indemnified Liabilities</U>&rdquo;), incurred by the Investor Indemnitees or any of them as a result of, or arising out
of, or relating to (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for
the registration of the Put Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment
thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading; provided, however, that the Company will not be liable
in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement
or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information
furnished to the Company by or on behalf of the Investor specifically for inclusion therein; (b) any material misrepresentation or breach
of any material representation or material warranty made by the Company in this Agreement or any other certificate, instrument or document
contemplated hereby or thereby; or (c) any material breach of any material covenant, material agreement or material obligation of the
Company contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby. To the extent that
the foregoing undertaking by the Company may be unenforceable under Applicable Law, the Company shall make the maximum contribution to
the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.3 <U>INDEMNIFICATION BY INVESTOR</U>. In consideration of the Company&rsquo;s execution and delivery of this Agreement, and in addition
to all of the Investor&rsquo;s other obligations under this Agreement, the Investor shall defend, protect, indemnify and hold harmless
the Company and all of its officers, directors, shareholders, employees and agents (including, without limitation, those retained in
connection with the transactions contemplated by this Agreement) and each person who controls the Investor within the meaning of Section
15 of the Securities Act or Section 20 of the Exchange Act (collectively, the &ldquo;<U>Company Indemnitees</U>&rdquo;) from and against
any and all Indemnified Liabilities incurred by the Company Indemnitees or any of them as a result of, or arising out of, or relating
to (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration
of the Put Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement
thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading; provided, however, that the Investor will only be liable for written information
relating to the Investor furnished to the Company by or on behalf of the Investor specifically for inclusion in the documents referred
to in the foregoing indemnity, and will not be liable in any such case to the extent that any such loss, claim, damage or liability arises
out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance
upon and in conformity with written information furnished to the Investor by or on behalf of the Company specifically for inclusion therein;
(b) any misrepresentation or breach of any representation or warranty made by the Investor in this Agreement or any instrument or document
contemplated hereby or thereby executed by the Investor; or (c) any breach of any covenant, agreement or obligation of the Investor contained
in this Agreement or any other certificate, instrument or document contemplated hereby or thereby executed by the Investor. To the extent
that the foregoing undertaking by the Investor may be unenforceable under Applicable Laws, the Investor shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under Applicable Laws</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.4 <FONT STYLE="text-transform: uppercase"><U>Notice of Claim</U></FONT>. Promptly after receipt by an Investor Indemnitee or Company
Indemnitee of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving an Indemnified
Liability, such Investor Indemnitee or Company Indemnitee, as applicable, shall, if a claim for an Indemnified Liability in respect thereof
is to be made against any indemnifying party under this Article IX, deliver to the indemnifying party a written notice of the commencement
thereof; but the failure to so notify the indemnifying party will not relieve it of liability under this Article IX except to the extent
the indemnifying party is prejudiced by such failure. The indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually reasonably satisfactory to the indemnifying party and the Investor Indemnitee or Company Indemnitee, as the case
may be; provided, however, that an Investor Indemnitee or Company Indemnitee shall have the right to retain its own counsel with the
actual and reasonable third party fees and expenses of not more than one counsel for such Investor Indemnitee or Company Indemnitee to
be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by
such counsel of the Investor Indemnitee or Company Indemnitee and the indemnifying party would be inappropriate due to actual or potential
differing interests between such Investor Indemnitee or Company Indemnitee and any other party represented by such counsel in such proceeding.
The Investor Indemnitee or Company Indemnitee shall cooperate fully with the indemnifying party in connection with any negotiation or
defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably
available to the Investor Indemnitee or Company Indemnitee which relates to such action or claim. The indemnifying party shall keep the
Investor Indemnitee or Company Indemnitee reasonably apprised as to the status of the defense or any settlement negotiations with respect
thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written
consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying
party shall, without the prior written consent of the Investor Indemnitee or Company Indemnitee, consent to entry of any judgment or
enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such Investor Indemnitee or Company Indemnitee of a release from all liability in respect to such claim or litigation. Following indemnification
as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Investor Indemnitee or Company Indemnitee
with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The indemnification
required by this Article IX shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received and payment therefor is due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
9.05 <FONT STYLE="text-transform: uppercase"><U>Remedies</U></FONT>. The remedies provided for in this Article IX are not exclusive and
shall not limit any right or remedy which may be available to any indemnified person at law or equity.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
X</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.1 <U>GOVERNING LAW; JURISDICTION</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of
Utah without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions
contemplated by this Agreement or any other agreement, certificate, instrument or document contemplated hereby shall be brought only
in the State of Utah. The Parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. <B>EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTIONS CONTEMPLATED HEREBY.</B> The prevailing party shall be entitled
to recover from the other party its reasonable attorney&rsquo;s fees and costs. Each party hereby irrevocably waives personal service
of process and consents to process being served in any suit, action or proceeding in connection with this Agreement or any other agreement,
certificate, instrument or document contemplated hereby or thereby by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.2 <U>PAYMENT SET ASIDE</U>. Further, to the extent that the (i) Company makes a payment or payments to the Investor pursuant to this
Agreement or any other agreement, certificate, instrument or document contemplated hereby or thereby, or (ii) the Investor enforces or
exercises its rights pursuant to this Agreement or any other agreement, certificate, instrument or document contemplated hereby or thereby,
and such payment or payments or the proceeds of such enforcement or exercise or any part thereof (including but not limited to the sale
of the Securities) are for any reason (i) subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
or disgorged by the Investor, or (ii) are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver,
government entity, or any other person or entity under any law (including, without limitation, any bankruptcy law, foreign, state or
federal law, common law or equitable cause of action), then (i) to the extent of any such restoration the obligation or part thereof
originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred and (ii) the Company shall immediately pay to the Investor a dollar amount equal to the amount
that was for any reason (i) subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, or disgorged
by the Investor, or (ii) required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver, government entity,
or any other person or entity under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common
law or equitable cause of action).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.3 <U>ASSIGNMENT</U>. This Agreement shall be binding upon and inure to the benefit of the Company and the Investor and their respective
successors. Neither this Agreement nor any rights of the Investor or the Company hereunder may be assigned by either party to any other
Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.4 <U>NO THIRD PARTY BENEFICIARIES</U>. This Agreement is intended for the benefit of the Company and the Investor and their respective
successors, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as set forth in Section
9.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.5 <U>TERMINATION</U>. The Company may terminate this Agreement at any time by written notice to the Investor, except during any Valuation
Period. In addition, this Agreement shall automatically terminate at the end of the Commitment Period. Notwithstanding anything in this
Agreement to the contrary, (i) the provisions of Articles III, IV, VI, IX of this Agreement and the agreements and covenants of the Company
and the Investor set forth in Article X of this Agreement shall survive the termination of this Agreement and (ii) the Investor shall
retain all rights to the Commitment Shares even if this Agreement is terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.6 <U>ENTIRE AGREEMENT</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding
of the Company and the Investor with respect to the matters covered herein and therein and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the Parties acknowledge have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.7 <U>FEES AND EXPENSES</U>. Except as expressly set forth in the Transaction Documents or any other writing to the contrary, each
party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay
all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered
by the Company), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Investor. Upon
execution of this Agreement, the Company shall issue the Commitment Shares to Investor for its commitment to enter into this Agreement.
The Commitment Shares shall be earned in full upon the execution of this Agreement, and the issuance of the Commitment Shares is not
contingent upon any other event or condition, including but not limited to the effectiveness of the Registration Statement or the Company&rsquo;s
submission of a Put Notice to the Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.8 <U>COUNTERPARTS</U>. This Agreement may be executed in multiple counterparts, each of which may be executed by less than all of
the Parties and shall be deemed to be an original instrument which shall be enforceable against the Parties actually executing such counterparts
and all of which together shall constitute one and the same instrument. This Agreement may be delivered to the other Parties hereto by
email of a copy of this Agreement bearing the signature of the Parties so delivering this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.9 <U>SEVERABILITY</U>. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that such
severability shall be ineffective if it materially changes the economic benefit of this Agreement to any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.10 <U>FURTHER ASSURANCES</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.11 <U>NO STRICT CONSTRUCTION</U>. The language used in this Agreement will be deemed to be the language chosen by the Parties to express
their mutual intent, and no rules of strict construction will be applied against any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.12 <U>EQUITABLE RELIEF</U>. The Company recognizes that in the event that it fails to perform, observe, or discharge any or all of
its obligations under this Agreement, any remedy at law may prove to be inadequate relief to the Investor. The Company therefore agrees
that the Investor shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual
damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.13 <U>TITLE AND SUBTITLES</U>. The titles and subtitles used in this Agreement are used for the convenience of reference and are not
to be considered in construing or interpreting this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.14 <U>AMENDMENTS; WAIVERS</U>. No provision of this Agreement may be amended or waived by the Parties from and after the date that
is one (1) Trading Day immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately
preceding sentence, (i) no provision of this Agreement may be amended other than by a written instrument signed by both Parties hereto
and (ii) no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement
of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other
right, power or privilege.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
10.15 <U>PUBLICITY</U>. The Company and the Investor shall consult with each other in issuing any press releases or otherwise making
public statements with respect to the transactions contemplated hereby and no party shall issue any such press release or otherwise make
any such public statement, other than as required by law, without the prior written consent of the other Parties, which consent shall
not be unreasonably withheld or delayed, except that no prior consent shall be required if such disclosure is required by law, in which
such case the disclosing party shall provide the other party with prior notice of such public statement. Notwithstanding the foregoing,
the Company shall not publicly disclose the name of the Investor without the prior written consent of the Investor, except to the extent
required by law. The Investor acknowledges that this Agreement and all or part of the Transaction Documents may be deemed to be &ldquo;material
contracts,&rdquo; as that term is defined by Item 601(b)(10) of Regulation S-K, and that the Company may therefore be required to file
such documents as exhibits to reports or registration statements filed under the Securities Act or the Exchange Act. The Investor further
agrees that the status of such documents and materials as material contracts shall be determined solely by the Company, in consultation
with its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have caused this Agreement to be duly executed by their respective officers thereunto duly authorized
as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>COMPANY</U>:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
    IMMUNOTECH, INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>s/Thomas
    Equels</I> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Equels, Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INVESTOR</U>:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATLAS
    SCIENCES, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>s/John
    Fife </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    M. Fife, President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Equity Purchase Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF PUT NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:
ATLAS SCIENCES, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE:
____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
refer to the Equity Purchase Agreement, dated March 28, 2024 (the &ldquo;<U>Agreement</U>&rdquo;), entered into by and between AIM ImmunoTech,
Inc. and you. Capitalized terms defined in the Agreement shall, unless otherwise defined herein, have the same meaning when used herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)
Give you notice that we require you to purchase ____________ Put Shares pursuant to the Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)
Certify that, as of the date hereof, the conditions set forth in Section 7.2 of the Agreement are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AIM
    IMMUNOTECH, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Equels, CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF OFFICER&rsquo;S CERTIFICATE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
AIM IMMUNOTECH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 7.2(i) of that certain Equity Purchase Agreement, dated March 28, 2024 (the &ldquo;<U>Agreement</U>&rdquo;), by and between
AIM ImmunoTech, Inc. (the &ldquo;<U>Company</U>&rdquo;) and Atlas Sciences, LLC (the &ldquo;<U>Investor</U>&rdquo;), the undersigned,
in his capacity as Chief Executive Officer of the Company, and not in his individual capacity, hereby certifies, as of the date hereof
(such date, the &ldquo;<U>Condition Satisfaction Date</U>&rdquo;), the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The representations and warranties of the Company are true and correct in all material respects as of the Condition Satisfaction Date
as though made on the Condition Satisfaction Date (except for representations and warranties specifically made as of a particular date)
with respect to all periods, and as to all events and circumstances occurring or existing to and including the Condition Satisfaction
Date, except for any conditions which have temporarily caused any representations or warranties of the Company set forth in the Agreement
to be incorrect and which have been corrected with no continuing impairment to the Company or the Investor; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
All of the conditions precedent to the obligation of the Investor to purchase Put Shares set forth in the Agreement, including but not
limited to Section 7.2 of the Agreement, have been satisfied as of the Condition Satisfaction Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
terms used herein shall have the meanings set forth in the Agreement unless otherwise defined herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the undersigned has hereunto affixed his hand as of the ________, 20__.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Equels, CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.105
<SEQUENCE>4
<FILENAME>ex10-105.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
10.105</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>REGISTRATION RIGHTS AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;), dated as of March 28, 2024, is entered into by and between
<B>AIM IMMUNOTECH, INC., </B>a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and <B>ATLAS SCIENCES, LLC,</B> a Utah limited
liability company (together with it permitted assigns, the &ldquo;<U>Investor</U>&rdquo;). Capitalized terms used herein and not otherwise
defined herein shall have the respective meanings set forth in the Equity Purchase Agreement by and between the parties hereto, dated
as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed, upon the terms and subject to the conditions of the Purchase Agreement, to sell to the Investor up to Fifteen Million
Dollars ($15,000,000.00) of Put Shares (as defined in the Purchase Agreement) and to induce the Investor to enter into the Purchase Agreement,
the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations
thereunder, or any similar successor statute (collectively, the &ldquo;<U>Securities Act</U>&rdquo;), and applicable state securities
laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Investor hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>DEFINITIONS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
&ldquo;<U>Investor</U>&rdquo; shall have the meaning set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
&ldquo;<U>Person</U>&rdquo; means any individual or entity including but not limited to any corporation, a limited liability company,
an association, a partnership, an organization, a business, an individual, a governmental or political subdivision thereof or a governmental
agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
&ldquo;<U>Register</U>,&rdquo; &ldquo;<U>registered</U>,&rdquo; and &ldquo;<U>registration</U>&rdquo; refer to a registration effected
by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and/or pursuant to Rule
415 under the Securities Act or any successor rule providing for offering securities on a continuous basis (&ldquo;<U>Rule 415</U>&rdquo;),
and the declaration or ordering of effectiveness of such registration statement(s) by the United States Securities and Exchange Commission
(the &ldquo;<U>SEC</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
&ldquo;<U>Registrable Securities</U>&rdquo; means (i) all of the Put Shares which have been, or which may, from time to time be issued,
including without limitation all of the shares of common stock, par value $0.001 per share (&ldquo;<U>Common Stock</U>&rdquo;), which
have been issued or will be issued to the Investor under the Purchase Agreement (without regard to any beneficial ownership limitation
or restriction on purchases therein), and (ii) the Commitment Shares (as defined in the Purchase Agreement), and shares of Common Stock
issued to the Investor as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
&ldquo;<U>Registration Statement</U>&rdquo; means one or more registration statements, as supplemented by any prospectus supplement or
amendment thereto, of the Company covering only the sale of the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>REGISTRATION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
<U>Registration. </U>The Company shall file with the SEC an initial Registration Statement within forty-five (45) calendar days from
the date of this Agreement covering at least 15,000,000 shares of Registrable Securities so as to permit the resale of such Registrable
Securities by the Investor, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and
not fixed prices), subject to the aggregate number of authorized shares of the Company&rsquo;s Common Stock then available for issuance
in its Certificate of Incorporation. The initial Registration Statement shall register only Registrable Securities. The Investor and
its counsel shall have a reasonable opportunity to review and comment upon such Registration Statement and any amendment or supplement
to such Registration Statement and any related prospectus prior to its filing with the SEC, and the Company shall give due consideration
to all reasonable comments. The Investor shall furnish all information reasonably requested by the Company for inclusion therein. The
Company shall use its reasonable best efforts to have the Registration Statement declared effective as soon as practicable, and any amendment
declared effective by the SEC at the earliest possible date. The Company shall use reasonable best efforts to keep the Registration Statement
effective, including but not limited to pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the
Investor of all of the Registrable Securities covered thereby at all times until the earlier of (i) the date on which the Investor shall
have sold all the Registrable Securities and the Maximum Commitment Amount (as defined in the Purchase Agreement) under the Purchase
Agreement has been drawn down by the Company pursuant to a Registration Statement and (ii) the date on which the Purchase Agreement is
terminated (the &ldquo;<U>Registration Period</U>&rdquo;). The Registration Statement (including any amendments or supplements thereto
and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.
In the event that (i) the Registration Statement or New Registration Statement (as defined below) becomes stale after the initial effectiveness
of such Registration Statement or New Registration Statement and (ii) the Investor still has ownership of any of the Registrable Securities
that the Investor cannot then sell without restriction pursuant to Rule 144 promulgated under the Securities Act, the Company shall immediately
file one or more post-effective amendments to facilitate the SEC&rsquo;s declaration of effectiveness with respect to such Registration
Statement or New Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
<U>Rule 424 Prospectus</U>. The Company shall, as required by applicable securities regulations, from time-to-time file with the SEC,
pursuant to Rule 424 promulgated under the Securities Act, the prospectus and prospectus supplements, if any, to be used in connection
with sales of the Registrable Securities under the Registration Statement. The Company shall file such initial prospectus covering the
Investor&rsquo;s sale of the Registrable Securities within three (3) business days of the date that the Registration Statement is declared
effective by the SEC. The Investor and its counsel shall have a reasonable opportunity to review and comment upon such prospectus prior
to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable
best efforts to comment upon such prospectus within one (1) Business Day from the date the Investor receives the final pre-filing version
of such prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
<U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under the Registration Statement is insufficient
to cover all of the Registrable Securities, the Company shall amend the Registration Statement or file a new Registration Statement (a
&ldquo;<U>New Registration Statement</U>&rdquo;), so as to cover all of such Registrable Securities (subject to the limitations set forth
in Section 2(a)) as soon as practicable, but in any event not later than ten (10) Business Days after the necessity therefor arises,
subject to any limits that may be imposed by the SEC pursuant to Rule 415 under the Securities Act as well as the Exchange Cap (as defined
in the Purchase Agreement). The Company shall use it reasonable best efforts to cause such amendment and/or New Registration Statement
to become effective as soon as practicable following the filing thereof. In the event that any of the Put Shares are not included in
the Registration Statement, or have not been included in any New Registration Statement and the Company files any other registration
statement under the Securities Act (other than on Form S-4, Form S-8, or with respect to other employee related plans or rights offerings)
(&ldquo;<U>Other Registration Statement</U>&rdquo;) then the Company shall include in such Other Registration Statement first all of
such Put Shares and second any other securities the Company wishes to include in such Other Registration Statement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
<U>Offering</U>. If the staff of the SEC (the &ldquo;<U>Staff</U>&rdquo;) or the SEC seeks to characterize any offering pursuant to a
Registration Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration
Statement to become effective and be used for resales by the Investor under Rule 415 at then-prevailing market prices (and not fixed
prices), or if after the filing of the initial Registration Statement with the SEC pursuant to Section 2(a), the Company is otherwise
required by the Staff or the SEC to reduce the number of Registrable Securities included in such initial Registration Statement, then
the Company shall reduce the number of Registrable Securities to be included in such initial Registration Statement until such time as
the Staff and the SEC shall so permit such Registration Statement to become effective and be used as aforesaid. In the event of any reduction
in Registrable Securities pursuant to this paragraph, the Company shall file one or more New Registration Statements in accordance with
Section 2(c) until such time as all Registrable Securities have been included in Registration Statements that have been declared effective
and the prospectus contained therein is available for use by the Investor, provided, however, that this obligation shall cease at the
end of the Registration Period. Notwithstanding any provision herein or in the Purchase Agreement to the contrary, the Company&rsquo;s
obligations to register Registrable Securities (and any related conditions to the Investor&rsquo;s obligations) shall be qualified as
necessary to comport with any requirement of the SEC or the Staff as addressed in this Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>RELATED OBLIGATIONS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the Registration Statement and whenever any Registrable Securities are to be registered pursuant to Section 2 including on
any New Registration Statement, the Company shall use its reasonable efforts to effect the registration of the Registrable Securities
in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to any registration
statement and the prospectus used in connection with such registration statement, which prospectus is to be filed pursuant to Rule 424
promulgated under the Securities Act, as may be necessary to keep the Registration Statement or any New Registration Statement effective
at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act with respect to
the disposition of all Registrable Securities of the Company covered by the Registration Statement or any New Registration Statement
until such time as all of such Registrable Securities shall have been disposed of in accordance with the intended methods of disposition
by the seller or sellers thereof as set forth in such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
The Company shall permit the Investor to review and comment upon the Registration Statement or any New Registration Statement and all
amendments and supplements thereto at least two (2) Business Days prior to their filing with the SEC, and not file any document in a
form to which Investor reasonably objects. The Investor shall use its reasonable best efforts to comment upon the Registration Statement
or any New Registration Statement and any amendments or supplements thereto within two (2) Business Days from the date the Investor receives
the final version thereof. The Company shall furnish to the Investor, without charge any correspondence from the SEC or the staff of
the SEC to the Company or its representatives relating to the Registration Statement or any New Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Upon request of the Investor, the Company shall furnish to the Investor, (i) promptly after the same is prepared and filed with the SEC,
at least one copy of such registration statement and any amendment(s) thereto, including financial statements and schedules, all documents
incorporated therein by reference and all exhibits, (ii) upon the effectiveness of any registration statement, a copy of the prospectus
included in such registration statement and all amendments and supplements thereto (or such other number of copies as the Investor may
reasonably request) and (iii) such other documents, including copies of any preliminary or final prospectus, as the Investor may reasonably
request from time to time in order to facilitate the disposition of the Registrable Securities owned by the Investor. For the avoidance
of doubt, any filing available to the Investor via the SEC&rsquo;s live EDGAR system shall be deemed &ldquo;furnished to the Investor&rdquo;
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
The Company shall use reasonable best efforts to (i) register and qualify the Registrable Securities covered by a registration statement
under such other securities or &ldquo;blue sky&rdquo; laws of such jurisdictions in the United States as the Investor reasonably requests,
(ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations
and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions
as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv)
take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided,
however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any
jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (y) subject itself to general taxation in
any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction. The Company shall promptly notify
the Investor who holds Registrable Securities of the receipt by the Company of any notification with respect to the suspension of the
registration or qualification of any of the Registrable Securities for sale under the securities or &ldquo;blue sky&rdquo; laws of any
jurisdiction in the United States or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
As promptly as practicable after becoming aware of such event or facts, the Company shall notify the Investor in writing of the happening
of any event or existence of such facts as a result of which the prospectus included in any registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare a supplement or
amendment to such registration statement and/or take any other necessary steps (which, if in accordance with applicable SEC rules and
regulations, may consist of a document to be filed by the Company with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act and to be incorporated by reference in the prospectus) to correct such untrue statement or omission, and deliver a copy of such supplement
or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company shall also promptly
notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when
a registration statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered
to the Investor by email on the same day of such effectiveness and by overnight mail), (ii) of any request by the SEC for amendments
or supplements to any registration statement or related prospectus or related information, and (iii) of the Company&rsquo;s reasonable
determination that a post-effective amendment to a registration statement would be appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.
The Company shall use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of any
registration statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such
an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify
the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of
any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.
The Company shall (i) cause all the Registrable Securities to be listed on each securities exchange on which securities of the same class
or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules
of such exchange, or (ii) secure designation and quotation of all the Registrable Securities on the Principal Market (as defined in the
Purchase Agreement). The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.
The Company shall cooperate with the Investor to facilitate the timely preparation and delivery of the Registrable Securities (not bearing
any restrictive legend) either by DWAC, DRS, or in certificated form if DWAC or DRS is unavailable, to be offered pursuant to any registration
statement and enable such Registrable Securities to be in such denominations or amounts as the Investor may reasonably request and registered
in such names as the Investor may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The Company shall at all times provide a transfer agent and registrar with respect to its Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.
If reasonably requested by the Investor, the Company shall (i) immediately incorporate in a prospectus supplement or post-effective amendment
such information as the Investor believes should be included therein relating to the sale and distribution of Registrable Securities,
including, without limitation, information with respect to the number of Registrable Securities being sold, the purchase price being
paid therefor and any other terms of the offering of the Registrable Securities; (ii) make all required filings of such prospectus supplement
or post-effective amendment as soon as practicable upon notification of the matters to be incorporated in such prospectus supplement
or post-effective amendment; and (iii) supplement or make amendments to any registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.
The Company shall use its reasonable best efforts to cause the Registrable Securities covered by any registration statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.
Within one (1) Business Day after any registration statement which includes the Registrable Securities is ordered effective by the SEC,
the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investor) confirmation that such registration statement has been declared effective by the SEC in the form attached
hereto as <U>Exhibit A</U>. Thereafter, if requested by the Investor at any time, the Company shall require its counsel to deliver to
the Investor a written confirmation whether or not the effectiveness of such registration statement has lapsed at any time for any reason
(including, without limitation, the issuance of a stop order) and whether or not the registration statement is current and available
to the Investor for sale of all of the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.
The Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable Securities
pursuant to any registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.
Notwithstanding anything to the contrary in this Agreement, the provisions in this Agreement and the Company&rsquo;s obligations thereunder
are subject to compliance with the Exchange Cap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>OBLIGATIONS OF THE INVESTOR</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in connection with
any registration statement hereunder. The Investor shall furnish to the Company such information regarding itself, the Registrable Securities
held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect
the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company
may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
The Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of any registration statement hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
The Investor agrees that, upon receipt of any notice from the Company of the happening of any event or existence of facts of the kind
described in Section 3(f) or the first sentence of 3(e), the Investor will immediately discontinue disposition of Registrable Securities
pursuant to any registration statement(s) covering such Registrable Securities until the Investor&rsquo;s receipt of the copies of the
supplemented or amended prospectus contemplated by Section 3(f) or the first sentence of 3(e). Notwithstanding anything to the contrary,
the Company shall cause its transfer agent to promptly deliver shares of Common Stock without any restrictive legend in accordance with
the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which the Investor has entered
into a contract for sale prior to the Investor&rsquo;s receipt of a notice from the Company of the happening of any event of the kind
described in Section 3(f) or the first sentence of Section 3(e) and for which the Investor has not yet settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>EXPENSES OF REGISTRATION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
reasonable expenses, other than sales or brokerage commissions, incurred in connection with registrations, filings or qualifications
pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting
fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>INDEMNIFICATION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each Person,
if any, who controls the Investor, the members, the directors, officers, partners, employees, agents, representatives of the Investor
and each Person, if any, who controls the Investor within the meaning of the Securities Act or the Securities Exchange Act of 1934, as
amended (the &ldquo;<U>Exchange Act</U>&rdquo;) (each, an &ldquo;<U>Indemnified Person</U>&rdquo;), against any losses, claims, damages,
liabilities, judgments, fines, penalties, charges, costs, attorneys&rsquo; fees, amounts paid in settlement or expenses, joint or several,
(collectively, &ldquo;<U>Claims</U>&rdquo;) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding,
investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body
or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&ldquo;<U>Indemnified Damages</U>&rdquo;),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in the Registration
Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification
of the offering under the securities or other &ldquo;blue sky&rdquo; laws of any jurisdiction in which Registrable Securities are offered
(&ldquo;<U>Blue Sky Filing</U>&rdquo;), or the omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained
in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or
the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances
under which the statements therein were made, not misleading, (iii) any violation or alleged violation by the Company of the Securities
Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating
to the offer or sale of the Registrable Securities pursuant to the Registration Statement or any New Registration Statement or (iv) any
material violation by the Company of this Agreement (the matters in the foregoing clauses (i) through (iv) being, collectively, &ldquo;<U>Violations</U>&rdquo;).
The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable
legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim
by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information about
the Investor furnished in writing to the Company by such Indemnified Person expressly for use in connection with the preparation of the
Registration Statement, any New Registration Statement or any such amendment thereof or supplement thereto, if such prospectus was timely
made available by the Company pursuant to Section 3(c) or Section 3(e); (ii) with respect to any superseded prospectus, shall not inure
to the benefit of any such person from whom the person asserting any such Claim purchased the Registrable Securities that are the subject
thereof (or to the benefit of any person controlling such person) if the untrue statement or omission of material fact contained in the
superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, if such revised prospectus was timely
made available by the Company pursuant to Section 3(c) or Section 3(e), and the Indemnified Person was promptly advised in writing not
to use the incorrect prospectus prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice,
used it; (iii) shall not be available to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered
the prospectus made available by the Company, if such prospectus was timely made available by the Company pursuant to Section 3(c) or
Section 3(e); and (iv) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written
consent of the Company, which consent shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless
of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the
Investor pursuant to Section 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Promptly after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action
or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall,
if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a
written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the
indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be;
provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the reasonable
fees and expenses of one counsel to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying
party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by
such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party in connection
with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all
information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying
party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as to the status of the defense or any settlement
negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected
without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent.
No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or
enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party or Indemnified Person of a release from all liability in respect to such claim or litigation. Following indemnification
as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with
respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver
written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying
party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying
party is prejudiced in its ability to defend such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or
Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant
to the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>CONTRIBUTION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law;
provided, however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent
misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds
received by such seller from the sale of such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>REPORTS AND DISCLOSURE UNDER THE SECURITIES ACTS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a view to making available to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or
regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration (&ldquo;<U>Rule
144</U>&rdquo;), at all times while the Purchase Agreement is in effect the Company agrees, at the Company&rsquo;s sole expense, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
make and keep public information available, as those terms are understood and defined in Rule 144;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the
applicable provisions of Rule 144;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
furnish to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company
that it has complied with the reporting and or disclosure provisions of Rule 144, the Securities Act and the Exchange Act, (ii) a copy
of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii)
such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
take such additional action as is reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant
to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions
to the Company&rsquo;s transfer agent as may be requested from time to time by the Investor and otherwise fully cooperate with Investor
and Investor&rsquo;s broker to effect such sale of securities pursuant to Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees that damages may be an inadequate remedy for any breach of the terms and provisions of this Section 8 and that Investor
shall, whether or not it is pursuing any remedies at law, be entitled to equitable relief in the form of a preliminary or permanent injunctions,
without having to post any bond or other security, upon any breach or threatened breach of any such terms or provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>ASSIGNMENT OF REGISTRATION RIGHTS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
party shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>AMENDMENT OF REGISTRATION RIGHTS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
provision of this Agreement may be amended or waived by the parties from and after the date that is one Business Day immediately preceding
the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement
may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived other than in a written instrument
signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this
Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>MISCELLANEOUS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same
Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of
such Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in
writing and shall be (a) personally served, (b) deposited in the mail, registered or certified, return receipt requested, postage prepaid,
(c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by hand delivery, telegram, or email as a PDF,
addressed as set forth below or to such other address as such party shall have specified most recently by written notice given in accordance
herewith. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (i) upon hand delivery
or delivery by email at the address designated below (if delivered on a business day during normal business hours where such notice is
to be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (ii) on the second business day following the date of mailing by express courier service
or on the fifth business day after deposited in the mail, in each case, fully prepaid, addressed to such address, or upon actual receipt
of such mailing, whichever shall first occur. The addresses for such communications shall be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11120
NE 2nd Street, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Thomas K. Equels</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2117
SW Highway 484</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocala,
Florida 34473</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5.95pt; text-align: justify; text-indent: 30.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas
Sciences, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">303
East Wacker Drive, Suite 1040</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chicago,
Illinios 60601</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
jfife@chicagoventure.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party hereto may from time to time change its address or email for notices under this Section 11.b by giving at least ten (10) days&rsquo;
prior written notice of such changed address to the other party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
The corporate laws of the State of Utah shall govern all issues concerning this Agreement. All other questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Utah, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdictions) that would
cause the application of the laws of any jurisdictions other than the State of Utah. Each party hereby irrevocably submits to the exclusive
jurisdiction of the State of Utah for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process
and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for
such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If any
provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect
the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision
of this Agreement in any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
This Agreement and the Purchase Agreement constitute the entire agreement among the parties hereto with respect to the subject matter
hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein
and therein. This Agreement and the Purchase Agreement supersede all prior agreements and understandings among the parties hereto with
respect to the subject matter hereof and thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
Subject to the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.
This Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by e-mail in a &ldquo;.pdf&rdquo;
format data file of a copy of this Agreement bearing the signature of the party so delivering this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules
of strict construction will be applied against any party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>*
* * * * *</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B> the parties have caused this Agreement to be duly executed as of day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>COMPANY</U>:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
    IMMUNOTECH, INC. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>s/
    Thomas Equels </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Equels, Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INVESTOR</U>:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATLAS
    SCIENCES, LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>s/John
    M. Fife </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    M. Fife, President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Registration Rights Agreement]</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TO
REGISTRATION RIGHTS AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF NOTICE OF EFFECTIVENESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
REGISTRATION STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">______,
2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Transfer
Agent}</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Address]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Effectiveness of Registration Statement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are counsel to <B>AIM IMMUNOTECH, INC.</B>, a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and have represented the Company
in connection with that certain Purchase Agreement, dated as of March 28, 2024 (the &ldquo;<U>Purchase Agreement</U>&rdquo;), entered
into by and between the Company and Atlas Sciences, LLC, a Utah limited liability company (the &ldquo;<U>Investor</U>&rdquo;) pursuant
to which the Company has agreed to issue to the Investor shares of the Company&rsquo;s common stock, $0.001 par value (the &ldquo;<U>Common
Stock</U>&rdquo;), in an amount up to Fifteen Million Dollars ($15,000,000.00) (the &ldquo;<U>Put Shares</U>&rdquo;), in accordance with
the terms of the Purchase Agreement. In connection with the transactions contemplated by the Purchase Agreement, the Company has registered
with the U.S. Securities &amp; Exchange Commission the following shares of Common Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________
    Put Shares to be issued to the Investor upon purchase from the Company by the Investor from time to time in accordance with the Purchase
    Agreement; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________
    Commitment Shares (as defined in the Purchase Agreement) (the &ldquo;<U>Commitment Shares</U>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Company also has entered into a registration rights agreement, of even date with the Purchase Agreement
with the Investor (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;) pursuant to which the Company agreed, among other things,
to register the Put Shares and Commitment Shares under the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;).
In connection with the Company&rsquo;s obligations under the Purchase Agreement and the Registration Rights Agreement, on [_____], 2024,
the Company filed a Registration Statement (File No. 333-[_________]) (the &ldquo;<U>Registration Statement</U>&rdquo;) with the Securities
and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) relating to the resale of the Put Shares and Commitment Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the foregoing, we advise you that a member of the SEC&rsquo;s staff has advised us by telephone that the SEC has entered
an order declaring the Registration Statement effective under the Securities Act at [_____] [A.M./P.M.] on [__________], 2024 and we
have no knowledge, after telephonic inquiry of a member of the SEC&rsquo;s staff, that any stop order suspending its effectiveness has
been issued or that any proceedings for that purpose are pending before, or threatened by, the SEC and the Put Shares and Commitment
Shares are available for resale under the Securities Act pursuant to the Registration Statement and may be issued without any restrictive
legend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Company
    Counsel]</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:
Atlas Sciences, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 69%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US Subsidiaries:</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPro Corp.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dormant</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioAegean Corp.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dormant</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign Subsidiaries:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aim ImmunoTech Europe N.V./S.A. (Belgium)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Consent of Independent Registered
Public Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-262280), Form S-1 (No.
333-217671, 333-220756, 333-226057, 333-229051 and 333-233657) and Form S-8 (No. 333-257614, 333-160499, 333-209060, 333-220296,
333-227543 and 333-240315) of AIM ImmunoTech, Inc. (the Company) of our report dated <FONT>March 29, 2024</FONT>, relating to the
consolidated financial statements which appears in this Annual Report on Form 10-K.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ BDO USA, P.C.</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 50%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0">Miami, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0">March 29, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0; margin-left: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Thomas K. Equels certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of AIM ImmunoTech Inc. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas K. Equels</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Dickey IV, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of AIM ImmunoTech Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Dickey IV</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of AIM ImmunoTech Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2023,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Thomas K. Equels, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002,
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas K. Equels</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of AIM ImmunoTech Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2023,
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert Dickey IV, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002,
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 29, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Dickey IV</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>ex97-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex97-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
ImmunoTech Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CLAWBACK
POLICY </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Introduction</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of AIM ImmunoTech Inc. (the &ldquo;<B>Company</B>&rdquo;) believes that it is in
the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability
and that reinforces the Company&rsquo;s pay-for-performance compensation philosophy. The Board has therefore adopted this policy which
provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance
with financial reporting requirements under the federal securities laws (the &ldquo;<B>Policy</B>&rdquo;). This Policy is designed to
comply with Section 10D of the Securities Exchange Act of 1934 (the &ldquo;<B>Exchange Act</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Administration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be administered by the Board&rsquo;s Compensation Committee. Any determinations made by the Compensation Committee shall
be final and binding on all affected individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Covered
Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former executive officers, as determined by the Compensation Committee in accordance
with Section 10D of the Exchange Act and the listing standards of the NYSE American, or such other national securities exchange on which
the Company&rsquo;s securities are listed (&ldquo;<B>Covered Executives</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recoupment;
Accounting Restatement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event the Company is required to prepare an accounting restatement of its financial statements due to the Company&rsquo;s material
noncompliance with any financial reporting requirement under the securities laws, the Compensation Committee will require reimbursement
or forfeiture of any excess Incentive Compensation received by any Covered Executive during the three completed fiscal years immediately
preceding the date on which the Company is required to prepare an accounting restatement, without regard to such Covered Executive&rsquo;s
individual knowledge or responsibility related to such restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Incentive
Compensation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, Incentive Compensation means any of the following; provided that, such compensation is granted, earned, or vested
based wholly or in part on the attainment of a financial reporting measure:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
bonuses and other short- and long-term cash incentives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Dated
November 28, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
appreciation rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Excess
Incentive Compensation: Amount Subject to Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over
the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated results, as determined
by the Compensation Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Compensation Committee cannot determine the amount of excess Incentive Compensation received by the Covered Executive directly from
the information in the accounting restatement, then it will make its determination based on a reasonable estimate of the effect of the
accounting restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of Incentive Compensation include bonuses and equity awards that are based on one or more financial performance goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Method
of Recoupment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee will determine, in its sole discretion, the method for recouping Incentive Compensation hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may pursue recovery of the Incentive Compensation in the manner it chooses, including by pursuing reimbursement
from the Covered Executives of all or part of the compensation awarded or paid, by electing to withhold unpaid compensation, or by rescinding
or canceling unvested stock or option awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the reasonable exercise of its business judgment under this Policy, the Compensation Committee may determine whether and to what extent
additional action is appropriate to address the circumstances surrounding a Restatement to minimize the likelihood of any recurrence
and to impose such other discipline as it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive Compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interpretation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or
advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the
requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission
or any national securities exchange on which the Company&rsquo;s securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
Rights</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements of this Policy are in addition to, and not in lieu of, any legal claims the Company may have or any actions that may be
imposed by law enforcement agencies, regulators, administrative bodies, or other authorities. Further, the exercise by the Compensation
Committee of any rights pursuant to this Policy will not impact any other rights that the Company may have with respect to any Covered
Executive subject to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Dated
November 28, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effective
Date</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy implemented on November ~, 2023, shall be effective as of October 2, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;) and shall
apply to Incentive Compensation that is approved, awarded or granted to Covered Executives on or after that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment;
Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to
reflect final regulations adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act and to comply with
any rules or standards adopted by a national securities exchange on which the Company&rsquo;s securities are listed. The Compensation
Committee may terminate this Policy at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
Recoupment Rights</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may require
that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition
to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment
under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company
pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal
remedies available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Impracticability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable,
as determined by the Compensation Committee in accordance with Rule 10D-1 of the Exchange Act and the listing standards of the national
securities exchange on which the Company&rsquo;s securities are listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Acknowledgment/Condition
of Eligibility</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will provide notice and seek acknowledgement of this Policy from each Covered Executive. However, failure to provide such notice
will not nullify the terms of this Policy. After the Effective Date, any grant of Incentive Compensation to a Covered Executive will
be deemed to have been made subject to the terms of this Policy. All Incentive Compensation subject to this Policy will remain subject
to this policy, even if already paid, until the Policy ceases to apply to such Incentive Compensation and any other vesting conditions
applicable to the Incentive Compensation are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Successors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Dated
November 28, 2023)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex97-1_001.jpg
<TEXT>
begin 644 ex97-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ '0# 2(  A$! Q$!_\0
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MXA\27L>F:)!K&JVWCS4[BR@U#5+BTTV&6+3[H_:[RW5XUC9Y8_SW_P"#MO\
M:G/A3X'? #]D/0=2:+5/BSXKO_BUX]M(6 8^"?A\/[*\*V5X"XS;:WXQU6ZU
M*WQ&Q^T^"F/F( 5D_BF\4?"3XN_ '1?V=OC7J-I>^&K'XP>'KCXM?![Q-:M+
M!<,G@KXAZ]X2>\@D9(VM]3TKQ#X4&I0;-RFPOM'OXI&CNXS7Z5X0^ 7"G&/
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MHM)RSVGAE[58Z\G3CALDKMR@O:O'3A448PJ*G5N?^#E;]C^WB\66_P#PS_\
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..2J)V4:DXJ]HR:29__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>aim-20231231.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGBKbP9z5Z8OekhvWB2bUmavykmShP1QSZNvwo2cUYP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:AIM="http://aimimmuno.com/20231231" elementFormDefault="qualified" targetNamespace="http://aimimmuno.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aimimmuno.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
          <link:definition>00000007 - Disclosure - Description of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/MarketableInvestments" id="MarketableInvestments">
          <link:definition>00000009 - Disclosure - Marketable Investments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" id="PatentsAndTrademarkRightsNet">
          <link:definition>00000010 - Disclosure - Patents and Trademark Rights, Net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>00000011 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000012 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformation" id="SegmentAndRelatedInformation">
          <link:definition>00000013 - Disclosure - Segment and Related Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" id="ResearchConsultingAndSupplyAgreements">
          <link:definition>00000014 - Disclosure - Research, Consulting and Supply Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/KPlan" id="KPlan">
          <link:definition>00000015 - Disclosure - 401(k) Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/EmploymentAgreements" id="EmploymentAgreements">
          <link:definition>00000016 - Disclosure - Employment Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Leases" id="Leases">
          <link:definition>00000017 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" id="IncomeTaxesFasbAsc740IncomeTaxes">
          <link:definition>00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" id="CertainRelationshipsAndRelatedTransactions">
          <link:definition>00000019 - Disclosure - Certain Relationships and Related Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ConcentrationsOfRisk" id="ConcentrationsOfRisk">
          <link:definition>00000020 - Disclosure - Concentrations of Risk</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValue" id="FairValue">
          <link:definition>00000021 - Disclosure - Fair Value</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Contingencies" id="Contingencies">
          <link:definition>00000022 - Disclosure - Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000023 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/MarketableInvestmentsTables" id="MarketableInvestmentsTables">
          <link:definition>00000026 - Disclosure - Marketable Investments (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" id="PatentsAndTrademarkRightsNetTables">
          <link:definition>00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>00000028 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000029 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000030 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" id="IncomeTaxesFasbAsc740IncomeTaxesTables">
          <link:definition>00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValueTables" id="FairValueTables">
          <link:definition>00000032 - Disclosure - Fair Value (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000033 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" id="ScheduleOfAvailableOfSaleDetails">
          <link:definition>00000035 - Disclosure - Schedule of Available of Sale (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" id="ScheduleOfEquitySecuritiesDetails">
          <link:definition>00000036 - Disclosure - Schedule of Equity Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" id="MarketableInvestmentsDetailsNarrative">
          <link:definition>00000037 - Disclosure - Marketable Investments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" id="ScheduleOfPatentAndTrademarkRightsDetails">
          <link:definition>00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" id="ScheduleOfChangesInPatentsTrademarkRightsDetails">
          <link:definition>00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" id="ScheduleOfAmortizationOfPatentsAndTrademarksDetails">
          <link:definition>00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" id="PatentsAndTrademarkRightsNetDetailsNarrative">
          <link:definition>00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>00000042 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" id="ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails">
          <link:definition>00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000044 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" id="ScheduleOfVestStockOptionActivityDetails">
          <link:definition>00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" id="ScheduleOfUnvestedStockOptionActivityDetails">
          <link:definition>00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" id="SegmentAndRelatedInformationDetailsNarrative">
          <link:definition>00000049 - Disclosure - Segment and Related Information (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" id="ResearchConsultingAndSupplyAgreementsDetailsNarrative">
          <link:definition>00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/KPlanDetailsNarrative" id="KPlanDetailsNarrative">
          <link:definition>00000051 - Disclosure - 401(k) Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" id="EmploymentAgreementsDetailsNarrative">
          <link:definition>00000052 - Disclosure - Employment Agreements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" id="ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails">
          <link:definition>00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" id="ScheduleOfOperatingLeaseFuturePaymentsDetails">
          <link:definition>00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000055 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" id="ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails">
          <link:definition>00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" id="IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative">
          <link:definition>00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" id="ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails">
          <link:definition>00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" id="ScheduleOfRangeOfProbabilitiesDetails">
          <link:definition>00000061 - Disclosure - Schedule of Range of Probabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
          <link:definition>00000062 - Disclosure - Fair Value (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000063 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="AIM_SeriesAJuniorParticipatingPreferredStockMember" name="SeriesAJuniorParticipatingPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PatentAndTrademarkRightsMember" name="PatentAndTrademarkRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MutualFundsMember" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_BoardMember" name="BoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DirectorsOfficersAndEmployeesMember" name="DirectorsOfficersAndEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AllianceGlobalPartnersLLCMember" name="AllianceGlobalPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_RepresentativeWarrantsMember" name="RepresentativeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MaximGroupLLCMember" name="MaximGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquityIncentivePlanTwoThousandNineMember" name="EquityIncentivePlanTwoThousandNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NonEmployeeMember" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquityIncentivePlansTwoThousandAndEighteenMember" name="EquityIncentivePlansTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquityIncentivePlans2009Member" name="EquityIncentivePlans2009Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquityIncentivePlans2018Member" name="EquityIncentivePlans2018Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClinicalStudiesMember" name="ClinicalStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ManufacturingAndEngineeringMember" name="ManufacturingAndEngineeringMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_QualityControlMember" name="QualityControlMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_RegulatoryMember" name="RegulatoryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AmarexClinicalResearchLLCMember" name="AmarexClinicalResearchLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PancreaticCancerMember" name="PancreaticCancerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PostCOVIDMember" name="PostCOVIDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_JubilantHollisterStierMember" name="JubilantHollisterStierMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ResearchConsultingAndSupplyAgreementsMember" name="ResearchConsultingAndSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PharmaSolutionsMember" name="PharmaSolutionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MasterServiceAgreementAndQualityAgreementMember" name="MasterServiceAgreementAndQualityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ErasmusMember" name="ErasmusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_JointClinicalStudyAgreementMember" name="JointClinicalStudyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_JjointClinicalStudyAgreementMember" name="JjointClinicalStudyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AzenovaSalesInternationalMember" name="AzenovaSalesInternationalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AlcamiMember" name="AlcamiMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FourZeroOnekPlanMember" name="FourZeroOnekPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EmploymentContractualAgreementsMember" name="EmploymentContractualAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NamedExecutiveOfficersMember" name="NamedExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EmploymentAgreementMember" name="EmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ThomasKEquelsMember" name="ThomasKEquelsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PeterRodinoMember" name="PeterRodinoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquelsandRodinoMember" name="EquelsandRodinoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EllenLintalMember" name="EllenLintalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquelsRodinoAndFormerOfficerLintalMember" name="EquelsRodinoAndFormerOfficerLintalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MarchTwoThousandNineteenWarrantsMember" name="MarchTwoThousandNineteenWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_UnsecuredPromissoryNoteMember" name="UnsecuredPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EmployeesPurchasePlanMember" name="EmployeesPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DirectorsPurchasePlanMember" name="DirectorsPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PreferredStockStatedValuePerShare" name="PreferredStockStatedValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_GainFromSaleOfIncomeTaxOperatingLoss" name="GainFromSaleOfIncomeTaxOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_CashlessWarrantConversion" name="CashlessWarrantConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_CashlessWarrantConversionShares" name="CashlessWarrantConversionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AbandonmentOfPatentAndTrademarkRights" name="AbandonmentOfPatentAndTrademarkRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" name="LossGainFromSaleOfIncomeTaxOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_UnrealizedGainLossOnMarketableInvestments" name="UnrealizedGainLossOnMarketableInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ConversionOfSeriesBPreferred" name="ConversionOfSeriesBPreferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" name="OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" name="DisclosureResearchConsultingAndSupplyAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" name="ResearchConsultingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DisclosureEmploymentAgreementsAbstract" name="DisclosureEmploymentAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EmploymentAgreementsTextBlock" name="EmploymentAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfOperatingLeaseTableTextBlock" name="ScheduleOfOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" name="ScheduleOfRangeOfProbabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FinitelivedIntangibleAssetsAbandonments" name="FinitelivedIntangibleAssetsAbandonments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AccruedClinicalTrialExpensesCurrent" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" name="WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" name="WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FaceValueOfStock" name="FaceValueOfStock" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" name="CommonStockSharesWithLimitationsAndRestrictionsOnUsage" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PercentageOfOutstandingStock" name="PercentageOfOutstandingStock" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WarrantModifications" name="WarrantModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" name="ResearchAndDevelopmentExpenseCostEstimatedLives" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_UnitsManufactured" name="UnitsManufactured" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NumberOfVials" name="NumberOfVials" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_Bonus" name="Bonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" name="OperationLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DeferredTaxAssetsAmortizationAndDepreciation" name="DeferredTaxAssetsAmortizationAndDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DeferredTaxAssetsRightOfUseAssets" name="DeferredTaxAssetsRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_IncomeTaxReconciliationForeignIncomeRTP" name="IncomeTaxReconciliationForeignIncomeRTP" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" name="EffectiveIncomeTaxRateReconciliationRTPPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" name="IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" name="EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" name="IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" name="EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" name="IncomeTaxReconciliationNondeductibleExpenseFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationOther" name="EffectiveIncomeTaxRateReconciliationOther" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" name="IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" name="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_OperatingLossCarryforwardsWithNoExpirationDate" name="OperatingLossCarryforwardsWithNoExpirationDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PercentageOfProbability" name="PercentageOfProbability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FairValueMeasurementInputPercentage" name="FairValueMeasurementInputPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" name="FloorRateUsedAsProxyForFutureVolatilityPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DebtIstrumentAxis" name="DebtIstrumentAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="AIM_DebtIstrumentDomain" name="DebtIstrumentDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_InternalResearchMember" name="InternalResearchMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock" name="ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>aim-20231231_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="aim-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:href="aim-20231231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestments" xlink:href="aim-20231231.xsd#MarketableInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlan" xlink:href="aim-20231231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreements" xlink:href="aim-20231231.xsd#EmploymentAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:href="aim-20231231.xsd#CertainRelationshipsAndRelatedTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:href="aim-20231231.xsd#ConcentrationsOfRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Contingencies" xlink:href="aim-20231231.xsd#Contingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:href="aim-20231231.xsd#MarketableInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityTables" xlink:href="aim-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:href="aim-20231231.xsd#ScheduleOfAvailableOfSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:href="aim-20231231.xsd#MarketableInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20231231.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfVestStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="aim-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:href="aim-20231231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#EmploymentAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20231231.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:href="aim-20231231.xsd#ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfRangeOfProbabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingCosts" xlink:label="loc_us-gaapManufacturingCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapManufacturingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="loc_AIMAbandonmentOfPatentAndTrademarkRights" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMAbandonmentOfPatentAndTrademarkRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NoncashLeaseExpense" xlink:label="loc_AIMNoncashLeaseExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:label="loc_AIMLossGainFromSaleOfIncomeTaxOperatingLosses" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMLossGainFromSaleOfIncomeTaxOperatingLosses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="loc_us-gaapProceedsFromSaleOfInvestmentProjects" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfInvestmentProjects" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestments" xlink:title="00000009 - Disclosure - Marketable Investments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000010 - Disclosure - Patents and Trademark Rights, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:title="00000013 - Disclosure - Segment and Related Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000014 - Disclosure - Research, Consulting and Supply Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlan" xlink:title="00000015 - Disclosure - 401(k) Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreements" xlink:title="00000016 - Disclosure - Employment Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:title="00000019 - Disclosure - Certain Relationships and Related Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:title="00000020 - Disclosure - Concentrations of Risk" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000021 - Disclosure - Fair Value" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Contingencies" xlink:title="00000022 - Disclosure - Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:title="00000026 - Disclosure - Marketable Investments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityTables" xlink:title="00000029 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000030 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000032 - Disclosure - Fair Value (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000033 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:title="00000035 - Disclosure - Schedule of Available of Sale (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Equity Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000042 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_AIMAccruedClinicalTrialExpensesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_AIMAccruedClinicalTrialExpensesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:title="00000049 - Disclosure - Segment and Related Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:title="00000051 - Disclosure - 401(k) Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Employment Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000055 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="101" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="102" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:label="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation" />
      <link:calculationArc order="103" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="104" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="105" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_AIMDeferredTaxAssetsRightOfUseAssets" />
      <link:calculationArc order="106" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_AIMDeferredTaxAssetsRightOfUseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="107" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:title="00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationForeignIncomeRTP" xlink:label="loc_AIMIncomeTaxReconciliationForeignIncomeRTP" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_AIMIncomeTaxReconciliationForeignIncomeRTP" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleStateNetOperatingLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleExpenseFixedAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:label="loc_AIMIncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_AIMIncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationRTPPercentage" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationOther" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:title="00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:title="00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:title="00000061 - Disclosure - Schedule of Range of Probabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000062 - Disclosure - Fair Value (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>aim-20231231_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="aim-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:href="aim-20231231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestments" xlink:href="aim-20231231.xsd#MarketableInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlan" xlink:href="aim-20231231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreements" xlink:href="aim-20231231.xsd#EmploymentAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:href="aim-20231231.xsd#CertainRelationshipsAndRelatedTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:href="aim-20231231.xsd#ConcentrationsOfRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Contingencies" xlink:href="aim-20231231.xsd#Contingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:href="aim-20231231.xsd#MarketableInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityTables" xlink:href="aim-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:href="aim-20231231.xsd#ScheduleOfAvailableOfSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:href="aim-20231231.xsd#MarketableInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20231231.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfVestStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="aim-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:href="aim-20231231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#EmploymentAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20231231.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:href="aim-20231231.xsd#ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfRangeOfProbabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversion" xlink:label="loc_AIMCashlessWarrantConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMCashlessWarrantConversion_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversionShares" xlink:label="loc_AIMCashlessWarrantConversionShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMCashlessWarrantConversionShares_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestments" xlink:title="00000009 - Disclosure - Marketable Investments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000010 - Disclosure - Patents and Trademark Rights, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:title="00000013 - Disclosure - Segment and Related Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000014 - Disclosure - Research, Consulting and Supply Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlan" xlink:title="00000015 - Disclosure - 401(k) Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreements" xlink:title="00000016 - Disclosure - Employment Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000017 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:title="00000019 - Disclosure - Certain Relationships and Related Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:title="00000020 - Disclosure - Concentrations of Risk" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000021 - Disclosure - Fair Value" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Contingencies" xlink:title="00000022 - Disclosure - Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:title="00000026 - Disclosure - Marketable Investments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityTables" xlink:title="00000029 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlanTwoThousandNineMember" xlink:label="loc_AIMEquityIncentivePlanTwoThousandNineMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlanTwoThousandNineMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlansTwoThousandAndEighteenMember" xlink:label="loc_AIMEquityIncentivePlansTwoThousandAndEighteenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlansTwoThousandAndEighteenMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000030 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000032 - Disclosure - Fair Value (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000033 - Disclosure - Schedule of Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PatentAndTrademarkRightsMember" xlink:label="loc_AIMPatentAndTrademarkRightsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_AIMPatentAndTrademarkRightsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:title="00000035 - Disclosure - Schedule of Available of Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MutualFundsMember" xlink:label="loc_AIMMutualFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AIMMutualFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapShortTermInvestments_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecurities_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Equity Securities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investments (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000042 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:label="loc_AIMWeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMWeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2009Member" xlink:label="loc_AIMEquityIncentivePlans2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlans2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2018Member" xlink:label="loc_AIMEquityIncentivePlans2018Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlans2018Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_310" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_310" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_310" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_310" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_310" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_310" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_130" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:label="loc_AIMShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_130" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_140" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_140" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="loc_AIMWeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMWeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_140" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_BoardMember" xlink:label="loc_AIMBoardMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMBoardMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesMember" xlink:label="loc_AIMEmployeesMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEmployeesMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NonEmployeeMember" xlink:label="loc_AIMNonEmployeeMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMNonEmployeeMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightsMember" xlink:label="loc_us-gaapRightsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRightsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlanTwoThousandNineMember" xlink:label="loc_AIMEquityIncentivePlanTwoThousandNineMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlanTwoThousandNineMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantsMember" xlink:label="loc_AIMWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMWarrantsMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RepresentativeWarrantsMember" xlink:label="loc_AIMRepresentativeWarrantsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMRepresentativeWarrantsMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreFundedWarrantsMember" xlink:label="loc_AIMPreFundedWarrantsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMPreFundedWarrantsMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="loc_AIMDirectorsOfficersAndEmployeesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AIMDirectorsOfficersAndEmployeesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="loc_AIMAllianceGlobalPartnersLLCMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAllianceGlobalPartnersLLCMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MaximGroupLLCMember" xlink:label="loc_AIMMaximGroupLLCMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMMaximGroupLLCMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_490" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_490" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare_490" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_490" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_490" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FaceValueOfStock" xlink:label="loc_AIMFaceValueOfStock_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMFaceValueOfStock_490" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_490" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_490" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_490" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_490" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_490" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_490" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_490" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage_490" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_490" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_490" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_490" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_490" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_490" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_490" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_490" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfOutstandingStock" xlink:label="loc_AIMPercentageOfOutstandingStock_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPercentageOfOutstandingStock_490" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_490" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_490" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_490" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantModifications" xlink:label="loc_AIMWarrantModifications_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMWarrantModifications_490" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_490" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_490" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_490" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_490" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_490" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_490" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_490" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_490" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_490" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_490" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_490" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_490" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:title="00000049 - Disclosure - Segment and Related Information (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ClinicalStudiesMember" xlink:label="loc_AIMClinicalStudiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMClinicalStudiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="loc_AIMManufacturingAndEngineeringMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMManufacturingAndEngineeringMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_QualityControlMember" xlink:label="loc_AIMQualityControlMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMQualityControlMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RegulatoryMember" xlink:label="loc_AIMRegulatoryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMRegulatoryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="loc_AIMAmarexClinicalResearchLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAmarexClinicalResearchLLCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JubilantHollisterStierMember" xlink:label="loc_AIMJubilantHollisterStierMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMJubilantHollisterStierMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PharmaSolutionsMember" xlink:label="loc_AIMPharmaSolutionsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMPharmaSolutionsMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ErasmusMember" xlink:label="loc_AIMErasmusMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMErasmusMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AzenovaSalesInternationalMember" xlink:label="loc_AIMAzenovaSalesInternationalMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAzenovaSalesInternationalMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AlcamiMember" xlink:label="loc_AIMAlcamiMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAlcamiMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PancreaticCancerMember" xlink:label="loc_AIMPancreaticCancerMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPancreaticCancerMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PostCOVIDMember" xlink:label="loc_AIMPostCOVIDMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPostCOVIDMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchConsultingAndSupplyAgreementsMember" xlink:label="loc_AIMResearchConsultingAndSupplyAgreementsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMResearchConsultingAndSupplyAgreementsMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="loc_AIMMasterServiceAgreementAndQualityAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMMasterServiceAgreementAndQualityAgreementMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="loc_AIMJointClinicalStudyAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJointClinicalStudyAgreementMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JjointClinicalStudyAgreementMember" xlink:label="loc_AIMJjointClinicalStudyAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJjointClinicalStudyAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostMaintenance_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnitsManufactured" xlink:label="loc_AIMUnitsManufactured_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMUnitsManufactured_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NumberOfVials" xlink:label="loc_AIMNumberOfVials_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMNumberOfVials_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaapInventoryWorkInProcessAndRawMaterials_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryWorkInProcessAndRawMaterials_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_300" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:title="00000051 - Disclosure - 401(k) Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaapRetirementPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FourZeroOnekPlanMember" xlink:label="loc_AIMFourZeroOnekPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_AIMFourZeroOnekPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Employment Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentContractualAgreementsMember" xlink:label="loc_AIMEmploymentContractualAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEmploymentContractualAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentAgreementMember" xlink:label="loc_AIMEmploymentAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEmploymentAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NamedExecutiveOfficersMember" xlink:label="loc_AIMNamedExecutiveOfficersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMNamedExecutiveOfficersMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ThomasKEquelsMember" xlink:label="loc_AIMThomasKEquelsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMThomasKEquelsMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PeterRodinoMember" xlink:label="loc_AIMPeterRodinoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMPeterRodinoMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsandRodinoMember" xlink:label="loc_AIMEquelsandRodinoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEquelsandRodinoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EllenLintalMember" xlink:label="loc_AIMEllenLintalMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEllenLintalMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsRodinoAndFormerOfficerLintalMember" xlink:label="loc_AIMEquelsRodinoAndFormerOfficerLintalMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEquelsRodinoAndFormerOfficerLintalMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_StockOptionsMember" xlink:label="loc_AIMStockOptionsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMStockOptionsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="94" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligationPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligationPercentage_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_Bonus" xlink:label="loc_AIMBonus_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMBonus_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_140" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaapLeaseCostAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000055 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:label="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOther_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_AIMDeferredTaxAssetsRightOfUseAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMDeferredTaxAssetsRightOfUseAssets_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:title="00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:title="00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaapNewJerseyDivisionOfTaxationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapNewJerseyDivisionOfTaxationMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="loc_countryBE_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ" xlink:label="loc_stprNJ_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprNJ_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperatingLossCarryforwardsWithNoExpirationDate" xlink:label="loc_AIMOperatingLossCarryforwardsWithNoExpirationDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AIMOperatingLossCarryforwardsWithNoExpirationDate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:title="00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MarchTwoThousandNineteenWarrantsMember" xlink:label="loc_AIMMarchTwoThousandNineteenWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AIMMarchTwoThousandNineteenWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:title="00000061 - Disclosure - Schedule of Range of Probabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfProbability" xlink:label="loc_AIMPercentageOfProbability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMPercentageOfProbability_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000062 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FairValueMeasurementInputPercentage" xlink:label="loc_AIMFairValueMeasurementInputPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMFairValueMeasurementInputPercentage_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfProbability" xlink:label="loc_AIMPercentageOfProbability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMPercentageOfProbability_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:label="loc_AIMFloorRateUsedAsProxyForFutureVolatilityPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMFloorRateUsedAsProxyForFutureVolatilityPercentage_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentAxis" xlink:label="loc_AIMDebtIstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_AIMDebtIstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentDomain" xlink:label="loc_AIMDebtIstrumentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_AIMDebtIstrumentAxis" xlink:to="loc_AIMDebtIstrumentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentDomain" xlink:label="loc_AIMDebtIstrumentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_AIMDebtIstrumentAxis" xlink:to="loc_AIMDebtIstrumentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnsecuredPromissoryNoteMember" xlink:label="loc_AIMUnsecuredPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_AIMDebtIstrumentDomain" xlink:to="loc_AIMUnsecuredPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesPurchasePlanMember" xlink:label="loc_AIMEmployeesPurchasePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEmployeesPurchasePlanMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsPurchasePlanMember" xlink:label="loc_AIMDirectorsPurchasePlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMDirectorsPurchasePlanMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>aim-20231231_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:to="AIM_SeriesAJuniorParticipatingPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember_lbl" xml:lang="en-US">Series A Junior Participating Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="AIM_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesBConvertiblePreferredStockMember" xlink:to="AIM_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PatentAndTrademarkRightsMember" xlink:label="AIM_PatentAndTrademarkRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PatentAndTrademarkRightsMember" xlink:to="AIM_PatentAndTrademarkRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PatentAndTrademarkRightsMember_lbl" xml:lang="en-US">Patent and Trademark Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MutualFundsMember" xlink:label="AIM_MutualFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MutualFundsMember" xlink:to="AIM_MutualFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MutualFundsMember_lbl" xml:lang="en-US">Mutual Funds[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_BoardMember" xlink:label="AIM_BoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_BoardMember" xlink:to="AIM_BoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_BoardMember_lbl" xml:lang="en-US">Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightsMember" xlink:label="us-gaap_RightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightsMember" xlink:to="us-gaap_RightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightsMember_lbl" xml:lang="en-US">Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="AIM_DirectorsOfficersAndEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsOfficersAndEmployeesMember" xlink:to="AIM_DirectorsOfficersAndEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DirectorsOfficersAndEmployeesMember_lbl" xml:lang="en-US">Directors, Officers and Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="AIM_AllianceGlobalPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AllianceGlobalPartnersLLCMember" xlink:to="AIM_AllianceGlobalPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AllianceGlobalPartnersLLCMember_lbl" xml:lang="en-US">Alliance Global Partners, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantsMember" xlink:label="AIM_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantsMember" xlink:to="AIM_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RepresentativeWarrantsMember" xlink:label="AIM_RepresentativeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RepresentativeWarrantsMember" xlink:to="AIM_RepresentativeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreFundedWarrantsMember" xlink:label="AIM_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreFundedWarrantsMember" xlink:to="AIM_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MaximGroupLLCMember" xlink:label="AIM_MaximGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MaximGroupLLCMember" xlink:to="AIM_MaximGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MaximGroupLLCMember_lbl" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlanTwoThousandNineMember" xlink:label="AIM_EquityIncentivePlanTwoThousandNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlanTwoThousandNineMember" xlink:to="AIM_EquityIncentivePlanTwoThousandNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquityIncentivePlanTwoThousandNineMember_lbl" xml:lang="en-US">Equity Incentive Plan 2009 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesMember" xlink:label="AIM_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmployeesMember" xlink:to="AIM_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NonEmployeeMember" xlink:label="AIM_NonEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NonEmployeeMember" xlink:to="AIM_NonEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NonEmployeeMember_lbl" xml:lang="en-US">Non-Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlansTwoThousandAndEighteenMember" xlink:label="AIM_EquityIncentivePlansTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlansTwoThousandAndEighteenMember" xlink:to="AIM_EquityIncentivePlansTwoThousandAndEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquityIncentivePlansTwoThousandAndEighteenMember_lbl" xml:lang="en-US">2018 Equity Incentive Plans [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2009Member" xlink:label="AIM_EquityIncentivePlans2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlans2009Member" xlink:to="AIM_EquityIncentivePlans2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquityIncentivePlans2009Member_lbl" xml:lang="en-US">Equity Incentive Plans 2009 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2018Member" xlink:label="AIM_EquityIncentivePlans2018Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlans2018Member" xlink:to="AIM_EquityIncentivePlans2018Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquityIncentivePlans2018Member_lbl" xml:lang="en-US">Equity Incentive Plans 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ClinicalStudiesMember" xlink:label="AIM_ClinicalStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClinicalStudiesMember" xlink:to="AIM_ClinicalStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="AIM_ManufacturingAndEngineeringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ManufacturingAndEngineeringMember" xlink:to="AIM_ManufacturingAndEngineeringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ManufacturingAndEngineeringMember_lbl" xml:lang="en-US">Manufacturing and Engineering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_QualityControlMember" xlink:label="AIM_QualityControlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_QualityControlMember" xlink:to="AIM_QualityControlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_QualityControlMember_lbl" xml:lang="en-US">Quality Control [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RegulatoryMember" xlink:label="AIM_RegulatoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RegulatoryMember" xlink:to="AIM_RegulatoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_RegulatoryMember_lbl" xml:lang="en-US">Regulatory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="AIM_AmarexClinicalResearchLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmarexClinicalResearchLLCMember" xlink:to="AIM_AmarexClinicalResearchLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AmarexClinicalResearchLLCMember_lbl" xml:lang="en-US">Amarex Clinical Research LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PancreaticCancerMember" xlink:label="AIM_PancreaticCancerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PancreaticCancerMember" xlink:to="AIM_PancreaticCancerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PancreaticCancerMember_lbl" xml:lang="en-US">Pancreatic Cancer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PostCOVIDMember" xlink:label="AIM_PostCOVIDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PostCOVIDMember" xlink:to="AIM_PostCOVIDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PostCOVIDMember_lbl" xml:lang="en-US">Post COVID [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JubilantHollisterStierMember" xlink:label="AIM_JubilantHollisterStierMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JubilantHollisterStierMember" xlink:to="AIM_JubilantHollisterStierMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_JubilantHollisterStierMember_lbl" xml:lang="en-US">Jubilant HollisterStier [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchConsultingAndSupplyAgreementsMember" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsMember" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsMember_lbl" xml:lang="en-US">Research Consulting and Supply Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PharmaSolutionsMember" xlink:label="AIM_PharmaSolutionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PharmaSolutionsMember" xlink:to="AIM_PharmaSolutionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PharmaSolutionsMember_lbl" xml:lang="en-US">Pharma Solutions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:to="AIM_MasterServiceAgreementAndQualityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember_lbl" xml:lang="en-US">Master Service Agreement and Quality Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ErasmusMember" xlink:label="AIM_ErasmusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ErasmusMember" xlink:to="AIM_ErasmusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ErasmusMember_lbl" xml:lang="en-US">Erasmus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="AIM_JointClinicalStudyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JointClinicalStudyAgreementMember" xlink:to="AIM_JointClinicalStudyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_JointClinicalStudyAgreementMember_lbl" xml:lang="en-US">Joint Clinical Study Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JjointClinicalStudyAgreementMember" xlink:label="AIM_JjointClinicalStudyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JjointClinicalStudyAgreementMember" xlink:to="AIM_JjointClinicalStudyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_JjointClinicalStudyAgreementMember_lbl" xml:lang="en-US">Jjoint Clinical Study Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AzenovaSalesInternationalMember" xlink:label="AIM_AzenovaSalesInternationalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AzenovaSalesInternationalMember" xlink:to="AIM_AzenovaSalesInternationalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AzenovaSalesInternationalMember_lbl" xml:lang="en-US">Azenova Sales International [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AlcamiMember" xlink:label="AIM_AlcamiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AlcamiMember" xlink:to="AIM_AlcamiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AlcamiMember_lbl" xml:lang="en-US">Alcami [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FourZeroOnekPlanMember" xlink:label="AIM_FourZeroOnekPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FourZeroOnekPlanMember" xlink:to="AIM_FourZeroOnekPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FourZeroOnekPlanMember_lbl" xml:lang="en-US">401(k) Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentContractualAgreementsMember" xlink:label="AIM_EmploymentContractualAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentContractualAgreementsMember" xlink:to="AIM_EmploymentContractualAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EmploymentContractualAgreementsMember_lbl" xml:lang="en-US">Employment Contractual Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NamedExecutiveOfficersMember" xlink:label="AIM_NamedExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NamedExecutiveOfficersMember" xlink:to="AIM_NamedExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NamedExecutiveOfficersMember_lbl" xml:lang="en-US">Named Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentAgreementMember" xlink:label="AIM_EmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentAgreementMember" xlink:to="AIM_EmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EmploymentAgreementMember_lbl" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_StockOptionsMember" xlink:label="AIM_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockOptionsMember" xlink:to="AIM_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ThomasKEquelsMember" xlink:label="AIM_ThomasKEquelsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ThomasKEquelsMember" xlink:to="AIM_ThomasKEquelsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ThomasKEquelsMember_lbl" xml:lang="en-US">Thomas K. Equels [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PeterRodinoMember" xlink:label="AIM_PeterRodinoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PeterRodinoMember" xlink:to="AIM_PeterRodinoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PeterRodinoMember_lbl" xml:lang="en-US">Peter Rodino [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsandRodinoMember" xlink:label="AIM_EquelsandRodinoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquelsandRodinoMember" xlink:to="AIM_EquelsandRodinoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquelsandRodinoMember_lbl" xml:lang="en-US">Equels and Rodino [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EllenLintalMember" xlink:label="AIM_EllenLintalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EllenLintalMember" xlink:to="AIM_EllenLintalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EllenLintalMember_lbl" xml:lang="en-US">Ellen Lintal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsRodinoAndFormerOfficerLintalMember" xlink:label="AIM_EquelsRodinoAndFormerOfficerLintalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquelsRodinoAndFormerOfficerLintalMember" xlink:to="AIM_EquelsRodinoAndFormerOfficerLintalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquelsRodinoAndFormerOfficerLintalMember_lbl" xml:lang="en-US">Equels, Rodino and Former Officer Lintal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="us-gaap_NewJerseyDivisionOfTaxationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="us-gaap_NewJerseyDivisionOfTaxationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewJerseyDivisionOfTaxationMember_lbl" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="country_BE" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US">BELGIUM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ" xlink:label="stpr_NJ" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_NJ" xlink:to="stpr_NJ_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_NJ_lbl" xml:lang="en-US">NEW JERSEY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MarchTwoThousandNineteenWarrantsMember" xlink:label="AIM_MarchTwoThousandNineteenWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MarchTwoThousandNineteenWarrantsMember" xlink:to="AIM_MarchTwoThousandNineteenWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MarchTwoThousandNineteenWarrantsMember_lbl" xml:lang="en-US">March 2019 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentAxis" xlink:label="AIM_DebtIstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DebtIstrumentAxis" xlink:to="AIM_DebtIstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DebtIstrumentAxis_lbl" xml:lang="en-US">Debt Istrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnsecuredPromissoryNoteMember" xlink:label="AIM_UnsecuredPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnsecuredPromissoryNoteMember" xlink:to="AIM_UnsecuredPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_UnsecuredPromissoryNoteMember_lbl" xml:lang="en-US">Unsecured Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesPurchasePlanMember" xlink:label="AIM_EmployeesPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmployeesPurchasePlanMember" xlink:to="AIM_EmployeesPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EmployeesPurchasePlanMember_lbl" xml:lang="en-US">Employees Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsPurchasePlanMember" xlink:label="AIM_DirectorsPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsPurchasePlanMember" xlink:to="AIM_DirectorsPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DirectorsPurchasePlanMember_lbl" xml:lang="en-US">Directors Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Funds receivable from New Jersey net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent and trademark rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liability:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 8, 10, 11, 16)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 49,102,484 and 48,084,287 (including 701,667 and 694,324 of unvested stock awards) as of December 31, 2023 and 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="AIM_PreferredStockStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreferredStockStatedValuePerShare" xlink:to="AIM_PreferredStockStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Clinical treatment programs &#8211; US</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingCosts" xlink:label="us-gaap_ManufacturingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingCosts" xlink:to="us-gaap_ManufacturingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingCosts_lbl" xml:lang="en-US">Production costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total Costs and Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Gain (loss) on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest and other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Redeemable warrants valuation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_lbl" xml:lang="en-US">Gain from sale of income tax operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Weighted average shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issuance, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issuance, net of costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Equity-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B preferred shares converted to common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B preferred shares converted to common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversion" xlink:label="AIM_CashlessWarrantConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CashlessWarrantConversion" xlink:to="AIM_CashlessWarrantConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_CashlessWarrantConversion_lbl" xml:lang="en-US">Cashless warrant conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversionShares" xlink:label="AIM_CashlessWarrantConversionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CashlessWarrantConversionShares" xlink:to="AIM_CashlessWarrantConversionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_CashlessWarrantConversionShares_lbl" xml:lang="en-US">Cashless warrant conversion, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Redeemable warrants valuation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AbandonmentOfPatentAndTrademarkRights" xlink:to="AIM_AbandonmentOfPatentAndTrademarkRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights_lbl" xml:lang="en-US">Abandonment and expiration of patents and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patent and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NoncashLeaseExpense" xlink:label="AIM_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NoncashLeaseExpense" xlink:to="AIM_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:label="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:to="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_lbl" xml:lang="en-US">Loss from sale of income tax operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Loss (gain) on sale of marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Funds receivable from New Jersey operating loss sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xml:lang="en-US">Proceeds from sale of marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of patent and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnrealizedGainLossOnMarketableInvestments" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnrealizedGainLossOnMarketableInvestments" xlink:to="AIM_UnrealizedGainLossOnMarketableInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments_lbl" xml:lang="en-US">Unrealized gain (loss) on marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ConversionOfSeriesBPreferred" xlink:label="AIM_ConversionOfSeriesBPreferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfSeriesBPreferred" xlink:to="AIM_ConversionOfSeriesBPreferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ConversionOfSeriesBPreferred_lbl" xml:lang="en-US">Conversion of Series B preferred</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" xlink:label="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" xlink:to="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset_lbl" xml:lang="en-US">Operating lease liability arising from obtaining right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Description of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Marketable Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Patents and Trademark Rights, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment and Related Information</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract_lbl" xml:lang="en-US">Research Consulting And Supply Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_lbl" xml:lang="en-US">Research, Consulting and Supply Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">401(k) Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureEmploymentAgreementsAbstract" xlink:label="AIM_DisclosureEmploymentAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DisclosureEmploymentAgreementsAbstract" xlink:to="AIM_DisclosureEmploymentAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DisclosureEmploymentAgreementsAbstract_lbl" xml:lang="en-US">Employment Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentAgreementsTextBlock" xlink:label="AIM_EmploymentAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentAgreementsTextBlock" xlink:to="AIM_EmploymentAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EmploymentAgreementsTextBlock_lbl" xml:lang="en-US">Employment Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="AIM_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DisclosureLeasesAbstract" xlink:to="AIM_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes (FASB ASC 740 Income Taxes)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Certain Relationships and Related Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">Concentrations of Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patent and Trademark Rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Accounting for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards and Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Common Stock Per Share Calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="us-gaap_InvestmentIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeTextBlock" xlink:to="us-gaap_InvestmentIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeTextBlock_lbl" xml:lang="en-US">Schedule of Available of Sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xml:lang="en-US">Schedule of Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Patent and Trademark Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Patents, Trademark Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortization of Patents and Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Vest Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ScheduleOfOperatingLeaseTableTextBlock" xlink:label="AIM_ScheduleOfOperatingLeaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfOperatingLeaseTableTextBlock" xlink:to="AIM_ScheduleOfOperatingLeaseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ScheduleOfOperatingLeaseTableTextBlock_lbl" xml:lang="en-US">[custom:ScheduleOfOperatingLeaseTableTextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Future Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Net Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Tax Rate and Statutory Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions to Estimate Fair Value of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" xlink:label="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" xlink:to="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Range of Probabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture, fixture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federlly insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives of patent and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Equivalent Common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-Term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xml:lang="en-US">Net losses recognized during the period on equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Less: Net gains and losses recognized during the period on equity securities sold during the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net carrying value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FinitelivedIntangibleAssetsAbandonments" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_lbl" xml:lang="en-US">Abandonments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_2_lbl" xml:lang="en-US">Finite lived intangible assets, estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AccruedClinicalTrialExpensesCurrent" xlink:to="AIM_AccruedClinicalTrialExpensesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent_lbl" xml:lang="en-US">Clinical trial expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:label="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:to="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_lbl" xml:lang="en-US">Weighted average grant date fair value for options issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Option price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_lbl" xml:lang="en-US">Option price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Option price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_lbl" xml:lang="en-US">Option price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, ending of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Option price exercisable, end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options exercisable, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_lbl" xml:lang="en-US">Option price exercisable, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years) Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years) Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options,expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Expected to Vest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_lbl" xml:lang="en-US">Grants in period, weighted average grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of Options, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:label="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:to="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Number of Options Unvested, brginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Unvested, beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Average Remaining Contractual Term (years) Unvested, End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Unvested, beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Average Remaining Contractual Term granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Average Remaining Contractual Term vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_lbl" xml:lang="en-US">Number of Options, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Number of Options Unvested, End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Unvested, Ending of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Unvested, End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_lbl" xml:lang="en-US">Warrant price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_lbl" xml:lang="en-US">Warrant price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_lbl" xml:lang="en-US">Warrant price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_lbl" xml:lang="en-US">Warrant price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_2_lbl" xml:lang="en-US">Warrant price outstanding, end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_2_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_lbl" xml:lang="en-US">Number of options outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_lbl" xml:lang="en-US">Warrant price exercisable, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Weighted average exercise price outstanding, beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_lbl" xml:lang="en-US">Weighted average remaining contracted term (years) outstanding, ending of year</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_lbl" xml:lang="en-US">Years exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:to="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_lbl" xml:lang="en-US">Years exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred stock conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FaceValueOfStock" xlink:label="AIM_FaceValueOfStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FaceValueOfStock" xlink:to="AIM_FaceValueOfStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FaceValueOfStock_lbl" xml:lang="en-US">Preferred stock face value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Number of shares to be issued on conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:to="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_lbl" xml:lang="en-US">Common stock specific limitations and restrictions on usage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Common stock shares issued, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised aggregate</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfOutstandingStock" xlink:label="AIM_PercentageOfOutstandingStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfOutstandingStock" xlink:to="AIM_PercentageOfOutstandingStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PercentageOfOutstandingStock_lbl" xml:lang="en-US">Percentage of outstanding stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Pre-funded warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Warrant gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantModifications" xlink:label="AIM_WarrantModifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantModifications" xlink:to="AIM_WarrantModifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WarrantModifications_lbl" xml:lang="en-US">Warrant modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Transaction fee rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of common stock reserved for potential issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based payment award options vested in period fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized stock-based compensation cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_3_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense excluding acquired in process cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="us-gaap_DevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentCosts_lbl" xml:lang="en-US">Development cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:to="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_lbl" xml:lang="en-US">Estimated lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Invigilators cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnitsManufactured" xlink:label="AIM_UnitsManufactured" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnitsManufactured" xlink:to="AIM_UnitsManufactured_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_UnitsManufactured_lbl" xml:lang="en-US">Number of units manufactured</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NumberOfVials" xlink:label="AIM_NumberOfVials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NumberOfVials" xlink:to="AIM_NumberOfVials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NumberOfVials_lbl" xml:lang="en-US">Additional number of vials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessAndRawMaterials_lbl" xml:lang="en-US">Inventory work in process and raw materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Stock options, aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Stock options, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Percentage of maximum annual contribution per employee, as percentage of their annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred compensation arrangementl, cash awards granted, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_Bonus" xlink:label="AIM_Bonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_Bonus" xlink:to="AIM_Bonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_Bonus_lbl" xml:lang="en-US">Bonus</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Options term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Stock options exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term and variable lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DisclosureLeasesAbstract" xlink:to="AIM_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Future Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Operating lease, remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and Development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:label="AIM_DeferredTaxAssetsAmortizationAndDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:to="AIM_DeferredTaxAssetsAmortizationAndDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DeferredTaxAssetsAmortizationAndDepreciation_lbl" xml:lang="en-US">Amortization &amp; depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsRightOfUseAssets" xlink:label="AIM_DeferredTaxAssetsRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DeferredTaxAssetsRightOfUseAssets" xlink:to="AIM_DeferredTaxAssetsRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DeferredTaxAssetsRightOfUseAssets_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Pre Tax Book Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Other Perms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Other Perms</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationForeignIncomeRTP" xlink:label="AIM_IncomeTaxReconciliationForeignIncomeRTP" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationForeignIncomeRTP" xlink:to="AIM_IncomeTaxReconciliationForeignIncomeRTP_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_IncomeTaxReconciliationForeignIncomeRTP_lbl" xml:lang="en-US">RTP</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_lbl" xml:lang="en-US">RTP</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Income Tax Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Income Tax Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US">State Rate Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_lbl" xml:lang="en-US">State Rate Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:label="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:to="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_lbl" xml:lang="en-US">State NOL</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_lbl" xml:lang="en-US">State NOL</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:label="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:to="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_lbl" xml:lang="en-US">NJ NOL True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_lbl" xml:lang="en-US">NJ NOL True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock Compensation True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock Compensation True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:label="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:to="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets_lbl" xml:lang="en-US">Fixed Assets True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_lbl" xml:lang="en-US">Fixed Assets True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:label="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:to="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_lbl" xml:lang="en-US">NOL Refund VA True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_lbl" xml:lang="en-US">NOL Refund VA True Up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_lbl" xml:lang="en-US">Statutory Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Statutory Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperatingLossCarryforwardsWithNoExpirationDate" xlink:label="AIM_OperatingLossCarryforwardsWithNoExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLossCarryforwardsWithNoExpirationDate" xlink:to="AIM_OperatingLossCarryforwardsWithNoExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_OperatingLossCarryforwardsWithNoExpirationDate_lbl" xml:lang="en-US">Operating loss carry forwards with no expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Effective income tax rate reconciliation, tax credit, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalent-Marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Underlying price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfProbability" xlink:label="AIM_PercentageOfProbability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfProbability" xlink:to="AIM_PercentageOfProbability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PercentageOfProbability_lbl" xml:lang="en-US">Percentage of probability</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FairValueMeasurementInputPercentage" xlink:label="AIM_FairValueMeasurementInputPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FairValueMeasurementInputPercentage" xlink:to="AIM_FairValueMeasurementInputPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FairValueMeasurementInputPercentage_lbl" xml:lang="en-US">Fair value measurement, input percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:label="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:to="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage_lbl" xml:lang="en-US">Floor rate used as proxy for future volatility percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DebtIstrumentAxis" xlink:to="AIM_DebtIstrumentAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_DebtIstrumentAxis_2_lbl" xml:lang="en-US">DebtIstrumentAxis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Net Proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Purchase commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:to="AIM_SeriesAJuniorParticipatingPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember_doc" xml:lang="en-US">Series A Junior Participating Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesBConvertiblePreferredStockMember" xlink:to="AIM_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_doc" xml:lang="en-US">Gain from sale of income tax operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CashlessWarrantConversion" xlink:to="AIM_CashlessWarrantConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_CashlessWarrantConversion_doc" xml:lang="en-US">Cashless warrant conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CashlessWarrantConversionShares" xlink:to="AIM_CashlessWarrantConversionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_CashlessWarrantConversionShares_doc" xml:lang="en-US">Cashless warrant conversion shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AbandonmentOfPatentAndTrademarkRights" xlink:to="AIM_AbandonmentOfPatentAndTrademarkRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights_doc" xml:lang="en-US">Abandonment of patent and trademark rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NoncashLeaseExpense" xlink:to="AIM_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NoncashLeaseExpense_doc" xml:lang="en-US">Non-cash lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:to="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_doc" xml:lang="en-US">Loss gain from sale of income tax operating losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnrealizedGainLossOnMarketableInvestments" xlink:to="AIM_UnrealizedGainLossOnMarketableInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments_doc" xml:lang="en-US">Unrealized gain loss on marketable investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfSeriesBPreferred" xlink:to="AIM_ConversionOfSeriesBPreferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ConversionOfSeriesBPreferred_doc" xml:lang="en-US">Conversion of Series B preferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_doc" xml:lang="en-US">Research, Consulting and Supply Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PatentAndTrademarkRightsMember" xlink:to="AIM_PatentAndTrademarkRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PatentAndTrademarkRightsMember_doc" xml:lang="en-US">Patent and Trademark Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmarexClinicalResearchLLCMember" xlink:to="AIM_AmarexClinicalResearchLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AmarexClinicalResearchLLCMember_doc" xml:lang="en-US">Amarex Clinical Research LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MutualFundsMember" xlink:to="AIM_MutualFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MutualFundsMember_doc" xml:lang="en-US">Mutual Funds[Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClinicalStudiesMember" xlink:to="AIM_ClinicalStudiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClinicalStudiesMember_doc" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ManufacturingAndEngineeringMember" xlink:to="AIM_ManufacturingAndEngineeringMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ManufacturingAndEngineeringMember_doc" xml:lang="en-US">Manufacturing and Engineering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_InternalResearchMember" xlink:label="AIM_InternalResearchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_InternalResearchMember" xlink:to="AIM_InternalResearchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_InternalResearchMember_doc" xml:lang="en-US">Internal Research [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:to="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_doc" xml:lang="en-US">Research and development expense cost estimated lives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PancreaticCancerMember" xlink:to="AIM_PancreaticCancerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PancreaticCancerMember_doc" xml:lang="en-US">Pancreatic Cancer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_doc" xml:lang="en-US">Finite lived intangible assets abandonments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PostCOVIDMember" xlink:to="AIM_PostCOVIDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PostCOVIDMember_doc" xml:lang="en-US">Post COVID [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnitsManufactured" xlink:to="AIM_UnitsManufactured_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_UnitsManufactured_doc" xml:lang="en-US">Units manufactured.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JubilantHollisterStierMember" xlink:to="AIM_JubilantHollisterStierMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_JubilantHollisterStierMember_doc" xml:lang="en-US">Jubilant HollisterStier [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsMember" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsMember_doc" xml:lang="en-US">Research Consulting and Supply Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NumberOfVials" xlink:to="AIM_NumberOfVials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NumberOfVials_doc" xml:lang="en-US">Number of vials.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PharmaSolutionsMember" xlink:to="AIM_PharmaSolutionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PharmaSolutionsMember_doc" xml:lang="en-US">Pharma Solutions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:to="AIM_MasterServiceAgreementAndQualityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember_doc" xml:lang="en-US">Master Service Agreement And Quality Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ErasmusMember" xlink:to="AIM_ErasmusMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ErasmusMember_doc" xml:lang="en-US">Erasmus [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JjointClinicalStudyAgreementMember" xlink:to="AIM_JjointClinicalStudyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_JjointClinicalStudyAgreementMember_doc" xml:lang="en-US">Jjoint Clinical Study Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AccruedClinicalTrialExpensesCurrent" xlink:to="AIM_AccruedClinicalTrialExpensesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent_doc" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AlcamiMember" xlink:to="AIM_AlcamiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AlcamiMember_doc" xml:lang="en-US">Alcami [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_BoardMember" xlink:to="AIM_BoardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_BoardMember_doc" xml:lang="en-US">Board [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AzenovaSalesInternationalMember" xlink:to="AIM_AzenovaSalesInternationalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AzenovaSalesInternationalMember_doc" xml:lang="en-US">Azenova Sales International [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FaceValueOfStock" xlink:to="AIM_FaceValueOfStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FaceValueOfStock_doc" xml:lang="en-US">Face value of stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentAgreementsTextBlock" xlink:to="AIM_EmploymentAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EmploymentAgreementsTextBlock_doc" xml:lang="en-US">Employment Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentContractualAgreementsMember" xlink:to="AIM_EmploymentContractualAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EmploymentContractualAgreementsMember_doc" xml:lang="en-US">Employment Contractual Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NamedExecutiveOfficersMember" xlink:to="AIM_NamedExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NamedExecutiveOfficersMember_doc" xml:lang="en-US">Named Executive Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_Bonus" xlink:to="AIM_Bonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_Bonus_doc" xml:lang="en-US">Bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:to="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_doc" xml:lang="en-US">Common stock shares with limitations and restrictions on usage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentAgreementMember" xlink:to="AIM_EmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EmploymentAgreementMember_doc" xml:lang="en-US">Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockOptionsMember" xlink:to="AIM_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ThomasKEquelsMember" xlink:to="AIM_ThomasKEquelsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ThomasKEquelsMember_doc" xml:lang="en-US">Thomas K. Equels [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsOfficersAndEmployeesMember" xlink:to="AIM_DirectorsOfficersAndEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_DirectorsOfficersAndEmployeesMember_doc" xml:lang="en-US">Directors, Officers and Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PeterRodinoMember" xlink:to="AIM_PeterRodinoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PeterRodinoMember_doc" xml:lang="en-US">Peter Rodino [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AllianceGlobalPartnersLLCMember" xlink:to="AIM_AllianceGlobalPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AllianceGlobalPartnersLLCMember_doc" xml:lang="en-US">Alliance Global Partners, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantsMember" xlink:to="AIM_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RepresentativeWarrantsMember" xlink:to="AIM_RepresentativeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_RepresentativeWarrantsMember_doc" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreFundedWarrantsMember" xlink:to="AIM_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfOutstandingStock" xlink:to="AIM_PercentageOfOutstandingStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PercentageOfOutstandingStock_doc" xml:lang="en-US">Percentage of outstanding stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantModifications" xlink:to="AIM_WarrantModifications_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WarrantModifications_doc" xml:lang="en-US">Warrant modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MaximGroupLLCMember" xlink:to="AIM_MaximGroupLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MaximGroupLLCMember_doc" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlanTwoThousandNineMember" xlink:to="AIM_EquityIncentivePlanTwoThousandNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquityIncentivePlanTwoThousandNineMember_doc" xml:lang="en-US">Equity Incentive Plan 2009 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:to="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_doc" xml:lang="en-US">Weighted average grant date fair value for options and equity warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlans2009Member" xlink:to="AIM_EquityIncentivePlans2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquityIncentivePlans2009Member_doc" xml:lang="en-US">Equity Incentive Plans 2009 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock" xlink:label="AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock" xlink:to="AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfAIMRecognizedCashFlowsAssociatedWithOperatingLeaseTableTextBlock_doc" xml:lang="en-US">Schedule of AIM Recognized Cash Flows Associated with Operating Lease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by sharebased payment value of award options forfeitures in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment value of award options exercisedin period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Sharebased compensation arrangement by share-based payment award options granted weighted average remaining contractual term 2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfOperatingLeaseTableTextBlock" xlink:to="AIM_ScheduleOfOperatingLeaseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfOperatingLeaseTableTextBlock_doc" xml:lang="en-US">Schedule of Operating Lease [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_doc" xml:lang="en-US">Price at which option holders acquired shares when converting their stock options into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLossCarryforwardsWithNoExpirationDate" xlink:to="AIM_OperatingLossCarryforwardsWithNoExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_OperatingLossCarryforwardsWithNoExpirationDate_doc" xml:lang="en-US">Net operating loss carryforwards with no expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:to="AIM_DeferredTaxAssetsAmortizationAndDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_DeferredTaxAssetsAmortizationAndDepreciation_doc" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp; depreciation expensed in connection with a business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DeferredTaxAssetsRightOfUseAssets" xlink:to="AIM_DeferredTaxAssetsRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_DeferredTaxAssetsRightOfUseAssets_doc" xml:lang="en-US">Deferred tax assets right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationOther_doc" xml:lang="en-US">Effective income tax rate reconciliation other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_doc" xml:lang="en-US">Effective income tax rate reconciliation foreign income tax rate valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment value of award options grants in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlans2018Member" xlink:to="AIM_EquityIncentivePlans2018Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquityIncentivePlans2018Member_doc" xml:lang="en-US">Equity Incentive Plans 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MarchTwoThousandNineteenWarrantsMember" xlink:to="AIM_MarchTwoThousandNineteenWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MarchTwoThousandNineteenWarrantsMember_doc" xml:lang="en-US">March 2019 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FairValueMeasurementInputPercentage" xlink:to="AIM_FairValueMeasurementInputPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FairValueMeasurementInputPercentage_doc" xml:lang="en-US">Fair value measurement, input Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" xlink:to="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Range of Probabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfProbability" xlink:to="AIM_PercentageOfProbability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PercentageOfProbability_doc" xml:lang="en-US">Percentage of probability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:to="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage_doc" xml:lang="en-US">Floor rate used as proxy for future volatility percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityIncentivePlansTwoThousandAndEighteenMember" xlink:to="AIM_EquityIncentivePlansTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquityIncentivePlansTwoThousandAndEighteenMember_doc" xml:lang="en-US">2018 Equity Incentive Plans [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmployeesMember" xlink:to="AIM_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options nonvested weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options granted weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by share-based payment award options vested weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_doc" xml:lang="en-US">Sharebased bompensation arrangement by share-based payment award options nonvested options expired number of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options nonvested options expired weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_doc" xml:lang="en-US">Grants in period, weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NonEmployeeMember" xlink:to="AIM_NonEmployeeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NonEmployeeMember_doc" xml:lang="en-US">Non-Employee [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_doc" xml:lang="en-US">Number of options exercisable, end of year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_doc" xml:lang="en-US">Weighted average remaining contracted term (years) outstanding, ending of year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_doc" xml:lang="en-US">Description of warrants outstanding years exercisable during the reporting period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_doc" xml:lang="en-US">Warrant price outstanding, including both vested and non-vested options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_doc" xml:lang="en-US">Gross warrant price granted during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_doc" xml:lang="en-US">Warrant price, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_doc" xml:lang="en-US">Gross warrant price exercised during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_doc" xml:lang="en-US">Gross warrant price exercisable during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_doc" xml:lang="en-US">Weighted average exercise price outstanding, year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_doc" xml:lang="en-US">Weighted average exercise price, granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_doc" xml:lang="en-US">Weighted average exercise price, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_doc" xml:lang="en-US">Weighted average exercise price, exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Weighted average exercise price exercisable, end of year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:to="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_doc" xml:lang="en-US">Weighted based compensation arrangement by sharebased payment award options exercisable weighted average remaining contractual term year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:to="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_doc" xml:lang="en-US">Share-based compensation arrangements by share-based payment award options exercises in period weighted average expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FourZeroOnekPlanMember" xlink:to="AIM_FourZeroOnekPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FourZeroOnekPlanMember_doc" xml:lang="en-US">401(k) Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquelsandRodinoMember" xlink:to="AIM_EquelsandRodinoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquelsandRodinoMember_doc" xml:lang="en-US">Equels and Rodino [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquelsRodinoAndFormerOfficerLintalMember" xlink:to="AIM_EquelsRodinoAndFormerOfficerLintalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquelsRodinoAndFormerOfficerLintalMember_doc" xml:lang="en-US">Equels, Rodino and Former Officer Lintal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EllenLintalMember" xlink:to="AIM_EllenLintalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EllenLintalMember_doc" xml:lang="en-US">Ellen Lintal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreferredStockStatedValuePerShare" xlink:to="AIM_PreferredStockStatedValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PreferredStockStatedValuePerShare_doc" xml:lang="en-US">Preferred stock stated value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment value of award options granted in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options expired weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JointClinicalStudyAgreementMember" xlink:to="AIM_JointClinicalStudyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_JointClinicalStudyAgreementMember_doc" xml:lang="en-US">Joint Clinical Study Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" xlink:to="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset_doc" xml:lang="en-US">Operating lease liability arising from obtaining right of use asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_doc" xml:lang="en-US">Operation lease right of use asset accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:to="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_doc" xml:lang="en-US">Income tax reconciliation nondeductible state net operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_doc" xml:lang="en-US">Effective income tax rate reconciliation nondeductible state net operating loss percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:to="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_doc" xml:lang="en-US">Income tax reconciliation nondeductible new jersey state net operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_doc" xml:lang="en-US">Effective income tax rate reconciliation nondeductible new jersey state net operating loss percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:to="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets_doc" xml:lang="en-US">Income tax reconciliation nondeductible expense fixed assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_doc" xml:lang="en-US">Effective income tax rate reconciliation nondeductible expense fixed assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:to="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_doc" xml:lang="en-US">Income tax reconciliation net operating loss refund valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_IncomeTaxReconciliationForeignIncomeRTP" xlink:to="AIM_IncomeTaxReconciliationForeignIncomeRTP_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_IncomeTaxReconciliationForeignIncomeRTP_doc" xml:lang="en-US">Income tax reconciliation foreign income RTP.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_doc" xml:lang="en-US">Effective income tax rate reconciliation rtp percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmployeesPurchasePlanMember" xlink:to="AIM_EmployeesPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EmployeesPurchasePlanMember_doc" xml:lang="en-US">Employees Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsPurchasePlanMember" xlink:to="AIM_DirectorsPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_DirectorsPurchasePlanMember_doc" xml:lang="en-US">Directors Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_doc" xml:lang="en-US">Effective income tax rate reconciliation net operating loss refund valuation allowance percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_QualityControlMember" xlink:to="AIM_QualityControlMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_QualityControlMember_doc" xml:lang="en-US">Quality Control [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RegulatoryMember" xlink:to="AIM_RegulatoryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_RegulatoryMember_doc" xml:lang="en-US">Regulatory [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_3_lbl" xml:lang="en-US">GainFromSaleOfIncomeTaxOperatingLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:to="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_LossGainFromSaleOfIncomeTaxOperatingLosses_3_lbl" xml:lang="en-US">LossGainFromSaleOfIncomeTaxOperatingLosses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xml:lang="en-US">Marketable Security, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EmploymentAgreementsTextBlock" xlink:to="AIM_EmploymentAgreementsTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EmploymentAgreementsTextBlock_3_lbl" xml:lang="en-US">EmploymentAgreementsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_2_lbl" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_2_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_3_lbl" xml:lang="en-US">FinitelivedIntangibleAssetsAbandonments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:to="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_4_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_3_lbl" xml:lang="en-US">Number of options exercisable, end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_3_lbl" xml:lang="en-US">Weighted average exercise price exercisable, end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:to="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_3_lbl" xml:lang="en-US">WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xml:lang="en-US">OperationLeaseRightOfUseAssetAccumulatedAmortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationRTPPercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationOther_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationOther_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationOther</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:to="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>aim-20231231_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="aim-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:href="aim-20231231.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestments" xlink:href="aim-20231231.xsd#MarketableInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlan" xlink:href="aim-20231231.xsd#KPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreements" xlink:href="aim-20231231.xsd#EmploymentAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:href="aim-20231231.xsd#CertainRelationshipsAndRelatedTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:href="aim-20231231.xsd#ConcentrationsOfRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20231231.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Contingencies" xlink:href="aim-20231231.xsd#Contingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:href="aim-20231231.xsd#MarketableInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityTables" xlink:href="aim-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20231231.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="aim-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:href="aim-20231231.xsd#ScheduleOfAvailableOfSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:href="aim-20231231.xsd#MarketableInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20231231.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20231231.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20231231.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfVestStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20231231.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="aim-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:href="aim-20231231.xsd#SegmentAndRelatedInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:href="aim-20231231.xsd#KPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:href="aim-20231231.xsd#EmploymentAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20231231.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20231231.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:href="aim-20231231.xsd#ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:href="aim-20231231.xsd#IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:href="aim-20231231.xsd#ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:href="aim-20231231.xsd#ScheduleOfRangeOfProbabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20231231.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManufacturingCosts" xlink:label="loc_us-gaapManufacturingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapManufacturingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversion" xlink:label="loc_AIMCashlessWarrantConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMCashlessWarrantConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CashlessWarrantConversionShares" xlink:label="loc_AIMCashlessWarrantConversionShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMCashlessWarrantConversionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="loc_AIMAbandonmentOfPatentAndTrademarkRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMAbandonmentOfPatentAndTrademarkRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NoncashLeaseExpense" xlink:label="loc_AIMNoncashLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LossGainFromSaleOfIncomeTaxOperatingLosses" xlink:label="loc_AIMLossGainFromSaleOfIncomeTaxOperatingLosses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMLossGainFromSaleOfIncomeTaxOperatingLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="loc_us-gaapProceedsFromSaleOfInvestmentProjects" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfInvestmentProjects" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnrealizedGainLossOnMarketableInvestments" xlink:label="loc_AIMUnrealizedGainLossOnMarketableInvestments" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMUnrealizedGainLossOnMarketableInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ConversionOfSeriesBPreferred" xlink:label="loc_AIMConversionOfSeriesBPreferred" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMConversionOfSeriesBPreferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" xlink:label="loc_AIMOperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMOperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - Description of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestments" xlink:title="00000009 - Disclosure - Marketable Investments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000010 - Disclosure - Patents and Trademark Rights, Net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000011 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformation" xlink:title="00000013 - Disclosure - Segment and Related Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000014 - Disclosure - Research, Consulting and Supply Agreements">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:label="loc_AIMResearchConsultingAndSupplyAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="loc_AIMResearchConsultingAndSupplyAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlan" xlink:title="00000015 - Disclosure - 401(k) Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreements" xlink:title="00000016 - Disclosure - Employment Agreements">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureEmploymentAgreementsAbstract" xlink:label="loc_AIMDisclosureEmploymentAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentAgreementsTextBlock" xlink:label="loc_AIMEmploymentAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureEmploymentAgreementsAbstract" xlink:to="loc_AIMEmploymentAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000017 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="loc_AIMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes" xlink:title="00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions" xlink:title="00000019 - Disclosure - Certain Relationships and Related Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ConcentrationsOfRisk" xlink:title="00000020 - Disclosure - Concentrations of Risk">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000021 - Disclosure - Fair Value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Contingencies" xlink:title="00000022 - Disclosure - Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsTables" xlink:title="00000026 - Disclosure - Marketable Investments (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeTextBlock" xlink:label="loc_us-gaapInvestmentIncomeTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="loc_us-gaapTradingSecuritiesAndCertainTradingAssetsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapTradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000028 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityTables" xlink:title="00000029 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlanTwoThousandNineMember" xlink:label="loc_AIMEquityIncentivePlanTwoThousandNineMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlanTwoThousandNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlansTwoThousandAndEighteenMember" xlink:label="loc_AIMEquityIncentivePlansTwoThousandAndEighteenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlansTwoThousandAndEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000030 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="loc_AIMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ScheduleOfOperatingLeaseTableTextBlock" xlink:label="loc_AIMScheduleOfOperatingLeaseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_AIMScheduleOfOperatingLeaseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables" xlink:title="00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000032 - Disclosure - Fair Value (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock" xlink:label="loc_AIMScheduleOfRangeOfProbabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMScheduleOfRangeOfProbabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000033 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PatentAndTrademarkRightsMember" xlink:label="loc_AIMPatentAndTrademarkRightsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_AIMPatentAndTrademarkRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails" xlink:title="00000035 - Disclosure - Schedule of Available of Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MutualFundsMember" xlink:label="loc_AIMMutualFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_AIMMutualFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails" xlink:title="00000036 - Disclosure - Schedule of Equity Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiUnrealizedGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative" xlink:title="00000037 - Disclosure - Marketable Investments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FinitelivedIntangibleAssetsAbandonments" xlink:label="loc_AIMFinitelivedIntangibleAssetsAbandonments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_AIMFinitelivedIntangibleAssetsAbandonments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000042 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_AIMAccruedClinicalTrialExpensesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_AIMAccruedClinicalTrialExpensesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails" xlink:title="00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:label="loc_AIMWeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMWeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000044 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2009Member" xlink:label="loc_AIMEquityIncentivePlans2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlans2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlans2018Member" xlink:label="loc_AIMEquityIncentivePlans2018Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlans2018Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails" xlink:title="00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:label="loc_AIMShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:label="loc_AIMWeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_AIMWeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_BoardMember" xlink:label="loc_AIMBoardMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesMember" xlink:label="loc_AIMEmployeesMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NonEmployeeMember" xlink:label="loc_AIMNonEmployeeMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMNonEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightsMember" xlink:label="loc_us-gaapRightsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquityIncentivePlanTwoThousandNineMember" xlink:label="loc_AIMEquityIncentivePlanTwoThousandNineMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AIMEquityIncentivePlanTwoThousandNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantsMember" xlink:label="loc_AIMWarrantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RepresentativeWarrantsMember" xlink:label="loc_AIMRepresentativeWarrantsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMRepresentativeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreFundedWarrantsMember" xlink:label="loc_AIMPreFundedWarrantsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="loc_AIMDirectorsOfficersAndEmployeesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AIMDirectorsOfficersAndEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="loc_AIMAllianceGlobalPartnersLLCMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAllianceGlobalPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MaximGroupLLCMember" xlink:label="loc_AIMMaximGroupLLCMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMMaximGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FaceValueOfStock" xlink:label="loc_AIMFaceValueOfStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMFaceValueOfStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfOutstandingStock" xlink:label="loc_AIMPercentageOfOutstandingStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPercentageOfOutstandingStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_WarrantModifications" xlink:label="loc_AIMWarrantModifications" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMWarrantModifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative" xlink:title="00000049 - Disclosure - Segment and Related Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ClinicalStudiesMember" xlink:label="loc_AIMClinicalStudiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMClinicalStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="loc_AIMManufacturingAndEngineeringMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMManufacturingAndEngineeringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_QualityControlMember" xlink:label="loc_AIMQualityControlMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMQualityControlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_RegulatoryMember" xlink:label="loc_AIMRegulatoryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMRegulatoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="loc_AIMAmarexClinicalResearchLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAmarexClinicalResearchLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JubilantHollisterStierMember" xlink:label="loc_AIMJubilantHollisterStierMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMJubilantHollisterStierMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PharmaSolutionsMember" xlink:label="loc_AIMPharmaSolutionsMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMPharmaSolutionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ErasmusMember" xlink:label="loc_AIMErasmusMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMErasmusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AzenovaSalesInternationalMember" xlink:label="loc_AIMAzenovaSalesInternationalMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAzenovaSalesInternationalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_AlcamiMember" xlink:label="loc_AIMAlcamiMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAlcamiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PancreaticCancerMember" xlink:label="loc_AIMPancreaticCancerMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPancreaticCancerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PostCOVIDMember" xlink:label="loc_AIMPostCOVIDMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPostCOVIDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchConsultingAndSupplyAgreementsMember" xlink:label="loc_AIMResearchConsultingAndSupplyAgreementsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMResearchConsultingAndSupplyAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="loc_AIMMasterServiceAgreementAndQualityAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMMasterServiceAgreementAndQualityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="loc_AIMJointClinicalStudyAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJointClinicalStudyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_JjointClinicalStudyAgreementMember" xlink:label="loc_AIMJjointClinicalStudyAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJjointClinicalStudyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnitsManufactured" xlink:label="loc_AIMUnitsManufactured" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMUnitsManufactured" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NumberOfVials" xlink:label="loc_AIMNumberOfVials" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMNumberOfVials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:label="loc_us-gaapInventoryWorkInProcessAndRawMaterials" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryWorkInProcessAndRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/KPlanDetailsNarrative" xlink:title="00000051 - Disclosure - 401(k) Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaapRetirementPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRetirementPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaapRetirementPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanNameAxis" xlink:to="loc_us-gaapRetirementPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FourZeroOnekPlanMember" xlink:label="loc_AIMFourZeroOnekPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRetirementPlanNameDomain" xlink:to="loc_AIMFourZeroOnekPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Employment Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureEmploymentAgreementsAbstract" xlink:label="loc_AIMDisclosureEmploymentAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureEmploymentAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentContractualAgreementsMember" xlink:label="loc_AIMEmploymentContractualAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEmploymentContractualAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmploymentAgreementMember" xlink:label="loc_AIMEmploymentAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_NamedExecutiveOfficersMember" xlink:label="loc_AIMNamedExecutiveOfficersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMNamedExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_ThomasKEquelsMember" xlink:label="loc_AIMThomasKEquelsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMThomasKEquelsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PeterRodinoMember" xlink:label="loc_AIMPeterRodinoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMPeterRodinoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsandRodinoMember" xlink:label="loc_AIMEquelsandRodinoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEquelsandRodinoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EllenLintalMember" xlink:label="loc_AIMEllenLintalMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEllenLintalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EquelsRodinoAndFormerOfficerLintalMember" xlink:label="loc_AIMEquelsRodinoAndFormerOfficerLintalMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_AIMEquelsRodinoAndFormerOfficerLintalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_StockOptionsMember" xlink:label="loc_AIMStockOptionsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligationPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_Bonus" xlink:label="loc_AIMBonus" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="loc_AIMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaapLeaseCostAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="loc_AIMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000055 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DisclosureLeasesAbstract" xlink:label="loc_AIMDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srtRestatementAdjustmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRestatementAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsAmortizationAndDepreciation" xlink:label="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMDeferredTaxAssetsAmortizationAndDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DeferredTaxAssetsRightOfUseAssets" xlink:label="loc_AIMDeferredTaxAssetsRightOfUseAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMDeferredTaxAssetsRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails" xlink:title="00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxExemptIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationForeignIncomeRTP" xlink:label="loc_AIMIncomeTaxReconciliationForeignIncomeRTP" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMIncomeTaxReconciliationForeignIncomeRTP" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationRTPPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationRTPPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleStateNetOperatingLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleStateNetOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:label="loc_AIMIncomeTaxReconciliationNondeductibleExpenseFixedAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMIncomeTaxReconciliationNondeductibleExpenseFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationOther" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationOther" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:label="loc_AIMIncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMIncomeTaxReconciliationNetOperatingLossRefundValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:label="loc_AIMEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_AIMEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative" xlink:title="00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="loc_us-gaapNewJerseyDivisionOfTaxationMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapNewJerseyDivisionOfTaxationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE" xlink:label="loc_countryBE" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryBE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_NJ" xlink:label="loc_stprNJ" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprNJ" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_OperatingLossCarryforwardsWithNoExpirationDate" xlink:label="loc_AIMOperatingLossCarryforwardsWithNoExpirationDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_AIMOperatingLossCarryforwardsWithNoExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails" xlink:title="00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_MarchTwoThousandNineteenWarrantsMember" xlink:label="loc_AIMMarchTwoThousandNineteenWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_AIMMarchTwoThousandNineteenWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails" xlink:title="00000061 - Disclosure - Schedule of Range of Probabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfProbability" xlink:label="loc_AIMPercentageOfProbability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMPercentageOfProbability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000062 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FairValueMeasurementInputPercentage" xlink:label="loc_AIMFairValueMeasurementInputPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMFairValueMeasurementInputPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_PercentageOfProbability" xlink:label="loc_AIMPercentageOfProbability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMPercentageOfProbability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:label="loc_AIMFloorRateUsedAsProxyForFutureVolatilityPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_AIMFloorRateUsedAsProxyForFutureVolatilityPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentAxis" xlink:label="loc_AIMDebtIstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_AIMDebtIstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DebtIstrumentDomain" xlink:label="loc_AIMDebtIstrumentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDebtIstrumentAxis" xlink:to="loc_AIMDebtIstrumentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_UnsecuredPromissoryNoteMember" xlink:label="loc_AIMUnsecuredPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDebtIstrumentDomain" xlink:to="loc_AIMUnsecuredPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_EmployeesPurchasePlanMember" xlink:label="loc_AIMEmployeesPurchasePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMEmployeesPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20231231.xsd#AIM_DirectorsPurchasePlanMember" xlink:label="loc_AIMDirectorsPurchasePlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMDirectorsPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139891005738640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 27, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-27072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AIM
IMMUNOTECH INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000946644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-0845822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2117
    SW Highway 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ocala<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">448-7797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AIM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,829,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,901,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami,
Florida<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139891005710272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,439,000<span></span>
</td>
<td class="nump">$ 27,053,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable investments</a></td>
<td class="nump">7,631,000<span></span>
</td>
<td class="nump">7,137,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Funds receivable from New Jersey net operating loss</a></td>
<td class="nump">1,184,000<span></span>
</td>
<td class="nump">1,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,556,000<span></span>
</td>
<td class="nump">36,321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">697,000<span></span>
</td>
<td class="nump">829,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent and trademark rights, net</a></td>
<td class="nump">2,313,000<span></span>
</td>
<td class="nump">1,941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,688,000<span></span>
</td>
<td class="nump">1,202,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">19,381,000<span></span>
</td>
<td class="nump">40,488,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,443,000<span></span>
</td>
<td class="nump">377,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,986,000<span></span>
</td>
<td class="nump">806,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">223,000<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,652,000<span></span>
</td>
<td class="nump">1,361,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">495,000<span></span>
</td>
<td class="nump">659,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,147,000<span></span>
</td>
<td class="nump">2,020,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 8, 10, 11, 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 49,102,484 and 48,084,287 (including 701,667 and 694,324 of unvested stock awards) as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">419,004,000<span></span>
</td>
<td class="nump">418,270,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(409,508,000)<span></span>
</td>
<td class="num">(380,546,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">10,234,000<span></span>
</td>
<td class="nump">38,468,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">19,381,000<span></span>
</td>
<td class="nump">40,488,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Value</a></td>
<td class="nump">$ 689,000<span></span>
</td>
<td class="nump">$ 696,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890977265200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">49,102,484<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">49,102,484<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock awards</a></td>
<td class="nump">701,667<span></span>
</td>
<td class="nump">694,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970727408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Clinical treatment programs &#8211; US</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Production costs</a></td>
<td class="nump">42<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,939<span></span>
</td>
<td class="nump">6,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,137<span></span>
</td>
<td class="nump">13,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Costs and Expenses</a></td>
<td class="nump">32,118<span></span>
</td>
<td class="nump">20,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(31,916)<span></span>
</td>
<td class="num">(19,923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on investments</a></td>
<td class="nump">200<span></span>
</td>
<td class="num">(1,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Redeemable warrants valuation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss', window );">Gain from sale of income tax operating losses</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (28,962)<span></span>
</td>
<td class="num">$ (19,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average shares outstanding basic</a></td>
<td class="nump">48,585,404<span></span>
</td>
<td class="nump">48,047,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding diluted</a></td>
<td class="nump">48,585,404<span></span>
</td>
<td class="nump">48,047,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain from sale of income tax operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_GainFromSaleOfIncomeTaxOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971144640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 417,217<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (361,101)<span></span>
</td>
<td class="nump">$ 56,879<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,994,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,445)<span></span>
</td>
<td class="num">(19,445)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_CashlessWarrantConversion', window );">Cashless warrant conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_CashlessWarrantConversionShares', window );">Cashless warrant conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(380,546)<span></span>
</td>
<td class="nump">38,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(28,962)<span></span>
</td>
<td class="num">(28,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 419,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (409,508)<span></span>
</td>
<td class="nump">$ 10,234<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_CashlessWarrantConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless warrant conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_CashlessWarrantConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_CashlessWarrantConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cashless warrant conversion shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_CashlessWarrantConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971305552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,962,000)<span></span>
</td>
<td class="num">$ (19,445,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Redeemable warrants valuation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of fixed assets</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_AbandonmentOfPatentAndTrademarkRights', window );">Abandonment and expiration of patents and trademark rights</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent and trademark rights</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">287,000<span></span>
</td>
<td class="num">(680,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_LossGainFromSaleOfIncomeTaxOperatingLosses', window );">Loss from sale of income tax operating losses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="nump">954,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Loss (gain) on sale of marketable investments</a></td>
<td class="num">(200,000)<span></span>
</td>
<td class="nump">1,679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Funds receivable from New Jersey operating loss sales</a></td>
<td class="nump">492,000<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">153,000<span></span>
</td>
<td class="num">(151,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(274,000)<span></span>
</td>
<td class="nump">688,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(486,000)<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,066,000<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,180,000<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,267,000)<span></span>
</td>
<td class="num">(16,108,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInvestmentProjects', window );">Proceeds from sale of marketable investments</a></td>
<td class="nump">1,299,000<span></span>
</td>
<td class="nump">10,083,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of marketable investments</a></td>
<td class="num">(1,593,000)<span></span>
</td>
<td class="num">(2,724,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of patent and trademark rights</a></td>
<td class="num">(585,000)<span></span>
</td>
<td class="num">(185,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(832,000)<span></span>
</td>
<td class="nump">10,988,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock, net of issuance costs</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">485,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(21,614,000)<span></span>
</td>
<td class="num">(5,040,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">27,053,000<span></span>
</td>
<td class="nump">32,093,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">5,439,000<span></span>
</td>
<td class="nump">27,053,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_UnrealizedGainLossOnMarketableInvestments', window );">Unrealized gain (loss) on marketable investments</a></td>
<td class="nump">376,000<span></span>
</td>
<td class="num">(928,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ConversionOfSeriesBPreferred', window );">Conversion of Series B preferred</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset', window );">Operating lease liability arising from obtaining right of use asset</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="nump">$ 736,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_AbandonmentOfPatentAndTrademarkRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Abandonment of patent and trademark rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_AbandonmentOfPatentAndTrademarkRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ConversionOfSeriesBPreferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Series B preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ConversionOfSeriesBPreferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_LossGainFromSaleOfIncomeTaxOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss gain from sale of income tax operating losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_LossGainFromSaleOfIncomeTaxOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability arising from obtaining right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_UnrealizedGainLossOnMarketableInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain loss on marketable investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_UnrealizedGainLossOnMarketableInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInvestmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInvestmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880911728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYoXxHAglyRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(1)
<span id="xdx_82D_zOYCi5rn3MF3">Description of Business </span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A<span style="color: Black">IM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM&#8217;s
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (&#8220;CFS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company&#8217;s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;) molecule being developed
for globally important cancers, viral diseases and disorders of the immune system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM
currently is proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Conducting
    a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced
    pancreatic cancer patients.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating
Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses
to check point inhibitors.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Exploring
    Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated
    viruses thereof. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Evaluating
    Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;) and fatigue and/or Post-COVID
    conditions of fatigue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">AIM
is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer,
ME/CFS and Post-COVID conditions having priority over antiviral experimentation. AIM intends that priority clinical work be conducted
in trials authorized by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or European Medicines Agency (&#8220;EMA&#8221;), which
trials support a potential future NDA. However, the Company&#8217;s antiviral experimentation is designed to accumulate additional preliminary
data supporting its hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced
immunity and cross-protection. Accordingly, the Company will conduct antiviral programs in those venues most readily available and able
to generate valid proof-of-concept data, including foreign venues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Basis of Preparation and Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements include the accounts of AIM ImmunoTech and all entities in which a controlling interest is held by the Company. All
significant intercompany balances and transactions have been eliminated in consolidation. The consolidated financial statements are prepared
in accordance with accounting principles generally accepted in the U.S. (&#8220;GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890881487472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zJ1ZOSYNwxG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(2)
<span id="xdx_823_zw8y4UAd3rS8">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
<span id="xdx_86B_zmgK91eyCGD6">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid
instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year
ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit">250</span>
thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
<span id="xdx_861_zilUSHqnAcu">Marketable Investment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company&#8217;s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments
using the specific identification method and measure the fair value of our marketable investments using a market approach where identical
or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices
from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
<span id="xdx_869_z8KJmsuGquql">Property and Equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective
assets, ranging from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">three</span></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life">ten years</span>. Depreciation expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense">39,000</span>
and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense">38,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $<span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges">1,800,000</span> during
the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
<span id="xdx_862_zxLttbDekJv3">Patent and Trademark Rights, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful
life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights">17</span> years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value,
or their value has become impaired. Such review includes an analysis of the patent and trademark&#8217;s ultimate revenue and profitability
potential. Management&#8217;s review addresses whether each patent continues to fit into the Company&#8217;s strategic business plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
<span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#8220;GAAP&#8221;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
<span id="xdx_863_zYVcu2A7t1be">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with
Customers (&#8220;Topic 606&#8221;). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model
to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses
whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that
is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped.
The Company has no other obligation associated with its products once shipment has been accepted by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)
<span id="xdx_86A_zzDBc4KDPNel">Accounting for Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement
of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized.
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes
are enacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#8217;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating
loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company
has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at
this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)
<span id="xdx_86E_z3BzQaCVKJkf">Recent Accounting Standards and Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements. </i>The standard requires additional or amended disclosure requirements
for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation
for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective
dependent upon the SEC&#8217;s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has
evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined
that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) Improvements to Income Tax Disclosures. </i>The amendments in
this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and
(2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items
is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income
tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting
currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about
income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign
taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid
(net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments
in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income
tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated
by federal (national), state, and foreign.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably
possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range
cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference
when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries
and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations
and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#8217;s
present or future financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
<span id="xdx_86F_zmfAfvjRbn6g">Stock-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &#8220;Compensation &#8211; Stock Compensation&#8221;,
which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee
is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net
of estimated forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j)
<span id="xdx_866_zorjzfOx4Rcg">Common Stock Per Share Calculation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic
and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period.
Equivalent Common shares, consisting of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares">3,523,949</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares">2,966,538</span> of stock options and warrants, are excluded from the calculation of diluted
net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k)
<span id="xdx_864_zU9Jock3a3v3">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets
or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which
a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business
climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an
accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset
(asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or
forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that,
more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously
estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">When
assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing
the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#8217;s
carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company measures the impairment by comparing the difference between the asset grouping&#8217;s carrying value and its fair value. Long-lived
assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are
determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments
in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing
process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated,
it accelerates the rate of depreciation over the assets&#8217; new, shorter useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(l) Lease accounting</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a party to leases
for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception
of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification
affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases,
which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit
rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate
the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lease term is defined as the
non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will
exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments
made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs,
are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease
liability, while any variable portion is recognized as variable lease expenses as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected not to
recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months
or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(m) <span>Reclassifications</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior year amounts have
been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders&#8217;
equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_85A_z1fn1KYI6FM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878406480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investments</a></td>
<td class="text"><p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zTbja26Cmuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(3)
<span id="xdx_82A_zSViMNDiu0Ed">Marketable Investments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Marketable
investments consist of mutual funds. At December 31, 2023 and 2022, it was determined that none of the marketable investments had an
other-than-temporary impairment. At December 31, 2023 and 2022, all securities were measured as Level 1 instruments of the fair value
measurements standard (See Note 15: Fair Value). As of December 31, 2023 and 2022, the Company held $<span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaK6yejGQ241" title="Marketable securities">7,631,000</span> and $<span id="xdx_908_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zComyrmh8nje" title="Marketable securities">7,137,000</span>, respectively,
in mutual funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mutual
Funds classified as available for sale consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2SSJvsud5uh" style="display: none">Schedule
of Available of Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="margin: 0pt">Fair</p>
                                                                                <p style="margin: 0pt">Value</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_z6vVU3pLgF7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zUPSSRfoE6P7" style="display: none">Schedule
of Equity Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity
    securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_z0kzXWEdl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_C02_gL3IITB-MRQXJLX_zIFPIMa84vC9">Mutual
Funds classified as available for sale consisted of:</span></span></p>

<div id="xdx_C02_gL3IITB-MRQXJLX_zRHdn8ayZMe7" style="margin: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0B_gL3IITB-MRQXJLX_zg71DmxfXC4c"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_C0A_gL3TSACTATB-ODD_zwKXQc3515c9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></span></p>

<div id="xdx_C09_gL3TSACTATB-ODD_zph8HTxAKTql" style="margin: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_C04_gL3TSACTATB-ODD_zItYqthd6dId">&#160;</span></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970790480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents and Trademark Rights, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Patents and Trademark Rights, Net</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zhCBjNsh8aZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(4)
<span id="xdx_824_zIwSq2BmzXGd">Patents and Trademark Rights, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patent and trademark rights consist of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;<span id="xdx_8BC_zivttU9adyx8">Schedule
of Patent and Trademark Rights</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zltZ3lxz6Vhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt">The following table presents the changes in the patents and
trademark rights:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_8BF_z0tf6fFOuc0c" style="display: none">Schedule
of Changes in Patents, Trademark Rights</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(in thousands)</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Acquisitions</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Abandonments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> Amortization</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zc2mmwIFrD0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life
of <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwhL5qbgPzK4" title="Finite lived intangible assets, estimated useful life">17</span> years and <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOWuHlDIF6i2" title="Finite lived intangible assets, estimated useful life">10</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
of patents and trademarks for each of the next five years is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B9_zhAkaswPrKwl" style="display: none">Schedule
of Amortization of Patents and Trademarks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zGJII59iaimi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880938144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zeEijkQZOUYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(5)
<span id="xdx_827_zSBL5lj9xQkf">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accrued
expenses at December 31, 2023 and 2022 consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BC_zyhFSMGVUH97" style="display: none">Schedule
of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zEU7bP6y9Fl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878287296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqitzPN2xp8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(6)
<span id="xdx_823_z4u6BXmAK5W">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company is authorized to issue <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zS1iQPwaahH" title="Preferred stock, shares authorized">5,000,000</span> shares of $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zyt8J7mVj9tg" title="Preferred stock stated value">0.01</span> par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zealkqpR9eDc" title="Preferred stock, shares authorized">4,000,000</span> shares have been designated as Series A Junior Participating
Preferred Stock and <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvlMIC5enur8" title="Preferred stock, shares authorized">10,000</span> shares have been designated as Series B Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series
A Junior Participating Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z74l9b9hkGJ9" title="Preferred stock, shares authorized">4,000,000</span> from <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zCjyE5nJ0rU8" title="Preferred stock, shares authorized">250,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Series
B Convertible Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has designated <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zyUvHgfAa0n9">10,000</span> shares of its preferred stock as Series B Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;).
Each share of Preferred Stock has a par value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUZVOl7yMsYl" title="Preferred stock, par value">0.01</span> per share and a stated value equal to $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zluVtpLH6Osk" title="Preferred stock, stated value">1,000</span> (the &#8220;Stated Value&#8221;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#8220;DTC&#8221;) shall initially be the sole registered holder of the shares of Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20231231_zPphwTZ4MXS9" title="Preferred stock conversion price">0.20</span>,
subject to adjustment herein (the &#8220;Conversion Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant
to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its
holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable
subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase
one unit, at a subscription price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_znVBEGKrxhSj" title="Warrant exercise price">1,000</span> per unit, consisting of one share of Series B Convertible Preferred Stock with a face value
of $<span id="xdx_907_ecustom--FaceValueOfStock_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zQesT79xUSc9" title="Preferred stock face value">1,000</span> (and immediately convertible into common stock at an assumed conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqTl7bQPcnMf" title="Preferred stock conversion price">8.80</span>) and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFAs70jaJFbe" title="Number of warrants">114</span> warrants with an assumed exercise
price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRa77juDYnRb" title="Subscription/exercise price">8.80</span>. The redeemable warrants are exercisable for <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGXFztwsjXVk">five years</span> after the date of issuance. The net proceeds realized from the
rights offering were approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zRJF43tg183l" title="Proceeds from warrants">4,700,000</span>. During the year ended December 31, 2023, <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zn2II1ahpKN5">7</span> shares of Series B Convertible Preferred Stock
were converted into common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2023 and 2022, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP6HJLnaOIZi" title="Preferred stock, shares outstanding">689</span> and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zufJWl3Cz0u4" title="Preferred stock, shares outstanding">696</span> shares of Series B Convertible Preferred Stock outstanding, respectively.
Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis) to and in the same form as dividend actually paid on shares of Common Stock when as and if such dividends are paid on shares of
the Common Stock. Each such Preferred Share is convertible into <span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zsjCPknBszub" title="Number of shares to be issued on conversion">114</span> shares of common stock. Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary, the Holders shall be entitled to receive out of the assets, whether capital or surplus
of the Company the same amount that a holder of Common Stock would receive if the Preferred Stock was fully converted. The Series B Convertible
Preferred Stock does not carry voting Rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
Common Stock and Equity Finances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has authorized shares of <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zKs6QK6ZjIs8" title="Common stock, shares authorized">350,000,000</span> with specific limitations and restrictions on the usage of <span id="xdx_903_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20231231_zCFCveCaorp9" title="Common stock specific limitations and restrictions on usage">8,000,000</span> of the <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zGTsqQZ6xYxa" title="Common stock, shares authorized">350,000,000</span>
authorized shares. <span style="background-color: white">As of December 31, 2023 and 2022, there were <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zl0Rlmup6df6" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z6db1PxcsX1" title="Common stock, shares outstanding">49,102,484</span></span> and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zEB324dHpD77" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zo4X699gHUUj" title="Common stock, shares outstanding">48,084,287</span></span> shares
of Common Stock issued and outstanding, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Employee
Stock Purchase Plan (Not equity compensation)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200706__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zA3rkt9liEhk" title="Common stock shares issued, value">500,000</span> worth of shares at the market price (including subsequent plans, the &#8220;Employee Stock Purchase Plan&#8221;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#8217;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board in January 2024 and expires in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023, the Company issued a total of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zviztUmxoLje" title="Number of shares issued upon transaction">419,285</span> shares of its Common Stock at a price ranging from $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zdJMaElsXvJ1" title="Shares issued price per share">0.31</span> to $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zZJhuARTYw22" title="Shares issued price per share">0.67</span>
for total proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSPJHE2neJwb" title="Proceeds from issuance of common stock">150,500</span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zfTmenNILks9" title="Number of shares issued upon transaction">86,817</span> shares of its Common Stock at prices ranging from $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z44dlehfZ2uf" title="Shares issued price per share">0.76</span> to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zcYvfoEWRseb" title="Shares issued price per share">1.02</span>
for total proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMIIUdDZAHO5" title="Proceeds from issuance of common stock">80,000</span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Warrants
(Rights offering)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#8220;Offering&#8221;)
of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zPxn6Z5v7yPa" title="Number of shares issued upon transaction">1,740,550</span> shares of Common Stock; (ii) pre-funded warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z95jjsb0xCgf" title="Warrants issued">7,148,310</span> shares of Common Stock (the &#8220;Pre-funded
Warrants&#8221;), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zZktK4vOrA5a" title="Number of warrant to purchase shares of common stock">8,888,860</span> shares of Common Stock (the &#8220;Warrants&#8221;).
In conjunction with the Offering, we issued </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a
Representative&#8217;s Warrant to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zcUVBXAOEfFe" title="Number of warrant to purchase shares of common stock">266,665</span> shares of common stock (the &#8220;Representative&#8217;s Warrant&#8221;)<span style="background-color: white">.
The shares of Common Stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zG0XCk86BvSl" title="Shares issued price per share">0.90</span>, less underwriting discounts and commissions.
Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of
$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z45VysI4Rdh7" title="Warrant exercise price">0.99</span> per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zQODiBo59fs7" title="Shares issued price per share">0.899</span>, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKDoG8e4n7Nk" title="Percentage of outstanding stock">4.99</span>% of the Company&#8217;s
outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant
represents the right to purchase one share of Common Stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqDXj99Nqi93" title="Exercise price">0.001</span> per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zZNgiCM0cLbl" title="Proceeds from Issuance or Sale of Equity">7,200,000</span>. During the year ended </span>December 31<span style="background-color: white">, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z3g8fsCi3e93" title="Stock issued during period shares other">1,870,000</span> of the Pre-funded Warrants
were exercised and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TUJZd6f9eb" title="Pre-funded warrants exercised">8,873,960</span> Warrants were exercised. </span>In addition, on March 25, 2020, the Representative&#8217;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020 and an aggregate of
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBNFf2hF7fXf" title="Warrants exercised aggregate">266,665</span> shares were issued upon exercise of this warrant for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zt1Btk7f3ku4" title="Warrant gross proceeds">264,000</span> and a $<span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_z781IO7BCGn9" title="Warrant modification">46,000</span> expense for the warrant
modification. No Warrants were exercised during the year ended December 31, 2023 and 2022. As of December 31, 2023 and 2022 there are
<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zkWxC6X5Uyl1" title="Warrant outstanding"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zrwFNaFiUAVi" title="Warrant outstanding">15,000</span></span> Warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Equity
Distribution Agreement</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#8220;EDA&#8221;) with Maxim Group LLC
(&#8220;Maxim&#8221;), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate
offering price of up to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zNlgcvJurGw">8,500,000</span>
through Maxim, as agent (the &#8220;Offering&#8221;). Sales under the EDA were registered under the S-3 Shelf Registration
Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zMbKWKkSgAB1" title="Transaction fee rate">3.0</span>%
of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zIliAU2gMc1a" title="Shares sold">598,114</span>
shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zCHyKPIRBnx6" title="Gross proceeds from issuance of common stock">344,000</span>,
which includes a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zTOA1FDdlyr4" title="Transaction fee rate">3.0</span>%
fee to Maxim of $<span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zxan4REYwBEh">10,326</span>. Subsequent to the year ended December 31, 2023, the Company sold <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDyG2c83P0r1" title="Shares sold">699,568</span> shares under the EDA for total gross proceeds
of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRQPJ8F7ZeUj" title="Proceeds from issuance of common stock">316,392</span>, which includes a <span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBW1BZtSXEI7" title="Transaction fee rate">3.0</span>% fee to Maxim of $<span id="xdx_90D_eus-gaap--DebtInstrumentFeeAmount_iI_c20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYidNbQUvnb3">9,492</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Rights
Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp; Trust Company as
Rights Agent (the &#8220;Rights Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
Common Stock Options and Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>(i)
Stock Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock
Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards,
(vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zxtEOC1VeTG4" title="Number of common stock reserved for potential issuance">7,000,000</span> shares of common stock is reserved for
potential issuance pursuant to awards under the 2018 Equity Incentive Plan. Unless sooner terminated, the 2018 Equity Incentive Plan
will continue in effect for a period of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zJTZfbENHDnc">10</span> years from its effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Equity Incentive Plans of 2018 are administered by the Board of Directors. The Plans provide for awards to be made to such Officers,
other key employees, non-employee Directors, consultants and advisors of the Company and its subsidiaries as the Board may select.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
options awarded under the Plans may be exercisable at such times (not later than 10 years after the date of grant) and at such exercise
prices (not less than fair market value at the date of grant) as the Board may determine. The Board may provide for options to become
immediately exercisable upon a &#8220;change in control&#8221;, which is defined in the Plans to occur upon any of the following events:
(a) the acquisition by any person or group, as beneficial owner, of 20% or more of the outstanding shares or the voting power of the
outstanding securities of the Company; (b) either a majority of the Directors of the Company at the annual stockholders meeting has been
nominated other than by or at the direction of the incumbent Directors of the Board, or the incumbent Directors cease to constitute a
majority of the Company&#8217;s Board; (c) the Company&#8217;s stockholders approve a merger or other business combination pursuant to
which the outstanding common stock of the Company no longer represents more than 50% of the combined entity after the transaction; (d)
the Company&#8217;s stockholders approve a plan of complete liquidation or an agreement for the sale or disposition of all or substantially
all of the Company&#8217;s assets; or (e) any other event or circumstance determined by the Company&#8217;s Board to affect control of
the Company and designated by resolution of the Board as a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate
expected dividend yield, life and forfeiture rates. The expected life of the options and equity warrants was estimated based on historical
option and equity warrant holders&#8217; behavior and represents the period of time that options and equity warrants are expected to
be outstanding. The fair values of the options granted were estimated based on the following weighted average assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zRdQc4lhI2ed" style="display: none">Schedule
of Options and Equity Estimated Based on Weighted Average Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate">4.37</span></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate">1.74</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate">3.88</span>%</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Expected life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility">99.91</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility">98.43</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility">107.18</span>%</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</span></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zpgKNkwD8rIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
exercise price of all stock options and equity warrants granted was equal to or greater than the fair market value of the underlying
common stock on the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June
24, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year">13.20</span> &#8211; <span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year">1,003.20</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year">13.20</span> &#8211; <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year">2,127.84</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited">9.68</span>-<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited">327.36</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited">16.76</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited">2,127.84</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0885">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0889">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)">4.06</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)">5.98</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zwEfEfkEYN0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zjBHKIJSnVTc" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year">0.31</span>-<span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year">1.11</span> &#8211; <span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted">0.47</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted">0.47</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted">0.31</span> &#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted">1.71</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited">0.31</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited">1.85</span> &#8211; <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0979">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year">0.31</span> &#8211; <span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year">327.36</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right">4.71</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year">0.41</span> &#8211; <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right">2.22</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)">7.96</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)">9.65</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zCt6AGdS0HJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
option activity during the years ended December 31, 2023 and 2022 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zF0PfjjCWiX8" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period">4.22</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.11</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted">0.49</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited">17.71</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period">3.01</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)">8.86</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1055">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted">0.47</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired">41.61</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period">2.50</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1093">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zaPFwFMU6Lmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
weighted-average grant-date fair value of employee options vested during the year ended December 31, 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDLLW4mKBtch" title="Share-based payment award options vested in period fair value">184,000</span> for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zexAY94cljFd" title="Number of options, granted">424,999</span> options
at $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwhJUHGEuao6" title="Weighted average exercise price, granted">0.43</span> per option and during year ended December 31, 2022 was $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqKhD2stjHF7" title="Number of options, granted">768,666</span> for <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z3UmXsez7IE1" title="Number of options, granted">575,000</span> options at $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIGmU7JOYkvk">1.34</span> per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_znkiS1cgVg4i" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2021</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period">412,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">5.85</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested">(541,590</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested">9.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Unvested December 31, 2022</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period">392,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">0.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">8.86</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested">(413,884</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested">6.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">366,666</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">2.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period">12.44</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AD_zG18YW8IC09l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_zsalMMWYrOo9" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period">279,723</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">6.12</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding">7.93</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1183">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period">579,155</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period">3.09</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.36</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right">360,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.46</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value">10.04</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1236">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zHocvI0bZukb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
weighted-average grant-date fair value of non-employee options vested during year 2023 was $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_znEFRK5NZ8l7" title="Share-based payment award options vested in period fair value">90,000</span> for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zzSmpvfyg8Q2" title="Number of options, granted">191,666</span> options at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zSgr1cy7Cd98" title="Weighted average exercise price, granted">0.47</span> per option
and during the year 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zuhPnyCsCu55" title="Share-based payment award options vested in period fair value">247,166</span> for<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zvJmne3ZNVc1" title="Number of options, granted"> 229,053</span> options at $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zBl8iBiuAg14" title="Weighted average exercise price, granted">1.08</span> per option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zmTaiMUsaseh" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2021</span></td><td style="width: 2%; color: Black; text-align: left">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period">97,831</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.89</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">7.82</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.82</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2022</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period">166,789</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">4.05</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">9.49</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted">360,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right">0.46</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted">10.18</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested">9.47</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expired</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period">10.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z4C2lN2A5n75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
compensation expense was approximately $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMWuIx6ShLVe" title="Share based compensation expense">243,000 </span>and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjGrfLdWeJ5" title="Share based compensation expense">954,000</span> for the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2023 and 2022, there was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20231231_zXhQqABm0kwh" title="Unrecognized stock-based compensation cost">294,000</span> and $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20221231_zjMEq1YsxSw2" title="Unrecognized stock-based compensation cost">217,000</span>, respectively, of unrecognized stock-based compensation cost related to
options granted under the Equity Incentive Plans. Stock-based compensation related to options granted under the Equity Incentive Plans
will be recorded over the vesting period which is typically one year or upon reaching agreed upon Company and/or individual performance
milestones being met which is indefinite.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(ii)
Stock Warrants</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
warrants are issued as needed by the Board of Directors and have no formal plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend
yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder&#8217;s behavior
and represents the period of time that options are expected to be outstanding. No warrants were granted in 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding warrants outstanding and exercisable into shares of common stock is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_z5LMDxbstbGf" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year <br/>&#160; <br/></td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year">132.00</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year">0.99</span> &#8211; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year">469.92</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1336">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1338">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired">17.05</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">17.05</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired">469.92</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">469.92</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1358">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year">8.80</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year">132.00</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year">8.80</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year">132.00</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.75 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year">.94</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable">2024</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable">2023</span>-<span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable">2024</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zEdcVdPnO2dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock
warrants are issued at the discretion of the Board. During the year ended December 31, 2023, there were <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20230101__20231231_zkkhVy30p3Zg" title="Warrants issued::XDX::-"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_doxL_c20230101__20231231_zlawOgcMWi01" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1406"><span style="-sec-ix-hidden: xdx2ixbrl1408">no</span></span></span></span> warrants issued or exercised.
During the year ended December 31, 2022, there were <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20220101__20221231_zaNSjiTXnKtd" title="Warrants issued::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1410">no</span></span> warrants issued and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_dixL_c20220101__20221231_zHfpY7YXfrz5" title="Warrants exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1412">114</span></span> were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970306896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Related Information</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zJJslBquIkL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(7)
<span id="xdx_82D_zREfYxgxL3z4">Segment and Related Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company operates in <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zc5D3JCz9mj5" title="Number of segment">one</span> segment, which performs research and development activities related to Ampligen and other drugs under development.
The Company&#8217;s revenues for the two-year period ended December 31, 2023, were earned in the United States. All assets are maintained
in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879997824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Consulting and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract', window );"><strong>Research Consulting And Supply Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ResearchConsultingAndSupplyAgreementsTextBlock', window );">Research, Consulting and Supply Agreements</a></td>
<td class="text"><p id="xdx_805_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4fLtYbN7Vll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(8)
<span id="xdx_822_zEJLf0INZyc8">Research, Consulting and Supply Agreements</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the year ended December 31, 2023, research and development expenses
were comprised of: clinical studies ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyjDnZGFgh62" title="Research and development expense">6,014,000</span>), manufacturing and engineering ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zfI5Va6rI0d5" title="Research and development expense">3,220,000</span>), quality control ($<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--QualityControlMember_zj6NBYEJsDr9" title="Research and development expense">1,271,000</span>) and regulatory
($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--RegulatoryMember_z6SeNVOYYyG5" title="Research and development expense">434,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span>During the year ended December 31, 2022, research and development expenses
were comprised of: clinical studies ($<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyuQ9B3Ls66h" title="Research and development expense">4,070,000</span>), manufacturing and engineering ($<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zrzfkeFObV29" title="Research and development expense">1,241,000</span>), quality control ($<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--QualityControlMember_zGzSy0BCHlT8" title="Research and development expense">1,236,000</span>) and regulatory
($<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--RegulatoryMember_zwhviG7susAi" title="Research and development expense">443,000</span>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Amarex
Clinical Research LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amarex
is the principal administrator of several of AIM&#8217;s largest clinical studies. AIM has multiple contracts with Amarex Clinical
Research LLC (&#8220;Amarex&#8221;). During the year ended December 31, 2023 and 2022, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zjsKeSbwVgt3" title="Research and development expense">4,290,000</span>
and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zoTYVGpzRIHh" title="Research and development expense">2,272,000</span>, respectively, related to these ongoing agreements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pancreatic
    Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally
    advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex&#8217;s management of the
    study will cost approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj0b7yetqVHi" title="Research and development expense excluding acquired in process cost">8,400,000</span>. This estimate includes pass-through costs of approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z6E238Oy8zCa" title="Development cost">1,000,000</span> and excludes certain
    third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately
    <span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zvzpsBBUJNJ6" title="Estimated lives">4.6</span> years to complete.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zEogaZmww6xe" title="Research and development expense">600,000</span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zRA9HhWySi2b" title="Research and development expense">1,691,000</span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Post-COVID
    Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients
    with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z3OtcXkdCxH5">6,400,000</span>, which
    includes pass through costs of approximately $<span id="xdx_90C_eus-gaap--DevelopmentCosts_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z68nU02VjkCg" title="Development cost">125,000</span>, investigator costs estimated at about $<span id="xdx_900_eus-gaap--CostMaintenance_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zwAikhPsTji7" title="Invigilators cost">4,400,000</span>, and excludes certain other
    third-party costs and escalations. During 2023, the original work order increased to approximately $<span id="xdx_904_eus-gaap--DevelopmentCosts_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zN5anhmwgnI8" title="Development cost">6,600,000</span> for the addition of
    patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the
    ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which
    resulted in additional IND submissions to FDA. This study was effectively concluded in 2023.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zX4oZsJX0Xcg" title="Research and development expense">3,690,000</span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zBWSLzE4RDt" title="Research and development expense">581,000</span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Jubilant
HollisterStier</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Jubilant
HollisterStier (&#8220;Jubilant&#8221;) is AIM&#8217;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company
entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen&#174; for the Company. Since the
2017 engagement of Jubilant, two lots of Ampligen consisting of more than <span id="xdx_90F_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zJaL14ANND35" title="Number of units manufactured">16,000</span> units were manufactured and released in the year 2018.
The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials.
The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant
manufactured additional two lots of Ampligen in December 2019 and January 2020. In March 2023, the Company ordered an additional <span id="xdx_904_ecustom--NumberOfVials_uInteger_c20230101__20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zpL9XLWaZCf5" title="Additional number of vials">27,900</span>
vials from Jubilant at a cost of approximately $<span id="xdx_90E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zCBLLFuNAPH9" title="Inventory work in process and raw materials">1,432,000</span>. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zfI7t5QWlnMa" title="Research and development expense">1,432,000</span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zCKeu8FivXJ" title="Research and development expense">79,000</span> related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Sterling
Pharma Solutions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#8220;Sterling&#8221;)
for the manufacture of the Company&#8217;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--PharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zKzuIfnLYHIk" title="Research and development expense">363,000</span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Erasmus</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#8217;s limited responsibilities
are limited to providing Ampligen. Additionally, AIM agreed to provide a grant of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20221201__20221231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zrZLNisgBPx" title="Research and development expense">200,000</span> for the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JjointClinicalStudyAgreementMember_zbzGQ71Oq9Yg" title="Research and development expense">100,000</span> pursuant to the Grant Agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova
Sales International</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services
for AIM&#8217;s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange
for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zDtRuFC8pDte" title="Stock options, aggregate intrinsic value">30,000</span> per month in addition to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zoUQauZAXSz5" title="Stock options, vested">360,000</span> stock options that vest monthly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zwr8JgvdTSQa" title="Research and development expense">75,000</span> related to this agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiMember_zF5WPVvD5UFa" title="Research and development expense">30,000</span> upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AlcamiMember_zjgWBiPtStJ3" title="Research and development expense">65,000</span> of lab services from Alcami.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9675;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2022, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AlcamiMember_zKyWKv2prIx3" title="Research and development expense">18,000</span> of lab services from Alcami.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ResearchConsultingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research, Consulting and Supply Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ResearchConsultingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970624256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Plan</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z41Ccz5PSXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(9)
<span id="xdx_827_zYskLrLHgAXi">401(k) Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
has a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the &#8220;401(k) Plan&#8221;).
AIM&#8217;s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations
imposed by federal tax laws, participants are eligible to contribute up to <span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOnekPlanMember_zux9xhht0cd7" title="Percentage of maximum annual contribution per employee, as percentage of their annual salary">15</span>% of their salary (including bonuses and/or commissions)
per annum. Participants&#8217; contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
participant immediately vests in his or her deferred salary contributions as well as the Company&#8217;s safe harbor contributions.
A <span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20230101__20231231_zPmL7gjec7M6" title="Deferred compensation arrangementl, cash awards granted, percentage">6</span>%
safe harbor matching contribution by us was reinstated effective January 1, 2021. For the year ended December 31, 2023 and 2022, the
Company&#8217;s matching contributions were approximately $<span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zDzlD8umTTua" title="Contribution amount">162,000</span>
and $<span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zWVac5329b" title="Contribution amount">122,000</span>,
respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890877522464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureEmploymentAgreementsAbstract', window );"><strong>Employment Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EmploymentAgreementsTextBlock', window );">Employment Agreements</a></td>
<td class="text"><p id="xdx_80E_ecustom--EmploymentAgreementsTextBlock_z3dZg3hif1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(10)
<span id="xdx_829_zMyC1KKbWmIl">Employment Agreements</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had contractual agreements with Named Executive Officers (&#8220;NEO&#8221;) in 2023, and 2022. The aggregate annual base compensation
for these NEO under their respective contractual agreements for 2023 and 2022 was $<span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zj0ShGkuJnL1" title="Employee benefits and share-based compensation">1,275,000</span> and $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zaEP2bBxhiGd" title="Employee benefits and share-based compensation">1,275,000</span>, respectively. In addition,
certain of these Officers were entitled to receive performance bonuses of up to <span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zAWrRcxlY5Ya" title="Revenue, remaining performance obligation, percentage">25</span>% or <span id="xdx_902_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_ziu4G3VqCNwd" title="Revenue, remaining performance obligation, percentage">20</span>% of their respective annual base salary, at
the sole discretion of the Compensation Committee of the Board of Directors. For the years ended December 31, 2023 and 2022, Officers&#8217;
bonuses were $<span id="xdx_903_ecustom--Bonus_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zEMZSOc8AYE5">450,000</span>, to be deferred and paid in 2024 and $<span id="xdx_90B_ecustom--Bonus_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_z1JvkmqZRr9h">450,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, equity was granted as a form of compensation to these Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLuhZd8cUGIg" title="Number of options, granted">300,000</span> <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5g6mpgvgvc3" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1513">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5z5Hbpc0Nte" title="Stock options exercise price per share">0.47</span> per share to vest in <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zP3lUqpy1hlg">one year</span> to
    Thomas K. Equels, Chief Executive Officer. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zC6zjeGF8sLe" title="Number of options, granted">100,000</span> <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zwzTNS7Bj5Xe" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1520">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zTrS2M1Re0Ai" title="Stock options exercise price per share">0.47</span> per share which vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_ztOxwIqUCeed" title="Vesting period">one year</span>
    to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock compensation expense of approximately $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsandRodinoMember_zf8vnYpJe6ol" title="Stock compensation expense">14,000</span> during the year ended December 31, 2023 with regard to these issuances
to Officers Equels and Rodino.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, equity was granted as a form of compensation to these Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z6KkeQwFNM9l" title="Number of options, granted">300,000</span> <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zkTwRI3bRFRj" title="Options term::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1530">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zlND1tOnooGc" title="Stock options exercise price per share">0.41</span> per share to vest in <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLAigI8Ixqb6">one year</span> to
    Thomas K. Equels, Chief Executive Officer. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zqR0Vn4Va4Ni" title="Number of options, granted">150,000</span><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zCXKUdCehaDe" title="Options term::XDX::P10Y"> <span style="-sec-ix-hidden: xdx2ixbrl1537">ten-year</span></span> options to purchase common stock with exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MinimumMember_zVGM4kglJob6" title="Stock options exercise price per share">0.41</span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MaximumMember_z0pDSSJI41T5" title="Stock options exercise price per share">0.70</span> per share which vest in <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zW8O62SfRcNh" title="Vesting period">one
    year</span> to Peter Rodino, Chief Operating Officer and General Counsel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_zF2JjGbqRn9h">50,000</span> <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z9axaCjww9u9" title="::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1545">ten-year</span></span> options to purchase common stock with an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3sSALWeLDHh">0.70</span> per share which vest in <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_ztrwY3O2VUSk">one year</span>
    to Ellen Lintal, former Chief Financial Officer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock compensation expense of approximately $<span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsRodinoAndFormerOfficerLintalMember_zy4Yu23qvXD1" title="Stock compensation expense">107,000</span> during the year ended December 31, 2023 with regard to these issuances
to Officers Equels, Rodino, and former Officer Lintal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureEmploymentAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureEmploymentAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EmploymentAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EmploymentAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878247248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zQOOVYpaB976" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(11)
<span id="xdx_829_zlz5v5PdPTu6">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zVaiRjTuXbg8" title="Operating lease term">1</span> to <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zeNDPYLL2htc" title="Operating lease term">5</span> years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_903_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zPaGW6A9yk8l" title="Operating lease Payment">1,000</span>
to $<span id="xdx_905_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ziPjjkhnYaY2" title="Operating lease Payment">17,000</span>. Certain leases include additional renewal options ranging from <span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zYHnZjDWxwf3" title="Operating lease term">1</span> to <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zlgXnWxMrNn7" title="Operating lease term">5</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



<p id="xdx_8A2_z85JlF1Xgu1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
has classified all of its leases as operating leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023 and 2022, the balance of the right of use assets was $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zbMGwrMOU9uc" title="Right of use asset">697,000</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_zdRwzGCHavDc" title="Right of use asset">829,000</span>, respectively,
and the corresponding operating lease liability balance was $<span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_c20231231_z1GBWvCTxGS2" title="Lease liability">718,000</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20221231_z4bM4Ll48O9g" title="Lease liability">837,000</span>, respectively. Right of use assets are recorded net
of accumulated amortization of $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20231231_zJhI6zUqL3P8" title="Accumulated amortization">363,000</span> and $<span id="xdx_90A_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20221231_zLjp2IYKIKjg" title="Accumulated amortization">158,000</span> as of December 31, 2023 and 2022, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;&#160;&#160;<span id="xdx_8BF_zGZL5uejvTRh" style="display: none">Schedule of AIM
Recognized Rent Expense Associated with Operating Lease</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Classification of lease costs</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Research &amp; development</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost </td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zvy3LB7wwUQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s leases have remaining lease terms between <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zATfJuQh90Y8" title="Operating lease, remaining lease term">3</span> and <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_zmpjeMDRy71c" title="Operating lease, remaining lease term">44</span> months. As of December
31, 2023 and 2022, the weighted-average remaining term was <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zDINuqx6mOY4" title="Weighted average remaining lease term">41</span> and <span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20221231_zbLzyoyha2G3" title="Weighted average remaining lease term">43</span> months, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted average incremental borrowing rate for its leases was <span id="xdx_90A_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zbCfGO82WmBh" title="Weighted average incremental borrowing rate"><span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20221231_z0MPgINDETAf" title="Weighted average incremental borrowing rate">10</span></span>%
as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zbWNcHMSJbZg" style="display: none">Schedule of Operating Lease Future Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zcJjykldx2C">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zZYGeQSguPLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878340528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FASB ASC 740 Income Taxes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes (FASB ASC 740 Income Taxes)</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zrklqGUSkgpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(12)
<span id="xdx_827_zvlAk2Kg9xT7">Income Taxes (FASB ASC 740 Income Taxes)</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#8217;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses and research and development credits generated in New Jersey, all tax benefits will likely not be recognized
due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of December 31, 2023,
the Company has approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL6twwVY9lF2" title="Operating loss carryforwards">166,300,000</span> of Federal net operating loss carryforwards (expiring in the years 2023 through 2038), and
$<span id="xdx_90D_ecustom--OperatingLossCarryforwardsWithNoExpirationDate_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zEauPMWJIJW4" title="Operating loss carry forwards with no expiration date">103,300,000</span> of Federal net operating loss carryforwards with no expiration date, both of which have been limited by Internal Revenue
Code Section 382, available to offset future federal taxable income. The Company has approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--NewJerseyDivisionOfTaxationMember_z6XxYw8iV7C5" title="Operating loss carryforwards">28,800,000</span> of New Jersey state net
operating loss carryforwards (expiring in 2044). The Company has approximately $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdUMO0kEmCag" title="Operating loss carryforwards">82,500,000</span> of Florida state net operating loss carryforwards
with no expiration date to offset future Florida taxable income. The Company has approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__country--BE_zG6U1zZnlsSc" title="Operating loss carryforwards">3,600,000</span> of Belgium net operating loss
carryforwards with no expiration date to offset future taxable income In December 2023, the Company effectively sold $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__stpr--NJ_zMjFiyczoPS9" title="Operating loss carryforwards">14,156,000</span> of its
New Jersey state net operating loss carryforward and $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20230101__20231231__srt--StatementGeographicalAxis__stpr--NJ_zcApvIcqtUC4" title="Effective income tax rate reconciliation, tax credit, amount">38,600</span> in R&amp;D credits for the year 2022 for approximately $<span id="xdx_905_eus-gaap--IncomeTaxReconciliationTaxCredits_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__stpr--NJ_zEMfLp5M7ibk" title="Effective income tax rate reconciliation, tax credit, amount">1,313,000</span>. The utilization
of certain state net operating loss carryforwards may be subject to annual limitations. With no tax due for the foreseeable future, the
Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary
at this time.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Tax Reform Act of 1986, the utilization of a corporation&#8217;s net operating loss carryforward is limited following a greater than
50% change in ownership. As noted above, due to the Company&#8217;s prior and current equity transactions, some of the Company&#8217;s
net operating loss carryforwards are subject to an annual limitation generally determined by multiplying the value of the Company on
the date of the ownership change by the federal long-term tax-exempt rate. Any unused annual limitation may be carried forward to future
years for the balance of the net operating loss carryforward period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the carrying amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management considers
whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net
future deductible amounts become deductible. With the exception of net operating losses generated in New Jersey which can be surrendered
for 80% of their value, due to the uncertainty of the Company&#8217;s ability to realize the benefit of the deferred tax asset, the remainder
of our deferred tax assets are fully offset by a valuation allowance at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an
immaterial deferred tax error of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax">1.4</span>
million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022,
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none">Schedule of Components of Net Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research and Development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization &amp; depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,342</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">R&amp;D credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A0_zeUFKzIwyEv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are included within other assets in the accompanying Consolidated Balance Sheets. The benefits of deferred tax assets are
included within the gain from sale of income tax operating losses in the accompanying Consolidated Statements of Operations and
Comprehensive Loss. The Company&#8217;s deferred tax asset estimates the projected sale of 2023 and 2022 New Jersey state operating
losses to be sold in the subsequent year, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate
Reconciliation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zluv3XFKo1Aj" style="display: none">Schedule of Effective Tax Rate and Statutory Tax Rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Perms</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RTP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Income Tax Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State Rate Change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&amp;D">(272</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&amp;D">0.94</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State NOL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"><span style="-sec-ix-hidden: xdx2ixbrl1717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>NJ NOL True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock Compensation True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fixed Assets True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right" title="Other">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1745">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AD_zyVBat4fM2Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878361600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Relationships and Related Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Certain Relationships and Related Transactions</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpy4TpPKA85b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(13)
<span id="xdx_827_zxlV1UX3tDal">Certain Relationships and Related Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an employment agreement with its NEOs and has granted its NEOs and directors options to purchase its common stock. Please
see details of these Employment Agreements in Note 10 - Employment Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878361600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentrations of Risk</a></td>
<td class="text"><p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zyjoNCG16AJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(14)
<span id="xdx_827_zJu5FExLjD6e">Concentrations of Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments
and accounts receivable. The Company places its cash with high-quality financial institutions and, at times, such amounts in non-interest-bearing
accounts may be in excess of Federal Deposit Insurance Corporation insurance limits. There were no credit-based sales for 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use
in manufacturing Ampligen and Alferon N Injection. At present, the Company does not have any agreements with third parties for the supply
of any of these materials or it is relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection.
Jubilant HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. The Company anticipates that additional
orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, it added Pharmaceutics
International Inc. (&#8220;Pii&#8221;) as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce the drug Ampligen.
This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment the Company&#8217;s
existing fill and finish capacity. If the Company is unable to place adequate acceptable purchase orders with Jubilant or Pii in the
future at acceptable prices upon acceptable terms, it will need to find another manufacturer. The costs and availability of products
and materials the Company would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond
our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations.
There can be no assurance that the Company will be able to obtain such products and materials on terms acceptable to it or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
the Alferon N Injection manufacturing process is on hold and there is no definitive timetable to restart production. If the Company is
unable to acquire FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection inventory or contract
with a CMO, its operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no
assurances that the approved Alferon N Injection product will be returned to production on a timely basis, if at all, or that if and
when it is again made commercially available, it will return to prior sales levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880984896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_z7t6Ujmx0eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(15)
<span id="xdx_82A_zGHl6kYoQvOj">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the provisions of FASB ASC 820 &#8220;Fair Value Measurements&#8221; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 &#8211; Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this
    includes debt and equity securities that are traded in an active market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 &#8211; Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets
    that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full
    term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models,
    discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value
    requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash
    settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As
    discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYDPDRYoMkN5" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1763">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1769">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1771">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1777">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1779">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1785">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A5_zBi8m8zL5Qy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash balances are representative of their fair values as these balances are comprised of deposits available on demand.
For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was
estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair
value of the redeemable warrants (&#8220;Redeemable Warrants&#8221;) related to the Company&#8217;s March 2019 common stock and warrant
issuance, are calculated using a Monte Carlo Simulation (Level 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such
value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions
or the numbers input based on such assumptions, the resulting fair value could be materially different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zrbXdtHsst85" style="display: none">Schedule
of Assumptions to Estimate Fair Value of Warrants&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term">.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term">1.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants measurement input</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zsBs6amkn04c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
    Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate
    with the remaining expected holding periods of the warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Holding Period</i>. The expected holding period represents the period of time that the Warrants are expected to be outstanding until
    they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding
    period.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Volatility</i>. Expected stock volatility is based on daily observations of the Company&#8217;s historical stock values for a period
    commensurate with the remaining expected holding period on the last day of the period for which the computation is made.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Dividend Yield</i>. Expected dividend yield is based on the Company&#8217;s anticipated dividend payments over the remaining expected
    holding period. As the Company has never issued dividends, the expected dividend yield is <span id="xdx_901_ecustom--FairValueMeasurementInputPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zqowt4ev68Yb" title="Fair value measurement, input percentage">0</span>% and this assumption will be continued
    in future calculations unless the Company changes its dividend policy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Probability of a Fundamental Transaction.</i> The possibility of the occurrence of a Fundamental Transaction triggering a Put right
    is extremely remote. As discussed above, a Put right would only arise if a Fundamental Transaction 1) is an all cash transaction;
    (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities
    exchange. The Company believes such an occurrence is highly unlikely because:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company only has one product that is FDA approved but is currently not available for commercial sales.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company will have to perform additional clinical trials for FDA approval of its flagship product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
    and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Available
    capital for a potential buyer in a cash transaction continues to be limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research &amp; Development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction
    at their manufacturing facility; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the above factors utilized in analysis of the likelihood of the Put&#8217;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:</span></p>

<p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z3IoaIciMb6l" style="display: none">Schedule of Range of Probabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: center">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zq7Luw79jzU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Monte Carlo Simulation has incorporated a <span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231_zaqAl3tBTbV6" title="Percentage of probability">5.0</span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation of a Fundamental Transaction,
    for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to
    model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future volatility is necessary as there is no
    mechanism for directly measuring future stock price movements. Daily observations of the Company&#8217;s historical stock values
    for the 100 days immediately prior to the Warrants&#8217; grant dates, with a floor of <span id="xdx_902_ecustom--FloorRateUsedAsProxyForFutureVolatilityPercentage_pid_dp_uPure_c20230101__20231231_zW1ASrkrbeO6" title="Floor rate used as proxy for future volatility percentage">100</span>%, were utilized as a proxy for the future
    volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized a risk-free interest rate corresponding
    to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental
    Transaction and the Warrant expiration date for each simulation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix)
    </i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected time between the announcement and the consummation
    of a Fundamental Transaction is based on the Company&#8217;s experience with the due diligence process performed by acquirers and
    is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant
    Holders would experience in receiving the proceeds of the Put.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period
to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above
Warrants was approximately $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKtiUPvS1ARh">0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879545216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaZ4cv9BcK5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(16)</b> <b><span id="xdx_82D_zZ6GqmFQwI41">Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Because litigation is inherently
unpredictable, assessing contingencies&#160;related to litigation is a complex process involving highly subjective judgment about potential
outcomes of future events. When evaluating litigation contingencies, the Company may be unable to provide a meaningful estimate due to
a number of factors, including the procedural status of the matter in question, the availability of appellate remedies, insurance coverage
related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery and development
of information important to the matter. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated,
or unrelated to possible outcomes, and as such are not meaningful indicators of the Company&#8217;s potential liability or financial exposure.
Accordingly, the Company reviews the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and it assesses
the probability and range of possible losses associated with&#160;contingencies&#160;for potential accrual in the condensed consolidated
financial statements. However, the ultimate resolution of litigated claims may differ from the Company current estimates.</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In the normal course of business,
there are various claims in process, matters in litigation, and other contingencies, certain of which are covered by insurance policies.
When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. We do not record liabilities for
reasonably possible loss contingencies but do disclose a range of reasonably possible losses if they are material and we are able to estimate
such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such
a range. Historically, adjustments to our estimates have not been material. While it is not possible to predict the outcome of these suits,
legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential losses associated with
these matters has been made in the financial statements and that the ultimate resolution of any one of these matters will not have a material
adverse effect on the Company&#8217;s financial position and results of operations. A significant increase in the number of these claims,
or one or more successful claims resulting in greater liabilities than the Company currently anticipates, could materially and adversely
affect the Company&#8217;s business, financial condition, results of operations, and cash flows.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890984254448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_z12tS2VfdSp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(17)
<span id="xdx_82E_znFnaiO3kAei">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2024, the Company entered into a Note Purchase Agreement with an unrelated party raising $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240216__20240216__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__custom--DebtIstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zPd1bN9HZ8Q7" title="Net Proceeds">2,500,000</span>
in net proceeds from the sale of an unsecured promissory Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 28, 2024, the Company entered into a purchase agreement and a
registration rights agreement with an unrelated party, pursuant to which this party committed to purchase up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240328__20240328__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zph9uGpTxlja" title="Purchase commitment">15,000,000</span> of common
stock of the Company for a period of 24 months from the date of the agreement. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, the Company sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zlBh2vNi0Dkc" title="Sale of stock, number of shares issued in transaction">204,547</span> and <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zZhZfO9CzpT4" title="Sale of stock, number of shares issued in transaction">38,462</span> shares of its common stock at prices of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zDVhkDDuwSc3" title="Sale of stock, price per share">0.33</span> and $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zxIPrz3YjgB3" title="Sale of stock, price per share">0.39</span> per share, respectively, under
the Employees and Directors Purchase Plan.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890885206592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(a)
<span id="xdx_86B_zmgK91eyCGD6">Cash and Cash Equivalents</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid
instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year
ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit">250</span>
thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Investment</a></td>
<td class="text"><p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(b)
<span id="xdx_861_zilUSHqnAcu">Marketable Investment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company&#8217;s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments
using the specific identification method and measure the fair value of our marketable investments using a market approach where identical
or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices
from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(c)
<span id="xdx_869_z8KJmsuGquql">Property and Equipment, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective
assets, ranging from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0515">three</span></span> to <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life">ten years</span>. Depreciation expense for the years ended December 31, 2023 and 2022 was $<span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense">39,000</span>
and $<span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense">38,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $<span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges">1,800,000</span> during
the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent and Trademark Rights, net</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(d)
<span id="xdx_862_zxLttbDekJv3">Patent and Trademark Rights, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful
life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights">17</span> years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value,
or their value has become impaired. Such review includes an analysis of the patent and trademark&#8217;s ultimate revenue and profitability
potential. Management&#8217;s review addresses whether each patent continues to fit into the Company&#8217;s strategic business plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(e)
<span id="xdx_86B_zSaIIheXlof5">Use of Estimates</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#8220;GAAP&#8221;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(f)
<span id="xdx_863_zYVcu2A7t1be">Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with
Customers (&#8220;Topic 606&#8221;). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model
to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses
whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that
is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped.
The Company has no other obligation associated with its products once shipment has been accepted by the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Revenue
from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Accounting for Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(g)
<span id="xdx_86A_zzDBc4KDPNel">Accounting for Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Deferred
income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement
of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized.
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes
are enacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#8217;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating
loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company
has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at
this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards and Pronouncements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(h)
<span id="xdx_86E_z3BzQaCVKJkf">Recent Accounting Standards and Pronouncements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2023, the FASB issued ASU 2023-06, <i>Disclosure Improvements. </i>The standard requires additional or amended disclosure requirements
for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation
for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective
dependent upon the SEC&#8217;s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has
evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined
that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740) Improvements to Income Tax Disclosures. </i>The amendments in
this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and
(2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items
is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income
tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting
currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about
income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign
taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid
(net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments
in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income
tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated
by federal (national), state, and foreign.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably
possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range
cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference
when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries
and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations
and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#8217;s
present or future financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(i)
<span id="xdx_86F_zmfAfvjRbn6g">Stock-Based Compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &#8220;Compensation &#8211; Stock Compensation&#8221;,
which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee
is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net
of estimated forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Common Stock Per Share Calculation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(j)
<span id="xdx_866_zorjzfOx4Rcg">Common Stock Per Share Calculation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Basic
and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period.
Equivalent Common shares, consisting of <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares">3,523,949</span> and <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares">2,966,538</span> of stock options and warrants, are excluded from the calculation of diluted
net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(k)
<span id="xdx_864_zU9Jock3a3v3">Long-Lived Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets
or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which
a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business
climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an
accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset
(asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or
forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that,
more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously
estimated useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">When
assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing
the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#8217;s
carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company measures the impairment by comparing the difference between the asset grouping&#8217;s carrying value and its fair value. Long-lived
assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are
determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments
in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing
process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated,
it accelerates the rate of depreciation over the assets&#8217; new, shorter useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(l) Lease accounting</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is a party to leases
for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception
of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification
affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases,
which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit
rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate
the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease
term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The lease term is defined as the
non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will
exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments
made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs,
are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease
liability, while any variable portion is recognized as variable lease expenses as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected not to
recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months
or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">(m) <span>Reclassifications</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior year amounts have
been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders&#8217;
equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878195104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zXpk4uRIk7o7" style="display: none">Schedule
of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Furniture, fixture and equipment</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1,448</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">2,233</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,321</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Property and equipment, net</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">127</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">195</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879990704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeTextBlock', window );">Schedule of Available of Sale</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Mutual
Funds classified as available for sale consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2SSJvsud5uh" style="display: none">Schedule
of Available of Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="margin: 0pt">Fair</p>
                                                                                <p style="margin: 0pt">Value</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Totals</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments">7,631</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

Mutual
Funds classified as available for sale consisted of:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left">Mutual Funds</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Totals</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments">7,137</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">Schedule of Equity Securities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zUPSSRfoE6P7" style="display: none">Schedule
of Equity Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net gain recognized during the year on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">200</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the year on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(176</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the year on equity
    securities still held at the end of the year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">376</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(in
thousands)</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">December
31, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black">Securities</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black; text-align: left">Net losses recognized during the period on equity securities</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">(1,679</td><td style="width: 1%; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Less: Net gains and losses recognized during the period on equity securities sold during the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(751</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(928</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890885171472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents and Trademark Rights, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Patent and Trademark Rights</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Patent and trademark rights consist of the following (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;<span id="xdx_8BC_zivttU9adyx8">Schedule
of Patent and Trademark Rights</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Gross Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Net Carrying Value</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value">2,389</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization">(595</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value">1,794</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">229</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value">216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(69</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value">147</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net amortizable patents and trademarks rights</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">2,605</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(664</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">1,941</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Changes in Patents, Trademark Rights</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_8BF_z0tf6fFOuc0c" style="display: none">Schedule
of Changes in Patents, Trademark Rights</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: right">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(in thousands)</p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; color: Black">December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance">1,941</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Acquisitions</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions">585</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Abandonments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments">(14</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"> Amortization</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization">(199</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">2,313</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Amortization of Patents and Trademarks</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
of patents and trademarks for each of the next five years is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B9_zhAkaswPrKwl" style="display: none">Schedule
of Amortization of Patents and Trademarks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">241</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,213</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880956832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accrued
expenses at December 31, 2023 and 2022 consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BC_zyhFSMGVUH97" style="display: none">Schedule
of Accrued Expenses</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(in thousands) December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Compensation</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">414</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">1</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Professional fees</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,352</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">492</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Clinical trial expenses</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">184</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">36</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">203</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">806</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971329024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Options and Equity Estimated Based on Weighted Average Assumptions</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zRdQc4lhI2ed" style="display: none">Schedule
of Options and Equity Estimated Based on Weighted Average Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black; text-align: left">Risk-free interest rate</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate">4.37</span></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 14%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate">1.74</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate">3.88</span>%</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Expected life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life">10</span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility">99.91</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility">98.43</span>% - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility">107.18</span>%</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average grant date fair value for options issued</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued">$0.43 per option for 400,000 options</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued">$0.51 per option for 850,000 options</span></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding warrants outstanding and exercisable into shares of common stock is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_z5LMDxbstbGf" style="display: none">Schedule
of Warrants Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center"></td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Warrant</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: justify">Outstanding, beginning of year <br/>&#160; <br/></td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year">132.00</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">294,939</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 8%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year">0.99</span> &#8211; <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year">469.92</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">15.19</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1336">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1338">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1341">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(74,450</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired">17.05</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">17.05</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">(68,215</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired">469.92</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">469.92</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1355">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"><span style="-sec-ix-hidden: xdx2ixbrl1358">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">(114</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.80</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year">8.80</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year">0.99</span>-<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year">132.00</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">152,160</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year">8.80</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">8.03</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year">226,610</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$ <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year">0.99</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year">132.00</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">9.10</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Weighted average remaining contractual life</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.75 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year">.94</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Years exercisable</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable">2024</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable">2023</span>-<span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable">2024</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Vest Stock Option Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zF0PfjjCWiX8" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,498,798</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period">4.22</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 10%; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.11</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted">550,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted">0.49</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited">17.71</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,020,214</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period">3.01</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)">8.86</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1055">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted">0.47</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Expired</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired">41.61</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">2,408,438</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period">2.50</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1085">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">2,041,772</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.90</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">6.73</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1093">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Unvested Stock Option Activity</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_znkiS1cgVg4i" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average Exercise</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Average Remaining Contracted Term</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Aggregate Intrinsic</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 12pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2021</span></td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period">412,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">5.85</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1114">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted">550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted">0.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted">9.71</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested">(541,590</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested">9.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(28,584</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">17.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Unvested December 31, 2022</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period">392,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">0.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">8.86</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted">10.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Vested</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested">(413,884</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested">1.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested">6.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited">(7,601</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">9.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired">(4,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">41.61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">366,666</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">2.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period">12.44</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1165">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Vest Stock Option Activity</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B7_zsalMMWYrOo9" style="display: none">Schedule
of Vest Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Remaining Contracted Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black">Outstanding December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period">279,723</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">6.12</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding">7.93</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1183">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1185">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(568</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">153.12</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Outstanding December 31, 2022</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period">579,155</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period">3.09</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.36</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right">360,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.46</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value">10.04</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;Expired</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired">(653</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black">Forfeited</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Outstanding December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period">885,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">2.02</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Vested and expected to vest at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1228">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period">550,055</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">2.56</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.02</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1236">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Unvested Stock Option Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zmTaiMUsaseh" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Number of</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted Average Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contracted <br/>Term</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Aggregate Intrinsic</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Options</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">(Years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2021</span></td><td style="width: 2%; color: Black; text-align: left">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period">97,831</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.89</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 13%; color: Black; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">7.82</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1258">&#8212;</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted">300,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted">0.54</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted">9.68</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested">(229,053</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.82</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(1,989</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2022</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period">166,789</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period">4.05</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">9.49</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1278">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Granted</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted">360,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right">0.46</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted">10.18</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Vested</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested">(137,565</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested">9.47</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Expired</span></td><td style="color: Black; text-align: left">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested">(776</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired">145.24</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Forfeited</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited">(53,447</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited">1.31</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Unvested December 31, 2023</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period">335,001</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">1.83</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period">10.70</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1305">&#8212;</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlanTwoThousandNineMember', window );">Equity Incentive Plan 2009 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Vest Stock Option Activity</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June
24, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">124,399</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year">13.20</span> &#8211; <span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year">1,003.20</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">22.23</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">128,504</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year">13.20</span> &#8211; <span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year">2,127.84</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">25.58</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl0863">&#8212;</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited">(5,047</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited">9.68</span>-<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited">327.36</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">57.79</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited">(4,105</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited">16.76</span>-<span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited">2,127.84</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">129.88</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0883">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0885">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0887">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0889">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0891">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">119,352</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">20.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">124,399</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">22.23</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year">119,352</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year">2,127.84</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year">124,399</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year">13.20</span>-<span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year">1,003.20</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)">4.06</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)">5.98</span> years</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlansTwoThousandAndEighteenMember', window );">2018 Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Vest Stock Option Activity</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zjBHKIJSnVTc" style="display: none">Schedule
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Option</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black; text-align: center">Weighted <br/>Average <br/>Exercise</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center">Price</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; color: Black; text-align: left">Outstanding, beginning of year</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">2,474,971</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year">0.31</span>-<span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">1.72</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,650,017</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; width: 7%; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year">1.11</span> &#8211; <span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year">9.68</span></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year">2.35</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted">400,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted">0.47</span>-<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted">0.47</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.47</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted">850,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted">0.31</span> &#8211; <span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted">1.71</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted">0.51</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Forfeited</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited">(60,829</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited">0.31</span>-<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.98</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited">(25,046</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited">1.85</span> &#8211; <span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited">1.86</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black">Exercised</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0979">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0985">&#8212;</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; color: Black; text-align: left">Outstanding, end of year</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,814,142</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.54</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year">2,474,971</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year">0.31</span> &#8211; <span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year">9.68</span></span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year">1.72</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Exercisable, end of year</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year">2,397,474</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year">0.31</span>-<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year">327.36</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right">4.71</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year">1,916,637</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year">0.41</span> &#8211; <span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year">9.68</span></span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right">2.22</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Weighted average remaining contractual life (years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)">7.96</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="white-space: nowrap; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)">9.65</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">Available for future grants</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">1,210,286</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year">466,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlanTwoThousandNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_EquityIncentivePlanTwoThousandNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlansTwoThousandAndEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_EquityIncentivePlansTwoThousandAndEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880008560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ScheduleOfOperatingLeaseTableTextBlock', window );">[custom:ScheduleOfOperatingLeaseTableTextBlock]</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;&#160;&#160;<span id="xdx_8BF_zGZL5uejvTRh" style="display: none">Schedule of AIM
Recognized Rent Expense Associated with Operating Lease</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">128</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Short-term and variable lease costs</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">335</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: justify">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Classification of lease costs</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">Research &amp; development</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">498</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Lease cost </td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">339</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Future Payments</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zbWNcHMSJbZg" style="display: none">Schedule of Operating Lease Future Payments</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, (in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20231231_zcJjykldx2C">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 35%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1627">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">718</td><td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ScheduleOfOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ScheduleOfOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970867920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FASB ASC 740 Income Taxes) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an
immaterial deferred tax error of approximately $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax">1.4</span>
million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022,
consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none">Schedule of Components of Net Deferred Tax Assets and Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">Deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Net operating losses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,114</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Research and Development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Amortization &amp; depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,342</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">R&amp;D credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,472</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,958</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(36,816</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate and Statutory Tax Rate</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zluv3XFKo1Aj" style="display: none">Schedule of Effective Tax Rate and Statutory Tax Rate</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Pre Tax Book Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss">(28,962</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Federal Rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate">(6,082</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate">21.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State Taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes">(2,244</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes">7.75</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Perms</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms">(83</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms">0.29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>RTP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP">(8</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP">0.03</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Income Tax Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income">(479</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income">1.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State Rate Change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change">-2.13</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>R&amp;D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&amp;D">(272</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&amp;D">0.94</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>State NOL</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"><span style="-sec-ix-hidden: xdx2ixbrl1717">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL">0.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>NJ NOL True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up">1,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up">-3.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock Compensation True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up">(1,347</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up">4.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fixed Assets True Up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up">925</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up">-3.19</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other">(22</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other">0.08</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">NOL Refund VA True Up</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">486</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up">-1.68</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right" title="Other">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance">7,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance">-25.50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl1745">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890878400336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zYDPDRYoMkN5" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="font-size: 10pt">4,805</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1763">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities">7,631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1769">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1771">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 10pt">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments">25,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1777">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1779">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities">7,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1785">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Warrants</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zrbXdtHsst85" style="display: none">Schedule
of Assumptions to Estimate Fair Value of Warrants&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center">December 31,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.31</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.80</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.47</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.67</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term">.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term">1.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants measurement input</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock', window );">Schedule of Range of Probabilities</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_z3IoaIciMb6l" style="display: none">Schedule of Range of Probabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Probability</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: center">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability">1.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability">5.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Range of Probabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890885265024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture, fixture and equipment</a></td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 2,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,321)<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890977203648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federlly insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Equivalent Common shares</a></td>
<td class="nump">3,523,949<span></span>
</td>
<td class="nump">2,966,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=AIM_PatentAndTrademarkRightsMember', window );">Patent and Trademark Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives of patent and trademark rights</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=AIM_PatentAndTrademarkRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=AIM_PatentAndTrademarkRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971529264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Available of Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 7,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">7,631<span></span>
</td>
<td class="nump">$ 7,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=AIM_MutualFundsMember', window );">Mutual Funds[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">7,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">$ 7,631<span></span>
</td>
<td class="nump">7,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=AIM_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=AIM_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880406960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net losses recognized during the period on equity securities</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="num">$ (1,679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains and losses recognized during the period on equity securities sold during the year</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="num">$ (928)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890881487472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Investments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 7,631,000<span></span>
</td>
<td class="nump">$ 7,137,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970907968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Patent and Trademark Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">$ 3,176<span></span>
</td>
<td class="nump">$ 2,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(863)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(750)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879718048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Patents, Trademark Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Beginning balance</a></td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquisitions</a></td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FinitelivedIntangibleAssetsAbandonments', window );">Abandonments</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Accumulated Amortization</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Ending balance</a></td>
<td class="nump">$ 2,313<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FinitelivedIntangibleAssetsAbandonments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets abandonments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FinitelivedIntangibleAssetsAbandonments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970902160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Amortization of Patents and Trademarks (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 2,313<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890983320352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Patents and Trademark Rights, Net (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, estimated useful life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971184960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_AccruedClinicalTrialExpensesCurrent', window );">Clinical trial expenses</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971056544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued', window );">Weighted average grant date fair value for options issued</a></td>
<td class="text">$0.43 per option for 400,000 options<span></span>
</td>
<td class="text">$0.51 per option for 850,000 options<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.43%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.18%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value for options and equity warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890977344480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2009Member', window );">Equity Incentive Plans 2009 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">124,399<span></span>
</td>
<td class="nump">128,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 22.23<span></span>
</td>
<td class="nump">$ 25.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod', window );">Option price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(5,047)<span></span>
</td>
<td class="num">(4,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 57.79<span></span>
</td>
<td class="nump">$ 129.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod', window );">Option price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending of year</a></td>
<td class="nump">119,352<span></span>
</td>
<td class="nump">124,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, end of year</a></td>
<td class="nump">$ 20.72<span></span>
</td>
<td class="nump">$ 22.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, end of year</a></td>
<td class="nump">119,352<span></span>
</td>
<td class="nump">124,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="text">5 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2009Member', window );">Equity Incentive Plans 2009 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price outstanding, beginning of year</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod', window );">Option price, forfeited</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="nump">16.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">13.20<span></span>
</td>
<td class="nump">13.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">13.20<span></span>
</td>
<td class="nump">13.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2009Member', window );">Equity Incentive Plans 2009 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price outstanding, beginning of year</a></td>
<td class="nump">1,003.20<span></span>
</td>
<td class="nump">2,127.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod', window );">Option price, forfeited</a></td>
<td class="nump">327.36<span></span>
</td>
<td class="nump">2,127.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">2,127.84<span></span>
</td>
<td class="nump">1,003.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">$ 2,127.84<span></span>
</td>
<td class="nump">$ 1,003.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2018Member', window );">Equity Incentive Plans 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">2,474,971<span></span>
</td>
<td class="nump">1,650,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, granted</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, forfeited</a></td>
<td class="num">(60,829)<span></span>
</td>
<td class="num">(25,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod', window );">Option price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending of year</a></td>
<td class="nump">2,814,142<span></span>
</td>
<td class="nump">2,474,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, end of year</a></td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="nump">$ 1.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, end of year</a></td>
<td class="nump">2,397,474<span></span>
</td>
<td class="nump">1,916,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">9 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">1,210,286<span></span>
</td>
<td class="nump">466,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2018Member', window );">Equity Incentive Plans 2018 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price outstanding, beginning of year</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod', window );">Option price, forfeited</a></td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">1.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod', window );">Option price, granted</a></td>
<td class="nump">0.47<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2018Member', window );">Equity Incentive Plans 2018 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price outstanding, beginning of year</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="nump">9.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod', window );">Option price, forfeited</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="nump">9.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">9.68<span></span>
</td>
<td class="nump">9.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice', window );">Option price exercisable, end of year</a></td>
<td class="nump">327.36<span></span>
</td>
<td class="nump">9.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod', window );">Option price, granted</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment value of award options exercisedin period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by sharebased payment value of award options forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment value of award options granted in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment value of award options grants in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_EquityIncentivePlans2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880215424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Vest Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">2,020,214<span></span>
</td>
<td class="nump">1,498,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">9 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years) Granted</a></td>
<td class="text">10 years 2 months 1 day<span></span>
</td>
<td class="text">9 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(7,601)<span></span>
</td>
<td class="num">(28,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 9.68<span></span>
</td>
<td class="nump">$ 17.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options,expired</a></td>
<td class="num">(4,175)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 41.61<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending of year</a></td>
<td class="nump">2,408,438<span></span>
</td>
<td class="nump">2,020,214<span></span>
</td>
<td class="nump">1,498,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, end of year</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and Expected to Vest</a></td>
<td class="nump">2,041,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest</a></td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</a></td>
<td class="text">6 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, end of year</a></td>
<td class="nump">2,041,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">6 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">579,155<span></span>
</td>
<td class="nump">279,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(53,447)<span></span>
</td>
<td class="num">(568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 153.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options,expired</a></td>
<td class="num">(653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending of year</a></td>
<td class="nump">885,055<span></span>
</td>
<td class="nump">579,155<span></span>
</td>
<td class="nump">279,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price outstanding, end of year</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and Expected to Vest</a></td>
<td class="nump">550,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</a></td>
<td class="text">10 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to Vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable, end of year</a></td>
<td class="nump">550,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">10 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted', window );">Grants in period, weighted average grant date fair value</a></td>
<td class="text">10 years 14 days<span></span>
</td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 145.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants in period, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangements by share-based payment award options exercises in period weighted average expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by share-based payment award options granted weighted average remaining contractual term 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880222848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unvested Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, brginning of Period</a></td>
<td class="nump">694,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, End of Period</a></td>
<td class="nump">701,667<span></span>
</td>
<td class="nump">694,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, brginning of Period</a></td>
<td class="nump">392,326<span></span>
</td>
<td class="nump">412,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, beginning of Period</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term (years) Unvested, End of Period</a></td>
<td class="text">12 years 5 months 8 days<span></span>
</td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term granted</a></td>
<td class="text">10 years 2 months 1 day<span></span>
</td>
<td class="text">9 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(413,884)<span></span>
</td>
<td class="num">(541,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term vested</a></td>
<td class="text">6 years 8 months 23 days<span></span>
</td>
<td class="text">9 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Forfeited</a></td>
<td class="num">(7,601)<span></span>
</td>
<td class="num">(28,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 9.68<span></span>
</td>
<td class="nump">$ 17.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(4,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 41.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, End of Period</a></td>
<td class="nump">366,666<span></span>
</td>
<td class="nump">392,326<span></span>
</td>
<td class="nump">412,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Ending of Period</a></td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, brginning of Period</a></td>
<td class="nump">166,789<span></span>
</td>
<td class="nump">97,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, beginning of Period</a></td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term (years) Unvested, End of Period</a></td>
<td class="text">10 years 8 months 12 days<span></span>
</td>
<td class="text">9 years 5 months 26 days<span></span>
</td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term granted</a></td>
<td class="text">10 years 2 months 4 days<span></span>
</td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(137,565)<span></span>
</td>
<td class="num">(229,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term vested</a></td>
<td class="text">9 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Forfeited</a></td>
<td class="num">(53,447)<span></span>
</td>
<td class="num">(1,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, End of Period</a></td>
<td class="nump">335,001<span></span>
</td>
<td class="nump">166,789<span></span>
</td>
<td class="nump">97,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Ending of Period</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 145.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options expired weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options granted weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased bompensation arrangement by share-based payment award options nonvested options expired number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options nonvested options expired weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award options nonvested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by share-based payment award options vested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879935328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Outstanding and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of options outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of options outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">226,610<span></span>
</td>
<td class="nump">294,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 9.10<span></span>
</td>
<td class="nump">$ 15.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of options outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross', window );">Warrant price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of options outstanding, beginning of year</a></td>
<td class="num">(74,450)<span></span>
</td>
<td class="num">(68,215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross', window );">Warrant price, expired</a></td>
<td class="nump">$ 17.05<span></span>
</td>
<td class="nump">$ 469.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 17.05<span></span>
</td>
<td class="nump">$ 469.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of options outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod', window );">Warrant price, exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">152,160<span></span>
</td>
<td class="nump">226,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable', window );">Number of options outstanding, beginning of year</a></td>
<td class="nump">152,160<span></span>
</td>
<td class="nump">226,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable', window );">Weighted average exercise price outstanding, beginning of year</a></td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="nump">$ 9.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber', window );">Weighted average remaining contracted term (years) outstanding, ending of year</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear', window );">Years exercisable</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber', window );">Warrant price outstanding, beginning of year</a></td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber', window );">Warrant price outstanding, end of year</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice', window );">Warrant price exercisable, end of year</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear', window );">Years exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber', window );">Warrant price outstanding, beginning of year</a></td>
<td class="nump">132.00<span></span>
</td>
<td class="nump">$ 469.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber', window );">Warrant price outstanding, end of year</a></td>
<td class="nump">8.80<span></span>
</td>
<td class="nump">132.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice', window );">Warrant price exercisable, end of year</a></td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="nump">$ 132.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear', window );">Years exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross warrant price exercisable during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options exercisable, end of year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price exercisable, end of year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contracted term (years) outstanding, ending of year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price outstanding, year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant price outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross warrant price exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross warrant price granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of warrants outstanding years exercisable during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted based compensation arrangement by sharebased payment award options exercisable weighted average remaining contractual term year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890868035808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Apr. 19, 2023</div></th>
<th class="th"><div>Jul. 07, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 12, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage', window );">Common stock specific limitations and restrictions on usage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_WarrantModifications', window );">Warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,000<span></span>
</td>
<td class="nump">$ 217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember', window );">Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,148,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_MaximGroupLLCMember', window );">Maxim Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Transaction fee rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_MaximGroupLLCMember', window );">Maxim Group LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="nump">699,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 316,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Transaction fee rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="nump">$ 9,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember', window );">Directors, Officers and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017,399<span></span>
</td>
<td class="nump">88,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember', window );">Warrants [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,888,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | Maximum [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,665<span></span>
</td>
<td class="nump">266,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfOutstandingStock', window );">Percentage of outstanding stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,873,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RightsMember', window );">Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_EquityIncentivePlanTwoThousandNineMember', window );">Equity Incentive Plan 2009 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock reserved for potential issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FaceValueOfStock', window );">Preferred stock face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares to be issued on conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,285<span></span>
</td>
<td class="nump">86,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,500<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=AIM_BoardMember', window );">Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=AIM_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based payment award options vested in period fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,000<span></span>
</td>
<td class="nump">$ 768,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,999<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.43<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=AIM_NonEmployeeMember', window );">Non-Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based payment award options vested in period fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 247,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,666<span></span>
</td>
<td class="nump">229,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares with limitations and restrictions on usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FaceValueOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face value of stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FaceValueOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_WarrantModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_WarrantModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_MaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_MaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=AIM_EquityIncentivePlanTwoThousandNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=AIM_EquityIncentivePlanTwoThousandNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_BoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_BoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890881495792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Related Information (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890883586736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Consulting and Supply Agreements (Details Narrative)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Integer</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,939,000<span></span>
</td>
<td class="nump">$ 6,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,290,000<span></span>
</td>
<td class="nump">2,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense excluding acquired in process cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ResearchAndDevelopmentExpenseCostEstimatedLives', window );">Estimated lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Invigilators cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member] | Post COVID [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,690,000<span></span>
</td>
<td class="nump">581,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember', window );">Jubilant HollisterStier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_UnitsManufactured', window );">Number of units manufactured | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_NumberOfVials', window );">Additional number of vials | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Inventory work in process and raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember', window );">Jubilant HollisterStier [Member] | Research Consulting and Supply Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_PharmaSolutionsMember', window );">Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_ErasmusMember', window );">Erasmus [Member] | Joint Clinical Study Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_ErasmusMember', window );">Erasmus [Member] | Jjoint Clinical Study Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AzenovaSalesInternationalMember', window );">Azenova Sales International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AlcamiMember', window );">Alcami [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember', window );">Clinical Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,014,000<span></span>
</td>
<td class="nump">4,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember', window );">Manufacturing and Engineering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,220,000<span></span>
</td>
<td class="nump">1,241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_QualityControlMember', window );">Quality Control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271,000<span></span>
</td>
<td class="nump">1,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_RegulatoryMember', window );">Regulatory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 443,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_NumberOfVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_NumberOfVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ResearchAndDevelopmentExpenseCostEstimatedLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense cost estimated lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ResearchAndDevelopmentExpenseCostEstimatedLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_UnitsManufactured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Units manufactured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_UnitsManufactured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_PancreaticCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_PancreaticCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_JubilantHollisterStierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_ResearchConsultingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_ResearchConsultingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_PharmaSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_PharmaSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_ErasmusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_ErasmusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_JjointClinicalStudyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_JjointClinicalStudyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AzenovaSalesInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AzenovaSalesInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AlcamiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AlcamiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_QualityControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_QualityControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_RegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_RegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970820016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred compensation arrangementl, cash awards granted, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution amount</a></td>
<td class="nump">$ 162,000<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=AIM_FourZeroOnekPlanMember', window );">401(k) Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of maximum annual contribution per employee, as percentage of their annual salary</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=AIM_FourZeroOnekPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=AIM_FourZeroOnekPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971131360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=AIM_EquelsandRodinoMember', window );">Equels and Rodino [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=AIM_EquelsRodinoAndFormerOfficerLintalMember', window );">Equels, Rodino and Former Officer Lintal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentContractualAgreementsMember', window );">Employment Contractual Agreements [Member] | Named Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">$ 1,275,000<span></span>
</td>
<td class="nump">$ 1,275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_Bonus', window );">Bonus</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember', window );">Employment Agreement [Member] | Thomas K. Equels [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price per share</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember', window );">Employment Agreement [Member] | Peter Rodino [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price per share</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember', window );">Employment Agreement [Member] | Peter Rodino [Member] | Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember', window );">Employment Agreement [Member] | Peter Rodino [Member] | Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember', window );">Employment Agreement [Member] | Ellen Lintal [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_Bonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_Bonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_EquelsandRodinoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_EquelsandRodinoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_EquelsRodinoAndFormerOfficerLintalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_EquelsRodinoAndFormerOfficerLintalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentContractualAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_EmploymentContractualAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_NamedExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_NamedExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_EmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_ThomasKEquelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_ThomasKEquelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_PeterRodinoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_PeterRodinoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=AIM_EllenLintalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=AIM_EllenLintalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970484912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term and variable lease costs</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970398928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Future Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(123,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 718,000<span></span>
</td>
<td class="nump">$ 837,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890977253968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 697,000<span></span>
</td>
<td class="nump">$ 829,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">718,000<span></span>
</td>
<td class="nump">837,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 363,000<span></span>
</td>
<td class="nump">$ 158,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">41 months<span></span>
</td>
<td class="text">43 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease Payment</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease Payment</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">44 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operation lease right of use asset accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880830992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax</a></td>
<td class="nump">$ 1,604<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">25,114<span></span>
</td>
<td class="nump">19,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and Development costs</a></td>
<td class="nump">3,517<span></span>
</td>
<td class="nump">7,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DeferredTaxAssetsAmortizationAndDepreciation', window );">Amortization &amp; depreciation</a></td>
<td class="nump">6,791<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credits</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DeferredTaxAssetsRightOfUseAssets', window );">Right of use asset</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">38,420<span></span>
</td>
<td class="nump">31,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(36,816)<span></span>
</td>
<td class="num">(30,840)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 1,604<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Revision of Prior Period, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DeferredTaxAssetsAmortizationAndDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp; depreciation expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DeferredTaxAssetsAmortizationAndDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DeferredTaxAssetsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DeferredTaxAssetsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971103904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Tax Rate and Statutory Tax Rate (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Pre Tax Book Loss</a></td>
<td class="num">$ (28,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="num">$ (6,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="num">$ (2,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="nump">7.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Other Perms</a></td>
<td class="num">$ (83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Other Perms</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_IncomeTaxReconciliationForeignIncomeRTP', window );">RTP</a></td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage', window );">RTP</a></td>
<td class="nump">0.03%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Income Tax Income</a></td>
<td class="num">$ (479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Income Tax Income</a></td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal', window );">State Rate Change</a></td>
<td class="nump">$ 618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal', window );">State Rate Change</a></td>
<td class="num">(2.13%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D</a></td>
<td class="num">$ (272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D</a></td>
<td class="nump">0.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss', window );">State NOL</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage', window );">State NOL</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss', window );">NJ NOL True Up</a></td>
<td class="nump">$ 1,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage', window );">NJ NOL True Up</a></td>
<td class="num">(3.88%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Compensation True Up</a></td>
<td class="num">$ (1,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock Compensation True Up</a></td>
<td class="nump">4.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets', window );">Fixed Assets True Up</a></td>
<td class="nump">$ 925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets', window );">Fixed Assets True Up</a></td>
<td class="num">(3.19%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationOther', window );">Other</a></td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance', window );">NOL Refund VA True Up</a></td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage', window );">NOL Refund VA True Up</a></td>
<td class="num">(1.68%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="nump">$ 7,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance', window );">Statutory Valuation Allowance</a></td>
<td class="num">(25.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Statutory Total</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation foreign income tax rate valuation allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating loss refund valuation allowance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible expense fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible new jersey state net operating loss percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation nondeductible state net operating loss percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation rtp percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_IncomeTaxReconciliationForeignIncomeRTP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation foreign income RTP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_IncomeTaxReconciliationForeignIncomeRTP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation net operating loss refund valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible new jersey state net operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible state net operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890880005280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">BELGIUM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">14,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Effective income tax rate reconciliation, tax credit, amount</a></td>
<td class="nump">38,600<span></span>
</td>
<td class="nump">$ 1,313,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">166,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_OperatingLossCarryforwardsWithNoExpirationDate', window );">Operating loss carry forwards with no expiration date</a></td>
<td class="nump">103,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_NewJerseyDivisionOfTaxationMember', window );">New Jersey Division of Taxation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 82,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_OperatingLossCarryforwardsWithNoExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards with no expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_OperatingLossCarryforwardsWithNoExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971458000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalent-Marketable investments</a></td>
<td class="nump">$ 4,805,000<span></span>
</td>
<td class="nump">$ 25,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">7,631,000<span></span>
</td>
<td class="nump">7,137,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalent-Marketable investments</a></td>
<td class="nump">4,805,000<span></span>
</td>
<td class="nump">25,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">7,631,000<span></span>
</td>
<td class="nump">7,137,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalent-Marketable investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalent-Marketable investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890879741616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assumptions to Estimate Fair Value of Warrants (Details) - March 2019 Warrants [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Underlying price per share</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">8.80<span></span>
</td>
<td class="nump">8.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">5.47<span></span>
</td>
<td class="nump">4.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">2 months 8 days<span></span>
</td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=AIM_MarchTwoThousandNineteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890877417552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Range of Probabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfProbability', window );">Percentage of probability</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfProbability', window );">Percentage of probability</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfProbability', window );">Percentage of probability</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfProbability', window );">Percentage of probability</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PercentageOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PercentageOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890971171520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfProbability', window );">Percentage of probability</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage', window );">Floor rate used as proxy for future volatility percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (35,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FairValueMeasurementInputPercentage', window );">Fair value measurement, input percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FairValueMeasurementInputPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement, input Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FairValueMeasurementInputPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate used as proxy for future volatility percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PercentageOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PercentageOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139890970587584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employees Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Directors Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Nonrelated Party [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase commitment</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Unsecured Promissory Note [Member] | Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_EmployeesPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_EmployeesPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_DirectorsPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_DirectorsPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DebtIstrumentAxis=AIM_UnsecuredPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DebtIstrumentAxis=AIM_UnsecuredPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MDJ5H0'N%);NX;?3M;A^K&ZQ6 Z!+K4JOM  FG+L7]*:1R[A,:#-P)V@F9*^
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M]P^=\O+\,Y)KDKJ"& 5T(4.-TY[L^'G^94:^(]@Z^U9ASH1@8;:YHL2C/+U
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M,N/M2X'V0K*=/E<_,0FG=/TSIR2C7!G _QO&Y,N%>D#W:F;U/U!+ P04
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MSE^N2N/_DL>M;=(A^=I8M=P.!@1+6=7_^=,V$0<#:-8R@&T'L)<#^BT#TNV
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M1/XA=C$6I4$@T+A"N--BQ66QZV)U+95=" W[*ZU]8VXE5=KD=CK 5A.B >B
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M7 A0B]H9P/=SI>SNPCU@_QN-R7]02P,$%     @ 1ZI]6+%7+-H\"   -Q(
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MX\ 'U?6.;F'DVM7K4AJJ?C>MJ-VBL@ZT7TII=@M[0-_ LW]02P,$%     @
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M3S%99Z,32.JA0$#O_)=+&[DM*9L.3J-*4(.*"];\GK9ZQCEP' W[/HDZ!77
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M9DAQS8EPZ>@'KN4%/9#]_MC7CP8?731D<J!$A -G"./0-F,W 5B'*\(F$Y<
M'A**K3CH'L3A7P%?UXP=^(SOCI@(_*/Z. Y;%^B,:)::H?W2)\D=,W%",_18
M-;T.8=JG@#>RDI!(!,9TDV8Y]^&4?FY:+JMN50)Q3->Q33<&!V$(%[)'^QKJ
M31B"ZH)/ T1W&E ?.V_H3V?X_+_6=0@*C=^0Z0'"84K;4N?CM6XC9XQZFG<$
M^I_Z8]N]FJ2#P.!)O]?^ 0K+BCJ;=UMW&O^3?RG%\0GM$ I[4I*E_"0V(Z#P
M&4P':1,"?0>C#O)!CVT_P8C(.12E*0D@; '%T6#$L+SA9/<(Z.X?T@!TM+'O
M.C[X]>A%@1B.LL?OR$4=VX(S'V X,D,0T&EEETW*+!%E%M^QPGUI3G'ID3/9
ML>E[I%77"NA$,[+[N0I!J@S:%L]B0P!!P7V(G.T[9H3@](PBABV0[+P!QZ,M
MN4=.YZJM*ZV?CZK'Y[O5([6>W;9DERXV2I@=MSKJ553?@8M8G[T@Q25\?H,2
M- IC,PPILZNC&,?R?/%KL7FBOW4S_P.?ZVY\Z8/4.QVD,/H7:C4?ZXP]4_N>
MZ#LN'U>2'SH!LC52P</]4&-J$L#2 4Q,N83#^  H#_?5HVRZPDM</LRAD[C8
M?K3[=7SZCF?&BH,]0'_'11_KJD>%\83'9X$A>ZE#=:SE^_W\[P;ZX3;]7Q7L
M_W0$GDX';I28$13S#!9Q7$J]WIYUO=ZZ*!MV8N<#ZY51<0\"0$'@T8*/2P8!
MN'6"0*6"!%CT]K'HA3T60\*B[3^!W1YI8> 1LWY@N?Y)H3S3YY:%O?!QR2..
M$?]8*I=>,TBHPWIRZN"(H8D%2@'NK@*.9XY3LQ^9.$9G6H>3AZHJMUDBT<=U
MB<-.RM'$]2/3P87K)N#,HS<QXH<DB1.^^B<DBB<79R?R 6KK&-@A;,<)/#%V
M'^&)79CMU$0]1[SO7@/$HF2/J3<YY@(G4@+L84:83)G+IOX%R>E[;NCL\^IX
MD1F$ ?,*2R?TL>> 413^"0YX*B5X5'TX7"K%M+TVJ-P40I[S_J0Q?-.*G;&H
M)0.7&^AOO-N8WY/K^!Z+G@2^?AWL 2^N55([@9NH6:[#!]A\>J_?(>A?*U"=
MSFA7MGM_J1:%E(N3W3RMNX3_TO$0;P[DO#MU]."AVU?^_Y.')YP\/.F<0>R=
M,QC_P3G#PP\5.JNH$X1>:]T)@O'8$X3Q:8'8/2WX5 YXDUUKKP[/V4-*3@_N
ML9W;?O+P/%2ERFV>XW>SMN\^C;:*O[MSU7O<YYT5!IETL)'5O3/7IX?=&W_2
M5I:+*M:QU<MQM%^(NH&NT,K;'#\2+^D>^F%B)=P(!I:3/'ES=AN/?=,/;-5(
M(/:KSPDZ.=?ABEPMI_X\H.":T*MCY^J]7_HXL0\;N"@$>J%YQC/\L;V3^AC5
M/$^E\9A=+ N=B=IHLA*?CY7J$1X!%%]TD/%/A?+N!8=Z7LF]TV-+O^;ZW0Y\
M]+(Q(C[^D<X/_8[G8O 3*WX[@7Y(QB_\%HWZM55_M_^MVE3]1&L[7/W0[6-:
M ;6UR.4-IB*G!F?J]?'NHBG7_(.M6=DTY8J_+F6*J$,#\/RF+)ON@A;H?\'W
MYG\!4$L#!!0    ( $>J?5@H$^U#(P(  /X$   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;)U436_;, R]]U<(&C!LP! [3IH.G6T@23>LAP)!LH_#
ML(-B,[90?7@24[?_OI+L>!F0IL NMBB1C^]))--6FWM; R!YE$+9C-:(S744
MV:(&R>Q(-Z#<R4X;R="9IHIL8X"5(4B**(GC62095S1/P][*Y*G>H^ *5H;8
MO93,/"U Z#:C8WK86/.J1K\1Y6G#*M@ ?F]6QEG1@%)R"<IRK8B!74;GX^O%
MU/L'AQ\<6GNT)E[)5NM[;]R6&8T](1!0H$=@[O< 2Q#" SD:?WI,.J3T@<?K
M _J7H-UIV3(+2RU^\A+KC'ZDI(0=VPM<Z_8K]'HN/5ZAA0U?TG:^DX228F]1
MRS[8,9!<=7_VV-_#4<#L\H6 I ]( N\N46!YPY#EJ=$M,=[;H?E%D!JB'3FN
M_*-LT+A3[N(PWT#EKA@)4R59@V ();E5W6.[6TLC=$F\:U3T@(L.,'D!<)R0
M.ZVPMN2S*J'\%R!R[ :*R8'B(CF+> /%B$S&'T@2)Y,S>)-!\B3@35Z1O(9&
M&^2J(K_F6XO&%<CO4WH[M.EI--\TU[9A!634=84%\P T?_MF/(L_G>$Z';A.
MSZ'_S_.<!3Q-]]W5^XM7,I%O-5PLM6R8>B)N)!CG8 E71"L@IX1&1S4IP52A
M\RPI]%YA5Y[#[M#<\ZZF_[IWD^&.F8HK2P3L7&@\NG*M8;INZPS43:CPK4;7
M+V%9NP$%QCNX\YW6>#!\@F'DY<]02P,$%     @ 1ZI]6#WN/";:"   Z!D
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ML7[DY8V^8WW;^-ESC0^BQP^+ILWTSA8\$6<=[!8KS$9TSM^\&DX&)T\ 'S?
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MA5D*A=A[L.6!+>@9PV.S^8=[0:#*T1$W+%!22Q*A=#^2NK:>B][LH<0"G5!
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MC0^@[Q.MW<KQ"=K'?_P74$L#!!0    ( $>J?5AC+7#Q-00  %,)   9
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M>,[YSNWCD2XV2G\W:R$L>RKRTESVUM96YX.!2=>BX*:O*E'BR5+I@EO<ZM7
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M@.=+A3>AYH8,=)\JK_X+4$L#!!0    ( $>J?5A2_$GXA@(  /(%   9
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MZK:(55!O=$8(]*F9DI(ZGIHG>QC 0B =G!A$:E?2+@BX!EN2+;A^UC+=:3%
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MX %S82N=LH.?#5%6K54FLC\D:8+9LH.'8E,2YD#%"G:MRER+0X1*BOULI'N
MQ#8GBRAE,C:!M3.UBV5WQZ PE1!O IP/)@B>RL/AS%L6LWVN?>PF4W/J,[^
M8D+/;.1]=CKR.#=W,7-VP(P'/"@@T7"4:<K2.05ZS .L5)RJ?<2#6^0BB0#C
M+O5@%.2QA8LTJ<DWVEGSPE(:SO]>M/]'Y @C9E/+3-6LX/@MV57<4 2Z'UE5
M$5+#X8OECS-83!E\4#BA.8B$YJF6U7><V-)9 UF#7O?D$ZW<)H$I")T=J^4]
M2R$MC">Z'.L8,XT;4=QOD_XFU<I*!(C]H (8FV8]<I-87K*L9=JFD4W\"WNF
MKH'<QGU53:IF>]06R8/BDP0%2H#&P_?AD!_7A45*:AR-%K*:"T5/1I"/#'[>
M7V1X:NYYG*V9U3Z&V2FM(VH173G!NI 5I@L+"=H  /-D/)3O^X2 NDI;#6LA
ML9Y&>'#[<7&\,2LWPJO&J!KM9OA,R?R:BKL_#:044P/B-A13=Z*SCKM6LHCP
M]I);E*(QM^"I@4^6]?D8 AUS3-DT*W> 7O1,L!7KF:XF"'32]0P$CF\R07$,
MATG_9HBP>.<]^B@>F6;2MZ+&U0[X'#OJKF=7DXY<$R]@/FY-(=U2IK?3'>\F
M76WNEZ<+XB?I&B@E-K<:IJ<GKUXLA4N7KO00;!\O.H4-N#;%GRWNJ>1X ;[7
M%AS.#QQ@NOE>_P-02P,$%     @ 1ZI]6%4=3(BO @  %08  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&ULC95+;]LP#,?O^12$5PP;$-2/.&G:)0&2
M/K >N@4MMAV&'12;L87:DBO)=?OM1\F.EZ%MT(NL!_GCGY(HSQJI[G6.:."I
M+(2>>[DQU9GOZR3'DNEC6:&@E:U4)3,T5)FO*X4L=4YEX4=!,/%+QH6WF+FY
MM5K,9&T*+G"M0-=ER=3S"@O9S+W0VTW<\BPW=L)?S"J6X1V:']5:T<CO*2DO
M46@N!2C<SKUE>+:*K;TS^,FQT7M]L)ELI+RW@^MT[@56$!:8&$M@]'G$<RP*
M"R(9#QW3ZT-:Q_W^CG[E<J=<-DSCN2Q^\=3D<V_J08I;5A?F5C9?L<MG;'F)
M++1KH6EMHU,/DEH;67;.I*#DHOVRIVX?]ARFP1L.4><0.=UM(*?R@AFVF"G9
M@++61+,=EZKS)G%<V$.Y,XI6.?F9Q5V]T?A0HS!P^4BMGOF&L';13SK$JD5$
M;R#""&ZD,+F&2Y%B^C_ )SV]J&@G:A4=)%Y@<@RC< A1$(T.\$9]DB/'&[TW
M2?B]W&BCZ$K\>2W?EA:_3K-E<J8KEN#<HSK0J![16WS\$$Z"+P>TQKW6^!#]
M?0=R&/$I//D\>)GS=S&XPHVJJ?8@G+C-C8=@<H1S659,/ .9H<(4N# 2&'R3
M!F%=JR2G:P_+3"&6EM=PDP,34 N%!3/D4#%EGD$QKKG(X BBX3@(AD$04%"X
M842 :/J.B-4N&.N#,9$"&RC,N#TP5\G*5IK>LWE#T-#R=,W(@NA-SDF&R;GN
MY":R++FQUK3:1ZXK.SR"<&SUNQRNQ:#+X85^+8N4IN/A.#Z!T7083R((CD<C
MVYR^=AO\O5(M467N0=*DI1:FK=I^MG_SEFVI_S-O'TS2E'&AH< MN0;')V.O
MW9K=P,C*%?Y&&GI&7#>G=QN5-:#UK:0#[@8V0/\G6/P%4$L#!!0    ( $>J
M?5AN=H59DQ0  (<[   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)U;
M69/C-I)^YZ] U&Q,5$6HZ^RCVGU$5+?=L]ZP=SI<]OIA8Q\@$I+@I@@9(.N8
M7[]?9@(@J))4,_-@MXH",Q-Y?IF WM\[_RVLC.G5P[KMPH>C5=]OOCL["_7*
MK'4X=1O3X9N%\VO=XT^_/ L;;W3#+ZW;L\OS\]=G:VV[HX_O^=E7__&]&_K6
M=N:K5V%8K[5__&1:=__AZ.(H/?C%+E<]/3C[^'ZCE^;6]+]MOGK\=9:I-'9M
MNF!=I[Q9?#BZN?CNT\5+>H%7_(\U]Z'XK&@K<^>^T1\_-A^.SDDBTYJZ)Q(:
M_]R9SZ9MB1+D^#,2/<H\Z<7R<Z+^A3>/S<QU,)]=^[MM^M6'H^LCU9B%'MK^
M%W?_GR9NZ!71JUT;^/_J7M:^>GFDZB'T;AU?A@1KV\F_^B$JHGCA^GS/"Y?Q
MA4N66QBQE-_K7G]\[]V]\K0:U.@#;Y7?AG"V(ZO<]A[?6KS7?[P5:RBW4+=V
MV=F%K777JYNZ=D/7VVZIOKK6UM8$=9P^G;P_Z\&:")S5D<TG87.YA\W%I?K9
M=?TJJ!^ZQC13 F>0.0M^F03_='F0XO>F/E57%S-U>7YY=8#>55;$%=.[VD-O
MUX[_]V8>>@_'^;]=.Q9Z+W?3HVCZ+FQT;3X<(5R"\7?FZ.-?_W+Q^OS= 6E?
M9FE?'J+^\;,.*Z6[1O&''_X<[)UN3=>'78(>)+5;T&-]4NWEP0\JV]7MT$!+
M<]U]0R!L7+#XCC)!C_],HW2O@KDS7K=J83O=U1:?;!=ZVP\4DN%4_;HRZK-;
M;W3WJ&H\L8WQ0:T02NVC:BUX-A6]X8<U<[ZW/<FDG+=+D&S!KA^\[=F!^Y4W
M1JW%SYQ7K0E!]4[-C:II"V;<PJFZZ=6=]M8-6((T$^AM-RQ7R%SX:-2CT;XR
MY*P*KF;6<^.SN\U4<&N#C,(N WE-R[O=O4MU;[S!$V4>:I*()35J81I2#?:)
MQ8,'G]:N;4]?_X>Z?'6N#KC)J^PFKPZZR<_:?S.]GK=&_=C=F="3%G>YR$$R
M>UQD?E+MI$]&K:)1__J7Z\N+-^_(+?)*FU<&L7F G[C6M&S$]= /Y#!#U\!*
MOQMX5F\\,I]!$="M_0<4M81_!7;-UH4 VZ$Z[>%0#8%"FA0>-J:F_*;@9 AT
MRG1<&-:F7[F&R:V-)E.(?;3U<)%V,"26&_9Q4,)!QZ^5WFR\T_5*W:_8[LRL
MUFT%&6O2BF<*&V_A#4ICB;[3MJ6'I^K'A?IS<#WV&*D5RSK7CTMGA7SL4J5$
MM#JKK8D""J5JX=T:PM)?])2,B>>S_&#M&M.&61(C\M]BP&$8X*ZMQJ96FG*D
M\3"DK3GR&ALX-$" (V^!XA\IGQ[RZ]?9KU\?].NO'K#$(^K):)29-B373'5F
MIW<?)+;'N^N3Z@ 7=0MXU RMJ:"9W>LJRA24+BZK8P0_?&P(6!!.)OFD6/5E
M\!URAB?;V@?ZP 1-(HBT<#%[^?*:TL/L\NJJ^@G9Y#O*0L-Z:#4I&UG8P\G%
MKX\O9E>7%^I$'5_.SJ^NU=:&S'1#('[YAO[_]E7>4#7E3VX%\LXWDMQK%_I3
M[*;@:0/[^-!GM^/(0Q$E=/2"5)_BS:$R\+?P*KO6\H99#"WRX)W):1(6V1B&
M;I5&K/=P3:^[)9%F5Y:DWYN.,W905V]GY^?GZNJ:_RE2$2*J@499F-XLD0?"
MRBZ0;R%U]X*L ]%T-RS@RR@I%-+8_;A?+ ,=ZUD5*8?KVK94?=C H+XFKY<4
M?C&[/C]G(0XX_)OL\&\..SQ$)@M HE\]]D'903&$#GN]_B#%/5[?P$F>8:5D
M06#GZ-,*23JA9SM&WU#'R![XTE(M-TO*Z@;HD4ESWEL[WW-"_Q=<!<G/ NXF
M9ZE:N^ $??'FD)ZOLYZO#^KYM\#$?H@NN1-.':2P1Z_FI-HFS;Z))500.';P
MY0@@6).2;.%;*)/4@)&G"0(:P2I4C#<VP#IJ:;J(*/"]V9 EHE_^AL2"OVY[
M9@Q&-VNDZUK#O1'=$+."YZ,)8]\&8EKK;V-<2J5%\ WKC0":?@4+Z\4"<1EC
M= -+DN'7 HC 08)5BK35<PH3&TE1=4#AI@1W3 #A\OS=WVYNOO+'BW<GE%*Q
M8=H=.^(>0L*Z@8 Y&G=IC[UTCXP>Z+0;HE3F 9UN A-XHY(W6,=0EFN &6O&
M)M 7>C[*=$-+NX$B?$I&+A2*FT7N]%"6F8ZJZ5H_$BBE-1[BGJ9V*T1[I&"
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M3>2X=(>RLIIV.>G9Y0W3]VC96B!\D ]H+ 7<&AC<N25S/(\L&7&B47H O*P
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M+30U!'984 >&TAR@_8T0^C Q"OJ>;ODO4$L#!!0    ( $>J?5C<#$2*G (
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M$X?MB</.$_<G@<KA^O,MW&.JUI+_A1D-I86/S_2E&X1K8U3*F:7U+;<%M+S
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MEAL<,$%9 ;Q?26GV&VN@&UG'?P)02P,$%     @ 1ZI]6"5ER@,&!   TPH
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MYZB82O*-QS2\=8>RUA1%OSN%_[=BWIE+A'B(18RJY:+W( T3<.V@A5L9;>7
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MF.#G!2B[ 9_/I33;B0U0?K"$?P!02P,$%     @ 1ZI]6,(AL-3( @  ? D
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M@%_KA2$K[%4*48&R0BMFH)P'I_')V<SY>X=O AJ[,V:NDJ76#\ZX*N9!Y(!
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M8+_RA_EJX7I,KP& 5)>EU,%ZK:,F$;VW!T@2V-OC@51OI:[!6BW0/3WU 3A
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M^D(&K+"!6VZU3.HEMG_;ID.XETA*N0LB"I@)Z=ZR'652V+#]FS2];J,,Z,5
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M42JM5A3:0LM3*%6M\<,K"B469 ^;C$_F9S!";<:[D-)42FD*2^F3(;0VL?!
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M)\@P[$GD!_%H=ED<NZ6SRV2;A4%,;BE(MU'DTY<;$B9/5R,X>CWP.5BML_S
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M$P^*L>QF"+DNM"?6K@BS1LP;>(Z7BY4 >#D SUS$"4>0BXIWA$G. TCZ?Y*
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MD^>;AT_* ;[DQ6^[PW[[?U!+ P04    " !'JGU85];C:"8"  "G!   &0
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MKX;S:B%9:>;;%9-J6C:76_5! UP+J.=KQN330H_,S2?2]!=02P,$%     @
M1ZI]6-SO8!N%!   EQ,  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
MI9A;<^(V%,>_BL;=[F1G6FQ)!D,6F(&P.]W.7A@@Z4.G#XHMP!/;8B4Y9+]]
M99M8I$B";E[ %YWS/^=8^NDRW#/^(+:42O"49X48>5LI=]>^+^(MS8GHL!TM
MU)LUXSF1ZI9O?+'CE"2U49[Y* AZ?D[2PAL/ZV=S/AZR4F9I0><<B#+/"?\Q
MI1G;CSSH/3]8I)NMK![XX^&.;.B2RMO=G*L[O_62I#DM1,H*P.EZY$W@]12'
ME4'=XBZE>W%T#:I4[AE[J&X^)2,OJ"*B&8UEY8*HOT=Z0[.L\J3B^'YPZK6:
ME>'Q];/WCW7R*IE[(N@-R_Y*$[D=>7T/)'1-RDPNV/X/>DBH6_F+62;J7[!O
MVD8##\2ED"P_&*L(\K1H_LG3H1!'!@A9#-#! -5Q-T)UE#,BR7C(V1[PJK7R
M5EW4J=;6*KBTJ+[*4G+U-E5V<KQ4GSDI,PK8&GQ8KVE=)+ B3V!!) 6D2,!2
M$EE*QG_HQU<S*DF:B7?@#4@+L-JR4JBF8NA+%5/EV8\/^M-&'UGT(0)?6"&W
M GPH$IJ\=."K9-J,T'-&4^3T.*-Q!V#X&T !PN!V.0-7;]XY_.*V4KCVBRU^
M/Q4QRYO2S%(19TR4G(*_)_="<M6W_C'EWG@,S1ZK 7<M=B2F(T^-*$'Y(_7&
M;W^!O>"](]ZPC3=T>1_/>1/L5(T(\)D)X\=I7'1K%]4 ?AS_COJ#'AKZCP;I
M;BO==4I_I GE)*O[BDFU>ZK:"_H6T5XKVGN5:&,-X9%JT$'0+!JUHI%3M!H;
M=9FIL;R1H;PH#,V:_5:S_QK-QGCP(LT@BKIFT4$K.G"*?I-;RL&<\MPH.CA-
MM(_-BC#0: I>HWFP_D^F 1I8=(^0")VZB]7<J <-25JTD-9"/Z6%C+D%MIIJ
MB$$G<XXIUEP:U?%IIF%DJZL&$G03Z3+MT)0Y[%GZ+]1,@FXH-<.FGKYNMJ38
MF-5/T=2#MH^LR03=:+I,VNWC"G4@_M4UD4$-+>BFUN(MR7?O9\8H3,B*+&B&
M&EG0S2R7HA%8P<!"2:B)!=W(:JK^]=MGHZK3UCPU ]?J1%,-N:GF#.M@^W*6
M,A<":9XA-\^^_EG)@14O*;C=&65/T08ALL &:;@A-]PN$'8[N,*=?M_9Z9$F
M'W*3;RE9_ !N6*XV-(+46P)78 8$0AQ&EI)H!B(W _]G%$88AC88(@U#=&:%
MEC[1!$R$H%(X SCEX0#9U#4/T9FEVJ7J9Y"(.W#@[AT:B<B-Q'JM88S!N(:S
M5$#S$+EY:)<STS"PS$%(TQ"Y:5@-Q 5=EVI#=S=Q%OUT+1?V>V9YK*F'W=2[
M6/Z,GRO8Z;F)@#47L9N+=R0KFR$XR3*V)T5LG)CQ*1PCW+<, JSAB-ULT]OJ
M2^,XPTK4[70#=VF.]KIN6*Z8))DQB)_8TKKF3:S)B<^1LSV&L 87GI\]_:.S
MDISR37TB)$#,RD(VQR;MT_;4:=*<M>CFS9'5%\(W:2% 1M?*-.A$JHOPYA2H
MN9%L5Y^\W#,I65Y?;BE1V]2J@7J_9DP^WU0"[5G<^%]02P,$%     @ 1ZI]
M6+)$IB,/!   $A0  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULM5C;
M;N,V$/T50ET4"9"-1,F6G=0V$%^V39"D0=QT42SZP$ACFUA)=$GZDK\O22FZ
MK!6U">0\Q"*E.>0YG+&.9[!C_+M8 4BTCZ-$#*V5E.M+VQ;!"F(BSMD:$G5G
MP7A,I!KRI2W6'$AH@N+(=AW'MV-"$VLT,',/?#1@&QG1!!XX$ILX)OQE#!';
M#2ULO4X\TN5*Z@E[-%B3)<Q!/JT?N!K9.4I(8T@$90GBL!A:5_AR@B]T@'GB
M3PH[4;I&FLHS8]_UX#H<6H[>$4002 U!U,<6)A!%&DGMXY\,U,K7U('EZU?T
M+X:\(O-,!$Q8])6&<C6T^A8*84$VD7QDN]\@(]35> &+A/F/=NFS/;5BL!&2
MQ5FP&L<T23_)/A.B%(#]-P+<+,#],:#S1H"7!7B&:+HS0VM*)!D-.-LAKI]6
M:/K":&.B%1N:Z&.<2Z[N4A4G1]=)P&) ?Y ]"'3RY6H^1E?S">IU'%2^=8I.
MIB )C02Z)YP3K?TI^HR>YE-T\NET8$NU%XUH!]FZXW1=]XUUL8ON6")7 LV2
M$,(J@*U(Y$S<5R9CMQ%Q"L$Y\O 9<AW7J]G0Y/^'NPW;\7)A/8/7>0-O/+O]
M]?KIKDZ9QD!=MY=B30(86JHP!? M6*.??\*^\TL=JY; *AP[.<>.0??>X/C[
M&G0J)$MTRX1 $Y49+^J;94=X*-"W6_4TNI80B[_K5.BTJ4)+8!45NKD*W<:3
M+E2(M I!684ZXBE:UZ#I;]GMR/,=_3>PMV5.C:M^D).?<_(;.=W/OJ*;V>-\
M]E<=@\;8]QY=2V 5FKV<9N]X"=QK4X66P"HJ]',5^JTF<(KFEQ(8=W#7/\S@
MQF4_2.HB)W712&JV6("Q"(BF[S%)]DC1!&4^ I8$-*)$&XDS<R/@$%)YADC,
M-HFL(WUQ0-KK^P>,+PYJ&WO8*RM3(8.=XC7M--*9*@I"TD"_CM'51JX8I_(%
M?;N#^!EX;7XV([XW0=M"J_(OV11\O$K-L-M2HB6TJA)NH83;:K5F<)5R]7VO
M[HW3O/)'F16."3=;ICIF*#_D'94KE# $^S7EIG11J,JYEK)W2-GQZBD?PS_A
MPD#A1F<RNE>_<VZ "WA!4[JEYL<16^@B3QDVUG>K#JHMM*H0A8?"W2/6=TM6
M*5/B&,8+%\X+-UNO=]>W?Y#L;K]?F^O'L%JX\%JXT<2,YE*_?4D2JB,.2(1N
M-IR*D ;_G>BM.JVVT*HJ%%X+]X^8Z"TYJDR)8_@S7!@TW.S0WIWHA^:J[W9K
M$[UQX?<2LTO=E1CXTC2=U'ZU4TS;$_ELWMBZ,NV<'^;'NN%ENC8%3-HMNR-\
M21.!(E@H2.>\ITCRM &5#B1;FQ[.,Y.2Q>9R!20$KA]0]Q>,R=>!7B!O X[^
M!5!+ P04    " !'JGU80<ZF:W8#   9$@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6S-6%UOFS 4_2L6FZ9-Z@J&?+5+D-I4TRJU4]6JW4.U!R?<
M)%8-SFR3;/]^-E "*_&:ADI]23#<>SCG<*]U8;CFXD$N !3Z';-$CIR%4LMC
MUY73!<1$'O(E)/K*C(N8*+T4<U<N!9 H2XJ9ZWM>SXT)39QPF)V[$N&0IXK1
M!*X$DFD<$_'G%!A?CQSL/)ZXIO.%,B?<<+@D<[@!=;N\$GKEEB@1C2&1E"=(
MP&SDG.#C,>Z9A"SBCL):5HZ1D3+A_,$LSJ.1XQE&P&"J# 31?RL8 V,&2?/X
M58 ZY3U-8O7X$?UK)EZ+F1 )8\Y^T$@M1L[ 01',2,K4-5]_@T)0U^!-.9/9
M+UH7L9Z#IJE4/"Z2-8.8)OD_^5T844G G2T)?I'@/S<A*!*"3&C.+)-U1A0)
MAX*OD3#1&LT<9-YDV5H-3<QCO%%"7Z4Z3X4WNBZBE 'B,W0B)2B)2!*A"THF
ME%%%0:)+(#(5$"&BT%="!;HC+-4)^AF@:YBF0M!DCDZ)I!)]/ -%*).?T&=T
M>W.&/K[_-'25YFGNYDX+3J<Y)W\+IS.8'J( 'R#?\X.&]/'ST_UZNJO=*2WR
M2XO\#"_8@K?1?/!?B[0I&TM,U'>>B'\\NK_0-T#G"F+YL\F<G$VGF8UIZV.Y
M)%,8.;IO)8@5..&'=[CG?6FRJB6PFG%!:5Q@0P_'1"X0_$KIBC!(U.=+(AYT
M>4QTM=%D!5+I[4#))@MRW&Z&:S:B5=@9>%W/\X;NJJKN:9S?Q0.O&EACWBF9
M=ZS,*TRE>7K94VXBFL/T*@3ZO0 _)=H0AX/^5I[=DF?7RK-:FN?),E7R %W
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M-P$V [DS0YT(+\Q0W/*+WT/T^ U".FQ#.GP]T6NHX7/-]XE^U#(XZF1PZRY
MR-')$J3ET:5^)]0+4S5LB0[?0_WA&X04!IMK/'@]_1NL/T]]N'L#A%MO2=A]
M[O'C7\]]-\1+\Q1M*$;O(7[C]96CVCQB8>>#\I_J]__ISO>WB@H&<N%*)X4R
M47%=UQ?M:%N>G=1%R69Y7=M-L%P0KA"%N3$->H?F\I=UN51WM"A=B3(3VA0\
MKEF8$A.D76#FYT+H=<<Z:(O6]#=02P,$%     @ 1ZI]6(@]N<MG P  GPT
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MW6]V:JKZ6.4LPH%#9:M0SM$)W[WQ>][')D6V!+:ASWZMSWX;>CA"&9$@M!F
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MYUI)]>-'(^JT/K7AZ?F+^A<3O IF303<LORO+)6[A3-S4 H;4N7R&SO\#DU
M$ZV7L%R8(SK4;:>1@Y)*2%8TQJH'14;K?_*S 7%BX(=G#(+&('BKP;@Q&+\V
MF)PQ"!N#T)"I0S$<,)$DGG-V0%RW5FKZQ, TUBK\C.KWOI)</<V4G8Q7U5K
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M7-2"BRX!5_(L 50J=@9<'Z%!O4L)V13#M=CLA) W&H_[^4Q;/M-!/CCC:AW
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M_SNI'L_WENOC+\NODY-7Y8)SNJVHSW\!4$L#!!0    ( $>J?5CNU>T8Y@$
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M9VN7?QP_///6U-TAGPW_=IJ] 5!+ 0(4 Q0    ( $>J?5@'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 1ZI]6.8YI_/O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 1ZI]6)E<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !'JGU8
M?-/IO\D'   K,P  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 1ZI]6&<T:45J!@  (QT  !@
M     ("!#1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M $>J?5@"N<:_G0,  ,\/   8              " @:T6  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " !'JGU8ZKH.3[D$  "F$0  &
M            @(& &@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ 1ZI]6 =U^G#T!0  &BL  !@              ("!;Q\  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $>J?5@-536210<  *\A
M   8              " @9DE  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " !'JGU8L5<LVCP(   W$@  &               @($4+0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 1ZI]6-[_W5F]
M$P  334  !@              ("!AC4  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( $>J?5CZ9#=@WP,  ,L*   8              "
M@7E)  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !'JGU8
MU)K+4.\#  !F"0  &0              @(&.30  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( $>J?5CGK.'PF (  ,P%   9
M      " @;11  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ 1ZI]6)+3IFWQ$0  S3<  !D              ("!@U0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !'JGU8*!/M0R,"  #^!
M&0              @(&K9@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( $>J?5@][CPFV@@  .@9   9              " @05I  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 1ZI]6%-,2J@6
M P  K@8  !D              ("!%G(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " !'JGU8M*B<Q0L#   ("   &0
M@(%C=0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $>J
M?5AC+7#Q-00  %,)   9              " @:5X  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ 1ZI]6!*7IE^Y"   MA0  !D
M         ("!$7T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " !'JGU84OQ)^(8"  #R!0  &0              @($!A@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $>J?5B9M4K8X08  &X/
M   9              " @;Z(  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ 1ZI]6'5[X:"N"P  V1T  !D              ("!UH\
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !'JGU882DT
MWU@&   %#P  &0              @(&[FP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( $>J?5A5'4R(KP(  !4&   9
M  " @4JB  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M1ZI]6&YVA5F3%   ASL  !D              ("!,*4  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " !'JGU8 ZXEJY4"  "T!0  &0
M            @('ZN0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( $>J?5AF$,&U5 ,  'H)   9              " @<:\  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 1ZI]6-G&P9B\ P
MWPD  !D              ("!4<   'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " !'JGU8W Q$BIP"  #,!0  &0              @(%$
MQ   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $>J?5BQ
M>FKU[ @  )HE   9              " @1?'  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ 1ZI]6.C$T!F* P  N0@  !D
M     ("!.M   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $>J?5ASJ4OCP0(  *,*   9              "
M@43D  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 1ZI]
M6.QY^![G @  W0<  !D              ("!/.<  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " !'JGU8\V5@@RH"   8!0  &0
M        @(%:Z@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( $>J?5C63]9@8 ,  "\.   9              " @;OL  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 1ZI]6$PE?P\  P  O @
M !D              ("!4O   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " !'JGU8PB&PU,@"  !\"0  &0              @(&)\P
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $>J?5BT,#9C
M5 (   \'   9              " @8CV  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ 1ZI]6$K&BF6> @  9@<  !D
M ("!$_D  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !'
MJGU8 @%(:'P#  "S#0  &0              @('H^P  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $>J?5A_W"7[]@<  +TV   9
M          " @9O_  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ 1ZI]6'T XDXH"   F3P  !D              ("!R <! 'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !'JGU8%1@2A8$'  !"
M-   &0              @($G$ $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    ( $>J?5A-,=R]G 4  & B   9              " @=\7
M 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 1ZI]6"AV
MF*4X&P  C\D! !D              ("!LAT! 'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    " !'JGU85];C:"8"  "G!   &0
M    @($A.0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M $>J?5A*X^H=^ D  $YW   9              " @7X[ 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ 1ZI]6!; 0I0) P  K0D  !D
M             ("!K44! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " !'JGU8]4>K0@0%   E'   &0              @('M2 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( $>J?5AB\\$"0 ,
M  P,   9              " @2A. 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ 1ZI]6/P\#+ZG @  @ D  !D              ("!
MGU$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !'JGU8
MS6E:27X#  "$#@  &0              @(%]5 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( $>J?5@D!?X.Q@,  "X-   9
M      " @3)8 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ 1ZI]6-SO8!N%!   EQ,  !D              ("!+UP! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !'JGU8LD2F(P\$   2%
M&0              @('K8 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( $>J?5A!SJ9K=@,  !D2   9              " @3%E 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 1ZI]6$%?QNS;
M P  .Q0  !D              ("!WF@! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " !'JGU8\&+.\M8"  # "@  &0
M@('P; $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $>J
M?5B(/;G+9P,  )\-   9              " @?UO 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ 1ZI]6"[+9ICU P  YA4  !D
M         ("!FW,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M    " !'JGU8OS3H\"X#  #N$@  #0              @ ''=P$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( $>J?5B7BKL<P    !,"   +
M  "  2![ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $>J?5@J1WPY9 4  +8I
M   /              "  0E\ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !'JGU8)V75I0P"  "$)0  &@              @ &:@0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !'JGU8[M7M&.8!  #U)
M$P              @ '>@P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..1P!' &@3  #UA0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>371</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Marketable Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/MarketableInvestments</Role>
      <ShortName>Marketable Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Patents and Trademark Rights, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNet</Role>
      <ShortName>Patents and Trademark Rights, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Segment and Related Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SegmentAndRelatedInformation</Role>
      <ShortName>Segment and Related Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Research, Consulting and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements</Role>
      <ShortName>Research, Consulting and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Employment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/EmploymentAgreements</Role>
      <ShortName>Employment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes</Role>
      <ShortName>Income Taxes (FASB ASC 740 Income Taxes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Certain Relationships and Related Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions</Role>
      <ShortName>Certain Relationships and Related Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ConcentrationsOfRisk</Role>
      <ShortName>Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Marketable Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/MarketableInvestmentsTables</Role>
      <ShortName>Marketable Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/MarketableInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables</Role>
      <ShortName>Patents and Trademark Rights, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PatentsAndTrademarkRightsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables</Role>
      <ShortName>Income Taxes (FASB ASC 740 Income Taxes) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/FairValue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Available of Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails</Role>
      <ShortName>Schedule of Available of Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails</Role>
      <ShortName>Schedule of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Marketable Investments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative</Role>
      <ShortName>Marketable Investments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/MarketableInvestmentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails</Role>
      <ShortName>Schedule of Patent and Trademark Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails</Role>
      <ShortName>Schedule of Changes in Patents, Trademark Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails</Role>
      <ShortName>Schedule of Amortization of Patents and Trademarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative</Role>
      <ShortName>Patents and Trademark Rights, Net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails</Role>
      <ShortName>Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails</Role>
      <ShortName>Schedule of Vest Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails</Role>
      <ShortName>Schedule of Unvested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Segment and Related Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative</Role>
      <ShortName>Segment and Related Information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SegmentAndRelatedInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative</Role>
      <ShortName>Research, Consulting and Supply Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - 401(k) Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/KPlanDetailsNarrative</Role>
      <ShortName>401(k) Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/KPlan</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Employment Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative</Role>
      <ShortName>Employment Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/EmploymentAgreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails</Role>
      <ShortName>Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails</Role>
      <ShortName>Schedule of Operating Lease Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/LeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails</Role>
      <ShortName>Schedule of Effective Tax Rate and Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails</Role>
      <ShortName>Schedule of Assumptions to Estimate Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Schedule of Range of Probabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails</Role>
      <ShortName>Schedule of Range of Probabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Fair Value (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValueDetailsNarrative</Role>
      <ShortName>Fair Value (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/FairValueTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 -  form10-k.htm 84, 140, 141, 142, 143, 144</Log>
  </Logs>
  <InputFiles>
    <File>aim-20231231.xsd</File>
    <File>aim-20231231_cal.xml</File>
    <File>aim-20231231_def.xml</File>
    <File>aim-20231231_lab.xml</File>
    <File>aim-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="814">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "AIM",
   "nsuri": "http://aimimmuno.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "aim-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aim-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aim-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aim-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aim-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 74,
   "axisStandard": 21,
   "axisCustom": 1,
   "memberStandard": 33,
   "memberCustom": 47,
   "hidden": {
    "total": 137,
    "http://fasb.org/us-gaap/2023": 106,
    "http://aimimmuno.com/20231231": 28,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 227,
   "entityCount": 1,
   "segmentCount": 84,
   "elementCount": 580,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 814,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://aimimmuno.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aimimmuno.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://aimimmuno.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://aimimmuno.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aimimmuno.com/role/DescriptionOfBusiness",
     "longName": "00000007 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aimimmuno.com/role/MarketableInvestments",
     "longName": "00000009 - Disclosure - Marketable Investments",
     "shortName": "Marketable Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNet",
     "longName": "00000010 - Disclosure - Patents and Trademark Rights, Net",
     "shortName": "Patents and Trademark Rights, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aimimmuno.com/role/AccruedExpenses",
     "longName": "00000011 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aimimmuno.com/role/StockholdersEquity",
     "longName": "00000012 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aimimmuno.com/role/SegmentAndRelatedInformation",
     "longName": "00000013 - Disclosure - Segment and Related Information",
     "shortName": "Segment and Related Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements",
     "longName": "00000014 - Disclosure - Research, Consulting and Supply Agreements",
     "shortName": "Research, Consulting and Supply Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aimimmuno.com/role/KPlan",
     "longName": "00000015 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aimimmuno.com/role/EmploymentAgreements",
     "longName": "00000016 - Disclosure - Employment Agreements",
     "shortName": "Employment Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:EmploymentAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:EmploymentAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aimimmuno.com/role/Leases",
     "longName": "00000017 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes",
     "longName": "00000018 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes)",
     "shortName": "Income Taxes (FASB ASC 740 Income Taxes)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions",
     "longName": "00000019 - Disclosure - Certain Relationships and Related Transactions",
     "shortName": "Certain Relationships and Related Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aimimmuno.com/role/ConcentrationsOfRisk",
     "longName": "00000020 - Disclosure - Concentrations of Risk",
     "shortName": "Concentrations of Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aimimmuno.com/role/FairValue",
     "longName": "00000021 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aimimmuno.com/role/Contingencies",
     "longName": "00000022 - Disclosure - Contingencies",
     "shortName": "Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aimimmuno.com/role/SubsequentEvents",
     "longName": "00000023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aimimmuno.com/role/MarketableInvestmentsTables",
     "longName": "00000026 - Disclosure - Marketable Investments (Tables)",
     "shortName": "Marketable Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentIncomeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentIncomeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables",
     "longName": "00000027 - Disclosure - Patents and Trademark Rights, Net (Tables)",
     "shortName": "Patents and Trademark Rights, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aimimmuno.com/role/AccruedExpensesTables",
     "longName": "00000028 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aimimmuno.com/role/StockholdersEquityTables",
     "longName": "00000029 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aimimmuno.com/role/LeasesTables",
     "longName": "00000030 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:ScheduleOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:ScheduleOfOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables",
     "longName": "00000031 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Tables)",
     "shortName": "Income Taxes (FASB ASC 740 Income Taxes) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aimimmuno.com/role/FairValueTables",
     "longName": "00000032 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000033 - Disclosure - Schedule of Property and Equipment (Details)",
     "shortName": "Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FurnitureAndFixturesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FurnitureAndFixturesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails",
     "longName": "00000035 - Disclosure - Schedule of Available of Sale (Details)",
     "shortName": "Schedule of Available of Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentIncomeTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentIncomeTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails",
     "longName": "00000036 - Disclosure - Schedule of Equity Securities (Details)",
     "shortName": "Schedule of Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative",
     "longName": "00000037 - Disclosure - Marketable Investments (Details Narrative)",
     "shortName": "Marketable Investments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails",
     "longName": "00000038 - Disclosure - Schedule of Patent and Trademark Rights (Details)",
     "shortName": "Schedule of Patent and Trademark Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
     "longName": "00000039 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)",
     "shortName": "Schedule of Changes in Patents, Trademark Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails",
     "longName": "00000040 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)",
     "shortName": "Schedule of Amortization of Patents and Trademarks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
     "longName": "00000041 - Disclosure - Patents and Trademark Rights, Net (Details Narrative)",
     "shortName": "Patents and Trademark Rights, Net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "00000042 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
     "longName": "00000043 - Disclosure - Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)",
     "shortName": "Schedule of Options and Equity Estimated Based on Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000044 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_EquityIncentivePlans2009Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_custom_EquityIncentivePlans2009Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
     "longName": "00000045 - Disclosure - Schedule of Vest Stock Option Activity (Details)",
     "shortName": "Schedule of Vest Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
     "longName": "00000046 - Disclosure - Schedule of Unvested Stock Option Activity (Details)",
     "shortName": "Schedule of Unvested Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "00000047 - Disclosure - Schedule of Warrants Outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants Outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000048 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockConvertibleConversionPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockConvertibleConversionPrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative",
     "longName": "00000049 - Disclosure - Segment and Related Information (Details Narrative)",
     "shortName": "Segment and Related Information (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
     "longName": "00000050 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)",
     "shortName": "Research, Consulting and Supply Agreements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://aimimmuno.com/role/KPlanDetailsNarrative",
     "longName": "00000051 - Disclosure - 401(k) Plan (Details Narrative)",
     "shortName": "401(k) Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
     "longName": "00000052 - Disclosure - Employment Agreements (Details Narrative)",
     "shortName": "Employment Agreements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_EquelsandRodinoMember",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "AIM:EmploymentAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_EquelsandRodinoMember",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "AIM:EmploymentAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
     "longName": "00000053 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)",
     "shortName": "Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails",
     "longName": "00000054 - Disclosure - Schedule of Operating Lease Future Payments (Details)",
     "shortName": "Schedule of Operating Lease Future Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://aimimmuno.com/role/LeasesDetailsNarrative",
     "longName": "00000055 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "00000056 - Disclosure - Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Components of Net Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails",
     "longName": "00000057 - Disclosure - Schedule of Effective Tax Rate and Statutory Tax Rate (Details)",
     "shortName": "Schedule of Effective Tax Rate and Statutory Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationTaxExemptIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationTaxExemptIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative",
     "longName": "00000058 - Disclosure - Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)",
     "shortName": "Income Taxes (FASB ASC 740 Income Taxes) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_country_BE",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_country_BE",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "00000059 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
     "longName": "00000060 - Disclosure - Schedule of Assumptions to Estimate Fair Value of Warrants (Details)",
     "shortName": "Schedule of Assumptions to Estimate Fair Value of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails",
     "longName": "00000061 - Disclosure - Schedule of Range of Probabilities (Details)",
     "shortName": "Schedule of Range of Probabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:PercentageOfProbability",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_srt_MinimumMember",
      "name": "AIM:PercentageOfProbability",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://aimimmuno.com/role/FairValueDetailsNarrative",
     "longName": "00000062 - Disclosure - Fair Value (Details Narrative)",
     "shortName": "Fair Value (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:PercentageOfProbability",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000063 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "AIM_AbandonmentOfPatentAndTrademarkRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AbandonmentOfPatentAndTrademarkRights",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abandonment and expiration of patents and trademark rights",
        "documentation": "Abandonment of patent and trademark rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r687"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funds receivable from New Jersey net operating loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227"
     ]
    },
    "AIM_AccruedClinicalTrialExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial expenses",
        "documentation": "Accrued clinical trial expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r147",
      "r525"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r30",
      "r415",
      "r418",
      "r454",
      "r542",
      "r543",
      "r748",
      "r749",
      "r750",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r687",
      "r894"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r564",
      "r759",
      "r760",
      "r761",
      "r872",
      "r895"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r348"
     ]
    },
    "AIM_AlcamiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AlcamiMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcami [Member]",
        "documentation": "Alcami [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_AllianceGlobalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AllianceGlobalPartnersLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Global Partners, LLC [Member]",
        "documentation": "Alliance Global Partners, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_AmarexClinicalResearchLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AmarexClinicalResearchLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amarex Clinical Research LLC [Member]",
        "documentation": "Amarex Clinical Research LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of patent and trademark rights",
        "negatedLabel": "Accumulated Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r50"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equivalent Common shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r150",
      "r170",
      "r205",
      "r212",
      "r217",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r410",
      "r412",
      "r434",
      "r518",
      "r601",
      "r687",
      "r700",
      "r776",
      "r777",
      "r882"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r154",
      "r170",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r410",
      "r412",
      "r434",
      "r687",
      "r776",
      "r777",
      "r882"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "AIM_AzenovaSalesInternationalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "AzenovaSalesInternationalMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Azenova Sales International [Member]",
        "documentation": "Azenova Sales International [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_BE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BE",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BELGIUM"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_BoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "BoardMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board [Member]",
        "documentation": "Board [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_Bonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "Bonus",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus",
        "documentation": "Bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r100",
      "r101"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r146",
      "r669"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalent-Marketable investments",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r97",
      "r167"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r97"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federlly insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_CashlessWarrantConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "CashlessWarrantConversion",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless warrant conversion",
        "documentation": "Cashless warrant conversion."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_CashlessWarrantConversionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "CashlessWarrantConversionShares",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless warrant conversion, shares",
        "documentation": "Cashless warrant conversion shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r151",
      "r152",
      "r153",
      "r170",
      "r190",
      "r191",
      "r193",
      "r195",
      "r199",
      "r200",
      "r260",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r300",
      "r301",
      "r305",
      "r308",
      "r316",
      "r434",
      "r555",
      "r556",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r589",
      "r610",
      "r630",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r723",
      "r755",
      "r762"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r199",
      "r300",
      "r301",
      "r303",
      "r305",
      "r308",
      "r314",
      "r316",
      "r555",
      "r556",
      "r557",
      "r558",
      "r678",
      "r723",
      "r755"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised aggregate",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Studies [Member]",
        "documentation": "Clinical Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 8, 10, 11, 16)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r73",
      "r519",
      "r588"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r281",
      "r282",
      "r654",
      "r773"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock reserved for potential issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r759",
      "r760",
      "r872",
      "r893",
      "r895"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r589"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r79",
      "r589",
      "r607",
      "r895",
      "r896"
     ]
    },
    "AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "CommonStockSharesWithLimitationsAndRestrictionsOnUsage",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock specific limitations and restrictions on usage",
        "documentation": "Common stock shares with limitations and restrictions on usage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 49,102,484 and 48,084,287 (including 701,667 and 694,324 of unvested stock awards) as of December 31, 2023 and 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r521",
      "r687"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r156",
      "r158",
      "r164",
      "r514",
      "r529"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/ConcentrationsOfRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Risk",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "AIM_ConversionOfSeriesBPreferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ConversionOfSeriesBPreferred",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B preferred",
        "documentation": "Conversion of Series B preferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares to be issued on conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r56",
      "r78",
      "r110",
      "r311"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invigilators cost",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Costs and Expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "AIM_DebtIstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DebtIstrumentAxis",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Istrument [Axis]",
        "verboseLabel": "DebtIstrumentAxis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DebtIstrumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DebtIstrumentDomain",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average incremental borrowing rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation arrangementl, cash awards granted, percentage",
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DeferredTaxAssetsAmortizationAndDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DeferredTaxAssetsAmortizationAndDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 103.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization &amp; depreciation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp; depreciation expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 102.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax",
        "totalLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 101.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 105.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r870"
     ]
    },
    "AIM_DeferredTaxAssetsRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DeferredTaxAssetsRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 106.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset",
        "documentation": "Deferred tax assets right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 104.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 107.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r870"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of maximum annual contribution per employee, as percentage of their annual salary",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51"
     ]
    },
    "us-gaap_DevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development cost",
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "AIM_DirectorsOfficersAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DirectorsOfficersAndEmployeesMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors, Officers and Employees [Member]",
        "documentation": "Directors, Officers and Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DirectorsPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DirectorsPurchasePlanMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors Purchase Plan [Member]",
        "documentation": "Directors Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DisclosureEmploymentAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DisclosureEmploymentAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Lease Future Payments"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "DisclosureResearchConsultingAndSupplyAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Consulting And Supply Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715",
      "r717"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r177",
      "r178",
      "r180",
      "r181",
      "r183",
      "r188",
      "r190",
      "r193",
      "r194",
      "r195",
      "r197",
      "r424",
      "r425",
      "r515",
      "r530",
      "r671"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r177",
      "r178",
      "r180",
      "r181",
      "r183",
      "r190",
      "r193",
      "r194",
      "r195",
      "r197",
      "r424",
      "r425",
      "r515",
      "r530",
      "r671"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Per Share Calculation",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Statutory Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal Rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r392",
      "r405"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Perms",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "AIM_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory Valuation Allowance",
        "documentation": "Effective income tax rate reconciliation foreign income tax rate valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NOL Refund VA True Up",
        "documentation": "Effective income tax rate reconciliation net operating loss refund valuation allowance percentage.",
        "label": "EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed Assets True Up",
        "documentation": "Effective income tax rate reconciliation nondeductible expense fixed assets.",
        "label": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Tax Income",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Compensation True Up",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "AIM_EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NJ NOL True Up",
        "documentation": "Effective income tax rate reconciliation nondeductible new jersey state net operating loss percentage.",
        "label": "EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State NOL",
        "documentation": "Effective income tax rate reconciliation nondeductible state net operating loss percentage.",
        "label": "EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EffectiveIncomeTaxRateReconciliationOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationOther",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "documentation": "Effective income tax rate reconciliation other.",
        "label": "EffectiveIncomeTaxRateReconciliationOther"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EffectiveIncomeTaxRateReconciliationRTPPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationRTPPercentage",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RTP",
        "documentation": "Effective income tax rate reconciliation rtp percentage.",
        "label": "EffectiveIncomeTaxRateReconciliationRTPPercentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State Taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State Rate Change",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r871"
     ]
    },
    "AIM_EllenLintalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EllenLintalMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ellen Lintal [Member]",
        "documentation": "Ellen Lintal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "AIM_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "documentation": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EmployeesPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EmployeesPurchasePlanMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Purchase Plan [Member]",
        "documentation": "Employees Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EmploymentAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Agreement [Member]",
        "documentation": "Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EmploymentAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EmploymentAgreementsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employment Agreements",
        "documentation": "Employment Agreements [Text Block]",
        "label": "EmploymentAgreementsTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EmploymentContractualAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EmploymentContractualAgreementsMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment Contractual Agreements [Member]",
        "documentation": "Employment Contractual Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "AIM_EquelsRodinoAndFormerOfficerLintalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquelsRodinoAndFormerOfficerLintalMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equels, Rodino and Former Officer Lintal [Member]",
        "documentation": "Equels, Rodino and Former Officer Lintal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EquelsandRodinoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquelsandRodinoMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equels and Rodino [Member]",
        "documentation": "Equels and Rodino [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r141",
      "r160",
      "r161",
      "r162",
      "r172",
      "r173",
      "r174",
      "r176",
      "r184",
      "r186",
      "r198",
      "r261",
      "r264",
      "r318",
      "r380",
      "r381",
      "r382",
      "r401",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r423",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r454",
      "r542",
      "r543",
      "r544",
      "r564",
      "r630"
     ]
    },
    "AIM_EquityIncentivePlanTwoThousandNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquityIncentivePlanTwoThousandNineMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2009 [Member]",
        "documentation": "Equity Incentive Plan 2009 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EquityIncentivePlans2009Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquityIncentivePlans2009Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans 2009 [Member]",
        "documentation": "Equity Incentive Plans 2009 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EquityIncentivePlans2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquityIncentivePlans2018Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plans 2018 [Member]",
        "documentation": "Equity Incentive Plans 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_EquityIncentivePlansTwoThousandAndEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "EquityIncentivePlansTwoThousandAndEighteenMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2018 Equity Incentive Plans [Member]",
        "documentation": "2018 Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net losses recognized during the period on equity securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r769"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Net gains and losses recognized during the period on equity securities sold during the year",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r769"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r769"
     ]
    },
    "AIM_ErasmusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ErasmusMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erasmus [Member]",
        "documentation": "Erasmus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_FaceValueOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "FaceValueOfStock",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock face value",
        "documentation": "Face value of stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redeemable warrants valuation adjustment",
        "label": "Redeemable warrants valuation adjustment",
        "verboseLabel": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r431"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428",
      "r431"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions to Estimate Fair Value of Warrants",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r428",
      "r467",
      "r468",
      "r469",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r330",
      "r335",
      "r428",
      "r467",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r330",
      "r335",
      "r428",
      "r468",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r428",
      "r469",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683"
     ]
    },
    "AIM_FairValueMeasurementInputPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "FairValueMeasurementInputPercentage",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement, input percentage",
        "documentation": "Fair value measurement, input Percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r467",
      "r468",
      "r469",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r298",
      "r314",
      "r420",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r528",
      "r675",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of patent and trademark rights",
        "verboseLabel": "Finite lived intangible assets, estimated useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r277"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r276",
      "r277",
      "r278",
      "r499",
      "r500"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying value",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r500"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails",
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and trademark rights, net",
        "verboseLabel": "Net carrying value",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r499"
     ]
    },
    "AIM_FinitelivedIntangibleAssetsAbandonments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "FinitelivedIntangibleAssetsAbandonments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Abandonments",
        "documentation": "Finite lived intangible assets abandonments.",
        "label": "FinitelivedIntangibleAssetsAbandonments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "AIM_FloorRateUsedAsProxyForFutureVolatilityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "FloorRateUsedAsProxyForFutureVolatilityPercentage",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor rate used as proxy for future volatility percentage",
        "documentation": "Floor rate used as proxy for future volatility percentage."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_FourZeroOnekPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "FourZeroOnekPlanMember",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) Plan [Member]",
        "documentation": "401(k) Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture, fixture and equipment",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "AIM_GainFromSaleOfIncomeTaxOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "GainFromSaleOfIncomeTaxOperatingLoss",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain from sale of income tax operating losses",
        "documentation": "Gain from sale of income tax operating loss.",
        "label": "GainFromSaleOfIncomeTaxOperatingLoss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of fixed assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r722"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r612"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r106"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280",
      "r615"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r615"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (FASB ASC 740 Income Taxes)",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r388",
      "r393",
      "r394",
      "r399",
      "r403",
      "r406",
      "r407",
      "r408",
      "r560"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r137",
      "r185",
      "r186",
      "r208",
      "r391",
      "r404",
      "r534"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting for Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r389",
      "r390",
      "r394",
      "r395",
      "r398",
      "r400",
      "r554"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "AIM_IncomeTaxReconciliationForeignIncomeRTP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "IncomeTaxReconciliationForeignIncomeRTP",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RTP",
        "documentation": "Income tax reconciliation foreign income RTP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Perms",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "AIM_IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL Refund VA True Up",
        "documentation": "Income tax reconciliation net operating loss refund valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_IncomeTaxReconciliationNondeductibleExpenseFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets True Up",
        "documentation": "Income tax reconciliation nondeductible expense fixed assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Income",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "R&amp;D",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation True Up",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "AIM_IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NJ NOL True Up",
        "documentation": "Income tax reconciliation nondeductible new jersey state net operating loss."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_IncomeTaxReconciliationNondeductibleStateNetOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "IncomeTaxReconciliationNondeductibleStateNetOperatingLoss",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State NOL",
        "documentation": "Income tax reconciliation nondeductible state net operating loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingenciesStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Rate Change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in state and local income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation, tax credit, amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfEffectiveTaxRateAndStatutoryTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Tax Book Loss",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Funds receivable from New Jersey operating loss sales",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r753"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Trademark Rights, Net",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Trademark Rights, net",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r495",
      "r496",
      "r497",
      "r499",
      "r670"
     ]
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory work in process and raw materials",
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_InvestmentIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/MarketableInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available of Sale",
        "documentation": "Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r92",
      "r93",
      "r891"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/MarketableInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r128",
      "r129",
      "r140",
      "r228",
      "r229",
      "r432",
      "r433"
     ]
    },
    "AIM_JjointClinicalStudyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "JjointClinicalStudyAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jjoint Clinical Study Agreement [Member]",
        "documentation": "Jjoint Clinical Study Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_JointClinicalStudyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "JointClinicalStudyAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Joint Clinical Study Agreement [Member]",
        "documentation": "Joint Clinical Study Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_JubilantHollisterStierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "JubilantHollisterStierMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jubilant HollisterStier [Member]",
        "documentation": "Jubilant HollisterStier [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r686"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of AIM Recognized Rent Expense Associated with Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Future Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "documentation": "Thereafter.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r170",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r411",
      "r412",
      "r413",
      "r434",
      "r587",
      "r672",
      "r700",
      "r776",
      "r882",
      "r883"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r124",
      "r523",
      "r687",
      "r756",
      "r770",
      "r875"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r145",
      "r170",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r411",
      "r412",
      "r413",
      "r434",
      "r687",
      "r776",
      "r882",
      "r883"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liability:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_LossGainFromSaleOfIncomeTaxOperatingLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "LossGainFromSaleOfIncomeTaxOperatingLosses",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from sale of income tax operating losses",
        "documentation": "Loss gain from sale of income tax operating losses.",
        "label": "LossGainFromSaleOfIncomeTaxOperatingLosses"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ManufacturingAndEngineeringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ManufacturingAndEngineeringMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Engineering [Member]",
        "documentation": "Manufacturing and Engineering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManufacturingCosts",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Production costs",
        "documentation": "The aggregate costs incurred in the production of goods for sale."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "AIM_MarchTwoThousandNineteenWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "MarchTwoThousandNineteenWarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2019 Warrants [Member]",
        "documentation": "March 2019 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r742"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/MarketableInvestmentsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable investments",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on sale of marketable investments",
        "label": "Marketable Security, Gain (Loss)",
        "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Investment",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_MasterServiceAgreementAndQualityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "MasterServiceAgreementAndQualityAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Service Agreement and Quality Agreement [Member]",
        "documentation": "Master Service Agreement And Quality Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_MaximGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "MaximGroupLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maxim Group LLC [Member]",
        "documentation": "Maxim Group LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r340",
      "r494",
      "r541",
      "r579",
      "r580",
      "r638",
      "r640",
      "r642",
      "r643",
      "r645",
      "r664",
      "r665",
      "r674",
      "r678",
      "r684",
      "r689",
      "r778",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r340",
      "r494",
      "r541",
      "r579",
      "r580",
      "r638",
      "r640",
      "r642",
      "r643",
      "r645",
      "r664",
      "r665",
      "r674",
      "r678",
      "r684",
      "r689",
      "r778",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ]
    },
    "AIM_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mutual Funds[Member]",
        "documentation": "Mutual Funds[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_NJ": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "NJ",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_NamedExecutiveOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "NamedExecutiveOfficersMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers [Member]",
        "documentation": "Named Executive Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r99",
      "r127",
      "r143",
      "r155",
      "r157",
      "r162",
      "r170",
      "r175",
      "r177",
      "r178",
      "r180",
      "r181",
      "r185",
      "r186",
      "r192",
      "r205",
      "r211",
      "r216",
      "r219",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r425",
      "r434",
      "r527",
      "r609",
      "r628",
      "r629",
      "r673",
      "r698",
      "r776"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Standards and Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewJerseyDivisionOfTaxationMember",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Jersey Division of Taxation [Member]",
        "documentation": "Designated tax department of the government of the state of New Jersey."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Employee [Member]",
        "documentation": "Non-Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Non-cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r758"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://aimimmuno.com/role/SegmentAndRelatedInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "AIM_NumberOfVials": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "NumberOfVials",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional number of vials",
        "documentation": "Number of vials."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r211",
      "r216",
      "r219",
      "r673"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r686"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "verboseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "AIM_OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability arising from obtaining right of use asset",
        "documentation": "Operating lease liability arising from obtaining right of use asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease Payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r450"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset, net",
        "verboseLabel": "Right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r686"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "AIM_OperatingLossCarryforwardsWithNoExpirationDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "OperatingLossCarryforwardsWithNoExpirationDate",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carry forwards with no expiration date",
        "documentation": "Net operating loss carryforwards with no expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "OperationLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated amortization",
        "documentation": "Operation lease right of use asset accumulated amortization.",
        "label": "OperationLeaseRightOfUseAssetAccumulatedAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r771"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "AIM_PancreaticCancerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PancreaticCancerMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pancreatic Cancer [Member]",
        "documentation": "Pancreatic Cancer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PatentAndTrademarkRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PatentAndTrademarkRightsMember",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and Trademark Rights [Member]",
        "documentation": "Patent and Trademark Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of patent and trademark rights",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "AIM_PercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PercentageOfOutstandingStock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of outstanding stock",
        "documentation": "Percentage of outstanding stock."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PercentageOfProbability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PercentageOfProbability",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of probability",
        "documentation": "Percentage of probability."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PeterRodinoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PeterRodinoMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peter Rodino [Member]",
        "documentation": "Peter Rodino [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PharmaSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PharmaSolutionsMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharma Solutions [Member]",
        "documentation": "Pharma Solutions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityTables",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityTables",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866"
     ]
    },
    "AIM_PostCOVIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PostCOVIDMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post COVID [Member]",
        "documentation": "Post COVID [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "AIM_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r893",
      "r895"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r300"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r589"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r300"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r589",
      "r607",
      "r895",
      "r896"
     ]
    },
    "AIM_PreferredStockStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "PreferredStockStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, stated value",
        "documentation": "Preferred stock stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r520",
      "r687"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Purchase commitment",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of stock, net of issuance costs",
        "verboseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r555"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ProceedsFromSaleOfInvestmentProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfInvestmentProjects",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of marketable investments",
        "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant gross proceeds",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r498",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r667",
      "r679",
      "r688",
      "r732",
      "r774",
      "r775",
      "r780",
      "r892"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "auth_ref": [
      "r221",
      "r498",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r667",
      "r679",
      "r688",
      "r732",
      "r774",
      "r775",
      "r780",
      "r892"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r517",
      "r526",
      "r687"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r136",
      "r524"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_QualityControlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "QualityControlMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quality Control [Member]",
        "documentation": "Quality Control [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r329",
      "r340",
      "r375",
      "r376",
      "r377",
      "r470",
      "r494",
      "r541",
      "r579",
      "r580",
      "r638",
      "r640",
      "r642",
      "r643",
      "r645",
      "r664",
      "r665",
      "r674",
      "r678",
      "r684",
      "r689",
      "r692",
      "r772",
      "r778",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r329",
      "r340",
      "r375",
      "r376",
      "r377",
      "r470",
      "r494",
      "r541",
      "r579",
      "r580",
      "r638",
      "r640",
      "r642",
      "r643",
      "r645",
      "r664",
      "r665",
      "r674",
      "r678",
      "r684",
      "r689",
      "r692",
      "r772",
      "r778",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ]
    },
    "AIM_RegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "RegulatoryMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory [Member]",
        "documentation": "Regulatory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r458",
      "r459",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r606",
      "r608",
      "r637"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r458",
      "r459",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r606",
      "r608",
      "r637",
      "r881"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/CertainRelationshipsAndRelatedTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Relationships and Related Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r561",
      "r562",
      "r563",
      "r613",
      "r614",
      "r615",
      "r634",
      "r636"
     ]
    },
    "AIM_RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "RepresentativeWarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Warrants [Member]",
        "documentation": "Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r387",
      "r890"
     ]
    },
    "AIM_ResearchAndDevelopmentExpenseCostEstimatedLives": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseCostEstimatedLives",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated lives",
        "documentation": "Research and development expense cost estimated lives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense excluding acquired in process cost",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ResearchConsultingAndSupplyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ResearchConsultingAndSupplyAgreementsMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Consulting and Supply Agreements [Member]",
        "documentation": "Research Consulting and Supply Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ResearchConsultingAndSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ResearchConsultingAndSupplyAgreementsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research, Consulting and Supply Agreements",
        "documentation": "Research, Consulting and Supply Agreements [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r183",
      "r184",
      "r197",
      "r423",
      "r424",
      "r724",
      "r725",
      "r727",
      "r728",
      "r730",
      "r733",
      "r734"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r197",
      "r262",
      "r263",
      "r402",
      "r422",
      "r423",
      "r424",
      "r425",
      "r442",
      "r453",
      "r454",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "auth_ref": [
      "r142",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r197",
      "r262",
      "r263",
      "r402",
      "r422",
      "r423",
      "r424",
      "r425",
      "r442",
      "r453",
      "r454",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r112",
      "r522",
      "r546",
      "r551",
      "r559",
      "r590",
      "r687"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r172",
      "r173",
      "r174",
      "r176",
      "r184",
      "r186",
      "r261",
      "r264",
      "r380",
      "r381",
      "r382",
      "r401",
      "r402",
      "r414",
      "r416",
      "r417",
      "r419",
      "r423",
      "r542",
      "r544",
      "r564",
      "r895"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r684",
      "r726",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r684",
      "r726",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical treatment programs \u2013 US",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r210",
      "r214",
      "r215",
      "r221",
      "r223",
      "r225",
      "r327",
      "r328",
      "r498"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r666"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, remaining performance obligation, percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r170",
      "r206",
      "r207",
      "r210",
      "r214",
      "r215",
      "r221",
      "r223",
      "r225",
      "r260",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r434",
      "r516",
      "r776"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights [Member]",
        "documentation": "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction fee rate",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Net Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://aimimmuno.com/role/KPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Tax Rate and Statutory Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r428"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r499"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Patents, Trademark Rights",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Patent and Trademark Rights",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Stock Option Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "AIM_ScheduleOfOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ScheduleOfOperatingLeaseTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ScheduleOfOperatingLeaseTableTextBlock]",
        "documentation": "Schedule of Operating Lease [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "AIM_ScheduleOfRangeOfProbabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ScheduleOfRangeOfProbabilitiesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Range of Probabilities",
        "documentation": "Schedule of Range of Probabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Vest Stock Option Activity",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options and Equity Estimated Based on Weighted Average Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r109",
      "r111",
      "r112",
      "r151",
      "r152",
      "r153",
      "r199",
      "r300",
      "r301",
      "r303",
      "r305",
      "r308",
      "r314",
      "r316",
      "r555",
      "r556",
      "r557",
      "r558",
      "r678",
      "r723",
      "r755"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortization of Patents and Trademarks",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "auth_ref": [
      "r223",
      "r224",
      "r576",
      "r577",
      "r578",
      "r639",
      "r641",
      "r644",
      "r646",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r668",
      "r680",
      "r692",
      "r780",
      "r892"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SegmentAndRelatedInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment and Related Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r209",
      "r213",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225"
     ]
    },
    "AIM_SeriesAJuniorParticipatingPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SeriesAJuniorParticipatingPreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Junior Participating Preferred Stock [Member]",
        "documentation": "Series A Junior Participating Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity-based compensation",
        "label": "Share based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Warrant price exercisable, end of year",
        "documentation": "Gross warrant price exercisable during the period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of options outstanding, beginning of year",
        "documentation": "Number of options exercisable, end of year.",
        "label": "Number of options exercisable, end of year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options outstanding, beginning of year",
        "label": "Warrants exercised",
        "negatedTerseLabel": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options outstanding, beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding, beginning of year",
        "verboseLabel": "Warrants issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning of year",
        "periodEndLabel": "Number of options outstanding, beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price outstanding, beginning of year",
        "documentation": "Weighted average exercise price exercisable, end of year.",
        "label": "Weighted average exercise price exercisable, end of year"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price outstanding, beginning of year",
        "documentation": "Weighted average exercise price, exercised.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price outstanding, beginning of year",
        "documentation": "Weighted average exercise price, expired.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contracted term (years) outstanding, ending of year",
        "documentation": "Weighted average remaining contracted term (years) outstanding, ending of year."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning of year",
        "periodEndLabel": "Weighted average exercise price outstanding, beginning of year",
        "documentation": "Weighted average exercise price outstanding, year.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price outstanding, beginning of year",
        "documentation": "Weighted average exercise price, granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options outstanding, beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options exercisable, end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options,expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, forfeited",
        "negatedTerseLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, granted",
        "verboseLabel": "Number of Options, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "verboseLabel": "Number of options, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants in period, weighted average grant date fair value",
        "documentation": "Grants in period, weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, beginning of Period",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning of year",
        "periodEndLabel": "Number of options outstanding, ending of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant price outstanding, beginning of year",
        "periodEndLabel": "Warrant price outstanding, end of year",
        "documentation": "Warrant price outstanding, including both vested and non-vested options.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price outstanding, beginning of year",
        "periodEndLabel": "Weighted average exercise price outstanding, end of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Option price exercisable, end of year",
        "documentation": "Price at which option holders acquired shares when converting their stock options into shares.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and Expected to Vest",
        "label": "Stock options, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Outstanding and Exercisable",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Vested and Expected to Vest",
        "label": "Stock options, vested",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and Expected to Vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant price, exercised",
        "documentation": "Gross warrant price exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant price, expired",
        "documentation": "Warrant price, expired."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant price, granted",
        "documentation": "Gross warrant price granted during the period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option price, exercised",
        "documentation": "Share-based compensation arrangement by share-based payment value of award options exercisedin period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option price, forfeited",
        "documentation": "Share-based compensation arrangement by sharebased payment value of award options forfeitures in period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option price, granted",
        "documentation": "Share-based compensation arrangement by share-based payment value of award options granted in period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Option price, granted",
        "documentation": "Share-based compensation arrangement by share-based payment value of award options grants in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "verboseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "AIM_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Share-based compensation arrangements by share-based payment award options exercises in period weighted average expired.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "terseLabel": "Stock options exercise price per share",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r353",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Option price outstanding, beginning of year",
        "periodEndLabel": "Option price exercisable, end of year",
        "label": "Underlying price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable at End of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (years)",
        "verboseLabel": "Weighted Average Remaining Contracted Term (years), Exercisable at End of Period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Years exercisable",
        "documentation": "Description of warrants outstanding years exercisable during the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Share-based compensation arrangement by share-based payment award options expired weighted average grant date fair value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Remaining Contractual Term granted",
        "documentation": "Share-based compensation arrangement by share-based payment award options granted weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years) Granted",
        "documentation": "Sharebased compensation arrangement by share-based payment award options granted weighted average remaining contractual term 2."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Unvested, beginning of Period",
        "periodEndLabel": "Aggregate Intrinsic Value Unvested, End of Period",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested stock awards",
        "periodStartLabel": "Number of Options Unvested, brginning of Period",
        "periodEndLabel": "Number of Options Unvested, End of Period",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Vested",
        "documentation": "Sharebased bompensation arrangement by share-based payment award options nonvested options expired number of shares.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Share-based compensation arrangement by share-based payment award options nonvested options expired weighted average grant date fair value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Unvested, beginning of Period",
        "periodEndLabel": "Weighted Average Exercise Price Unvested, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Remaining Contractual Term (years) Unvested, End of Period",
        "documentation": "Share-based compensation arrangement by share-based payment award options nonvested weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years) Outstanding",
        "verboseLabel": "Options term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award options vested in period fair value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Remaining Contractual Term vested",
        "documentation": "Sharebased compensation arrangement by share-based payment award options vested weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r746"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term and variable lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r686"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r168"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r151",
      "r152",
      "r153",
      "r170",
      "r190",
      "r191",
      "r193",
      "r195",
      "r199",
      "r200",
      "r260",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r300",
      "r301",
      "r305",
      "r308",
      "r316",
      "r434",
      "r555",
      "r556",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r589",
      "r610",
      "r630",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r723",
      "r755",
      "r762"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r141",
      "r160",
      "r161",
      "r162",
      "r172",
      "r173",
      "r174",
      "r176",
      "r184",
      "r186",
      "r198",
      "r261",
      "r264",
      "r318",
      "r380",
      "r381",
      "r382",
      "r401",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r423",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r454",
      "r542",
      "r543",
      "r544",
      "r564",
      "r630"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://aimimmuno.com/role/IncomeTaxesFasbAsc740IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r576",
      "r577",
      "r578",
      "r639",
      "r641",
      "r644",
      "r646",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r668",
      "r680",
      "r692",
      "r780",
      "r892"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r498",
      "r553",
      "r575",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r611",
      "r612",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r693"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
      "http://aimimmuno.com/role/ScheduleOfComponentsOfNetDeferredTaxAssetsAndLiabilitiesDetails",
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r498",
      "r553",
      "r575",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r611",
      "r612",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r693"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred shares converted to common shares, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r28",
      "r56",
      "r112",
      "r297"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuance, net of costs, shares",
        "verboseLabel": "Shares sold",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r555",
      "r630",
      "r648"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants exercised",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfVestStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercised",
        "verboseLabel": "Number of Options, exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r359"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred shares converted to common shares",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r29",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuance, net of costs",
        "verboseLabel": "Common stock shares issued, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r78",
      "r79",
      "r112",
      "r564",
      "r630",
      "r648",
      "r699"
     ]
    },
    "AIM_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r102",
      "r591",
      "r607",
      "r631",
      "r632",
      "r687",
      "r700",
      "r756",
      "r770",
      "r875",
      "r895"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r169",
      "r299",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r421",
      "r633",
      "r635",
      "r652"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r462"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r463"
     ]
    },
    "AIM_ThomasKEquelsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "ThomasKEquelsMember",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thomas K. Equels [Member]",
        "documentation": "Thomas K. Equels [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r880"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/MarketableInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAvailableOfSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r298",
      "r314",
      "r420",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r528",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aimimmuno.com/role/EmploymentAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "AIM_UnitsManufactured": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "UnitsManufactured",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units manufactured",
        "documentation": "Units manufactured."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_UnrealizedGainLossOnMarketableInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "UnrealizedGainLossOnMarketableInvestments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain (loss) on marketable investments",
        "documentation": "Unrealized gain loss on marketable investments."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_UnsecuredPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "UnsecuredPromissoryNoteMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aimimmuno.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r131",
      "r132",
      "r134",
      "r135"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "AIM_WarrantModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "WarrantModifications",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant modification",
        "documentation": "Warrant modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueOfWarrantsDetails",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "AIM_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOptionsAndEquityEstimatedBasedOnWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value for options issued",
        "documentation": "Weighted average grant date fair value for options and equity warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfRangeOfProbabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r884",
      "r886",
      "r889"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "AIM_WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20231231",
     "localname": "WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Years exercisable",
        "documentation": "Weighted based compensation arrangement by sharebased payment award options exercisable weighted average remaining contractual term year.",
        "label": "WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001493152-24-012058-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-012058-xbrl.zip
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M26!B;CTL=54G\#S$5\/I-9E1F$#8B/H#VV8!]6'6/P)_MPF.ZY(>K19P[XK
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MFM26'8P+I:Q':H!- ]<E<ECWV643Y,H&B(*V%Q<G>7N:R0RP)8Z.YE4O?35
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M,/1,'F+$+EG*JXAAZCJ3ISVBJU?207LR,M(G-W7P$+TS$R]DWG""W/C-F9,
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MIH_!!Q2WK8E-*DS(4YK4,9D^.A].W /E+S6_V@>D:Y,_T2Q&]JY=/U2FLY&
M<NS/X)Y-VZ^A3_UE=M6*I6=XM.EDR?[J.7?;T9G..M(X@;O&S*I=57:3'G;V
M)81!BFOXI@Z[V%.+)&03;3;GB5'9\UIW[G.>^A56XY+2K:$T!K+IA_W%4J6*
MKMA]?2?KC!_(5KHSO6$41J-"F_2.32>@&3LED-5QG;RMO>G-'U N6Q9'SKU-
MZXE *2L6D0UO$) G5G5:06A-P*:W<IHDV#XN5E6/%^BNO4M\1DW^>DZB)S?R
M52:C# GT!=@1YVA]MG4(MGN K)ZO[+E*PMR6(NQ(E]%S](@"TE'C01T35-(C
MSF4E20.':NA]F^CX5'+>.4F;HA/-VS4U#%"Q#7>\ A.;,F-[,#OI+V?T;YS4
M#$NA?PJ3LPL15,C#':KL-C=A V6UK'F"I<JBFK6'2FZX8Y0=U\\JVZ/;3GXC
M9C;_&K>_>-1D5T0PJ!B&.]3H;R7;!L'JZ4)_V7IAFVW<Z<_"V']"(9KC)+Y=
MN!'B^;;5!O+(_C"]077DG:535>.06W4L5BF)Q%\!P8^LVB-[%81E]25NDE)]
M7N<?20^6I#FG)7)^CL1P96E]10>;CPT?)I4%+W,IYV)MGRZM &9L14D.RU8+
M/;I9YWK20N4DF2(Z\=R@%,0&G@H#P+6>;DP?575(77Q>6?\8V[3@M##(&&!F
MX3/M-&@HT@]6DW9$ID^\M"A"USCM@:BG)**4A35-/<?4B+,+3]@-E$7>C=!T
M(H,6T4/';6AG'T+>S=UUL\L/!C:=C  4F0I+>S-#KPAS\U+J5-T'*.>_8QNM
MCLETEH*6.=DY4GL@;7;&4WT-I+;$*$N\ YOI% 4M4@>-V!Y(ODE[5>,5&E##
M=&*XW?M@EL!L0 -"*-?<*Y34HFU**S<$'4S /YD6\&Y,VB/4*_3T/RB*T5JS
M=+OPPL3\?D_$#!O%/;7R?0YO-:&'GM::5A.]7-MC'7)BI_@9^;+@3%]<0/D:
M/W#;@<6]F?I9<1G_]W3K:63PY!81 ,5K^3%:V\"8FJ!;J\L-FJ>A#\KYDZ@Q
M&"E0IL;/QW3PNC=S-WMSX3+<*154!VZ@=A@_BM/(LGU*4@8Y:\>_V2E$2I4^
MU_[*"\ -E205<-C$95V0O>.*6I";CB:JZ\%V[4U]0VS__-@UQK@;5M,!QU%T
M99\"DA!^^D<G]6 W':H<16EL"65":+VYN[Y&$7MHWGUH<<![H#$=WNPOYG[\
M[J<QZ!$(W1&MZ:CH*--_KZ*F$(9ZAE UH#8=3QU%7_8NWMIW$J@&7W7W8SH2
M:\SZF(W4*E/=&)+2X:6H]6(ZKCNX$]-GT*U3%GD@4[O6P+LS'2\>5WU4Q?#_
M83WK$V8>HB_C,6=C"YOYF'1?RCL#U%H0&X]6CVN$1HEF]U:#MJTUD%.UF[LV
MGKNJ,6J/X*#A5RW.1H^^C >XAY_EO25@@_XTG0=#LQ]TXC<>ZAY<3]1&VJKK
MQ)7@TI3ZL)/8>_?ZN/(AK/Z>\+Y+AL'A*)P7T\GM)V=R>^90W+6O?C#X'$5#
M';XOR&7T^Y-DZN*(21#-0BKJ-(JHFE"'#\M+]8DOP51?I&BNQ5?TZ;B)PWIU
M>+?LM2W7*;MV>-]C/VE4>=WKCA3/@6U&IGSR2#8F;X4G8[;&I'P_+"'EDV.U
M@:B\?S0R_S<LN64VOX[(/:A4XUOA(9DJKQP;^Z6&;QR>2J&!IO-;X2F9BCS&
MGK#I?8S^2-ES,8_@MW#>BD_#E&B<#$\['[D!9O^[IUL\^LF_ 5!+ P04
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MH7]G)"_*<HL!9XGXIO<:T=6=A"FB&_!#&*"<Z6L4X/L<&$6-AZYG=EYM>A$
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M9%2I)95FEM*!Y-\$EM/;SXI&DK0D=/K36N#TA_$U,\&!/8?^O?3G0>XM51;
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MB^L5:DQ X^2EI4GX'*U&0XEC!?Z"8YS%:?*DJELB;&[I=7'EAX+U2'=NP;M
MWW]#"4%/)^%#R#3X<DJYY(< %3[*KKVG5+4#2X\/$#F[;\FQ:#XZ>O1;EH1D
M$@8ZP"DZVBWJI V;#A?@+M9K#-/J0/XKPO>)OYB%@>RA>$GSH9A]<BY,WSVV
M R7?B,O4R2*?),W[#S13RQ;K$-Z3C=<3$$Y:=:; ZL&B(RCXZ1X_O IRFR6'
MK/AAC5CQB_&G4P$\Q1\_G8Y%)'4<=:96="RB$A2JD2UB*522+I)<HNQ?I0^
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M8J?$ 2^8?(42SH$6C)4>PX.L3KZ&WQ**=2U^S_YS1S=+^IO_#U!+ P04
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ME.I5CD4@\-[O.JV$.(G3(4X(QET4/DV_5]*C<>D:I.JU'4*'P#L<=%K)9Q-
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M??T!XS1,ET%4Z')*_];/]#'0N@:(4MT^2 1"4$!1::<$2\%088:S> 7,WW%
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MRU&38I%+EE[C):98I^I=X$R/*SV+TRG20OG.3*FA!P,M"R7[V#K-XU6*2,V
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M,5Z'RU 5OMDPN@27O2%MG)FYP$#.6E7)45%%B%8%I7?8B3&J=3#K>W5@MRJ
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M1X;V!W$1(1]RH73,-E*]#UG=K'G$[@^3E*IYN2[^G85W$6V ):74/!2UHTP
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M7C! '*BPY$7+YM7UFI<_9ND=G/V:0J=A'&;X/'S$*ZW3L^#S6?U):8:N]I/
M! : MIK*ZSXIRCY!@-^GE#T'FV;AAFJJ>A.N3^026'(%VRCJ4H"!C%0MX662
ME#^N6Y-YQ\,UI@N2'+.G!MB^"5OE_AQF#T=YFB4;3.QFS*%"W.:BC#&PFXXR
M1 (8/(Y26TREXD*\P[3.0[0#I)K<2T:H!<A4M&#@9%!0\Q+$.B&=S$_O8+K
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MYPK,>/=AX)GOQ0F-X.?.YT U0 W9F1IYXGN?@W3POB[Q;/C@R?C$[!$ SRI
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MG&-WEII4V@S@,J]/E:HX^V<AU\48VXA35:RR^:;WM:UC0_L#M6!%88P*1W*
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M;>6#9B-EN,+5:/,JA T6 ,6_[:+\#.";*W"]2.(57N74RKL(ESN.NH2]X6(
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M,0I4D,!:D5B!=1*I8%<99AA/(!**@Y[6'!<XGVNEP!.B%JM_Y&FF>Z'.FAM
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MC^A?PV405> Z/S^2]Y*!'%0WV>DJQ/V<"U5LJ.)#E-%G1WW,LSR(3O-XI1A
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M//G9(X[MPT\=/Z@>'ZE\O\-Y+*J(4WWFJNNO'D.^9FQWI1C$U>%=4PXN$OZ
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MX+Y<[Z^O"ZFE/<R[E\:I%^8E\<9:O&1'@Q5_;)P_^<Y7V27?R[)Y037(5+6
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MC-;3U2=V#+V*-E%#8S\-GHM'G[3R=6G+E8SO"B+;D3D=$4-?&NU&3MGB: ?
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MUFWM=U4OAFV]V#%>02R4([:*S1952TJ[)+:O;3^\R!! IT8AGB[GD+8F=MI
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M,#M?<T,7A'ILZA;?27[L?,%W_#9);ALHB]5+84>3V]3[!NDB>-!G7<LYG@^
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MU C2#.+/R33CZ5O/R8PI]O241.P?*6<CV78ST87&F37CQIUY!XZ;0]U,;/R
MNG8WM[ULS6LB2P^HNAOT=E+MEGT()+"E0#TC8^U:>7DG;[R%+&QO8Z$4ES\<
MZF02VHGPVXDJJ7N^5!1'W/4U4 -YL>G)?QEG]+\)C2<1^<*_I[IBE)7%OG;0
M*4S%.*(6%_V\4H[F/(0K>,R=M?->>B_!(EN,HRCC6=*V?TQN"5VG6RLSRVL7
MI]T:1[Y^-%J?Q6M5'^"ZH"CY9:GD!,4?+KYB1Z'G8,J%\I)YD6:O3'2V?81
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M]QZS4Y1RR!.N:A+U:RNZD<3<?$AK!<-/Y2_OXK4^MS^HLAOD 9433."U]><
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M\$0ORCU:YG#N14F1>D'NI0OO)( +O1<_^-Z+YR]>>3L%W,7[[WC^KS)]#WI
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M04]L[92MGK"1Y<G!.CF>P)EZ&*[2' ,>-]X$U:0)TB@P53F;@0C!OT"B,)]
MF%\G$D.@\0#.^T7)4+UJ'*<5M6V>L"UJWQWUQA,$=J876;#<X#S"M=IQ/ I
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MFQ)R:07_M0YXPS)9$&V*I7H;U:[+SJ;T:WNX/V'9WDA-A7^LP98SG-QGUI3
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MKDS*(+!Q8(86R]&$8GKSO\0R);-R>M/T$S? '>1Y6% H8(HL,[[PT"W *I0
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M/L:"Q&LUH'I'@FIYQ@KT7=Q);.T7%8000.6G3B[\-W$W2\&7*1A&8E !S#>
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ME6&K%&]>DE*0MX":-\7]0OW"Y]$"W!7V3) 8);?(U+]RA2E0H'<4CTC/WM(
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M7GCE<4YA5-VD%[]37C\]9L'!-#A=_P0)ZL<WHC9H< ]!@^>OOR9J,$("-8$
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M-4K_I#\Z&0Q[D\;V]"AH"!&+$BY@=$- ')(EOK]Z'[MJ#WHE>8(>PE]BFEF
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MN0@D 2+'7!%E4M.J3C,=H%QK?%;!R09GG'LJ@*)("A)#8<<!6 Q8A @CAV.
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M_K(,+N*%*H(3=1.<98LP'?$'H^!<Y?'\.[@1;GW[L?<]"Q9A?AFG#\IL^32
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M<"/;D?30"OY,"RO]48UP8U.Y?PYN56AI:=$ZTS^*+3:IHY4K&D\%+P'>."/
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MZN0\..V8?*T1YLBU)EQDJ&-?)M]V)]P5J#0&2%#Y-68Z[TQWX9A3GRX+;+8
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M$J>"F80G(H+,(+?EV*^@-R0<.^ >BF*F(YE@U5R]I0I*>,(8'D\<"M2+^*W
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M7MSQ2Q %TE78Z^KMC>QU#O76QU]02P,$%     @ 2:I]6")4;7&*!   /R$
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M0YL,R?+)#>0/;G9#(+S,$Q1T[R]-PYC0P.O F%S1+AJXGE/NJH%=&,6ILNK
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MZ/[*_AX2;#P\H,0B@F$!C \8<E2#C$_^FR;S_,#HVR-T(B.R(?QVRWV=PV<
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MI(N1HC(K<6E\Z7Y$3&XFEK02Q:8]I>5KW\$/BQ_2E\;Q@^3_ U!+ P04
M" !)JGU8D+TCN&T.  !K;@  "@   &5X.3<M,2YH=&WM7>MOVT82_RY _\.>
M@0M:0/(CN;976S$@/](:YSB&K=XAGPY+<B5M3'+97=*R[L/][3<SNWS)E.,V
MLF7Y6#211.YC]C&_G==.!K^./IX?=CN#7T^')_#)\+_!Z&QT?GHXV+&?\';'
MO1X<?3KYS*Y'G\]/WV^-59SNL[W=)&4C&0G#+L2,7:F(QSW[H,>NA9;C+:@(
M52__:+T#%G$]D?$^PZ*[6X>##Y\N1M56^F,>R7"^_[5VJ*R1_Q&VVZW#-[%G
MDH/!#C8(X[Q<#84'+!5W:9^'<@*/M)Q,TU42/3@Z/+V;2D^FW<[//VWO#7:.
M#E<VA'ZJ$AI&\<!3::HB]ZPZ,%_$J= K'EF^(J]F2,M&<;];6WME(X.^SS[^
MPJZOCM]OB;N??^KO_7MW=V_[2S+98L/ST?NMK6^:VR;Z'T?51G'ODVSRX=G'
M;N<LBK)8C80_96>QO\U6NN>?;RQ/P+#/1_SQ^?!?1\/C?W0[EY_.SXX_MXOP
M,/%?,I/*\7S%U ]^.SR+4ZV"S$^EB@<[OQUNY%"> X^>@.S15'0[1XKK@*DQ
M.Y%:^*G2AGV73@5[$P:_9^H 5HE*X+J\T?3H>RP-2,86@6RAWK&*$A[/:S4]
M$4IQ"U2F4YXR"?\;)N-N!VMZPL!O9!+X8K 3?.I:83P.H+QA)E7^S52%@0!*
M4\5\+7@JZ'7$H3;\89SY69AF6MAN1)1,.0[<4/,3+5/;'O=]E4$53X;PJ-O!
M9U1#"QF/E?:)T(*&-]K@* Q+^+P/K_N)T/ !4^T+YD,9$1N.&YDE4QDJHY+I
M?)O!+#,[R4 $-J<%5 ** Y6D CN$.4A4*/TYFTVE/^UV$JUN90"=0T$B %9&
M94D$"(+3X@M-PQ1WPL]2>;O0.;S!.C#-MCB/\X'*>,)P<F'"J"WX#O.$3\=:
M13!_,/>2ARQ6,;882AQ9MS.3Z92-90R_\*T6B=*NK=\SV#78EF%9#$M"/8\%
M?(."!LB#N98PD)#/[NVK2QIS=7O@9,%DV!>X-6 .8//C)*ENATB".4)JK@4A
M!FSDDWRC7)>]G=[Y4QY/!!OZ- -[/[_[VV+OU3(U&C:.C3<4?2S^#X-(QM*D
MFK<GP#I. &E !++\9J8\# &% 9GLF@!2!<R;$W<1@A4 >%S%&_@1R3058IL-
M :@# 16A 7II8$"!R!MIKF8[[G:@9P29D*#9DW& $ ,%D2H^'@/' SGX&+ Q
MXZ%I.?59.?58W>*&Z'9.\V/'M.RZ1G;E"1S0@F2@)AD%#D.-9SPR$PHI<#:7
M\H(:CR5($= 5-P7#ELR^A$^E%21T4!$+&@[BVNEK12K!0L 3Y&<0/N( H*20
M[RX^7Y^R(9 G?9P!$'A,!@*E0D&)61"IBQ(B;QYZ=?)2T_@K-;BV_<, OZN*
MI[2?674[MV+ FL#EJA!P#[J=82FM7I72:@LVSTOVF5/+K!Y15<5 ,'>2/PKF
M+ &% %ELN9X!K(ZJ6ZE"%*\ ?3*Q#,)R?:3;J2DD5@- 0KZBDU14D@55I/<0
MS,UD&.;-H"88>9DVU&"W _ $8#H6DK1+4J[FB$C"&-2!H0S":ZUAT-T$/"1P
MQ=+W< >F0"/E2%(ZU<*J<Z% O!I+X\/PYH*#MBNC2 02)B6<HXX([09YO0!U
MX!P0OVFQ>C2]*D/M<():*U0B1+Y'=[Y.W4XIE+&;6,U"$2 \:VPV 1E06OT:
M?H8\%66+E5Y;N'UFJYO;JMU.=:^V$/N\9']0&A@YTXDRP@E$A?FCMPQ/(L%!
MK4+6=A+46(6AF@$;'S!G.+)6K)[ELKIMR+")YC%P88\!IL3X"8P*PD^*HKW'
M#52>3:'%.3X'B0_0(D5DP9YXBG:G'-)Y(_X">0:P<7_C%N-I]E#^9_OM#S)N
M'(-["!@JL(<5N\J&<9SA">JI.,--AO*XE:W-%%:L3P]"%4_ZJ 0PGYLIK+K;
M>*V*O5]9O=5'(7QWPHGM+N!HC3Q8D[=_[[&WNV_???\ZYAT(_TN_SSY($0;[
M[))/Q $T\'LF8(-!Q0/V*2$CT3YVY#3) _9/'F;XFO7[+B!E<'+VSYS*!<_R
MC^AM]D G%;IX=A1R_X;M;?\ (S< I@$,=#0\.C]EQZ?GYY?#DY.SBU_>;^UN
MT>_KR^%Q_MOUX=KS 09Y8H"6_-L!"$=!.L5![_ZUZ70=7>5M@+"4@DH;YG.>
MJJ2^"*$84XV3IL  BAVI]09%*W.9S^(!&\T3Z'ZHN2?] W;!(V%G^D+A_.U5
M*^WDM?#-8&=T@G]=X5\X.? )T]PPXYX6_*;OD==B'\X#7,6JP_]'&OEE?8$<
MD.7;XK+>>I4H)-8N]<;N\XT_):[1J0;:C67'E:/^"QD>3U!IDDXM0PY[?4-%
M@XF6/ATKY"I]_2,$-5^^PI6\+)W+,- I*.VO?(Q/LXQN@(\<7]].Q<L_,9[)
M4'!*IJUNIUD7!;DC0A,2N\Z\+R"^H64'+;D@^\Q;6\(:@GFX70Y8!L\&C5B3
M'5DT/6'#0JRQTMD.EM@8$BZ#TBJ[:*^T5@)G$Q!:JUBHS* -DC,L;.W&2YJF
M^)J9RD*,A\'&A/A:?U..H3^V9*UO9T ,7"#+HCL+M-Z'_%FM<OM<GH1QZ:)K
ML+?[/(Y56JZ;-379G0S;]/'6]>;=$U!<6SBG&"=+" 5W1;P:+;7,& [O8MQ\
MQ$(1OQ'DR:C%.)1[DD-=;E3,O1 8 ^8Q(K.\935!(0SN%[!J8X?MGGPFLD_O
M./I8X&B#!5FRMV3LAQE&KU1L9^A*P>C!&?FP"<S0G5)L <!"-)Q&&.%7FD>K
M@8(3M9&Q*Z\AV/BC2*<JH"4O'<ZMH+(&0>4AUVMQ$/00G"GF5X6(X\;7 BM8
M[VU$BTDALC8\%J%T"2=CT"TY@S>/[U[A*D=\SI),FZR04>=?D4?=(0T=QT+C
M<>Q/%?K,>@ZC<>D]UZ@]46M>>XIN;I0.2!#& $/81=;39>FH.<T([!'>-0FJ
M/>Q*A&BN1N^[(H<Y1J2S+"9!MEJ9W&L>^KZ-;T,:*8C QZ,@Q/I9;)UO-K =
M2ULKG#MBV@W[S.$N50GN3FA?&I''KWB9 50"6?1+%DQJ 285K^T#@B[N^U+*
MG4T%^>$H0@XV$=U4N$MIP_(@D"[RC?NYXQ;-ERK1& ""%:",1F)HNTKM9Q'&
MUN&5!9.!3I;9^%E>#:'":AC:&\&X753>#>Q"X*4@CV71P@8.HD'&428C]$]7
MP_(0BF42XBA X9(HNXNH1N#F;=O7(-]<*+34!"**Y5CZO WI6..YA\QD(^I1
MN95N59:$@ 'O3+B,C8VS"Y4UT%#X5NPK[138_!QJ/B1;EEO3_46A$Y!+6VY[
M85(FGI@9J @:RMMS+%\J.G)]!>RF,?BT<N7,G7ADY^$5583;NRRQ0%,4UW#,
M5\XZ%/'PR+Z5AL2&_-(>KUUM6@COVF9G[O(CG/AYQ%:-%D^4%-/%%SC+G0!L
M+T\:&@/&M<>IC8DEPU+M4AYT^I@(?;I@B?<)?!J!SD*4C'4E6C^_K>C,;)7+
M=EB_:)"FWQCHC\1<;/=1,?R-\;^-(?PMS*T#YCZAW-?M7)'3O$6Y-:#<(EO7
M8$O;RSE.:P (ZQ%;6LD#&$=D4*5'[!B*"?"B'W(9U2XWDW9"'AG'MU;Q<#9.
M?.D!%587(!@(^8P)>TN:= L^ :U!XCBTF&0AQZODO1H(HK='!50$U5RK_5B(
M1B;?9A\RC0][SE'EM*\&)PZ!OL/Y7'&AK6E- -RJ.M4I(LL2S0>,EE!O[BAP
M%1W^-LP'02N&LCL/9T6"JUR& _VH\(%6<7[C=MN3PE4;2/DMT_]P/.7;-G1R
ME:&3;__/0B?;@S:/>2%'+5V.05AII9TU7G*6Z*1%\<)Z5PM\_Z^%]UZ9M$#D
MJX8F29 )/OFIHI/ EKR7_J,H;M>XDJ,&)2>7D@!UHCF>Z \%L^2FV5N\3%/Q
M%;B+-EB]R>\0DZ U3G-]+FC-INO*00(;+'!WCT>EOM\R_LLQYJ PSG&9:D*]
M]>M!JR1TXZ=S&)>^XI*;&^I7G1>%;8=R#6DQ1@>?2TCB%!I2A_ZP(<0YB1Z5
M*$&Q2I(C=,#,OV*+X2LWKU"^JF6Z%BY#;A%;L)Q9E0H7H06Q=5IHRDQAK;'F
MI:&8-?::^[;>/$#7YG0I0F''61AB4CSK%LYA(^2S^URZ@)7.6H0N;<>9 G!%
MS9VE1@L7WE@-9ZL^1[R1, %<ET\9); D4S305Y=? ,QJ I6%7(K'Y6BFMH8I
M(,<.C$2CW'+CB5B,96I3XQ%8]HKT"[PAH!--,$@3??%DF5X*D6G1-F9S4I%.
MB&_*1'IXWV#!>6_M\8\SHSG;D<",#!:?G1VIUDG5>,;X+8<)1?MZ/=\%70&O
M&*TJ R$GHEL'ER(0"5S-<N:&?SL4L@OBP>=&M(S:%MW7XF:,$HT&6=_EJFQ1
M_>6@NI4N723;(Q+"U-)HY8Z[$H2R.,3*+D.*"X^S%R;0)5ANA%#T0$3\L_F[
M;,=7(%VB2-K?^W/9NW+IL]MIO7N;R(Y. ?;SM#UX,.P<E^<U+/,I="Y;U%E[
M,!')B"[!"XHDTK=9CXT0-\#71>*EJ! 5%Q1EP9NR.&VS7]5,W*+0-883GY(F
MJZ(?0B';&2;\<SZT&.12C&5Z0.A:(A=:X:D0_Y:9U52CX(?]4YI0U-BME%Q>
M(:,\HS4?W%+:8!1+.F[VX>49P3"_=%[$B;)%ZN8>Y4EC$J.)M>#!W(4*XQ6?
MD(AQ;?F"XUT2'&)N7*1)7D)174C#4&'$X4*B-M9&Z>(VW+"7-05+BU_-6+9
MNQZ@O<Y\E R4;M7R%Y'I.,\R3#>[;"P#,5(>C8G%FH(UK5@DM=-=?<DUA37@
M,_BPB587XQ\PM7X>]]#MV#@,+1(M#' K?YI\2U^Y_?[R-\;&!PRL>P4>CAEX
M5\G!=,YAQ[>! ]\<./#NSP8.O+:L2#OXC\79?ST._Y&Y_P%02P,$%     @
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MG,?L]/.3'9</^\Q]?W$L><Y./S]Q<AG0SMK;O6?CA6YT [@AV[<DE( S$,V
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M*=IY2)$$$)6._=VMG8^S\&.1I ]\^OQKY]3H'EU>=*^-RZ_=JZ^=\VOC^L(
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M4B:':?JHXB!X-K0-\*6WW.%]NB.*'*?H1.^>CE'J *5$[.EM\CG[6>MQD,,
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M(4NF<N A8W0&3D[2J,\CS4FJ5Y138^C=S=!M#)6V&C-I*17,]@"F@8.&@'"
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MU(EL+-+*;0Q,Z80>E:UANZB=RT"Y#/UK:TE52Z<+-E-9+"@"KO, BCE%MGE
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MUL=XKB.M*.V RMD2&;B4O^BD0O0K4/=>#"]Z#G?B;O&J5V1&R)+.._W<BHH
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M8F%/#YS_I)!/MS6(AMWC4$UJ*6)K<5Z1\-5I.@26%JG3SRQ<4G<TRA<YKDR
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M-.EIT^M/(L ;18!5-6'0_\D#J1K+,:-I(:'S;S /1C6#(R#D7 ^\+]E&24Q
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M=H]*+H_C;+-D"V6?IW]2\$(Z 8)]M(RV2%Z0N*M*+4RC'VY*9L[Q."HMV19
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M4@^';/LI^ZH;A.;# &J!4U%="Q[C>6I!_S;%<BOU\[C5[^:HA2?@U1][U/B
MO'C[[5;S\1RU<VE"%:D1':8/0/5@?5'ME\]VU886\IBPT;ND-OJM$"^7Z5N0
MH'*G6+M9FZ/$I '<<KB>ZHFWGL1*/ACO:P.]3+@I5EH*2,-BS4\=F..UTG@
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MZ+TMN&9$CB7]'K*646YTVNL,KE>G7U:C'IK'P1HJT9D=+&:<<Q08%J2^DT"
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M&B-PLRWF-M;3"QH3<UB#-.6F"JZJUK<,P6M6AQF/JHR;*N!*C35%TEE1:^M
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M(,$3JNT]ATK6"B[&TG76N.<-E:58+F9ULSW"XI/>A^BO8/.::1V)(P&O]28
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MX:**KA8UD_\(+ XU9+Z=.1FWN;86A\Q%L8?5)Y);6*^S>>+]L^-!S$4"(>C
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M62L0CV?.D%Z1C6+:^BMZ\>G@EX'#@,V6E^6LK*KRM@Y*KVCH.&TY;;^Z+X)
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M*K:%SB$=F#4%\'>,U>0D:Q-#KWNN/S=JZ1U4=70@5\#NGPU6RB;!ZIZ7M>9
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M0IWOXMRZ#1IN! T)IK.;(-<,)!AMP'3$0L>9NYB[N\AJ0I',!5*UH\4IQ9.
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M4M2,<%MQ8?W>\BY#E\V>VTA8\I -M4YTCL>RV7M/>N]IYU';=BT])WP\-5E
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M^7S!,$LOG,81#1SF=\'7"R^3I/4L^K[SNK"!NZ.Q9@7>;1SO"J<ZD#7ZGI1
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M]N7']CJXNY'L!@2?UC\-?V\;I[+IG<3I#-I O!PR=PMD(W\]B_CM2K!,>@U
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ML3G "R12HIJ\1G_]2"1#:_^92=(5'_G;L#"@_.3TMH9UN)&3E/DE6A.&745
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M$REI</,5Z4PF&W$#<-0A6JZQG'/;C8\[I>N:ZW&3\?<M#RF2!6>-ST/5;$-
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M>T,77Z[]EM5AX!(AG:OX8MRMX-F3Y,G1DX"!N G'YZBOP2;N:FJXRUEFNY/
M5!BAP6$^I9?:1Z"7BS.&[$9NHT!K,HWN!&XBH7FT):&Y51*:1_>;A.:N!?M>
MGL\-G #=<E$C^&VV&;C3%I"<59NKF_8FK>BBYZX0"-I6N%3?E%(0A7OKO)W-
M<$O_9J/#]!V) -#50\,&?AH%W7I9S_2KN.*Y89:]5,-[+)(72$\=SG[$AOLE
MC<,^K7R_<TLN7/$:P-2K6\?/"'*%<$O/3@!5YPP@(G-DGB-0:0.K8C9Q5Q_Y
MVA@.9I3:*Q?#UY=(6':A,6J$'V)&/Y(OBS&ZH7SD,A$DE-"/J:A18=2!!>HX
M'?E;Q@D?Q8*2B2&ME%"0&CFSA7GIF".N,&5;YPN[;>^@?VWX!:/F9^8+_9:W
M4>I@X!P&_JVE3V&/.52J0PZ#WAP[+:<<C@F&U<1X2Z5+-Z^,")/,2@H!SLV\
MT393_'R_TE;8"AUXUL5><GM)D0/(V?ON D8L/-:,D<\E\54ZECP#UE&@R_)L
MU#*KH-HTAFR\D_B")BB?Q8_?25QH:PFMR32@J 9W2#O#J*+Q&D:3P$-;OJ1V
MG/E_PU=%K4A,+=+#J^=-:E-E''SL_*%;TFR=8]@YA1_< V=E:1O<S8U0G/>/
M(O?2>T$>$O?2>Y+XL\O,MS0)?<!YRW0#5?S />*A'C^,F4>;S6PQ##Z3YC(6
M]TWY-**:<"$J;G:F'8O/]&7\C<B6$K.?TUP#:J8/GH3)-M9C11G&.<GGRLP5
M5N%MT*X;??M&1L*H'%8V\M;PPN+HGUL<_IE$1FTI4+B*&CKMOL4&@C7&'+Z4
M([-9+4 %^Q#;_[*CQNU"N+O$\VM&K&%JS?4UOM6\+O;W#CW=?ICI^W5T^S'C
M/SY]$TF4\(,97W( <3>^(AEN)V6UF\0G"'6_+7=QJ/9W3HYW#I\=Q@_>(%=2
MX#1P-N'5ZX<_+$*VO0^64<5%=-Q>T+OB_4/6?OMB671V*3[)JG'+=;+0%4;)
M &@(W,31&DR_6DOBMY),K]#F>%DT%6>)SYMLWDJPZM27,CZP*!SW(]NT+8G$
M"J-#K^ =%BXM4*/)I%Q '6OKM ZL2%KJ<AKFHZ3I?"9$6CR@TACY_;&QZ7Y,
M/1B8AO@B?BE*8Z25+#_B*BMSIY+]=]S+H.1MDSEK[=J0H9P0?!(V:L'WP#3+
M)0@V\S:[#*[WALBUNK0U6[")T>&'XW--4U:%6;B+<FI)W]&+H[8-O:3_+%:-
MDY!UJC/N1 OMJH>++M.&/A83MKM66SMOG?(8OY7511Z11N[F<U13&[KU<ZCI
MW>-=JZ8/=O:>/'FV\_KCQ_C!"T,6S,GE[H_3SYN^MS],9ZN?R>V&T1OWMY+,
M**1\><>=/N5_N?Z74^D9*0 IY/*C (5D[2WZ?[$S8W/8@84&.C"KZ>6[/+I,
MB6WW&#;BE%$==S2[&,=^+(Y+9J(&OY(UK!X#*S[&N;IYNMB]Q#=8N;*!7I1L
M:<*<+F&:3C(I_>RT]VQ*14D,ODY-]5%:9[5'&^C+M"$G2C0QHX4G_ADM:(DT
MF')B9^LB ]K*VN<9NG.)=-P,E2+'P3?A=#Q1JMKIP9E-R?C7=I$10 ;BIF=F
M@^Z:!4NBE/K2"<KB ^HD"AG3/+<^]Q&O:$X<V($9@%)G@UX?!7[M+PAE*"&;
M/RTDO.6N#E/\7LH3O"NI$&>FZN"+2O)T45 [+&+%GS.?R17,:L%;UO#'#"0I
M6+Y*NDX[\/3,/SE D@CE?T9'E7&(JQ8I<NW:2W2/JFQ42SD-9M)\5:A6?*>5
M[>6X)M,(C-['5H7Z<)J&0+I['T0T;I1]&Q-A/ST(OL[)@;?4KJ[7>93&ER85
MZ2EZ+QP^1/I,VW?7/G?B0:S2V*;*S)39A(:BA!:K1?][1[H-D8^#IW8=:/8+
ML>%73']X8!Q(>4LCX CEOK^8<$0=XI9MS;GM0*^$BY>,6K,'%50'9>6Y!4 T
M(*GM3K/:HFPY@<_LN_-*[7T&5UE]![2EI&LMK8D-,2,;S[$/Q*=@0P,&P%$$
M]0$B7C(W>PTNVZ4)]G;U@G15+X8ON"P:5LW /<Z@AQGEJU)K)+TFB59I$B9H
MLXV4;]8ZV&:W,8=V8QQ38_C)RNSP90@WZY).4AV__*,U4/X?D>I.9_&;K"'A
MS16E>]Z8:Q12'"-P!/K8RTZ+[*V^6Y-I0-_1C973WML(I]Z=:A)Z345Z9)9I
MN"\TV_A\_]86)GB&URU!1(#UH'V,/2WADR+?F N__IUNSQH(51U .OF]9;2Z
MX;O90EO(B^5[N;T+C/16KE;*E2:\K$B$]MN2;-67V;3A'&90"<'A"5:+6<'Q
MF<D0A69?B/ X^;>8Y5%@EL-(K\2^%EI;7ZE3D/D^@;%.CPP=%/C'KXQ-?WD7
MY3BO2[Z:N[-<<7@BF:#%9@FJ6N97ABMC1WG3A/6FDXA0W8[FI2G2\"%@J_$)
MA$X)1:0@[*NLMG;,\CT;ZSV;Q+^DG^C$_E<ZFS^/_U76C6ER^O?KUV<#/MS0
M(GVXT1&,7*+#KHLW56P..W.&B.3'Y_)));'!(+H;I/!YEU,7(^Y1(LK'IGPT
MB^++G\C<^ITCDUJ[)%0Y/3;([IO</=F?/N\2C?MP+YZD"PTQ.GAU</'K* 1E
M;BY*;G-(([%&H/,936.<W6:W51=HHW(;/R: =C?HL,=;=-BMHL,>_X>BP[:G
M[GMBONXDWYGX>#J<T,?_/#C8&5_M[.T='B#IN?MB-WZ5EU4V2=D#VP;5UVP:
M-JCN(T+71DT\;@9O8^6OJK3XTV[YAW(R(=NG;6K(PP<SB?Z;E':!0% W))_$
M'],<$9O7:=O\F="81FAJ?W*9(? I]LR;;'R9FCQ^CX#R VAUH^2,XFJI(2:Y
MN%_)PIW[T#X38DOHX<HH$T.45A(1M1WOX]Y7.;9A0Z6:UV-Z=LF#G@N9':R7
MEY^U^P59W_PRQ+L]QR @;)4$AB_P<,M%S4:7%#.83E&P>I.TW$^[D2*U:M,O
M!_%ME*$3S1^8:"?$'VET!:_LA4VD!0[G$]2 U"&,A$$ XC#"NEYU?VUC3&'<
MG_,$'(!/R/X'THY<GO2:"_NLI1S1'V(U\@:$CR0[W3K/8VS F"&,82,:7='1
M(GB54F]-/ ,_GD(VKN!E4@\7+?GIFAB/=%)+ZX9\@V;7Q3^!_<X>^GS.5K2,
MF+;$=15O96FXP)'NTVS"!>&<R(;AC=_->EGD(%G!@8%@N;R0['="#@)8T@B#
M;H;+(_&2]CRS*3/(=E"/EN:R#X.2V.]NY!_2BPS:]X++7-&YM4>7<61C:BHI
M+J*5+:_%/PH<-T9UR<-G ?S79N!K!QH@A](F]AMF2;5.7MT$HDY.I#0P=L4G
M=/VXZ94-?>.R+28D+GJPR[8&W2W^,8'ER(2@ML9_N5")=5,4LH6VW*H%GC'D
MWI%:3Q(6#G#'UIS8(B&L&/ 70.SB_6?+6XD8.$DEMITN@5:P&%T'B!=1?:F(
MW&%F:T>/FKK9L2%T=IX"?@?+2>'W1ZQ$'[?:_$#2QD_@/L$MOL4^!-YB[Y\X
M">A:GNT?/CYZ$C_8WZ?;XR2K&(MQN+41UVP:($G7J\7;)]WK0<+?T*WVGO#9
M+XF,:Q()6*W5]Y,MLP #D,;6Z?[T,!X6L.C;'9!44#X/XP?IB&X6C=YYX._$
MI!.4-M<,8:N;=$%O;DG!YUH)>LV,%=#:B.NYKGL.&?S= U8;".7\D3I(_8\O
M@+Z@6+K K\.=O:='R\"OK>Y9EVEXS(*&NP_9X8SI6.N>.]B7_GLU\"L> 'Y-
M0SJB+P+ HF\#@-D1W@@!BP,(V(/]AY+:GI3.N$W),)RX!H](^J23*RX34V7L
MV68L%)C]"FFW]X"4WC<#RX*57 4MBYQ7>IG-:I-/947)0U5Z'^>>VN*8 &^V
M:@3>33W\BNQ^+__E_#*Y2;Z(4.-U96_2(]7\IL ;@5$] VK8-;P3CJ E]%J$
M?9.*^W"O>);BI/*5UA;T]VF;\\[\C*(:W1Q>"A^:F,_SH*^E>ZX;Z^J=BI87
M /ZL?7',\1*XT1Q;9A?%U]?M[P^D,U7@NY(<.(E%?<T<F-RU6=VWOO@$!U X
MSOS)],5,TI>J4][$>S $%K3'A)<C7'0<29EJ)+2?G'RPYV!9K/N+-135"-",
M&Z]-[\FE\&\2MDBSAWI*O@42Q@@B"7^L$&]$&6QJ]M!'8<H^U.MP*Q)K,HT/
M%KW6N8P'P7\N**/H/P[* /_*:D9OX66U+!I7Q6VU*HD"O:M:EX'+5NDFK(H"
MNKM!1<;W!:LO">P\..Q\Q^*UA[^7%?S-7:N(N?A2_#47-QS ^4FLL["(@!MF
MWX-4R(Q]!*H_JLC'O 05X6?7(\K1,.&7QYI:8VAY"09?YI8D"*B1.5@)+-(/
MW1EVY^T<5*W6P!. 11*H&:]87#RT**\=IH&NLTY@CW[M\:_P? 69IB'>1UL]
MLB;3.,X1*KZX=&?'<DM*.D$[AHG/7YA&X-!, ,Z71KO"8DH ?,(QQ&,JFTMA
M<#Y#Q(#&K4PV&X%NTU;EZ8&/ D25-#&?,X>4?^/T)MEMY["9:XV:\S%PMJ7C
MT[I]^T8IYS=1!C9>B+>=K&XIL-1M!O*XTPPD?G3GK4#>D#,7GZ=3TRS(B_9I
MYN_=$&1SFUE]]Y&_+9OH6!QX>-@;-?8!M7$S+O#)%A=XJ[C )UM<X(98H]\'
M:]>];IZXZ^;L^/V'Z/1T ^E25FGQK37RM\7CJ&.-T-@>W[T]DE:?3*-T:X#'
M52%UE;()OT0D9)'0)Z3$Z=R']:,WRH$/-^<4L9LJ/FNK,3E.AK,R\MT HG<W
MID[/?M_9O_6]WE#KQTEI*'(K2,1%6*)3C_!S4]V\6?_ _?H1#5?'<E0YX\:=
M3 %U%08&.M,37X#U]O^<OXR/9_0H$)_Q[DI][6(V*G/DXK>1K;N1R'])HC3R
M-.ZL:+>'ZV[#B[PAG?J]0]M1AP/5Z9QKYH%E9E3^7NPRWE-&2TG.','_<%L1
M1T>D4CJK(/=@>0:-$G_(=]&.*2L0\S.3:+3@Y^"6KM&>B8Q[S=%.2B-A3VT>
M&(],8:89]T IKXL (U%[M/SU9<G]"]T/$(OD7)OM^Y+.Y!JW?8,FB/)7C(#^
MF=N<*:0UU;9 6]UQ-P?.VU?1<=M<EA7]6KH,P"AC[,F_6=6K/0:"'U/4$E8^
MRTF<-D[-W(OTQ?-XE(X_H1:EF" B4E;_1':J,6CKY<RL2/HOA@>UN\F9W62Y
MSW',C6ST.-QHT(O4TE:25 NX86 C0)5Q1L&7!"##P9U&]P]P^K4)Z6FD+43C
M;0O1NY9^.O,O,F9(GVR/[MVAK#GYS=G&E/G.%M)*;&*WQC9C"V]^H3U'\"9>
MT/4)TG3.-L]<NSKG@ MX3S/V0L[ B ? PN;<I5'?$PV\)XE';2/(,TX9TKL*
MP<-EW&4N<5UH7#LTFZTD-1&B$Y6H='O0?_A9N>%^( WPGJ4H.D]SL=+^7=@:
M1T1I_&VQ<0IB@^,I7QM,.=C;?QJI-79:8!]1$ M3S,UW@Z9]3S3Z"V9(9/03
M5',L&%X'/SO<#TJN71\)J5VDX_?T\5ZRM[<7"Q*\#H(KV.QX<+.3@" S /8>
M)!&^8Z%*3,HB_5=;;LJIK3ZAP-.8:?O9R=S?DRM%'$A4[OBG ]J]U>!K,HVO
M$[3#%8+V:&\K:/=$T.[D[GDYF^?EPABI9/?5'#9SL[V&[KR$BND$CE@+[ D2
M?F2K;R:^^@:A1Z&A8.90;A:@_3==4RC_^82^/<W&IM+:<V/%0'LLS^WV*TPQ
M:N=<*0_*_ N0CTGSE)\>J_JY)N>?.X+6E^23U+&6],PDIXAR8;,+F7)CZN8>
MN"XSD8 "#Q]!4*]&1.74V>=FL3-)%Y$J'VV)BJ!C.]><QJ3#9-9]BULC>#+G
M:$K*+A8ITM>9T-8=^^H=Z70@^G9_+SDZW+-S$U>HFV8!=YU,DY?E8/?P4$?M
M-/5/!X]YJ:R&UJFB$SKWMK%3)Y\K8[CREW:Z;D<UHTR:J,Y(NNCN</LAX1T>
MP?"V]W:==F34+NP,+39U<!?/W6OU+3[T?25QZ14#=WO$,TPMC%5HJ?E1 BC/
MTUKI;]U4]:$#56?6;YUF-2A'_ T:#=V@:1T0",<'3[9U(&LUC< 46MK/KS>]
MGR1/]X^ZAS7N'U:6Y3JNTN+"L0W]M+=[] 0GX:?]W;V#J']\G^YUCJ^1T[OQ
M:_Z?*#HKC>G]9\G!T\=_378.]UEV]G:?'"W)SCZY@X^WPG.[TS@-^I,^TMZ5
M9+H<[#U*'C\Z8GOV\&GRZ,G!U^TG]FD/]S:^B+\]@Y,CWTVX2-93FRWMXX^=
MN<=ZKK\=_M6>R/&?IBBOTJVO<9>^AM.43[J$Z;,Y$AJJ,4G-Z68E\>O7)XF4
M:%IZ .<ZB,O07%;&6#HOH5R#'>](O>('AT_X9GWHCVF$8ZHT#&$:0TD80FN;
M+%'2L:)X'SWQ)U8Q%>_FK@\-RJMP&82>D4RNJ-M<S'_4%'(!%]R(260-Q7U=
MC7ADFFNCG2CMHF .X7)TN</<.NX_[09JV&JVZ(U*5O4W<GDJLXC/T9; 5(UD
M8:*O^>IYDXX7\6^[\<LK^OESLK_!Z:>?J6WK--MSQ@2^"M9MXTL=-O&XH>J9
MW#'VP6O.V]B>Q,C?\X44I/DGIAY7V0AG""Q("A,B:>7M'\&K0ML1BQ<2 "\+
MO[^L@CP02#$SW[4:24.3,5/&N98*/WJ0/D2U<U9X?]J!"[ICTY.4CL>5%MAF
MQ96IV4&SK STDS)'>3 =P!$YV3%/G6MP@3@&J_C1WGX4OHW%-QT'0B]3<4 &
M=.$6<)/U1:6Q5$'?'#>VFZ(P!';0#VEMJ3XG^DP[@'MID]U<"'2T+02ZU4*@
MH__00J ?F_S=%J%\^UKVBE">]HM0GMQY$<K_\UY+[/_?^UP&NY7=ORV[S_JR
M>W3GLOMF&;2%NNZ6>:O%32C2? '.,S*?7F4%65)9FD<G(-]RD"LZ .2-\$?>
M62Q6O1O?Y^.P@486;/<IF2CE-3?9ZVYS:K<YJUTO,&64F]I=AY4:['KE=]TA
M\'QR \Q\DF-?CF=&[)BRLQORK=>7G,<;@1\^M=V:7)\_QXT& M>2244 'W:#
M"[J+RNAD$F#EK*7@@7T.V@+I(UE$KW;V8PL)?D6CH'7:^>_=^$S:&S+S=FT<
MM^+YW/![WM(#46VHO8SHBW#2X]=ER2PMY]UAG+>S&3A;WF?UI_A5R@D@&Q*@
M";(BV-^-?]EB%._TF+]*LRIBCV+S('OW2DE94+*&[>AH54S3%;*<?M0?.N)5
M.DBOS*AJ<= .]O:/$MM!$7^U;*[R#VW/",@0]P+18/S^,W'AF8V9CG%NF.X/
MN-68#)KL*D48O68_73NF<;0*X2G2:A-H.$>N5(X8L"S!>LX@NQ#6@]3%"-/<
MMPQG#8RF')G$4.PS(^VFS(Q-39,+I[Z=/^M:!FR[-'4Y%FI9"7=8MB5NXTQK
M:%+P$[LAG+6-IXC]U11H"&&;H-#O/,]K':6X-L*7QUKN%^?9'VTV 6"+/MY(
M'.9YEVP*:'% (GBHF6]05V=-J[?&-1>DX5OVN;YEJS"TQ3.3%ES,ALLA8UZL
M/+?<<1J&Y5@/[-3NJBN!G5NW!V;W8C?Q+T4MG+XNSLOB@FZID6'TQD6138'#
M:&P$2' %G"SKYV5H$?]57M-:5XEK9B+<<!+;0= 7EUV;IW%;R_WJBN9L2XE+
MW6B.Z%Y!(=G1.SG#UFAKDCIJZ\Y.I[0 ,PFY)M_X2*!-)AD"7+[IQ9348O<K
M=*YT52=>2B'+-IINXV!TS)??H9^A^]8]97OCK<DT/AIN@S)#Z]<5F^\.D&ZR
M*1C9 K6"_B05R7*^T':/.)F">0+\ACX@3Y(7I-HFE&L]:Z""?E?85%;0KZ-
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M6 4GA1YA,0>J'5)+?&KKC"H#'A^&@+H2/0:'L-K;'9116_?](QID?G?LY2;
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MP$83D,]W.T6&B2,UEBWV?=#EQPO-F)3YA4T!4 X+' U+%Z^EAV)9=97%4Y;
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MYZ(8JSC#AVB8I8.(_E)%4J?8_8@_$(7_AT#_[""*"]N3<3$<IPC-.$*S'H\
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MQQ2KG+0$75/J80H-C#\T9T#-ZNO,]M(J?Z94'#>*8AE6;Z<0Z">L>RA4ODK
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M#$8_=>GF6O-\O@V1=6Q5H3P(IQJ:D(_G559(=%X=B:Y)<MRW<>"]@<F]->\
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MA:=;DL=9A063HMJ)[<?:B94*N,$O%T4*Y.GM&_RRY"I=1O*M,P4?W(NSVO@
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M!WB?[-XB]>?%;KVC9L74/':)R$)K#2>!6TC-_G;G<%W:@JY< .\Y >RH:84
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M_^2K')8%\L79:!0-)1SU#6"^S=9=%H^T9X]Y2RP[<C>=\MSL<W49)#[L:R%
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M40#K56ZJMW(DR7U?<VR@HHA.>,=[CO?NZ./%J9R9>(WAJ*/<^"X<4SFFNDO
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MLJA*DEA3:E+][8.LJ*K8O#-05U*U_9[?CYW"/7CB'BS$U718=@B5(8 3& 0
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M:EY7&=!1$NNR4E/?/LA*2Y+EN^QI#-\!1P!6)FN-W;YF:,(GI%E^3]=<5$W
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MED2 L%HX:*F1R3J/ZWUE.4[)QSD]T>7O9,B&IG?J*  A](13')VQ1S%_?5\
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MH8JK%89JY04. F:M##*U:F+'H+&&(//TRGA=<8$ ?V8'*(TIX,N\J&\WJ.*
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M_]7Z@_?"%1YZAJ>T5.<M;BY/-\$G%_="6Q>7J!+%=$XITI=E&9?3=2DL.X_
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MJ-P^O&Z(E:Z>%(9.>+'LT8MEP'/ /F$"^X37^"$X@"R+[P_ID\B_I/=O\(P
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M\19@0,+OS/H^H0,LQFO$6IQ8AH$[P!L*#PEQ&(\6&T%Q-"8,=;O4&K<Q5,^
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M=30/&;!HW)E1PP]LNZYFWY,XX,%P])$K;8A_U7[47.-R@#^(>ZD\( _LFHL
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M)QX7<]LXIY1,_A52[:A1JB]/L=[-J[A$?4E\0$L$7B&5)+/-YJZ4%[*3"Y.
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M1A+G8*S(6>D8%@(6:98E:QA]"GH"\L(>$@E9MVSV6;:=0F#6!@4#0[Z.G=I
MM#M@]%#;U@:;P99&CF:K8XUD;+!1*/_O8R&H"1O[H)HL:02]-*R),ITIV5?(
M0.VK8*5,\,_4%K,.I)]$&LH/!%0(M%54:PCSDF'_30.]I7C6LBO8-!DL.-DV
M3-C4L4GV^YJJHRV6H5F"_!\2/"^#@64/<5UC. 8Z;5AF:&6ZT]<(Z#A@)BIL
MGKIL.SAY%;7) 3%Q>PR)Z$-:#HY#N$_(.E9KT862 ;8SDJR)!<9]ANV8-'2
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MNR7R262A>T=NMX?DEV8,RN\^P5KQFGBK?1/Q6RGBT6P<"_A,""D8#4Q$L;Y
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MKP^?"[7IG![P/-9&+/#-#'Y3ZLNF.0%.\$B# ^SVT[%I*ZSP!S@0+NVKAA\
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MDC-FC2VD3JLII-*.C =98^E6''''VV6+!=$OR0U/%9(Z^[_P0#K[WPZD%K;
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M%'3?!NL7$^0]L]0'7Q660WD96O0X;?8HY<38#$5%N$/D$D2ELV?<F% =W+5
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MM,SR6KP'BRQ8OM+NS$)#:GTMIE6V7_3,LF*D;1MADJU"AW$H9B4>M)7T70H
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M.,K%\S+:N+;X8NK,IV$]Y?.)$3YWA,W&=$-NS("?I<T?0ZWV^\2J.GIAM]2
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M=JNA3T?, )480^J#F+H!7<[0":(%[</:=0O6A8.@=++ZIDJ_P%;M=SGRU)#
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M6I$2>$928CJ89\3FKZZ__E$J@SH1$X7GQN*6!ZU2._08)FQUS0Q"..-BMK[
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MNN$D!4HYL('PS]HSX8M4&1F*+"=DB?HWG/K.L0=3$3;*$:"$@E=V&'GYN@%
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MX>Y"N)?.N&:]M\[-\& \9)'9^RN>\L)HRC8O+!(BN&:)I4(I)HV!U^9,1<O
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MHM'"&!N%2/4CJX+P%;X$WO">>GOJI=D K<WUW)(!PEXYO,B-KL?,9;,\B-H
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M*6?Z=&T@Q4M'+4$/5/1&0/ P!="%8%'K4$(9<&HD#Z96<"Q1X[H(PA Y*D-
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M6<$^QV_O8V("OFN-]O$<BM6'I+;@1%9ZSS?3\?=UM]OSXD0Z2M,VO,B*ZS!
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M*A>I^M2<96.L-UYCVYC>#(8WC8?JER/\Y/35^3"P'GV?<L[-]TF6O 1T0=P
M@W[^"01D3&?PU>2F[/2,\E,)'AW'N'K+R>*8&#7L3FTFOHFV5F*9NKIANCG'
M<%ONHHLHC.$0;?\3::F,(A]/:Z-VSEC^OG;_+5XV>=P3:EVYUTO#.+P4CL\-
M+(>+H10\=,+RG57EI^%+,@2N@-/XV_!#<LS_3;O&-6?-UMD\CU/$(@[ ^"1I
MC.(7;#JTI7%Q(>?E'CB@%&+.&HM*%/%QHK^V*'ORQ4:^..,%3GE\=/R^Y=J0
M]*@R]O 7[]J8D-[HK?/Z+;8F>8<A7-8[6*=)H,E))W)(T\-H,BKA)G052I4,
M57!OS+=E1],N"Z^^W2R\6(3C?)B[R4_)P;SI.;R21E'QG7F'4X""39 V8ZY<
MEJPD78(PW7SA'!P4)IDN%N]F<O/]4&*X9OE^$&,V7;SW895\(K+IRMF<UT&\
MR1*DI3W*Q9\L%XL-*IPWA$MV=B%/*;_)<N&LC\>0?Z6(,^2_NUEQ./ES0U9<
M+/S(T_FSCM 6ZN0@*5#&0\H;MC82%N4=,N6MF.Z4-U\>0 0I;[&P^^RU_7E[
MFK\JWG1^;,I;-,*#(^4M[]XJ-5G2$Q3XKXZ,B#KE#=TH1M9NT4;.R/;]=VM8
M*W%G0BQI;]AXV@O,!^Y2_&EO%)DEO;973*>0[//>O)KJ,SQY;[%H@M?7NUNQ
M<GI;&CA.EXLN[XTF]WEOP?/>XD%EET^EYN/)^.FZF(2\-YK<Y[W]B,U$'IY0
M7V;,,]MJ?G1(E((V@;ZS*5<M%E7Q(@KSD_,9\UH2',P)MS(=:=MI:#;$B\TU
MH\EP<8UBP;WOB.]\L^AY?W6&6+2F$[%;O$93>KJ97E?JB]9Y)?C8L("A#$]N
M#R:JQB@HX6,85+Z0I7>U<&\/'^+T-O<9]%@RZ&/1Q:=?;(X?LG+WS'%"ZBYG
MT$>BD:EP$]8+N4P^7]HGT?OL/1-5$GTLHIBKO+9ZI?*,'Y5_6!)]-!(8/J&+
MRN8"#TK=YX#O4^C30;[XQK1Z3Z?/N>W3]HE^3]8ZT0G/I0;^1/PH)T;:M<Y=
M#%K\^+[[(G->$_'#3(I,3O:Q0Z(^3K.4#P4,R^5"AO20J.]!7H*KU2T(7V+Z
M[\8LC8O:P[BN< *K..0>.V7^!QYPEQS!]%T6@%-<BQ@&NI+^"S'3+J\^<)!?
MMEMOPI6(4H1X0N=75^>-3I5^:#MD 6(O18@W1XDJ)Z(4H9*EO3;VW7'A75K<
M?#RU#?6X:QN:Q9)4>F(&#]^LW]J&:+&OQ[0/FG1+^\# HO%>&GA<H#HVCP"G
M07#?8PZI.D4DX'A?@E'2[5?Z:N7J(FTJG:HCMJY1J2W"7VW?W;P\N^2N^Q>G
M=WW'%CZF<ZZ;SAG^.D6@UNLI1(UJZ6"Q4>-VHD#NG= (NC"XLT>B?%/Y:5:X
MO"&OA GK/8_CIPCR-IU6.EB,R>JT%MQ+6G9-ON-S6D\Q.JT;>%'C. 8LT*/3
M0\7KR^9NSLX_Y(?GS[Q#$W=77]99HR3.N:6+N)U;?,>OENK0>Z<WNC"SN]TP
MW,ZM.\6]UCF7([_>R!;G[A3':-B]^L3EA/O$8>Y.3=*]=W/7,W,A7;;DS[Y<
M/YQ_3L;ET9U#MW3"M,[T7M&L$3MJ7)L+V>1L[[9&8M0V0XWM^J=?7[5^Z_MD
MI"B,Y[O35<%,:UZ#QS.)7&+#)^'M/=%(/=&UN=\A7)'$NYQU_N5Z_MJ1+AZX
M4"[G"ORR&O#$^9PY[+W=]LXE+O"[%C[&<RI6YY':@O?X=-J^ZBS*IZ_?M!?O
MT5&BMN$^YES;R6%T'W\I<./'!P=KXC$V>*5<+;PO+L3NM$%VWB:?'8,J/2!I
MOPF*!%1H\T-.)FZY&?$@#IE11OU%AFB!A_7^$$-&ZO-@(21<IWEE'Q-9X7OS
M%>K !Q_UF"$OS'^[/1I]5N87G+J23=*E$7(,MSI.TP;: ^Y ;_IS9&GZ<[32
M] ?R+3C!(UT@"%'S^:9J@(1%O4X(J*:1JT[,&)GX*TJSK$9F].J,,[!232O8
M*@-94HZ.VE!@F[T& ,!3G@4Z7%4&>ETRD/?ZBKR/ZF</5X7;M[)0,N0=K>H(
M+8L8J^LB&+BP59H8G97LFB<Y(>0(J.*Q0D4EQ?L:)59,K]=)#J05_1X>5S;U
MY$,B!!]*K/(,SJM(:VNG<TF49:SLLF@-Q]/>O%^^IVW")*)^[=_7FTC%V;@1
M[18K&^3#!2ZH"I4I%NV\()49=&D"AG--D?AB"HS-$7$R2ZLO4=UYZ92ME-=A
MNZZ,]3Y,Q%B]:,;%.K'W-/3(4N$]:S)K6V*J\M082B+:X0$,Z6M62QEPAN6B
M[2T73D3K:+G6>G\'Y*[)X&XT/Y5/)X7"#EJN]3;B'OG+:P[!FN6B\Z4,Y:"M
MP%-=T4X$E@L7NTPOAR,N]W;[U*4\62XB&:8K,!\$*X PHG=T)4/:]N%Q-UV^
MVBU@-EVXN.5$*/,G_*3:AW5?.V:Z K,4AO%F6=)NQ."JZ<JFV..T<YGC"RQR
M<I<9@PTI$K!GEM,KD&O1Q.Z 8R=0,,"#5+N(WE8%QS+EE7D;!C?:8*4G@@AW
M9@YJ5"S]'7P]Z'T02=?/845J*;FS^5FJ BR/&KT.9-@X56-_@M$(A]Q%<U!"
M_HU3,M(4-XINK5;S53ZIOR^&;8:_>90!\RUG%+"\/!88\#9P'@ JZCQ_ ,"#
M?H@$ZGZK)0L0.O<;5# 3 P4.B2XG"%HX$@$R^#/X5%?_V3?!M$@KV*# C&6P
M8?U??X@9SRH#^!3R[T-/N2_.K29Q]MT"GX"T^=\A[:%-7!?(/]!TQP9V\_R^
MZ->T\98ZB6O\KR/].M87BGY8WJ"A'TW7:.AG>!^4H(W8W$IX7YW7!+! 7=)B
M:'QB0[$PS4ITFFH ,^PR$[Q#!(MW>'__O**[[AW>(0J:A-Y?M%61FK'-T7^[
M:X:HH>5:EBFUX6)46[27-3O<NNLXP]]37#KSA(BZ&2Z)"AB:/=47-<\"C64:
MH4A7G_JY O]9=^@C;4#)#''B,'Q-IW'.D<C>$];PD]<V08W"EZ!6"%<)62EE
MRAYZQ 7G96>1PB5 =AFB.$N4C,.UFQ%3 ]#+"&+'+DZ]5WYQ>37J7^=YSTFB
MZ14N5_I'+F_A2Q-SV;+[F-VD2YSC2SVRS/K%FZ5O? 3\LBF[S\CBI R1I:(3
MV?[#\REU\W%Q\;;LB;4Y>1,LT=K\QEEZ/61O4D:0-:1@>,K>+!371G;%>+*'
MQZ5LV6O69LJ$;FGKJA&(SL9"/F#@6"T3,Q8+UYPJM"+>*+VZE\&]4=@VCRF7
M!=>*O8!G'?&TG#B=,6-L<-CA3MC&E>!LBF]W=Q\K&N0J-T_5\>/GU<*A>B_^
MN:J1Y0!@0'3%<+EM.3+=PX=QMD1SGZ=I]95B%8UGF:&H7/WD?F"3A)>4 <1X
M"1RC$.'(YBOLZOB>54]G=4)6"+BF,:A?/R<6B;L5KDL?"^7Q9-;SX^>L9@\Y
M>#+8>-F3)U/,X_1D_)T<[.=9+.^G$&^SQ>.V,+.:+YL@R%S#GB*]>B=A&205
MB[+JSE\O\E=Y;O+QZ=['$>]X2\S4B]'J1Y5;ZX_%MS#C<JWG2^@S3!A:SC<O
M@0@\U3[/?,RX]"L<<<A&DD!R^+QATA3,W#&0O)]Q&7MK+H\I6U'A&M,(34\%
MZOXSS&*<\U>-XKK9.J,N"3#IYN;VX>Z-N:#J'XF<MQD]U>.S%Z605;>9BH>+
MYIT=P8F/[_:3__;DVT7R[6:T9&.Z)YV@" K.H4\>$COCF80A,A^OER< ASA,
MPC#=SW>DS??S2<DW\Y#,B=/@ATOFI(K%3,F#R=^R2^6IG6?LR9JQB$BK*M*=
MSY/7U^]>@&3-CD-"2U($)EB")DX9"I^@F<^2[DUVTQF7L&E<L?6<RUC\UI-9
M7_[\;)!WS>Y6<B[CO:DL;3GGLI+-5U)Y5[FT2/4MI53&T]RRNA@5N<5KX7+@
M*Z4RG 7RF$99<DVCW.=.)L2-6:NQB2AW,A:A>*S/<P_7XB/',SN8.XFMLXK9
MSI1#YDX6TYT[N>;%;R%W,IZA(%>CIY?[44/X2B;;![ODC48D*!Q]#=TG!B1+
M)A+@?P3,A(QGTN15^RW_S H/+W1$F9#Q=N0OY[:9"4F166J?"ODC@_N)2X4L
MQIL*&8NVNA,^J]5;ZJKUD-O%5,AHS'XA7.@^5\H4BN&CCEM(A<1YE>4W%3(6
M<9@,\VR+^NZ=/SL,W=G=5,AHQ*445??O73#_JR@YAP\EVW)",D!ROMW\_CP?
M*#==S@](5F.3"<3(%9P8V=>YH0!\:8^0?TQDN/X]YJ5$X>*3"*Y/C#%A:+/;
MQ\E?=\S5Y.:F\]9PS(7%A).QWN0YD3(^%% )%BO3$4"I%#Y,MIW:(5RBH9U?
MP@#S5?M3+' ?S;N>CTI[;2MA$3,.*?%*U1@%)1=^XD"^D*5WM<!^7SL49_!O
M7T8471G16CN6V,N(8C$1N=G7_/'FJ5+O=_9E1%$;CW"AR4(ND_<0:=G9.J*(
MD_97N21A6*Y%7PF79UQQ;+H+<,5RD8CMEJ0V22@P?-"4RGKH]KROS-IV9=:>
M?%LK;/-8.N]Q6'KL16ZYR(:]>^(LK\/LDS#WH!ZO)66_[AN=T3@_?[*;N[E>
M'E<?L399UJ&HGKC:.9S&L1(N%357R(#'^+:-_N7(W\.B%D&[8CR<.2U^BO%B
M%DBF-A9?/^_G9,USF-(JGO9U$"F2T&#%>OB$%APS!D1;=N\@MFM2ZP.3^>6\
ME=2#*.[Q$IE]0'Y+2OWZHT$U^N$*!*UV.VEI"3D2:^JN_]) BLR62(^I"3LN
MMDN+BS'!Q[W8L!YSL6%E49RQ=\7!Z2OKJ]@P0@#LK1(Q1Q;<*A$Q<*CNK/Y"
MHW#A3-Q5X3"-FZZ6WQ?Y4UJXI:N%4:D0P8AG[9?\"! #/#)/IVL\\O;WA&8?
M'R'Q/.B:1)C@ON&_.6+&R 0S'DOB-P W"B?,B;]6K:Y[7>7[>$S&*<0WSY/&
M=[$UN'Y:)N>A1Q!HIX3=3H/5@,463\V17N.I< )UEX%;)JTH]/"8SN=L2Q@)
MC:D9H,36CG>M5Z#3\<;2'N'C7.I= R-^6=C&Z4;1/2]'>@T(.)QNI9#?4*"*
M#A>-I5<&'(% (,$!_6(3D2,@#\"]97=+T>VB\J[*<([]YB/,P..65!V^)M;F
MJ&5=XTSPVBG?Y>R%88G5(("3VZ+"".:_GXHRX'+EE0,LV17[([!L]IUOF'4_
M4@F+E\']5_5D2'[.EOT<'D>2\25 *<,H686Y"U[A)LF1[<4IO& 59LIKH,!)
M55><A=E655/QGZFJYA<?-_4OZE7^;LWHU)\I;7NF7I/:G,Z4*CF=:8:0.'G,
M@=]- <[*0'=BXIF$X+L" V.!BG@@:N%YK2(7/ 4X(4CUU[\FO#(';@P<RPU>
M0]P)S$C.$JU-CUX^E?#[U(,9+PA$AR/@%B1H;,2I]@5X3C! ,4;>$C$;\-T!
MP<N$,A_#>R\ ,H&U1':* #9K,D8+8;H#^!T&^&+P[?"7\'B9T1P*PR_P0:!U
M^2G/PG '>#(Z+;"D Z!JP?O $V6P&OB((:<LWPE5=0]X_PJW^Q;O (H9]]T5
M)BQW_-__'1T19SPGL+^).Z8/7-$6]S7A ,5^$^7B']7#!8\FCHZT\ *@KO<;
M5946QB>*:*O(:R2ZG"!HOBB2$O@S6&57_]GZ#K K@1G+8"GZO_X0^FA"DOQ[
MC0[P-1NO4A5Q;'OSN722S7]4A]=;7G=X?'9DIIQ.LS]$>SX&*ZA*3(?O_B%N
M@0)3Z7HK0@I29?.W?NE?@W]:>M:Z6_W?+T!J&Z(#(0!2R@'.!L\>HS/3R SV
MI=/8X%L3-RZY86QYN'E)<*WJ<DQ,$HT<I![F1;>!N'4078I2!_W#\_\>(.-"
M/#,2ZH*R6QO<CEM!9@O\*.*@T,%,.S ">M:\+$^ U06.Q A87_"OSAQ9\A,1
M8"V(5&H\,/.*"!Q+B$P'#$ !(U%%3, : SP0NW6-F$@[>?+M 7?08WB)F*+P
M-CA7"+L(C14(!B)K")H@?ALB8 A0&.0#%D;'P<<1."0F,D)JZE./6MV!"!#8
MT0VPQ>#C8XGOHLMHA"?1FU2L.1193LC"VAK 21Q[,!4!]N0%""W!*U5PJKUN
MP - )T'#3I@^!=X/_SA&E]_:#QI$1('QTA]9!=%9 FR4D'CY\Z@'T"3 @,#,
M<Q!$PVV87_:8;64/VL#NRA-IKDJ!#." ,@"[4^"5&K#C8!$ 'L.7<=K2"8'O
M&2O0B*>^4T>L$QD\Q[0+0#\&/D4G[/)1"-)R(_9@#NUT1GTTE+&>FO0Y =()
MERVK+W!:@HPB <NS,W9I6HAV*N#$ /8RJ-;A@$3SHG0 7RQQ8T L#CX/D5L%
M\?!5@-7 KQC%\!6@ZC!6!+8'O %QHL@*@_(1L@3 1LNUP5"%[ESP(S64 5#]
M5H)16U >7J]>%=$<=^" LSF&L%6""1 6C[5PB+F-F5H;6AVQNHBV1?BKYO)$
MT=]0#@K$L6WT_\ N3@0181O3W5"EA+$=7;B%O2^XQO7][?,E]P5=^12!Q<9(
M#4D &AS &TH)9?D8$F42-:0QN"4%H,H3"1FEI4#1!4[_4!RIVA$J0'DR!-M"
M88<.)XBSWRF&U.GW"2QAOO))Z7U1N+ZI?7=DI7/>,SB6Y64 M,#;@!KA (KK
M#CAV(G P1JR#;Z*YPA(FH3 (9*:3+X?=.RV]N?:'GO*B,93\J7X^]JQV\ E(
MR_\=4FM!C4"IZ/HRU<SI<(M,^/[HT/OSFE;OIR^&,Y_X(!CMH7)<>]DO3Z^(
M?!G'F@KQ_+885J2GO_[7D7X=Z^EOZ <]$38YJ]T?8RS'&%SJ$V<T:*PZ5<U
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MU($TCX>!$<"%CZ\$NA-+NYQ&VGO2GY^$/6SR->Y+S1)=;W]@F-:3.A%T$[-
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MQVDU?O"+2R_AX9JGW:TC4>GM^I:7^R=WWUL-QU*T;3C6NF\]1NNVJQ7(&;C
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M95!1,=J\6)K"FQ:[@B ")\BX! Y0-&PY&U4/A6D9;W#<JBQ/C#*F'NKJKK8
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M>J:8S_)W3Q32/NQ$ XO.+I"!<TBI#.V21FJ+:\C S+5VJ9(XYF+J=W3GY'O
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M#?"OMG+IG)BL^ ]-V7\\N"L_D,?+YZ6R>DQJGFD*RF!HH_M,X:ZCC<_6^KJ
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M$(=AM1E'.G-!"9$THL\X/69V _E[ZOG"97U#(>T.7$\#EFXX%@A-:Z>?S!#
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MEXTIOL)7_&10#T1? [S'[E%5V)IL>)0C[T =.%X75XHC=>DZW87L"J?= (_
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M>L/ VUT"0/43[E@?GT7(H9PGAT0)M&D8E5(UO5.0N@SN8H('@A>G?W8PI?\
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M3I9>JYZ\W+Z2/VF$4RC9\KOSBFG")VVL*VU,=YX3RT[JN"'A!"<0XHE**IY
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M _7[_P=02P$"% ,4    " !)JGU8ECT54+@4  !A^   $
M@ $     86EM+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( $FJ?5BM444XX!<
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M,C$M,2YH=&U02P$"% ,4    " !)JGU8:_3^.%H#  ">#   "@
M    @ '"Z0$ 97@R,RTQ+FAT;5!+ 0(4 Q0    ( $FJ?5@K<$#].0@  %9&
M   *              "  43M 0!E>#,Q+3$N:'1M4$L! A0#%     @ 2:I]
M6'L"@^LR"   <T8   H              ( !I?4! &5X,S$M,BYH=&U02P$"
M% ,4    " !)JGU8>#@]0)T$  #\(0  "@              @ '__0$ 97@S
M,BTQ+FAT;5!+ 0(4 Q0    ( $FJ?5@B5&UQB@0  #\A   *
M  "  <0" @!E>#,R+3(N:'1M4$L! A0#%     @ 2:I]6/,JP6/6$   EWP
M  H              ( !=@<" &5X-"TR-2YH=&U02P$"% ,4    " !)JGU8
MD+TCN&T.  !K;@  "@              @ %T& ( 97@Y-RTQ+FAT;5!+ 0(4
M Q0    ( $FJ?5@*E'GT64P#  ,:(@ ,              "  0DG @!F;W)M
>,3 M:RYH=&U02P4&     !  $ "T P  C',%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AIM="http://aimimmuno.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aim-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2024-03-27</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">AIM:PatentAndTrademarkRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AIM:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MutualFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AIM:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:BoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AIM:DirectorsOfficersAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-06</startDate>
            <endDate>2020-07-07</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-03-302020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-182023-04-19_custom_MaximGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-18</startDate>
            <endDate>2023-04-19</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MaximGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MaximGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-12</instant>
        </period>
    </context>
    <context id="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-12</startDate>
            <endDate>2018-09-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlanTwoThousandNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlansTwoThousandAndEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EquityIncentivePlans2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember289844531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PancreaticCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PancreaticCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_JubilantHollisterStierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_JubilantHollisterStierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_JubilantHollisterStierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ResearchConsultingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ResearchConsultingAndSupplyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:PharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JjointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_AzenovaSalesInternationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaSalesInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaSalesInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_AlcamiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AlcamiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AlcamiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">AIM:FourZeroOnekPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:NamedExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentContractualAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:ThomasKEquelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquelsandRodinoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EquelsandRodinoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:ThomasKEquelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:PeterRodinoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EllenLintalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AIM:EquelsRodinoAndFormerOfficerLintalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_BE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_stpr_NJ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_NJ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_NJ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RestatementAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AIM:MarchTwoThousandNineteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember289848921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="AIM:DebtIstrumentAxis">AIM:UnsecuredPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EmployeesPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:DirectorsPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:EmployeesPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:DirectorsPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Integer">
        <measure>AIM:Integer</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005">0000946644</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0128"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0130"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0132"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0134"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ManufacturingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:CashlessWarrantConversion
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:AbandonmentOfPatentAndTrademarkRights
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:LossGainFromSaleOfIncomeTaxOperatingLosses
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="xdx2ixbrl0515">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0817"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0819"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0853"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0855"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0857"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0859"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0861"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0863"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0881"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0883"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0885"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0887"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0889"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="xdx2ixbrl0891"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0975"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0977"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0979"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0981"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0983"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      id="xdx2ixbrl0985"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1045"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1047"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1055"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1093"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1114"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1138"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1183"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1185"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1203"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1205"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1236"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1258"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1278"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1333"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1334"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1336"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1338"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1339"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1341"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1355"
      unitRef="Shares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1356"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1358"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1406"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1408"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1410"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1412"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      id="xdx2ixbrl1513">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      id="xdx2ixbrl1520">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      id="xdx2ixbrl1530">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      id="xdx2ixbrl1537">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember"
      id="xdx2ixbrl1545">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <AIM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1627"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:IncomeTaxReconciliationNondeductibleStateNetOperatingLoss
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1769"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1771"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1785"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1807"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1808"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1810"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1811"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018">001-27072</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019">AIM IMMUNOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021">52-0845822</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022">2117     SW Highway 484</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000023">Ocala</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000024">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000025">34473</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">(352)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000027">448-7797</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000028">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000029">AIM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000030">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000031">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000038">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000039">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000041"
      unitRef="USD">31829482</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-27"
      decimals="INF"
      id="Fact000042"
      unitRef="Shares">49901177</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000043">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000044">243</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000045">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000046">Miami, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">5439000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">27053000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">7137000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">1184000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">1676000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">302000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">455000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">14556000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">36321000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">697000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">829000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">1941000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">1688000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">1202000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">19381000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">40488000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">6443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">377000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">1986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">806000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">223000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">178000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">8652000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">1361000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">495000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">659000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">9147000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">2020000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000120"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000122"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">250000</us-gaap:PreferredStockSharesAuthorized>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">689</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">689</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">696</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000153"
      unitRef="Shares">696</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">689000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">696000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000163"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">48084287</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000175"
      unitRef="Shares">48084287</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">701667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">694324</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">48000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">419004000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">418270000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">-409508000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">-380546000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000187"
      unitRef="USD">10234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">38468000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">19381000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">40488000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">202000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">141000</us-gaap:Revenues>
    <us-gaap:ManufacturingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">42000</us-gaap:ManufacturingCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">10939000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">6990000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">21137000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">13074000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">32118000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">20064000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">-31916000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">-19923000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">200000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">-1679000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">1069000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">629000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">18000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-35000</us-gaap:FairValueAdjustmentOfWarrants>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-1667000</AIM:GainFromSaleOfIncomeTaxOperatingLoss>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-1490000</AIM:GainFromSaleOfIncomeTaxOperatingLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">-28962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-19445000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000240"
      unitRef="USDPShares">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000242"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000244"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">48585404</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">48585404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">48047288</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">48047288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">696000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000261"
      unitRef="Shares">48084287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">418270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">-380546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">38468000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">1017399</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">484000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">485000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">243000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000286"
      unitRef="Shares">798</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-28962000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">-28962000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">689000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000302"
      unitRef="Shares">49102484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">419004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">-409508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">10234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">715000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000311"
      unitRef="Shares">47994672</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">417217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">-361101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">56879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">715000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">47994672</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">417217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">-361101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">56879000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000329"
      unitRef="Shares">88749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">80000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000333"
      unitRef="USD">954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <AIM:CashlessWarrantConversionShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000345"
      unitRef="Shares">638</AIM:CashlessWarrantConversionShares>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">-19000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">-19445000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">-19445000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">696000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">48084287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">418270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">-380546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">38468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">696000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">48084287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">418270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">-380546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">38468000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-28962000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">-19445000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">39000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">38000</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">-35000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">18000</us-gaap:GainLossOnDispositionOfAssets1>
    <AIM:AbandonmentOfPatentAndTrademarkRights
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">14000</AIM:AbandonmentOfPatentAndTrademarkRights>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">199000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">218000</us-gaap:AmortizationOfIntangibleAssets>
    <AIM:NoncashLeaseExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">287000</AIM:NoncashLeaseExpense>
    <AIM:NoncashLeaseExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">-680000</AIM:NoncashLeaseExpense>
    <AIM:LossGainFromSaleOfIncomeTaxOperatingLosses
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">-197000</AIM:LossGainFromSaleOfIncomeTaxOperatingLosses>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">243000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">954000</us-gaap:ShareBasedCompensation>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">200000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">-1679000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000420"
      unitRef="USD">-492000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">35000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">-153000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000424"
      unitRef="USD">151000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000426"
      unitRef="USD">-274000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000427"
      unitRef="USD">688000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">486000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">83000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000432"
      unitRef="USD">6066000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">179000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">1180000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">368000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">-21267000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">-16108000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">1299000</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">10083000</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">1593000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">2724000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">86000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">47000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">3900000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">585000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">185000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">-832000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">10988000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">485000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">80000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">485000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">80000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">-21614000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">-5040000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">27053000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">32093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">5439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">27053000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <AIM:UnrealizedGainLossOnMarketableInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">376000</AIM:UnrealizedGainLossOnMarketableInvestments>
    <AIM:UnrealizedGainLossOnMarketableInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">-928000</AIM:UnrealizedGainLossOnMarketableInvestments>
    <AIM:ConversionOfSeriesBPreferred
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">7000</AIM:ConversionOfSeriesBPreferred>
    <AIM:ConversionOfSeriesBPreferred
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">19000</AIM:ConversionOfSeriesBPreferred>
    <AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">73000</AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset>
    <AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">736000</AIM:OperatingLeaseLiabilityArisingFromObtainingRightOfUseAsset>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000492">&lt;p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYoXxHAglyRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(1)
&lt;span id="xdx_82D_zOYCi5rn3MF3"&gt;Description of Business &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A&lt;span style="color: Black"&gt;IM
ImmunoTech Inc. and its subsidiaries (collectively, &#x201c;AIM&#x201d;, &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;) are
an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;AIM&#x2019;s
flagship products are Ampligen (rintatolimod), a first-in-class drug of large macromolecular RNA (ribonucleic acid) molecules, and Alferon
N Injection (Interferon Alfa-N3). Ampligen has not been approved by the FDA or marketed in the United States. Ampligen is approved for
commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (&#x201c;CFS&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company&#x2019;s primary business focus involves Ampligen. Ampligen is a double-stranded RNA (&#x201c;dsRNA&#x201d;) molecule being developed
for globally important cancers, viral diseases and disorders of the immune system.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;AIM
currently is proceeding primarily in four areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Conducting
    a randomized, controlled study to evaluate efficacy and safety of Ampligen compared to a control group to treat locally advanced
    pancreatic cancer patients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Evaluating
Ampligen in other cancers, as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses
to check point inhibitors.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Exploring
    Ampligen&#x2019;s antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated
    viruses thereof. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Evaluating
    Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#x201c;ME/CFS&#x201d;) and fatigue and/or Post-COVID
    conditions of fatigue.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;AIM
is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer,
ME/CFS and Post-COVID conditions having priority over antiviral experimentation. AIM intends that priority clinical work be conducted
in trials authorized by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or European Medicines Agency (&#x201c;EMA&#x201d;), which
trials support a potential future NDA. However, the Company&#x2019;s antiviral experimentation is designed to accumulate additional preliminary
data supporting its hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced
immunity and cross-protection. Accordingly, the Company will conduct antiviral programs in those venues most readily available and able
to generate valid proof-of-concept data, including foreign venues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Preparation and Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated
financial statements include the accounts of AIM ImmunoTech and all entities in which a controlling interest is held by the Company. All
significant intercompany balances and transactions have been eliminated in consolidation. The consolidated financial statements are prepared
in accordance with accounting principles generally accepted in the U.S. (&#x201c;GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000494">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zJ1ZOSYNwxG7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(2)
&lt;span id="xdx_823_zw8y4UAd3rS8"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)
&lt;span id="xdx_86B_zmgK91eyCGD6"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid
instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year
ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit"&gt;250&lt;/span&gt;
thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)
&lt;span id="xdx_861_zilUSHqnAcu"&gt;Marketable Investment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company&#x2019;s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments
using the specific identification method and measure the fair value of our marketable investments using a market approach where identical
or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices
from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)
&lt;span id="xdx_869_z8KJmsuGquql"&gt;Property and Equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_zXpk4uRIk7o7" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(in thousands) December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;Furniture, fixture and equipment&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;2,233&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(2,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;195&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective
assets, ranging from &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life"&gt;ten years&lt;/span&gt;. Depreciation expense for the years ended December 31, 2023 and 2022 was $&lt;span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense"&gt;39,000&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense"&gt;38,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $&lt;span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges"&gt;1,800,000&lt;/span&gt; during
the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)
&lt;span id="xdx_862_zxLttbDekJv3"&gt;Patent and Trademark Rights, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful
life of &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights"&gt;17&lt;/span&gt; years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value,
or their value has become impaired. Such review includes an analysis of the patent and trademark&#x2019;s ultimate revenue and profitability
potential. Management&#x2019;s review addresses whether each patent continues to fit into the Company&#x2019;s strategic business plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(e)
&lt;span id="xdx_86B_zSaIIheXlof5"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#x201c;GAAP&#x201d;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(f)
&lt;span id="xdx_863_zYVcu2A7t1be"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with
Customers (&#x201c;Topic 606&#x201d;). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model
to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses
whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that
is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Revenue
from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped.
The Company has no other obligation associated with its products once shipment has been accepted by the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Revenue
from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery
program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(g)
&lt;span id="xdx_86A_zzDBc4KDPNel"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Deferred
income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement
of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized.
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes
are enacted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#x2019;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating
loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company
has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at
this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(h)
&lt;span id="xdx_86E_z3BzQaCVKJkf"&gt;Recent Accounting Standards and Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
October 2023, the FASB issued ASU 2023-06, &lt;i&gt;Disclosure Improvements. &lt;/i&gt;The standard requires additional or amended disclosure requirements
for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation
for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective
dependent upon the SEC&#x2019;s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has
evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined
that the adoption of the new standard will not have a material effect on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740) Improvements to Income Tax Disclosures. &lt;/i&gt;The amendments in
this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and
(2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items
is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income
tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting
currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about
income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign
taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid
(net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments
in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income
tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated
by federal (national), state, and foreign.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably
possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range
cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference
when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries
and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations
and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#x2019;s
present or future financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(i)
&lt;span id="xdx_86F_zmfAfvjRbn6g"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d;,
which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee
is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net
of estimated forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(j)
&lt;span id="xdx_866_zorjzfOx4Rcg"&gt;Common Stock Per Share Calculation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Basic
and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period.
Equivalent Common shares, consisting of &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares"&gt;3,523,949&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares"&gt;2,966,538&lt;/span&gt; of stock options and warrants, are excluded from the calculation of diluted
net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss
of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(k)
&lt;span id="xdx_864_zU9Jock3a3v3"&gt;Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets
or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which
a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business
climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an
accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset
(asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or
forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that,
more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously
estimated useful life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;When
assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing
the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#x2019;s
carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company measures the impairment by comparing the difference between the asset grouping&#x2019;s carrying value and its fair value. Long-lived
assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are
determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments
in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing
process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated,
it accelerates the rate of depreciation over the assets&#x2019; new, shorter useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;(l) Lease accounting&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is a party to leases
for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception
of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification
affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases,
which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit
rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate
the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease
term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The lease term is defined as the
non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will
exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments
made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs,
are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease
liability, while any variable portion is recognized as variable lease expenses as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has elected not to
recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months
or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;(m) &lt;span&gt;Reclassifications&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain prior year amounts have
been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders&#x2019;
equity, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_85A_z1fn1KYI6FM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000496">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zEMbe0TZb6q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)
&lt;span id="xdx_86B_zmgK91eyCGD6"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid
instruments with an original maturity of three months or less to be cash equivalents. At various times throughout the year
ended December 31, 2023, some accounts held at financial institutions were in excess of the federally insured limit of $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20231231_zvmWs7SbPgOl" title="Federlly insured limit"&gt;250&lt;/span&gt;
thousand. The Company has not experienced any losses on these accounts and believes credit risk to be minimal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000500">&lt;p id="xdx_849_eus-gaap--MarketableSecuritiesPolicy_zMjHrxGrLQu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)
&lt;span id="xdx_861_zilUSHqnAcu"&gt;Marketable Investment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company&#x2019;s marketable investments consist solely of mutual funds. We determine realized gains and losses for marketable investments
using the specific identification method and measure the fair value of our marketable investments using a market approach where identical
or comparable prices are available. If quoted market prices are not available, fair values of investments are determined using prices
from a pricing service, pricing models, quoted prices of investments with similar characteristics or discounted cash flow models.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000502">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zt86W6m9bIGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)
&lt;span id="xdx_869_z8KJmsuGquql"&gt;Property and Equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_zXpk4uRIk7o7" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(in thousands) December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;Furniture, fixture and equipment&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;2,233&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(2,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;195&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zP7FoIv57dY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Property
and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective
assets, ranging from &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231__srt--RangeAxis__srt--MinimumMember_zQeGYbdvAT61" title="Estimated useful life::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0515"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20231231__srt--RangeAxis__srt--MaximumMember_zjZDTdYNecA6" title="Estimated useful life"&gt;ten years&lt;/span&gt;. Depreciation expense for the years ended December 31, 2023 and 2022 was $&lt;span id="xdx_90B_eus-gaap--Depreciation_pp0p0_c20230101__20231231_zJEkdatNVYS" title="Depreciation expense"&gt;39,000&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--Depreciation_pp0p0_c20220101__20221231_zurcxXJtkB1j" title="Depreciation expense"&gt;38,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company made a strategic shift on in-house manufacturing and recorded an impairment of the facility in the amount of $&lt;span id="xdx_906_eus-gaap--OtherAssetImpairmentCharges_c20210101__20211231_ze1OKV82sk66" title="Impairment charges"&gt;1,800,000&lt;/span&gt; during
the year ended December 31, 2021. The Company sold the manufacturing facility on November 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000504">&lt;p id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zLX6LA2TACTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_zXpk4uRIk7o7" style="display: none"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zBTXS1S9qlF" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zlTanW87pzie" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(in thousands) December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAENzOpl_ziOhCb9E1NVd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;Furniture, fixture and equipment&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;2,233&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzOpl_zIqM0sdA1y97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(2,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzOpl_zCu6iyz0oMgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;195&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">1448000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">2233000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">1321000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">2038000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">195000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="Fact000517">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">39000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">38000</us-gaap:Depreciation>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2021-01-012021-12-31"
      decimals="0"
      id="Fact000523"
      unitRef="USD">1800000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000525">&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zkfmnEf1SS5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(d)
&lt;span id="xdx_862_zxLttbDekJv3"&gt;Patent and Trademark Rights, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over the established useful
life of &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentAndTrademarkRightsMember_zv543jSCSu9d" title="Estimated useful lives of patent and trademark rights"&gt;17&lt;/span&gt; years. The Company reviews its patents and trademark rights periodically to determine whether they have continuing value,
or their value has become impaired. Such review includes an analysis of the patent and trademark&#x2019;s ultimate revenue and profitability
potential. Management&#x2019;s review addresses whether each patent continues to fit into the Company&#x2019;s strategic business plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_custom_PatentAndTrademarkRightsMember"
      id="Fact000527">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000529">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zji90h29FOr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(e)
&lt;span id="xdx_86B_zSaIIheXlof5"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#x201c;GAAP&#x201d;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000531">&lt;p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zCyBjoarLLyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(f)
&lt;span id="xdx_863_zYVcu2A7t1be"&gt;Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company accounts for revenue in accordance with Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with
Customers (&#x201c;Topic 606&#x201d;). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or
services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity
performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the
contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract;
and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model
to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company
assesses the goods or services promised within each contract and determines those that are performance obligations and assesses
whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that
is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Revenue
from the sale of Ampligen under cost recovery clinical treatment protocols approved by the FDA is recognized when the product is shipped.
The Company has no other obligation associated with its products once shipment has been accepted by the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Revenue
from the sale Ampligen under the EAP is recognized as the product is distributed and administered to patients involved in the cost recovery
program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000533">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zbNDmc81sD8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(g)
&lt;span id="xdx_86A_zzDBc4KDPNel"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Deferred
income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement
of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits which are not expected to be realized.
The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes
are enacted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#x2019;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses generated in New Jersey, all tax benefits will likely not be recognized due to the substantial net operating
loss carryforwards which will most likely not be realized prior to expiration. With no tax due for the foreseeable future, the Company
has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary at
this time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000535">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zxT3b35BONPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(h)
&lt;span id="xdx_86E_z3BzQaCVKJkf"&gt;Recent Accounting Standards and Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
October 2023, the FASB issued ASU 2023-06, &lt;i&gt;Disclosure Improvements. &lt;/i&gt;The standard requires additional or amended disclosure requirements
for a variety of transactions. The provisions most applicable to the Company include the method used in diluted earnings per share computation
for each dilutive security including interim periods, preferences in involuntary liquidation for preferred stock. This ASU becomes effective
dependent upon the SEC&#x2019;s removal of related disclosures from Regulation S-X or S-K. Early adoption is permitted. The Company has
evaluated the impact of adoption of this ASU on its financial condition, results of operations and cash flows, and, as such, has determined
that the adoption of the new standard will not have a material effect on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740) Improvements to Income Tax Disclosures. &lt;/i&gt;The amendments in
this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and
(2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items
is equal to or greater than 5 percent of the amount computed by multiplying pretax income [or loss] by the applicable statutory income
tax rate). Specifically, public business entities are required to disclose a tabular reconciliation, using both percentages and reporting
currency amounts. The amendments in this Update require that all entities disclose on an annual basis the following information about
income taxes paid: 1. The amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign
taxes 2. The amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid
(net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received). The amendments
in this Update require that all entities disclose the following information: 1. Income (or loss) from continuing operations before income
tax expense (or benefit) disaggregated between domestic and foreign 2. Income tax expense (or benefit) from continuing operations disaggregated
by federal (national), state, and foreign.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
amendments in this Update eliminate the requirement for all entities to (1) disclose the nature and estimate of the range of the reasonably
possible change in the unrecognized tax benefits balance in the next 12 months or (2) make a statement that an estimate of the range
cannot be made. The amendments in this Update remove the requirement to disclose the cumulative amount of each type of temporary difference
when a deferred tax liability is not recognized because of the exceptions to comprehensive recognition of deferred taxes related to subsidiaries
and corporate joint ventures. The Company has evaluated the impact of adoption of this ASU on its financial condition, results of operations
and cash flows, and, as such, has determined that the adoption of the new standard will not have a material effect on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#x2019;s
present or future financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000537">&lt;p id="xdx_841_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zmYgeKZu2NQi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(i)
&lt;span id="xdx_86F_zmfAfvjRbn6g"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &#x201c;Compensation &#x2013; Stock Compensation&#x201d;,
which requires recognition of compensation expense related to stock-based compensation awards over the period during which an employee
is required to provide service for the award. Compensation expense is equal to the fair value of the award at the date of grant, net
of estimated forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000539">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zASBYDA4SHd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(j)
&lt;span id="xdx_866_zorjzfOx4Rcg"&gt;Common Stock Per Share Calculation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Basic
and diluted net loss per share is computed using the weighted average number of shares of Common Stock outstanding during the period.
Equivalent Common shares, consisting of &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_z8HgufNrRUs1" title="Equivalent Common shares"&gt;3,523,949&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zrDjzIlgwIK6" title="Equivalent Common shares"&gt;2,966,538&lt;/span&gt; of stock options and warrants, are excluded from the calculation of diluted
net loss per share for the years ended December 31, 2023 and 2022, respectively, since their effect is antidilutive due to the net loss
of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">3523949</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000543"
      unitRef="Shares">2966538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000545">&lt;p id="xdx_845_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD2EdXEU7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(k)
&lt;span id="xdx_864_zU9Jock3a3v3"&gt;Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company assesses long-lived assets for impairment when events or changes in circumstances indicate that the carrying value of the assets
or the asset grouping may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant decreases in the market price of a long-lived asset or group, a significant adverse change in the extent or manner in which
a long-lived asset (asset group) is being used or its physical condition, a significant adverse change in legal factors or in the business
climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator, an
accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset
(asset group), a current period operating or cash flow loss combined with a history of operating or cash flow losses or projection or
forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group) or a current expectation that,
more likely than not, a long-lived asset (asset group) will be sold or otherwise disposed of significantly before the end of its previously
estimated useful life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;When
assessing for impairment, the Company measures the recoverability of assets that it will continue to use in its operations by comparing
the carrying value of the asset grouping to our estimate of the related total future undiscounted net cash flows. If an asset grouping&#x2019;s
carrying value is not recoverable through the related undiscounted cash flows, the asset grouping is considered to be impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company measures the impairment by comparing the difference between the asset grouping&#x2019;s carrying value and its fair value. Long-lived
assets are considered a non-financial asset and are recorded at fair value only if an impairment charge is recognized. Impairments are
determined for groups of assets related to the lowest level of identifiable independent cash flows. The Company makes subjective judgments
in determining the independent cash flows that can be related to specific asset groupings. In addition, as the Company reviews its manufacturing
process and other manufacturing planning decisions, if the useful lives of assets are shorter than the Company had originally estimated,
it accelerates the rate of depreciation over the assets&#x2019; new, shorter useful lives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;(l) Lease accounting&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is a party to leases
for office space, lab facilities and other equipment. The Company determines if a contract contains a lease arrangement at the inception
of the contract. For leases in which the Company is the lessee, leases are classified as either finance or operating, with classification
affecting the pattern of expense recognition. The Company records right of use assets and operating lease liabilities for its operating leases,
which are initially recognized at the present value of future lease payments over the lease term. For leases that do not provide an implicit
rate, the Company utilizes an estimated incremental borrowing rate based on market observations existing at lease inception to calculate
the present value of future payments. The Company amortizes its right of use assets on a straight-line basis over the associated lease
term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The lease term is defined as the
non-cancelable period of the lease, plus any options to extend or terminate the lease when it is reasonably certain that the Company will
exercise the option. The Company has elected to include both lease and non-lease components in the determination of lease payments. Payments
made to a lessor for items such as taxes, insurance, common area maintenance, or other costs commonly referred to as executory costs,
are also included in lease payments if they are fixed. The fixed portion of these payments are included in the calculation of the lease
liability, while any variable portion is recognized as variable lease expenses as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has elected not to
recognize right of use assets and lease obligations for its short term leases, which are defined as leases with an initial term of 12 months
or less. Lease payments for short term leases are recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;(m) &lt;span&gt;Reclassifications&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain prior year amounts have
been reclassified to conform with current year presentation. These changes did not have any effect on net income, stockholders&#x2019;
equity, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000547">&lt;p id="xdx_804_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zTbja26Cmuk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(3)
&lt;span id="xdx_82A_zSViMNDiu0Ed"&gt;Marketable Investments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Marketable
investments consist of mutual funds. At December 31, 2023 and 2022, it was determined that none of the marketable investments had an
other-than-temporary impairment. At December 31, 2023 and 2022, all securities were measured as Level 1 instruments of the fair value
measurements standard (See Note 15: Fair Value). As of December 31, 2023 and 2022, the Company held $&lt;span id="xdx_909_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20231231_zaK6yejGQ241" title="Marketable securities"&gt;7,631,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesCurrent_iI_pp0p0_c20221231_zComyrmh8nje" title="Marketable securities"&gt;7,137,000&lt;/span&gt;, respectively,
in mutual funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Mutual
Funds classified as available for sale consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_z2SSJvsud5uh" style="display: none"&gt;Schedule
of Available of Sale&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;&lt;p style="margin: 0pt"&gt;Fair&lt;/p&gt;
                                                                                &lt;p style="margin: 0pt"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Short-Term Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left"&gt;Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z6vVU3pLgF7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zUPSSRfoE6P7" style="display: none"&gt;Schedule
of Equity Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black; text-align: left"&gt;Net gain recognized during the year on equity securities&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: Net gains and losses recognized during the year on equity securities sold during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Unrealized gains and losses recognized during the year on equity
    securities still held at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z0kzXWEdl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_C02_gL3IITB-MRQXJLX_zIFPIMa84vC9"&gt;Mutual
Funds classified as available for sale consisted of:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C02_gL3IITB-MRQXJLX_zRHdn8ayZMe7" style="margin: 0pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Short-Term Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left"&gt;Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_C0B_gL3IITB-MRQXJLX_zg71DmxfXC4c"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_C0A_gL3TSACTATB-ODD_zwKXQc3515c9"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C09_gL3TSACTATB-ODD_zph8HTxAKTql" style="margin: 0pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black; text-align: left"&gt;Net losses recognized during the period on equity securities&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;(1,679&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: Net gains and losses recognized during the period on equity securities sold during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(928&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_C04_gL3TSACTATB-ODD_zItYqthd6dId"&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000551"
      unitRef="USD">7137000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InvestmentIncomeTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000556">&lt;p id="xdx_89A_eus-gaap--InvestmentIncomeTextBlock_gL3IITB-MRQXJLX_zawSbmUnjXd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Mutual
Funds classified as available for sale consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2023&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_z2SSJvsud5uh" style="display: none"&gt;Schedule
of Available of Sale&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;&lt;p style="margin: 0pt"&gt;Fair&lt;/p&gt;
                                                                                &lt;p style="margin: 0pt"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Short-Term Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left"&gt;Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zEzMh98ckm5k" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zsSyuNwNsPYi" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231_zEq0xHy4IhXc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShortTermInvestments_iI_pn3n3_c20231231_zMSiEellIrAg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Short-Term Investments"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

Mutual
Funds classified as available for sale consisted of:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_zu1pC4E1zr3i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Available of Sale (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Short-Term Investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%; color: Black; text-align: left"&gt;Mutual Funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_z3k12DcUzTz5" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Fair Value"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231__us-gaap--FinancialInstrumentAxis__custom--MutualFundsMember_zYJwmW50BXP4" style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right" title="Short-Term Investments"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecurities_iI_pn3n3_c20221231_zrAMmxiVvmLl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermInvestments_iI_pn3n3_c20221231_zzNqdDHNDj43" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Short-Term Investments"&gt;7,137&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;</us-gaap:InvestmentIncomeTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">7631000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000560"
      unitRef="USD">7631000</us-gaap:ShortTermInvestments>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">7631000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000564"
      unitRef="USD">7631000</us-gaap:ShortTermInvestments>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000569">&lt;p id="xdx_891_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_gL3TSACTATB-ODD_zoD58OSmTXgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zUPSSRfoE6P7" style="display: none"&gt;Schedule
of Equity Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zo7axtVjrHnl" style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zMcKVnqaRsG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black; text-align: left"&gt;Net gain recognized during the year on equity securities&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zUJebfHrNdf2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: Net gains and losses recognized during the year on equity securities sold during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zPGkT0qmkTxc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Unrealized gains and losses recognized during the year on equity
    securities still held at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(in
thousands)&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;December
31, 2022&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zwD3uXDq1SQd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - Schedule of Equity Securities (Details)"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zdzvY7OURvTb" style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black"&gt;Securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_zAlE6NSGtK1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black; text-align: left"&gt;Net losses recognized during the period on equity securities&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;(1,679&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiRealizedGainLoss_pn3n3_zBwBR2AQSmQd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Less: Net gains and losses recognized during the period on equity securities sold during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(751&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pn3n3_zWCJniVZcw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Unrealized gains and losses recognized during the reporting period on equity securities still held at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(928&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&#160;</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000571"
      unitRef="USD">200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">-176000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">376000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2022-12-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000577"
      unitRef="USD">7137000</us-gaap:MarketableSecurities>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2022-12-31_custom_MutualFundsMember"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">7137000</us-gaap:ShortTermInvestments>
    <us-gaap:MarketableSecurities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">7137000</us-gaap:MarketableSecurities>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000583"
      unitRef="USD">7137000</us-gaap:ShortTermInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">-1679000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">-751000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">-928000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000591">&lt;p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zhCBjNsh8aZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(4)
&lt;span id="xdx_824_zIwSq2BmzXGd"&gt;Patents and Trademark Rights, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;Patent and trademark rights consist of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BC_zivttU9adyx8"&gt;Schedule
of Patent and Trademark Rights&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value"&gt;2,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization"&gt;(750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value"&gt;2,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value"&gt;2,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization"&gt;(595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value"&gt;1,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value"&gt;216&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Net amortizable patents and trademarks rights&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(863&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;2,605&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(664&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;1,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zltZ3lxz6Vhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt"&gt;The following table presents the changes in the patents and
trademark rights:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_8BF_z0tf6fFOuc0c" style="display: none"&gt;Schedule
of Changes in Patents, Trademark Rights&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black"&gt;December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance"&gt;1,941&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Acquisitions&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions"&gt;585&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Abandonments&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments"&gt;(14&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization"&gt;(199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zc2mmwIFrD0k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method of the estimated useful life
of &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwhL5qbgPzK4" title="Finite lived intangible assets, estimated useful life"&gt;17&lt;/span&gt; years and &lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zOWuHlDIF6i2" title="Finite lived intangible assets, estimated useful life"&gt;10&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Amortization
of patents and trademarks for each of the next five years is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B9_zhAkaswPrKwl" style="display: none"&gt;Schedule
of Amortization of Patents and Trademarks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zGJII59iaimi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000593">&lt;p id="xdx_89C_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zeZl2SnX3HQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;Patent and trademark rights consist of the following (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BC_zivttU9adyx8"&gt;Schedule
of Patent and Trademark Rights&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 12pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzvNjdk7uxNj" style="width: 6%; text-align: right" title="Gross carrying value"&gt;2,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zuEHFRVno8Ge" style="width: 6%; text-align: right" title="Accumulated amortization"&gt;(750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z6xMddfMv6e" style="width: 6%; text-align: right" title="Net carrying value"&gt;2,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zgIY2qunWgI3" style="width: 6%; text-align: right" title="Gross carrying value"&gt;2,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIgKRmUMCSWj" style="width: 6%; text-align: right" title="Accumulated amortization"&gt;(595&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zPH5MCb8XEjd" style="width: 6%; text-align: right" title="Net carrying value"&gt;1,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Trademarks&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zTs9laN5Csuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value"&gt;229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zirHDIOXETv6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zEFQz01qQE5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVhl8YLs7un2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross carrying value"&gt;216&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z6SgSVZnxDE" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;(69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zRP7uw6GWs5e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net carrying value"&gt;147&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Net amortizable patents and trademarks rights&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zzT8MWSMSGIl" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,176&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zTbz9oVbWAah" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(863&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zWKCRe2eohkb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231_zTEMciTBq7Tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;2,605&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231_zq6sAwxaDIdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(664&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20221231_zZVHq8bHupJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;1,941&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">2947000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">-750000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">2197000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">2389000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">-595000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">1794000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">-113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000611"
      unitRef="USD">116000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">216000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">-69000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">147000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">3176000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">-863000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">2605000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">-664000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">1941000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000631">&lt;p id="xdx_89F_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zYtNsydlyl54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;span id="xdx_8BF_z0tf6fFOuc0c" style="display: none"&gt;Schedule
of Changes in Patents, Trademark Rights&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; color: Black"&gt;December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20230101__20231231_zWf1azlUCzjh" style="width: 14%; color: Black; text-align: right" title="Beginning balance"&gt;1,941&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Acquisitions&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20230101__20231231_zlvaUo9dNZWg" style="color: Black; text-align: right" title="Acquisitions"&gt;585&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Abandonments&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20230101__20231231_zpySyQpF5fy7" style="color: Black; text-align: right" title="Abandonments"&gt;(14&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20230101__20231231_z57U6T6P5Gqe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Accumulated Amortization"&gt;(199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20230101__20231231_z9INryp97Ec2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">1941000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">585000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <AIM:FinitelivedIntangibleAssetsAbandonments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">14000</AIM:FinitelivedIntangibleAssetsAbandonments>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">199000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      id="Fact000643">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      id="Fact000645">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000647">&lt;p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zHnSpfwsAuH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Amortization
of patents and trademarks for each of the next five years is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B9_zhAkaswPrKwl" style="display: none"&gt;Schedule
of Amortization of Patents and Trademarks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20231231_zCKkXJBtsaz9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="4" style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zbJLLb14u2z6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zPNQZrxa9Ja1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zDGbXedYbRol" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zCtJZhxKZ7cl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzzOp_zOUaQlCLJmCj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzzOp_zlBjww1Mhkag" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zLS4S6CRxsel" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000649"
      unitRef="USD">241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">232000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">230000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000655"
      unitRef="USD">208000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">189000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">1213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000663">&lt;p id="xdx_80C_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zeEijkQZOUYa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(5)
&lt;span id="xdx_827_zSBL5lj9xQkf"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Accrued
expenses at December 31, 2023 and 2022 consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BC_zyhFSMGVUH97" style="display: none"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(in thousands) December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black"&gt;Compensation&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;414&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;492&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Clinical trial expenses&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;184&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;110&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;1,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;806&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zEU7bP6y9Fl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000665">&lt;p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zSIIjs6SKLoi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Accrued
expenses at December 31, 2023 and 2022 consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BC_zyhFSMGVUH97" style="display: none"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_z2rxv0k69Rv6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zn2RaoZy28Qg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(in thousands) December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zYBrjBcp2QAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black"&gt;Compensation&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;414&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zKIYB1fK0Ddc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;492&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_zzqPBPZ4UD2b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Clinical trial expenses&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;184&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;110&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ztQDNe2ckn7c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zbtnnJc115Ec" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;1,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;806&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">414000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000668"
      unitRef="USD">1000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">1352000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000671"
      unitRef="USD">492000</us-gaap:AccruedProfessionalFeesCurrent>
    <AIM:AccruedClinicalTrialExpensesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000673"
      unitRef="USD">184000</AIM:AccruedClinicalTrialExpensesCurrent>
    <AIM:AccruedClinicalTrialExpensesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000674"
      unitRef="USD">110000</AIM:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000676"
      unitRef="USD">36000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">203000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">1986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000680"
      unitRef="USD">806000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000682">&lt;p id="xdx_803_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqitzPN2xp8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(6)
&lt;span id="xdx_823_z4u6BXmAK5W"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(a)
Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is authorized to issue &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zS1iQPwaahH" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares of $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--BoardMember_zyt8J7mVj9tg" title="Preferred stock stated value"&gt;0.01&lt;/span&gt; par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, &lt;span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zealkqpR9eDc" title="Preferred stock, shares authorized"&gt;4,000,000&lt;/span&gt; shares have been designated as Series A Junior Participating
Preferred Stock and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zvlMIC5enur8" title="Preferred stock, shares authorized"&gt;10,000&lt;/span&gt; shares have been designated as Series B Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
A Junior Participating Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to &lt;span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z74l9b9hkGJ9" title="Preferred stock, shares authorized"&gt;4,000,000&lt;/span&gt; from &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zCjyE5nJ0rU8" title="Preferred stock, shares authorized"&gt;250,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Series
B Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company has designated &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zyUvHgfAa0n9"&gt;10,000&lt;/span&gt; shares of its preferred stock as Series B Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;).
Each share of Preferred Stock has a par value of $&lt;span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zUZVOl7yMsYl" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share and a stated value equal to $&lt;span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zluVtpLH6Osk" title="Preferred stock, stated value"&gt;1,000&lt;/span&gt; (the &#x201c;Stated Value&#x201d;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#x201c;DTC&#x201d;) shall initially be the sole registered holder of the shares of Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of Common Stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $&lt;span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20231231_zPphwTZ4MXS9" title="Preferred stock conversion price"&gt;0.20&lt;/span&gt;,
subject to adjustment herein (the &#x201c;Conversion Price&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Pursuant
to a registration statement relating to a rights offering declared effective by the SEC on February 14, 2019, AIM distributed to its
holders of common stock and to holders of certain options and redeemable warrants as of February 14, 2019, at no charge, one non-transferable
subscription right for each share of common stock held or deemed held on the record date. Each right entitled the holder to purchase
one unit, at a subscription price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_znVBEGKrxhSj" title="Warrant exercise price"&gt;1,000&lt;/span&gt; per unit, consisting of one share of Series B Convertible Preferred Stock with a face value
of $&lt;span id="xdx_907_ecustom--FaceValueOfStock_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zQesT79xUSc9" title="Preferred stock face value"&gt;1,000&lt;/span&gt; (and immediately convertible into common stock at an assumed conversion price of $&lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqTl7bQPcnMf" title="Preferred stock conversion price"&gt;8.80&lt;/span&gt;) and &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zFAs70jaJFbe" title="Number of warrants"&gt;114&lt;/span&gt; warrants with an assumed exercise
price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zRa77juDYnRb" title="Subscription/exercise price"&gt;8.80&lt;/span&gt;. The redeemable warrants are exercisable for &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGXFztwsjXVk"&gt;five years&lt;/span&gt; after the date of issuance. The net proceeds realized from the
rights offering were approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfWarrants_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zRJF43tg183l" title="Proceeds from warrants"&gt;4,700,000&lt;/span&gt;. During the year ended December 31, 2023, &lt;span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zn2II1ahpKN5"&gt;7&lt;/span&gt; shares of Series B Convertible Preferred Stock
were converted into common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2023 and 2022, the Company had &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zP6HJLnaOIZi" title="Preferred stock, shares outstanding"&gt;689&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zufJWl3Cz0u4" title="Preferred stock, shares outstanding"&gt;696&lt;/span&gt; shares of Series B Convertible Preferred Stock outstanding, respectively.
Holders shall be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-Common-Stock
basis) to and in the same form as dividend actually paid on shares of Common Stock when as and if such dividends are paid on shares of
the Common Stock. Each such Preferred Share is convertible into &lt;span id="xdx_907_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zsjCPknBszub" title="Number of shares to be issued on conversion"&gt;114&lt;/span&gt; shares of common stock. Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary, the Holders shall be entitled to receive out of the assets, whether capital or surplus
of the Company the same amount that a holder of Common Stock would receive if the Preferred Stock was fully converted. The Series B Convertible
Preferred Stock does not carry voting Rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(b)
Common Stock and Equity Finances&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company has authorized shares of &lt;span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zKs6QK6ZjIs8" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt; with specific limitations and restrictions on the usage of &lt;span id="xdx_903_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20231231_zCFCveCaorp9" title="Common stock specific limitations and restrictions on usage"&gt;8,000,000&lt;/span&gt; of the &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zGTsqQZ6xYxa" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt;
authorized shares. &lt;span style="background-color: white"&gt;As of December 31, 2023 and 2022, there were &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zl0Rlmup6df6" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_z6db1PxcsX1" title="Common stock, shares outstanding"&gt;49,102,484&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zEB324dHpD77" title="Common stock, shares issued"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zo4X699gHUUj" title="Common stock, shares outstanding"&gt;48,084,287&lt;/span&gt;&lt;/span&gt; shares
of Common Stock issued and outstanding, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Employee
Stock Purchase Plan (Not equity compensation)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200706__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zA3rkt9liEhk" title="Common stock shares issued, value"&gt;500,000&lt;/span&gt; worth of shares at the market price (including subsequent plans, the &#x201c;Employee Stock Purchase Plan&#x201d;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#x2019;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board in January 2024 and expires in March 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2023, the Company issued a total of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zviztUmxoLje" title="Number of shares issued upon transaction"&gt;419,285&lt;/span&gt; shares of its Common Stock at a price ranging from $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zdJMaElsXvJ1" title="Shares issued price per share"&gt;0.31&lt;/span&gt; to $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zZJhuARTYw22" title="Shares issued price per share"&gt;0.67&lt;/span&gt;
for total proceeds of approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zSPJHE2neJwb" title="Proceeds from issuance of common stock"&gt;150,500&lt;/span&gt; as part of the employee stock purchase plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company issued a total of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zfTmenNILks9" title="Number of shares issued upon transaction"&gt;86,817&lt;/span&gt; shares of its Common Stock at prices ranging from $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_z44dlehfZ2uf" title="Shares issued price per share"&gt;0.76&lt;/span&gt; to $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zcYvfoEWRseb" title="Shares issued price per share"&gt;1.02&lt;/span&gt;
for total proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zMIIUdDZAHO5" title="Proceeds from issuance of common stock"&gt;80,000&lt;/span&gt; as part of the employee stock purchase plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Warrants
(Rights offering)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#x201c;Offering&#x201d;)
of (i) &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zPxn6Z5v7yPa" title="Number of shares issued upon transaction"&gt;1,740,550&lt;/span&gt; shares of Common Stock; (ii) pre-funded warrants exercisable for &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z95jjsb0xCgf" title="Warrants issued"&gt;7,148,310&lt;/span&gt; shares of Common Stock (the &#x201c;Pre-funded
Warrants&#x201d;), and (iii) warrants to purchase up to an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zZktK4vOrA5a" title="Number of warrant to purchase shares of common stock"&gt;8,888,860&lt;/span&gt; shares of Common Stock (the &#x201c;Warrants&#x201d;).
In conjunction with the Offering, we issued &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;a
Representative&#x2019;s Warrant to purchase up to an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zcUVBXAOEfFe" title="Number of warrant to purchase shares of common stock"&gt;266,665&lt;/span&gt; shares of common stock (the &#x201c;Representative&#x2019;s Warrant&#x201d;)&lt;span style="background-color: white"&gt;.
The shares of Common Stock and Warrants were sold at a combined Offering price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zG0XCk86BvSl" title="Shares issued price per share"&gt;0.90&lt;/span&gt;, less underwriting discounts and commissions.
Each Warrant sold with the shares of Common Stock represents the right to purchase one share of Common Stock at an exercise price of
$&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z45VysI4Rdh7" title="Warrant exercise price"&gt;0.99&lt;/span&gt; per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zQODiBo59fs7" title="Shares issued price per share"&gt;0.899&lt;/span&gt;, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of Common Stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than &lt;span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zKDoG8e4n7Nk" title="Percentage of outstanding stock"&gt;4.99&lt;/span&gt;% of the Company&#x2019;s
outstanding Common Stock immediately following the consummation of the Offering, in lieu of shares of Common Stock. Each Pre-Funded Warrant
represents the right to purchase one share of Common Stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zqDXj99Nqi93" title="Exercise price"&gt;0.001&lt;/span&gt; per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zZNgiCM0cLbl" title="Proceeds from Issuance or Sale of Equity"&gt;7,200,000&lt;/span&gt;. During the year ended &lt;/span&gt;December 31&lt;span style="background-color: white"&gt;, 2020, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_z3g8fsCi3e93" title="Stock issued during period shares other"&gt;1,870,000&lt;/span&gt; of the Pre-funded Warrants
were exercised and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TUJZd6f9eb" title="Pre-funded warrants exercised"&gt;8,873,960&lt;/span&gt; Warrants were exercised. &lt;/span&gt;In addition, on March 25, 2020, the Representative&#x2019;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020 and an aggregate of
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zBNFf2hF7fXf" title="Warrants exercised aggregate"&gt;266,665&lt;/span&gt; shares were issued upon exercise of this warrant for gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zt1Btk7f3ku4" title="Warrant gross proceeds"&gt;264,000&lt;/span&gt; and a $&lt;span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_z781IO7BCGn9" title="Warrant modification"&gt;46,000&lt;/span&gt; expense for the warrant
modification. No Warrants were exercised during the year ended December 31, 2023 and 2022. As of December 31, 2023 and 2022 there are
&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zkWxC6X5Uyl1" title="Warrant outstanding"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231_zrwFNaFiUAVi" title="Warrant outstanding"&gt;15,000&lt;/span&gt;&lt;/span&gt; Warrants outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Equity
Distribution Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#x201c;EDA&#x201d;) with Maxim Group LLC
(&#x201c;Maxim&#x201d;), pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate
offering price of up to $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zNlgcvJurGw"&gt;8,500,000&lt;/span&gt;
through Maxim, as agent (the &#x201c;Offering&#x201d;). Sales under the EDA were registered under the S-3 Shelf Registration
Statement. Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of &lt;span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230418__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zMbKWKkSgAB1" title="Transaction fee rate"&gt;3.0&lt;/span&gt;%
of the gross sales price of shares sold under the EDA. During the year ended December 31, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zIliAU2gMc1a" title="Shares sold"&gt;598,114&lt;/span&gt;
shares under the EDA for total gross proceeds of approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zCHyKPIRBnx6" title="Gross proceeds from issuance of common stock"&gt;344,000&lt;/span&gt;,
which includes a &lt;span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zTOA1FDdlyr4" title="Transaction fee rate"&gt;3.0&lt;/span&gt;%
fee to Maxim of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zxan4REYwBEh"&gt;10,326&lt;/span&gt;. Subsequent to the year ended December 31, 2023, the Company sold &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDyG2c83P0r1" title="Shares sold"&gt;699,568&lt;/span&gt; shares under the EDA for total gross proceeds
of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRQPJ8F7ZeUj" title="Proceeds from issuance of common stock"&gt;316,392&lt;/span&gt;, which includes a &lt;span id="xdx_903_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBW1BZtSXEI7" title="Transaction fee rate"&gt;3.0&lt;/span&gt;% fee to Maxim of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFeeAmount_iI_c20240101__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYidNbQUvnb3"&gt;9,492&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Rights
Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp;amp; Trust Company as
Rights Agent (the &#x201c;Rights Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(c)
Common Stock Options and Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;(i)
Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
2018 Equity Incentive Plan, effective September 12, 2018, authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock
Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards,
(vii) Performance Cash Awards, and (viii) Other Stock Awards. Initially, a maximum of &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zxtEOC1VeTG4" title="Number of common stock reserved for potential issuance"&gt;7,000,000&lt;/span&gt; shares of common stock is reserved for
potential issuance pursuant to awards under the 2018 Equity Incentive Plan. Unless sooner terminated, the 2018 Equity Incentive Plan
will continue in effect for a period of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanTwoThousandNineMember_zJTZfbENHDnc"&gt;10&lt;/span&gt; years from its effective date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Equity Incentive Plans of 2018 are administered by the Board of Directors. The Plans provide for awards to be made to such Officers,
other key employees, non-employee Directors, consultants and advisors of the Company and its subsidiaries as the Board may select.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Stock
options awarded under the Plans may be exercisable at such times (not later than 10 years after the date of grant) and at such exercise
prices (not less than fair market value at the date of grant) as the Board may determine. The Board may provide for options to become
immediately exercisable upon a &#x201c;change in control&#x201d;, which is defined in the Plans to occur upon any of the following events:
(a) the acquisition by any person or group, as beneficial owner, of 20% or more of the outstanding shares or the voting power of the
outstanding securities of the Company; (b) either a majority of the Directors of the Company at the annual stockholders meeting has been
nominated other than by or at the direction of the incumbent Directors of the Board, or the incumbent Directors cease to constitute a
majority of the Company&#x2019;s Board; (c) the Company&#x2019;s stockholders approve a merger or other business combination pursuant to
which the outstanding common stock of the Company no longer represents more than 50% of the combined entity after the transaction; (d)
the Company&#x2019;s stockholders approve a plan of complete liquidation or an agreement for the sale or disposition of all or substantially
all of the Company&#x2019;s assets; or (e) any other event or circumstance determined by the Company&#x2019;s Board to affect control of
the Company and designated by resolution of the Board as a change in control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of each option award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#x2019;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical data to estimate
expected dividend yield, life and forfeiture rates. The expected life of the options and equity warrants was estimated based on historical
option and equity warrant holders&#x2019; behavior and represents the period of time that options and equity warrants are expected to
be outstanding. The fair values of the options granted were estimated based on the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zRdQc4lhI2ed" style="display: none"&gt;Schedule
of Options and Equity Estimated Based on Weighted Average Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate"&gt;1.74&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate"&gt;3.88&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility"&gt;99.91&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility"&gt;98.43&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility"&gt;107.18&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Weighted average grant date fair value for options issued&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued"&gt;$0.43 per option for 400,000 options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued"&gt;$0.51 per option for 850,000 options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zpgKNkwD8rIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
exercise price of all stock options and equity warrants granted was equal to or greater than the fair market value of the underlying
common stock on the date of the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June
24, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;124,399&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year"&gt;13.20&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;22.23&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;128,504&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year"&gt;13.20&lt;/span&gt; &#x2013; &lt;span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;25.58&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(5,047&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited"&gt;9.68&lt;/span&gt;-&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited"&gt;327.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;57.79&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(4,105&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited"&gt;16.76&lt;/span&gt;-&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;129.88&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0887"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;119,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;20.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;124,399&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;22.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;119,352&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;124,399&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Weighted average remaining contractual life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)"&gt;4.06&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)"&gt;5.98&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zwEfEfkEYN0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zjBHKIJSnVTc" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,474,971&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,650,017&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year"&gt;1.11&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;2.35&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted"&gt;400,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted"&gt;0.47&lt;/span&gt;-&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted"&gt;0.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;0.47&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted"&gt;850,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted"&gt;0.31&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;0.51&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(60,829&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;1.98&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(25,046&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited"&gt;1.85&lt;/span&gt; &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;1.86&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0979"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;2,814,142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;1.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;2,474,971&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;1.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;2,397,474&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year"&gt;327.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;1,916,637&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year"&gt;0.41&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right"&gt;2.22&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Weighted average remaining contractual life (years)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)"&gt;7.96&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)"&gt;9.65&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Available for future grants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,210,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;466,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zCt6AGdS0HJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Stock
option activity during the years ended December 31, 2023 and 2022 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zF0PfjjCWiX8" style="display: none"&gt;Schedule
of Vest Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contracted &lt;br/&gt;Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; color: Black"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,498,798&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; color: Black; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted"&gt;550,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;9.71&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(28,584&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited"&gt;17.71&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,020,214&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted"&gt;400,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted"&gt;0.47&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;10.17&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(7,601&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"&gt;(4,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired"&gt;41.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Outstanding December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,408,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1077"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Vested and expected to vest at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,041,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,041,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zaPFwFMU6Lmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
weighted-average grant-date fair value of employee options vested during the year ended December 31, 2023 was $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zDLLW4mKBtch" title="Share-based payment award options vested in period fair value"&gt;184,000&lt;/span&gt; for &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zexAY94cljFd" title="Number of options, granted"&gt;424,999&lt;/span&gt; options
at $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwhJUHGEuao6" title="Weighted average exercise price, granted"&gt;0.43&lt;/span&gt; per option and during year ended December 31, 2022 was $&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zqKhD2stjHF7" title="Number of options, granted"&gt;768,666&lt;/span&gt; for &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_z3UmXsez7IE1" title="Number of options, granted"&gt;575,000&lt;/span&gt; options at $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesMember_zIGmU7JOYkvk"&gt;1.34&lt;/span&gt; per option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BF_znkiS1cgVg4i" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average Remaining Contracted Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;412,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted"&gt;550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;9.71&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested"&gt;(541,590&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested"&gt;1.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;9.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(28,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;17.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period"&gt;392,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted"&gt;400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;10.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested"&gt;(413,884&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited"&gt;(7,601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;9.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired"&gt;(4,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;41.61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;366,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;2.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;12.44&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AD_zG18YW8IC09l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B7_zsalMMWYrOo9" style="display: none"&gt;Schedule
of Vest Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Remaining Contracted Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; color: Black"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;279,723&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;6.12&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;7.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;300,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1183"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(568&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;153.12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period"&gt;579,155&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period"&gt;3.09&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.46&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value"&gt;10.04&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&#160;Expired&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired"&gt;(653&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;145.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(53,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Outstanding December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;885,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Vested and expected to vest at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;550,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;10.02&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period"&gt;550,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.02&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zHocvI0bZukb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
weighted-average grant-date fair value of non-employee options vested during year 2023 was $&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_znEFRK5NZ8l7" title="Share-based payment award options vested in period fair value"&gt;90,000&lt;/span&gt; for &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zzSmpvfyg8Q2" title="Number of options, granted"&gt;191,666&lt;/span&gt; options at $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zSgr1cy7Cd98" title="Weighted average exercise price, granted"&gt;0.47&lt;/span&gt; per option
and during the year 2022 was $&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zuhPnyCsCu55" title="Share-based payment award options vested in period fair value"&gt;247,166&lt;/span&gt; for&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zvJmne3ZNVc1" title="Number of options, granted"&gt; 229,053&lt;/span&gt; options at $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__srt--TitleOfIndividualAxis__custom--NonEmployeeMember_zBl8iBiuAg14" title="Weighted average exercise price, granted"&gt;1.08&lt;/span&gt; per option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zmTaiMUsaseh" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contracted &lt;br/&gt;Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;97,831&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;3.89&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; color: Black; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;300,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(229,053&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.82&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(1,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period"&gt;166,789&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period"&gt;4.05&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;9.49&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;360,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(137,565&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested"&gt;9.47&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(776&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;145.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(53,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period"&gt;335,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z4C2lN2A5n75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Stock-based
compensation expense was approximately $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMWuIx6ShLVe" title="Share based compensation expense"&gt;243,000 &lt;/span&gt;and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjGrfLdWeJ5" title="Share based compensation expense"&gt;954,000&lt;/span&gt; for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2023 and 2022, there was $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20231231_zXhQqABm0kwh" title="Unrecognized stock-based compensation cost"&gt;294,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20221231_zjMEq1YsxSw2" title="Unrecognized stock-based compensation cost"&gt;217,000&lt;/span&gt;, respectively, of unrecognized stock-based compensation cost related to
options granted under the Equity Incentive Plans. Stock-based compensation related to options granted under the Equity Incentive Plans
will be recorded over the vesting period which is typically one year or upon reaching agreed upon Company and/or individual performance
milestones being met which is indefinite.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(ii)
Stock Warrants&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Stock
warrants are issued as needed by the Board of Directors and have no formal plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of each warrant award is estimated on the date of grant using a Black-Scholes-Merton pricing option valuation model. Expected
volatility is based on the historical volatility of the price of the Company&#x2019;s stock. The risk-free interest rate is based on U.S.
Treasury issues with a term equal to the expected life of the warrant. The Company uses historical data to estimate expected dividend
yield, life and forfeiture rates. The expected life of the warrants was estimated based on historical option holder&#x2019;s behavior
and represents the period of time that options are expected to be outstanding. No warrants were granted in 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding warrants outstanding and exercisable into shares of common stock is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B7_z5LMDxbstbGf" style="display: none"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Warrant&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Warrant&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: justify"&gt;Outstanding, beginning of year &lt;br/&gt;&#160; &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;294,939&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year"&gt;0.99&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year"&gt;469.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;15.19&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1334"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1336"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1338"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1339"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Expired&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(74,450&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired"&gt;17.05&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;17.05&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(68,215&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired"&gt;469.92&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;469.92&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;152,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.03&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;152,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Weighted average remaining contractual life&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.75 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year"&gt;.94&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Years exercisable&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable"&gt;2023&lt;/span&gt;-&lt;span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zEdcVdPnO2dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Stock
warrants are issued at the discretion of the Board. During the year ended December 31, 2023, there were &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20230101__20231231_zkkhVy30p3Zg" title="Warrants issued::XDX::-"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_doxL_c20230101__20231231_zlawOgcMWi01" title="Warrants exercised::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1406"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1408"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; warrants issued or exercised.
During the year ended December 31, 2022, there were &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_doxL_c20220101__20221231_zaNSjiTXnKtd" title="Warrants issued::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;no&lt;/span&gt;&lt;/span&gt; warrants issued and &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_dixL_c20220101__20221231_zHfpY7YXfrz5" title="Warrants exercised::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1412"&gt;114&lt;/span&gt;&lt;/span&gt; were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_BoardMember"
      decimals="INF"
      id="Fact000684"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_BoardMember"
      decimals="INF"
      id="Fact000686"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000688"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000690"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000692"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000694"
      unitRef="Shares">250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000695"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000697"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000699"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000701"
      unitRef="USDPShares">0.20</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_RightsMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">1000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <AIM:FaceValueOfStock
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember_us-gaap_RightsMember"
      decimals="0"
      id="Fact000705"
      unitRef="USD">1000</AIM:FaceValueOfStock>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000707"
      unitRef="USDPShares">8.80</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">114</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000711"
      unitRef="USDPShares">8.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="Fact000712">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_RightsMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">4700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-01-012023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000715"
      unitRef="Shares">7</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000717"
      unitRef="Shares">689</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">696</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">114</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">8000000</AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000727"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000729"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000731"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">48084287</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">48084287</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-062020-07-07_custom_DirectorsOfficersAndEmployeesMember"
      decimals="0"
      id="Fact000737"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265"
      decimals="INF"
      id="Fact000739"
      unitRef="Shares">419285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">0.31</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000743"
      unitRef="USDPShares">0.67</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember289842265"
      decimals="0"
      id="Fact000745"
      unitRef="USD">150500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296"
      decimals="INF"
      id="Fact000747"
      unitRef="Shares">86817</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000749"
      unitRef="USDPShares">0.76</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000751"
      unitRef="USDPShares">1.02</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember289842296"
      decimals="0"
      id="Fact000753"
      unitRef="USD">80000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember"
      decimals="INF"
      id="Fact000755"
      unitRef="Shares">1740550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">7148310</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">8888860</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">266665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000763"
      unitRef="USDPShares">0.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-27_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">0.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000767"
      unitRef="USDPShares">0.899</us-gaap:SharesIssuedPricePerShare>
    <AIM:PercentageOfOutstandingStock
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Pure">0.0499</AIM:PercentageOfOutstandingStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember"
      decimals="0"
      id="Fact000773"
      unitRef="USD">7200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-12-31_custom_PreFundedWarrantsMember"
      decimals="0"
      id="Fact000775"
      unitRef="Shares">1870000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">8873960</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">266665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-03-302020-03-31"
      decimals="0"
      id="Fact000781"
      unitRef="USD">264000</us-gaap:ProceedsFromWarrantExercises>
    <AIM:WarrantModifications
      contextRef="From2020-03-302020-03-31"
      decimals="0"
      id="Fact000783"
      unitRef="USD">46000</AIM:WarrantModifications>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">15000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">15000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">8500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-04-182023-04-19_custom_MaximGroupLLCMember"
      decimals="INF"
      id="Fact000790"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember"
      decimals="INF"
      id="Fact000792"
      unitRef="Shares">598114</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember"
      decimals="0"
      id="Fact000794"
      unitRef="USD">344000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2023-12-31_custom_MaximGroupLLCMember"
      decimals="0"
      id="Fact000797"
      unitRef="USD">10326</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Shares">699568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">316392</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2024-01-012024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2024-01-01_custom_MaximGroupLLCMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact000804"
      unitRef="USD">9492</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-09-12_custom_EquityIncentivePlanTwoThousandNineMember"
      decimals="INF"
      id="Fact000806"
      unitRef="Shares">7000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2018-09-122018-09-12_custom_EquityIncentivePlanTwoThousandNineMember"
      id="Fact000807">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000809">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwBn9bZOROJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zRdQc4lhI2ed" style="display: none"&gt;Schedule
of Options and Equity Estimated Based on Weighted Average Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zwsTOtjinuEg" title="Risk-free interest rate"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zyu0LDV1Orji" title="Risk-free interest rate"&gt;1.74&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_z7IM9rf56CHf" title="Risk-free interest rate"&gt;3.88&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20231231_zLRWWWaQR3E9" style="color: Black; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0817"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20221231_zGhPgwxEQY9a" style="color: Black; text-align: right" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zRPHlQrFeOEf" title="Expected life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_ze6P7e4vBhy7" title="Expected life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zpSADdjUppo7" title="Expected volatility"&gt;99.91&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zqFkVRZdLFeg" title="Expected volatility"&gt;98.43&lt;/span&gt;% - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_zbNkTV8pKtak" title="Expected volatility"&gt;107.18&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Weighted average grant date fair value for options issued&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_904_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20230101__20231231_zDcZCd9f8oq8" title="Weighted average grant date fair value for options issued"&gt;$0.43 per option for 400,000 options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued_c20220101__20221231_zwLGodKu5o01" title="Weighted average grant date fair value for options issued"&gt;$0.51 per option for 850,000 options&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Pure">0.0174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="Fact000821">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact000823">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000825"
      unitRef="Pure">0.9991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Pure">0.9843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact000829"
      unitRef="Pure">1.0718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued contextRef="From2023-01-01to2023-12-31" id="Fact000831">$0.43 per option for 400,000 options</AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued>
    <AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued contextRef="From2022-01-012022-12-31" id="Fact000833">$0.51 per option for 850,000 options</AIM:WeightedAverageGrantDateFairValueForOptionsAndEquityWarrantsIssued>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlanTwoThousandNineMember"
      id="Fact000835">&lt;p id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlanTwoThousandNineMember_z5ECVcr9LKd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding the options approved by the Board of Directors under the Equity Plan of 2009 is summarized below. The plan expired on June
24, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_z2r3OQ5v0nMb" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zyDxeqphjbwl" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;124,399&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zxwHdtQPhQRl" title="Option price outstanding, beginning of year"&gt;13.20&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zUvFe764HwR1" title="Option price outstanding, beginning of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXR0wPDoayE9" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;22.23&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z58yybuTjzag" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;128,504&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zL37ie7VDOo5" title="Option price outstanding, beginning of year"&gt;13.20&lt;/span&gt; &#x2013; &lt;span id="xdx_909_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zZH7zfDN4kwe" title="Option price outstanding, beginning of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zZVXpZMZWUk3" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;25.58&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJpxjOdQrXP5" style="color: Black; text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEiDo8XYt6ji" style="color: Black; text-align: right" title="Option price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1vaUNUBJ9Lk" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zXREqcdUViH5" style="color: Black; text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zJouwSlxcz4c" style="color: Black; text-align: right" title="Option price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtSE9KhTfWf" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0863"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zSz346mvRzqe" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(5,047&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zvrLx2fgS4n" title="Option price, forfeited"&gt;9.68&lt;/span&gt;-&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zvOUj8mO8cW9" title="Option price, forfeited"&gt;327.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zTTIYX7nlGm" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;57.79&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zVTFyT72V1P7" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(4,105&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zeAPvCW0iP6l" title="Option price, forfeited"&gt;16.76&lt;/span&gt;-&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zpMqhGQSPp0h" title="Option price, forfeited"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zcqllAbQ2tF6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;129.88&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z18DmVOsWDG4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zkPHisNO4j4e" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEJEklSgmZP7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEF8oX7qioI2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0887"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zwkacwJmgPY8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zAYwZMXI0UG2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zoBzU2hbFi5a" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;119,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zbJCCgyupPl9" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zmDKs07uvwPf" title="Option price exercisable, end of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zfG1XOAqxnWi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;20.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zvF6i9mV3AVl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;124,399&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zh6uBgLlzTng" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zXu4uzXR0lye" title="Option price exercisable, end of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zL1lIOUUh3j8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;22.23&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zQtOL6t0A84c" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;119,352&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zhq3muq2nUC4" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zYqUKFECPByh" title="Option price exercisable, end of year"&gt;2,127.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_z1OAXnd2DIL5" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;124,399&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MinimumMember_zk7y8OaHVdG3" title="Option price exercisable, end of year"&gt;13.20&lt;/span&gt;-&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member__srt--RangeAxis__srt--MaximumMember_zCBdKfReAHJh" title="Option price exercisable, end of year"&gt;1,003.20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Weighted average remaining contractual life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zuO6mBNBKiS3" title="Weighted average remaining contractual life (years)"&gt;4.06&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2009Member_zEz3nLpaJO8h" title="Weighted average remaining contractual life (years)"&gt;5.98&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000837"
      unitRef="Shares">124399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000839"
      unitRef="USDPShares">13.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000841"
      unitRef="USDPShares">1003.20</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000843"
      unitRef="USDPShares">22.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000845"
      unitRef="Shares">128504</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000847"
      unitRef="USDPShares">13.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000849"
      unitRef="USDPShares">2127.84</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000851"
      unitRef="USDPShares">25.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000865"
      unitRef="Shares">5047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">9.68</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000869"
      unitRef="USDPShares">327.36</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000871"
      unitRef="USDPShares">57.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000873"
      unitRef="Shares">4105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000875"
      unitRef="USDPShares">16.76</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000877"
      unitRef="USDPShares">2127.84</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000879"
      unitRef="USDPShares">129.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000893"
      unitRef="Shares">119352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000895"
      unitRef="USDPShares">13.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000897"
      unitRef="USDPShares">2127.84</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000899"
      unitRef="USDPShares">20.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000901"
      unitRef="Shares">124399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000903"
      unitRef="USDPShares">13.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000905"
      unitRef="USDPShares">1003.20</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000907"
      unitRef="USDPShares">22.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">119352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000911"
      unitRef="USDPShares">13.20</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000913"
      unitRef="USDPShares">2127.84</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">124399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000917"
      unitRef="USDPShares">13.20</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2009Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000919"
      unitRef="USDPShares">1003.20</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2009Member"
      id="Fact000921">P4Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2009Member"
      id="Fact000923">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlansTwoThousandAndEighteenMember"
      id="Fact000925">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--EquityIncentivePlansTwoThousandAndEighteenMember_zAiKbRs8u0ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding the options approved by the Board of Directors under the Equity Plan of 2018 is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zjBHKIJSnVTc" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Option&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: left"&gt;Outstanding, beginning of year&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zY8TdhJVuvQk" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,474,971&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zVYEt9sxdiZ" title="Option price outstanding, beginning of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_903_eus-gaap--SharePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_z2rNeV89tPai" title="Option price outstanding, beginning of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zbMybyjAV6bd" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvIdOAMVrKhf" style="width: 7%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,650,017&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 7%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_za8xt9HeolC9" title="Option price outstanding, beginning of year"&gt;1.11&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zG0Jrw48ZFRe" title="Option price outstanding, beginning of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zTolGtT0cWY7" style="width: 7%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;2.35&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zvvgWvWDNKf4" style="color: Black; text-align: right" title="Number of options, granted"&gt;400,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zHwdNuwTBrXe" title="Option price, granted"&gt;0.47&lt;/span&gt;-&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zqSZB6vsmL4l" title="Option price, granted"&gt;0.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3Z2NtWcprWa" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;0.47&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoOGxTxPaFf2" style="color: Black; text-align: right" title="Number of options, granted"&gt;850,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zRwCHfg9H1sf" title="Option price, granted"&gt;0.31&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zm8tE7cwMMI5" title="Option price, granted"&gt;1.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCtFRvKSBhF9" style="color: Black; text-align: right" title="Weighted average exercise price, granted"&gt;0.51&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zQU5yoP1BaQe" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(60,829&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zc1uJU6MXwq9" title="Option price, forfeited"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zcSqfq5LYhIg" title="Option price, forfeited"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zoAUy8QKADD5" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;1.98&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zafqHYOhNG7k" style="color: Black; text-align: right" title="Number of options, forfeited"&gt;(25,046&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_z1UHLlVk9Lck" title="Option price, forfeited"&gt;1.85&lt;/span&gt; &#x2013; &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_znIS51EDLl6h" title="Option price, forfeited"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zOw8BdlBCRg6" style="color: Black; text-align: right" title="Weighted average exercise price, forfeited"&gt;1.86&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_za9zosND1Nb8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z3YcSiWVvL9b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCrE5j3jPCEd" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0979"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCa1C61l8a2k" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsExercisedInPeriod_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8VpDauNgOV4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Option price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zuAwoTRYyAQg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zKBd7YNedvef" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;2,814,142&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_ziSamlBxMNJ8" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zDnIoZJDr0G7" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_znS6WrtDV1Hi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;1.54&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zhuLay5MN263" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, ending of year"&gt;2,474,971&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90D_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zIIlppJooD0k" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt; &#x2013; &lt;span id="xdx_901_eus-gaap--SharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zmrKoiA61a5k" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWr1FaPC9Gyk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, end of year"&gt;1.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Exercisable, end of year&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zWKmTaWD9rXk" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;2,397,474&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zUBZQpHHdkQh" title="Option price exercisable, end of year"&gt;0.31&lt;/span&gt;-&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zyNfZEZGjY7e" title="Option price exercisable, end of year"&gt;327.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zCD5NSe1LC96" style="color: Black; text-align: right"&gt;4.71&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zV4AA1jdL17j" style="color: Black; text-align: right" title="Number of options exercisable, end of year"&gt;1,916,637&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MinimumMember_zFNBhjSmkwo6" title="Option price exercisable, end of year"&gt;0.41&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member__srt--RangeAxis__srt--MaximumMember_zfMiYZ3wyc4l" title="Option price exercisable, end of year"&gt;9.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_ztzNs9InbFV6" style="color: Black; text-align: right"&gt;2.22&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Weighted average remaining contractual life (years)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zSd2YiyZrKt1" title="Weighted average remaining contractual life (years)"&gt;7.96&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_zz081jStHDR4" title="Weighted average remaining contractual life (years)"&gt;9.65&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Available for future grants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8rTmEuI5Bg2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,210,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlans2018Member_z8NQ3MnKjyYg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;466,120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">2474971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000929"
      unitRef="USDPShares">0.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000931"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000933"
      unitRef="USDPShares">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000935"
      unitRef="Shares">1650017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">1.11</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000939"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000941"
      unitRef="USDPShares">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">0.47</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000947"
      unitRef="USDPShares">0.47</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000949"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">0.31</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">1.71</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000957"
      unitRef="USDPShares">0.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">60829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">0.31</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">9.68</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000965"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">25046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000969"
      unitRef="USDPShares">1.85</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000971"
      unitRef="USDPShares">9.68</AIM:ShareBasedCompensationArrangementByShareBasedPaymentValueOfAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000973"
      unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">2814142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000989"
      unitRef="USDPShares">0.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000993"
      unitRef="USDPShares">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact000995"
      unitRef="Shares">2474971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact000997"
      unitRef="USDPShares">0.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact000999"
      unitRef="USDPShares">9.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001001"
      unitRef="USDPShares">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001003"
      unitRef="Shares">2397474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact001005"
      unitRef="USDPShares">0.31</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact001007"
      unitRef="USDPShares">327.36</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001010"
      unitRef="Shares">1916637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MinimumMember"
      decimals="INF"
      id="Fact001012"
      unitRef="USDPShares">0.41</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member_srt_MaximumMember"
      decimals="INF"
      id="Fact001014"
      unitRef="USDPShares">9.68</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsValueExercisableSharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001015"
      unitRef="USDPShares">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_EquityIncentivePlans2018Member"
      id="Fact001017">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_EquityIncentivePlans2018Member"
      id="Fact001019">P9Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001021"
      unitRef="Shares">1210286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-12-31_custom_EquityIncentivePlans2018Member"
      decimals="INF"
      id="Fact001023"
      unitRef="Shares">466120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001025">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3XyNvJ9gsf9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zF0PfjjCWiX8" style="display: none"&gt;Schedule
of Vest Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contracted &lt;br/&gt;Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; color: Black"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zO1TgIVsrq3b" style="width: 10%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;1,498,798&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; color: Black; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmuq5cZqvpD1" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsJ97lMV98Kh" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zq9gGVhvysT5" style="width: 10%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHWslta3k897" style="color: Black; text-align: right" title="Number of options, granted"&gt;550,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsjODRHZRBU4" title="Weighted Average Exercise Price, Granted"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYRFovyjgKfd" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;9.71&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMZbdMXUmn7h" style="color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(28,584&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8yzOyFJPC1i" title="Weighted Average Exercise Price, Forfeited"&gt;17.71&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl65lMGPS3Ol" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzTauXEBh8Bf" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHCcpauMSbZ" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,020,214&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zacgZgdlDl7j" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN3H21xyxjt4" title="Weighted Average Remaining Contracted Term (years)"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvg3m0wkDAXe" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1055"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrdSKYkaXDOa" style="color: Black; text-align: right" title="Number of options, granted"&gt;400,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOVWpyGMHwm5" title="Weighted Average Exercise Price, Granted"&gt;0.47&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zi6E1SbAFp31" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;10.17&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcQGwKQHoVwf" style="color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(7,601&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zapcVRUqDmL7" title="Weighted Average Exercise Price, Forfeited"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7DeSaNwESe9" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Expired"&gt;(4,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoNz9hltHWEb" title="Weighted Average Exercise Price, Expired"&gt;41.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Outstanding December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zcNhF6wBaGpl" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,408,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z6h0jEL4K4Be" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zC2GiteBVcEf" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGLvweXtYT3d" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1077"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Vested and expected to vest at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFy1OWgL3JOh" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,041,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0oWA11Q0s1d" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7NaQghpaf4" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeCECss9Spk3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziJBXkFM5CQj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,041,772&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTkUx06vDIdk" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbU0KvwGWSzh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9fWMvpxLccf" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001027"
      unitRef="Shares">1498798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001029"
      unitRef="USDPShares">4.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001031">P9Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001037"
      unitRef="USDPShares">0.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001039">P9Y8M15D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">28584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001043"
      unitRef="USDPShares">17.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001049"
      unitRef="Shares">2020214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001051"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001053">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001061">P10Y2M1D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">7601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001065"
      unitRef="USDPShares">9.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">4175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001069"
      unitRef="USDPShares">41.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Shares">2408438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001073"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001075">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">2041772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001081"
      unitRef="USDPShares">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001083">P6Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">2041772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001089"
      unitRef="USDPShares">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001091">P6Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-01-012023-12-31_custom_EmployeesMember"
      decimals="0"
      id="Fact001095"
      unitRef="USD">184000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmployeesMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">424999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesMember"
      decimals="INF"
      id="Fact001099"
      unitRef="USDPShares">0.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-01-012022-12-31_custom_EmployeesMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">768666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_EmployeesMember"
      decimals="INF"
      id="Fact001103"
      unitRef="Shares">575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesMember"
      decimals="INF"
      id="Fact001104"
      unitRef="USDPShares">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001106">&lt;p id="xdx_898_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCvDRE2gnWB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BF_znkiS1cgVg4i" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Average Remaining Contracted Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYPcWmfJ2bFa" style="width: 13%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;412,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfTmqmYk7oZi" style="width: 13%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;4.15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFao3ebbr6Kk" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_za0d7W3RS2Xc" style="width: 13%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1114"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUmwAfngLDy7" style="text-align: right" title="Number of Options, Granted"&gt;550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWlXu0GmreYe" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFIDIyoHTT51" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;9.71&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUd9hMgV906j" style="text-align: right" title="Number of Options, Vested"&gt;(541,590&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zvY5uzFb8gml" style="text-align: right" title="Weighted Average Exercise Price, Vested"&gt;1.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIct0KcJzpa" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;9.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmC8aMjsw6P8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(28,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zfvXdF3IyfI8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;17.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJytXXS7WdLg" style="text-align: right" title="Number of Options Unvested, brginning of Period"&gt;392,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYqo1XyBaiW8" style="text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zzU6tzWxcv9h" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z52rYMIINNBe" style="text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z20vLrXDNmCd" style="text-align: right" title="Number of Options, Granted"&gt;400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2ibJo58kDtg" style="text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z74w8QEON2Lj" title="Weighted Average Remaining Contracted Term (years) Granted"&gt;10.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z2Vl6Zu9x53k" style="text-align: right" title="Number of Options, Vested"&gt;(413,884&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7xkHbiObAq3" style="text-align: right" title="Weighted Average Exercise Price, Vested"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyXuLX3gvPZ2" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXha9Elcmyj6" style="text-align: right" title="Number of Options, Forfeited"&gt;(7,601&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zxLNQ5Ziljpf" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;9.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zweDV8Orlgoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Expired"&gt;(4,175&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8ut2qIb6Hr7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;41.61&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unvested December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zuhtlgLdSXq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;366,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zwsYE33HGdii" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;2.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zijWQVLsXHS3" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;12.44&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zmvRfA3i91T" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1165"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001108"
      unitRef="Shares">412500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">4.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001112">P5Y10M6D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001118"
      unitRef="USDPShares">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001120">P9Y8M15D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">541590</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001124"
      unitRef="USDPShares">1.31</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001126">P9Y8M23D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Shares">28584</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001130"
      unitRef="USDPShares">17.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001132"
      unitRef="Shares">392326</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001134"
      unitRef="USDPShares">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001136">P8Y10M9D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001141"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001143">P10Y2M1D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">413884</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001147"
      unitRef="USDPShares">1.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001149">P6Y8M23D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Shares">7601</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001153"
      unitRef="USDPShares">9.68</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">4175</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001157"
      unitRef="USDPShares">41.61</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001159"
      unitRef="Shares">366666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001161"
      unitRef="USDPShares">2.13</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001163">P12Y5M8D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001167">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKEj4qh8kNW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B7_zsalMMWYrOo9" style="display: none"&gt;Schedule
of Vest Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Remaining Contracted Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; color: Black"&gt;Outstanding December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeLMRFWVSE3" style="width: 13%; color: Black; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;279,723&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjxZzSWuCEzg" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;6.12&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; color: Black; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGT7T885f6n" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;7.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwTf0HgrbKA4" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHqBdcQNNThg" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;300,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zDLQRLU0QIA5" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zklP6kdTEUS2" title="Grants in period, weighted average grant date fair value"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIvMhmMIRAqg" style="color: Black; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1183"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabhqOevdvF1" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFdiQDQxoJOi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(568&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTDeOwOSFy4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;153.12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Outstanding December 31, 2022&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfnZbYxoSu4d" style="color: Black; text-align: right" title="Number of Options Outstanding, beginning of Period"&gt;579,155&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGm3M4v0hyO1" style="color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, beginning of Period"&gt;3.09&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuMxR7aeO8Qh" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5GIlJdwHsv1" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zi24FblTlE0h" style="color: Black; text-align: right"&gt;360,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwYTkNC4K6Mb" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.46&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted_pid_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0TQxSmD7eFl" title="Grants in period, weighted average grant date fair value"&gt;10.04&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYYPNo9CN7h6" style="color: Black; text-align: right" title="Number of Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwJV7OUBpVL6" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&#160;Expired&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXolyBGwaY7l" style="color: Black; text-align: right" title="Number of Options,expired"&gt;(653&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrVMvL9EzSG9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;145.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCqd3imdscFa" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(53,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z39YSf78win8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Outstanding December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zezhSipQcXse" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;885,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzDRpEteldth" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zrKKGIbA2RTb" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zO67r7VahRxd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;Vested and expected to vest at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJFJeLgHCPgi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;550,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsVw5JM0Klud" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3MFGjsRWk45" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;10.02&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfSGe30qZ0Se" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1228"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLRGkup8nPg" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Exercisable, End of Period"&gt;550,055&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqqDgSxBntta" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEiXLyYbrHRe" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.02&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCTKbz8CYx2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1236"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001169"
      unitRef="Shares">279723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001173">P7Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001177"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001179"
      unitRef="USDPShares">0.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001181">P9Y8M4D</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001188"
      unitRef="USDPShares">153.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001190"
      unitRef="Shares">579155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001192"
      unitRef="USDPShares">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001194">P8Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001201">P10Y14D</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <AIM:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">145.24</AIM:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001211"
      unitRef="Shares">53447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001212"
      unitRef="USDPShares">1.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">885055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001216"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001218">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Shares">550055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001226">P10Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">550055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001234">P10Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember"
      decimals="0"
      id="Fact001238"
      unitRef="USD">90000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Shares">191666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonEmployeeMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember"
      decimals="0"
      id="Fact001244"
      unitRef="USD">247166</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember"
      decimals="INF"
      id="Fact001246"
      unitRef="Shares">229053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonEmployeeMember"
      decimals="INF"
      id="Fact001248"
      unitRef="USDPShares">1.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001250">&lt;p id="xdx_896_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYm9rSt3FyF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zmTaiMUsaseh" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contracted &lt;br/&gt;Term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Aggregate Intrinsic&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;(Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 32%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo2AVg35ikEl" style="width: 13%; color: Black; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;97,831&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfYizJKngL4i" style="width: 13%; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;3.89&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; color: Black; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zgRWC1MjHHZh" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;7.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOvt2toMtfE1" style="width: 13%; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1258"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ze9MVApUkKzg" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;300,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWsa113EBQh8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;0.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNlL7jztUBwf" title="Average Remaining Contractual Term granted"&gt;9.68&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcyYH4K4eujk" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(229,053&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4OJtleVDkF9" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.82&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMMNRPZaH1Ej" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(1,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zJoajYJB220i" style="color: Black; text-align: right" title="Number of Options Unvested, brginning of Period"&gt;166,789&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zSAo2bkBYYxf" style="color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, beginning of Period"&gt;4.05&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBwgskkI0POc" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;9.49&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVAzn6ezY5Jh" style="color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUEy3RLoUeia" style="color: Black; text-align: right" title="Number of Options, Granted"&gt;360,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXKnVXQnIlq" style="color: Black; text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsKTZ4WdlRX2" title="Average Remaining Contractual Term granted"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPlkAAN1KSR3" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(137,565&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zum4dS1xfGWe" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z4TOxkGhtMce" title="Average Remaining Contractual Term vested"&gt;9.47&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPaKuMMbZIj" style="color: Black; text-align: right" title="Number of Options, Vested"&gt;(776&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKTko5ejOPf8" style="color: Black; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;145.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z3wqyUMV9Egb" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Options, Forfeited"&gt;(53,447&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zS2KlJFe6pR3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;1.31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Unvested December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdqQIbnp4yV1" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of Options Unvested, End of Period"&gt;335,001&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaDpoYkQy0D8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0xrtELjI1Ig" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pdp0_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9z6wdP6hCYd" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">97831</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001254"
      unitRef="USDPShares">3.89</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2021-01-012021-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001256">P7Y9M25D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001262"
      unitRef="USDPShares">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001264">P9Y8M4D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Shares">229053</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001268"
      unitRef="USDPShares">0.82</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001270"
      unitRef="Shares">1989</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001272"
      unitRef="Shares">166789</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001274"
      unitRef="USDPShares">4.05</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001276">P9Y5M26D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001280"
      unitRef="Shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001281"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001283">P10Y2M4D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001285"
      unitRef="Shares">137565</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001287"
      unitRef="USDPShares">0.47</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001289">P9Y5M19D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Shares">776</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsExpiredNumberOfShares>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001293"
      unitRef="USDPShares">145.24</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001295"
      unitRef="Shares">53447</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001297"
      unitRef="USDPShares">1.31</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">335001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001301"
      unitRef="USDPShares">1.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001303">P10Y8M12D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="0"
      id="Fact001307"
      unitRef="USD">243000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="0"
      id="Fact001309"
      unitRef="USD">954000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001311"
      unitRef="USD">294000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001313"
      unitRef="USD">217000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001315">&lt;p id="xdx_897_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zeILQNWJeqal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Information
regarding warrants outstanding and exercisable into shares of common stock is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B7_z5LMDxbstbGf" style="display: none"&gt;Schedule
of Warrants Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Warrant&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Warrant&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; color: Black; text-align: justify"&gt;Outstanding, beginning of year &lt;br/&gt;&#160; &lt;br/&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqRozs5Y4jkd" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zmXSSkkOT8w5" title="Warrant price outstanding, beginning of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zpbRlEk5oJtd" title="Warrant price outstanding, beginning of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zahnLtP5LwO2" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrmgCjc9Rzvj" style="width: 8%; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;294,939&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyJrDi4sOWgk" title="Warrant price outstanding, beginning of year"&gt;0.99&lt;/span&gt; &#x2013; &lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn0GmmO3P6qd" title="Warrant price outstanding, beginning of year"&gt;469.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh5LIcPleKMc" style="width: 8%; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;15.19&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwY5sI38OOzh" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLEgVWTRsnak" style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1334"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zc7yT8hEfSb5" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1336"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVlIghCmTL7f" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1338"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkmmxnyXbMd3" style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1339"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstandingGrantsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z58kY4rBtdG9" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Expired&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAwCgD0h9s57" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(74,450&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdvdRHtoavji" title="Warrant price, expired"&gt;17.05&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ1pTsT6w837" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;17.05&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQH6C4gMbi8" style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(68,215&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXoTkDQNvH9c" title="Warrant price, expired"&gt;469.92&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIgnvUGFmM5g" style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;469.92&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwO6JRyXJYlg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1355"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XKH76Mu3L1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4vIQJiOvFfi" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zszAruL7seU1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;(114&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn6j9lU4Wks7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTEpQNEKrwue" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;Outstanding, end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvoaBmP9KhK2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;152,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z0BKR7zQaTR9" title="Warrant price outstanding, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYSZCmEsGPj3" title="Warrant price outstanding, end of year"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrRvhpq3yLm8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.03&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6cQec3WhGe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zsrEUrBv1Q1h" title="Warrant price outstanding, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEF2kNXhsAR3" title="Warrant price outstanding, end of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA3doCO4NgPj" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; color: Black"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zagMEkNX966k" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;152,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z2cMmWZxTZu4" title="Warrant price exercisable, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zn2YWcIasnj2" title="Warrant price exercisable, end of year"&gt;8.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyybKuv1rSx7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;8.03&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqpgrO72ETjj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;226,610&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$ &lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zjyk7kIgfru" title="Warrant price exercisable, end of year"&gt;0.99&lt;/span&gt;-&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2KaO7qSI7lb" title="Warrant price exercisable, end of year"&gt;132.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRPxw92JECg8" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;9.10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Weighted average remaining contractual life&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8AuyJMA2PU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.75 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQN9lfUrImB4" title="Weighted average remaining contracted term (years) outstanding, ending of year"&gt;.94&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Years exercisable&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9BxMoyx0vGj" title="Years exercisable"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Number of options outstanding, beginning of year"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zo81gQDW6ad6" title="Years exercisable"&gt;2023&lt;/span&gt;-&lt;span id="xdx_90A_ecustom--WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9dvWViWs0rj" title="Years exercisable"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right" title="Weighted average exercise price outstanding, beginning of year"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">226610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001321"
      unitRef="USDPShares">132.00</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001323"
      unitRef="USDPShares">9.10</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">294939</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001327"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001329"
      unitRef="USDPShares">469.92</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001331"
      unitRef="USDPShares">15.19</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001343"
      unitRef="Shares">74450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001345"
      unitRef="USDPShares">17.05</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001347"
      unitRef="USDPShares">17.05</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">68215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001351"
      unitRef="USDPShares">469.92</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExpiredInPeriodGross>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001353"
      unitRef="USDPShares">469.92</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExpiredInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001360"
      unitRef="Shares">114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001361"
      unitRef="USDPShares">8.80</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantPriceExercisedInPeriod>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001363"
      unitRef="USDPShares">8.80</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">152160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001367"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001369"
      unitRef="USDPShares">8.80</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember289844531"
      decimals="INF"
      id="Fact001371"
      unitRef="USDPShares">8.03</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">226610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001375"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001377"
      unitRef="USDPShares">132.00</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWarrantPriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001379"
      unitRef="USDPShares">9.10</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceOutstanding>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001381"
      unitRef="Shares">152160</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001383"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001385"
      unitRef="USDPShares">8.80</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001387"
      unitRef="USDPShares">8.03</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">226610</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001391"
      unitRef="USDPShares">0.99</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001393"
      unitRef="USDPShares">132.00</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisableSharePrice>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001395"
      unitRef="USDPShares">9.10</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceExercisable>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001396">P0Y9M</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="Fact001398">P0Y11M8D</AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceNumber>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001400">2024</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      id="Fact001402">2023</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
    <AIM:WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      id="Fact001404">2024</AIM:WeightedbasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermYear>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001414">&lt;p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zJJslBquIkL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(7)
&lt;span id="xdx_82D_zREfYxgxL3z4"&gt;Segment and Related Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company operates in &lt;span id="xdx_909_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20230101__20231231_zc5D3JCz9mj5" title="Number of segment"&gt;one&lt;/span&gt; segment, which performs research and development activities related to Ampligen and other drugs under development.
The Company&#x2019;s revenues for the two-year period ended December 31, 2023, were earned in the United States. All assets are maintained
in the United States of America.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001416"
      unitRef="Integer">1</us-gaap:NumberOfOperatingSegments>
    <AIM:ResearchConsultingAndSupplyAgreementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001418">&lt;p id="xdx_805_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4fLtYbN7Vll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;(8)
&lt;span id="xdx_822_zEJLf0INZyc8"&gt;Research, Consulting and Supply Agreements&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During the year ended December 31, 2023, research and development expenses
were comprised of: clinical studies ($&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyjDnZGFgh62" title="Research and development expense"&gt;6,014,000&lt;/span&gt;), manufacturing and engineering ($&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zfI5Va6rI0d5" title="Research and development expense"&gt;3,220,000&lt;/span&gt;), quality control ($&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--QualityControlMember_zj6NBYEJsDr9" title="Research and development expense"&gt;1,271,000&lt;/span&gt;) and regulatory
($&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__srt--ProductOrServiceAxis__custom--RegulatoryMember_z6SeNVOYYyG5" title="Research and development expense"&gt;434,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;During the year ended December 31, 2022, research and development expenses
were comprised of: clinical studies ($&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zyuQ9B3Ls66h" title="Research and development expense"&gt;4,070,000&lt;/span&gt;), manufacturing and engineering ($&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zrzfkeFObV29" title="Research and development expense"&gt;1,241,000&lt;/span&gt;), quality control ($&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--QualityControlMember_zGzSy0BCHlT8" title="Research and development expense"&gt;1,236,000&lt;/span&gt;) and regulatory
($&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__srt--ProductOrServiceAxis__custom--RegulatoryMember_zwhviG7susAi" title="Research and development expense"&gt;443,000&lt;/span&gt;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Amarex
Clinical Research LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Amarex
is the principal administrator of several of AIM&#x2019;s largest clinical studies. AIM has multiple contracts with Amarex Clinical
Research LLC (&#x201c;Amarex&#x201d;). During the year ended December 31, 2023 and 2022, the Company incurred approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zjsKeSbwVgt3" title="Research and development expense"&gt;4,290,000&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zoTYVGpzRIHh" title="Research and development expense"&gt;2,272,000&lt;/span&gt;, respectively, related to these ongoing agreements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Pancreatic
    Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is managing a Phase 2 clinical trial in locally
    advanced pancreatic cancer patients designated AMP-270. Per the work order, AIM anticipates that Amarex&#x2019;s management of the
    study will cost approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj0b7yetqVHi" title="Research and development expense excluding acquired in process cost"&gt;8,400,000&lt;/span&gt;. This estimate includes pass-through costs of approximately $&lt;span id="xdx_904_eus-gaap--DevelopmentCosts_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z6E238Oy8zCa" title="Development cost"&gt;1,000,000&lt;/span&gt; and excludes certain
    third-party and investigator costs and escalations necessary for study completion. AIM anticipates that the study will take approximately
    &lt;span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zvzpsBBUJNJ6" title="Estimated lives"&gt;4.6&lt;/span&gt; years to complete.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zEogaZmww6xe" title="Research and development expense"&gt;600,000&lt;/span&gt; related to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company incurred approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PancreaticCancerMember_zRA9HhWySi2b" title="Research and development expense"&gt;1,691,000&lt;/span&gt; related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Post-COVID
    Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which Amarex is managing a Phase 2 trial in patients
    with Post-COVID Conditions. AIM is sponsoring the study. AIM anticipates that the study will cost approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z3OtcXkdCxH5"&gt;6,400,000&lt;/span&gt;, which
    includes pass through costs of approximately $&lt;span id="xdx_90C_eus-gaap--DevelopmentCosts_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z68nU02VjkCg" title="Development cost"&gt;125,000&lt;/span&gt;, investigator costs estimated at about $&lt;span id="xdx_900_eus-gaap--CostMaintenance_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zwAikhPsTji7" title="Invigilators cost"&gt;4,400,000&lt;/span&gt;, and excludes certain other
    third-party costs and escalations. During 2023, the original work order increased to approximately $&lt;span id="xdx_904_eus-gaap--DevelopmentCosts_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zN5anhmwgnI8" title="Development cost"&gt;6,600,000&lt;/span&gt; for the addition of
    patient reported outcome (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated with the
    ePRO system and additional safety monitoring services as well as changes to study documentation (such as protocol amendments) which
    resulted in additional IND submissions to FDA. This study was effectively concluded in 2023.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zX4oZsJX0Xcg" title="Research and development expense"&gt;3,690,000&lt;/span&gt; related to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company incurred approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDMember_zBWSLzE4RDt" title="Research and development expense"&gt;581,000&lt;/span&gt; related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Jubilant
HollisterStier&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Jubilant
HollisterStier (&#x201c;Jubilant&#x201d;) is AIM&#x2019;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company
entered into an agreement with Jubilant pursuant to which Jubilant will manufacture batches of Ampligen&#xae; for the Company. Since the
2017 engagement of Jubilant, two lots of Ampligen consisting of more than &lt;span id="xdx_90F_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zJaL14ANND35" title="Number of units manufactured"&gt;16,000&lt;/span&gt; units were manufactured and released in the year 2018.
The first lot was designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials.
The second lot has been designated for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant
manufactured additional two lots of Ampligen in December 2019 and January 2020. In March 2023, the Company ordered an additional &lt;span id="xdx_904_ecustom--NumberOfVials_uInteger_c20230101__20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zpL9XLWaZCf5" title="Additional number of vials"&gt;27,900&lt;/span&gt;
vials from Jubilant at a cost of approximately $&lt;span id="xdx_90E_eus-gaap--InventoryWorkInProcessAndRawMaterials_iI_c20230331__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zCBLLFuNAPH9" title="Inventory work in process and raw materials"&gt;1,432,000&lt;/span&gt;. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zfI7t5QWlnMa" title="Research and development expense"&gt;1,432,000&lt;/span&gt; related to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company incurred approximately $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--ResearchConsultingAndSupplyAgreementsMember_zCKeu8FivXJ" title="Research and development expense"&gt;79,000&lt;/span&gt; related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Sterling
Pharma Solutions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#x201c;Sterling&#x201d;)
for the manufacture of the Company&#x2019;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#x2019;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--PharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zKzuIfnLYHIk" title="Research and development expense"&gt;363,000&lt;/span&gt; related to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Erasmus&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#x2019;s limited responsibilities
are limited to providing Ampligen. Additionally, AIM agreed to provide a grant of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20221201__20221231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zrZLNisgBPx" title="Research and development expense"&gt;200,000&lt;/span&gt; for the study.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--ErasmusMember__us-gaap--TypeOfArrangementAxis__custom--JjointClinicalStudyAgreementMember_zbzGQ71Oq9Yg" title="Research and development expense"&gt;100,000&lt;/span&gt; pursuant to the Grant Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Azenova
Sales International&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development services
for AIM&#x2019;s Ampligen product for solid tumors for a 12 month term that is extendable upon the agreement of the parties. In exchange
for its services, Azenova will receive a fixed monthly retainer of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zDtRuFC8pDte" title="Stock options, aggregate intrinsic value"&gt;30,000&lt;/span&gt; per month in addition to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231031__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zoUQauZAXSz5" title="Stock options, vested"&gt;360,000&lt;/span&gt; stock options that vest monthly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AzenovaSalesInternationalMember_zwr8JgvdTSQa" title="Research and development expense"&gt;75,000&lt;/span&gt; related to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company did not incur any expense related to this agreement.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Alcami&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiMember_zF5WPVvD5UFa" title="Research and development expense"&gt;30,000&lt;/span&gt; upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2023, the Company incurred approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__dei--LegalEntityAxis__custom--AlcamiMember_zjgWBiPtStJ3" title="Research and development expense"&gt;65,000&lt;/span&gt; of lab services from Alcami.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cb;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During the year ended December 31, 2022, the Company incurred approximately $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231__dei--LegalEntityAxis__custom--AlcamiMember_zKyWKv2prIx3" title="Research and development expense"&gt;18,000&lt;/span&gt; of lab services from Alcami.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AIM:ResearchConsultingAndSupplyAgreementsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001420"
      unitRef="USD">6014000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001422"
      unitRef="USD">3220000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_QualityControlMember"
      decimals="0"
      id="Fact001424"
      unitRef="USD">1271000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_RegulatoryMember"
      decimals="0"
      id="Fact001426"
      unitRef="USD">434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001428"
      unitRef="USD">4070000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001430"
      unitRef="USD">1241000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_QualityControlMember"
      decimals="0"
      id="Fact001432"
      unitRef="USD">1236000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_RegulatoryMember"
      decimals="0"
      id="Fact001434"
      unitRef="USD">443000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001436"
      unitRef="USD">4290000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001438"
      unitRef="USD">2272000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001440"
      unitRef="USD">8400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DevelopmentCosts
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">1000000</us-gaap:DevelopmentCosts>
    <AIM:ResearchAndDevelopmentExpenseCostEstimatedLives
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      id="Fact001444">P4Y7M6D</AIM:ResearchAndDevelopmentExpenseCostEstimatedLives>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember"
      decimals="0"
      id="Fact001446"
      unitRef="USD">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PancreaticCancerMember"
      decimals="0"
      id="Fact001448"
      unitRef="USD">1691000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">6400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DevelopmentCosts
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">125000</us-gaap:DevelopmentCosts>
    <us-gaap:CostMaintenance
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">4400000</us-gaap:CostMaintenance>
    <us-gaap:DevelopmentCosts
      contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001455"
      unitRef="USD">6600000</us-gaap:DevelopmentCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember"
      decimals="0"
      id="Fact001457"
      unitRef="USD">3690000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDMember"
      decimals="0"
      id="Fact001459"
      unitRef="USD">581000</us-gaap:ResearchAndDevelopmentExpense>
    <AIM:UnitsManufactured
      contextRef="From2017-01-012017-12-31_custom_JubilantHollisterStierMember"
      decimals="INF"
      id="Fact001461"
      unitRef="Integer">16000</AIM:UnitsManufactured>
    <AIM:NumberOfVials
      contextRef="From2023-01-012023-03-31_custom_JubilantHollisterStierMember"
      decimals="INF"
      id="Fact001463"
      unitRef="Integer">27900</AIM:NumberOfVials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="AsOf2023-03-31_custom_JubilantHollisterStierMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">1432000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember"
      decimals="0"
      id="Fact001467"
      unitRef="USD">1432000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_JubilantHollisterStierMember_custom_ResearchConsultingAndSupplyAgreementsMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">79000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_PharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">363000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-12-012022-12-31_custom_ErasmusMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ErasmusMember_custom_JjointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-10-31_custom_AzenovaSalesInternationalMember"
      decimals="INF"
      id="Fact001479"
      unitRef="Shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AzenovaSalesInternationalMember"
      decimals="0"
      id="Fact001481"
      unitRef="USD">75000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-09-012023-09-30_custom_AlcamiMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">30000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AlcamiMember"
      decimals="0"
      id="Fact001485"
      unitRef="USD">65000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_AlcamiMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">18000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001489">&lt;p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_z41Ccz5PSXFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(9)
&lt;span id="xdx_827_zYskLrLHgAXi"&gt;401(k) Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
has a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the &#x201c;401(k) Plan&#x201d;).
AIM&#x2019;s full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations
imposed by federal tax laws, participants are eligible to contribute up to &lt;span id="xdx_90A_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231__us-gaap--RetirementPlanNameAxis__custom--FourZeroOnekPlanMember_zux9xhht0cd7" title="Percentage of maximum annual contribution per employee, as percentage of their annual salary"&gt;15&lt;/span&gt;% of their salary (including bonuses and/or commissions)
per annum. Participants&#x2019; contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
participant immediately vests in his or her deferred salary contributions as well as the Company&#x2019;s safe harbor contributions.
A &lt;span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_pid_dp_uPure_c20230101__20231231_zPmL7gjec7M6" title="Deferred compensation arrangementl, cash awards granted, percentage"&gt;6&lt;/span&gt;%
safe harbor matching contribution by us was reinstated effective January 1, 2021. For the year ended December 31, 2023 and 2022, the
Company&#x2019;s matching contributions were approximately $&lt;span id="xdx_90F_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20230101__20231231_zDzlD8umTTua" title="Contribution amount"&gt;162,000&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_c20220101__20221231_zWVac5329b" title="Contribution amount"&gt;122,000&lt;/span&gt;,
respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="From2023-01-012023-12-31_custom_FourZeroOnekPlanMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Pure">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001493"
      unitRef="Pure">0.06</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001495"
      unitRef="USD">162000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001497"
      unitRef="USD">122000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <AIM:EmploymentAgreementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001499">&lt;p id="xdx_80E_ecustom--EmploymentAgreementsTextBlock_z3dZg3hif1Cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(10)
&lt;span id="xdx_829_zMyC1KKbWmIl"&gt;Employment Agreements&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had contractual agreements with Named Executive Officers (&#x201c;NEO&#x201d;) in 2023, and 2022. The aggregate annual base compensation
for these NEO under their respective contractual agreements for 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zj0ShGkuJnL1" title="Employee benefits and share-based compensation"&gt;1,275,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zaEP2bBxhiGd" title="Employee benefits and share-based compensation"&gt;1,275,000&lt;/span&gt;, respectively. In addition,
certain of these Officers were entitled to receive performance bonuses of up to &lt;span id="xdx_90C_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zAWrRcxlY5Ya" title="Revenue, remaining performance obligation, percentage"&gt;25&lt;/span&gt;% or &lt;span id="xdx_902_eus-gaap--RevenueRemainingPerformanceObligationPercentage_iI_pid_dp_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_ziu4G3VqCNwd" title="Revenue, remaining performance obligation, percentage"&gt;20&lt;/span&gt;% of their respective annual base salary, at
the sole discretion of the Compensation Committee of the Board of Directors. For the years ended December 31, 2023 and 2022, Officers&#x2019;
bonuses were $&lt;span id="xdx_903_ecustom--Bonus_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_zEMZSOc8AYE5"&gt;450,000&lt;/span&gt;, to be deferred and paid in 2024 and $&lt;span id="xdx_90B_ecustom--Bonus_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentContractualAgreementsMember__srt--TitleOfIndividualAxis__custom--NamedExecutiveOfficersMember_z1JvkmqZRr9h"&gt;450,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, equity was granted as a form of compensation to these Officers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLuhZd8cUGIg" title="Number of options, granted"&gt;300,000&lt;/span&gt; &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5g6mpgvgvc3" title="Options term::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1513"&gt;ten-year&lt;/span&gt;&lt;/span&gt; options to purchase common stock with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z5z5Hbpc0Nte" title="Stock options exercise price per share"&gt;0.47&lt;/span&gt; per share to vest in &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zP3lUqpy1hlg"&gt;one year&lt;/span&gt; to
    Thomas K. Equels, Chief Executive Officer. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zC6zjeGF8sLe" title="Number of options, granted"&gt;100,000&lt;/span&gt; &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zwzTNS7Bj5Xe" title="Options term::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1520"&gt;ten-year&lt;/span&gt;&lt;/span&gt; options to purchase common stock with an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zTrS2M1Re0Ai" title="Stock options exercise price per share"&gt;0.47&lt;/span&gt; per share which vest in &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_ztOxwIqUCeed" title="Vesting period"&gt;one year&lt;/span&gt;
    to Peter Rodino, Chief Operating Officer and General Counsel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock compensation expense of approximately $&lt;span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsandRodinoMember_zf8vnYpJe6ol" title="Stock compensation expense"&gt;14,000&lt;/span&gt; during the year ended December 31, 2023 with regard to these issuances
to Officers Equels and Rodino.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2022, equity was granted as a form of compensation to these Officers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_z6KkeQwFNM9l" title="Number of options, granted"&gt;300,000&lt;/span&gt; &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zkTwRI3bRFRj" title="Options term::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1530"&gt;ten-year&lt;/span&gt;&lt;/span&gt; options to purchase common stock with an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zlND1tOnooGc" title="Stock options exercise price per share"&gt;0.41&lt;/span&gt; per share to vest in &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--ThomasKEquelsMember_zLAigI8Ixqb6"&gt;one year&lt;/span&gt; to
    Thomas K. Equels, Chief Executive Officer. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zqR0Vn4Va4Ni" title="Number of options, granted"&gt;150,000&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zCXKUdCehaDe" title="Options term::XDX::P10Y"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl1537"&gt;ten-year&lt;/span&gt;&lt;/span&gt; options to purchase common stock with exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MinimumMember_zVGM4kglJob6" title="Stock options exercise price per share"&gt;0.41&lt;/span&gt; to $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember__srt--RangeAxis__srt--MaximumMember_z0pDSSJI41T5" title="Stock options exercise price per share"&gt;0.70&lt;/span&gt; per share which vest in &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--PeterRodinoMember_zW8O62SfRcNh" title="Vesting period"&gt;one
    year&lt;/span&gt; to Peter Rodino, Chief Operating Officer and General Counsel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company granted &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_zF2JjGbqRn9h"&gt;50,000&lt;/span&gt; &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxL_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z9axaCjww9u9" title="::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1545"&gt;ten-year&lt;/span&gt;&lt;/span&gt; options to purchase common stock with an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_z3sSALWeLDHh"&gt;0.70&lt;/span&gt; per share which vest in &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--StockOptionsMember__srt--TitleOfIndividualAxis__custom--EllenLintalMember_ztrwY3O2VUSk"&gt;one year&lt;/span&gt;
    to Ellen Lintal, former Chief Financial Officer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock compensation expense of approximately $&lt;span id="xdx_90B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EquelsRodinoAndFormerOfficerLintalMember_zy4Yu23qvXD1" title="Stock compensation expense"&gt;107,000&lt;/span&gt; during the year ended December 31, 2023 with regard to these issuances
to Officers Equels, Rodino, and former Officer Lintal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</AIM:EmploymentAgreementsTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="0"
      id="Fact001501"
      unitRef="USD">1275000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="0"
      id="Fact001503"
      unitRef="USD">1275000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="AsOf2023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Pure">0.25</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="AsOf2022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Pure">0.20</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <AIM:Bonus
      contextRef="From2023-01-012023-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="0"
      id="Fact001508"
      unitRef="USD">450000</AIM:Bonus>
    <AIM:Bonus
      contextRef="From2022-01-012022-12-31_custom_EmploymentContractualAgreementsMember_custom_NamedExecutiveOfficersMember"
      decimals="0"
      id="Fact001509"
      unitRef="USD">450000</AIM:Bonus>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      decimals="INF"
      id="Fact001511"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      decimals="INF"
      id="Fact001515"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      id="Fact001516">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      decimals="INF"
      id="Fact001518"
      unitRef="Shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      decimals="INF"
      id="Fact001522"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      id="Fact001524">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EquelsandRodinoMember"
      decimals="0"
      id="Fact001526"
      unitRef="USD">14000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      decimals="INF"
      id="Fact001532"
      unitRef="USDPShares">0.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_ThomasKEquelsMember"
      id="Fact001533">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      decimals="INF"
      id="Fact001535"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001539"
      unitRef="USDPShares">0.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001541"
      unitRef="USDPShares">0.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_PeterRodinoMember"
      id="Fact001543">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember"
      decimals="INF"
      id="Fact001546"
      unitRef="USDPShares">0.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-01-012022-12-31_custom_EmploymentAgreementMember_custom_StockOptionsMember_custom_EllenLintalMember"
      id="Fact001547">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_EquelsRodinoAndFormerOfficerLintalMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">107000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001551">&lt;p id="xdx_803_eus-gaap--LesseeOperatingLeasesTextBlock_zQOOVYpaB976" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(11)
&lt;span id="xdx_829_zlz5v5PdPTu6"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zVaiRjTuXbg8" title="Operating lease term"&gt;1&lt;/span&gt; to &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zeNDPYLL2htc" title="Operating lease term"&gt;5&lt;/span&gt; years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $&lt;span id="xdx_903_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_zPaGW6A9yk8l" title="Operating lease Payment"&gt;1,000&lt;/span&gt;
to $&lt;span id="xdx_905_eus-gaap--OperatingLeasePayments_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_ziPjjkhnYaY2" title="Operating lease Payment"&gt;17,000&lt;/span&gt;. Certain leases include additional renewal options ranging from &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zYHnZjDWxwf3" title="Operating lease term"&gt;1&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zlgXnWxMrNn7" title="Operating lease term"&gt;5&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



&lt;p id="xdx_8A2_z85JlF1Xgu1h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
has classified all of its leases as operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2023 and 2022, the balance of the right of use assets was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zbMGwrMOU9uc" title="Right of use asset"&gt;697,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20221231_zdRwzGCHavDc" title="Right of use asset"&gt;829,000&lt;/span&gt;, respectively,
and the corresponding operating lease liability balance was $&lt;span id="xdx_90D_eus-gaap--OperatingLeaseLiability_iI_c20231231_z1GBWvCTxGS2" title="Lease liability"&gt;718,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLeaseLiability_iI_c20221231_z4bM4Ll48O9g" title="Lease liability"&gt;837,000&lt;/span&gt;, respectively. Right of use assets are recorded net
of accumulated amortization of $&lt;span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20231231_zJhI6zUqL3P8" title="Accumulated amortization"&gt;363,000&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_c20221231_zLjp2IYKIKjg" title="Accumulated amortization"&gt;158,000&lt;/span&gt; as of December 31, 2023 and 2022, respectively.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
recognized rent expense associated with these leases are follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&#160;&#160;&lt;span id="xdx_8BF_zGZL5uejvTRh" style="display: none"&gt;Schedule of AIM
Recognized Rent Expense Associated with Operating Lease&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease costs:&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Operating lease costs&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Short-term and variable lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Total lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Classification of lease costs&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Research &amp;amp; development&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Lease cost &lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zvy3LB7wwUQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s leases have remaining lease terms between &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MinimumMember_zATfJuQh90Y8" title="Operating lease, remaining lease term"&gt;3&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231__srt--RangeAxis__srt--MaximumMember_zmpjeMDRy71c" title="Operating lease, remaining lease term"&gt;44&lt;/span&gt; months. As of December
31, 2023 and 2022, the weighted-average remaining term was &lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20231231_zDINuqx6mOY4" title="Weighted average remaining lease term"&gt;41&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20221231_zbLzyoyha2G3" title="Weighted average remaining lease term"&gt;43&lt;/span&gt; months, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s weighted average incremental borrowing rate for its leases was &lt;span id="xdx_90A_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zbCfGO82WmBh" title="Weighted average incremental borrowing rate"&gt;&lt;span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20221231_z0MPgINDETAf" title="Weighted average incremental borrowing rate"&gt;10&lt;/span&gt;&lt;/span&gt;%
as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zbWNcHMSJbZg" style="display: none"&gt;Schedule of Operating Lease Future Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31, (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zcJjykldx2C"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 35%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zZYGeQSguPLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="Fact001553">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="Fact001555">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="0"
      id="Fact001557"
      unitRef="USD">1000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="0"
      id="Fact001559"
      unitRef="USD">17000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="Fact001561">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="Fact001563">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <AIM:ScheduleOfOperatingLeaseTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001565">&lt;p id="xdx_89F_ecustom--ScheduleOfOperatingLeaseTableTextBlock_z2R0fdzjTYpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;



</AIM:ScheduleOfOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001567"
      unitRef="USD">697000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001569"
      unitRef="USD">829000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001571"
      unitRef="USD">718000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001573"
      unitRef="USD">837000</us-gaap:OperatingLeaseLiability>
    <AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001575"
      unitRef="USD">363000</AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
    <AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001577"
      unitRef="USD">158000</AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001579">&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_z347Q1dQ6oSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
recognized rent expense associated with these leases are follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#160;&#160;&#160;&lt;span id="xdx_8BF_zGZL5uejvTRh" style="display: none"&gt;Schedule of AIM
Recognized Rent Expense Associated with Operating Lease&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zOpJDHWcVJ16" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zHCAqJ15Tuz3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_zqjVluk5je56" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease costs:&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzBan_zrUS37aqDnY8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Operating lease costs&lt;/td&gt;
    &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ShortTermLeaseCost_maLCzBan_z0oaYLfb69V" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Short-term and variable lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;335&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzBan_zHnIVoksKHL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Total lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Classification of lease costs&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5rTSLGM7Tnj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Research &amp;amp; development&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;498&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJVt6hY4kXC8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zVRkgMAIalx1" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Lease cost &lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_zGcpqXYxXvwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001584"
      unitRef="USD">288</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001585"
      unitRef="USD">128</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001587"
      unitRef="USD">335</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001588"
      unitRef="USD">211</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001590"
      unitRef="USD">623</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001591"
      unitRef="USD">339</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001593"
      unitRef="USD">498</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001594"
      unitRef="USD">220</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001596"
      unitRef="USD">125</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001597"
      unitRef="USD">119</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">125</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001600"
      unitRef="USD">119</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001602"
      unitRef="USD">623</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001603"
      unitRef="USD">339</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="Fact001605">P3M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="Fact001607">P44M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001609">P41M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31" id="Fact001611">P43M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001613"
      unitRef="Pure">0.10</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001615"
      unitRef="Pure">0.10</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001617">&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zAMUZzGqHFyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zbWNcHMSJbZg" style="display: none"&gt;Schedule of Operating Lease Future Payments&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 40%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31, (in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zcJjykldx2C"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maOLLzSP3_zow9nISDSi32" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 35%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maOLLzSP3_zspBNmYAFgze" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maOLLzSP3_zacWzTUp42Ef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maOLLzSP3_zsWcEBYzPYp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pn3n3_maOLLzSP3_zdEIthtFppgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1627"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzSP3_ziCYDT3WeYNk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSP3_zT2MBhLj3nr" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;718&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001619"
      unitRef="USD">279000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001621"
      unitRef="USD">229000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001623"
      unitRef="USD">200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001625"
      unitRef="USD">133000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001629"
      unitRef="USD">123000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001631"
      unitRef="USD">718000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001633">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zrklqGUSkgpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(12)
&lt;span id="xdx_827_zvlAk2Kg9xT7"&gt;Income Taxes (FASB ASC 740 Income Taxes)&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of FASB ASC 740-10 Uncertainty in Income Taxes. As a result of the implementation, there has been no material
change to the Company&#x2019;s tax positions as they have not paid any corporate income taxes due to operating losses. With the exception
of net operating losses and research and development credits generated in New Jersey, all tax benefits will likely not be recognized
due to the substantial net operating loss carryforwards which will most likely not be realized prior to expiration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;As of December 31, 2023,
the Company has approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zL6twwVY9lF2" title="Operating loss carryforwards"&gt;166,300,000&lt;/span&gt; of Federal net operating loss carryforwards (expiring in the years 2023 through 2038), and
$&lt;span id="xdx_90D_ecustom--OperatingLossCarryforwardsWithNoExpirationDate_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zEauPMWJIJW4" title="Operating loss carry forwards with no expiration date"&gt;103,300,000&lt;/span&gt; of Federal net operating loss carryforwards with no expiration date, both of which have been limited by Internal Revenue
Code Section 382, available to offset future federal taxable income. The Company has approximately $&lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--NewJerseyDivisionOfTaxationMember_z6XxYw8iV7C5" title="Operating loss carryforwards"&gt;28,800,000&lt;/span&gt; of New Jersey state net
operating loss carryforwards (expiring in 2044). The Company has approximately $&lt;span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zdUMO0kEmCag" title="Operating loss carryforwards"&gt;82,500,000&lt;/span&gt; of Florida state net operating loss carryforwards
with no expiration date to offset future Florida taxable income. The Company has approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__country--BE_zG6U1zZnlsSc" title="Operating loss carryforwards"&gt;3,600,000&lt;/span&gt; of Belgium net operating loss
carryforwards with no expiration date to offset future taxable income In December 2023, the Company effectively sold $&lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20231231__srt--StatementGeographicalAxis__stpr--NJ_zMjFiyczoPS9" title="Operating loss carryforwards"&gt;14,156,000&lt;/span&gt; of its
New Jersey state net operating loss carryforward and $&lt;span id="xdx_90B_eus-gaap--IncomeTaxReconciliationTaxCredits_c20230101__20231231__srt--StatementGeographicalAxis__stpr--NJ_zcApvIcqtUC4" title="Effective income tax rate reconciliation, tax credit, amount"&gt;38,600&lt;/span&gt; in R&amp;amp;D credits for the year 2022 for approximately $&lt;span id="xdx_905_eus-gaap--IncomeTaxReconciliationTaxCredits_pp0p0_c20220101__20221231__srt--StatementGeographicalAxis__stpr--NJ_zEMfLp5M7ibk" title="Effective income tax rate reconciliation, tax credit, amount"&gt;1,313,000&lt;/span&gt;. The utilization
of certain state net operating loss carryforwards may be subject to annual limitations. With no tax due for the foreseeable future, the
Company has determined that a policy to determine the accounting for interest or penalties related to the payment of tax is not necessary
at this time.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the Tax Reform Act of 1986, the utilization of a corporation&#x2019;s net operating loss carryforward is limited following a greater than
50% change in ownership. As noted above, due to the Company&#x2019;s prior and current equity transactions, some of the Company&#x2019;s
net operating loss carryforwards are subject to an annual limitation generally determined by multiplying the value of the Company on
the date of the ownership change by the federal long-term tax-exempt rate. Any unused annual limitation may be carried forward to future
years for the balance of the net operating loss carryforward period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between carrying amounts of assets and liabilities for financial reporting
purposes and the carrying amounts used for income tax purposes. In assessing the realizability of deferred tax assets, Management considers
whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of deferred
tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net
future deductible amounts become deductible. With the exception of net operating losses generated in New Jersey which can be surrendered
for 80% of their value, due to the uncertainty of the Company&#x2019;s ability to realize the benefit of the deferred tax asset, the remainder
of our deferred tax assets are fully offset by a valuation allowance at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an
immaterial deferred tax error of approximately $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax"&gt;1.4&lt;/span&gt;
million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022,
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none"&gt;Schedule of Components of Net Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;25,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Research and Development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization &amp;amp; depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;R&amp;amp;D credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,472&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(36,816&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,840&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,604&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A0_zeUFKzIwyEv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are included within other assets in the accompanying Consolidated Balance Sheets. The benefits of deferred tax assets are
included within the gain from sale of income tax operating losses in the accompanying Consolidated Statements of Operations and
Comprehensive Loss. The Company&#x2019;s deferred tax asset estimates the projected sale of 2023 and 2022 New Jersey state operating
losses to be sold in the subsequent year, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rate
Reconciliation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation
between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zluv3XFKo1Aj" style="display: none"&gt;Schedule of Effective Tax Rate and Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Pre Tax Book Loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss"&gt;(28,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate"&gt;(6,082&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate"&gt;21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes"&gt;(2,244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes"&gt;7.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Perms&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms"&gt;(83&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;RTP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP"&gt;(8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Income Tax Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income"&gt;(479&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income"&gt;1.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State Rate Change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change"&gt;-2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&amp;amp;D"&gt;(272&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&amp;amp;D"&gt;0.94&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State NOL&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;NJ NOL True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up"&gt;1,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up"&gt;-3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock Compensation True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up"&gt;(1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fixed Assets True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up"&gt;925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up"&gt;-3.19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other"&gt;(22&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;NOL Refund VA True Up&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up"&gt;486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up"&gt;-1.68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Other"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance"&gt;7,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance"&gt;-25.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zyVBat4fM2Ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001635"
      unitRef="USD">166300000</us-gaap:OperatingLossCarryforwards>
    <AIM:OperatingLossCarryforwardsWithNoExpirationDate
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">103300000</AIM:OperatingLossCarryforwardsWithNoExpirationDate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_NewJerseyDivisionOfTaxationMember"
      decimals="0"
      id="Fact001639"
      unitRef="USD">28800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001641"
      unitRef="USD">82500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_country_BE"
      decimals="0"
      id="Fact001643"
      unitRef="USD">3600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_stpr_NJ"
      decimals="0"
      id="Fact001645"
      unitRef="USD">14156000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="From2023-01-012023-12-31_stpr_NJ"
      decimals="0"
      id="Fact001647"
      unitRef="USD">38600</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="From2022-01-012022-12-31_stpr_NJ"
      decimals="0"
      id="Fact001649"
      unitRef="USD">1313000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001651">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zKGiWrm15ang" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022, which include the correction of an
immaterial deferred tax error of approximately $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pn5n6_c20221231__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9hjvJsKXZy4" title="Deferred tax"&gt;1.4&lt;/span&gt;
million in the stock compensation component and the corresponding valuation allowance for the same amount as of December 31, 2022,
consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zLYR9HsUI8Bi" style="display: none"&gt;Schedule of Components of Net Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231_zQizh4fUHDyf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_zzMXzulSyTS3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGz4fF_zB9lf9LWXyi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;25,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGz4fF_zV5Om2Fyq4f9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Research and Development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsAmortizationAndDepreciation_iI_pn3n3_maDTAGz4fF_zl6vRunZmmY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Amortization &amp;amp; depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGz4fF_zdK4YaDglam8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;R&amp;amp;D credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGz4fF_zJgnBkSZlTKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsRightOfUseAssets_iI_pn3n3_maDTAGz4fF_zF5P7tqSWyT8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGz4fF_zk6eNAaNVGm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Stock compensation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,479&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,472&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGz4fF_maDTALNzkn6_zA3rlcq0Axhl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,958&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzkn6_zBxfBSX6VBS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(36,816&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(30,840&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzkn6_zpwwp20T4oY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,604&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31_srt_RestatementAdjustmentMember"
      decimals="-5"
      id="Fact001653"
      unitRef="USD">1400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001655"
      unitRef="USD">25114000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001656"
      unitRef="USD">19674000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001658"
      unitRef="USD">3517000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">7647000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <AIM:DeferredTaxAssetsAmortizationAndDepreciation
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001661"
      unitRef="USD">6791000</AIM:DeferredTaxAssetsAmortizationAndDepreciation>
    <AIM:DeferredTaxAssetsAmortizationAndDepreciation
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001662"
      unitRef="USD">2342000</AIM:DeferredTaxAssetsAmortizationAndDepreciation>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001664"
      unitRef="USD">1376000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001665"
      unitRef="USD">744000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">137000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001668"
      unitRef="USD">77000</us-gaap:DeferredTaxAssetsOther>
    <AIM:DeferredTaxAssetsRightOfUseAssets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001670"
      unitRef="USD">6000</AIM:DeferredTaxAssetsRightOfUseAssets>
    <AIM:DeferredTaxAssetsRightOfUseAssets
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001671"
      unitRef="USD">2000</AIM:DeferredTaxAssetsRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001673"
      unitRef="USD">1479000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">1472000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001676"
      unitRef="USD">38420000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">31958000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001679"
      unitRef="USD">36816000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001680"
      unitRef="USD">30840000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">1604000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001683"
      unitRef="USD">1118000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001685">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zZ3JfXDPGIw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation
between the effective tax rate on income from continuing operations and the statutory tax rate is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zluv3XFKo1Aj" style="display: none"&gt;Schedule of Effective Tax Rate and Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Pre Tax Book Loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_pn3n3_c20230101__20231231_zUk0H7uzSRJb" style="width: 16%; text-align: right" title="Pre Tax Book Loss"&gt;(28,962&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Federal Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maETR001_c20230101__20231231_znu4O9r1ncFb" style="text-align: right" title="Federal Rate"&gt;(6,082&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR002_c20230101__20231231_z0BQdbFnmgqa" style="text-align: right" title="Federal Rate"&gt;21.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State Taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maETR001_c20230101__20231231_zCZxcFyxAGzg" style="text-align: right" title="State Taxes"&gt;(2,244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR002_c20230101__20231231_zPImplBdhmRk" style="text-align: right" title="State Taxes"&gt;7.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other Perms&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_pn3n3_maETR001_c20230101__20231231_z6e5LDis58Za" style="text-align: right" title="Other Perms"&gt;(83&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maETR002_c20230101__20231231_zEh9cf06xrO5" style="text-align: right" title="Other Perms"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;RTP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IncomeTaxReconciliationForeignIncomeRTP_pn3n3_maETR001_c20230101__20231231_zPwOrZmSpQu3" style="text-align: right" title="RTP"&gt;(8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectiveIncomeTaxRateReconciliationRTPPercentage_pid_dp_uPure_maETR002_c20230101__20231231_z0n8SGqv0Gsc" style="text-align: right" title="RTP"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Income Tax Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_pn3n3_maETR001_c20230101__20231231_z6ZOb67rMmA5" style="text-align: right" title="Income Tax Income"&gt;(479&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maETR002_c20230101__20231231_zgZVHoTKxwyc" style="text-align: right" title="Income Tax Income"&gt;1.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State Rate Change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxReconciliationTaxContingenciesStateAndLocal_pn3n3_maETR001_c20230101__20231231_zOyuWYbHXo67" style="text-align: right" title="State Rate Change"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_pid_dp_uPure_maETR002_c20230101__20231231_zailtWVZsBfc" style="text-align: right" title="State Rate Change"&gt;-2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;R&amp;amp;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_iN_pn3n3_di_maETR001_c20230101__20231231_zr2krjEZgE06" style="text-align: right" title="R&amp;amp;D"&gt;(272&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_pid_dp_uPure_maETR002_c20230101__20231231_zTvgnMlejgce" style="text-align: right" title="R&amp;amp;D"&gt;0.94&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State NOL&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IncomeTaxReconciliationNondeductibleStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zAOC9dhg9GI3" style="text-align: right" title="State NOL"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1717"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zAmrjfO7TxRf" style="text-align: right" title="State NOL"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;NJ NOL True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss_pn3n3_maETR001_c20230101__20231231_zYOisKRm787" style="text-align: right" title="NJ NOL True Up"&gt;1,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage_pid_dp_uPure_maETR002_c20230101__20231231_zcFqvOOxl0Hg" style="text-align: right" title="NJ NOL True Up"&gt;-3.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock Compensation True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_pn3n3_maETR001_c20230101__20231231_z5uJr9GZg3Q6" style="text-align: right" title="Stock Compensation True Up"&gt;(1,347&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maETR002_c20230101__20231231_ziNmP9CO1Bli" style="text-align: right" title="Stock Compensation True Up"&gt;4.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fixed Assets True Up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncomeTaxReconciliationNondeductibleExpenseFixedAssets_pn3n3_maETR001_c20230101__20231231_zd65WviK2WLe" style="text-align: right" title="Fixed Assets True Up"&gt;925&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets_pid_dp_uPure_maETR002_c20230101__20231231_zKM1twI8vXO6" style="text-align: right" title="Fixed Assets True Up"&gt;-3.19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maETR001_c20230101__20231231_zEF2kURlkc33" style="text-align: right" title="Other"&gt;(22&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationOther_pid_dp_uPure_maETR002_c20230101__20231231_zdXp5XMKqZ4c" style="text-align: right" title="Other"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;NOL Refund VA True Up&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance_pn3n3_maETR001_c20230101__20231231_zHNGbba5HNbg" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up"&gt;486&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage_pid_dp_uPure_maETR002_c20230101__20231231_z5nEMEpYqbR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="NOL Refund VA True Up"&gt;-1.68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Other"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Statutory Other"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maETR001_c20230101__20231231_z5zuuPmopnO4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation Allowance"&gt;7,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance_pid_dp_uPure_maETR002_c20230101__20231231_zT30nw9ITP5i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Statutory Valuation Allowance"&gt;-25.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtETR001_c20230101__20231231_zoFjKVU71yQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR002_c20230101__20231231_zkYkQzPqUIXk" style="border-bottom: Black 2.5pt double; text-align: right" title="Statutory Total"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001687"
      unitRef="USD">-28962000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">-6082000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001691"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001693"
      unitRef="USD">-2244000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001695"
      unitRef="Pure">0.0775</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001697"
      unitRef="USD">-83000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001699"
      unitRef="Pure">0.0029</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <AIM:IncomeTaxReconciliationForeignIncomeRTP
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">-8000</AIM:IncomeTaxReconciliationForeignIncomeRTP>
    <AIM:EffectiveIncomeTaxRateReconciliationRTPPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001703"
      unitRef="Pure">0.0003</AIM:EffectiveIncomeTaxRateReconciliationRTPPercentage>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">-479000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001707"
      unitRef="Pure">0.0165</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001709"
      unitRef="USD">618000</us-gaap:IncomeTaxReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001711"
      unitRef="Pure">-0.0213</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">272000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001715"
      unitRef="Pure">0.0094</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <AIM:EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001719"
      unitRef="Pure">0.0000</AIM:EffectiveIncomeTaxRateReconciliationNondeductibleStateNetOperatingLossPercentage>
    <AIM:IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001721"
      unitRef="USD">1123000</AIM:IncomeTaxReconciliationNondeductibleNewJerseyStateNetOperatingLoss>
    <AIM:EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001723"
      unitRef="Pure">-0.0388</AIM:EffectiveIncomeTaxRateReconciliationNondeductibleNewJerseyStateNetOperatingLossPercentage>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001725"
      unitRef="USD">-1347000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001727"
      unitRef="Pure">0.0465</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <AIM:IncomeTaxReconciliationNondeductibleExpenseFixedAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001729"
      unitRef="USD">925000</AIM:IncomeTaxReconciliationNondeductibleExpenseFixedAssets>
    <AIM:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001731"
      unitRef="Pure">-0.0319</AIM:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFixedAssets>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">-22000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <AIM:EffectiveIncomeTaxRateReconciliationOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001735"
      unitRef="Pure">0.0008</AIM:EffectiveIncomeTaxRateReconciliationOther>
    <AIM:IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">486000</AIM:IncomeTaxReconciliationNetOperatingLossRefundValuationAllowance>
    <AIM:EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001739"
      unitRef="Pure">-0.0168</AIM:EffectiveIncomeTaxRateReconciliationNetOperatingLossRefundValuationAllowancePercentage>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001741"
      unitRef="USD">7385000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <AIM:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001743"
      unitRef="Pure">-0.2550</AIM:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001747"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001749">&lt;p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zpy4TpPKA85b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(13)
&lt;span id="xdx_827_zxlV1UX3tDal"&gt;Certain Relationships and Related Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has an employment agreement with its NEOs and has granted its NEOs and directors options to purchase its common stock. Please
see details of these Employment Agreements in Note 10 - Employment Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001751">&lt;p id="xdx_806_eus-gaap--ConcentrationRiskDisclosureTextBlock_zyjoNCG16AJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(14)
&lt;span id="xdx_827_zJu5FExLjD6e"&gt;Concentrations of Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents, investments
and accounts receivable. The Company places its cash with high-quality financial institutions and, at times, such amounts in non-interest-bearing
accounts may be in excess of Federal Deposit Insurance Corporation insurance limits. There were no credit-based sales for 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are a limited number of suppliers in the United States and abroad available to provide the raw and packaging materials/reagents for use
in manufacturing Ampligen and Alferon N Injection. At present, the Company does not have any agreements with third parties for the supply
of any of these materials or it is relying on a limited source of reagent suppliers necessary for the manufacture of Alferon N Injection.
Jubilant HollisterStier LLC has manufactured batches of Ampligen for us pursuant to purchase orders. The Company anticipates that additional
orders will be placed upon approved quotes and purchase orders provided by us to Jubilant. On December 22, 2020, it added Pharmaceutics
International Inc. (&#x201c;Pii&#x201d;) as a &#x201c;Fill &amp;amp; Finish&#x201d; provider to enhance our capacity to produce the drug Ampligen.
This addition amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment the Company&#x2019;s
existing fill and finish capacity. If the Company is unable to place adequate acceptable purchase orders with Jubilant or Pii in the
future at acceptable prices upon acceptable terms, it will need to find another manufacturer. The costs and availability of products
and materials the Company would need for the production of Ampligen are subject to fluctuation depending on a variety of factors beyond
our control, including competitive factors, changes in technology, ownership of intellectual property, FDA and other governmental regulations.
There can be no assurance that the Company will be able to obtain such products and materials on terms acceptable to it or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Currently,
the Alferon N Injection manufacturing process is on hold and there is no definitive timetable to restart production. If the Company is
unable to acquire FDA approvals related to the manufacturing process and/or final product of new Alferon N Injection inventory or contract
with a CMO, its operations most likely will be materially and/or adversely affected. In light of these contingencies, there can be no
assurances that the approved Alferon N Injection product will be returned to production on a timely basis, if at all, or that if and
when it is again made commercially available, it will return to prior sales levels.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001753">&lt;p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_z7t6Ujmx0eg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(15)
&lt;span id="xdx_82A_zGHl6kYoQvOj"&gt;Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the provisions of FASB ASC 820 &#x201c;Fair Value Measurements&#x201d; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 &#x2013; Quoted prices are available in active markets for identical assets or liabilities at the reporting date. Generally, this
    includes debt and equity securities that are traded in an active market.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 &#x2013; Observable inputs other than Level 1 prices such as quote prices for similar assets or liabilities; quoted prices in markets
    that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full
    term of the assets or liabilities. Generally, this includes debt and equity securities that are not traded in an active market.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
    assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models,
    discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value
    requires significant management judgment or estimation. As of September 30, 2023, the Company has classified the warrants with cash
    settlement features as Level 3. Management evaluates a variety of inputs and then estimates fair value based on those inputs. As
    discussed above, the Company utilized the Monte Carlo Simulation Model in valuing the warrants. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zYDPDRYoMkN5" style="display: none"&gt;Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 10pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="font-size: 10pt"&gt;4,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1763"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Marketable investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 10pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;25,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;25,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Marketable investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1785"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zBi8m8zL5Qy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash balances are representative of their fair values as these balances are comprised of deposits available on demand.
For certain instruments, including funds receivable from New Jersey net operating loss, accounts payable and accrued expenses, it was
estimated that the carrying values approximated the fair value due to the short-term maturities of these instruments (Level 1).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has certain redeemable warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair
value of the redeemable warrants (&#x201c;Redeemable Warrants&#x201d;) related to the Company&#x2019;s March 2019 common stock and warrant
issuance, are calculated using a Monte Carlo Simulation (Level 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recomputes the fair value of the Redeemable Warrants at the issuance date and the end of each quarterly reporting period. Such
value computation includes subjective input assumptions that are consistently applied each period. If the Company were to alter its assumptions
or the numbers input based on such assumptions, the resulting fair value could be materially different.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zrbXdtHsst85" style="display: none"&gt;Schedule
of Assumptions to Estimate Fair Value of Warrants&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term"&gt;.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants measurement input&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zsBs6amkn04c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
    Interest Rate&lt;/i&gt;. The risk-free interest rates for the Warrants are based on U.S. Treasury constant maturities for periods commensurate
    with the remaining expected holding periods of the warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Holding Period&lt;/i&gt;. The expected holding period represents the period of time that the Warrants are expected to be outstanding until
    they are exercised. The Company utilizes the remaining contractual term of the Warrants at each valuation date as the expected holding
    period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Volatility&lt;/i&gt;. Expected stock volatility is based on daily observations of the Company&#x2019;s historical stock values for a period
    commensurate with the remaining expected holding period on the last day of the period for which the computation is made.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Dividend Yield&lt;/i&gt;. Expected dividend yield is based on the Company&#x2019;s anticipated dividend payments over the remaining expected
    holding period. As the Company has never issued dividends, the expected dividend yield is &lt;span id="xdx_901_ecustom--FairValueMeasurementInputPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zqowt4ev68Yb" title="Fair value measurement, input percentage"&gt;0&lt;/span&gt;% and this assumption will be continued
    in future calculations unless the Company changes its dividend policy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Probability of a Fundamental Transaction.&lt;/i&gt; The possibility of the occurrence of a Fundamental Transaction triggering a Put right
    is extremely remote. As discussed above, a Put right would only arise if a Fundamental Transaction 1) is an all cash transaction;
    (2) results in the Company going private; or (3) is a transaction involving a person or entity not traded on a national securities
    exchange. The Company believes such an occurrence is highly unlikely because:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company only has one product that is FDA approved but is currently not available for commercial sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company will have to perform additional clinical trials for FDA approval of its flagship product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Industry
    and market conditions continue to include uncertainty, adding risk to any transaction.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Available
    capital for a potential buyer in a cash transaction continues to be limited.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    nature of a life sciences company is heavily dependent on future funding and high fixed costs, including Research &amp;amp; Development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company has minimal revenues streams which are insufficient to meet the funding needs for the cost of operations or construction
    at their manufacturing facility; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company&#x2019;s Rights Agreement and Executive Agreements make it less attractive to a potential buyer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the above factors utilized in analysis of the likelihood of the Put&#x2019;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z3IoaIciMb6l" style="display: none"&gt;Schedule of Range of Probabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of Probability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Probability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: center"&gt;Low&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Medium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;High&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zq7Luw79jzU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Monte Carlo Simulation has incorporated a &lt;span id="xdx_902_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231_zaqAl3tBTbV6" title="Percentage of probability"&gt;5.0&lt;/span&gt;% probability of a Fundamental Transaction to date for the life of the securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vi)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Timing of Announcement of a Fundamental Transaction.&lt;/i&gt; As the Company has no specific expectation of a Fundamental Transaction,
    for reasons elucidated above, the Company utilized a discrete uniform probability distribution over the Expected Holding Period to
    model in the potential announcement of a Fundamental Transaction occurring during the Expected Holding Period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vii)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    100 Day Volatility at Announcement of a Fundamental Transaction&lt;/i&gt;. An estimate of future volatility is necessary as there is no
    mechanism for directly measuring future stock price movements. Daily observations of the Company&#x2019;s historical stock values
    for the 100 days immediately prior to the Warrants&#x2019; grant dates, with a floor of &lt;span id="xdx_902_ecustom--FloorRateUsedAsProxyForFutureVolatilityPercentage_pid_dp_uPure_c20230101__20231231_zW1ASrkrbeO6" title="Floor rate used as proxy for future volatility percentage"&gt;100&lt;/span&gt;%, were utilized as a proxy for the future
    volatility.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(viii)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Risk-Free Interest Rate at Announcement of a Fundamental Transaction&lt;/i&gt;. The Company utilized a risk-free interest rate corresponding
    to the forward U.S. Treasury rate for the period equal to the time between the date forecast for the public announcement of a Fundamental
    Transaction and the Warrant expiration date for each simulation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ix)
    &lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    Time Between Announcement and Consummation of a Fundamental Transaction.&lt;/i&gt; The expected time between the announcement and the consummation
    of a Fundamental Transaction is based on the Company&#x2019;s experience with the due diligence process performed by acquirers and
    is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional period to reflect the delay Warrant
    Holders would experience in receiving the proceeds of the Put.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the numbers input change from period
to period (e.g., the actual historical prices input for the relevant period). The carrying amount and estimated fair value of the above
Warrants was approximately $&lt;span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKtiUPvS1ARh"&gt;0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001755">&lt;p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zYiMEAm4C2Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zYDPDRYoMkN5" style="display: none"&gt;Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 10pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231_z83nUSICobL2" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_znsQe2H7u0gd" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="font-size: 10pt"&gt;4,805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zIW3jxiL3P41" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlmAm9oNMtB6" style="width: 11%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1763"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Marketable investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231_zRkd83lWcec" style="text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zpcudr0UJGae" style="text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxHMxlgIYp7b" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1769"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4DudObjdsQh" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1771"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-left: 10pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231_z7Uw3Enumzkj" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;25,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEyBWYxyzx58" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;25,180&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9GOjxHIscC2" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zit80g8CwPqh" style="width: 11%; text-align: right" title="Cash equivalent-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Marketable investments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231_zRecHcLji644" style="text-align: right" title="Marketable securities"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6d9mpbR8Ei" style="text-align: right" title="Marketable securities"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWmeqeM5NaVg" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1785"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--MarketableSecuritiesCurrent_iI_pn3n3_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXTjtmbPREHl" style="text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001757"
      unitRef="USD">4805000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001759"
      unitRef="USD">4805000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001765"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001767"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001773"
      unitRef="USD">25180000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001775"
      unitRef="USD">25180000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001781"
      unitRef="USD">7137000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001783"
      unitRef="USD">7137000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001789">&lt;p id="xdx_893_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zuol2aaJulp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the March 2019 Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zrbXdtHsst85" style="display: none"&gt;Schedule
of Assumptions to Estimate Fair Value of Warrants&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_z5oIAaJPapa6" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zBYs1s5O9yza" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--SharePrice_iI_pid_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember_zjhTwrN654kc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;0.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zto65HqSveZc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zfvhNrKoA4yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.47&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5SLkXNkHcag" title="Warrant term"&gt;.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6EQrbmcDZdb" title="Warrant term"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pip0_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbbdzooHRxWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z1U3UjDe3iZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--AwardTypeAxis__custom--MarchTwoThousandNineteenWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zlO3oEZcdMQj" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants measurement input&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember"
      decimals="INF"
      id="Fact001791"
      unitRef="USDPShares">0.44</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember"
      decimals="INF"
      id="Fact001792"
      unitRef="USDPShares">0.31</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001794"
      unitRef="Pure">8.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Pure">8.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Pure">5.47</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001798"
      unitRef="Pure">4.67</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001800">P0Y2M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001802">P1Y2M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001804"
      unitRef="Pure">80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_MarchTwoThousandNineteenWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001805"
      unitRef="Pure">70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <AIM:FairValueMeasurementInputPercentage
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001813"
      unitRef="Pure">0</AIM:FairValueMeasurementInputPercentage>
    <AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001815">&lt;p id="xdx_89C_ecustom--ScheduleOfRangeOfProbabilitiesTableTextBlock_zLaqpS9nTXRh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_z3IoaIciMb6l" style="display: none"&gt;Schedule of Range of Probabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of Probability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Probability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: center"&gt;Low&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_903_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z0pMBIHZAcY" title="Percentage of probability"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Medium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--WeightedAverageMember_zAn4iSQ52m1d" title="Percentage of probability"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;High&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--PercentageOfProbability_pid_dp_uPure_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zygQUr4pY1p3" title="Percentage of probability"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AIM:ScheduleOfRangeOfProbabilitiesTableTextBlock>
    <AIM:PercentageOfProbability
      contextRef="From2023-01-012023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001817"
      unitRef="Pure">0.005</AIM:PercentageOfProbability>
    <AIM:PercentageOfProbability
      contextRef="From2023-01-012023-12-31_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001819"
      unitRef="Pure">0.010</AIM:PercentageOfProbability>
    <AIM:PercentageOfProbability
      contextRef="From2023-01-012023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001821"
      unitRef="Pure">0.050</AIM:PercentageOfProbability>
    <AIM:PercentageOfProbability
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001823"
      unitRef="Pure">0.050</AIM:PercentageOfProbability>
    <AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001825"
      unitRef="Pure">1</AIM:FloorRateUsedAsProxyForFutureVolatilityPercentage>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember289848921"
      decimals="0"
      id="Fact001826"
      unitRef="USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001828">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaZ4cv9BcK5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(16)&lt;/b&gt; &lt;b&gt;&lt;span id="xdx_82D_zZ6GqmFQwI41"&gt;Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"&gt;Because litigation is inherently
unpredictable, assessing contingencies&#160;related to litigation is a complex process involving highly subjective judgment about potential
outcomes of future events. When evaluating litigation contingencies, the Company may be unable to provide a meaningful estimate due to
a number of factors, including the procedural status of the matter in question, the availability of appellate remedies, insurance coverage
related to the claim or claims in question, the presence of complex or novel legal theories, and the ongoing discovery and development
of information important to the matter. In addition, damage amounts claimed in litigation against the Company may be unsupported, exaggerated,
or unrelated to possible outcomes, and as such are not meaningful indicators of the Company&#x2019;s potential liability or financial exposure.
Accordingly, the Company reviews the adequacy of accruals and disclosures each quarter in consultation with legal counsel, and it assesses
the probability and range of possible losses associated with&#160;contingencies&#160;for potential accrual in the condensed consolidated
financial statements. However, the ultimate resolution of litigated claims may differ from the Company current estimates.&lt;/p&gt;

&lt;p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"&gt;In the normal course of business,
there are various claims in process, matters in litigation, and other contingencies, certain of which are covered by insurance policies.
When a loss is probable, we record an accrual based on the reasonably estimable loss or range of loss. We do not record liabilities for
reasonably possible loss contingencies but do disclose a range of reasonably possible losses if they are material and we are able to estimate
such a range. If we cannot provide a range of reasonably possible losses, we explain the factors that prevent us from determining such
a range. Historically, adjustments to our estimates have not been material. While it is not possible to predict the outcome of these suits,
legal proceedings, and claims with certainty, management is of the opinion that adequate provision for potential losses associated with
these matters has been made in the financial statements and that the ultimate resolution of any one of these matters will not have a material
adverse effect on the Company&#x2019;s financial position and results of operations. A significant increase in the number of these claims,
or one or more successful claims resulting in greater liabilities than the Company currently anticipates, could materially and adversely
affect the Company&#x2019;s business, financial condition, results of operations, and cash flows.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001830">&lt;p id="xdx_80F_eus-gaap--SubsequentEventsTextBlock_z12tS2VfdSp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(17)
&lt;span id="xdx_82E_znFnaiO3kAei"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2024, the Company entered into a Note Purchase Agreement with an unrelated party raising $&lt;span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20240216__20240216__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__custom--DebtIstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zPd1bN9HZ8Q7" title="Net Proceeds"&gt;2,500,000&lt;/span&gt;
in net proceeds from the sale of an unsecured promissory Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 28, 2024, the Company entered into a purchase agreement and a
registration rights agreement with an unrelated party, pursuant to which this party committed to purchase up to $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240328__20240328__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zph9uGpTxlja" title="Purchase commitment"&gt;15,000,000&lt;/span&gt; of common
stock of the Company for a period of 24 months from the date of the agreement. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, the Company sold &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zlBh2vNi0Dkc" title="Sale of stock, number of shares issued in transaction"&gt;204,547&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240301__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zZhZfO9CzpT4" title="Sale of stock, number of shares issued in transaction"&gt;38,462&lt;/span&gt; shares of its common stock at prices of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--EmployeesPurchasePlanMember_zDVhkDDuwSc3" title="Sale of stock, price per share"&gt;0.33&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--DirectorsPurchasePlanMember_zxIPrz3YjgB3" title="Sale of stock, price per share"&gt;0.39&lt;/span&gt; per share, respectively, under
the Employees and Directors Purchase Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-02-162024-02-16_us-gaap_SubsequentEventMember_custom_UnsecuredPromissoryNoteMember_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact001832"
      unitRef="USD">2500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-03-282024-03-28_us-gaap_SubsequentEventMember_us-gaap_NonrelatedPartyMember_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001834"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember"
      decimals="INF"
      id="Fact001836"
      unitRef="Shares">204547</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-03-012024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember"
      decimals="INF"
      id="Fact001838"
      unitRef="Shares">38462</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_EmployeesPurchasePlanMember"
      decimals="INF"
      id="Fact001840"
      unitRef="USDPShares">0.33</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_DirectorsPurchasePlanMember"
      decimals="INF"
      id="Fact001842"
      unitRef="USDPShares">0.39</us-gaap:SaleOfStockPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
